PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GLERUM, DM; KOERNER, TJ; TZAGOLOFF, A				GLERUM, DM; KOERNER, TJ; TZAGOLOFF, A			CLONING AND CHARACTERIZATION OF COX14, WHOSE PRODUCT IS REQUIRED FOR ASSEMBLY OF YEAST CYTOCHROME-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; NUCLEAR GENE; ESCHERICHIA-COLI; SUBUNIT-II; PET GENES; PROTEIN; TRANSFORMATION; MUTANTS	Nuclear respiration-deficient mutants of Saccharomyces cerevisiae previously assigned to complementation group G93 lack cytochromes a and a(3) and detectable cytochrome oxidase activity, Other respiratory chain carriers and the ATPase complex are present at near wild-type levels, indicating that the mutations specifically affect cytochrome oxidase, Since synthesis of the mitochondrially derived subunits 1, 2, and 3 of cytochrome oxidase is normal, the defect cannot be related to transcription of the endogenous genes or processing and translation of the corresponding RNAs, The results of Western analysis of the cytochrome oxidase subunits encoded in nuclear DNA also argues against an effect of the mutations on expression of these constituents. The G93 mutants are complemented by a nuclear gene, designated COX14, The product of this gene is a low molecular mass protein of 7,960 Da, A gene fusion expressing a biotinylated form of Cox14p complements cox14 mutants, indicating partial functional equivalence. The biotinylated derivative has been helpful in localizing Cox14p to the mitochondrial membrane and demonstrating that it is not a hitherto unrecognized subunit of cytochrome oxidase, although it does appear to be associated with a high molecular weight complex, This evidence, combined with the assembly-arrested phenotype of cox14 mutants, indicates that Cox14p, like several other recently described mitochondrial constituents, provides an important function at some late stage of the cytochrome oxidase assembly pathway.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1985, J BIOL CHEM, V260, P5871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; POUTRE CG, 1987, GENETICS, V115, P637; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	37	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15585	15590		10.1074/jbc.270.26.15585	http://dx.doi.org/10.1074/jbc.270.26.15585			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797555	hybrid			2022-12-25	WOS:A1995RG53800025
J	HORREVOETS, AJG; SMILDE, AE; FREDENBURGH, JC; PANNEKOEK, H; NESHEIM, ME				HORREVOETS, AJG; SMILDE, AE; FREDENBURGH, JC; PANNEKOEK, H; NESHEIM, ME			THE ACTIVATION-RESISTANT CONFORMATION OF RECOMBINANT HUMAN PLASMINOGEN IS STABILIZED BY BASIC RESIDUES IN THE AMINO-TERMINAL HINGE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYS-PLASMINOGEN; GLU-PLASMINOGEN; N-GLYCOSYLATION; BINDING SITES; FIBRINOLYSIS; UROKINASE; INTERMEDIATE; EXPRESSION; INVITRO; DNA	Fully activable recombinant human plasminogen (rPlg) was expressed in mammalian cells employing either recombinant vaccinia virus or stable lines coexpressing alpha(2)-plasmin inhibitor. A panel of eight variants of rPlg was constructed, in which progressively up to 6 basic amino acid residues in the hinge region of rPlg between the NH2-terminal acidic domain (''proactivation peptide'') and kringle 1 were substituted by neutral residues. Analysis of the cleavage rates of these variants by plasmin revealed that the peptide bond at Arg(68) is most susceptible, followed by Lys(62) and Lys(77). A variant with all 6 basic residues substituted was cleaved at Lys(20). Three of these variants, PlgB (R68A, R70A), PlgF (R68A, R70A, K77H, K78H), and PlgG (R61A, K62A, R68A, R70A, K77H, K78H), as well as rPlg, were analyzed in more detail. The conformation of these plasminogens was analzed by monitoring the change in intrinsic fluorescence upon binding of lysine analogs. This revealed that rPlg exhibits the native tight Glu(1)-plasminogen, conformation, whereas PlgB, PlgF, and Plg G display an open confirmation similar to Lys(78)-plasminogen, leading to an increased affinity for lysine analogs. This allowed a direct study of the impact of the activation-resistant conformation on the properties of Glu(1)-plasminogen. The open conformation of rPlg variants leads to an increased rate of activation by urokinase-type plasminogen activator and streptokinase and increased binding to a fibrin clot. Fibrin clot lysis mediated by tissue-type plasminogen activator was accelerated for the variants as a result of a lower K-m for tissue-type plasminogen activator-mediated plasminogen activation, resulting from the increased affinity of rPlg (variants) for intact fibrin. We conclude that the basic residues in the extremely plasmin susceptible hinge region of plasminogen are directly involved in maintaining the activation resistant Glu(1)-plasminogen conformation.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada	HORREVOETS, AJG (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1-163,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.							BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MCCANCE SG, 1994, J BIOL CHEM, V269, P32405; MULLERTZ S, 1984, BIOCHEM J, V223, P169; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1990, J BIOL CHEM, V265, P22228; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; URANO T, 1991, THROMB RES, V61, P349, DOI 10.1016/0049-3848(91)90648-G; VALI Z, 1982, J BIOL CHEM, V257, P2104; VIOLAND BN, 1976, J BIOL CHEM, V251, P3906; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1973, EUR J BIOCHEM, V39, P1, DOI 10.1111/j.1432-1033.1973.tb03096.x; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022; WU HL, 1990, J BIOL CHEM, V265, P19658	39	39	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15770	15776		10.1074/jbc.270.26.15770	http://dx.doi.org/10.1074/jbc.270.26.15770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797579	hybrid			2022-12-25	WOS:A1995RG53800052
J	LEE, BH; LEY, BW; KANTROWITZ, ER; OLEARY, MH; WEDLER, FC				LEE, BH; LEY, BW; KANTROWITZ, ER; OLEARY, MH; WEDLER, FC			DOMAIN CLOSURE IN THE CATALYTIC CHAINS OF ESCHERICHIA-COLI ASPARTATE TRANSCARBAMOYLASE INFLUENCES THE KINETIC MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; BINDING; C-13; COOPERATIVITY; MODEL; PROBE	The closure of the two domains of the catalytic chains of Escherichia coli aspartate transcarbamoylase, which is critical for completion of the T --> R transition, is stabilized by salt-bridges between Glu-50 and both Arg-167 and Arg-234. Mutation of Glu-50 to Ala shifts the enzyme toward a low activity, low affinity state (Newton, C. J., and Kantrowitz, E. R. (1990) Biochemistry, 29, 1444-1451), Kinetic isotope effects (KIE) and equilibrium isotope exchange kinetics (EIEK) have been used to probe the dynamic properties of the Glu-50 --> Ala enzyme. Unlike the behavior of the wild-type enzyme, the observed kinetic isotope effect for C-13 versus C-12 at the carbonyl group of carbamoyl phosphate (CP) increased upon the binding of ligands which promote the formation of the R-state (Asp, N-phosphonacetyl-L-aspartate (PALA), or ATP). The maximum rate for the [C-14]Asp reversible arrow Carbamoyl aspartate (CAsp) exchange with the Glu-50 --> Ala enzyme was 500-fold slower than for the wild-type enzyme; however, the rate for the [C-14]Cp reversible arrow CAsp exchange was only 50-fold slower, reversing the relative rates observed with the wild-type enzyme. In addition, upon variation of substrate pairs involving Asp or CAsp, loss of inhibition effects in the CP reversible arrow CAsp exchange indicated that the Glu-50 --> Ala substitution caused the kinetic mechanism for the mutant enzyme to shift from ordered to random. Computer simulations of the EIEK data indicate that the Glu-50 --> Ala mutation specifically causes strong decreases in the rates of catalysis and association-dissociation for Asp and CAsp, with minimal effects on the GP and P-i on-off rates, With substrates bound, the Glu-50 --> Ala enzyme apparently does not attain a full R-state conformation. The PALA-activated Glu-50 --> Ala enzyme, however, exhibits substrate affinities comparable to those for the wild-type enzyme, but fails to restore the preferred order substrate binding. Unlike the wild-type enzyme, both the T and R-states of the Glu-50 --> Ala enzyme contribute to catalysis. A third state, I, is proposed for the Glu-50 --> Ala enzyme, in which random order substrate binding is exhibited, and the catalytic step contributes significantly to overall rate limitation.	UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA; PENN STATE UNIV, PM ALTHOUSE LAB, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; BOSTON COLL, MERKERT CHEM CTR, DEPT CHEM, CHESTNUT HILL, MA 02167 USA	University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Boston College					NIGMS NIH HHS [GM43043, GM26237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043043, R01GM026237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; ALLEWELL NM, 1989, ANNU REV BIOPHYS BIO, V18, P71, DOI 10.1146/annurev.bb.18.060189.000443; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOYER PD, 1978, ACCOUNTS CHEM RES, V11, P218, DOI 10.1021/ar50125a007; COOK PF, 1991, ENZYME MECHANISM ISO; HERVE G, 1989, ALLOSTERIC ENZYMES, P61; HSUANYU Y, 1988, J BIOL CHEM, V263, P4172; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; OLEARY MH, 1989, ANNU REV BIOCHEM, V58, P377; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6577, DOI 10.1021/bi00143a030; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6598, DOI 10.1021/bi00143a033; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6570, DOI 10.1021/bi00143a029; PORTER RW, 1969, J BIOL CHEM, V244, P1846; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; STARK GR, 1971, J BIOL CHEM, V246, P3064; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TSURUTA H, 1994, BIOCHEMISTRY-US, V33, P10007, DOI 10.1021/bi00199a026; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6585, DOI 10.1021/bi00143a031; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6592, DOI 10.1021/bi00143a032; WEDLER FC, 1995, J BIOL CHEM, V270, P9725, DOI 10.1074/jbc.270.17.9725; WEDLER FC, 1994, ANAL BIOCHEM, V218, P449, DOI 10.1006/abio.1994.1205; WEDLER FC, 1974, J BIOL CHEM, V249, P5080; WEDLER FC, 1995, IN PRESS METHODS ENZ	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15620	15627		10.1074/jbc.270.26.15620	http://dx.doi.org/10.1074/jbc.270.26.15620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797560	hybrid			2022-12-25	WOS:A1995RG53800030
J	PEREGO, M; GLASER, P; MINUTELLO, A; STRAUCH, MA; LEOPOLD, K; FISCHER, W				PEREGO, M; GLASER, P; MINUTELLO, A; STRAUCH, MA; LEOPOLD, K; FISCHER, W			INCORPORATION OF D-ALANINE INTO LIPOTEICHOIC ACID AND WALL TEICHOIC-ACID IN BACILLUS-SUBTILIS - IDENTIFICATION OF GENES AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; STAPHYLOCOCCUS-AUREUS; LACTOBACILLUS-CASEI; ESTER SUBSTITUTION; DNA-SEQUENCE; BIOSYNTHESIS; CLONING; TRANSCRIPTION; SPORULATION; EXPRESSION	The Bacillus subtilis dlt operon (D-alanyl-lipoteichoic acid) is responsible for D alanine esterification of both lipoteichoic acid (LTA) and wall teichoic acid (WTA). The dlt operon contains five genes, dltA-dltE. Insertional inactivation of dltA-dltD results in complete absence of D-alanine from both LTA and WTA. Based on protein sequence similarity with the Lactobacillus casei dlt gene products (Heaton, M. P., and Neuhaus, F. C. (1992) J. Bacteriol. 174, 4707-4717), we propose that dltA encodes the D-alanine-n-alanyl carrier protein ligase (Dcl) and dltC the D-alanyl carrier protein (Dcp). We further hypothesize that the products of dltB and dltD are concerned with the transport of activated n-alanine through the membrane and the final incorporation of D-alanine into LTA. The hydropathy profiles of the dltB and dltD gene products suggest a transmembrane location for the former and an amino-terminal signal peptide for the latter. The incorporation of D-alanine into LTA and WTA did not separate in any of the mutants studied which indicates that either one and the same enzyme is responsible for D-alanine incorporation into both polymers or a separate enzyme, encoded outside the dlt operon, transfers the D-alanyl residues from LTA to WTA (Haas, R., Koch, H.-U., and Fischer, W. (1984) FEMS Microbiol Lett. 21, 27-31). Inactivation of dltE has no effect on D-alanine ester content of both LTA and WTA and at present we cannot propose any function for its gene product. Transcription analysis shows that the dlt operon is transcribed from a sigma(D)-dependent promoter and follows the pattern of transcription of genes belonging to the sigma(D) regulon. However, the turn off of transcription observed before sporulation starts seems to be dependent on the SpoOA and AbrB sporulation proteins and results in a D-alanine-free purely anionic LTA in the spore membrane. The dlt operon is dispensable for cell growth; its inactivation does not affect cell growth or morphology as described for L. casei.	UNIV PARMA, FAC FARM, DIPARTIMENTO FARMACEUT, I-43100 PARMA, ITALY; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV, I-27100 PAVIA, ITALY; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS, FRANCE; UNIV ERLANGEN NURNBERG, FAK MED, INST BIOCHEM, D-91054 ERLANGEN, GERMANY	University of Parma; University of Pavia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Erlangen Nuremberg	PEREGO, M (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTINI AM, 1991, J BACTERIOL, V173, P3573, DOI 10.1128/jb.173.11.3573-3579.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; [Anonymous], 1994, NEW COMPREHENSIVE BI; BIERBAUM G, 1987, J BACTERIOL, V169, P5452, DOI 10.1128/jb.169.12.5452-5458.1987; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHERET G, 1993, YEAST, V9, P661, DOI 10.1002/yea.320090612; CHIN T, 1968, J BACTERIOL, V95, P2044, DOI 10.1128/JB.95.6.2044-2050.1968; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; FISCHER W, 1981, J BACTERIOL, V146, P467, DOI 10.1128/JB.146.2.467-475.1981; FISCHER W, 1980, J BIOL CHEM, V255, P4557; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; Fischer W., 1990, HDB LIPID RES, P123; GLASER L, 1964, J BIOL CHEM, V239, P3187; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GRASSL M, 1985, METHOD ENZYMAT AN, V8, P336; HAAS R, 1984, FEMS MICROBIOL LETT, V21, P27, DOI 10.1111/j.1574-6968.1984.tb00180.x; HANCOCK IC, 1985, ENZYMES BIOL MEMBR, V2, P279; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HEATON MP, 1992, J BACTERIOL, V174, P4707, DOI 10.1128/JB.174.14.4707-4717.1992; HELMANN JD, 1988, J BACTERIOL, V170, P1568, DOI 10.1128/jb.170.4.1568-1574.1988; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; IWASAKI H, 1986, J BACTERIOL, V167, P508, DOI 10.1128/jb.167.2.508-516.1986; JOHNSTONE K, 1982, BIOCHEM J, V202, P459, DOI 10.1042/bj2020459; KATES M, 1994, TECHNIQUES LIPIDOLOG; KELEMEN MV, 1961, BIOCHEM J, V80, P246, DOI 10.1042/bj0800246; KOCH HU, 1984, EUR J BIOCHEM, V138, P357, DOI 10.1111/j.1432-1033.1984.tb07923.x; KOCH HU, 1985, J BACTERIOL, V164, P1211, DOI 10.1128/JB.164.3.1211-1217.1985; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEOPOLD K, 1991, EUR J BIOCHEM, V196, P475, DOI 10.1111/j.1432-1033.1991.tb15839.x; MANCUSO DJ, 1982, J BACTERIOL, V152, P616; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller JH., 1972, EXPT MOL GENETICS; NAGELE U, 1985, METHOD ENZYMAT AN, V8, P2; NTAMERE AS, 1987, J BACTERIOL, V169, P1702, DOI 10.1128/jb.169.4.1702-1711.1987; Ordal Geroge W., 1993, P765; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perego Marta, 1993, P615; PLATT MW, 1990, J BACTERIOL, V172, P5440, DOI 10.1128/jb.172.9.5440-5444.1990; POSTBEITTENMILLER MA, 1989, NUCLEIC ACIDS RES, V17, P1777, DOI 10.1093/nar/17.4.1777; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; SCHNITGER H, 1959, BIOCHEM Z, V332, P167; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHIBAEV VN, 1973, BIOCHEM J, V135, P383, DOI 10.1042/bj1350383; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; STRAUCH MA, 1992, BIOCHIMIE, V74, P619, DOI 10.1016/0300-9084(92)90133-Y; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WARD JB, 1981, MICROBIOL REV, V45, P211, DOI 10.1128/MMBR.45.2.211-243.1981; YOKOYAMA K, 1988, EUR J BIOCHEM, V173, P453, DOI 10.1111/j.1432-1033.1988.tb14020.x	57	205	213	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15598	15606		10.1074/jbc.270.26.15598	http://dx.doi.org/10.1074/jbc.270.26.15598			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797557	hybrid			2022-12-25	WOS:A1995RG53800027
J	SCHWALBE, RA; WANG, ZG; WIBLE, BK; BROWN, AM				SCHWALBE, RA; WANG, ZG; WIBLE, BK; BROWN, AM			POTASSIUM CHANNEL STRUCTURE AND FUNCTION AS REPORTED BY A SINGLE GLYCOSYLATION SEQUON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION	Inwardly rectifying K+ channels (IRKs) are highly K+-selective, integral membrane proteins that help maintain resting the membrane potential and cell volume. Integral membrane proteins as a class are frequently N-glycosylated with the attached carbohydrate being extracellular and perhaps modulating function. However, dynamic effects of glycosylation have yet to be demonstrated at the molecular level. ROMK1, a member of the IRK family is particularly suited to the study of glycosylation because it has a single N-glycosylation consensus sequence (Ho, K., Nichols, C. G., Lederer, W. J., Lytton, J., Vassilev, P. M., Kanazirska, M. V., and Herbert, S. C. (1993) Nature 362, 31-38). We show that ROMK1 is expressed in a functional state in the plasma-Iemma of an insect cell line (Spodoptera frugiperda, Sf9) and has two structures, glycosylated and unglycosylated, To test functionality, glycosylation was abolished by an N117Q mutation or by treatment with tunicamycin. Whole cell currents were greatly reduced in both of the unglycosylated forms compared to wild-type. Single channel currents revealed a dramatic decrease in opening probability, p(o), as the causative factor. Thus we have shown biochemically that the N-glycosylation sequon is extracellular, a result consistent with present topological models of IRKs, and we conclude that sequon occupancy by carbohydrate stabilizes the open state of ROMK1.	CASE WESTERN RESERVE UNIV,RAMMELKEMP CTR EDUC & RES,CLEVELAND,OH 44109	Case Western Reserve University			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NINDS NIH HHS [NS23877] Funding Source: Medline; PHS HHS [NL36930] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHANG XB, 1994, J BIOL CHEM, V169, P18572; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GOOCHEE CF, 1990, BIO-TECHNOL, V8, P421, DOI 10.1038/nbt0590-421; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICOR.C, 1994, BIOCHEM J, V302, P253; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P216; Possee RD., 1992, BACULOVIRUS EXPRESSI; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RECOPINTO E, NEURON, V5, P675; ROBERDS SL, 1993, J CARDIOVASC ELECTR, V4, P68, DOI 10.1111/j.1540-8167.1993.tb01214.x; SAMBROOK J, 1992, MOL CLONING LABORATO; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; TAGLIALATELA M, 1994, SCIENCE, V264, P884; WIHLE BA, 1994, NATURE, V371, P246; ZONA C, 1990, PROC R SOC SER B-BIO, V239, P119, DOI 10.1098/rspb.1990.0011	27	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15336	15340		10.1074/jbc.270.25.15336	http://dx.doi.org/10.1074/jbc.270.25.15336			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797521	hybrid			2022-12-25	WOS:A1995RE66600073
J	ZHANG, JT; LEE, CH; DUTHIE, M; LING, V				ZHANG, JT; LEE, CH; DUTHIE, M; LING, V			TOPOLOGICAL DETERMINANTS OF INTERNAL TRANSMEMBRANE SEGMENTS IN P-GLYCOPROTEIN SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANCE; MEMBRANE-PROTEINS; CHARGED RESIDUES; ORIENTATION; GENE; HOMOLOGY; CHANNEL	P-glycoprotein (Pgp) is a polytopic membrane protein responsible for multidrug resistance in cancer cells, Previously, we have used a coupled cell-free translation/translocation system to investigate the membrane orientation of Pgp sequences and have made the unexpected observation that predicted transmembrane (TM) segments from both the NH2-terminal and COOH-terminal halves inserted in microsomal membranes in two different orientations (Zhang, J.-T., Duthie, M., and Ling, V. (1993) J. Biol, Chem, 268, 15101-15110). How these topological forms of Pgp are regulated is not known, In the present study, we have used site-directed mutagenesis to investigate if the amino acids surrounding the internal TM segments of Pgp may affect their orientation, We discovered that the charged amino acids flanking TM4 are important in determining the membrane orientation of the NH2-terminal half molecule of Pgp, This is a novel observation demonstrating the existence of internal topogenic sequences in a mammalian polytopic membrane protein, These findings thus suggest A) that the topological structure of a mammalian polytopic membrane protein does not integrate into the membrane simply by following the lead of the first inserted TM segment but that internal TMs may have independent topogenic information and B) that the TM segments in a multi-spanning membrane protein may be more dynamic than have been previously anticipated, i.e. mutations in the amino acids surrounding internal TMs could drastically change the overall topology of the molecule.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto			Zhang, Jian-Ting/L-8334-2015					ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145; ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Childs S, 1994, Important Adv Oncol, P21; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P458; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; PARKS GD, 1990, CELL, V64, P777; SKACH WR, 1993, J BIOL CHEM, V268, P6903; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101; ZHANG JT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P191, DOI 10.1016/0005-2736(93)90405-O	26	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1742	1746		10.1074/jbc.270.4.1742	http://dx.doi.org/10.1074/jbc.270.4.1742			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829509	hybrid			2022-12-25	WOS:A1995QD20400042
J	CHIONO, M; MAHEY, R; TATE, G; COOPER, DMF				CHIONO, M; MAHEY, R; TATE, G; COOPER, DMF			CAPACITATIVE CA2+ ENTRY EXCLUSIVELY INHIBITS CAMP SYNTHESIS IN C6-2B GLIOMA-CELLS - EVIDENCE THAT PHYSIOLOGICALLY EVOKED CA2+ ENTRY REGULATES CA2+-INHIBITABLE ADENYLYL-CYCLASE IN NONEXCITABLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; INTRACELLULAR CALCIUM; NCB-20 CELLS; PROTEIN-KINASE; RELEASE; MOBILIZATION; RECEPTORS; CHANNELS; CLONING; VI	Elevation of cytosolic free Ca2+ inhibits the type VI adenylyl cyclase that predominates in C6-2B cells, However, it is not known whether there is any selective requirement for Ca2+ entry or release for inhibition of cAMP accumulation to occur, In the present study, the effectiveness of intracellular Ca2+ release evoked by three independent methods (thapsigargin, ionomycin, and UTP) was compared with the capacitative Ca2+ entry that was triggered by these treatments. In each situation, only Ca2+ entry could inhibit cAMP accumulation (La3+ ions blocked the effect); Ca2+ release, which was substantial in some cases, was without effect, A moderate inhibition, as was elicited by a modest degree of Ca2+ entry, could be rendered substantial in the absence of phosphodiesterase inhibitors. Such conditions more closely mimic the physiological situation of normal cells. These results are particularly significant, in demonstrating not only that Ca2+ entry mediates the inhibitory effects of Ca2+ on cAMP accumulation, but also that diffuse elevations in [Ca2+](i) are ineffective in modulating cAMP synthesis, This property suggests that, as with certain Ca2+-sensitive ion channels, Ca2+-sensitive adenylyl cyclases may be functionally colocalized with Ca2+ entry channels.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM 07063, GM 32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483, T32GM007063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; ALBERT PR, 1986, AM J PHYSIOL, V251, pC887, DOI 10.1152/ajpcell.1986.251.6.C887; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ALTIOK N, 1993, CELL SIGNAL, V5, P279, DOI 10.1016/0898-6568(93)90018-H; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; COOPER DMF, 1993, TRENDS PHARMACOL SCI, V14, P34, DOI 10.1016/0165-6147(93)90027-H; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; DORFLINGER LJ, 1984, ENDOCRINOLOGY, V114, P1208, DOI 10.1210/endo-114-4-1208; ERNEUX C, 1985, MOL CELL ENDOCRINOL, V43, P123, DOI 10.1016/0303-7207(85)90075-9; EVANS T, 1984, MOL PHARMACOL, V26, P395; GARRITSEN A, 1992, J NEUROCHEM, V59, P1630, DOI 10.1111/j.1471-4159.1992.tb10992.x; GARRITSEN A, 1992, J NEUROCHEM, V59, P190, DOI 10.1111/j.1471-4159.1992.tb08890.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LIN WW, 1992, J NEUROSCI, V12, P1077; LIN WW, 1993, MOL PHARMACOL, V44, P158; LIU CM, 1978, J BIOL CHEM, V253, P5892; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MEEKER RB, 1982, MOL PHARMACOL, V22, P310; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; Newsholme E. A., 1973, REGULATION METABOLIS; PEREIRA ME, 1988, ENDOCRINOLOGY, V122, P2232, DOI 10.1210/endo-122-5-2232; PIANET I, 1989, BIOCHEM BIOPH RES CO, V163, P1150, DOI 10.1016/0006-291X(89)92341-3; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZGOMBICK JM, 1993, MOL PHARMACOL, V44, P575; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P9335, DOI 10.1073/pnas.90.20.9335	49	157	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1149	1155		10.1074/jbc.270.3.1149	http://dx.doi.org/10.1074/jbc.270.3.1149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836373	hybrid			2022-12-25	WOS:A1995QB15600028
J	DEBIE, I; SAVARIA, D; ROEBROEK, AJM; DAY, R; LAZURE, C; VANDEVEN, WJM; SEIDAH, NG				DEBIE, I; SAVARIA, D; ROEBROEK, AJM; DAY, R; LAZURE, C; VANDEVEN, WJM; SEIDAH, NG			PROCESSING SPECIFICITY AND BIOSYNTHESIS OF THE DROSOPHILA-MELANOGASTER CONVERTASES DFURIN1, DFURIN1-CRR, DFURIN1-X, AND DFURIN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; PROHORMONE CONVERTASES; SUBTILISIN FAMILY; CDNA SEQUENCE; KEX2-LIKE ENDOPROTEASE; PROPROTEIN CONVERTASE; FUNCTIONAL EXPRESSION; PRO-PROTEIN; YEAST KEX2; IDENTIFICATION	Pro-protein and pro-hormone convertases are subtilisin/kexin-like enzymes implicated in the activation of numerous precursors by cleavage at sites mostly composed of pairs of basic amino acids. Six members of this family of enzymes have been identified in mammals and named furin (also called PACE), PC1 (also called PC3), PC2, PACE4, PC4, and PC5 (also called PC6), Multiple transcripts are produced for all the mammalian convertases, but only in the cases of PC4, PACE4, and PC5 does differential splicing result in the modification of the C-terminal sequence of these enzymes. A similar molecular diversity is also observed for the convertases of Hydra vulgaris, Caenorhabditis elegans, and Drosophila melanogaster. In the third species, two genes homologous to human furin called Dfur1 and Dfur2 have been identified. The Dfur1 gene undergoes differential splicing to generate three type I membrane-bound proteins called dfurin1, dfurin1-CRR, and dfurin1-X, which differ only in their C-terminal sequence. By using recombinant vaccinia viruses that express each of the dfurin proteins, we investigated the potential effect of the C-terminal domain on their catalytic specificities. For this purpose, these enzymes were coexpressed with the precursors pro-7B2, pro-opiomelanocortin, and pro-dynorphin in a number of cell lines, and the processed products obtained were characterized. Our studies demonstrate that these proteases display cleavage specificities similar to that of mammalian furin but not to that of PC2. In contrast, we noted significant differences in the biosynthetic fates of these convertases. Al dfurins undergo rapid removal of their transmembrane domain within the endoplasmic reticulum, resulting in the release of several truncated soluble forms. However, in the media of cells containing secretory granules, such as GH4C1 and AtT-20, dfurin1-CRR and dfurin2 predominate over dfurin1, whereas dfurin1-X is never detected. While pro-segment removal occurs predominantly in the trans-Golgi network for ah the dfurins, in the presence of brefeldin A, only dfurin1-CRR and dfurin2 can undergo partial zymogen cleavage. The conclusions drawn from the results of this study may well be applicable to the mammalian convertases PC4, PACE4, and PC5, which also display C-terminal sequence heterogeneity.	CLIN RES INST MONTREAL,JA DESEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DESEVE LAB NEUROPEPTIDES STRUCT & METAB,MONTREAL,PQ H2W 1R7,CANADA; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL LAB,B-3000 LOUVAIN,BELGIUM	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; KU Leuven			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BRESNAHAN PA, 1992, MECHANISMS INTRACELL, P225; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHUN JY, 1994, NEURON, V12, P831, DOI 10.1016/0896-6273(94)90336-0; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; DAY R, 1992, P NATL ACAD SCI USA, V88, P1320; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; Hruby D E, 1986, Methods Enzymol, V124, P295; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; MBIKAY M, 1994, GENOMICS, V20, P231, DOI 10.1006/geno.1994.1158; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; OUIMET T, 1993, FEBS LETT, V330, P343, DOI 10.1016/0014-5793(93)80901-6; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAQUET L, 1994, J BIOL CHEM, V269, P19279; PAQUET L, 1991, FEBS LETT, V294, P23, DOI 10.1016/0014-5793(91)81334-5; PETERS K, 1991, WORM BREEDERS GAZETT, V11, P28; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; ROEBROEK AJM, 1993, EMBO J, V12, P1853, DOI 10.1002/j.1460-2075.1993.tb05834.x; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; ROTH WW, 1993, ENDOCRINOL J, V1, P131; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WEHRLI M, 1993, MECH DEVELOP, V43, P21, DOI 10.1016/0925-4773(93)90020-X	60	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1020	1028		10.1074/jbc.270.3.1020	http://dx.doi.org/10.1074/jbc.270.3.1020			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836354	hybrid			2022-12-25	WOS:A1995QB15600009
J	DESILVA, DM; ASKWITH, CC; EIDE, D; KAPLAN, J				DESILVA, DM; ASKWITH, CC; EIDE, D; KAPLAN, J			THE FET3 GENE-PRODUCT REQUIRED FOR HIGH-AFFINITY IRON TRANSPORT IN YEAST IS A CELL-SURFACE FERROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LACCASE	The yeast FET3 gene is required for high affinity iron transport (Askwith, C., Eide, D., Ho, A. V., Bernard, P. S., Li, L., Davis-Kaplan, S., Sipe, D. M., and Kaplan, J. (1994) Cell 76, 403-410). The gene has extensive sequence homology to the family of multi-copper oxidases. In this communication, we demonstrate that the gene product is a cell surface ferroxidase involved in iron transport. Cells that contain a functional FET3 gene product exhibited an iron-dependent non-mitochondrial increase in oxygen consumption, Comparison of the rate of iron oxidation to O-2, consumption yielded an approximate value of 4:1, as predicted for a ferroxidase. Spheroplasts obtained from cells grown under low iron conditions also displayed an iron-dependent increase in O-2 consumption. Treatment of spheroplasts with trypsin or affinity-purified antibodies directed against the putative external ferroxidase domain of Fet3 had no effect on basal O-2 consumption but inhibited the iron-dependent increase in O-2 consumption. Anti-peptide antibodies directed against the cytosolic domain of Fet3 had no effect on O-2 consumption. These studies indicate that Fets is a plasma membrane ferroxidase required for high affinity iron uptake, in which the ferroxidase-containing domain is localized on the external cell surface.	UNIV UTAH,COLL MED,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132; UNIV MINNESOTA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,DULUTH,MN 55812	Utah System of Higher Education; University of Utah; University of Minnesota System; University of Minnesota Duluth					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK-5-30534, T32 DK07115] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BAO W, 1993, SCIENCE, V260, P672, DOI 10.1126/science.260.5108.672; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; EIDE D, 1992, J BIOL CHEM, V267, P20774; EIDE D, 1992, J GEN MICROBIOL, V138, P34; FOX TD, 1981, METHOD ENZYMOL, V194, P149; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; HARLOW E, 1988, ANTIBODIES LABORATOR; KOJIMA Y, 1990, J BIOL CHEM, V265, P15224; LEE RL, 1968, J CLIN INVEST, V47, P2958; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; OSAKI S, 1971, J BIOL CHEM, V246, P3018; RYDEN L, 1981, COPPER PROTEINS COPP, V3, P37; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	17	195	199	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1098	1101		10.1074/jbc.270.3.1098	http://dx.doi.org/10.1074/jbc.270.3.1098			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836366	hybrid			2022-12-25	WOS:A1995QB15600021
J	LOBELLO, M; BATTISTONI, A; MAZZETTI, AP; BOARD, PG; MURAMATSU, M; FEDERICI, G; RICCI, G				LOBELLO, M; BATTISTONI, A; MAZZETTI, AP; BOARD, PG; MURAMATSU, M; FEDERICI, G; RICCI, G			SITE-DIRECTED MUTAGENESIS OF HUMAN GLUTATHIONE TRANSFERASE P1-1 - SPECTRAL, KINETIC, AND STRUCTURAL-PROPERTIES OF CYS-47 AND LYS-54 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; CLASS-PI; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; CONFERS RESISTANCE; ACID-RESIDUES; EXPRESSION; IDENTIFICATION; INACTIVATION; RESOLUTION	In the human placental glutathione transferase, Cys 47 possesses, at physiological pH values, a pK(a) value of 4.2 and may exist as an ion pair with the protonated epsilon-amino group of Lys-54, Using site directed mutagenesis we investigate spectral, kinetic, and structural properties of Cys-47 and Lys-54 mutants. The results shown indicate that the thiolate ion detected at 229 nm should be assigned exclusively to Cys-47. The contribution of Lys-54 to the activation of Cys-47 is assessed by the spectral properties of the K54A mutant enzyme. The induced cooperativity toward glutathione, as a consequence of mutation of Lys-54 to alanine, clearly parallels that observed for the Cys-47 mutant enzymes (see the preceding paper (Ricci, G., Lo Bello, M., Caccuri, A. M., Pastore, A., Nuccetelli, M., Parker, M. W,, and Federici, G, (1995) J. Biol. Chem. 270, 1243-1248) and points out the importance of this electrostatic interaction in shaping the correct spatial arrangement for the binding of glutathione and in anchoring the flexible helix alpha 2. When this ion pair is disrupted, by mutation of either residue, the flexibility of this region could be greatly increased, causing helix alpha 2 to come in contact with the other subunit and generating a structural communication, which is the basis of the observed cooperativity.	UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA; SAITAMA MED SCH,DEPT BIOCHEM,MOROYAMA,SAITAMA 35004,JAPAN	University of Rome Tor Vergata; Australian National University; John Curtin School of Medical Research; Saitama Medical University			Battistoni, Andrea/A-4778-2016	Battistoni, Andrea/0000-0003-4085-7917; Ricci, Giorgio/0000-0002-7108-2846				BAKER RT, 1994, J BIOL CHEM, V269, P25381; BATIST G, 1986, J BIOL CHEM, V261, P5544; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BOARD PG, 1994, J BIOL CHEM, V268, P15655; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Habig W H, 1981, Methods Enzymol, V77, P398; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; KANO T, 1987, CANCER RES, V47, P5626; KONG KH, 1992, J BIOCHEM-TOKYO, V112, P725, DOI 10.1093/oxfordjournals.jbchem.a123965; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; PHILLIPS MF, 1993, BIOCHEM J, V294, P57, DOI 10.1042/bj2940057; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; RICCI G, 1989, J BIOL CHEM, V264, P5462; SCHAGGER H, 1987, ANAL BIOCHEM, V155, P83; SIMMONS PC, 1977, ANAL BIOCHEM, V82, P334; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TSUCHIDA S, 1989, CANCER RES, V49, P5225; VANOMMEN B, 1990, BIOCHEM J, V269, P609, DOI 10.1042/bj2690609; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	40	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1249	1253						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836387				2022-12-25	WOS:A1995QB15600042
J	MIURA, Y; KAWABATA, S; WAKAMIYA, Y; NAKAMURA, T; IWANAGA, S				MIURA, Y; KAWABATA, S; WAKAMIYA, Y; NAKAMURA, T; IWANAGA, S			A LIMULUS INTRACELLULAR COAGULATION INHIBITOR TYPE-2 - PURIFICATION, CHARACTERIZATION, CDNA CLONING, AND TISSUE LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; SERINE-PROTEASE ZYMOGEN; PLASMINOGEN-ACTIVATOR INHIBITOR; AMINO-ACID-SEQUENCE; BINDING PROTEIN; FACTOR-C; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; PROCLOTTING ENZYME; ELASTASE INHIBITOR	We described in a foregoing report findings on serpin, a serine protease inhibitor, newly identified in horseshoe crab (Tachypleus tridentatus) hemocytes and we name it limulus intracellular coagulation inhibitor. LICI (Miura, Y., Kawabata, S., and Iwanaga, S. (1994) J. Biol. Chem. 269, 542-547). This serpin specifically inhibits limulus lipopolysaccharide-sensitive serine protease, factor ($) over bar C. In ongoing studies on limulus serpin, we have found another inhibitor, LICI type-2 (LICI-2), which inhibits not only factor ($) over bar C (k(1) = 7.1 x 10(4) M(-1) s(-1)) but also limulus clotting enzyme (k(1) = 4.3 x 10(5) M(-1) s(-1)). LICI-2 inhibits mammalian serine proteases, including alpha-thrombin, salivary kallikrein, plasmin, and tissue plasminogen activator. The inactivation of plasmin is the most rapid (k(1) = 1.2 x 10(6) M(-1) s(-1)). The purified LICI-2 is a single chain glycoprotein with an apparent M(r) = 42,000. A cDNA for LICI-2 was isolated and the open reading frame coded for a mature protein of 386 amino acids, of which 160 residues were confirmed by peptide sequencing. Although LICI-2 shows significant sequence similarity to the previous limulus serpin, LTCI-1 (42% identity), LICI-2 contains a unique putative reactive site, -Lys-Ser-, distinct from that of LICI-1 (-Arg-Ser-). Northern blotting revealed expression of LICI-2 mRNA only in hemocytes, and not in heart, brain, stomach, intestine, coral gland, and skeletal muscle. The immunoblot of large and small granule components with antiserum against purified LICI-2 suggests that LICI-2 is stored specifically in large granules, as in the case of LICI-1, and is released in response to external stimuli. We propose that the LICIs be classified into a new subfamily of intracellular serpins, regulated secretory serpins.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University			Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1990, BIOL BULL, V178, P137, DOI 10.2307/1541972; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DUBIN A, 1992, J BIOL CHEM, V267, P6576; DUMONT JN, 1966, J MORPHOL, V119, P181, DOI 10.1002/jmor.1051190206; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HJORK I, 1986, PROTEASE INHIBITORS, P489; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KANOST MR, 1989, J BIOL CHEM, V264, P965; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MULLER EH, 1975, J CELL PHYSL, V86, P533; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; MUTA T, 1995, IN PRESS J BIOL CHEM, V270; NAKAMURA H, 1993, EUR J BIOCHEM, V214, P181; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Nei M., 1987, MOL EVOLUT GENET, P293; ORNBERG RL, 1981, J CELL BIOL, V90, P40, DOI 10.1083/jcb.90.1.40; PANNEKOEK H, 1987, EMBO J, V5, P25339; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; Sambrook J, 1989, MOL CLONING LABORATO; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; TAKAGI H, 1990, J BIOCHEM, V108, P372, DOI 10.1093/oxfordjournals.jbchem.a123208; TESCHAUER WF, 1993, EUR J BIOCHEM, V217, P519, DOI 10.1111/j.1432-1033.1993.tb18272.x; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WOO SLC, 1981, BIOCHEMISTRY-US, V20, P6437, DOI 10.1021/bi00525a024; YE RD, 1987, J BIOL CHEM, V262, P3718; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	53	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					558	565		10.1074/jbc.270.2.558	http://dx.doi.org/10.1074/jbc.270.2.558			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822280	hybrid			2022-12-25	WOS:A1995QB81600012
J	NAGPAL, S; ATHANIKAR, J; CHANDRARATNA, RAS				NAGPAL, S; ATHANIKAR, J; CHANDRARATNA, RAS			SEPARATION OF TRANSACTIVATION AND AP1 ANTAGONISM FUNCTIONS OF RETINOIC ACID RECEPTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X RECEPTOR; PROMOTER; CELLS; GENE; AP-1; DIFFERENTIATION; INTERLEUKIN-6; COLLAGENASE; SITE; FOS	Retinoic acid receptors (RARs) regulate gene expression either by directly binding to the RAR-responsive elements or by antagonizing the action of c-Jun/c-Fos (AP1). AP1 is involved in the expression of metalloproteases, cytokines and other factors which play critical roles in the turnover of extracellular matrix, inflammation and hyperproliferation in diseases such as psoriasis, rheumatoid arthritis and in tumor metastases. We demonstrate here that synthetic retinoids inhibit 12-O-tetradecanoylphorbol-14-acetate-induced transcription from the stromelysin AP1 motif through RAR alpha, -beta, and -gamma. Interestingly, these diaryl acetylenic retinoids, which are potent agonists only for RAR beta and -beta, but not for RAR alpha, in transactivation assays, are able to in hibit AP1-dependent gene expression through RAR alpha. Thus these analogs can differentially affect the transactivation and AP1 antagonistic functions of RAR alpha. These results demonstrate that the transactivation and AP1 antagonistic functions are separable, and it should be possible to develop retinoids that are completely specific for AP1 antagonism through all RARs. Furthermore, using an RAR-selective ligand, we also demonstrate the separation of ligand binding and API antagonism functions of RARs.	ALLERGAN PHARMACEUT INC,DEPT CHEM,RETINOID RES,IRVINE,CA 92713	AbbVie; Allergan	NAGPAL, S (corresponding author), ALLERGAN PHARMACEUT INC,DEPT BIOL,RETINOID RES,IRVINE,CA 92713, USA.		Nagpal, Sunil/A-8007-2009					ABERGEL RP, 1985, ARCH DERMATOL, V121, P632, DOI 10.1001/archderm.121.5.632; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BAILLY C, 1990, J INVEST DERMATOL, V94, P47, DOI 10.1111/1523-1747.ep12873342; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DE LUCA LM, 1991, FASEB J, V5, P2924; ESGLEYESRIBOT T, 1994, J AM ACAD DERMATOL, V30, P581, DOI 10.1016/S0190-9622(94)70066-4; GILLARD EF, 1993, CURR BIOL, V3, P185, DOI 10.1016/0960-9822(93)90269-T; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LOTAN R, 1991, CANCER BIOL, V2, P197; Mangelsdorf David J., 1994, P319; MEYSKENS FL, 1986, J AM ACAD DERMATOL, V15, P826, DOI 10.1016/S0190-9622(86)70240-5; Mitsuyasu Ronald T., 1993, Current Opinion in Oncology, V5, P835, DOI 10.1097/00001622-199309000-00011; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OBRIEN TG, 1975, CANCER RES, V35, P1662; OHTA A, 1987, ANN RHEUM DIS, V46, P357, DOI 10.1136/ard.46.5.357; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; ROMNEY SL, 1981, AM J OBSTET GYNECOL, V141, P890; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; TEELMANN K, 1989, PHARMACOL THERAPEUT, V40, P29, DOI 10.1016/0163-7258(89)90072-7; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YANGYEN HF, 1991, NEW BIOL, V3, P1206	36	155	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					923	927		10.1074/jbc.270.2.923	http://dx.doi.org/10.1074/jbc.270.2.923			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822331	hybrid			2022-12-25	WOS:A1995QB81600066
J	BORNER, C; UEFFING, M; JAKEN, S; PARKER, PJ; WEINSTEIN, IB				BORNER, C; UEFFING, M; JAKEN, S; PARKER, PJ; WEINSTEIN, IB			2 CLOSELY-RELATED ISOFORMS OF PROTEIN-KINASE-C PRODUCE RECIPROCAL EFFECTS ON THE GROWTH OF RAT FIBROBLASTS - POSSIBLE MOLECULAR MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTERS; NIH 3T3 CELLS; SUBCELLULAR-DISTRIBUTION; TUMOR PROMOTION; ACTIVATION; PHOSPHORYLATION; GENE; RECEPTOR; OVEREXPRESSION; EXPRESSION	We have previously reported that two closely related protein kinase C (PKC) isoforms, PKC alpha and PKC beta I, had divergent effects on the growth and transformation of the same parental R6 rat embryo fibroblast cell line (Housey, G. M., Johnson, M. D., Hsiao, W.-L. W., O'Brian, C. A., Murphey, J. P., Kirschmeier, P., and Weinstein, I. B. (1988) Cell 52, 343-354; Borner, C., Filipuzzi, I., Weinstein, I. B., and Imber, R. (1991) Nature 353, 78-80). Whereas cells that overexpress PKC beta I lost anchorage dependence, grew to higher saturation densities, and generated small tumors when injected into nude mice, none of these properties were seen with cells that overexpress PKC alpha. In fact, the latter cells grew even slower and to lower saturation densities as compared to control cells. Here we investigate possible molecular mechanisms underlying the reciprocal effects of PKC alpha and PKC beta I. Overexpression of both isoforms enhanced 12-O-tetradecanoyl phorbol-13 acetate-induced expression of the growth regulatory genes c-jun, c-myc, and collagenase and enhanced feedback inhibition of epidermal growth factor receptor binding and cellular levels of diacylglycerol. However, the cells overexpressing PKC beta I differed from those overexpressing PKC alpha by displaying a decreased requirement for growth factors and by the production of a mitogenic factor. Thus, the basis for enhanced growth and transformation of cells overexpressing PKC beta I may be the establishment of an autocrine growth factor loop. These findings may be relevant to the roles of specific isoforms of PKC in carcinogenesis and tumor growth.	COLUMBIA UNIV,CANC RES INST,NEW YORK,NY 10032; UNIV FRIBOURG,INST BIOCHEM,CH-1700 FRIBOURG,SWITZERLAND; INST CLIN MOLEC BIOL & TUMORIGENET,W-8000 MUNICH,GERMANY; W ALTON JONES SCI CTR,NEW YORK,NY 12946; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Columbia University; University of Fribourg; Cancer Research UK	BORNER, C (corresponding author), COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032, USA.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933	NCI NIH HHS [CA 02111] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; AMES BN, 1964, METHOD ENZYMOL, V8, P115; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAUERLE PA, 1988, CELL, V53, P211; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1992, PROTEIN KINASE C CUR, P297; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRINKWATER NR, 1990, CANCER CELL-MON REV, V2, P8; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; Hinrichs Reimer, 1992, Biological Chemistry Hoppe-Seyler, V373, P776; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P236; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LISKOVITCH M, 1991, BIOCHEM SOC T, V19, P402; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NICHOLS SG, 1992, J BIOL CHEM, V267, P2697; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROGUE P, 1990, J BIOL CHEM, V265, P4161; SOZERI O, 1992, ONCOGENE, V7, P2259; STANTON LW, 1983, NATURE, V308, P401; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; UEFFING M, 1991, J CELL BIOCHEM, V37, P168; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	57	113	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					78	86		10.1074/jbc.270.1.78	http://dx.doi.org/10.1074/jbc.270.1.78			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814423	hybrid			2022-12-25	WOS:A1995QA28700018
J	CHAKRAVARTI, S; HORCHAR, T; JEFFERSON, B; LAURIE, GW; HASSELL, JR				CHAKRAVARTI, S; HORCHAR, T; JEFFERSON, B; LAURIE, GW; HASSELL, JR			RECOMBINANT DOMAIN-III OF PERLECAN PROMOTES CELL ATTACHMENT THROUGH ITS RGDS SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; LAMININ-A CHAIN; BASEMENT-MEMBRANE; CORE PROTEIN; EXTRACELLULAR-MATRIX; IDENTIFICATION; BINDING; VISUALIZATION; FIBRONECTIN	Perlecan has been previously been shown to support attachment of a wide variety of cells through interactions of its core protein with the cell surface. The core protein domains involved in cell adhesion are, however, unknown. The laminin-like domain III of murine perlecan can contains an RGDS sequence and is a likely candidate for supporting integrin-mediated cell attachment. We made a cDNA construct corresponding to domain III and containing an in frame signal peptide at the 5' end as well as in frame a stop codon at the 3' end by using cDNA clones to perlecan. The construct was inserted into the pRC/CMV vector and transfected into HT1080 cells, and the secreted recombinant domain III, a 130-kDa protein, was purified from the medium. The size of proteolytic fragments produced by digestion with V8 protease as well as analysis of the rotary shadowed image of the recombinant protein indicated it was produced in a native conformation. Recombinant domain III coated on tissue culture dishes, supports adhesion of an epithelial-like mouse mammary tumor cell line MMT 060562 in a dose-dependent manner. This interaction was inhibited specifically by the RGDS synthetic peptide and intact perlecan, but not laminin. This domain III RGD-dependent cell attachment activity indicates a role for perlecan in integrin-mediated signaling.	UNIV PITTSBURGH,SCH MED,INST EYE & EAR,DEPT OPHTHALMOL,PITTSBURGH,PA 15213; CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,CLEVELAND,OH 44106; UNIV VIRGINIA,DEPT CELL BIOL,CHARLOTTESVILLE,VA 22908	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University; University of Virginia			Laurie, Gordon W/A-5244-2008	Laurie, Gordon W/0000-0002-5311-2650	NEI NIH HHS [R01 EY009747-08, P30 EY08098] Funding Source: Medline; NIGMS NIH HHS [GM45380] Funding Source: Medline; PHS HHS [FY09747] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009747, P30EY008098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045380] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENT B, 1990, EXP CELL RES, V187, P320, DOI 10.1016/0014-4827(90)90098-U; CLEMENT B, 1989, J BIOL CHEM, V264, P12467; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P512; Farquhar M. G., 1981, CELL BIOL EXTRACELLU, V1981, P335; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; HASSELL JR, 1993, ADV MOL CELL BIOL, V6, P69; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KALLUNKI P, 1992, J CELL BIOL, V116, P59; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LAURIE GW, 1988, AM J ANAT, V181, P320, DOI 10.1002/aja.1001810308; LAURIE GW, 1985, DEV BIOL, V108, P299, DOI 10.1016/0012-1606(85)90034-X; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PATTHY L, 1994, NEUROCHEM INT, V24, P301, DOI 10.1016/0197-0186(94)90108-2; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sambrook J, 1989, MOL CLONING LABORATO; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	32	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					404	409		10.1074/jbc.270.1.404	http://dx.doi.org/10.1074/jbc.270.1.404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814401	hybrid			2022-12-25	WOS:A1995QA28700064
J	GROEBE, DR; ABRAMSON, SN				GROEBE, DR; ABRAMSON, SN			LOPHOTOXIN IS A SLOW BINDING IRREVERSIBLE INHIBITOR OF NICOTINIC ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; NUMERICAL-INTEGRATION; CHOLINERGIC RECEPTOR; LIGAND-BINDING; ALPHA-SUBUNIT; AGONIST SITES; KINETICS; ANTAGONISTS; AFFINITY; TRANSITIONS	Lophotoxin and the bipinnatins are members of the lophotoxin family of marine neurotoxins, which covalently react with Tyr(190) in the alpha-subunits of the nicotinic acetylcholine receptor. Bipinnatin-A, -B, and -C are protoxins that have been shown to spontaneously convert from inactive to active toxins during preincubation in buffer. However, in this report, we show that preincubation of lophotoxin did not result in an increase in the subsequent rate of irreversible inhibition of nicotinic receptors, Thus, unlike the bipinnatins, lophotoxin does not appear to be an inactive protoxin. Lophotoxin preferentially inhibited one of the two acetylcholine-binding sites on the receptor, and this preference resulted from both a higher reversible affinity and a faster rate of irreversible inhibition at this site. Association of I-125-alpha-bungarotoxin in the presence of lophotoxin was analyzed to obtain the apparent reversible association and dissociation rate constants for lophotoxin. The apparent association rate constant of lophotoxin was approximately 10(6)-fold slower than expected for a diffusion-limited interaction, indicating that lophotoxin is a slow binding irreversible inhibitor. The kinetic constants that describe the interaction of lophotoxin with the receptor did not change in the presence of dibucaine, suggesting that, unlike agonists, the slow apparent association of lophotoxin does not result from a slow transition of the receptor to a desensitized conformation.	UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS029951, R29NS029951] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29951] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1991, J MED CHEM, V34, P1798, DOI 10.1021/jm00110a007; ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; ALLEN KN, 1989, BIOCHEMISTRY-US, V28, P8466, DOI 10.1021/bi00447a029; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; CHANDLER JP, 1972, COMPUT BIOMED RES, V5, P515, DOI 10.1016/0010-4809(72)90058-4; CONTRERAS ML, 1986, J PHARMACOL EXP THER, V239, P136; CULVER P, 1985, MOL PHARMACOL, V28, P436; CULVER P, 1984, J BIOL CHEM, V259, P3763; FENICAL W, 1981, SCIENCE, V212, P1512, DOI 10.1126/science.6112796; FRIEDEN C, 1993, TRENDS BIOCHEM SCI, V18, P58, DOI 10.1016/0968-0004(93)90056-S; GROEBE DR, 1994, J BIOL CHEM, V269, P8885; HAWKINSON JE, 1992, MOL PHARMACOL, V42, P1069; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2199, DOI 10.1073/pnas.86.7.2199; KARLIN A, 1967, J THEOR BIOL, V16, P306, DOI 10.1016/0022-5193(67)90011-2; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; LEJCZAK B, 1989, BIOCHEMISTRY-US, V28, P3549, DOI 10.1021/bi00434a060; LIUCHEN LY, 1990, MOL PHARMACOL, V37, P243; MAIN AR, 1964, SCIENCE, V144, P992, DOI 10.1126/science.144.3621.992; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOTULSKY HJ, 1984, MOL PHARMACOL, V25, P1; RAKITZIS ET, 1984, BIOCHEM J, V217, P341, DOI 10.1042/bj2170341; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SINE SM, 1982, J BIOL CHEM, V257, P8106; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1991, J BIOL CHEM, V266, P13679; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VAUQUELIN G, 1980, MOL PHARMACOL, V17, P163; WEILAND G, 1976, MOL PHARMACOL, V12, P1091; WEILAND G, 1977, J BIOL CHEM, V252, P7648; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WRIGHT AE, 1989, TETRAHEDRON LETT, V30, P3491, DOI 10.1016/S0040-4039(00)99421-8; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	36	22	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					281	286		10.1074/jbc.270.1.281	http://dx.doi.org/10.1074/jbc.270.1.281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814387	hybrid			2022-12-25	WOS:A1995QA28700045
J	MA, JX; YANG, ZR; CHAO, J; CHAO, L				MA, JX; YANG, ZR; CHAO, J; CHAO, L			INTRAMUSCULAR DELIVERY OF RAT KALLIKREIN-BINDING PROTEIN GENE REVERSES HYPOTENSION IN TRANSGENIC MICE EXPRESSING HUMAN TISSUE KALLIKREIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; URINARY KALLIKREIN; MUSCLE INVIVO; SYSTEMIC DELIVERY; DIRECT INJECTION; BLOOD-PRESSURE; EXCRETION; PURIFICATION; STABILITY; MYOBLASTS	The tissue kallikrein-kinin system has been postulated to play a role in blood pressure regulation. The activity of tissue kallikrein is controlled by a number of factors in vivo. Rat kallikrein-binding protein (RKBP) is a serine proteinase inhibitor which binds to and inhibits tissue kallikrein's activity in vitro. We have recently developed several hypotensive transgenic mouse Lines which express human tissue kallikrein. In order to investigate the role of RKBP in blood pressure regulation, we delivered the RKBP to these transgenic mice by intramuscular injection. Expression of the RKBP was detected in skeletal muscle by reverse transcription-polymerase chain reaction and Southern blot analysis at 10, 20, 30, and 40 days post-injection. Immunoreactive RKBP levels in the muscle and serum of these mice were quantified by a RKBP-specific enzyme-linked immunosorbent assay and Western blot analysis. The levels of RKBP mRNA and immunoreactive protein were detectable at 10 days post-injection and increased significantly at 20 and 30 days, During this period, RKBP delivery significantly increased systemic blood pressure in the kallikrein transgenic mice to a level comparable to that of normotensive control mice. The RKBP and vector DNA delivery had no effect on the blood pressure of normotensive control mice. No serum antibodies to RKBP or its DNA were detected in the mice 40 days post injection. These results suggest that the increase of systemic blood pressure by RKBP delivery in these hypotensive transgenic mice may be mediated by inhibiting tissue kallikrein activity.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425	Medical University of South Carolina					NHLBI NIH HHS [HL 44083, HL 29397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029397, R01HL044083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADER JL, 1985, AM J PHYSIOL, V248, pF396, DOI 10.1152/ajprenal.1985.248.3.F396; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BERRY TD, 1989, HYPERTENSION, V13, P3, DOI 10.1161/01.HYP.13.1.3; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; ELLIOT R, 1934, ENDOCRINOLOGY, V18, P462; GEIGER R, 1981, HOPPESEYLERS Z PHYSL, V365, pS27; GELLER RG, 1975, CIRC RES, V36, P103, DOI 10.1161/01.RES.36.6.103; GILKESON GS, 1993, J IMMUNOL, V151, P1353; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HANSEN E, 1991, FEBS LETT, V290, P73, DOI 10.1016/0014-5793(91)81229-2; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LINDPAINTNER K, 1994, J HYPERTENSION S3, V12, pS66; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA JX, 1993, BIOCHEM J, V292, P825, DOI 10.1042/bj2920825; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MARGOLIUS HS, 1971, LANCET, V2, P1063; MARGOLIUS HS, 1974, CIRC RES, V35, P820, DOI 10.1161/01.RES.35.6.820; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; Sambrook J, 1989, MOL CLONING LABORATO; WANG J, 1994, HYPERTENSION, V23, P236, DOI 10.1161/01.HYP.23.2.236; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; ZHOU GX, 1992, J BIOL CHEM, V267, P25873; ZINNER SH, 1978, CIRCULATION, V58, P908, DOI 10.1161/01.CIR.58.5.908	31	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					451	455		10.1074/jbc.270.1.451	http://dx.doi.org/10.1074/jbc.270.1.451			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814410	hybrid			2022-12-25	WOS:A1995QA28700071
J	PARLATI, F; DOMINGUEZ, M; BERGERON, JJM; THOMAS, DY				PARLATI, F; DOMINGUEZ, M; BERGERON, JJM; THOMAS, DY			SACCHAROMYCES-CEREVISIAE CNE1 ENCODES AN ENDOPLASMIC-RETICULUM (ER) MEMBRANE-PROTEIN WITH SEQUENCE SIMILARITY TO CALNEXIN AND CALRETICULIN AND FUNCTIONS AS A CONSTITUENT OF THE ER QUALITY-CONTROL APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; CHAPERONE; HOMOLOG; BIOGENESIS; SEPARATION; MOLECULES; VECTORS; GROWTH; CELLS	We have used a polymerase chain reaction strategy to identify in the yeast Saccharomyces cerevisiae genes of the mammalian calnexin/calreticulin family, and we have identified and isolated a single gene, CNE1, The protein predicted from the CNE1 DNA sequence shares some of the motifs with calnexin and calreticulin, and it is 24% identical and 31% similar at the amino acid level with mammalian calnexin, On the basis of its solubility in detergents and its lack of extraction from membranes by 2.5 M urea, high salt, and sodium carbonate at pH 11.5, we have established that Cne1p is an integral membrane protein, However, unlike calnexins, the predicted carboxyl-terminal membrane-spanning domain of Cne1p terminates directly, Furthermore, based on its changed mobility from 76 to 60 kDa after endoglycosidase H digestion Cne1p was shown to be N-glycosylated, Localization of the Cne1p protein by differential and analytical subcellular fractionation as well as by confocal immunofluorescence microscopy showed that it was exclusively located in the endoplasmic reticulum (ER), despite the lack of known ER retention motifs, Although six Ca2+-binding proteins were detected in the ER fractions, they were all soluble proteins, and Ca2+ binding activity has not been detected for Cne1p, Disruption of the CNE1 gene did not lead to inviable cells or to gross effects on the levels of secreted proteins such as alpha-pheromone or acid phosphatase. However, in CNE1 disrupted cells, there was an increase of cell surface expression of an ER retained temperature sensitive mutant of the alpha-pheromone receptor, ste2-3p, and also an increase in the secretion of heterologously expressed mammalian alpha(1)-antitrypsin. Hence, Cne1p appears to function as a constituent of the S, cerevisiae ER protein quality control apparatus.	MCGILL UNIV, DEPT ANAT & CELL BIOL, MONTREAL, PQ H3A 2B2, CANADA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, GENET GRP, MONTREAL, PQ H4P 2R2, CANADA	McGill University; National Research Council Canada	PARLATI, F (corresponding author), MCGILL UNIV, DEPT BIOL, 3640 UNIV ST, MONTREAL, PQ H3A 2B2, CANADA.		Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BANDLOW W, 1972, BIOCHIM BIOPHYS ACTA, V282, P105, DOI 10.1016/0005-2736(72)90315-X; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEVIRGILIO C, 1993, YEAST, V9, P185, DOI 10.1002/yea.320090209; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P187, DOI 10.1093/oxfordjournals.jbchem.a131434; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LENTER M, 1994, J BIOL CHEM, V269, P12263; Maniatis T., 1982, MOL CLONING; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PIND S, 1994, J BIOL CHEM, V269, P12784; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RILES L, 1993, GENETICS, V134, P81; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WISE JA, 1991, METHOD ENZYMOL, V194, P405	48	132	137	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					244	253		10.1074/jbc.270.1.244	http://dx.doi.org/10.1074/jbc.270.1.244			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814381	hybrid			2022-12-25	WOS:A1995QA28700040
J	VISAI, L; BOZZINI, S; RAUCCI, G; TONIOLO, A; SPEZIALE, P				VISAI, L; BOZZINI, S; RAUCCI, G; TONIOLO, A; SPEZIALE, P			ISOLATION AND CHARACTERIZATION OF A NOVEL COLLAGEN-BINDING PROTEIN FROM STREPTOCOCCUS-PYOGENES STRAIN-6414	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; FIBRONECTIN RECEPTOR; MEDIATES ADHESION; MEMBRANES; CHROMATOGRAPHY; ATTACHMENT; CARTILAGE; SEQUENCE; AFFINITY; COWAN-1	In this report we have analyzed the binding of collagen to Streptococcus pyogenes strain 6414. This binding was rapid, specific, and involved a limited number of receptor molecules (11,600 copies per cell). When the proteins in a streptococcal lysate were blotted onto a nitrocellulose filter and probed with I-125-labeled collagen, a prominent collagen-binding protein of 57 kDa was identified as well as minor 130-150-kDa components. The major 57-kDa protein was isolated by affinity chromatography on collagen-Sepharose followed by gel filtration chromatography. The 57-kDa protein purified from S. pyogenes was used to raise a monospecific antibody which also reacted with a collagen-binding protein of similar molecular size isolated from Streptococcus zooepidemicus. The two collagen-binding proteins from streptococci have a similar amino acid composition and isoelectric points. Isolated collagen-binding protein was specifically recognized by I-125-collagen in a solid-phase binding assay and displayed an affinity for the ligand quite similar to that exhibited by intact bacteria (K-d = 3.1 versus 3.5 x 10(-9) M, respectively). Surface-labeled bacteria attached to microtiter wells coated with different collagen types and the 57-kDa protein blocked the adhesion to collagen substrate. We propose that the 57-kDa protein is an adhesin involved in the attachment of streptococci to host tissues.	UNIV PAVIA,DEPT BIOCHEM,I-27100 PAVIA,ITALY; MENARINI SUD,I-00040 POMEZIA,ITALY; UNIV PAVIA,INST MED & PUBL HLTH,I-21100 VARESE,ITALY	University of Pavia; Menarini Group; University of Pavia			Visai, Livia/R-7397-2017; Toniolo, Antonio Q./B-4103-2015; Toniolo, Antonio/AAA-2845-2021	Visai, Livia/0000-0003-1181-3632; Toniolo, Antonio Q./0000-0003-3008-2126; 				ADAMSON ED, 1983, COLLAGEN HLTH DISEAS, P218; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRILES EB, 1982, EXP CELL RES, V138, P436, DOI 10.1016/0014-4827(82)90194-X; COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; EMODY L, 1989, J BACTERIOL, V171, P6674; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HOLDERBAUM D, 1987, J CLIN MICROBIOL, V25, P2258, DOI 10.1128/JCM.25.12.2258-2261.1987; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KOSTRZYNSKA M, 1989, FEMS MICROBIOL LETT, V59, P229; LANTZ MS, 1986, INFECT IMMUN, V54, P654, DOI 10.1128/IAI.54.3.654-658.1986; LOHLER J, 1984, CELL, V38, P597, DOI 10.1016/0092-8674(84)90514-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLLENHAUER J, 1983, EMBO J, V2, P45, DOI 10.1002/j.1460-2075.1983.tb01378.x; PATTI JM, 1992, J BIOL CHEM, V267, P4766; RAJA RH, 1990, INFECT IMMUN, V58, P2593, DOI 10.1128/IAI.58.8.2593-2598.1990; RUBIN K, 1981, CELL, V24, P463, DOI 10.1016/0092-8674(81)90337-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPEZIALE P, 1987, FEMS MICROBIOL LETT, V48, P47, DOI 10.1016/0378-1097(87)90133-9; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; STAATZ WD, 1989, J CELL BIOL, P1917; STRAWICH E, 1971, BIOCHEMISTRY-US, V10, P3905, DOI 10.1021/bi00797a017; SWITALSKI LM, 1984, J BIOL CHEM, V259, P3734; SWITALSKI LM, 1993, INFECT IMMUN, V61, P4119, DOI 10.1128/IAI.61.10.4119-4125.1993; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WESTERLUND B, 1989, MOL MICROBIOL, V3, P329, DOI 10.1111/j.1365-2958.1989.tb00178.x	31	32	32	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					347	353		10.1074/jbc.270.1.347	http://dx.doi.org/10.1074/jbc.270.1.347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814395	hybrid			2022-12-25	WOS:A1995QA28700055
J	WATANABE, Y; PERRINO, BA; CHANG, BH; SODERLING, TR				WATANABE, Y; PERRINO, BA; CHANG, BH; SODERLING, TR			IDENTIFICATION IN THE CALCINEURIN A SUBUNIT OF THE DOMAIN THAT BINDS THE REGULATORY B-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; CALMODULIN; DEPHOSPHORYLATION; NITROCELLULOSE; ANTIBODY; KINASE	Calcineurin (CaN) is the serine/threonine protein phosphatase (phosphatase 2B) that is activated by binding of Ca2+ to its B subunit and to calmodulin (CaM). This paper identifies residues between the catalytic region and the CaM-binding domain of the A subunit as the domain that binds the regulatory B subunit. A purified fusion protein containing residues 328-390 of the A subunit 1) binds CaN B subunit, and 2) inhibits (IC50 = 0.1 mu M) the in vitro stimulation of CaN A phosphatase activity by purified CaN B subunit. A synthetic peptide corresponding to residues 341-360 blocked the binding of CaN B to residues 328-390 in the fusion protein, so 4 hydrophobic residues within this region (Val(349)-Phe(350) and Phe(356)-Val(357)) were mutated to either Glu (E mutant) or Gin (Q mutant). The wild-type and mutant A subunits were expressed individually or coexpressed with B subunit in Sf9 cells, purified and characterized. The mutant A subunits were similar to wildtype A subunit in terms of basal phosphatase activity (1-3 nmol/min/mg) and activation by Mn2+/CaM. Addition of purified B subunit to purified wild-type A subunit at a 1:1 molar ratio gave a 40-fold increase in phosphatase activity whereas addition of B subunit to either of the mutant A subunits had no effect on phosphatase activity, even at a 3:1 molar excess of B subunit. Furthermore, when wild-type or mutant A subunits were coexpressed with B subunit and purified on CaM-Sepharose, the B subunit co-eluted with the wild-type A subunit but not with either mutant A subunit. These results demonstrate that residues 328-390 in the A subunit bind B subunit and that the mutated hydrophobic residues are essential.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University				Watanabe, Yasuo/0000-0003-2232-0091; Chang, Bill/0000-0003-3783-1820	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V257, P418; HUBBARD MJ, 1989, EUR J BIOCHEM, V185, P411, DOI 10.1111/j.1432-1033.1989.tb15130.x; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	22	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					456	460		10.1074/jbc.270.1.456	http://dx.doi.org/10.1074/jbc.270.1.456			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814411	hybrid			2022-12-25	WOS:A1995QA28700072
J	CIOSSEK, T; MILLAUER, B; ULLRICH, A				CIOSSEK, T; MILLAUER, B; ULLRICH, A			IDENTIFICATION OF ALTERNATIVELY SPLICED MESSENGER-RNAS ENCODING VARIANTS OF MDK1, A NOVEL RECEPTOR TYROSINE KINASE EXPRESSED IN THE MURINE NERVOUS	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; NEURAL DEVELOPMENT	GROWTH-FACTOR RECEPTOR; PROTO-ONCOGENE; W-LOCUS; GENE; MOUSE; FAMILY; MEMBERS; CLONING; CHICKEN; DNA	A novel member of the eck/eph family of receptor tyrosine kinases (RTKs), termed mouse developmental kinase 1 (MDK1), was identified and shown to be closely related to the Eek, Ehk1/Cek7, Ehk2, Cek4/Mek4/hek and Sek/Cek8 subfamily. Northern blot analysis revealed MDK1 mRNA transcripts of 6.8, 5.7, 4.0, 3.2 and 2.6 kb that encode apparent splice variants. Sequence analyses of MDK1 cDNA clones from adult mouse brain predict the existence of at least five isoforms, including two truncated receptor variants lacking the kinase domain. Northern blot and in situ hybridization analysis indicate that in the adult mouse MDK1 RNA expression is restricted to brain, testes and spleen. The distinct patterns of MDK1 gene expression during mouse development suggest an important role in the formation of neuronal structures and possibly other morphogenic processes.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Max Planck Society								BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Ito M, 1984, CEREBELLUM NEURAL CO; Jensen D, 1980, HUMAN NERVOUS SYSTEM; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROHEN JW, 1985, FUNKTIONELLE ANATOMI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1992, J BIOL CHEM, V267, P1470; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					97	108						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824284				2022-12-25	WOS:A1995QA98000012
J	KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T				KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T			GROWTH ENHANCEMENT OF NORMAL HUMAN KERATINOCYTES BY THE ANTISENSE OLIGONUCLEOTIDE OF RETINOBLASTOMA SUSCEPTIBILITY GENE	ONCOGENE			English	Article						RB; P53; ANTISENSE; KERATINOCYTES	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; P53 GENE; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; CYCLE PROGRESSION; BREAST-CANCER; FACTOR BETA-1	We have found that the growth of normal human keratinocytes, grown in serum-free medium, was significantly stimulated by the antisense oligonucleotide of retinoblastoma susceptibility gene (Rb). Normal human keratinocytes were exposed to phosphorothionate oligonucleotides which were complementary to translation initiation codon of Rb gene. The growth of keratinocytes was enhanced by the antisense, but not the sense, oligonucleotide of Rb gene in a dose-dependent manner from 1 to 10 mu M. The Rb antisense oligonucleotide, however, did not result in any appreciable change in transcription of the gene when examined by reverse-transcription polymerase chain reaction (RT-PCR) analysis or in the protein expression and the phosphorylation pattern when examined by immunoprecipitation and Western blotting.	UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011; HUH, Nam-ho/B-1613-2011; Koike, Manabu/AAP-3107-2021	Kuroki, Toshio/0000-0001-6369-4351; 				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALABRETTA B, 1991, CANCER RES, V51, P4505; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROOK T, 1991, ONCOGENE, V6, P873; Crouch R. J., 1982, NUCLEASES, P211; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1991, EUR J CANCER, V27, P1466, DOI 10.1016/0277-5379(91)90033-A; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MOLES JP, 1993, ONCOGENE, V8, P583; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RINA ZH, 1985, EMBO J, V4, P1251; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEELE C, 1993, CANCER RES, V53, P2330; STOREY A, 1991, NUCLEIC ACIDS RES, V19, P4109, DOI 10.1093/nar/19.15.4109; STRAUSS M, 1992, ONCOGENE, V7, P769; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YASUMOTO S, 1992, MOL PATHWAYS KINASES, P35; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					117	122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824264				2022-12-25	WOS:A1995QA98000014
J	QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI				QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI			INTERMOLECULAR ASSOCIATION AND TRANS-PHOSPHORYLATION OF DIFFERENT NEU-KINASE FORMS PERMIT SH2-DEPENDENT SIGNALING AND ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR FAMILY; NIH 3T3 CELLS; POINT MUTATION; MONOCLONAL-ANTIBODIES; TRANSMEMBRANE DOMAIN; PDGF RECEPTOR; LIVING CELLS; HUMAN-BREAST	The nea oncogene encodes a 185 kDa receptor tyrosine kinase, A single point mutation (Val664-->Glu) within the p185(neu) transmembrane region results in higher efficiency of receptor dimerization, constitutive activity of tyrosine kinase and cellular transformation, The oncogenic potential of this mutated form of p185(neu) (termed Tneu) can be inactivated by site-directed alteration of a lysine residue in the conserved catalytic domain. In this report, we have utilized the physical and functional interaction of a full-length kinase-deficient neu protein (T757) and truncated kinase-active Tneu forms to determine critical protein domains for Tneu oligomerization and the resultant biological consequences. Analysis of various truncated Tneu mutants confirmed that the transmembrane region was crucial for p185 dimerization. Receptor association facilitates intermolecular phosphorylation of kinase-deficient mutant T757 by truncated kinase-active p185 proteins, and the trans-phosphorylated kinase-deficient T757 was able to associate in vitro with proteins containing SH2 domains. Receptor-receptor interactions resulted in enhanced signal transduction potential and transformation of cell-lines co-expressing different neu-kinase forms. These studies emphasize a novel feature of protein-protein interaction and the functional significance of p185 dimerization, intermolecular phosphorylation and signaling which may result in cellular transformation.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,CTR RECEPTOR BIOL,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HACK N, 1993, J BIOL CHEM, V268, P26441; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEVEA CM, 1993, RECEPTOR, V3, P293; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MARGOLIS B, 1992, CELL GROWTH DIFFER, V7, P73; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MYERS JN, 1992, RECEPTOR, V2, P1; OTSU M, 1991, CELL, V65, P359; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1992, J BIOL CHEM, V267, P12266; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1993, UNPUB SCIENCE; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SELVA E, 1993, J BIOL CHEM, V268, P2250; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAMOTO T, 1992, J BIOL CHEM, P11337; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	58	34	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824275				2022-12-25	WOS:A1995QA98000025
J	KLUMPP, S; HANKE, C; DONELLADEANA, A; BEYER, A; KELLNER, R; PINNA, LA; SCHULTZ, JE				KLUMPP, S; HANKE, C; DONELLADEANA, A; BEYER, A; KELLNER, R; PINNA, LA; SCHULTZ, JE			A MEMBRANE-BOUND PROTEIN PHOSPHATASE TYPE 2C FROM PARAMECIUM-TETRAURELIA - PURIFICATION, CHARACTERIZATION, AND CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MOLECULAR-CLONING; MESSENGER-RNA; DEHYDROGENASE PHOSPHATASE; CELLULAR-REGULATION; CILIARY MEMBRANES; SPECIFICITY; LIVER; IDENTIFICATION; SEQUENCE	We isolated the first membrane-bound type 2C serine/threonine protein phosphatase from the ciliated protozoan Paramecium tetraurelia (PtPP2C). Three isozymes of 33, 32, and 31 kDa with a specific activity of 1 mu mol.min(-1).mg(-1) were purified from the ciliary membrane. Ah enzymatic properties including (a) insensitivity toward inhibitors of other protein phosphatase families such as okadaic acid and microcystin, (b) absolute requirement for divalent cat ions, and (c) substrate specificity tested with synthetic phosphopeptides were identical to mammalian PP2C enzymes and identified the PtPP2C as a canonical PP2C in spite of it being about 25% smaller, The NH2-terminal was blocked. Microsequencing of six tryptic peptides established a relationship to other PP2C enzymes. The PtPP2C gene was obtained using degenerate oligonucleotide primers and the polymerase chain reaction. The gene coded for a 33-kDa protein with 300 amino acids and had an (A+T) content of 62%, typical for this protozoan. Nine of 15 Gln residues are encoded by TAA, a universal stop codon which codes for Gln in Paramecium. A large truncation at the COOH-terminal is responsible for the smaller size of the PtPP2C. Only a single transcript of 1 kilobase was detected with a Northern blot indicating that the 32- and 31-kDa proteins were proteolytic products of the 33-kDa enzyme. Sequence comparisons with PP2C enzymes from rat, rabbit, yeast, Arabidopsis, and Leishmania defined a highly diverged enzyme family which shares three conserved domains, I, II, and III, accounting for about 25% of the primary structure. We demonstrated further that the distances between domains I/II and II/III are very similar in all PP2C enzymes (9-13 and 74-80 amino acids, respectively). However, the amino acid sequences of the spacer regions are unrelated. In addition, the COOH-terminal ends of 100-200 amino acids which comprise 30-50% of the enzyme, display no identity. A dendrogramm shows that PtPP2C surprisingly is most closely related to the mammalian PP2C, and enzymes from Leishmania, Arabidopsis, and yeast are more distant relatives.	UNIV TUBINGEN,FAC CHEM & PHARM,D-72076 TUBINGEN,GERMANY; UNIV PADUA,DIPARTIMENTO CHIM BIOL,I-35121 PADUA,ITALY; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Eberhard Karls University of Tubingen; University of Padua; European Molecular Biology Laboratory (EMBL)								ADOUTTE A, 1980, J CELL BIOL, V84, P717, DOI 10.1083/jcb.84.3.717; AEBERSOLD R, 1990, ADV ELECTROPHORESIS, P81; AGOSTINIS P, 1987, J BIOL CHEM, V262, P1060; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRAUTIGAN DL, 1986, J BIOL CHEM, V261, P4924; BURNS JM, 1994, J BIOL CHEM, V268, P17155; CARON F, 1985, NATURE, V314, P185, DOI 10.1038/314185a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FOULKES JG, 1981, FEBS LETT, V130, P197, DOI 10.1016/0014-5793(81)81118-0; GOUY M, 1989, MOL BIOL EVOL, V6, P109; HINRICHSEN RD, 1992, P NATL ACAD SCI USA, V89, P8601, DOI 10.1073/pnas.89.18.8601; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KLUMPP S, 1990, J CHROMATOGR, V521, P179, DOI 10.1016/0021-9673(90)85042-T; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MIESKES G, 1984, EUR J BIOCHEM, V140, P375, DOI 10.1111/j.1432-1033.1984.tb08112.x; OHISHI S, 1992, TOHOKU J EXP MED, V168, P279, DOI 10.1620/tjem.168.279; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; THIELE J, 1982, EUR J CELL BIOL, V28, P3; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G	36	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32774	32780						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806499				2022-12-25	WOS:A1994QA63800012
J	LILJELUND, P; GHOSH, P; VANDENPOL, AN				LILJELUND, P; GHOSH, P; VANDENPOL, AN			EXPRESSION OF THE NEURAL AXON ADHESION MOLECULE L1 IN THE DEVELOPING AND ADULT-RAT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL NILE GLYCOPROTEIN; CEREBELLAR GRANULE CELLS; X-LINKED HYDROCEPHALUS; 2ND MESSENGER SYSTEMS; NEURITE OUTGROWTH; N-CAM; BIOCHEMICAL-CHARACTERIZATION; NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; POSTNATAL-DEVELOPMENT	L1 is a developmentally regulated adhesion molecule that may play a role in some aspects of axonal guidance. With Northern blots we find peak expression of L1 RNA at postnatal day 1 (P1) in the developing rat brain. Western blots show a peak of protein on P15. The major form of L1 is 200 kDa, but lower molecular mass forms are found including 140 and 80 kDa, representing, respectively, the extracellular and intracellular regions of L1. Ah molecular mass forms of L1 change during development. Although expressed at lower levels than during development, L1 is found in all brain regions in the adult rat. Different regions of the brain show differential expression and regulation of L1 and its peptide fragments. For instance, the hypothalamus showed an enhanced L1-80/L1-200 ratio at P10 and P15 relative to that expressed by cerebellum and hippocampus. Cerebellar granule cells in culture showed strong L1-200 and almost no L1-60, 80, or -140, in contrast to the intact cerebellum at the same age, which showed weaker L1-200 and strong L1-60, -80, and -140. Control experiments indicated that the L1 proteolytic cleavage found in different developing brain regions occurred in vivo and was not a result of sample preparation. The amount of L1-200 in cultured granule cells was proportional to the measured length of the growing axon. Neuronal activity (increased with 25 mM K+, 100 mu m N-methyl-D-aspartate, and 100 mu m 4-aminopyridine) enhanced L1 transcription and translation. Together, these data suggest differential regulation of L1 expression and proteolytic cleavage specific for developmental ages and brain regions.	YALE UNIV,SCH MED,NEUROSURG SECT,NEW HAVEN,CT 06510	Yale University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010174, R01NS016296] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16296, NS10174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; ALTMAN J, 1982, EXP BRAIN RES S, V6, P8; APPEL F, 1993, J NEUROSCI, V13, P4764; ASOU H, 1992, NEUROREPORT, V3, P481, DOI 10.1097/00001756-199206000-00006; ASOU H, 1992, J CELL PHYSIOL, V153, P313, DOI 10.1002/jcp.1041530211; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BALAZS R, 1990, NEUROSCIENCE, V37, P251, DOI 10.1016/0306-4522(90)90211-L; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; BUYUKUYSAL RL, 1990, J NEUROCHEM, V54, P1302, DOI 10.1111/j.1471-4159.1990.tb01963.x; CHUONG CM, 1984, J NEUROSCI, V4, P2354; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FISCHER G, 1986, J NEUROSCI, V6, P605; GAARDSVOLL H, 1991, FEBS LETT, V294, P94, DOI 10.1016/0014-5793(91)81350-H; GALLO V, 1987, J NEUROSCI, V7, P2203; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P267, DOI 10.1073/pnas.81.1.267; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; JOUET M, 1993, NAT GENET, V4, P331, DOI 10.1038/ng0893-331; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; LEGIUS E, 1994, CLIN GENET, V45, P165; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINNEMANN D, 1988, DEV NEUROSCI-BASEL, V10, P34, DOI 10.1159/000111953; MCGUIRE JC, 1978, CELL, V15, P357, DOI 10.1016/0092-8674(78)90004-1; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1992, J BIOL CHEM, V267, P10752; MOGENSEN NW, 1990, DEV BRAIN RES, V54, P81, DOI 10.1016/0165-3806(90)90067-9; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MURRAY BA, 1986, J CELL BIOL, V103, P1431, DOI 10.1083/jcb.103.4.1431; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NYBROE O, 1990, INT J DEV NEUROSCI, V8, P273, DOI 10.1016/0736-5748(90)90033-X; PERIDES G, 1993, J BIOL CHEM, V268, P25197; PERIDES G, 1994, J BIOL CHEM, V269, P765; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PERSOHN E, 1990, J NEUROCYTOL, V19, P807, DOI 10.1007/BF01186812; PRATTIS SM, 1994, J COMP PATHOL, V110, P253, DOI 10.1016/S0021-9975(08)80278-2; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RATHJEN FG, 1984, EMBO J, V3, P1; RATHJEN FG, 1988, TRENDS NEUROSCI, V11, P183, DOI 10.1016/0166-2236(88)90116-6; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; RICHTERLANDSBER.C, 1988, CELL TISSUE RES, V252, P181; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SADOUL K, 1988, J NEUROCHEM, V50, P510, DOI 10.1111/j.1471-4159.1988.tb02941.x; SALTON SRJ, 1983, J NEUROSCI, V3, P441; SALTON SRJ, 1983, J NEUROSCI, V3, P2420; SALZER JL, 1989, DEV NEUROSCI-BASEL, V11, P377, DOI 10.1159/000111914; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; STALLCUP WB, 1985, P NATL ACAD SCI USA, V82, P1276, DOI 10.1073/pnas.82.4.1276; STALLCUP WB, 1985, J NEUROSCI, V5, P1090; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; TIBBS GR, 1989, J NEUROCHEM, V52, P201, DOI 10.1111/j.1471-4159.1989.tb10917.x; VACCARINO FM, 1992, MOL BRAIN RES, V12, P233, DOI 10.1016/0169-328X(92)90089-T; VANDENPOL AN, 1985, SCIENCE, V228, P332, DOI 10.1126/science.2858916; VANDENPOL AN, 1993, J COMP NEUROL, V332, P237, DOI 10.1002/cne.903320208; VANDENPOL AN, 1994, J NEUROSCI, V14, P3816; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WALLACE DR, 1993, NEUROCHEM RES, V18, P1271, DOI 10.1007/BF00975047; WILLE W, 1981, J NEUROCHEM, V37, P443, DOI 10.1111/j.1471-4159.1981.tb00475.x; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WOLFF JM, 1988, J BIOL CHEM, V263, P11943; WOLFF JM, 1987, EUR J BIOCHEM, V168, P551, DOI 10.1111/j.1432-1033.1987.tb13453.x	81	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32886	32895						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806515				2022-12-25	WOS:A1994QA63800028
J	SHAN, SO; ARMSTRONG, RN				SHAN, SO; ARMSTRONG, RN			RATIONAL RECONSTRUCTION OF THE ACTIVE-SITE OF A CLASS-MU GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ISOENZYME 3-3; AZAARENE OXIDES; COMPLEX; PI; RESOLUTION; ARENE; S-(4-BROMO-2,3-DIOXOBUTYL)GLUTATHIONE; STEREOSELECTIVITY; IDENTIFICATION	Isoenzymes 3-3 and 4-4 of the mu class glutathione S-transferases share 77% sequence identity but have distinctly different catalytic properties. Analysis of the crystal structure of isoenzyme 3-3 in complex with the diastereomeric products of the addition of GSH to phenanthrene 9,10-oxide (Ji, X., Johnson, W. W., Sesay, M. A, Dickert, L., Prasad, S. M., Ammon, H. L., Armstrong, R. N., and Gilliland, G. L. (1994) Biochemistry 33, 1043-1052) reveals that 3 residues that are in van der Waals contact with the xenobiotic portion of the product are different in the type 4 subunit. The three mutations, V9I, I111A, and S209A, have been introduced into isoenzyme 3-3 individually and in combination in an attempt to minimally reconstruct the active site of the enzyme to mimic the type 4 subunit in structure and function. The results suggest that the V9I mutation is an important determinant in the stereoselectivity of the enzyme toward enones and epoxides. The I111A mutation increases the catalytic efficiency of the enzyme toward para-substituted 4-phenyl-3-buten-2-ones (XPBO) as measured by k(cat)/K-m(XPBO) but does not affect k(cat). The S209A mutation has no effect on catalysis. The double and triple mutants V9I/I111A and V9I/I111A/S209A exhibit both a high stereoselectivity and high k(cat)/K-m(XPBO) comparable to that of isoenzyme 4-4. Analysis of substituent effects on the kinetics and stereoselectivity of the enzyme toward the enone substrates suggests that the mechanistic bases for the catalytic behavior of the isoenzyme 4-4 and the reconstructed mutants are not identical. The results provide functional evidence for the catalytic importance of specific residues previously identified by x-ray crystallography.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NIGMS NIH HHS [GM30910] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BOEHLERT CC, 1984, BIOCHEM BIOPH RES CO, V121, P980, DOI 10.1016/0006-291X(84)90773-3; BRUICE PY, 1976, J AM CHEM SOC, V98, P2973, DOI 10.1021/ja00426a049; Cleland W W, 1979, Methods Enzymol, V63, P103; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; FUJITA T, 1964, J AM CHEM SOC, V86, P5175, DOI 10.1021/ja01077a028; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; Hansch C, 1979, SUBSTITUENT CONSTANT; HIGUCHI R, 1991, PCR TECHNOLOGY, P61; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KUBO Y, 1989, CHEM RES TOXICOL, V2, P144, DOI 10.1021/tx00009a003; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WANG RW, 1992, J BIOL CHEM, V267, P19866; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZHANG PH, 1991, J BIOL CHEM, V266, P19475; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121; ZHANG PH, 1992, BIOCHEMISTRY-US, V31, P10185, DOI 10.1021/bi00157a005	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32373	32379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798237				2022-12-25	WOS:A1994PX30400055
J	SJOLING, S; ERIKSSON, A; GLASER, E				SJOLING, S; ERIKSSON, A; GLASER, E			A HELICAL ELEMENT IN THE C-TERMINAL DOMAIN OF THE N-PLUMBAGINIFOLIA F-1-BETA PRESEQUENCE IS IMPORTANT FOR RECOGNITION BY THE MITOCHONDRIAL PROCESSING PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPINACH LEAF MITOCHONDRIA; YEAST MITOCHONDRIA; PROTEIN IMPORT; ALDEHYDE DEHYDROGENASE; PRECURSOR; ENZYME; PURIFICATION; REDUCTASE; POTATO	The mitochondrial processing peptidase (MPP) in lower eucaryots and mammals is a matrix enzyme, whereas MPP in plants constitutes an integral part of the be, complex of the respiratory chain, The isolated spinach leaf be, complex catalyzes cleavage of the precursor of Nicotiana plumbaginifolia F1 beta subunit of the ATP synthase, resulting in a production of mature protein and a presequence that consists of 54 amino acids, A synthetic peptide derived from the C-terminal part of the presequence, containing 17 amino acids with a helical structural element, p-F-1 beta(38-54), was an efficient inhibitor of the processing, whereas a peptide derived from the N-terminal part of the presequence, p-F-1 beta(1-18), was much less effective, ATIII, a helical peptide derived from antithrombin III, was not recognized by MPP. Synthetic peptides corresponding to 4, 6, and 11 amino acids of the C terminus of the presequence, p-F-1 beta(51-54), p-F-1 beta(49-54), and p-F-1 beta(44-54) were almost completely inert, Competition studies show that MPP recognizes the C-terminal domain of the presequence rather than the N-terminal domain, Furthermore, the alpha-helical element of the C-terminal domain is shown to be required for the recognition event.	UNIV STOCKHOLM,DEPT BIOCHEM,ARRHENIUS LABS NAT SCI,S-10691 STOCKHOLM,SWEDEN	Stockholm University								ARRETZ M, 1994, J BIOL CHEM, V269, P4959; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P404; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHU TW, 1989, J BIOL CHEM, V264, P9552; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; HAMASUR B, 1990, PHYSIOL PLANTARUM, V78, P367, DOI 10.1111/j.1399-3054.1990.tb09050.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SHULTE U, 1989, NATURE, V339, P147; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANG Y, 1993, J BIOL CHEM, V268, P4759; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG M, 1991, J BIOL CHEM, V266, P6416	29	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32059	32062						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798199				2022-12-25	WOS:A1994PX30400010
J	TAKEUCHI, Y; KODAMA, Y; MATSUMOTO, T				TAKEUCHI, Y; KODAMA, Y; MATSUMOTO, T			BONE-MATRIX DECORIN BINDS TRANSFORMING GROWTH-FACTOR-BETA AND ENHANCES ITS BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT TGF-BETA; SULFATE PROTEOGLYCANS; OSTEOBLASTIC CELLS; PURIFICATION; COMPLEX; IDENTIFICATION; PROTEINS; FORMS	In an effort to clarify the regulation of distribution and actions of transforming growth factor (TGF)-beta in bone, TGF-beta 1 binding to extracted bone matrix proteins and the influence of such binding on TGF-beta 1 actions were examined. In-gel binding of I-125-TGF-beta 1 using extracts from mineralized bovine bone matrix demonstrated that I-125-TGF-beta 1 was almost exclusively bound to a proteoglycan, decorin. The binding was via the core protein of decorin. Scatchard analysis of the binding of I-125-TGF-beta 1 to immobilized decorin purified from osteoblastic MC3T3-E1 cell conditioned medium revealed that there were two specific binding sites with high and low affinities for TGF-beta 1 (K-d = 0.3 and 5 nM, respectively). The addition of decorin along with TGF-beta 1 enhanced the inhibitory effect of TGF-beta 1 on MC3T3-E1 cell proliferation. Decorin in itself did not affect their proliferation. These cells possessed types I and IZ TGF-P receptors and betaglycan, and the addition of decorin increased the binding of I-125-TGF-beta 1 to all these receptors. These results demonstrate that the core protein of decorin specifically binds TGF-beta 1 with high affinities and that the binding of TGF-beta 1 to decorin increases TGF-beta 1 binding to its receptors and enhances its bioactivity. Because TGF-beta is released by bone resorption along with matrix proteins, including decorin, and because it stimulates the synthesis of these proteins, it is suggested that the binding and enhancement of the activities of TGF-beta by decorin may play a role in maintaining bone formation during bone remodeling process.			TAKEUCHI, Y (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.							BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FUKUSHIMA D, 1993, J BIOL CHEM, V268, P22710; GEHRONROBEY P, 1987, J CELL BIOL, V105, P457; HARADA S, 1991, J BONE MINER RES, V6, P903; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; RITTER NM, 1992, J BONE MINER RES, V7, P877; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAKEUCHI Y, 1989, J BIOL CHEM, V264, P18407; TAKEUCHI Y, 1992, ARCH BIOCHEM BIOPHYS, V298, P371, DOI 10.1016/0003-9861(92)90424-U; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P821; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	28	182	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32634	32638						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798269				2022-12-25	WOS:A1994PX30400091
J	LEEYOON, D; EASTON, D; MURAWSKI, M; BURD, R; SUBJECK, JR				LEEYOON, D; EASTON, D; MURAWSKI, M; BURD, R; SUBJECK, JR			IDENTIFICATION OF A MAJOR SUBFAMILY OF LARGE HSP70-LIKE PROTEINS THROUGH THE CLONING OF THE MAMMALIAN 110-KDA HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEINS; NUCLEOLAR LOCALIZATION; BINDING DOMAIN; CELL; SIMILARITY; ACTIN; SITE; GLIA; AXON	A major mammalian heat shock protein of 110 kDa (hsp110) has long been observed, but has not been cloned. We have cloned the hamster cDNA for hsp110 and show that it hybridizes on a Northern blot to a 3.5-kilobase heat-inducible message in hamster and mouse. The hsp110 sequence was found to share an similar to 30-33% amino acid identity with members of the hsp70 family, most of which occurs in the conserved ATP-binding domain of these molecules. In addition, five sequences were found to be highly similar to hsp110. These are the sea urchin egg receptor for sperm (Foltz, K. R., Partin, J. S., and Lennarz, W. J. (1993) Science 259, 1421-1425) and additional sequences from human and Caenorhaditis elegans and two from yeast. The carboxyl-teminal two-thirds of hsp110 and these five related proteins contain a pattern of highly conserved regions of sequence unique to this group. A probe containing these conserved sequences was found to strongly cross-react on a Southern blot with genomic sequences from yeast to man. A Western blot analysis of several murine tissues indicates that hsp110 is constitutively expressed in all mouse tissues and is highly expressed in brain. Therefore, hsp110 belongs to a new category of large and structurally unique stress proteins that are the most distantly related known members of the hsp70 family.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; SUNY COLL BUFFALO, DEPT BIOL, BUFFALO, NY 14222 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; Buffalo State College			Easton, Douglas/A-9359-2009; Easton, Douglas/AAU-4216-2020	Easton, Douglas/0000-0003-4288-0774; Easton, Douglas/0000-0003-4288-0774; Burd, Randy/0000-0001-9195-2733	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LANDRY J, 1982, CANCER RES, V42, P2457; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MEIER UT, 1992, CELL, V70, P127; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Moore DD, 1995, GLOB MOB SURV; MUKAI H, 1993, GENE, V132, P57; OHLENDIECK K, 1994, J CELL BIOL, V125, P817, DOI 10.1083/jcb.125.4.817; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; POSNETT DN, 1989, METHOD ENZYMOL, V178, P739; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; Sambrook J, 1989, MOL CLONING LABORATO; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; SUBJECK JR, 1983, J CELL BIOL, V97, P1389, DOI 10.1083/jcb.97.5.1389; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOMASOVIC SP, 1983, RADIAT RES, V95, P399, DOI 10.2307/3576265; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; TYTELL M, 1987, AXONAL TRANSPORT, P473; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	43	107	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15725	15733		10.1074/jbc.270.26.15725	http://dx.doi.org/10.1074/jbc.270.26.15725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797574	hybrid			2022-12-25	WOS:A1995RG53800046
J	OHTA, T; KOBAYASHI, M; HIROSE, S				OHTA, T; KOBAYASHI, M; HIROSE, S			CLONING OF A CDNA FOR DNA SUPERCOILING FACTOR REVEALS A DISTINCTIVE CA2+-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II; TORSIONAL TENSION; ESCHERICHIA-COLI; HUMAN-CELLS; BINDING; SEQUENCE; PURIFICATION; POLYMERASE; EXPRESSION; REGIONS	DNA supercoiling factor is a protein capable of generating negative supercoils into a relaxed DNA in conjunction with eukaryotic DNA topoisomerase II. A cDNA clone encoding the Bombyx mori supercoiling factor has been isolated and characterized. The cDNA sequence contains an open reading frame of 322 amino acids rich in acidic residues. A local region of the predicted polypeptide shares a weak homology with the central portion of bacterial DNA gyrase A subunit. The cDNA sequence also predicts two direct repeats within the factor. Each repeat unit consists of a potential EF-hand domain. The factor contains three other potential EF-hand domains and actually binds Ca2+. Moreover, the supercoiling reaction has been shown to be activated by Ca2+. These results implicate Ca2+ in the control of the superhelical state of DNA.	NATL INST GENET,DEPT DEV GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,DEPT GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan			Hirose, Susumu/I-8865-2019					ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BATES AD, 1993, DNA TOPOLOGY, P73; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; JUPE ER, 1993, EMBO J, V12, P1067, DOI 10.1002/j.1460-2075.1993.tb05748.x; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MILLER KG, 1981, J BIOL CHEM, V256, P9334; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OHTA T, 1990, P NATL ACAD SCI USA, V87, P5307, DOI 10.1073/pnas.87.14.5307; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABUCHI H, 1993, BIOCHEM BIOPH RES CO, V192, P1432, DOI 10.1006/bbrc.1993.1576; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; WANG JC, 1992, TRANSCRIPTIONAL REGU, P1253	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15571	15575		10.1074/jbc.270.26.15571	http://dx.doi.org/10.1074/jbc.270.26.15571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797553	hybrid			2022-12-25	WOS:A1995RG53800023
J	KULIK, VP; KAVSAN, VM; VANSCHAIK, FMA; NOLTEN, LA; STEENBERGH, PH; SUSSENBACH, JS				KULIK, VP; KAVSAN, VM; VANSCHAIK, FMA; NOLTEN, LA; STEENBERGH, PH; SUSSENBACH, JS			THE PROMOTER OF THE SALMON INSULIN-LIKE GROWTH-FACTOR-I GENE IS ACTIVATED BY HEPATOCYTE NUCLEAR FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; INVITRO TRANSCRIPTION; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; TISSUE DISTRIBUTION; MOLECULAR-CLONING; XENOPUS-LAEVIS; ADULT-RAT; EXPRESSION; LIVER	Hepatocyte nuclear factor 1 (HNF-1) was found to have a potent stimulatory action on the activity of the promoter of the salmon insulin-like growth factor I (IGF-I) gene in transient transfection experiments. This liver-enriched transcription factor was shown to bind to an element in the proximal region of the promoter with distinct nucleotide sequence homology to the HNF-1 consensus binding sequence. Mutating this sequence to a variant no longer capable of HNF-1 binding resulted in the loss of the stimulatory effect. Since the sequence of the HNF-1 binding site is conserved in all mammalian, avian, and amphibian species from which the IGF-I promoter sequences have been derived to date, we propose that HNF-1 may be an important regulator of IGF-I gene expression in all of these species.	UNIV UTRECHT,PHYSIOL CHEM LAB,3508 TA UTRECHT,NETHERLANDS; UKRAINIAN ACAD SCI,INST MOLEC BIOL & GENET,DEPT BIOSYNTH NUCLEIC ACIDS,KIEV 252627,UKRAINE	Utrecht University; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BARTKOWSKI S, 1993, MOL CELL BIOL, V13, P421, DOI 10.1128/MCB.13.1.421; BAUMHUETER S, 1990, GENE DEV, V49, P372; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAO QP, 1989, MOL ENDOCRINOL, V3, P2005, DOI 10.1210/mend-3-12-2005; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUGUAY SJ, 1994, J MOL ENDOCRINOL, V12, P25, DOI 10.1677/jme.0.0120025; ELSHOLTZ HP, 1992, MOL ENDOCRINOL, V6, P515, DOI 10.1210/me.6.4.515; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoerlein Andreas, 1993, Biological Chemistry Hoppe-Seyler, V374, P419; JANSEN E, 1991, MOL CELL ENDOCRINOL, V78, P115, DOI 10.1016/0303-7207(91)90192-U; JANSEN E, 1992, BIOCHEM BIOPH RES CO, V187, P1219, DOI 10.1016/0006-291X(92)90433-L; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KAJIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1907, DOI 10.1210/mend-3-12-1907; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KAVSAN VM, 1994, DNA CELL BIOL, V13, P555, DOI 10.1089/dna.1994.13.555; KAVSAN VM, 1993, DNA CELL BIOL, V12, P729, DOI 10.1089/dna.1993.12.729; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOVAL A, 1994, DNA CELL BIOL, V13, P1057, DOI 10.1089/dna.1994.13.1057; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LI YC, 1994, GENE, V138, P257, DOI 10.1016/0378-1119(94)90819-2; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; ONO M, 1992, GENE, V226, P275; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; ROBERTS CT, 1986, J BIOL CHEM, V261, P25; ROLS MP, 1994, NUCLEIC ACIDS RES, V22, P540, DOI 10.1093/nar/22.3.540; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; Sambrook J, 1989, MOL CLONING LABORATO; SAWADAISHI K, 1988, MOL CELL BIOL, V8, P5179, DOI 10.1128/MCB.8.12.5179; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; STEENBERGH PH, 1991, BIOCHEM BIOPH RES CO, V175, P507, DOI 10.1016/0006-291X(91)91593-2; WARD A, 1992, INSULIN LIKE GROWTH, P45; WONG EA, 1989, DNA-J MOLEC CELL BIO, V8, P649, DOI 10.1089/dna.1.1989.8.649; YAMADA S, 1993, J BIOL CHEM, V268, P24361	45	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1068	1073		10.1074/jbc.270.3.1068	http://dx.doi.org/10.1074/jbc.270.3.1068			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836361	hybrid			2022-12-25	WOS:A1995QB15600016
J	SANCHEZ, HB; YIEH, L; OSBORNE, TF				SANCHEZ, HB; YIEH, L; OSBORNE, TF			COOPERATION BY STEROL REGULATORY ELEMENT-BINDING PROTEIN AND SP1 IN STEROL REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; POLYMERASE-II TRANSCRIPTION; NF-KAPPA-B; DNA-BINDING; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; SYNERGISTIC ACTIVATION; PROMOTER; SEQUENCE; IDENTIFICATION; EXPRESSION	Regulation of the low density lipoprotein (LDL) receptor promoter by cholesterol requires a well defined sterol regulatory site and an adjacent binding site for the universal transcription factor Sp1. These elements are located in repeats 2 and 3 of the wild type promoter, respectively, The experiments reported here demon strate that Sp1 participates in sterol regulation of the LDL receptor in an orientation-specific fashion. We pre sent data which suggest that sterol regulatory element binding protein (SREBP) increases the binding of Sp1 to the adjacent repeat 3 sequence. We also demonstrate that SREBP and Sp1 synergistically activate expression from the LDL receptor promoter inside the cell by cotransfecting expression vectors encoding each protein into Drosophila tissue culture cells that are devoid of endogenous Sp1. In addition, other transcription factor sites were unable to substitute for Sp1 in sterol regulation when placed next to the SREBP-binding site, These studies together with recent data from others provide the basis of a working model for sterol regulation of the LDL receptor promoter, The presence of Sp1 sites in several other regulated promoters suggests that this universal transcription factor has been recruited to participate in many regulatory responses possibly by a similar mechanism.			SANCHEZ, HB (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.							BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, SCIENCE, V242, P540; BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COURNEY AJ, 1988, CELL, V59, P827; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DYNAN WS, 1993, CELL, V35, P79; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIL G, 1988, J BIOL CHEM, V263, P19009; GILL G, 1994, P NATL ACAD SCI USA, P192; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUWAHARA J, 1993, BIOCHEMISTRY-US, V32, P5994, DOI 10.1021/bi00074a010; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSBORNE TF, 1992, J BIOL CHEM, V267, P18973; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PTASHNE M, 1992, GENETIC SWITCH, P143; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1994, J BIOL CHEM, V209, P17267; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SMITH JR, 1990, THESIS U TEXAS SW ME; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P1	52	276	276	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1161	1169		10.1074/jbc.270.3.1161	http://dx.doi.org/10.1074/jbc.270.3.1161			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836375	hybrid			2022-12-25	WOS:A1995QB15600030
J	HANAKAM, F; ECKERSKORN, C; LOTTSPEICH, F; MULLERTAUBENBERGER, A; SCHAFER, W; GERISCH, G				HANAKAM, F; ECKERSKORN, C; LOTTSPEICH, F; MULLERTAUBENBERGER, A; SCHAFER, W; GERISCH, G			THE PH-SENSITIVE ACTIN-BINDING PROTEIN HISACTOPHILIN OF DICTYOSTELIUM EXISTS IN 2 ISOFORMS WHICH BOTH ARE MYRISTOYLATED AND DISTRIBUTED BETWEEN PLASMA-MEMBRANE AND CYTOPLASM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; GROWTH-FACTOR; DISCOIDEUM	The histidine-rich protein hisactophilin is known to be associated with the inner surface of the plasma membrane and to be present as a soluble protein in the cytoplasm of Dictyostelium discoideum cells. Mass spectrometry of hisactophilin from the cytosol or extracted from a membrane fraction showed that none of the hisactophilin purified from D. discoideum cells had the mass predicted from the known cDNA-derived amino acid sequence of the protein. Electrospray mass spectrometry and Liquid secondary ion mass spectrometry of tryptic fragments separated by reversed-phase high performance liquid chromatography (HPLC) identified the most hydrophobic peptide as a myristoylated fragment from the N terminus of hisactophilin, Taken together the analytical data, it is concluded that all hisactophilin in D. discoideum cells is N terminally modified by myristoylation. By reversed-phase HPLC, two isoforms of hisactophilin, HsI and HsII, were recovered from the cytosolic as well as the membrane fraction of D. discoideum cells. Whereas the masses of HsI fragments produced by trypsin fit into the previously published sequence of hisactophilin (myristoylation considered), HsII is another protein distinguished from HsI by several amino acid exchanges. HsI and HsII can form homo- and heterodimers by disulfide bridges. Hisactophilin is phosphorylated in vivo. Both isoforms proved to be substrates of membrane-associated threonine/serine kinase from D. discoideum, which may regulate the interaction of hisactophilin with the plasma membrane.			HANAKAM, F (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Müller-Taubenberger, Annette/AAM-3671-2021	Muller-Taubenberger, Annette/0000-0003-1163-9232				BARTH A, 1994, J CELL BIOL, V124, P205, DOI 10.1083/jcb.124.1.205; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; DAVIES L, 1993, CELL, V75, P321, DOI 10.1016/0092-8674(93)80073-N; GERISCH G, 1993, SYM SOC EXP BIOL, V47, P297; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; HITT AL, 1994, J CELL BIOL, V126, P1433, DOI 10.1083/jcb.126.6.1433; HITT AL, 1994, J CELL BIOL, V126, P1421, DOI 10.1083/jcb.126.6.1421; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; LESSEL J, 1990, THESIS U BONN; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MALCHOW D, 1972, EUR J BIOCHEM, V28, P136, DOI 10.1111/j.1432-1033.1972.tb01894.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBAN MB, 1989, THESIS U TUBINGEN; WALKER F, 1993, J BIOL CHEM, V268, P19552; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	25	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					596	602		10.1074/jbc.270.2.596	http://dx.doi.org/10.1074/jbc.270.2.596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822284	hybrid			2022-12-25	WOS:A1995QB81600017
J	SUPAKAR, PC; JUNG, MH; SONG, CS; CHATTERJEE, B; ROY, AK				SUPAKAR, PC; JUNG, MH; SONG, CS; CHATTERJEE, B; ROY, AK			NUCLEAR FACTOR KAPPA-B FUNCTIONS AS A NEGATIVE REGULATOR FOR THE RAT ANDROGEN RECEPTOR GENE AND NF-KAPPA-B ACTIVITY INCREASES DURING THE AGE-DEPENDENT DESENSITIZATION OF THE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; P65 SUBUNIT; PROMOTER; ACTIVATION; ENHANCER; EXPRESSION; SUPERFAMILY; SEQUENCES; PROTEIN	Transcriptional regulation of the steroid hormone receptor genes plays a central role in temporal changes of target cell sensitivity during development, maturation, and aging, Sequence-specific DNA-protein interactions mediate these regulatory functions, Progressive 5' deletion of the rat androgen receptor (rAR) gene immediately beyond the -572 base pair (bp) region causes a marked increase in its promoter activity. DNase I footprinting with nuclear proteins revealed a protected area encompassing -574- to -554-bp positions that begins with a perfectly palindromic nuclear factor kappa B (NF-kappa B) motif. Electrophoretic mobility shift analyses (EMSA) showed that the decameric rAR NF-kappa B site at positions -574 to -565 cross-competes with the authentic kappa immunoglobulin light chain enhancer for specific protein binding, Supershift with specific antibodies to NP-kappa B subunits confirmed that the two retarded bands observed in the EMSA with the labeled rAR probe are due to p50/p65 and p50/p50 dimers of the NF-kappa B/Rel proteins, Fragments of rAR promoter with either deletion or point mutation of the NF-kappa B site are found to be about 2- to S-fold more effective as compared to the wild type control in driving a heterologous reporter gene in cellulo. Thus, unlike most other known cases, NF-kappa B acts as a negative regulator for the rAR gene, The physiological relevance of this repressor function is evident from a 10-fold increase in the p50/p50 form of the NF-kappa B activity in the liver of aged rats exhibiting hepatic androgen desensitization. The newly identified repressor element is a rare example of a naturally occurring perfect palindromic binding motif for the NF-kappa B/Rel family of transcription factors, This repressor factor and the positively acting age-dependent factor, ADF, described earlier (Supakar, P. C., Song C. S., Jung, M., H., Slomczynska, M. A., Kim, J.-M., Vellanoweth, R. L., Chatterjee, B. & Poy, A. K. (1993) J. Biol. Chem. 268, 26400-26408) function to coordinate the tissue-specific down-regulation of the rAR gene during aging.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIA NIH HHS [P01 AG06872, R01 AG10486] Funding Source: Medline; NIDDK NIH HHS [R-37 DK14744] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006872, R01AG010486] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; DEWET JR, 1987, MOL CELL BIOL, V2, P1044; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1993, J BIOL CHEM, V268, P9296; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LINDZEY J, 1993, MOL ENDOCRINOL, V7, P1530, DOI 10.1210/me.7.12.1530; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; POST DJ, 1991, ANN NY ACAD SCI, V621, P66; ROY AK, 1983, ANNU REV PHYSIOL, V45, P37, DOI 10.1146/annurev.ph.45.030183.000345; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SONG CS, 1993, BIOCHEM J, V294, P779, DOI 10.1042/bj2940779; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	31	137	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					837	842		10.1074/jbc.270.2.837	http://dx.doi.org/10.1074/jbc.270.2.837			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822319	hybrid			2022-12-25	WOS:A1995QB81600053
J	GERHARDINGER, C; MARION, MS; ROVNER, A; GLOMB, M; MONNIER, VM				GERHARDINGER, C; MARION, MS; ROVNER, A; GLOMB, M; MONNIER, VM			NOVEL DEGRADATION PATHWAY OF GLYCATED AMINO-ACIDS INTO FREE FRUCTOSAMINE BY A PSEUDOMONAS SP SOIL STRAIN EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL DIABETES-MELLITUS; VASCULAR DYSFUNCTION; AMINOGUANIDINE; COMPLICATIONS; GLYCOSYLATION; PURIFICATION; INCREASE; PROTEINS; GLUCOSE; OXIDASE	A Pseudomonas sp, soil strain, selected for its ability to grow on epsilon-(1-deoxyfructosyl) aminocaproic acid, was induced to express a membrane bound enzymatic activity which oxidatively degrades Amadori products into free fructosamine, Apparent K-m values for fructosyl aminocaproate, epsilon-fructosyl lysine, fructosyl glycine, and ribated lysine were 0.21 mM, 2.73 mM, 3.52 mM, and 1.57 mM, respectively, The enzyme was also active against alpha-fructosyl lysine and borohydride-reduced Amadori product, weakly active with ribated and glycated polylysine, and inactive with reducing sugars, amino acids, and glycated proteins, The enzymatic activity was highest at pH 6.5 and 25 degrees C in 0.1 M sodium phosphate, while over 80% of the activity was lost above 65 degrees C, Complete inhibition was observed by HgCl2, NaN3, and NaCN suggesting a role for SH groups and copper in the enzymatic activity. The reaction products were characterized by H-1 NMR, C-13 NMR, and GC/MS and found to correspond to 1-deoxy-1-aminofructose, i,e, free ''fructosamine,'' and adipic acid, Confirmation of the free fructosamine structure was based on the complete spectroscopic identity of the borohydride reduction product with commercially available glucamine (1-amino-1-deoxyglucitol). The new enzyme is provisorily classified as fructosyl N-alkyl amino acid oxidase (EC 1.5.3) (fructosyl-amino acid:oxygen oxidoreductase) and may thus belong to a novel class of ''Amadoriases'' which deglycate Amadori products oxidatively, In contrast, however, the new enzyme acts on the alkylamine bond rather than the ketoamine bond of the Amadori product.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; Bergmeyer H.U., 1983, METHOD ENZYMAT AN, V2, P201; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; CAGLIERO E, 1991, J BIOL CHEM, V266, P14244; CERAMI A, 1979, METABOLISM, V28, P431, DOI 10.1016/0026-0495(79)90051-9; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; ELLIS EN, 1991, METABOLISM, V40, P1016, DOI 10.1016/0026-0495(91)90122-D; FINOT PA, 1986, HELV CHIM ACTA, V52, P1488; GERHARDINGER C, 1994, J BIOL CHEM, V269, P27297; GREENE DA, 1988, DIABETES METAB REV, V4, P202; HAMMES HP, 1992, P NATL ACAD SCI USA, V88, P11555; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; JANAUER GA, 1978, J CHROMATOGR, V153, P539, DOI 10.1016/S0021-9673(00)95518-3; KUMURI K, 1991, DIABETES, V40, P1079; Malmstrom B.G., 1975, ENZYMES B, V12, P507, DOI DOI 10.1016/S1874-6047(08)60231-0; MORTENSEN HB, 1982, BIOCHIM BIOPHYS ACTA, V707, P154, DOI 10.1016/0167-4838(82)90409-5; NAGARAJ RH, 1993, DIABETES S, V142, pA240; OXLUND H, 1992, DIABETOLOGIA, V35, P19, DOI 10.1007/BF00400847; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; SCHLEICHER E, 1986, BIOCHIM BIOPHYS ACTA, V884, P199, DOI 10.1016/0304-4165(86)90244-8; SCHWARTZ BA, 1977, ARCH BIOCHEM BIOPHYS, V181, P542, DOI 10.1016/0003-9861(77)90261-2; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; Stryer L., 1988, BIOCHEMISTRY-US; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; 1993, NEW ENGL J MED, V329, P977	31	41	46	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					218	224		10.1074/jbc.270.1.218	http://dx.doi.org/10.1074/jbc.270.1.218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814378	hybrid			2022-12-25	WOS:A1995QA28700037
J	RYE, KA; HIME, NJ; BARTER, PJ				RYE, KA; HIME, NJ; BARTER, PJ			THE INFLUENCE OF CHOLESTERYL ESTER TRANSFER PROTEIN ON THE COMPOSITION, SIZE, AND STRUCTURE OF SPHERICAL, RECONSTITUTED HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA-LIPOPROTEINS; EGG PHOSPHATIDYLCHOLINE; GEL-ELECTROPHORESIS; CONVERSION FACTOR; TRANSGENIC MICE; LIPID-TRANSFER; TRIGLYCERIDE; CHARGE; ATHEROSCLEROSIS	The effect of cholesteryl ester transfer protein (CETP) on the size, composition, and structure of spherical, reconstituted HDL (rHDL) which contain apolipoprotein (ape) A-I as their sole apolipoprotein has been studied. Spherical rHDL were incubated with CETP and Intralipid for up to 24 h, During this time CETP promoted transfers of cholesteryl esters (CE) and triglyceride (TG) between rHDL and Intralipid, As a result, the rHDL became depleted of CE and enriched in TG, However, as the loss of CE from the rHDL was greater than the gain of TG, the concentration of core lipids in the rHDL decreased, The decrease in the concentration of rHDL core lipids, which was evident throughout the incubation, was accompanied by a reduction in rHDL diameter from 9.2 to 8.0 nm, the dissociation of apoA-I hom rHDL and a decrease in the number of apoA-I molecules, from three/particle in the 9.2-nm rHDL, to two/particle in the 8.0 nm rHDL, Spectroscopic studies showed that the lipid-water interface and phospholipid packing of the 8,0-nm rHDL were, respectively, more polar and less ordered than those of the 9,2-nm rHDL, Quenching studies with KI revealed that the number of exposed apoA-I Trp residues in the 9.2- and 8,0-nm rHDL was two and three, respectively, Circular dichroism established that the 9.2- and 8,0-nm rHDL had identical apoA-I alpha-helical contents, The 9.2- and 8.0 nm rHDL also had identical surface charges as determined by agarose gel electrophoresis, Denaturation studies with guanidine hydrochloride demonstrated that apoA-I is more stable in 8.0 nm rHDL than in 9,2-nm rHDL, It is concluded that CETP converts rHDL to small, TG-enriched, apoA-I-depleted particles with increased lipid-water interfacial hydration and less ordered phospholipid packing, These changes are associated with enhanced stability and minor changes to the conformation of the apoA-I which remains associated with the rHDL.	ROYAL ADELAIDE HOSP, DIV CARDIOVASC SCI, ADELAIDE, SA 5000, AUSTRALIA; UNIV ADELAIDE, ROYAL ADELAIDE HOSP, DEPT MED, ADELAIDE, SA, AUSTRALIA	Royal Adelaide Hospital; Royal Adelaide Hospital; University of Adelaide								AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER PJ, 1990, ATHEROSCLEROSIS, V84, P13, DOI 10.1016/0021-9150(90)90003-2; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTER PJ, 1982, ATHEROSCLEROSIS, V44, P27, DOI 10.1016/0021-9150(82)90050-8; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BARTER PJ, 1979, ATHEROSCLEROSIS, V34, P67, DOI 10.1016/0021-9150(79)90107-2; BARTER PJ, 1980, J LIPID RES, V21, P238; BENYASHAR V, 1991, CHEM PHYS LIPIDS, V60, P1, DOI 10.1016/0009-3084(91)90009-Z; BISGAIER CL, 1991, J LIPID RES, V32, P21; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BURSTEIN M, 1970, J LIPID RES, V11, P583; DALTON MB, 1993, J BIOL CHEM, V268, P19274; HOPKINS GJ, 1989, ATHEROSCLEROSIS, V75, P73, DOI 10.1016/0021-9150(89)90209-8; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; HOPKINS GJ, 1982, METAB CLIN BIOL, V29, P546; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JONAS A, 1990, J BIOL CHEM, V265, P22123; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEROY A, 1993, J BIOL CHEM, V268, P4798; LIANG HQ, 1994, J LIPID RES, V35, P1187; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MORTON RE, 1983, J BIOL CHEM, V258, P1751; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; PIRAN U, 1979, J LIPID RES, V20, P1040; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; RAJARAM OV, 1985, BIOCHIM BIOPHYS ACTA, V835, P41, DOI 10.1016/0005-2760(85)90028-1; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; SATA T, 1972, J LIPID RES, V13, P757; SEGREST JP, 1992, J LIPID RES, V33, P141; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	46	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					189	196		10.1074/jbc.270.1.189	http://dx.doi.org/10.1074/jbc.270.1.189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814372	hybrid			2022-12-25	WOS:A1995QA28700032
J	ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD				ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD			INCREASED MUTATION-RATE AT THE HPRT LOCUS ACCOMPANIES MICROSATELLITE INSTABILITY IN COLON-CANCER	ONCOGENE			English	Article						REPLICATION ERRORS (RER); GENOMIC INSTABILITY; COLON CANCER; HPRT; HPRT (HEREDITARY NONPOLYPOSIS COLON CANCER)	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; HUMAN-LYMPHOBLASTS; CELLS; CARCINOMA; MECHANISM; CULTURE; HOMOLOG	Hereditary Non-Polyposis Colon Cancer (HNPCC) tumors and some sporadic colon cancers acquire somatic changes in the length of microsatellite sequences, We hypothesized that this 'replication error' (RER) phenotype in these cancers reflects a more general defect which should result in hypermutability of expressed genes. To test this hypothesis mutations of hprt were studied in RER and non-PER tumor cell lines. Increased mutation rates of greater than 100-fold were found in RER compared to non-RER lines. Heterogeneity within the RER group suggests the likely existence of different classes of RER tumors. One non-REP demonstrated a greater than 10-fold increase mutation rate, suggesting that a novel mutator phenotype may exist in some non-PER tumors.	UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231	Case Western Reserve University; Johns Hopkins University; Johns Hopkins Medicine				Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA 54031, R01 CA 57208, R29 CA 51504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA054031, R29CA051504, R01CA057208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; BRONNER CE, 1994, NATURE, V17, P258; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; Glantz S.A., 1981, PRIMER BIOSTATISTICS, V2nd ed.; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Luria SE, 1943, GENETICS, V28, P491; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOTRING LL, 1980, CANCER RES, V40, P1458; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994	30	225	237	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					33	37						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824277				2022-12-25	WOS:A1995QA98000005
J	LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL				LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL			IDENTIFICATION OF SOLUBLE AND MEMBRANE-BOUND ISOFORMS OF THE MURINE FLT3 LIGAND GENERATED BY ALTERNATIVE SPLICING OF MESSENGER-RNAS	ONCOGENE			English	Article						FT13 LIGAND; GROWTH FACTOR; GENE LOCATION; TYROSINE KINASE RECEPTOR; HEMATOPOIESIS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; KIT-LIGAND; MOLECULAR-CLONING; HUMAN CSF-1; GENE; MOUSE; TRANSMEMBRANE; ORGANIZATION	We have recently described a novel hematopoietic growth factor, referred to as the flt3 ligand, that stimulates the proliferation of sub-populations of hematopoietic cells that are enriched for stem and progenitor cells, This factor is a transmembrane protein that undergoes proteolytic cleavage to generate a soluble form of the protein. We have isolated additional flt3 ligand isoforms by PCR that contain an extra exon and encode what are predicted to be either a soluble form of the ligand or a longer version of the transmembrane protein. We have also isolated cDNAs from murine T cell libraries that encode an isoform of the flt3 ligand that has an unusual C-terminus, This isoform results from a failure to splice out an intron during mRNA processing. The protein encoded by this cDNA is expressed on the cell surface, where it is biologically active. However, this novel isoform does not appear to give rise to a soluble form of the protein, Regulation of mRNA splicing is likely to control the generation of cell bound or soluble forms of this hematopoietic growth factor, Genetic mapping studies localize the gene encoding the flt3 ligand to the proximal portion of mouse chromosome 7 and to human chromosome 19q13.3.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine	LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Green EL, 1981, GENETICS PROBABILITY, P77; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUANG EJ, 1990, CELL, V5, P225; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LAW CL, 1993, J IMMUNOL, V151, P175; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LU HS, 1991, J BIOL CHEM, V266, P8102; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1991, BLOOD CELL GROWTH FACTORS : THEIR PRESENT AND FUTURE USE IN HEMATOLOGY AND ONCOLOGY, P183; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SIRACUSA LD, 1991, GENETICS, V127, P169; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	32	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					149	157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824267				2022-12-25	WOS:A1995QA98000017
J	TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP				TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP			SPATIAL AND TEMPORAL EXPRESSION OF THE RET PROTOONCOGENE PRODUCT IN EMBRYONIC, INFANT AND ADULT-RAT TISSUES	ONCOGENE			English	Note						C-RET; RECEPTOR TYROSINE KINASE; RAT EMBRYOGENESIS; NERVOUS SYSTEM; EXCRETORY SYSTEM	PROTOONCOGENE PRODUCTS; SEQUENCE SIMILARITY; TYROSINE KINASE; CADHERIN; NEUROBLASTOMA; MUTATIONS; CLONING; CELLS; CDNA	Immunohistochemical analysis with the anti-Ret antibody was performed to investigate the expression of the c-ret proto-oncogene product (c-Ret protein) in embryonic, infant and adult rat tissues. During embryogenesis, the c-Ret expression became detectable by day 11.5 in the developing peripheral and central nervous systems as well as in the excretory system. In the peripheral nervous system of the trunk, it was expressed at high levels in the enteric neuroblasts and the autonomic and dorsal root ganglia, c-Ret positive cells appeared in the mesenchyme around the foregut and the dorsal aorta at day 11.5 and formed the myenteric plexus of the whole embryonic gut and the sympathetic trunk at later stages respectively. Examination of the cranial region revealed that the c-Ret protein was expressed in neural crest cells migrating from rhombomere 4 at day 11.5 and then became positive in the facial, glossopharyngeal and vagus cranial ganglia at day 12.5-13.5. After day 16.5 of gestation, the c-Ret expression was also observed in the trigeminal ganglion. In the central nervous system, the c-Ret protein was expressed in the neuroepithelial cells of the ventral neural tube (day 11.5-14.5), the motor neurons of the spinal cord (day 18.5) as well as in the embryonic neuroretina (day 18.5). In addition to the nervous system, the c-Ret expression was detected in the nephric duct (day 11.5), the ureteric bud (day 13.5) and the collecting ducts of the kidney (day 16.5). After birth, neurons in the nervous systems mentioned above continued to express the c-Ret protein at variable levels while no c-Ret expression was observed in the kidney of adult rats. Furthermore, the c-Ret expression was found in the acinar cells of the salivary gland, the epithelial cells of the thymus and the follicular dendritic cells of the spleen and lymph node in infant and adult rats. A small number of adrenal chromaffin cells and thyroid C cells also expressed the c-Ret protein. These results demonstrated that the c-Ret protein is expressed in several cell lineages in spatially and temporally controlled manner throughout life of the rat.	NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014	Takahashi, Masahide/0000-0002-2803-2683; Tsuzuki, Toyonori/0000-0002-4855-4366				ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1993, MOL BIOL EVOL, V10, P539; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	21	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824273				2022-12-25	WOS:A1995QA98000022
J	LEHRICH, RW; FORREST, JN				LEHRICH, RW; FORREST, JN			PROTEIN-KINASE-C-ZETA IS ASSOCIATED WITH THE MITOTIC APPARATUS IN PRIMARY-CELL CULTURES OF THE SHARK RECTAL GLAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SACCHAROMYCES-CEREVISIAE; ACTIVATION; IMMUNOCHARACTERIZATION; EXPRESSION; ISOFORMS; TUBULES	Protein kinase C zeta (PKC zeta) is an atypical PKC isoform that has recently been implicated in cell division and cell growth. However, there has been no morphologic evidence for the involvement of PKC zeta in mitogenic signal transduction. Here we use immunocytochemistry to demonstrate that PKC zeta co-localizes with microtubules in both interphase and metaphase cells of the shark rectal gland in primary culture. This co-localization is present after non-ionic detergent treatment and is disrupted by nocodazole. During mitosis, PKC zeta is associated with the mitotic apparatus and co-localizes with beta-tubulin in spindle microtubules, while entirely sparing astral microtubules. These findings provide the first evidence that PKC zeta is associated with the mitotic apparatus. The striking presence of PKC zeta in the central portion of the mitotic apparatus suggests a functional role for this kinase isoform in cell division.	YALE UNIV,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,NEW HAVEN,CT 06510; MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672	Yale University; Mount Desert Island Biological Laboratory					NIDDK NIH HHS [DK 34208-09] Funding Source: Medline; NIEHS NIH HHS [P30-ES 3828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; CHURCH DJ, 1993, BIOCHEM J, V290, P477, DOI 10.1042/bj2900477; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVOR DC, 1994, IN PRESS AM J PHYSL; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; FORREST JN, 1983, J CLIN INVEST, V72, P1163, DOI 10.1172/JCI111041; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; GREGER R, 1988, COMP BIOCHEM PHYS A, V90, P733, DOI 10.1016/0300-9629(88)90692-5; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRICH RW, 1994, J AM SOC NEPHROL, V5, P721; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; STASIA MJ, 1990, FEBS LETT, V274, P61, DOI 10.1016/0014-5793(90)81329-M; VALENTICH J, 1990, AM J PHYSIOL, V260, pC813; Valentich JD, 1991, J TISS CULT METHODS, V13, P149; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817	35	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32446	32450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798244				2022-12-25	WOS:A1994PX30400065
J	TEPPER, AD; DAMMANN, H; BOMINAAR, AA; VERON, M				TEPPER, AD; DAMMANN, H; BOMINAAR, AA; VERON, M			INVESTIGATION OF THE ACTIVE-SITE AND THE CONFORMATIONAL STABILITY OF NUCLEOSIDE DIPHOSPHATE KINASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; DICTYOSTELIUM-DISCOIDEUM; DROSOPHILA DEVELOPMENT; MYXOCOCCUS-XANTHUS; HEXAMERIC ENZYME; GENE; NM23; MUTATION; CLONING; PROTEIN	Nucleoside-diphosphate kinase (EC 2.7.4.6) catalyzes phosphate exchange between nucleoside triphosphates and nucleoside diphosphates. Its 17 kDa subunits are highly conserved throughout evolution in both sequence and tertiary structure. Using site-directed mutagenesis we investigated the function of 8 amino acids (LyS(16), Tyr(56), Arg(92), Thr(98), Arg(109), Asn(119), Ser(124) and Glu(193)) that are totally conserved among all nucleoside diphosphate kinases known to date. The mutant proteins all show decreased specific activity and support roles for these residues in catalysis, substrate binding, or both, as was previously proposed on the basis of the x-ray structure (Morera, S., Lascu, I., Dumas, C., LeBras, G., Briozzo, P., Veron, M., and Janin, J. (1994) Biochemistry 33, 459-467), Furthermore, residues Lys(16), Arg(109), and Asn(119) were identified to play important roles in conformational stability or subunit interactions. We show that Lys(16) and Asn(119) form a rigid structure that is important for enzymatic function and that Arg(109), known to interact with the phosphate moiety of the substrate, also plays an important role in subunit association. The dual roles of Lys(16), Arg(109), and Asn(119) in both substrate binding and subunit assembly provide further evidence for a functional coupling between catalytic activity and quaternary structure in nucleoside diphosphate kinase.	INST PASTEUR,CNRS,URA 1129,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WALLET V, 1992, THESIS U PARIS 7; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	29	69	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32175	32180						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798215				2022-12-25	WOS:A1994PX30400027
J	ELHAYEK, R; YANO, M; IKEMOTO, N				ELHAYEK, R; YANO, M; IKEMOTO, N			A CONFORMATIONAL CHANGE IN THE JUNCTIONAL FOOT PROTEIN IS INVOLVED IN THE REGULATION OF CA2+ RELEASE FROM SARCOPLASMIC-RETICULUM - STUDIES ON POLYLYSINE-INDUCED CA2+ RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CALCIUM RELEASE; RYANODINE RECEPTOR; ADENINE-NUCLEOTIDES; TRANSVERSE TUBULE; CHARGE MOVEMENT; CA-2+ RELEASE; CHANNEL; BINDING	We investigated both conformational changes in the junctional foot protein (JFP) and Ca2+ release from sarcoplasmic reticulum (SR) in parallel after stimulation of triadic vesicles by the JFP-specific ligand, polylysine, To monitor protein conformational change, the JFP was labeled in a site-directed fashion with the fluorescent conformational probe methylcoumarin acetate (MCA) (Kang, J, J,, Tarcsafalvi, A., Carlos, A. D,, Fujimoto, E,, Shahrokh, Z,, Thevenin, B, J,-M,, Shohet; S, B,, and Ikemoto, N, (1992) Biochemistry 31, 3288-3293), The induction of SR Ca2+ release by polylysine produced a rapid increase in the fluorescence intensity of the JFP-bound MCA. The polylysine concentration dependence of the fluorescence change was essentially the same as that of Ca2+ release, suggesting that the two events are tightly coupled, However, the rate constant of MCA fluorescence change was much larger than that of Ca2+ release; i.e. the conformational change preceded Ca2+ release, Prevention of protein conformational change by lysine (0.2 M) inhibited Ca2+ release from SR, Inhibition of Ca2+ release by Mg2+ (5 mM), however, had little effect on the conformational change, These results suggest that binding of polylysine to the JFP produces conformational changes in the protein, which in turn activates the Ca2+ channel, leading to Ca2+ release from the SR.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR 16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CHU A, 1990, MOL PHARMACOL, V37, P735; CIFUENTES ME, 1989, ARCH BIOCHEM BIOPHYS, V273, P554, DOI 10.1016/0003-9861(89)90515-8; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1985, J BIOL CHEM, V260, P4096; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOUIS CF, 1992, ANESTHESIOLOGY, V77, P114, DOI 10.1097/00000542-199207000-00017; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OHKUSA T, 1991, J BIOCHEM-TOKYO, V109, P609, DOI 10.1093/oxfordjournals.jbchem.a123428; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; THEVENIN BJM, 1992, EUR J BIOCHEM, V206, P471, DOI 10.1111/j.1432-1033.1992.tb16949.x; YANO M, 1995, J BIOL CHEM, V270, P3017, DOI 10.1074/jbc.270.7.3017	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15634	15638		10.1074/jbc.270.26.15634	http://dx.doi.org/10.1074/jbc.270.26.15634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797562	hybrid			2022-12-25	WOS:A1995RG53800032
J	FRANCIS, JW; HOSLER, BA; BROWN, RH; FISHMAN, PS				FRANCIS, JW; HOSLER, BA; BROWN, RH; FISHMAN, PS			CUZN SUPEROXIDE-DISMUTASE (SOD-1)-TETANUS TOXIN FRAGMENT-C HYBRID PROTEIN FOR TARGETED DELIVERY OF SOD-1 TO NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS; RETROGRADE AXONAL-TRANSPORT; TETANUS TOXIN; ESCHERICHIA-COLI; TRANSGENIC MICE; HIGH-AFFINITY; OXIDATIVE STRESS; CULTURED NEURONS; BRAIN MEMBRANES	Increased levels of CuZn superoxide dismutase (SOD-1) are cytoprotective in experimental models of neurological disorders associated with free radical toxicity (e.g. stroke, trauma). Targeted delivery of SOD-1 to central nervous system neurons may therefore be therapeutic in such diseases. The nontoxic C-fragment of tetanus toxin (TTC) possesses the nerve cell binding/transport properties of tetanus holotoxin and has been used as a vector to enhance the neuronal uptake of proteins including enzymes. We have now produced a recombinant, hybrid protein in Escherichia coli tandemly joining human SOD-1 to TTC. The expressed hybrid protein (SOD:Tet451) has a subunit molecular mass of 68 kDa and is recognized by both anti-SOD-1 and anti-TTC antibodies. Calculated per mol, SOD:Tet451 has approximately 60% of the expected SOD-1 enzymatic activity. Analysis of the hybrid protein's interaction with the neuron-like cell line, N18-RE-105, and cultured hippocampal neurons by enzyme immunoassay for human SOD-1 revealed that SOD:Tet451 association with cells was neuron-specific and dose-dependent. The hybrid protein was also internalized, but there was substantial loss of internalized hybrid protein over the first 24 h. Hybrid protein associated with cells remained enzymatically active. These results suggest that human SOD-1 and TTC retain their respective functional properties when expressed together as a single peptide. SOD: Tet451 may prove to be a useful agent for the targeted delivery of SOD-1 to neurons.	UNIV MARYLAND, SCH MED, DEPT ANAT, BALTIMORE, MD 21201 USA; MASSACHUSETTS GEN HOSP, CECIL B DAY LAB NEUROMUSCULAR RES, BOSTON, MA 02129 USA; UNIV MARYLAND, SCH MED, VET ADM MED CTR, NEUROL SERV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT NEUROL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Maryland; University of Maryland Baltimore					NINDS NIH HHS [NS31248-01, 1P01NS31248] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031248, P50NS031248] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBINOTEIXEIRA A, 1991, N-S ARCH PHARMACOL, V344, P36; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEAUDE P, 1990, BIOCHEM J, V271, P87, DOI 10.1042/bj2710087; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BEYER WF, 1987, ANAL BIOCHEM, V161, P559, DOI 10.1016/0003-2697(87)90489-1; BIZZINI B, 1980, BRAIN RES, V193, P221, DOI 10.1016/0006-8993(80)90959-2; BIZZINI B, 1977, J NEUROCHEM, V28, P529, DOI 10.1111/j.1471-4159.1977.tb10423.x; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOUCHER P, 1994, INFECT IMMUN, V62, P449, DOI 10.1128/IAI.62.2.449-456.1994; CABOT JB, 1991, NEUROSCIENCE, V40, P805, DOI 10.1016/0306-4522(91)90014-F; CADET JL, 1994, J NEUROCHEM, V62, P380; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CRITCHLEY DR, 1985, J CELL BIOL, V100, P1499, DOI 10.1083/jcb.100.5.1499; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DOBRENIS K, 1992, P NATL ACAD SCI USA, V89, P2297, DOI 10.1073/pnas.89.6.2297; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; FAIRWEATHER NF, 1986, J BACTERIOL, V165, P21, DOI 10.1128/jb.165.1.21-27.1986; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; FISHMAN PS, 1990, J NEUROL SCI, V98, P311, DOI 10.1016/0022-510X(90)90272-O; FRANCIS J W, 1991, Society for Neuroscience Abstracts, V17, P754; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HABERMANN E, 1973, N-S ARCH PHARMACOL, V276, P327, DOI 10.1007/BF00499887; HABIG WH, 1986, J NEUROCHEM, V47, P930; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HARTMAN JR, 1986, P NATL ACAD SCI USA, V83, P7142, DOI 10.1073/pnas.83.19.7142; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; INOUE M, 1990, ADV EXP MED BIOL, V264, P5; INOUE M, 1991, J BIOL CHEM, V266, P16409; KINOSHITA A, 1991, PATHOBIOLOGY, V59, P340, DOI 10.1159/000163674; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1979, J BIOL CHEM, V254, P3826; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MAKOFF AJ, 1989, BIO-TECHNOL, V7, P1043; MAKOFF AJ, 1989, NUCLEIC ACIDS RES, V17, P10191, DOI 10.1093/nar/17.24.10191; MALOUF AT, 1984, J BIOL CHEM, V259, P2756; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MICHELSON AM, 1980, ACTA PHYSIOL SCAND, P67; MIRSKY R, 1978, BRAIN RES, V148, P251, DOI 10.1016/0006-8993(78)90399-2; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; PIERCE EJ, 1986, BIOCHEM J, V236, P845, DOI 10.1042/bj2360845; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; ROMANOS MA, 1991, NUCLEIC ACIDS RES, V19, P1461, DOI 10.1093/nar/19.7.1461; ROSEN DR, 1994, HUM MOL GENET, V3, P981, DOI 10.1093/hmg/3.6.981; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAEZ JC, 1987, P NATL ACAD SCI USA, V84, P3056, DOI 10.1073/pnas.84.9.3056; SANDBERG K, 1989, J BIOL CHEM, V264, P5679; STAUB GC, 1986, J NEUROSCI, V6, P1443; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKEDA Y, 1993, AM J PHYSIOL, V264, pH1708, DOI 10.1152/ajpheart.1993.264.5.H1708; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7	69	68	80	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15434	15442		10.1074/jbc.270.25.15434	http://dx.doi.org/10.1074/jbc.270.25.15434			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797532	hybrid			2022-12-25	WOS:A1995RE66600087
J	KWAK, SP; DIXON, JE				KWAK, SP; DIXON, JE			MULTIPLE DUAL-SPECIFICITY PROTEIN-TYROSINE PHOSPHATASES ARE EXPRESSED AND REGULATED DIFFERENTIALLY IN LIVER-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; VACCINIA VIRUS VH1; GROWTH-FACTOR; SEQUENCE; KINASE	An emerging subclass of protein-tyrosine phosphatases (PTPases) exhibits sequence identity to the vaccinia H-1 (VH-1) gene product. These VH-1-like PTPases possess the canonical HCXAGXXR(S/T) sequence common to all PTPases, but unlike other PTPases they exhibit dual catalytic activity toward phosphotyrosine and nearby phosphothreonine residues in substrate proteins. We have isolated a novel VH-1-like PTPase, hVH-3, from the human placenta and compared various aspects of its expression with previously isolated members of this subfamily. The mammalian members of this subfamily including hVH-3 commonly localize to the nucleus and exhibit catalytic activity toward phosphorylated extracellular signal-regulated kinase. However, while the expression of some VH-1-like PTPases is extremely transient and independent of protein synthesis, hVH-3 expression is sustained over 3 h after being cell stimulated. Tissue-specific expression of hVH-3 is also distinct from other VH-1-like PTPases. Although VH-1-like PTPases have overlapping substrate specificity, there are differences in their mRNA regulation, response to extracellular stimuli, and tissue-specific expression, suggesting they serve specific roles in cellular function.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R37DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK 18024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DENU JM, 1995, IN PRESS J BIOL CHEM, V270; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16114	30	115	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1156	1160		10.1074/jbc.270.3.1156	http://dx.doi.org/10.1074/jbc.270.3.1156			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836374	hybrid			2022-12-25	WOS:A1995QB15600029
J	LOO, TW; CLARKE, DM				LOO, TW; CLARKE, DM			MEMBRANE TOPOLOGY OF A CYSTEINE-LESS MUTANT OF HUMAN P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MULTIDRUG TRANSPORTER; FUNCTIONAL CONSEQUENCES; RESISTANCE; ORIENTATION; EXPRESSION; ANTIBODIES; MUTATIONS; SEQUENCE; PROTEINS	A human P-glycoprotein devoid of cysteine residues was constructed by site-directed mutagenesis for studying its topology, The cDNA for human P-glycoprotein-A52 in which codons for cysteines 137, 431, 717, 956, 1074, 1125, 1227, 1288, and 1304 were changed to Ala, was transfected into NIH 3T3 cells and analyzed with respect to its ability to confer resistance to various drugs, The cysteine-less P-glycoprotein-A52 retained the ability to confer resistance to vinblastine, colchicine, doxorubicin, and actinomycin D with only a small decrease in efficiency relative to wild-type enzyme, Cysteine residues were then reintroduced into predicted extracellular or cytoplasmic loops of the cysteine less P-glycoprotein-A52, and the topology of the protein was determined using membrane-permeant and impermeant thiol-specific reagents, It was found that 8 of 15 cysteine residues introduced into P-glycoprotein-A52 could be biotinylated, when cells expressing the mutant P-glycoprotein were incubated with membrane-permeant biotin maleimide, Biotinylation of a cysteine residue placed in predicted extracellular loops between transmembrane segment (TM) 5 and TM6, TM7 and TM8, or TM11 and TM12 was blocked by pretreatment of the cells with a membrane impermeant maleimide, suggesting that these residues have an extracellular location, By contrast, biotinylation of cysteine residues located in the predicted cytoplasmic loops between TM2 and TM3, TM4 and TM5, TM8 and TM9, or TM10 and TM11 were not blocked by pretreatment with membrane impermeant maleimide, suggesting that these residues were in the cytoplasm. These results are consistent with the model of P-glycoprotein, which predicts six transmembrane segments in each of the two homologous halves of the molecule.	UNIV TORONTO,DEPT MED,MRC,MEMBRANE BIOL GRP,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALLEY MC, 1988, CANCER RES, V48, P589; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1993, J BIOL CHEM, V268, P6903; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	25	263	269	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					843	848		10.1074/jbc.270.2.843	http://dx.doi.org/10.1074/jbc.270.2.843			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822320	hybrid			2022-12-25	WOS:A1995QB81600054
J	KAZAMA, Y; HAMAMOTO, T; FOSTER, DC; KISIEL, W				KAZAMA, Y; HAMAMOTO, T; FOSTER, DC; KISIEL, W			HEPSIN, A PUTATIVE MEMBRANE-ASSOCIATED SERINE-PROTEASE, ACTIVATES HUMAN FACTOR-VII AND INITIATES A PATHWAY OF BLOOD-COAGULATION ON THE CELL-SURFACE LEADING TO THROMBIN FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-FACTOR; FACTOR-X; TRANSMEMBRANE DOMAIN; EXTRINSIC PATHWAY; FACTOR-IX; PLASMA; PHOSPHOLIPIDS; PURIFICATION; INHIBITOR; CANCER	Previous studies have shown that hepsin is a putative membrane-associated serine protease that is required for cell growth (Torres-Rosado, A., O'Shea, K. S., Tsuji, A., Chou, S.-H., and Kurachi, K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7181 7185). In the present study, we have transfected baby hamster kidney (BHK) cells with a plasmid containing the cDNA for human hepsin and examined these cells for their ability to activate several blood coagulation factors including factors X, IX, VII, prothrombin, and protein C. Little, if any, proteolytic activation of factors X, IX, prothrombin, or protein C was observed when these clotting factors were incubated with hepsin-transfected cells. On the other hand, hepsin-transfected cells proteolytically activated significant concentrations of human factor VII in a time- and calcium-dependent manner, whereas essentially no activation of factor VII was observed in BHK cells transfected with plasmid lacking the cDNA for hepsin. The factor VII activating activity in the hepsin-transfected BHK cell line was confined exclusively to the total membrane fraction and was inhibited >95% by antibody raised against a fusion protein consisting of maltose-binding protein and the extracellular domain of human hepsin. An active site factor VII mutant, S344A factor VII, was cleaved as readily as plasma-derived factor VII by hepsin-transfected cells, indicating that factor VII was not converted to factor Wa autocatalytically on the cell surface. In contrast, an activation cleavage site factor VII mutant, R152E factor VII, was not cleaved by hepsin-transfected cells, suggesting that factor VII and S344A factor VII were activated on these cells by cleavage of the Arg(152)-Ile(153) peptide bond. In the copresence of factor VII and factor X, hepsin-transfected BHK cells supported the formation of factor Xa. In addition, in the copresence of factor VII, factor X, and prothrombin, hepsin-transfected BHK cells supported the formation of thrombin. These results strongly suggest that membrane associated hepsin converts zymogen factor VII to factor VIIa, which in turn, is capable of initiating a coagulation pathway on the cell surface that ultimately leads to thrombin formation.	UNIV NEW MEXICO, SCH MED, DEPT PATHOL, ALBUQUERQUE, NM 87131 USA; ZYMOGENET INC, SEATTLE, WA 98102 USA	University of New Mexico; Zymogenet Inc.					NHLBI NIH HHS [HL35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL WN, 1954, NATURE, V174, P880, DOI 10.1038/174880a0; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BOND JS, 1991, BIOMED BIOCHIM ACTA, V50, P775; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTANTINI V, 1993, THROMB HAEMOSTASIS, V69, P406; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; EDWARDS RL, 1993, THROMB HAEMOSTASIS, V69, P205; FALANGA A, 1985, BIOCHEMISTRY-US, V24, P5558, DOI 10.1021/bi00341a041; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN C, 1988, GENE, V67, P21; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HOFFMAN M, 1994, BLOOD, V83, P38; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KONDO S, 1987, BLOOD, V70, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; MAHONEY WC, 1980, EUR J BIOCHEM, V105, P545, DOI 10.1111/j.1432-1033.1980.tb04531.x; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MURRAY JC, 1991, BRIT J CANCER, V64, P422, DOI 10.1038/bjc.1991.325; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NICOLAISEN EM, 1992, FEBS LETT, V306, P157, DOI 10.1016/0014-5793(92)80989-T; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; OSTERUD B, 1983, HAEMOSTASIS, V13, P161; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; QUICK AJ, 1966, HEMORRHAGIC DISEASE, P438; RAO LVM, 1990, BLOOD, V75, P1069; RUF W, 1991, J BIOL CHEM, V266, P2158; SAKAI T, 1990, HAEMOSTASIS, V20, P125; Sambrook J, 1989, MOL CLONING LABORATO; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; TSUJI A, 1991, J BIOL CHEM, V266, P16948; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1989, BLOOD, V73, P1888; WILDGOOSE P, 1992, THROMB HAEMOSTASIS, V67, P679; WILDGOOSE P, 1992, BLOOD, V80, P25; WOJTUKIEWICZ MZ, 1990, ANTICANCER RES, V10, P579; ZACHARSKI LR, 1991, THROMB HAEMOSTASIS, V65, P545	46	93	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					66	72		10.1074/jbc.270.1.66	http://dx.doi.org/10.1074/jbc.270.1.66			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814421	hybrid			2022-12-25	WOS:A1995QA28700016
J	MIHIC, SJ; WHITING, PJ; KLEIN, RL; WAFFORD, KA; HARRIS, RA				MIHIC, SJ; WHITING, PJ; KLEIN, RL; WAFFORD, KA; HARRIS, RA			A SINGLE AMINO-ACID OF THE HUMAN GAMMA-AMINOBUTYRIC-ACID TYPE-A RECEPTOR GAMMA(2) SUBUNIT DETERMINES BENZODIAZEPINE EFFICACY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTOR; MOLECULAR-BIOLOGY; INVERSE AGONISTS; 2 FORMS; PHARMACOLOGY; CDNA; SITE; POTENTIATION; EXPRESSION; ETHANOL	Incorporation of the gamma(2) subunit into gamma-aminobutyric acid type A (GABA,) receptors is required for the expression of benzodiazepine pharmacology, but the regions of the subunit responsible for benzodiazepine actions have not been defined. Using mutagenesis, we identified a single amino acid of the gamma(2) subunit of the human GABA, receptor that profoundly alters the nature of this pharmacology, When threonine 142 was mutated to serine, the benzodiazepine receptor antagonist, flumazenil, and the weak inverse agonist, Ro 15-4513, both acted as po tent partial agonists. Further, potentiation of GABA responses by diazepam, alprazolam, clonazepam, or flunitrazepam doubled in receptors containing the Ser-142 gamma(2) subunit. In contrast, responses to the Type I benzodiazepine receptor selective ligands, zolpidem, alpidem, and CL218,872, were roughly halved. This change in pharmacology appears to occur at a stage following ligand binding, i.e. the mutation affects benzodiazepine efficacy. There was no effect on GABA affinity or efficacy or pentobarbital, Ro 5-4864, or alphaxalone modulation of GABA responses. These findings demonstrate that very minor changes in receptor structure can profoundly affect the efficacy of receptor ligands. Thus, agonism is determined not only by the structure of the drug, but also by the structure of the receptor, or protein complex, with which it interacts.	VET ADM MED CTR,DENVER,CO 80262; MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	US Department of Veterans Affairs; Veterans Health Administration (VHA); Merck & Company	MIHIC, SJ (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,4200 E 9TH AVE,DENVER,CO 80262, USA.			Whiting, Paul/0000-0002-4121-1379	NIAAA NIH HHS [AA06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006399, R01AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; GLENCORSE TA, 1990, NUCLEIC ACIDS RES, V18, P7157, DOI 10.1093/nar/18.23.7157; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970; HARRIS RA, 1988, J PHARMACOL EXP THER, V247, P1012; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; IM HK, 1993, MOL PHARMACOL, V44, P866; KLEIN RL, 1994, EUR J PHARM-MOLEC PH, V268, P237, DOI 10.1016/0922-4106(94)90194-5; KLEINGOOR C, 1993, NEUROREPORT, V4, P187, DOI 10.1097/00001756-199302000-00018; KNOFLACH F, 1991, FEBS LETT, V293, P1; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MIHIC SJ, 1994, J NEUROCHEM, V62, P1790; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRATHER PL, 1991, PROG NEURO-PSYCHOPH, V15, P921, DOI 10.1016/0278-5846(91)90019-W; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1989, P NATL ACAD SCI USA, V86, P7275, DOI 10.1073/pnas.86.18.7275; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WAFFORD KA, 1993, MOL PHARMACOL, V44, P437; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; WOOD PL, 1984, J PHARMACOL EXP THER, V231, P572; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; ZAMAN SH, 1992, EUR J PHARM-MOLEC PH, V225, P321, DOI 10.1016/0922-4106(92)90106-6	39	103	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32768	32773						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806498				2022-12-25	WOS:A1994QA63800011
J	SHIRATAKI, H; YAMAMOTO, T; HAGI, S; MIURA, H; OISHI, H; JINNO, Y; SENBONMATSU, T; TAKAI, Y				SHIRATAKI, H; YAMAMOTO, T; HAGI, S; MIURA, H; OISHI, H; JINNO, Y; SENBONMATSU, T; TAKAI, Y			RABPHILIN-3A IS ASSOCIATED WITH SYNAPTIC VESICLES THROUGH A VESICLE PROTEIN IN A MANNER INDEPENDENT OF RAB3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; SMG P25A; TARGET PROTEIN; PHOSPHOLIPID-BINDING; ACTIVATING PROTEIN; BOVINE BRAIN; MEMBRANE; NUCLEOTIDE; FUSION; LOCALIZATION	Rabphilin-3A is a putative target protein for Rab3A small GTP-binding protein, which is implicated in regulated secretion, particularly in neurotransmitter release. Rabphilin-3A is associated with synaptic vesicles, although it has no transmembrane segment. Here we have studied how rabphilin-3A is associated with synaptic vesicles. Treatment of the synaptic vesicles isolated from rat brain with 1 M NaCl completely solubilized rabphilin-3A from the vesicles. These vesicles deprived of rabphilin-3A still contained Rab3A and synaptophysin. Exogenous rabphilin-3A bound to the vesicles deprived of endogenous rabphilin-3A in dose-dependent and saturable manners. The concentration of exogenous rabphilin-3A giving a half maximal binding was about 50 nM and maximally 5 +/- 1 molecules of exogenous rabphilin-3A bound to one vesicle. Addition of exogenous Rab3A or removal of endogenous Rab3A by the action of Rab GDI did not affect the binding of exogenous rabphilin-3A BA to the vesicles. However, treatment of the vesicles with trypsin completely abolished the binding of exogenous rabphilin-3A. These results suggest that rabphilin-3A is associated with synaptic vesicles at least through a vesicle protein in a manner independent of Rab3A.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				Miura, Hisayuki/0000-0002-4780-9857				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1994, IN PRESS METHODS ENZ; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIYAZAKI A, 1994, FEBS LETT, V350, P333, DOI 10.1016/0014-5793(94)00804-3; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; SASAKI T, 1995, IN PRESS METHODS ENZ; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHIRATAKI H, 1995, IN PRESS METHODS ENZ; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	34	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32717	32720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806490				2022-12-25	WOS:A1994QA63800003
J	REID, MS; BLOBEL, CP				REID, MS; BLOBEL, CP			APEXIN, AN ACROSOMAL PENTAXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P-COMPONENT; C-REACTIVE PROTEIN; HUMAN C4B-BINDING PROTEIN; ACUTE-PHASE PROTEINS; AMINO-ACID-SEQUENCE; SPERM-EGG FUSION; GUINEA-PIG SPERM; MEMBRANE-PROTEIN; PENTRAXIN FAMILY; HUMAN-TISSUE	We report the initial biochemical characterization and the primary structure of a guinea pig sperm acrosomal pentaxin (apexin). Pentaxins are a family of penta- or decameric serum proteins that includes serum amyloid protein and C-reactive protein. Apexin consists of disulfide-linked 50-kDa subunits that give rise to an oligomeric protein, Apexin and a sperm protein related to complement receptors coelute with affinity-purified ferritin (PH-30), a potential sperm-egg membrane fusion protein. However, no evidence for a functional association of apexin with fertilin was found. Apexin is localized to the acrosome of mature guinea pig sperm and is thus the first pentaxin for which a defined intracellular localization has been reported. Whereas the C-terminal portion of apexin is clearly related to serum pentaxins, the N-terminal domain shows no strong homology to other known proteins. Northern blot analysis of different tissues revealed expression in the testis. Apexin is distinct from the pentaxins serum amyloid protein and C-reactive protein and may have evolved to perform functions other than those performed by serum pentaxins, such as intracellular protein sorting to the acrosome.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BLOBEL CP, 1991, THESIS U CALIFORNIA; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GREEN DPL, 1978, J CELL SCI, V32, P137; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HICKS PS, 1992, J IMMUNOL, V149, P3689; HILLARP A, 1993, J BIOL CHEM, V268, P15017; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1984, LANCET, V2, P376; KALARIA RN, 1993, BRAIN RES, V631, P151, DOI 10.1016/0006-8993(93)91202-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GW, 1993, J IMMUNOL, V150, P1804; MCINTYRE SS, 1983, BIOCHEM J, V210, P707; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PHELPS BM, 1987, DEV BIOL, V123, P63, DOI 10.1016/0012-1606(87)90428-3; PRELLI F, 1985, J BIOL CHEM, V260, P2895; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROBEY FA, 1981, J BIOL CHEM, V256, P969; RUBIO N, 1993, J BIOCHEM-TOKYO, V113, P277, DOI 10.1093/oxfordjournals.jbchem.a124039; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWALBE RA, 1992, BIOCHEMISTRY-US, V31, P4907, DOI 10.1021/bi00135a023; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SHEPHARD EG, 1991, BIOCHEM J, V279, P257, DOI 10.1042/bj2790257; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748	57	70	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32615	32620						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798266				2022-12-25	WOS:A1994PX30400088
J	WEMMIE, JA; SZCZYPKA, MS; THIELE, DJ; MOYEROWLEY, WS				WEMMIE, JA; SZCZYPKA, MS; THIELE, DJ; MOYEROWLEY, WS			CADMIUM TOLERANCE MEDIATED BY THE YEAST AP-1 PROTEIN REQUIRES THE PRESENCE OF AN ATP-BINDING CASSETTE TRANSPORTER-ENCODING GENE, YCF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RESISTANCE; TRANSCRIPTION; CLONING; DNA; IDENTIFICATION; OVEREXPRESSION; TRANSFORMATION; EXPRESSION; DISRUPTION	Elevations in gene dosage of the transcriptional regulatory protein yAP-1 in Saccharomyces cerevisiae can elicit pronounced phenotypic increases in tolerance of a variety of drugs including the toxic heavy metal cadmium, While a large elevation in cadmium tolerance occurs in response to overproduction of yAP-1, the target genes under yAP-1 control have not yet been identified that are responsible for this increase, We show here that the YCF1 gene, encoding a likely integral membrane protein, is required for yAP-1 to exert its normal effects on cadmium tolerance. Mutant strains of yeast that lack the YCF1 gene are hypersensitive to cadmium and this hypersensitivity is epistatic to yAP-1 overexpression. YCF1 mRNA levels and the expression of a YCF1-lacZ reporter construct positively correlates with changes in YAP1 gene dosage, A set of 5' truncation derivatives of the YCF1-lacZ fusion gene identified the region from -201 to +47 as being sufficient for the yAP-1-dependent increase in expression, DNase I footprinting using a probe from this segment of the YCF1 promoter showed that bacterially-produced yAP-1 protein was capable of binding a novel DNA element we have designated the yAP-1 response element, Insertion of the yAP-1 response element upstream of a CYC1-lacZ gene fusion led to the production of beta-galactosidase in a yAP-1-dependent fashion, These data establish that an important physiological target of yAP-1 transcriptional regulation is the YCF1 structural gene.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Iowa; University of Michigan System; University of Michigan			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NIGMS NIH HHS [GM49825, GM25295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; EDGINGTON NP, 1992, PROMEGA NOTES, V41, P14; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GADD GM, 1989, SPEC PUBL SOC GEN MI, V26, P19; GAN ZR, 1991, J BIOL CHEM, V266, P1692; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEPPERT G, 1990, GENETICS, V125, P13; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZHOU PB, 1993, BIOFACTORS, V4, P105	35	193	197	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32592	32597						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798263				2022-12-25	WOS:A1994PX30400085
J	YOUNG, JC; URSINI, J; LEGATE, KR; MILLER, JD; WALTER, P; ANDREWS, DW				YOUNG, JC; URSINI, J; LEGATE, KR; MILLER, JD; WALTER, P; ANDREWS, DW			AN AMINO-TERMINAL DOMAIN-CONTAINING HYDROPHOBIC AND HYDROPHILIC SEQUENCES BINDS THE SIGNAL RECOGNITION PARTICLE RECEPTOR-ALPHA SUBUNIT TO THE BETA-SUBUNIT ON THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION; NASCENT PROTEINS; ESCHERICHIA-COLI; DOCKING PROTEIN; MESSENGER-RNA; GTP-BINDING; COMPLEX; TRANSLATION; SEPARATION; INITIATION	The signal recognition particle receptor consists of two subunits of 72 kDa (SR alpha) and 30 kDa (SRP), Assembly of SR alpha on the endoplasmic reticulum membrane can occur independent of the signal recognition particle-mediated translocation pathway, To identify the sequences within SR alpha necessary for membrane binding, a series of amino-terminal and internal deletion mutants was constructed and translated in a cell-free system. In addition, nascent SR alpha polypeptides of varying lengths were generated by cycloheximide treatment of translation reactions, Microsome binding assays performed on these polypeptides revealed a membrane binding domain consisting of the amino-terminal 140 residues of SR alpha. This domain includes the two hydrophobic sequences originally proposed to bind to membranes and a highly charged region not previously implicated in membrane assembly. Furthermore, the domain forms a protease-resistant folding unit that after proteolysis can target and anchor onto microsomes, Extraction of microsomal SR alpha at high pH supplemented with 1 M NaSCN suggests that SR alpha and the membrane binding domain are not integrated in the endoplasmic reticulum membrane. The membrane binding domain is also the major site of tight binding with SR beta, suggesting that SR beta plays a role in the membrane assembly of SR alpha.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	McMaster University; University of California System; University of California San Francisco				Andrews, David/0000-0002-9266-7157; Legate, Kyle/0000-0003-3243-579X				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BLOHEL G, 1970, J CELL BIOL, V45, P130; BORDIER C, 1981, J BIOL CHEM, V256, P1604; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOBDEN AN, 1978, BIOCHEM J, V170, P57, DOI 10.1042/bj1700057; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; THEISEN N, 1986, ANAL BIOCHEM, V152, P211, DOI 10.1016/0003-2697(86)90399-4; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	39	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15650	15657		10.1074/jbc.270.26.15650	http://dx.doi.org/10.1074/jbc.270.26.15650			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797564	hybrid			2022-12-25	WOS:A1995RG53800035
J	MELY, Y; DEROCQUIGNY, H; SORINASJIMENO, M; KEITH, G; ROQUES, BP; MARQUET, R; GERARD, D				MELY, Y; DEROCQUIGNY, H; SORINASJIMENO, M; KEITH, G; ROQUES, BP; MARQUET, R; GERARD, D			BINDING OF THE HIV-1 NUCLEOCAPSID PROTEIN TO THE PRIMER TRNA(3)(LYS), IN-VITRO, IS ESSENTIALLY NOT SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEIC-ACID INTERACTIONS; REVERSE-TRANSCRIPTASE; LAC REPRESSOR; ZINC FINGERS; REPLICATION PRIMER; TRANSFER-RNAS; VIRAL-RNA; DOMAINS; SITE	The nucleocapsid protein NCp7 of human immunodeficiency virus, type 1, is a key component in the viral life cycle, Since, the first common step of all reported NCp7 activities corresponds to a nucleic acid-binding step, the NCp7 binding parameters to the natural primer tRNA(3)(Lys) were investigated. Using NCp7 intrinsic fluorescence, we found that (i) in 0.1 hr NaCl, NCp7 bound noncooperatively to tRNA(3)(Lys) with a K-obs = 3.2 x 10(6) M(-1) association constant and a n = 6 binding site size, (ii) four ionic interactions were formed in the NCp7.tRNA(3)(Lys) complex, and (iii) nonelectrostatic factors provided about 60% of the binding energy. These binding parameters were not significantly altered when the natural tRNA(3)(Lys) was replaced by either an in vitro synthetic tRNA(3)(Lys) transcript, the heterologous yeast tRNA(Phe) or the structurally unrelated 5 S RNA from Escherichia coli. Moreover, the environment of the intrinsic fluorescent reporters (Trp(37) and Trp(61)) was similar in the various complexes. Finally, experiments performed at low protein concentration provide no evidence of high affinity binding sites. Taken together, our data strongly suggested an essentially nonspecific binding of NCp7 to tRNA(3)(Lys) and thus did not seem to support a direct role of NCp7, per se, in the selection of tRNA(3)(Lys) from the pool of cellular tRNAs.	INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9002, F-67084 STRASBOURG, FRANCE; UFR SCI PHARMACEUT & BIOL, DEPT CHIM ORGAN, CNRS, INSERM, U266, F-75270 PARIS 06, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	MELY, Y (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, FAC PHARM,BIOPHYS LAB,CNRS,URA 491, BP 24, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE.			Marquet, Roland/0000-0002-4209-3976				ARNOLD E, 1991, ADV VIRUS RES, V39, P1; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3842, DOI 10.1021/bi00516a027; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BRUNEL C, 1991, J MOL BIOL, V221, P293; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1991, B I PASTEUR, V89, P211; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; GELFAND CA, 1993, J BIOL CHEM, V268, P18450; HELENE C, 1971, J MOL BIOL, V58, P349, DOI 10.1016/0022-2836(71)90251-8; ISEL C, 1993, J BIOL CHEM, V268, P25269; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KEITH G, 1983, BIOCHIMIE, V65, P661; KHAN R, 1992, J BIOL CHEM, V267, P6689; KHAN R, 1994, J BIOL CHEM, V269, P22538; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LEIS J, 1983, J VIROL, V48, P361, DOI 10.1128/JVI.48.2.361-369.1983; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MELY Y, 1993, BIOPHYS J, V65, P1513, DOI 10.1016/S0006-3495(93)81222-0; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WONDRAK EM, 1993, FEBS LETT, V333, P21, DOI 10.1016/0014-5793(93)80367-4	42	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1650	1656		10.1074/jbc.270.4.1650	http://dx.doi.org/10.1074/jbc.270.4.1650			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829498	hybrid			2022-12-25	WOS:A1995QD20400028
J	ZIEROLD, C; DARWISH, HM; DELUCA, HF				ZIEROLD, C; DARWISH, HM; DELUCA, HF			2 VITAMIN-D RESPONSE ELEMENTS FUNCTION IN THE RAT 1,25-DIHYDROXYVITAMIN-D-24-HYDROXYLASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE; EXPRESSION; RECEPTOR; BINDING; IDENTIFICATION; METABOLISM; INTESTINE; SEQUENCES; HORMONE; KIDNEY	The interaction between the two vitamin D response elements (DRE) located at -154 to -134 base pairs (bp) and -262 to -238 bp from the transcription initiation site has been studied using reporter gene assays and binding assays by electrophoretic gel shift measurements. 3 half-sites separated by 3 bp were found necessary for transactivation by the -154 to -125 DRE, while 2 half-sites separated by 3 bp were needed for the DRE at -262 to -238 to function. However, the two DREs together provided maximal activity. The 93-bp fragment separating the two DREs was not required and could be deleted. The most effective binding by receptor was found with the two complete DREs (dissociation constant (K-d) = 13.7 pM), although each DRE bound to the receptor and nuclear accessory factor with about 5 nM K-d. The two DREs (a total of 5 half-sites) apparently account for most if not all of the transactivation of the rat 24-hydroxylase by 1,25-dihydroxyvitamin D-3. This system represents the most powerful of the DREs reported to date.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMBRECHT HJ, 1991, FEBS LETT, V292, P17, DOI 10.1016/0014-5793(91)80823-L; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DELUCA HF, 1991, J BONE MINE METAB, V9, P17; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; ENGSTROM GW, 1986, ARCH BIOCHEM BIOPHYS, V250, P86, DOI 10.1016/0003-9861(86)90704-6; GRAY RW, 1990, STEROIDS, V55, P395, DOI 10.1016/0039-128X(90)90097-U; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1992, DNA CELL BIOL, V11, P377, DOI 10.1089/dna.1992.11.377; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1986, ARCH BIOCHEM BIOPHYS, V251, P222, DOI 10.1016/0003-9861(86)90069-X; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SHINKI T, 1992, J BIOL CHEM, V267, P13757; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	24	151	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1675	1678		10.1074/jbc.270.4.1675	http://dx.doi.org/10.1074/jbc.270.4.1675			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829502	hybrid			2022-12-25	WOS:A1995QD20400032
J	MITAMURA, T; HIGASHIYAMA, S; TANIGUCHI, N; KLAGSBRUN, M; MEKADA, E				MITAMURA, T; HIGASHIYAMA, S; TANIGUCHI, N; KLAGSBRUN, M; MEKADA, E			DIPHTHERIA-TOXIN BINDS TO THE EPIDERMAL GROWTH-FACTOR (EGF)-LIKE DOMAIN OF HUMAN HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR DIPHTHERIA-TOXIN RECEPTOR AND INHIBITS SPECIFICALLY ITS MITOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; CD9 ANTIGEN; LOW PH; FRAGMENT; MUTANTS; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION; MEMBRANE	The membrane anchored form of human heparin-binding epidermal growth factor-like growth factor (HB-EGF) acts as the diphtheria toxin (DT) receptor. Transfection of human HE-EGF cDNA into mouse LC cells, L cells stably expressing DRAP27, conferred sensitivity to DT, but transfection of mouse HB-EGF cDNA did not. To define the essential regions of HB-EGF that serve as the functional DT receptor, we examined the sensitivity to DT and DT binding of cells expressing several human/mouse HB-EGF chimeras. It was found that DT binds to the EGF-like domain of the human HB-EGF, However, mouse HB-EGF does not serve as a functional DT receptor due to non-conserved amino acid substitutions in this domain, In addition, CRM197, a non-toxic mutant of DT, inhibited strongly the mitogenic activity of the secreted form of human HB-EGF, but not of mouse HB-EGF and other EGF receptor-binding growth factors. These results confirmed further that DT interacts with the EGF-like domain of HB-EGF and that this interaction is specific for human HB-EGF.	KURUME UNIV, INST LIFE SCI, DIV CELL BIOL, KURUME, FUKUOKA 830, JAPAN; OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Kurume University; Osaka University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ibrahim, Essam Hassan/G-1960-2018; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Ibrahim, Essam Hassan/0000-0003-0130-2257; Taniguchi, Naoyuki/0000-0001-5889-5968; Mekada, Eisuke/0000-0001-8858-4781	NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLONTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; GABLIKS J, 1962, J IMMUNOL, V88, P505; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IHLE JN, 1982, J IMMUNOL, V129, P2431; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; LENNOX ES, 1957, P SOC EXP BIOL MED, V95, P700, DOI 10.3181/00379727-95-23335; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; SOUSA CP, 1957, BRIT J EXP PATHOL, V38, P644; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940	34	246	271	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1015	1019		10.1074/jbc.270.3.1015	http://dx.doi.org/10.1074/jbc.270.3.1015			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836353	hybrid			2022-12-25	WOS:A1995QB15600008
J	LEDEBUR, HC; PARKS, TP				LEDEBUR, HC; PARKS, TP			TRANSCRIPTIONAL REGULATION OF THE INTERCELLULAR-ADHESION MOLECULE-1 GENE BY INFLAMMATORY CYTOKINES IN HUMAN ENDOTHELIAL-CELLS - ESSENTIAL ROLES OF A VARIANT NF-KAPPA-B SITE AND P65 HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STIMULATING FACTOR GENE; NUCLEAR FACTOR; DIFFERENTIAL REGULATION; INTERLEUKIN-8 GENE; ONCOPROTEIN BCL-3; FAMILY MEMBERS; PHORBOL ESTER; C/EBP FAMILY; ICAM-1 GENE	Intercellular adhesion molecule-1 (ICAM-1) is greatly up-regulated on endothelial cells at sites of inflammation and is involved in leukocyte attachment and extravasation. Previously, we had shown that the ICAM-1 gene expression in human umbilical vein endothelial cells (HUVECs) was transcriptionally regulated by tumor necrosis factor-alpha (TNF-alpha) (Wertheimer, S. J., Myers, C. L., Wallace, R. W., and Parks, T. P. (1992) J. Biol. Chem. 267, 12030-12035). In the present investigation, TNF-alpha-induced transcription was found to be initiated exclusively at two sites, 40 and 41 base pairs upstream of the translation start site, Deletion analysis of the 5' regulatory region of the ICAM-1 gene revealed a 92-base pair sequence which was both necessary and sufficient to confer TNF-alpha responsiveness to a linked luciferase reporter gene in transient transfection assays, This TNF-alpha-responsive region contained a variant NF-kappa P site at -187 to -178, which when mutated, completely abolished ICAM-1 promoter activation by TNF-alpha, interleukin-1 beta, and lipopolysaccharide. Two inducible nuclear protein complexes bound to the ICAM-1 kappa B site and were identified as the NF-kappa D p65 homodimer and p65/p50 heterodimer. Overexpression of p65, but not p50, transactivated the ICAM-1 promoter in a kappa B site-dependent manner in HUVECs. In addition, p65-mediated transactivation was suppressed by co-expression of p50. Our results suggest that cytokine activation of the ICAM-1 promoter in HUVECs may critically depend on p65 homodimers binding to a variant kappa B site.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,RIDGEFIELD,CT 06877	Boehringer Ingelheim				Ledebur, Harry/0000-0001-8011-8655				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CORNELIUS LA, 1993, J INVEST DERMATOL, V100, P753, DOI 10.1111/1523-1747.ep12476300; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ENTMAN ML, 1992, J CLIN INVEST, V90, P1335, DOI 10.1172/JCI115999; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANIATIS T, 1989, MOL CLONING, V3; MENTZER SJ, 1988, J CELL PHYSIOL, V137, P173, DOI 10.1002/jcp.1041370121; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MYERS CL, 1992, AM J PHYSIOL, V262, pC865; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; POBER JS, 1987, J IMMUNOL, V138, P3319; POBER JS, 1986, J IMMUNOL, V137, P1893; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; ROOS E, 1987, J CELL BIOL, V105, P553, DOI 10.1083/jcb.105.1.553; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	64	522	532	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					933	943		10.1074/jbc.270.2.933	http://dx.doi.org/10.1074/jbc.270.2.933			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822333	hybrid			2022-12-25	WOS:A1995QB81600068
J	LEE, CC; YAMADA, KM				LEE, CC; YAMADA, KM			ALTERNATIVELY SPLICED JUXTAMEMBRANE DOMAIN OF A TYROSINE KINASE RECEPTOR IS A MULTIFUNCTIONAL REGULATORY SITE - DELETION ALTERS CELLULAR TYROSINE PHOSPHORYLATION PATTERN AND FACILITATES BINDING OF PHOSPHATIDYLINOSITOL-3-OH KINASE TO THE HEPATOCYTE GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SCATTER FACTOR-RECEPTOR; 3-KINASE	The hepatocyte growth factor (HGF) receptor is a tyrosine kinase receptor that mediates signal transduction upon ligand stimulation, This receptor is present in mouse tissues as two major isoforms differing by a 47-amino acid segment in the juxtamembrane domain, an alternatively spliced cytoplasmic region adjacent to the transmembrane domain of the receptor. We report here that the juxtamembrane domain of the receptor is involved in the regulation of downstream signal transduction, The two receptor isoforms were transiently expressed in COS-7 cells, Both exogenous receptors underwent autophosphorylation and subsequently stimulated a set of protein tyrosine phosphorylations that were not present in control cells. Comparisons of phosphotyrosine profiles of transfected cell lysates induced by receptor isoforms demonstrated that at least three phosphorylated proteins of similar to 62, similar to 35, and similar to 30 kDa were differentially induced by the receptor isoforms, suggesting that the juxtamembrane domain of a kinase receptor can play a role in selective signal transduction, Furthermore, the p85 subunit of phosphatidylinositol-3-OH kinase (PI3 kinase) co-precipitated with the small isoform of the HGF receptor, and this association was dramatically inhibited by treatment with 12-O-tetradecanoylphorbol-13-acetate. Since removal of the juxtamembrane domain facilitates the binding of p85 to the receptor, it is likely that the juxtamembrane region plays a role in negative regulation of the binding of PI3 kinase to the HGF receptor, Our study establishes novel molecular sequelae of alternative splicing of an intracellular domain of the HGF receptor.	NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; LEE CC, 1994, J BIOL CHEM, V269, P19457; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; POWIS G, 1994, CANCER METAST REV, V13, P91, DOI 10.1007/BF00690420; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; ZHEN Z, 1994, ONCOGENE, V9, P1691	22	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					507	510		10.1074/jbc.270.2.507	http://dx.doi.org/10.1074/jbc.270.2.507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822270	hybrid			2022-12-25	WOS:A1995QB81600002
J	TAKADA, T; IIDA, K; MOSS, J				TAKADA, T; IIDA, K; MOSS, J			CONSERVATION OF A COMMON MOTIF IN ENZYMES CATALYZING ADP-RIBOSE TRANSFER - IDENTIFICATION OF DOMAINS IN MAMMALIAN TRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; NAD-BINDING-SITE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; DIPHTHERIA-TOXIN; SKELETAL-MUSCLE; POLY(ADP-RIBOSE) POLYMERASE; RIBOSYLTRANSFERASE ACTIVITY; CRYSTAL-STRUCTURE; CHOLERA-TOXIN	Bacterial toxin ADP-ribosyltransferases, e.g. diphtheria toxin (DT) and pertussis toxin, have in common consensus sequences involved in catalytic activity, which are localized to three regions, Region I is notable for a histidine or arginine; region II, similar to 50-75 amino acids downstream, is rich in aromatic/hydrophobic amino acids; and region III, further downstream has a glutamate and other acidic amino acids, A similar motif was observed in the sequence of the glycosylphosphatidylinositol-linked muscle ADP-ribosyltransferase. Site-directed mutagenesis was performed to verify the role of this motif, Proteins were expressed in rat adenocarcinoma cells, released from the cell with phosphatidylinositol-specific phospholipase C, and quantified with polyclonal antibodies, Transferase His(114) in region I aligned with His(21) of DT; as with DT, the H114N mutant was active. Aromatic/hydrophobic amino acids (region II) were found similar to 30-50 amino acids downstream of this histidine, Although transferase has a Glu(278)-Tyr-Ile sequence characteristic of region III in DT, Glu(278) was not critical for activity, In an alternative region III containing Glu(238)-Glu(239)-Glu(240), Glu(238) and Glu(240) but not Glu(239) were critical, Glu(240) aligned with critical glutamates in DT, Pseudomonas exotoxin, and C3 transferase. Thus, the mammalian ADP-ribosyltransferases have motifs similar to toxin ADP-ribosyltransferases, suggesting that these sequences are important in ADP-ribose transfer reactions.			TAKADA, T (corresponding author), NHLBI, PULM & CRIT CARE MED BRANCH, RM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.							ANTOINE R, 1994, J BIOL CHEM, V269, P6450; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON VG, 1994, J BIOL CHEM, V269, P4349; JUNG M, 1993, J BIOL CHEM, V268, P23215; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOWERY RG, 1990, ADP RIBOSYLATING TOX, P459; MARSISCHKY GT, 1991, ADP RIBOSYLATION REA, P47; MOSS J, 1992, J BIOL CHEM, V267, P10481; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; SIMONIN F, 1993, J BIOL CHEM, V268, P8529; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1993, J BIOL CHEM, V268, P17837; TWETEN RK, 1985, J BIOL CHEM, V260, P392; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; YAMAMOTO T, 1984, J BIOL CHEM, V259, P5037; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352; [No title captured]	34	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					541	544		10.1074/jbc.270.2.541	http://dx.doi.org/10.1074/jbc.270.2.541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822277	hybrid			2022-12-25	WOS:A1995QB81600009
J	HODGESGARCIA, Y; HAGERMAN, PJ				HODGESGARCIA, Y; HAGERMAN, PJ			INVESTIGATION OF THE INFLUENCE OF CYTOSINE METHYLATION ON DNA FLEXIBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-CLOSURE PROBABILITIES; HELICAL REPEAT; CURVATURE; CYCLIZATION; DEPENDENCE; FRAGMENTS	To test the influence of pyrimidine methyl groups on DNA flexibility and helix repeat, two sets of 14 mixed sequence DNA molecules, spanning a range of lengths from 158 to 180 base pairs, were cyclized with T4 DNA ligase. The two sets differed only in that the Cyt-5 positions of all cytosines (80-90 cytosine residues per molecule) were fully methylated in the members of one set. Determination of the molar cyclization factors, persistence lengths, helix repeats, and torsional elastic constants revealed no significant differences between the two sets. These results imply that, at least for mixed sequence DNA the biological consequences of cytosine methylation are likely to derive from either local structural distortions in the helix, which do not propagate as altered twist, or from direct protein-methyl cytosine interactions.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; COLASANTI J, 1991, NUCLEIC ACIDS RES, V19, P391, DOI 10.1093/nar/19.2.391; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DIEKMANN S, 1987, EMBO J, V6, P4213, DOI 10.1002/j.1460-2075.1987.tb02769.x; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAGERMAN PJ, 1984, P NATL ACAD SCI-BIOL, V81, P4632, DOI 10.1073/pnas.81.15.4632; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HAGERMAN PJ, 1990, BIOCHEMISTRY-US, V29, P1980, DOI 10.1021/bi00460a003; HAGERMAN RJ, 1994, AM J MED GENET, V51, P298, DOI 10.1002/ajmg.1320510404; HAGERMAN RJ, 1991, FRAGILE X SYNDROME; HEINEMANN U, 1992, J BIOL CHEM, V267, P7332; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MIGEON B, 1993, AM J MED GENET, V47, P685; MURCHIE AI, 1993, J MOL BIOL, V205, P593; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHIMADA J, 1984, MACROMOLECULES, V17, P689, DOI 10.1021/ma00134a028; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SONG L, 1990, BIOPOLYMERS, V30, P229, DOI 10.1002/bip.360300302; STROBEL SA, 1993, NATURE, V350, P172; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; Trifonov E. N., 1987, DNA BENDING CURVATUR, P243; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; ZACHARIAS W, 1993, DNA METHYLATION MOL, P27; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	35	30	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					197	201		10.1074/jbc.270.1.197	http://dx.doi.org/10.1074/jbc.270.1.197			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814373	hybrid			2022-12-25	WOS:A1995QA28700033
J	LIU, RC; ZHU, J; JOSPE, N; FURLANETTO, RW; BASTIAN, W; LIVINGSTON, JN				LIU, RC; ZHU, J; JOSPE, N; FURLANETTO, RW; BASTIAN, W; LIVINGSTON, JN			DELETION OF LYSINE-121 CREATES A TEMPERATURE-SENSITIVE ALTERATION IN INSULIN BINDING BY THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; NEGATIVE COOPERATIVITY; ALPHA-SUBUNIT; SPECIFICITY; REGION; SITE; CELLS	Recently we reported the deletion of Lys-121 in one allele of the insulin receptor gene from a child with severe insulin resistance, In the present work, this mutant receptor (M121) was shown to have an abnormal sensitivity to temperature and an alteration in ''negative cooperativity.'' In contrast to the wild-type receptor (HIRC), insulin binding by the M121 receptor was rapidly and irreversibly lost at temperatures above 30 degrees C with the phosphorylated form of the receptor being more temperature-sensitive than the nonphosphorylated form, Although insulin binding activity was lost, Western analysis and other studies showed that the mutant receptor remained intact, Measurements of I-125-insulin dissociation at 21 degrees C in the presence of native insulin (an estimate of negative cooperativity) demonstrated a difference between the mutant and wild-type receptor, Insulin dissociation from the mutant receptor was not as pronounced as that found with the wild-type receptor, Thus, an abnormality in insulin binding by the mutation was evident at lower ''permissive'' temperatures, The results of these and other studies argue that Lys-121 occupies an important position for the regulation of insulin receptor conformation, This regulation apparently influences negative cooperative interactions with insulin and modulates signal transduction.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,ROCHESTER,NY 14642; MILES PHARMACEUT DIV,W HAVEN,CT 06515	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040394] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK40394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1978, NATURE, V273, P504; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEVRIES CP, 1990, DIABETES METAB, V16, P70; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HARRISON LC, 1980, J BIOL CHEM, V255, P2066; JOSPE N, 1994, IN PRESS J CLIN ENDO; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LECONTE I, 1992, J BIOL CHEM, V267, P17415; PILCH P, 1981, SERONO S, V41, P255; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHAPIRO DL, 1986, BIOCHIM BIOPHYS ACTA, V885, P216, DOI 10.1016/0167-4889(86)90091-1; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; TAYLOR S, 1990, DIABETES CARE, V18, P257; TAYLOR SI, 1981, P NATL ACAD SCI-BIOL, V78, P7157, DOI 10.1073/pnas.78.11.7157; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YIP CC, 1978, J BIOL CHEM, V253, P1743; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1992, J BIOL CHEM, V267, P18320	27	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					476	482		10.1074/jbc.270.1.476	http://dx.doi.org/10.1074/jbc.270.1.476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814414	hybrid			2022-12-25	WOS:A1995QA28700075
J	THOMPSON, DK; GARBERS, DL				THOMPSON, DK; GARBERS, DL			DOMINANT-NEGATIVE MUTATIONS OF THE GUANYLYL CYCLASE-A RECEPTOR - EXTRACELLULAR DOMAIN DELETION AND CATALYTIC DOMAIN POINT MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; ACTIVITY REQUIRES; ENZYME SUBUNITS; LIGAND-BINDING; EXPRESSION; IDENTIFICATION; MESODERM	Guanylyl cyclase-A (GC-A), a receptor for A-type natriuretic peptide (ANP), contains an extracellular ligand-binding domain, a single transmembrane domain, and intracellular protein kinase-like and cyclase catalytic domains. Expression of the putative cyclase catalytic region (HCAT) resulted in the formation of an active enzyme that migrated as a homodimer on gel filtration columns; treatment with sodium trichloroacetate caused dissociation of the dimer and a loss of cyclase activity. Co-transfection of HCAT and full-length GC-A led to elevated basal intact cell cGMP concentrations and increased cell homogenate guanylyl cyclase activity. However, atrial natriuretic peptide-induced elevations of cGMP and cyclase activity were inhibited by the introduction of HCAT. Alanine scanning mutagenesis of highly conserved residues within HCAT identified one mutation (D893A) that destroyed enzyme activity but not the ability of the mutant subunit to form homodimers. The mutant subunit inhibited the cyclase activity of wild-type HCAT (approximately 70%) as well as that of full-length GC-A (approximately 85%) in co-expression studies where the amount of wild-type HCAT or full-length GC-A was not altered. Unlike co-transfection with wild-type HCAT, co-transfection of HCATD893A and GC-A did not result in elevated basal intact cell cGMP concentrations. For the first time we describe deletion and point mutations within the plasma membrane family of guanylyl cyclase receptors that result in the formation of effective dominant negative proteins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University					NICHD NIH HHS [HD10254] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010254] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P2235; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; ISHIKAWA Y, 1992, J BIOL CHEM, V26, P13553; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKANE M, 1990, J BIOL CHEM, V265, P16841; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; TANG WJ, 1991, J BIOL CHEM, V266, P8595; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; YUEN PST, 1994, J BIOL CHEM, V269, P791	31	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					425	430		10.1074/jbc.270.1.425	http://dx.doi.org/10.1074/jbc.270.1.425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814405	hybrid			2022-12-25	WOS:A1995QA28700067
J	ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG				ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG			SCL, A GENE FREQUENTLY ACTIVATED IN HUMAN T-CELL LEUKEMIA, DOES NOT INDUCE LYMPHOMAS IN TRANSGENIC MICE	ONCOGENE			English	Note						TAL1; CD2 ENHANCER; TRANSGENE	LOOP-HELIX GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; C-MYC; TAL-1 GENE; N-MYC; TRANSLOCATION; LOCUS; OVEREXPRESSION; HEMATOPOIESIS	The scl gene is implicated in human T cell acute lymphoblastic leukaemia (T-ALL) through its involvement in the t(1;14)(p32;q11) chromosomal translocation and, more frequently, as a result of a tumour-specific interstitial deletion on chromosome 1. The consequence of both these chromosomal alterations is overexpression of scl in the leukaemic cells. Despite the strong inference of a role in human T-ALL, scl has not yet been demonstrated to be causally involved in neoplastic transformation. We attempted to do this by generating transgenic mice in which scl expression was directed to the T cell lineage using the CD2 enhancer and the strong SR alpha viral promoter (CD2-scl mice). Three transgenic lines, an of which expressed the scl transgene at a high level, were bred and analysed. No alterations in T cell development were seen in the mice. Unexpectedly CD2-scl mice did not develop tumours, nor did the transgene enhance tumourigenesis by Moloney murine leukaemia virus. These findings throw into question the mechanism by which aberrant scl expression contributes to T cell leukaemogenesis.			ROBB, L (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Rasko, John EJ/F-5754-2013	Strasser, Andreas/0000-0002-5020-4891; rasko, John/0000-0003-2975-807X	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCH P, 1992, ONCOGENE, V7, P2389; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HATANO M, 1992, BLOOD S, V80, pA355; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALLIANPUR AR, 1994, BLOOD, V83, P1200; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SOLOMON E, 1991, SCIENCE, V254, P1135; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VISVADER J, 1991, ONCOGENE, V6, P195; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	42	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824274				2022-12-25	WOS:A1995QA98000024
J	DELPRETE, G; DECARLI, M; ALMERIGOGNA, F; DANIEL, CK; DELIOS, MM; ZANCUOGHI, G; VINANTE, F; PIZZOLO, G; ROMAGNANI, S				DELPRETE, G; DECARLI, M; ALMERIGOGNA, F; DANIEL, CK; DELIOS, MM; ZANCUOGHI, G; VINANTE, F; PIZZOLO, G; ROMAGNANI, S			PREFERENTIAL EXPRESSION OF CD30 BY HUMAN CD4(+) T-CELLS PRODUCING TH2-TYPE CYTOKINES	FASEB JOURNAL			English	Article						MEMBRANE CD30; SOLUBLE CD30; HUMAN TH1 TH2; CELLS	HODGKINS-DISEASE; FUNCTIONAL SUBSETS; LYMPHOID-CELLS; HELPER; RECEPTOR; RESPONSES; CLONES; TH1; DEFINES; FAMILY	A large panel of human CD4(+) T helper (Th) cell clones with established Th1, Th2, or Th0 profiles of cytokine secretion were examined for the expression of CD30, a member of the tumor necrosis factor receptor superfamily. Th1 clones expressed poor or no CD30 mRNA, and showed low or undetectable expression of both membrane and soluble CD30 (sCD30) protein, whereas Th2 clones showed both CD30 mRNA and membrane CD30 and released substantial amounts of sCD30. Th0 clones exhibited an intermediate pattern of CD30 expression and release. When T cells from the same donor were stimulated with three different antigens (purified protein derivative, PPD; Toxocara canis excretory/secretory antigen, TES; Lolium perenne group I, Lo1 p I), production of high concentrations of IFN-gamma, but not expression of CD30 or production of IL-4 and IL-5, were observed at any time after stimulation with PPD. In contrast, both CD30 expression and production of IL-4 and IL-5, but not of IFN-gamma, were concomitantly detectable in TES- and Lo1 p I-reactive T cells, suggesting a temporal relationship between CD30 expression and beginning of Th2-type cytokine production. Finally, CD4(+)CD30(+) T cells specific for Lo1 p I and inducible to production of Th2-type cytokines were sorted out from the circulation of grass-sensitive patients in concomitance with the onset of allergic symptoms during the seasonal exposure to grass pollen. Thus, CD30 expression appears to be associated with the differentiation/activation pathway of human T cells producing Th2-type cytokines.	UNIV FLORENCE, IST CLIN MED 3, DIV CLIN IMMUNOL & ALLERGY, I-50134 FLORENCE, ITALY; UNIV PISA, POLICLIN SANTA CHIARA, IST CLIN MED 1, I-56100 PISA, ITALY; UNIV VERONA, POLICLIN BORGO ROMA, DEPT HEMATOL, I-37134 VERONA, ITALY	University of Florence; University of Pisa; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona			Almerigogna, Fabio/AAL-4583-2020; D'Elios, Mario Milco/Y-9573-2019; Almerigogna, Fabio/A-4636-2012	D'Elios, Mario Milco/0000-0001-9160-0930; Vinante, Fabrizio/0000-0002-3855-6747				ALZONA M, 1994, J IMMUNOL, V153, P2861; ANDREESEN R, 1984, BLOOD, V63, P1299; BOWEN MA, 1993, J IMMUNOL, V151, P5896; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; MAGGI E, 1992, J IMMUNOL, V148, P2142; MAGILAVY DB, 1989, J EXP MED, V170, P985, DOI 10.1084/jem.170.3.985; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MANETTI R, 1995, IN PRESS J EXP MED; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; REINER SL, 1993, PARASITOL TODAY, V9, P258, DOI 10.1016/0169-4758(93)90071-M; ROMAGNANI S, 1985, SEMIN HEMATOL, V22, P41; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STEIN H, 1985, BLOOD, V66, P848; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WILLIAMS IR, 1990, J IMMUNOL, V145, P85	33	370	377	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					81	86		10.1096/fasebj.9.1.7821763	http://dx.doi.org/10.1096/fasebj.9.1.7821763			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821763				2022-12-25	WOS:A1995QD20200013
J	MATSUDA, K; KASAMA, T; ISHIZUKA, I; HANDA, S; YAMAMOTO, N; TAKI, T				MATSUDA, K; KASAMA, T; ISHIZUKA, I; HANDA, S; YAMAMOTO, N; TAKI, T			STRUCTURE OF A NOVEL PHOSPHOCHOLINE-CONTAINING GLYCOGLYCEROLIPID FROM MYCOPLASMA-FERMENTANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; LIPOTEICHOIC ACID; CHOLINE PHOSPHATE; APLYSIA-KURODAI; CELL-LINES; HIV-1; LYMPHOCYTES; INCOGNITUS; INFECTION; AIDS	Mycoplasma fermentans is thought to be a pathogen of rheumatoid arthritis or cofactor of AIDS. A novel phosphocholine-containing glycoglycerophospholipid named GGPL-I was isolated from a M. fermentans infected human helper T-cell culture. It was revealed that GGPL-I is a lipid component of the M. fermentans and a major immunological determinant. The GGPL-I was purified by DEAE-Sephadex column chromatography and repeated Iatrobeads column chromatography. The purified glycophospholipid was subjected to structural characterization by thin-layer chromatography, Fourier-transform infrared spectrometry, liquid secondary ion mass spectrometry, and nuclear magnetic resonance spectroscopy. Its structure was determined to be as follows: 6'-O-phosphocholine-alpha-glucopyranosyl-(1'-3)-1,2-diacyl-sn-glycerol. This glycoglycerophospholipid is unique in containing phosphocholine, which is attached to C-6 of glucose. The stereospecific numbering (an) of naturally occurring GGPL-I was determined through comparison with chemically synthesized compounds.	TOKYO MED & DENT UNIV,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,BIOMED ANAL LAB,BUNKYO KU,TOKYO 113,JAPAN; TEIKYO UNIV,SCH MED,DEPT BIOCHEM,ITABASHI KU,TOKYO 173,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Teikyo University	MATSUDA, K (corresponding author), TOKYO MED & DENT UNIV,DEPT MICROBIOL,BUNKYO KU,5-45 YUSHIMA 1 CHOME,TOKYO 113,JAPAN.							ABE S, 1991, J BIOL CHEM, V266, P9939; [Anonymous], 1977, EUR J BIOCHEM, V79, P11; ARAKI S, 1986, J BIOL CHEM, V261, P5138; BEBEAR C, 1993, LANCET, V341, P758, DOI 10.1016/0140-6736(93)90531-K; BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; DAWSON MS, 1993, ARCH PATHOL LAB MED, V117, P511; DITTMER JC, 1964, J LIPID RES, V5, P126; HAUSER H, 1980, J MOL BIOL, V137, P265, DOI 10.1016/0022-2836(80)90316-2; KAGAN GY, 1982, ZH MIKROBIOL EPIDEMI, V3, P107; KAPLAN MH, 1974, J IMMUNOL, V112, P283; Kates M., 1986, TECHNIQUES LIPIDOLOG; KOCHANOWSKI B, 1993, EUR J BIOCHEM, V214, P747, DOI 10.1111/j.1432-1033.1993.tb17976.x; LEMAITRE M, 1990, RES VIROLOGY, V141, P5, DOI 10.1016/0923-2516(90)90052-K; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V41, P586, DOI 10.4269/ajtmh.1989.41.586; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; MANNOCK DA, 1990, CHEM PHYS LIPIDS, V55, P309, DOI 10.1016/0009-3084(90)90169-R; MARINETTI GV, 1962, J LIPID RES, V3, P1; MATSUBARA T, 1994, IN PRESS BIOCH BIOPH; MATSUDA K, 1993, BIOCHIM BIOPHYS ACTA, V1168, P123; MATSUDA K, 1993, GLYCOCONJUGATE J, V10, P340, DOI 10.1007/BF01210178; MIYOSHI I, 1980, GANN, V71, P155; NISHIDA Y, 1994, IN PRESS TETRAHEDRON; PHILLIPS DM, 1992, AIDS RES HUM RETROV, V8, P1863, DOI 10.1089/aid.1992.8.1863; SIMS RPA, 1962, J AM OIL CHEM SOC, V39, P232, DOI 10.1007/BF02635828; SUGITA M, 1992, J BIOL CHEM, V267, P22595; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TATE SI, 1992, J MAGN RESON, V96, P635, DOI 10.1016/0022-2364(92)90352-8; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; WILLIAMS MH, 1970, LANCET, V2, P277; WILLIAMS MH, 1971, ANN RHEUM DIS, V30, P271, DOI 10.1136/ard.30.3.271	34	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33123	33128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806541				2022-12-25	WOS:A1994QA63800059
J	PERLMAN, RK; ROSNER, MR				PERLMAN, RK; ROSNER, MR			IDENTIFICATION OF ZINC LIGANDS OF THE INSULIN-DEGRADING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RAT-LIVER; METALLOENDOPROTEASE INHIBITORS; DEGRADATION PRODUCTS; PROTEASE-III; FACTOR-ALPHA; ACTIVE-SITE; BINDING; HEPATOCYTES; PROTEINS	The insulin degrading enzyme (IDE), a nonlysosomal enzyme involved in the metabolism of internalized insulin, is a member of a new family of metalloproteases which has an HXXEH active site motif. We have previously shown that both His(108) and Glu(111) within the HX-CEH domain of human IDE are necessary for catalytic activity. Comparison to the prototypic zinc metalloprotease thermolysin, which contains an inversion of this motif, would predict that His(112), as well as a downstream glutamate, serves as the second and third zinc Ligands of IDE. To examine the role of His(112), we mutated this residue to glutamine, leucine, or arginine. To identify a downstream zinc ligand, we substituted a glutamine for glutamate at either Glu(182) or Glu(189), both of which are conserved in human, rat, and Drosophila IDE. Vectors containing wild type or mutant IDE genes were transfected into COS cells, and the enzymes were analyzed for insulin degradation, insulin cross-linking, and zinc binding. Our results suggest that His(108), His(112), and Glu(189) are the zinc ligands of human IDE, and Glu(182) can influence zinc binding. In addition to a catalytic role, zinc binding to these residues appears to play a role in stabilizing the structure of the enzyme.	UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007151] Funding Source: NIH RePORTER; NIGMS NIH HHS [2T32 GM07151-17] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ALI M, 1989, J BIOL CHEM, V264, P20992; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; EBRAHIM A, 1991, BIOCHEM BIOPH RES CO, V181, P1398, DOI 10.1016/0006-291X(91)92094-Z; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; GARCIA JV, 1987, J CELL BIOL, V105, P449, DOI 10.1083/jcb.105.1.449; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GEHM BD, 1993, J BIOL CHEM, V268, P7943; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KOZAK M, 1983, CELL, V34, P971, DOI 10.1016/0092-8674(83)90554-8; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; ODELL BL, 1992, NUTR REV, V50, P48, DOI 10.1111/j.1753-4887.1992.tb02513.x; OGAWA W, 1992, J BIOL CHEM, V267, P1310; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Sambrook J, 1989, MOL CLONING LABORATO; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WARD WF, 1985, DIABETES, V34, P446, DOI 10.2337/diabetes.34.5.446	41	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33140	33145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806544				2022-12-25	WOS:A1994QA63800062
J	SHEEHAN, JP; TOLLEFSEN, DM; SADLER, JE				SHEEHAN, JP; TOLLEFSEN, DM; SADLER, JE			HEPARIN-COFACTOR-II IS REGULATED ALLOSTERICALLY AND NOT PRIMARILY BY TEMPLATE EFFECTS - STUDIES WITH MUTANT THROMBINS AND GLYCOSAMINOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; FUNCTIONAL-PROPERTIES; DERMATAN SULFATE; BINDING; INHIBITION; PURIFICATION; SPECIFICITY; COAGULATION; ACTIVATION	Besides its critical role in hemostasis, the serine protease thrombin also participates in wound healing, inflammation, and atherosclerosis. Thrombin is inhibited by the serpins antithrombin and heparin cofactor II (HCII) in reactions that are accelerated markedly by specific glycosaminoglycans. Following vascular injury, thrombin must be inhibited at both intravascular and extravascular sites that impose different constraints on the recognition of thrombin by these inhibitors, The present study examines the role of anion-binding exosite II of thrombin in the interaction with glycosaminoglycans and HCII. Acceleration of thrombin inhibition by serpins in the presence of glycosaminoglycans is proposed to occur by a template mechanism, in which inhibitor and protease bind simultaneously to the same glycosaminoglycan chain, facilitating their interaction, According to the template model, disruption of protease binding to glycosaminoglycan should significantly reduce acceleration of the inhibition, Specific mutations in exosite II (R89E, R245E, K248E, and K252E) disrupted thrombin binding to both dermatan sulfate and heparin, indicating that both glycosaminoglycans bind to a common site in exosite II, The same mutations markedly decreased the rate constant for thrombin inhibition by antithrombin-heparin (up to 100-fold) but had little effect on the rate constant for thrombin inhibition by HCII-heparin (7-fold maximal reduction) and no effect on the rate constant for thrombin inhibition by HCII-dermatan sulfate, These results are incompatible with a template model for thrombin inhibition by HCII and dermatan sulfate, In the presence of glycosaminoglycan, HCII and antithrombin interact with opposing thrombin exosites and use distinct mechanisms of glycosaminoglycan catalysis, Antithrombin employs a template mechanism that requires heparin to interact with thrombin exosite II, whereas HCII employs an allosteric mechanism that requires thrombin exosite I but is largely independent of exosite II, These findings have potential implications for glycosaminoglycan therapy and for the respective physiologic roles of HCII and antithrombin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	SHEEHAN, JP (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED, 660 S EUCLID AVE, BOX 8022, ST LOUIS, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sheehan, John/0000-0002-4328-2613	NHLBI NIH HHS [1K08 HL 02923-01, HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, K08HL002923] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1989, J CLIN INVEST, V84, P1096, DOI 10.1172/JCI114272; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BROZE GJ, 1994, MOL BASIS BLOOD DISE, P629; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HATTON MWC, 1989, AM J PATHOL, V135, P499; HATTON MWC, 1993, BLOOD COAGUL FIBRIN, V4, P927, DOI 10.1097/00001721-199304060-00010; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KISIEL W, 1973, BIOCHIM BIOPHYS ACTA, V304, P103, DOI 10.1016/0304-4165(73)90119-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1994, J BIOL CHEM, V269, P3725; YE J, 1994, J BIOL CHEM, V269, P17965	37	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32747	32751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806495				2022-12-25	WOS:A1994QA63800008
J	RESNICK, RJ; TOMASKA, L				RESNICK, RJ; TOMASKA, L			STIMULATION OF YEAST ADENYLYL-CYCLASE ACTIVITY BY LYSOPHOSPHOLIPIDS AND FATTY-ACIDS - IMPLICATIONS FOR THE REGULATION OF RAS/EFFECTOR FUNCTION BY LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE-ACTIVITY; MAMMALIAN RAS PROTEINS; SACCHAROMYCES-CEREVISIAE; GROWTH-FACTOR; NEUROFIBROMATOSIS TYPE-1; ARACHIDONIC-ACID; GENE-PRODUCT; P21; DOMAIN	A reconstituted system containing membranes prepared from various Saccharomyces cerevisiae strains (CYR1 ras1 ras2) and a recombinant RAS2 protein was used to evaluate the effect of lipids on adenylyl cyclase activity. Incubation of wild-type membranes with lysophosphatidylinositol, lysophosphatidylserine, or lysophosphatidylcholine stimulated adenylyl cyclase activity in the absence and presence of RAS between 2-10-fold depending upon the individual lipid. Unsaturated fatty acids preferentially increased activity 2-3-fold in the presence of RAS. Other phospholipids as well as several detergents had only marginal effects on adenylyl cyclase activity. Lipids had no effect on either the binding or hydrolysis of GTP by RAS. LysoPI decreased both the K-m for ATP and the amount of RES required for enzyme activation. Four catalytically active deletion mutants of the CYR1 protein including one containing only the C-terminal 417 amino acids were similarly responsive to lysoPI when compared to the wild-type enzyme. These data suggest that lysophospholipids and fatty acids, metabolites of the mitogenically responsive enzyme phospholipase A(2), may represent a novel mechanism for modulating the activity of downstream effector molecules and their interaction with Ras proteins.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University			Tomaska, Lubomir/I-3071-2014	Tomaska, Lubomir/0000-0003-4886-1910	NATIONAL CANCER INSTITUTE [R01CA008964] Funding Source: NIH RePORTER; NCI NIH HHS [CA-08964] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BARSAGI D, 1986, SCIENCE, V233, P10061; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, NATURE, V348, P135; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAVARRETE R, 1983, BIOCHIM BIOPHYS ACTA, V728, P403, DOI 10.1016/0005-2736(83)90512-6; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAMANOI F, 1984, P NATL ACAD SCI-BIOL, V81, P6924, DOI 10.1073/pnas.81.22.6924; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK A, 1992, MOL CELL BIOL, V66, P497; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILSON BA, 1993, ONCOGENE, V8, P3441; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	70	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32336	32341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798234				2022-12-25	WOS:A1994PX30400050
J	WORLEY, JF; MCINTYRE, MS; SPENCER, B; DUKES, ID				WORLEY, JF; MCINTYRE, MS; SPENCER, B; DUKES, ID			DEPLETION OF INTRACELLULAR CA2+ STORES ACTIVATES A MAITOTOXIN-SENSITIVE NONSELECTIVE CATIONIC CURRENT IN BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM RELEASE; DEPOLARIZATION; CHANNELS; ISLETS	Glucose stimulation of beta-cell insulin secretion is initiated by membrane depolarization coupled with an elevation in intracellular Ca2+ concentration ([Ca2+](i)). Both depolarization-dependent Ca2+ entry and intracellular Ca2+ store release contribute to the sugar-induced rise in [Ca2+](i). Here we show that maneuvers depleting intracellular Ca2+ stores induce membrane depolarization and a sustained nitrendipine-sensitive Ca2+ influx, whereas interventions promoting Ca2+ store refilling produce a hyperpolarization and inhibit Ca2+ influx. Both intracellular Ca2+ store depletion and maitotoxin activated a depolarizing nonselective cation current carried principally by Na+ in the physiological range of membrane potentials, The activation of such a current may form the paradigm by which excitable cells refill depleted intracellular Ca2+ stores by depolarization-driven opening of voltage-activated Ca2+ channels.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DIETL P, 1994, MOL PHARMACOL, V45, P300; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GILON P, 1993, J BIOL CHEM, V268, P22265; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; SILVA AM, 1994, J BIOL CHEM, V269, P17095; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; XI D, 1992, J BIOL CHEM, V267, P25025	17	102	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32055	32058						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798198				2022-12-25	WOS:A1994PX30400009
J	GANJEIZADEH, M; ZOLOTARJOVA, N; HUANG, WH; ASKARI, A				GANJEIZADEH, M; ZOLOTARJOVA, N; HUANG, WH; ASKARI, A			INTERACTIONS OF PHOSPHORYLATION AND DIMERIZING DOMAINS OF THE ALPHA-SUBUNITS OF NA+/K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; (NA++K+)-ATPASE; NA,K-ATPASE; ANTIBODIES; ENZYME; SITES; UNIT; ION	Chemical cross-linking studies are among a number of experimental approaches that have suggested the functional significance of higher association states of alpha,beta-protomers of Na+/K+-ATPase. Formation of the phosphointermediate of the enzyme on Asp(369) Of the alpha-subunit is known to induce oxidative cross-linking of the alpha-subunits catalyzed by Cu2+-phenanthroline. To localize the phosphorylation-induced alpha,alpha-interface, we cleaved alpha at Arg(438)-Ala(439) by controlled proteolysis and exposed the partially cleaved enzyme to the cross-linking reagent. In addition to the alpha,alpha-dimer, two other phosphorylation-induced cross-linked products were obtained, Using gel electrophoretic resolution of the cross-linked P-32-labeled enzyme, N-terminal analyses of the products, and their reactivities with sequence-specific antibodies, the two products were identified as a homodimer of the C-terminal 64-kDa fragment of alpha and a heterodimer of alpha and the 64-kDa peptide. The latter dimer was also obtained when the cross-linked alpha,alpha-dimer was formed first and then subjected to proteolysis, The findings localize the dimerizing domain to the C-terminal side of Ala(439) and indicate that intersubunit proximities of dimerizing domains are regulated by phosphorylation-dephosphorylation of Asp(369) during the reaction cycle of the enzyme.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA						NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMER E, 1992, BIOPHYS J, V61, P553; ASKARI A, 1983, J BIOL CHEM, V258, P3453; ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BIGELOW DJ, 1992, J BIOL CHEM, V267, P6952; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BOLDYREV AA, 1994, INT J BIOCHEM, V26, P1323, DOI 10.1016/0020-711X(94)90174-0; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; ESMANN M, 1989, BIOCHIM BIOPHYS ACTA, V978, P209, DOI 10.1016/0005-2736(89)90117-X; Froehlich Jeffrey P., 1995, Biophysical Journal, V68, pA316; GANJEIZADEH M, 1992, BIOPHYS J, V61, P122; GANJEIZADEH M, 1991, BIOPHYS J, V59, P343; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HUANG WH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P65, DOI 10.1016/0005-2736(90)90239-K; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MAUNSBACH AB, 1991, SOC GEN PHY, V46, P159; MERSOL JV, 1995, BIOPHYS J, V68, P208, DOI 10.1016/S0006-3495(95)80176-1; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; MOHRAZ M, 1987, J CELL BIOL, V105, P1, DOI 10.1083/jcb.105.1.1; MOLNAR E, 1990, BIOCHIM BIOPHYS ACTA, V1023, P147, DOI 10.1016/0005-2736(90)90410-P; NORBY JG, 1989, J BIOL CHEM, V264, P19548; NORBY JG, 1991, SOC GEN PHY, V46, P173; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; Reynolds J A, 1988, Prog Clin Biol Res, V268A, P137; SCHONER W, 1994, SODIUM PUMP, P332; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; XIE ZJ, 1994, SODIUM PUMP, P49; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	35	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15707	15710		10.1074/jbc.270.26.15707	http://dx.doi.org/10.1074/jbc.270.26.15707			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797572	hybrid			2022-12-25	WOS:A1995RG53800043
J	HEATH, RJ; ROCK, CO				HEATH, RJ; ROCK, CO			REGULATION OF MALONYL-COA METABOLISM BY ACYL-ACYL CARRIER PROTEIN AND BETA-KETOACYL-ACYL CARRIER PROTEIN SYNTHASES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; THERMAL REGULATION; COENZYME-A; ANTIBIOTIC CERULENIN; MUTANTS; SYNTHETASE; INHIBITION; BACTERIA; FLUIDITY; INVIVO	The cessation of phospholipid biosynthesis by the in hibition of the sn-glycerol-3-phosphate acyltransferase using a plsB mutant led to an accumulation of long chain acyl-acyl carrier proteins (acyl-ACP) and the concomitant inhibition of de novo fatty acid biosynthesis in Escherichia coli. Malonyl-CoA did not accumulate when phospholipid and fatty acid synthesis was blocked. However, the inactivation of beta-ketoacyl-ACP synthases I and II: with the antibiotic cerulenin triggered a large increase in the accumulation of malonyl-CoA following the cessation of phospholipid synthesis, illustrating that the beta-ketoacyl-ACP synthases were responsible for the degradation of malonyl-CoA in the presence of long chain acyl-ACP. The acyl-ACP requirement for malonyl-CoA degradation activity was confirmed by shifting enoyl-ACP reductase mutants (fabI(Ts)) to the non-permissive temperature, leading to the abrupt cessation of fatty acid synthesis and the accumulation of malonyl-CoA in the absence of cerulenin. Analysis of the ACP pool composition before and after the temperature shift showed that the fabI block did not result in the accumulation of long chain acyl-ACP. These data indicate a feedback regulatory loop that functions to recycle malonyl-CoA to acetyl-CoA following the down-regulation of fatty acid and phospholipid formation and provides a physiological rationale for the acyl-ACP-dependent, malonyl-ACP decarboxylase reaction catalyzed by beta-ketoacyl-ACP synthases I and II.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; CLEWELL DB, 1969, P NATL ACAD SCI USA, V69, P2110; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MAJERUS PW, 1969, METHOD ENZYMOL, V14, P43; Miller J.H., 1972, EXPT MOL GENETICS; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; TSAY JT, 1992, J BIOL CHEM, V267, P6807; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; VAGELOS PR, 1960, J BIOL CHEM, V235, P2786; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994	37	68	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15531	15538		10.1074/jbc.270.26.15531	http://dx.doi.org/10.1074/jbc.270.26.15531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797547	hybrid			2022-12-25	WOS:A1995RG53800017
J	LEAH, R; KIGEL, J; SVENDSEN, I; MUNDY, J				LEAH, R; KIGEL, J; SVENDSEN, I; MUNDY, J			BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF A BARLEY SEED BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ZEA-MAYS L; NUCLEOTIDE-SEQUENCE; GERMINATING BARLEY; ALPHA-AMYLASE; ABSCISIC-ACID; PROTEINS; PURIFICATION; EXPRESSION; PLANTS	A 60-kDa beta-glucosidase (BGQ60) was purified and characterized from seeds of barley (Hordeum vulgare L.) BGQ60 catalytic activity was restricted to the cleavage of short-chain oligosaccharides composed of (1-2)-, (1-3)-, and/or (1-4)-beta-linked glucose or mannose units. These oligosaccharides are the primary products of endosperm cell wall polysaccharide hydrolysis by other enzymes. In keeping with this, complete hydrolysis of the major polysaccharide of barley starchy endosperm cell wall, (1.3, 1-4)-beta-glucan, to free glucose was shown to require the concerted action of endo-(1-3, 1-4)-beta-glucanase and BGQ60. The complete amino acid sequence of BGQ60 was determined by protein sequencing combined with the deduced sequence of the corresponding cDNA and genomic clones. The BGQ60 primary structure exhibits extensive homology to members of glycosyl hydrolase family 1 (EC 3.2.1.21). Southern and Northern blot analysis with the cDNA as probe indicated that BGQ60 is encoded by a single gene, and that BGQ60 mRNA only accumulates in the starchy endosperm tissue of late developing seeds. The bgq60 structural gene of approximately kilobases contains an open reading frame encoding 485 amino acids interrupted by 9 introns. The complete nucleotide sequence of the bgq60 structural gene represents the first characterized plant gene encoding a beta-glucosidase. The barley BGQ60 is a novel plant beta-glucosidase with a hitherto undescribed specific enzymatic activity. The possible biological functions of BGQ60 during barley seed development and germination are discussed.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK		LEAH, R (corresponding author), CARLSBERG RES LAB, DEPT CHEM, GAMLE CARLSBERG VEJ 10, DK-2500 COPENHAGEN, DENMARK.		mundy, john/A-2361-2013	mundy, john/0000-0001-7490-4588				AMAN P, 1989, J CEREAL SCI, V10, P45, DOI 10.1016/S0733-5210(89)80033-5; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; CAMPOS N, 1992, PLANT J, V2, P675, DOI 10.1111/j.1365-313X.1992.tb00136.x; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; ERB N, 1979, PHYTOCHEMISTRY, V18, P1515, DOI 10.1016/S0031-9422(00)98486-3; ESEN A, 1992, PLANT PHYSIOL, V98, P174, DOI 10.1104/pp.98.1.174; ESEN A, 1993, ACS S SERIES, V533; Fincher G. B., 1993, P247; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; GIESE H, 1984, PLANTA, V161, P172, DOI 10.1007/BF00395478; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; HAFF LA, 1983, J CHROMATOGR, V266, P409, DOI 10.1016/S0021-9673(01)90913-6; HENNIG J, 1993, PLANT J, V4, P593, DOI 10.1046/j.1365-313X.1993.04040593.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HUGHES MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P273, DOI 10.1016/0003-9861(92)90518-2; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LEAH R, 1989, PLANT MOL BIOL, V12, P673, DOI 10.1007/BF00044158; LEAH R, 1994, PLANT J, V6, P579, DOI 10.1046/j.1365-313X.1994.6040579.x; LEAH R, 1991, J BIOL CHEM, V266, P1564; Macgregor A. W., 1993, P73; MACGREGOR AW, 1987, CRIT REV BIOTECHNOL, V5, P117, DOI 10.3109/07388558709086972; MUNDY J, 1986, FEBS LETT, V198, P349, DOI 10.1016/0014-5793(86)80434-3; MUNDY J, 1986, PLANT PHYSIOL, V81, P630, DOI 10.1104/pp.81.2.630; NISIZAWA K, 1970, CARBOHYDRATES CHEM B, P241; OLSEN O, 1991, MOL GEN GENET, V225, P177, DOI 10.1007/BF00269845; OXTOBY E, 1991, PLANT MOL BIOL, V17, P209, DOI 10.1007/BF00039495; POLITZ O, 1993, EUR J BIOCHEM, V216, P829, DOI 10.1111/j.1432-1033.1993.tb18204.x; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; RODRIGUEZPALENZUELA P, 1988, GENE, V70, P271, DOI 10.1016/0378-1119(88)90199-0; SANTOS MAS, 1993, TRENDS BIOTECHNOL, V11, P500, DOI 10.1016/0167-7799(93)90028-8; SCHLIEMANN W, 1991, NATURWISSENSCHAFTEN, V78, P392, DOI 10.1007/BF01133410; SCHNEIDER G, 1992, P NATL ACAD SCI USA, V89, P8045, DOI 10.1073/pnas.89.17.8045; SHEWRY PR, 1993, BARLEY CHEM TECHNOLO, P73; SIMOS G, 1994, BBA-GEN SUBJECTS, V1199, P52, DOI 10.1016/0304-4165(94)90095-7; SKRIVER K, 1991, P NATL ACAD SCI USA, V88, P7266, DOI 10.1073/pnas.88.16.7266; SOPANEN T, 1989, PLANT PHYSIOL, V89, P244, DOI 10.1104/pp.89.1.244; STAHL E, 1967, DUNNSCHICHT CHROMATO; Stone BA, 1992, CHEM BIOL 1 3 GLUCAN, P431; SUN Z, 1990, PLANT PHYSIOL, V94, P320, DOI 10.1104/pp.94.1.320; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WOOD TM, 1988, METHOD ENZYMOL, V160, P87; Woodward J. R., 1983, Brewers' Digest, V58, P28; WOODWARD JR, 1982, EUR J BIOCHEM, V121, P663, DOI 10.1111/j.1432-1033.1982.tb05837.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	47	168	177	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15789	15797		10.1074/jbc.270.26.15789	http://dx.doi.org/10.1074/jbc.270.26.15789			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797581	hybrid			2022-12-25	WOS:A1995RG53800054
J	MUNDAY, NA; VAILLANCOURT, JP; ALI, A; CASANO, FJ; MILLER, DK; MOLINEAUX, SM; YAMIN, TT; YU, VL; NICHOLSON, DW				MUNDAY, NA; VAILLANCOURT, JP; ALI, A; CASANO, FJ; MILLER, DK; MOLINEAUX, SM; YAMIN, TT; YU, VL; NICHOLSON, DW			MOLECULAR-CLONING AND PRO-APOPTOTIC ACTIVITY OF ICE(REL)II AND ICE(REL)III, MEMBERS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; ENZYME	Cysteine proteases related to mammalian interleukin-1 beta-converting enzyme (ICE) and the nematode cell death abnormal ced-3 gene product have been implicated in the effector mechanism of apoptotic cell death. Two novel members of this new family of ICE/CED-3-related proteases, designated ICE(rel)-II and ICE(rel)-III, were cloned from human monocytic cells. Both were highly homologous to human ICE (52% identical) and CED-3(25% identical) and both contained the absolutely conserved pentapeptide sequence Gln-Ala-Cys-Arg-Asp containing the catalytic cysteine residue. Other structural motifs that were comparable with ICE suggest that ICE(rel)-II and ICE(rel)-III are also synthesized as larger proenzymes which are proteolytically processed to form heterodimeric active enzymes. Pro-interleukin-1 beta processing activity could not be detected in cells transfected with ICE(rel)-II or ICE(rel)-III, but pro-domain-less truncated forms of ICE(rel)-II and ICE(rel)-III were capable of effectively inducing fibroblast apoptosis. ICE(rel)-II and ICE(rel)-III may, therefore, participate in proteolytic events culminating in the apoptotic death of human cells.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; CARSON DA, 1994, LANCET, V341, P1251; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MIURA M, 1993, CELL, V78, P653; NICHOLSON DW, 1995, IN PRESS NATURE; SAMBROOK J, 1989, MOL CLONING LABORTOR; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WYLLIE AH, 1994, NATURE, V369, P272, DOI 10.1038/369272a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	272	301	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15870	15876		10.1074/jbc.270.26.15870	http://dx.doi.org/10.1074/jbc.270.26.15870			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797592	hybrid			2022-12-25	WOS:A1995RG53800066
J	SABHARWAL, AK; BIRKTOFT, JJ; GORKA, J; WILDGOOSE, P; PETERSEN, LC; BAJAJ, SP				SABHARWAL, AK; BIRKTOFT, JJ; GORKA, J; WILDGOOSE, P; PETERSEN, LC; BAJAJ, SP			HIGH-AFFINITY CA2+-BINDING SITE IN THE SERINE-PROTEASE DOMAIN OF HUMAN FACTOR VIIA AND ITS ROLE IN TISSUE FACTOR-BINDING AND DEVELOPMENT OF CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; CLOTTING FACTOR-VII; CALCIUM-BINDING; BLOOD-COAGULATION; FACTOR-X; ANTITHROMBIN-III; FACTOR-IX; ACTIVATION; COMPLEX; PURIFICATION	Factor VIIa, in the presence of Ca2+ and tissue factor (TF), initiates the extrinsic pathway of blood coagulation. The light chain (amino acids 1-152) of factor VIIa consists of an N terminal gamma-carboxyglutamic acid (Gla) domain followed by two epidermal growth factor-like domains, whereas the heavy chain (amino acids 153-406) contains the serine protease domain. In this study, both recombinant factor VIIa (rVIIa) and factor VIIa lacking the Gla domain were found to contain two high-affinity (K-d similar to 150 mu M) Ca2+ binding sites. The rVIIa also contained similar to 6-7 low-affinity (K-d similar to 1 mM) Ca2+-binding sites. By analogy to other serine proteases, one of the two high affinity Ca2+-binding sites in factor VIIa may be formed involving Glu-210 and Glu-220 of the protease domain. In support of this, a synthetic peptide composed of residues 206-242 of factor VIIa bound one Ca2+ with K-d similar to 230 mu M; however, Ca2+ binding was observed only in Tris buffer (pH 7.5) containing 1 M NaCl and not in buffer containing 0.1 M NaCl. In both low or high salt +/- Ca2+, the peptide existed as a monomer as determined by sedimentation equilibrium measurements and had no detectable secondary structure as determined by CD measurements. This indicates that subtle changes undetectable by CD may occur in the conformation of the peptide that favor calcium binding in high salt. In the presence of recombinant TF and 5 mM Ca2+, the peptide inhibited the amidolytic activity of rVIIa toward the synthetic substrate, 5-2288. The concentration of the peptide required for half-maximal inhibition was similar to 5-fold higher in the low salt buffer than that in the high salt buffer. From direct binding and competitive inhibition assays of active site-blocked I-125-rVIIa binding to TF, the K-d for peptide-TF interaction was calculated to be similar to 15 mu M in the high salt and similar to 55 pM in the low salt buffer containing 5 mM Ca2+. Moreover, as inferred from S-2288 hydrolysis, the K-d for VIIa TF interaction was similar to 1.5 mu M in the absence of Ca2+, and, as inferred from factor X activation studies, it was similar to 10 pM in thepresence of Ca2+. Thus, Ca2+ decreases the functional K-d of VIIa-. TF interaction similar to 150,000-fold. Furthermore, the amidoIytic activity of VIIa . Ca2+, VIIa . TF, and VIIa . Ca2+-TF was increased similar to 7-fold, similar to 100-fold, and similar to 350-fold, respectively, over that of factor VIIa alone; the half-maximal effect was observed at similar to 200 mu M Ca2+ when added. We conclude that TF can interact with the protease domain (and possibly other domains) of factor VIIa in the absence of Ca2+ and that the protease domain Ca2+-binding site, in part, enhances this interaction similar to 10(5)-fold.	ST LOUIS UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK	Saint Louis University; Saint Louis University; Saint Louis University; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Novo Nordisk					NHLBI NIH HHS [HL36365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036365, R56HL036365, R55HL036365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1988, J BIOL CHEM, V263, P9725; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GORKA J, 1989, Peptide Research, V2, P376; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KUMAR A, 1993, EUR J BIOCHEM, V217, P509, DOI 10.1111/j.1432-1033.1993.tb18271.x; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MORITA T, 1991, THROMB HAEMOSTASIS, V65, P939; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAO LVM, 1993, BLOOD, V81, P2600; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1986, BLOOD, V68, P685; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; RUF W, 1991, J BIOL CHEM, V266, P15719; SABHARWAL AK, 1993, BLOOD S1, V82, P64; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; STENFLO J, 1991, BLOOD, V78, P1637; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V190, P687; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WARNCRAMER BJ, 1986, BIOCHEM J, V239, P757, DOI 10.1042/bj2390757; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	51	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15523	15530		10.1074/jbc.270.26.15523	http://dx.doi.org/10.1074/jbc.270.26.15523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797546	hybrid			2022-12-25	WOS:A1995RG53800016
J	STOVER, DR; BECKER, M; LIEBETANZ, J; LYDON, NB				STOVER, DR; BECKER, M; LIEBETANZ, J; LYDON, NB			SRC PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT NOVEL SITES MEDIATES RECEPTOR INTERACTION WITH SRC AND P85-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BINDING-SITE; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH2 DOMAINS; IDENTIFICATION; ACTIVATION; PURIFICATION; PP60C-SRC	Following ligand binding, the epidermal growth factor receptor (EGF-R) autophosphorylates itself on tyrosine residues located in its carboxyl terminus; in vitro, three sites are highly phosphorylated, while two other sites are phosphorylated to lesser extents. In the presence of the Src protein-tyrosine kinase, in vitro phosphorylation of the minor autophosphorylation sites was increased, and four additional residues were phosphorylated. Following EGF stimulation, two (Tyr-891 and Tyr-920) were found to be phosphorylated in a colorectal cell line (DLD-1) and in a breast tumor cell line (MCF7). The remaining in vitro sites were not found to be highly phosphorylated in vivo. The sequences surrounding Tyr-891 and Tyr-920 match the reported consensus binding sequences for the SH2 domains of Src and the regulatory domain of phosphatidylinositol 3-kinase (p85 alpha), respectively. In vitro, both of these proteins were found to bind to Src-phosphorylated EGF-R with similar to 100-fold greater affinity than to autophosphorylated EGF-R, demonstrating that Src creates new sites for SH2 binding. Furthermore, Csk-inactivated Src was activated by interaction with Src-phosphorylated EGF-R but not by autophosphorylated EGF-R. Upon EGF treatment of MCF7 or three colorectal carcinoma cell lines (WiDr, DLD-1, and LS174T), the EGF-R coimmunoprecipitated with both p85 alpha and Src. Evidence is also presented that suggests that an EGF-R-related protein, ErbB2, may be involved in similar Src-mediated interactions. These data demonstrate that EGF-R is phosphorylated in vivo at non-autophosphorylation sites and that these novel sites can act as docking sites for Src, P85 alpha, and potentially other SH2 containing proteins. In addition, the data suggest a tyrosine phosphatase-independent mechanism for the elevation of Src activity in cells exposed to growth factors. Overexpression of Src, EGF-R, and/or ErbB2 in breast and colorectal tumor cells suggests the potential that such interactions may contribute to the transformed phenotype of these carcinomas.			STOVER, DR (corresponding author), CIBA GEIGY LTD, RES DEPT, DIV PHARMACEUT, K125420, CH-4002 BASEL, SWITZERLAND.							BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG JH, 1993, ONCOGENE, V8, P959; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; FENG GS, 1994, ONCOGENE, V9, P1545; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUY PM, 1992, J BIOL CHEM, V267, P13851; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MASANORI I, 1990, VIRCHOWS ARCH B, V59, P173; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOVER DR, 1994, J BIOL CHEM, V269, P26885; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003; TRAXLER PM, 1995, IN PRESS J MED CHEM; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	191	193	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15591	15597		10.1074/jbc.270.26.15591	http://dx.doi.org/10.1074/jbc.270.26.15591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797556	hybrid			2022-12-25	WOS:A1995RG53800026
J	MONGE, JC; STEWART, DJ; CERNACEK, P				MONGE, JC; STEWART, DJ; CERNACEK, P			DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS TO A NEURAL OR CARDIOMYOCYTE LINEAGE IS ASSOCIATED WITH SELECTIVE EXPRESSION OF ENDOTHELIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOREACTIVE ENDOTHELIN; SPINAL-CORD; RAT-HEART; PEPTIDE; GENES; CLONING; MUSCLE; HYPERTROPHY; HYDROLYSIS; MECHANISM	Endothelins (ETs) were initially characterized as potent vasoactive peptides acting through at least two distinct receptors, ET(A) and ET(B). Subsequently, their significant growth- and hypertrophy-promoting properties in cardiac and other cells were recognized. We investigated the expression of endothelin receptors during differentiation of a pluripotential embryonal carcinoma cell line (P19) to a cardiomyocyte or a neural lineage. These cells resemble those of the inner cell mass of the blastocyst, and their differentiation is believed to closely mimic critical events in early embryogenesis. Differentiation of P19 to a cardiomyocyte lineage, by aggregation and exposure to dimethyl sulfoxide resulted in induction of ET(A) receptors as demonstrated by radioligand binding studies, Northern blotting, and reporter gene analysis. Moreover, the P19 differentiated to a cardiac lineage responded to ET-1 with a 3-fold increase in the secretion of atrial natriuretic peptide. In contrast, differentiation to a neural lineage, by aggregation and exposure to retinoic acid, was associated with the induction of predominantly ET(B). Therefore, selective differentiation of the P19 led to the differential expression of endothelin receptors in a pattern consistent with that observed in normal myocardial and neural tissue. The induction of endothelin receptors in a model system of early embryogenesis provides strong support for the critical role of this peptide/receptor family in differentiation and development. As well, this model system is well suited for the study of the mechanisms controlling endothelin receptor expression during differentiation.	ROYAL VICTORIA HOSP,DIV CARDIOL,MCGILL VASC BIOL GRP,MONTREAL,PQ H3A 1A1,CANADA; ROYAL VICTORIA HOSP,DEPT MED,DEPT BIOCHEM MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	MONGE, JC (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DIV CARDIOL,30 BOND ST,TORONTO,ON M5B 1W8,CANADA.							ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1993, J BIOL CHEM, V268, P3463; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; CERNACEK P, 1988, AM J PHYSIOL, V255, pR929, DOI 10.1152/ajpregu.1988.255.6.R929; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CHOMCZYNSKI P, 1983, ANAL BIOCHEM, V162, P156; GIAID A, 1991, AM J RESP CELL MOL, V4, P50, DOI 10.1165/ajrcmb/4.1.50; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GIAID A, 1993, LANCET, V341, P1550; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOSODA K, 1994, CIRCULATION, V90, P634; HOSODA K, 1992, J BIOL CHEM, V267, P18787; IHARA M, 1991, BIOCHEM BIOPH RES CO, V178, P132, DOI 10.1016/0006-291X(91)91789-F; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LI K, 1991, CIRC RES, V69, P301, DOI 10.1161/01.RES.69.2.301; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LUSCHER TF, 1991, KIDNEY INT, V39, P575, DOI 10.1038/ki.1991.68; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MANTYMAA P, 1990, ENDOCRINOLOGY, V126, P587; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHINMI O, 1989, BIOCHEM BIOPH RES CO, V162, P340, DOI 10.1016/0006-291X(89)92001-9; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEWART DJ, 1994, AM J PHYSIOL, V266, pH944, DOI 10.1152/ajpheart.1994.266.3.H944; STEWART DJ, 1993, EUR HEART J, V14, P48; THIBAULT G, 1994, CIRC RES, V74, P460, DOI 10.1161/01.RES.74.3.460; YANAGISAWA M, 1982, NATURE, V332, P411; YOSHIMI H, 1989, PEPTIDES, V10, P805, DOI 10.1016/0196-9781(89)90117-4; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; [No title captured]	50	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15385	15390		10.1074/jbc.270.25.15385	http://dx.doi.org/10.1074/jbc.270.25.15385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797528	hybrid			2022-12-25	WOS:A1995RE66600080
J	CHAN, D; COLE, WG; CHOW, CW; MUNDLOS, S; BATEMAN, JF				CHAN, D; COLE, WG; CHOW, CW; MUNDLOS, S; BATEMAN, JF			A COL2A1 MUTATION IN ACHONDROGENESIS TYPE-II RESULTS IN THE REPLACEMENT OF TYPE-II COLLAGES BY TYPE-I AND TYPE-III COLLAGENS IN CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LANGER-SALDINO ACHONDROGENESIS; SPONDYLOEPIPHYSEAL DYSPLASIA; OSTEOGENESIS IMPERFECTA; SERINE SUBSTITUTION; ALPHA-1(II) CHAIN; GENE COL2A1; IDENTIFICATION; CHONDROCYTES; HYPOCHONDROGENESIS; ABNORMALITIES	An autosomal dominant mutation in the COL2A1 gene was identified in a fetus with achondrogenesis type II, A transition of G(2853) to A in exon 41 produced a substitution of Gly(769) by Ser within the triple helical domain of the alpha 1(II) chain of type II collagen, interrupting the mandatory Gly-X-Y triplet sequence required for the normal formation of stable triple helical type II collagen molecules, resulting in the complete absence of type II collagen in the cartilage, which had a gelatinous composition, Type I and III collagens were the major species found in cartilage tissue and synthesized by cultured chondrocytes along with cartilage type XI collagen, However, cultured chondrocytes produced a trace amount of type II collagen, which was retained within the cells and not secreted, In situ hybridization of cartilage sections showed that the chondrocytes produced both type II and type I collagen mRNA, As a result, it is likely that the chondrocytes produced type II collagen molecules, which were then degraded. The close proximity of the Gly(769) substitution by Ser to the mammalian collagenase cleavage site at Gly(775)-Leu(776) may have produced an unstable domain that was highly susceptible to proteolysis, The type I and III collagens that replaced type II collagen were unable to maintain the normal structure of the hyaline cartilage but did support chondrocyte maturation, evidenced by the expression of type X collagen in the hypertrophic zone of the growth plate cartilage.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOLEC BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT PATHOL ANAT,PARKVILLE,VIC 3052,AUSTRALIA; HOSP SICK CHILDREN,DIV ORTHOPAED,TORONTO,ON M5G 1X8,CANADA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Mundlos, Stefan/ABH-9585-2020; Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778; Bateman, John/0000-0001-8542-0730				AIGNER T, 1993, VIRCHOWS ARCH B, V63, P205, DOI 10.1007/BF02899263; ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BYERS PH, 1991, J MED GENET, V28, P433, DOI 10.1136/jmg.28.7.433; CHAN D, 1993, J BIOL CHEM, V268, P15238; CHAN D, 1991, J BIOL CHEM, V266, P12487; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; COLE WG, 1994, PROG NUCLEIC ACID RE, V47, P29, DOI 10.1016/S0079-6603(08)60249-4; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; EYRE DR, 1986, AM J HUM GENET, V39, P52; FESHCHENKO SP, 1989, HUM GENET, V82, P49, DOI 10.1007/BF00288271; FREISINGER P, 1994, J BIOL CHEM, V269, P13663; GIBSON GJ, 1982, J CELL BIOL, V93, P767, DOI 10.1083/jcb.93.3.767; GIBSON GJ, 1983, BIOCHEM J, V211, P417, DOI 10.1042/bj2110417; GODFREY M, 1988, AM J HUM GENET, V43, P904; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HORTON WA, 1987, PEDIATR RES, V22, P324, DOI 10.1203/00006450-198709000-00017; HORTON WA, 1992, P NATL ACAD SCI USA, V89, P4583, DOI 10.1073/pnas.89.10.4583; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LANGER LO, 1969, RADIOLOGY, V92, P285, DOI 10.1148/92.2.285; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MUNDLOS S, 1991, MATRIX, V11, P339, DOI 10.1016/S0934-8832(11)80205-2; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RITVANIEMI P, 1994, HUM MUTAT, V3, P261, DOI 10.1002/humu.1380030314; SALDINO RM, 1971, AMER J ROENTGENOL RA, V112, P185, DOI 10.2214/ajr.112.1.185; SILLENCE DO, 1979, AM J PATHOL, V96, P811; SPRANGER J, 1988, PATHOL IMMUNOPATH R, V7, P76, DOI 10.1159/000157098; TSCHAN T, 1993, J BIOL CHEM, V268, P5156; VIKKULA M, 1993, GENOMICS, V16, P282, DOI 10.1006/geno.1993.1179; VISSING H, 1989, J BIOL CHEM, V264, P18265; WHITLEY CB, 1983, RADIOLOGY, V148, P693, DOI 10.1148/radiology.148.3.6878687	39	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1747	1753		10.1074/jbc.270.4.1747	http://dx.doi.org/10.1074/jbc.270.4.1747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829510	hybrid			2022-12-25	WOS:A1995QD20400043
J	BILLY, D; SPEIJER, H; WILLEMS, G; HEMKER, HC; LINDHOUT, T				BILLY, D; SPEIJER, H; WILLEMS, G; HEMKER, HC; LINDHOUT, T			PROTHROMBIN ACTIVATION BY PROTHROMBINASE IN A TUBULAR FLOW REACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; BLOOD-COAGULATION; TISSUE FACTOR; FACTOR-XA; COMPLEX; SURFACE; BINDING	Thrombin production by the phospholipid-bound complex of blood clotting factors Xa and Va (prothrombinase) was studied in a tubular flow reactor. The inner wall of a glass capillary was coated with a phospholipid bilayer of 25% phosphatidylserine and 75% phosphatidylcholine. Prothrombinase was assembled on this bilayer by perfusion with a mixture containing an excess of factor Va (2 nM) and a limiting amount of factor Xa (1-100 pM), either in the absence or presence of prothrombin. The rate of assembly of prothrombinase in the presence of prothrombin appeared to be limited by the transfer rate of factor Xa to the phospholipid surface. A good agreement was found between the predicted mass transfer coefficient for factor Xa and the observed pre-steady state rate of thrombin production. The eventually obtained steady state rates of thrombin production were proportional to the prothrombin concentration and independent of the surface density of prothrombinase. The observed rate of thrombin production conversion was observed for prothrombinase densities exceeding 1 fmol/cm(2), which corresponds to 0.05% occupation of available binding sites. The kinetic parameters of the reaction were determined at low prothrombinase densities (0.02-0.04 fmol/cm(2)). Even in this situation the Michaelis-Menten equation had to be corrected for substrate depletion near the catalytic surface. We hereto employed an accurate approximation of the mass transfer coefficient. The kinetic parameter k(cat) was 60 s(-1) and the intrinsic K-m had a surprisingly low value of 3 nM. Both parameters were not influenced by the wall shear rate.	UNIV LIMBURG, CARDIOVASC RES INST MAASTRICHT, DEPT BIOCHEM, 6200 MD MAASTRICHT, NETHERLANDS	Hasselt University; Maastricht University				Hemker, Coen/0000-0003-1669-2358				ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BROWN GM, 1960, AICHE J, V6, P179, DOI 10.1002/aic.690060204; CONTINO P, 1991, THROMB HAEMOSTASIS, V66, P138; GEMMELL CH, 1990, MICROVASC RES, V40, P327, DOI 10.1016/0026-2862(90)90031-L; GEMMELL CH, 1988, BLOOD, V72, P1404; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KOBAYASHI T, 1974, BIOTECHNOL BIOENG, V66, P99; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Leveque M. A., 1928, ANN MINES, V13, P201; Levich VG, 1962, PHYSICOCHEMICAL HYDR, P112; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHOEN P, 1990, THROMB HAEMOSTASIS, V64, P542; TRACY PB, 1981, J BIOL CHEM, V256, P743; WILLEMS GM, 1993, BLOOD, V82, P497, DOI 10.1182/blood.V82.2.497.bloodjournal822497	24	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1029	1034		10.1074/jbc.270.3.1029	http://dx.doi.org/10.1074/jbc.270.3.1029			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836355	hybrid			2022-12-25	WOS:A1995QB15600010
J	PROSSNITZ, ER; KIM, CM; BENOVIC, JL; YE, RD				PROSSNITZ, ER; KIM, CM; BENOVIC, JL; YE, RD			PHOSPHORYLATION OF THE N-FORMYL PEPTIDE RECEPTOR CARBOXYL-TERMINUS BY THE G-PROTEIN-COUPLED RECEPTOR KINASE, GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; C5A CHEMOATTRACTANT RECEPTORS; HUMAN INTERLEUKIN-8 RECEPTOR; PLATELET-ACTIVATING-FACTOR; BETA-GAMMA-SUBUNITS; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; EXPRESSION; DESENSITIZATION; SITES	Attenuation of receptor-mediated signal amplification in response to external stimuli, an essential step in the balance of cellular activation, may be mediated by receptor phosphorylation, We have recently shown that the carboxyl-terminal cytoplasmic domain of the N-formyl peptide receptor (FPR) interacts with G proteins and demonstrate here that this same region of the FPR is specifically phosphorylated by a neutrophil cytosolic kinase with properties similar to the G protein-coupled receptor kinase, GRK2. Both kinase activities show a lack of sensitivity toward protein kinase A, protein kinase C, and tyrosine kinase inhibitors but demonstrate almost identical sensitivity toward the kinase inhibitor heparin, Kinetic studies demonstrated that GRK2 has a K-m for the carboxyl-terminal domain of the FPR of approximately 1.5 mu M and that denaturation of the substrate results in an almost complete loss of phosphorylation. Comparative studies reveal that GRK3 has approximately 50% of the activity of GRK2 toward the FPR carboxyl terminus, whereas GRK5 and GRK6 have no detectable activity. Site-directed mutagenesis of numerous regions of the FPR carboxyl terminus demonstrated that, whereas Glu(326)/Asp(327) and Asp(333) are critical for phosphorylation, the carboxyl-terminal 10 amino acids are not required, Simultaneous substitution of Thr(334), Thr(336), Sers(338) and Thr(339) resulted in an similar to 50% reduction in phosphorylation, whereas simultaneous substitution of the upstream Ser(328), Thr(329), Thr(331) and Ser(332) or merely the Ser(328) and Thr(329) residues resulted in an similar to 80% reduction in phosphorylation. The introduction of negatively charged glutamate residues for Ser(328) and Thr(329) or Thr(331) and Ser(332) resulted in marked stimulation of phosphorylation. These results suggest a hierarchical mechanism in which phosphorylation of amino-terminal serine and threonine residues is required for the subsequent phosphorylation of carboxyl-terminal residues. These results provide the first direct evidence that an intracellular domain of a chemoattractant receptor is a high affinity substrate for GRK2 and further suggest a role for GRK2 or a closely related kinase in the attenuation of receptor-mediated activation of inflammatory cells.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University	PROSSNITZ, ER (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM12, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ye, Richard/O-5223-2016; Prossnitz, Eric R./B-4543-2008; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033503, R29AI036357, R01AI033503, R01AI036357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36357, AI33503] Funding Source: Medline; NIGMS NIH HHS [GM46572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1993, J BIOL CHEM, V268, P24247; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BENOVIC JL, 1990, BR J CLIN PHARM, V1, pS3; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; HAGA K, 1992, J BIOL CHEM, V267, P2222; HALLET MB, 1989, NEUTROPHIL CELLULAR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1982, FEBS LETT, V20, P1; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PULLEN N, 1993, BIOCHEMISTRY-US, V32, P3958, DOI 10.1021/bi00066a016; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TARDIF M, 1993, J IMMUNOL, V150, P3534; WILDE MW, 1989, J BIOL CHEM, V264, P190; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	46	96	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1130	1137		10.1074/jbc.270.3.1130	http://dx.doi.org/10.1074/jbc.270.3.1130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836371	hybrid			2022-12-25	WOS:A1995QB15600026
J	ITO, K; SHINOMURA, T; ZAKO, M; UJITA, M; KIMATA, K				ITO, K; SHINOMURA, T; ZAKO, M; UJITA, M; KIMATA, K			MULTIPLE FORMS OF MOUSE PG-M, A LARGE CHONDROITIN SULFATE PROTEOGLYCAN GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO; CELLS; VERSICAN; CHONDROGENESIS; HYALURONATE; FIBRONECTIN; SEQUENCES; ADHESION; BINDING; MATRIX	We have isolated and sequenced cDNA clones that encode the core protein of PG-M-like proteoglycan produced by cultured mouse aortic endothelial cells (Morita, H., Takeuchi, T., Suzuki, S., Maeda, R., Yamada, R., Eguchi, G., and Kimata, R. (1990) Biochem. J. 265, 61-68). A homology search of the cDNA sequence has suggested that the core protein is a mouse equivalent of chick PG-M(V1), one of the alternatively spliced forms of the PG-M core protein, which may correspond to human versican. Northern blot analysis revealed three mRNA species of 10, 9, and 8 kilobases (kb) in size, The analysis of PG-M mRNA species in embryonic limb buds and adult brain revealed the presence of other mRNA species with different sizes; the one with the largest size (12 kb) was found in embryonic limb buds, and the ones with smaller sizes of 7.5 and 6.5 kb were in adult brain. Sequencing of cDNA clones for the smaller forms in the adult brain showed that they were different from PG-M(V1) in encoding the second chondroitin sulfate attachment domain (CS alpha) alone, Occurrence of the PCR products striding over the junction of the first and second chondroitin sulfate attachment domains suggested that a mRNA of 12 kb in size corresponded to a transcript without the alternative splicing (PG-M(V0)). It is likely, therefore, that multiforms of the PG-M core protein may be generated by alternative usage of either or both of the two different chondroitin sulfate attachment domains (alpha and beta) and that molecular forms of PG-M may vary from tissue to tissue by such an alternative splicing.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	Aichi Medical University								BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; Bourdon M. A., 1990, EXTRACELLULAR MATRIX, P166; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FERNANDEZ MS, 1991, DEV BIOL, V147, P46; FULOP C, 1993, J BIOL CHEM, V268, P17377; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; KAPOOR R, 1986, BIOCHEM J, V240, P575, DOI 10.1042/bj2400575; KARASAWA K, 1979, DEV BIOL, V70, P287, DOI 10.1016/0012-1606(79)90029-0; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KITAMURA K, 1976, FEBS LETT, V71, P337, DOI 10.1016/0014-5793(76)80965-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LARK MW, 1988, J HISTOCHEM CYTOCHEM, V36, P1211, DOI 10.1177/36.10.3047228; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; OKAYAMA M, 1976, P NATL ACAD SCI USA, V73, P3224, DOI 10.1073/pnas.73.9.3224; RAUCH U, 1992, J BIOL CHEM, V267, P19536; ROYAL PD, 1980, J BIOL CHEM, V255, P9870; SALISBURY BGJ, 1981, J BIOL CHEM, V256, P8050; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	35	148	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					958	965		10.1074/jbc.270.2.958	http://dx.doi.org/10.1074/jbc.270.2.958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822336	hybrid			2022-12-25	WOS:A1995QB81600071
J	JUNG, DW; BAYSAL, K; BRIERLEY, GP				JUNG, DW; BAYSAL, K; BRIERLEY, GP			THE SODIUM-CALCIUM ANTIPORT OF HEART-MITOCHONDRIA IS NOT ELECTRONEUTRAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-MITOCHONDRIA; RUTHENIUM RED; FLUORESCENT-PROBE; EFFLUX MECHANISM; MATRIX PH; TRANSPORT; CARRIER; CA-2+; STOICHIOMETRY; PURIFICATION	Heart mitochondria contain a nNa(+)/Ca2+ antiport that participates in the regulation of matrix [Ca2+]. Based largely on a single study (Brand, M. D. (1985) Biochem, J. 229, 161-166), there has been a consensus that this antiport promotes the electroneutral exchange of two Na+ for one Ca2+. However, a recent study in our laboratory (Baysal, K., Jung, D. W., Gunter, K. K., Gunter, T. P., and Brierley, G. P. (1994) Am. J. Physiol. 266, C800-C808) has shown that the Na+-dependent efflux of Ca2+ from heart mitochondria has more energy available to it than can be supplied by a passive 2Na(+)/Ca2+ exchange. We have therefore re-examined Brand's protocols using fluorescent probes to monitor matrix pH and free [Ca2+]. Respiring heart mitochondria, suspended in KCl and treated with ruthenium red to block Ca2+ influx, extrude Ca2+ and establish a large [Ca2+](out):[Ca2+](matrix) gradient. The extrusion of Ca2+ under these conditions is Na+-dependent and diltiazem-sensitive and can be attributed to the nNa(+)/Ca2+ antiport. Addition of nigericin increases the membrane potential (Delta Psi) and decreases Delta pH to 0.1 or less, but has virtually no effect on the magnitude of the [Ca2+] gradient, Under these conditions a gradient maintained by electroneutral 2Na(+)/Ca2+ antiport should be abolished because the mitochondrial Na+/H+ antiport keeps the [Na+] gradient equivalent to the [H+] gradient. The [Ca2+] gradient is abolished, however, when an uncoupler is added to dissipate Delta Psi or when the exogenous electroneutral antiport BrA23187 is added. In addition, [Ca2+] influx via the nNa(+)/Ca2+ antiport in nonrespiring mitochondria is enhanced when Delta Psi is abolished. These results are consistent with Ca2+ extrusion by an electrophoretic antiport that can respond to Delta Psi but not with an electroneutral antiport.			JUNG, DW (corresponding author), OHIO STATE UNIV, DEPT MED BIOCHEM, 333 HAMILTON HALL, COLUMBUS, OH 43210 USA.				NHLBI NIH HHS [HL09364-29] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFFOLTER H, 1980, BIOCHEM BIOPH RES CO, V95, P193, DOI 10.1016/0006-291X(80)90723-8; ANDEREGG G, 1982, PURE APPL CHEM, V54, P2693, DOI 10.1351/pac198254122693; AZZONE G, 1993, BIOCHIM BIOPHYS ACTA, V1183, P1, DOI 10.1016/0005-2728(93)90002-W; BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V291, P383, DOI 10.1016/0003-9861(91)90150-H; BAYSAL K, 1994, AM J PHYSIOL, V266, pC800, DOI 10.1152/ajpcell.1994.266.3.C800; BRAND MD, 1985, BIOCHEM J, V225, P413, DOI 10.1042/bj2250413; BRAND MD, 1985, BIOCHEM J, V229, P161, DOI 10.1042/bj2290161; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4347, DOI 10.1021/bi00436a034; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; CROMPTON M, 1977, EUR J BIOCHEM, V79, P549, DOI 10.1111/j.1432-1033.1977.tb11839.x; CROMPTON M, 1985, CURR TOP MEMBR TRANS, V25, P231; CROMPTON M, 1978, EUR J BIOCHEM, V91, P599, DOI 10.1111/j.1432-1033.1978.tb12713.x; CROMPTON M, 1990, INTRACELLULAR CALCIU, P181; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KK, 1991, J BIOL CHEM, V266, P21640; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; HAYAT LH, 1987, BIOCHEM J, V244, P533, DOI 10.1042/bj2440533; JENSEN BD, 1986, ARCH BIOCHEM BIOPHYS, V248, P305, DOI 10.1016/0003-9861(86)90427-3; JUNG DW, 1982, BIOCHEM BIOPH RES CO, V105, P432, DOI 10.1016/0006-291X(82)91452-8; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; JUNG DW, 1989, ANAL BIOCHEM, V178, P348, DOI 10.1016/0003-2697(89)90651-9; JUNG DW, 1992, AM J PHYSIOL, V262, pC1047, DOI 10.1152/ajpcell.1992.262.4.C1047; JUNG DW, 1988, ARCH BIOCHEM BIOPHYS, V263, P1928; KHANANSHVILI D, 1994, BIOCHEMISTRY-US, V33, P312, DOI 10.1021/bi00167a041; LI W, 1993, THESIS MED COLLEGE O; LI WH, 1992, J BIOL CHEM, V267, P17983; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MURPHY E, 1980, J BIOL CHEM, V255, P6600; NICHOLLS DG, 1992, BIOENERGETICS, V2, P27; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166	35	112	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					672	678		10.1074/jbc.270.2.672	http://dx.doi.org/10.1074/jbc.270.2.672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822294	hybrid			2022-12-25	WOS:A1995QB81600028
J	HASSETT, R; KOSMAN, DJ				HASSETT, R; KOSMAN, DJ			EVIDENCE FOR CU(II) REDUCTION AS A COMPONENT OF COPPER UPTAKE BY SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; FERRIC REDUCTASE; YEAST; RESISTANCE; TRANSPORT; KINETICS; CELLS	The yeast Saccharomyces cerevisiae contains a plasma membrane reductase activity associated with the gene product of the FRE1 locus. This reductase is required for Fe(III) uptake by this yeast; transcription from FRE1 is repressed by iron (Dancis, A., Klausner, R. D., Hinnebusch, A. G., and Barriocanal, J. G. (1990) Mol. Cell. Biol. 10, 2294-2301). We show here that Cu(II) is equally efficient at repressing FRE1 transcription and is an excellent substrate for the Fre1p reductase. This reductase activity is required for 50-70% of the uptake of Cu-64 by wild type cells. Under conditions of low Fre1-dependent activity, cells retain 30-70% of Cu(II) reductase activity but only 8-25% of Fe(III) reductase activity. While Fre1p-dependent activity is 100% inhibitable by Pt(II), this residual Cu(II) reduction is insensitive to this inhibitor. The data suggest the presence of a Fre1p-independent reductase activity in the yeast plasma membrane which is relatively specific for Cu(II) and which supports copper uptake in the absence of FRE1 expression. The gene product of MAC1, which is required for regulation of FRE1 transcription, is also required for expression of Cu(II) reduction activity. This is due in part to its role in the regulation of FRE1; however, it is required for expression of the putative Cu(II) reductase, as well. Similarly, a gain-of function mutation, MAC1(up1), which causes elevated and unregulated transcription from FRE1 and elevated Fe(III) reduction and Fe-59 uptake exhibits a similar phenotype with respect to Cu(II) reduction and Cu-64 uptake. Ascorbate, which reduces periplasmic Cu(II) to Cu(I), suppresses the dependence of Cu-64 uptake on plasma membrane reductase activity as is the case for ascorbate-supported Fe-59 uptake. The close parallels between Cu(II) and Fe(III) reduction, and Cu-64 and Fe-59 uptake, strongly suggest that Cu(II) uptake by yeast involves a Cu(I) intermediate. This results in the reductive mobilization of the copper from periplasmic chelating agents, making the free ion available for translocation across the plasma membrane.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BASOLO F, 1967, MECHANISMS INORGANIC; CARTWRIGHT GE, 1956, BLOOD, V11, P143, DOI 10.1182/blood.V11.2.143.143; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CRANE FL, 1982, J BIOENERG BIOMEMBR, V14, P191, DOI 10.1007/BF00745020; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DEROME L, 1987, FEMS MICROBIOL LETT, V43, P283, DOI 10.1016/0378-1097(87)90413-7; EIDE D, 1992, J BIOL CHEM, V267, P20774; EMERY T, 1987, IRON TRANSPORT MICRO, P235; FRIEDEN E, 1979, COPPER ENV, V2, P241; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KOSMAN DJ, 1993, METAL IONS FUNGI, P1; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESTER RL, 1961, BIOCHIM BIOPHYS ACTA, V47, P475, DOI 10.1016/0006-3002(61)90543-1; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y; LIN CM, 1993, J GEN MICROBIOL, V139, P1617, DOI 10.1099/00221287-139-7-1617; LIN CM, 1990, J BIOL CHEM, V265, P9194; NEILANDS JB, 1987, IRON TRANSPORT MICRO, P1; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928; PERCIVAL SS, 1989, J NUTR, V119, P779, DOI 10.1093/jn/119.5.779; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; SCHIENBERG IH, 1957, J CLIN INVEST, V36, P1193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stewart P R, 1975, Methods Cell Biol, V12, P111; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; WAKATSUKI T, 1988, J FERMENT BIOENG, V66, P257, DOI 10.1016/0385-6380(88)90102-1; WAKATSUKI T, 1991, J FERMENT BIOENG, V72, P158, DOI 10.1016/0922-338X(91)90209-Y; WALDROP GL, 1990, AM J PHYSIOL, V259, pG212, DOI 10.1152/ajpgi.1990.259.2.G212; 1984, DIFCO MANUAL, P1135	38	289	292	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					128	134		10.1074/jbc.270.1.128	http://dx.doi.org/10.1074/jbc.270.1.128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814363	hybrid			2022-12-25	WOS:A1995QA28700024
J	TAMAI, K; LI, KH; SILOS, S; RUDNICKA, L; HASHIMOTO, T; NISHIKAWA, T; UITTO, J				TAMAI, K; LI, KH; SILOS, S; RUDNICKA, L; HASHIMOTO, T; NISHIKAWA, T; UITTO, J			INTERFERON-GAMMA-MEDIATED INACTIVATION OF TRANSCRIPTION OF THE 230-KDA BULLOUS PEMPHIGOID ANTIGEN GENE (BPAG1) PROVIDES NOVEL INSIGHT INTO KERATINOCYTE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; PROTEIN-TYROSINE KINASES; BASEMENT-MEMBRANE ZONE; MESSENGER-RNA; IFN-GAMMA; CDNA CLONING; DNA; EXPRESSION; COLLAGEN; ACTIVATION	Interferon-gamma (IFN-gamma) has been shown to regulate epidermal keratinocyte growth and differentiation. In this study, we examined the effects of recombinant human IFN-gamma on the expression of the gene encoding the 230-kDa bullous pemphigoid antigen (BPAG1), a marker of the mitotic basal cell phenotype in the epidermis. Northern analysis revealed a dose- and time-dependent suppression of BPAG1 expression by IFN-gamma in cultured human keratinocytes from several different donors, and incubation of the cells with IFN-gamma in the presence of cycloheximide demonstrated that this effect required ongoing protein synthesis. The inhibition of BPAG1 gene expression was also demonstrated at the protein level by indirect immunofluorescence using a mono clonal antibody recognizing the human 230-kDa bullous pemphigoid antigen. Transient transfections of cultured keratinocytes with BPAG1 promoter-chloramphenicol acetyltransferase reporter gene plasmids indicated marked suppression of the promoter activity by IFN-gamma, and deletion constructs were able to identify a defined region containing the responsive element (IFN-gamma inhibitory element). Reduced transcription of the BPAG1 gene by IFN-gamma was also demonstrated by in vitro nuclear run-on assays. These data, which indicate inactivation of transcription of a basal keratinocyte-specific gene (BPAG1) by IFN-gamma, provide novel insight into the mechanisms of IFN-gamma-mediated keratinocyte gene regulation and epidermal differentiation in inflammatory diseases.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107; KEIO UNIV,SCH MED,DEPT DERMATOL,TOKYO 160,JAPAN	Jefferson University; Jefferson University; Jefferson University; Keio University			Rudnicka, Lidia/L-7529-2019	Rudnicka, Lidia/0000-0002-8308-1023	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR7561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASHAM TY, 1984, J INVEST DERMATOL, V83, P88, DOI 10.1111/1523-1747.ep12262597; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DAVIS L, 1994, BASIC METHODS MOL BI, P384; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEMAEYER E, 1992, CURR OPIN IMMUNOL, V4, P321, DOI 10.1016/0952-7915(92)90083-Q; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; DUSTIN ML, 1988, J EXP MED, V167, P132; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPUR AG, 1992, ONCOGENE, V7, P1347; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LEVER WF, 1965, PEMPHIGUS PEMPHIGOID, P75; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NICKOLOFF BJ, 1986, ULTRASTRUCT PATHOL, V10, P17, DOI 10.3109/01913128609015559; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SEN GC, 1992, J BIOL CHEM, V267, P5017; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TAMAI K, 1994, J BIOL CHEM, V269, P493; TAMAI K, 1994, J INVEST DERMATOL, V102, P524; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TANNENBAUM CS, 1993, J IMMUNOL, V151, P6833; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; WIKNER NE, 1986, J INVEST DERMATOL, V87, P559, DOI 10.1111/1523-1747.ep12455746; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	45	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					392	396		10.1074/jbc.270.1.392	http://dx.doi.org/10.1074/jbc.270.1.392			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814399	hybrid			2022-12-25	WOS:A1995QA28700062
J	WONG, VV; PEARSALL, D; ARRIAGA, R; IP, NY; STAHL, N; LINDSAY, RM				WONG, VV; PEARSALL, D; ARRIAGA, R; IP, NY; STAHL, N; LINDSAY, RM			BINDING CHARACTERISTICS OF CILIARY NEUROTROPHIC FACTOR TO SYMPATHETIC NEURONS AND NEURONAL CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; CNTF RECEPTOR; MOTOR-NEURONS; MOLECULAR-CLONING; ALPHA COMPONENT; SENSORY NEURONS; FACTOR PREVENTS; GROWTH-FACTOR; GP130; EXPRESSION	Ciliary neurotrophic factor (CNTF) is a cytokine whose actions are largely restricted to the nervous system because of the predominant neuronal distribution of its receptor, CNTFR alpha. In this study, we sought to define the binding characteristics of CNTF to cultured sympathetic neurons and cell lines of neuronal origin. We report that I-125-CNTF binds to cultured sympathetic neurons, MAH, PC12, and EW-1 cells via high and low affinity receptors that can be distinguished on the basis of their dissociation constants (K(D1 similar to)10(-12) M and K(D2)similar to 10(-9) M). Competition experiments showed that the IC50 for rat and human CNTF were, respectively, 65 pM and 5 an for sympathetic neurons and 75 pM. and 1.2 nM for EW-1 cells. Interestingly, leukemia inhibitory factor (LIF) did not compete for CNTF binding even at 100 nM concentration. The binding of I-125-CNTF to sympathetic neurons involved all three components of the CNTF receptor complex, namely CNTFR alpha; LIFR, and gp130, as shown by cross-linking experiments. CNTF and LIF treatments down-regulated CNTF binding to sympathetic neurons and EW-1 cells, suggesting that heterologous ligands can regulate CNTF receptor levels, which may in turn modulate the efficacy of CNTF in vitro and in vivo.			WONG, VV (corresponding author), REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA.		Lindsay, Ronald/GQP-8001-2022					ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FORGER NG, 1993, J NEUROSCI, V13, P4720; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, SEMIN NEUROSCI, V5, P249; KESSLER JA, 1984, DEV BIOL, V106, P61, DOI 10.1016/0012-1606(84)90061-7; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; LARKFORS L, 1994, EUR J NEUROSCI, V6, P1015, DOI 10.1111/j.1460-9568.1994.tb00596.x; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VERGE VMK, 1992, J NEUROSCI, V12, P4011; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					313	318		10.1074/jbc.270.1.313	http://dx.doi.org/10.1074/jbc.270.1.313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814393	hybrid			2022-12-25	WOS:A1995QA28700050
J	ALLEN, PG; JANMEY, PA				ALLEN, PG; JANMEY, PA			GELSOLIN DISPLACES PHALLOIDIN FROM ACTIN-FILAMENTS - A NEW FLUORESCENCE METHOD SHOWS THAT BOTH CA2+ AND MG2+ AFFECT THE RATE AT WHICH GELSOLIN SEVERS F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA GELSOLIN; BINDING-SITES; POLYMORPHONUCLEAR LEUKOCYTES; REGULATORY PROTEIN; COMPLEX; POLYMERIZATION; CELLS; STABILIZATION; PURIFICATION; TROPOMYOSIN	We describe an assay for measuring both the extent and kinetics of the severing of F-actin, based on the enhanced fluorescence emission of tetramethylrhodamine-phalloidin bound to F-actin, The enhanced fluorescence is lost after exposure to active gelsolin by displacement of the phalloidin from actin during severing. This assay requires small amounts of actin and gelsolin, can be used to measure reaction times ranging from 1 to 10(3) s, and does not require covalent modification of either protein. The rate of fluorescence loss is linearly related to the concentrations of both actin and gelsolin, However, the apparent rate constant of the reaction is highly dependent on the divalent cation concentration, varying between 10(4) and 10(6) M(-1) s(-1) when the [Ca2+] varies between 20 and 200 mu M. Addition of Mg2+ increases the apparent rate constant at equivalent Ca2+ concentration. These results suggest that in vitro the rate limiting step in the severing process is the activation of gelsolin by the binding of Ca2+ and Mg2+ to several low affinity (K-d approximate to 100 mu M) sites on gelsolin. While activation of gelsolin by Ca2+ is a slow process, the binding and severing of actin occurs at a rate approaching the diffusion limit,	HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115	Harvard University; Harvard Medical School	ALLEN, PG (corresponding author), BRIGHAM & WOMENS HOSP,DIV EXPTL MED,LMRC 301,221 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38910] Funding Source: Medline; PHS HHS [AL 07680] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARDEN JA, 1987, EUR J BIOCHEM, V162, P583, DOI 10.1111/j.1432-1033.1987.tb10679.x; BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; COLUCCIO LM, 1984, J CELL BIOL, V99, P529, DOI 10.1083/jcb.99.2.529; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DANCKER P, 1975, BIOCHIM BIOPHYS ACTA, V400, P407, DOI 10.1016/0005-2795(75)90196-8; DOI Y, 1990, BIOCHEMISTRY-US, V29, P1392, DOI 10.1021/bi00458a008; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; HARRIS HE, 1984, FEBS LETT, V177, P184, DOI 10.1016/0014-5793(84)81280-6; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; ILLNER H, 1992, PFLUG ARCH EUR J PHY, V422, P179, DOI 10.1007/BF00370418; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KANNO K, 1989, J CELL PHYSIOL, V139, P58, DOI 10.1002/jcp.1041390110; KILHOFFER MC, 1985, BIOCHEM BIOPH RES CO, V131, P1132, DOI 10.1016/0006-291X(85)90208-6; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH MC, 1984, J BIOL CHEM, V259, P7473; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LOEW I, 1975, Febs Letters, V54, P263; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Moore WJ, 1972, PHYS CHEM, V4th, P977; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SCHOEPPER B, 1992, J BIOL CHEM, V267, P13924; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TELLAM RL, 1991, ARCH BIOCHEM BIOPHYS, V288, P185, DOI 10.1016/0003-9861(91)90182-I; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x; VERKHOVSKY AB, 1984, BIOCHEM BIOPH RES CO, V123, P596, DOI 10.1016/0006-291X(84)90271-7; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YIN HL, 1980, J BIOL CHEM, V255, P9490; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121	51	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32916	32923						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806519				2022-12-25	WOS:A1994QA63800032
J	BROWN, CM; TATE, WP				BROWN, CM; TATE, WP			DIRECT RECOGNITION OF MESSENGER-RNA STOP SIGNALS BY ESCHERICHIA-COLI POLYPEPTIDE-CHAIN RELEASE FACTOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; MESSENGER-RNA; CROSS-LINKING; TRANSLATIONAL TERMINATION; PROTEIN-SYNTHESIS; DECODING SITE; CODON; ANALOGS; 4-THIOURIDINE; SUPPRESSOR	The interaction between the translational stop signal and the polypeptide chain release factor protein (RF) within complexes of Escherichia coli ribosomes has been investigated by site-directed photochemical crosslinking experiments. Twelve mRNA analogues containing 4-thiouridine residues as part of stop signals were synthesized. Highly efficient cross-linking to RF-2 from 4-thiouridine (sU) residues of sUGAN-containing mRNAs was observed, and cross-linking from those of sUAAN was observed at a lower efficiency. This indicates that RF-2 is in close physical contact with the stop signal on the ribosome, The yield of the RF-2 mRNA cross-link depended on the identity of the fourth base for the sUGAN set of signals, suggesting that the fourth base of the stop signal affects the interaction between RF-2 and the stop codon, A region previously implicated as part of the decoding site of the small ribosomal subunit, 1385-1420 of the 16 S rRNA, was also cross-linked with these mRNAs. No new cross-links were obtained in the presence of the release factor. The data are consistent with models in which the RF has an anticodon-like domain that contacts the stop signal directly at or near the ribosomal site in which sense codons are decoded.	UNIV OTAGO, DEPT BIOCHEM, DUNEDIN, NEW ZEALAND; UNIV OTAGO, CTR GENE RES, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago								BRIMACOMBE R, 1988, METHOD ENZYMOL, V164, P287; BRIMACOMBE R, 1990, RIBOSOMES PROTEIN SY, P131; BROWN CM, 1993, NUCLEIC ACIDS RES, V21, P2109, DOI 10.1093/nar/21.9.2109; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P2079, DOI 10.1093/nar/18.8.2079; BUCKINGHAM K, 1987, BIOCHIM BIOPHYS ACTA, V909, P92, DOI 10.1016/0167-4781(87)90030-3; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DUBREUIL YL, 1991, NUCLEIC ACIDS RES, V19, P3653; EGGERTSSON G, 1988, MICROBIOL REV, V52, P354, DOI 10.1128/MMBR.52.3.354-374.1988; FAVRE A, 1991, NEW J CHEM, V15, P593; FLUCK MM, 1977, MOL GEN GENET, V151, P137, DOI 10.1007/BF00338688; GORINGER HU, 1991, P NATL ACAD SCI USA, V88, P6603, DOI 10.1073/pnas.88.15.6603; GROSJEAN H, 1986, STRUCTURE DYNAMICS R, P161; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LIM VI, 1994, J MOL BIOL, V240, P8, DOI 10.1006/jmbi.1994.1413; MAJOR F, 1991, SCIENCE, V253, P1255, DOI 10.1126/science.1716375; MOFFAT JG, 1994, J BIOL CHEM, V269, P18899; MORAS D, 1986, P NATL ACAD SCI USA, V83, P932, DOI 10.1073/pnas.83.4.932; MURGOLA EJ, 1988, P NATL ACAD SCI USA, V85, P4162, DOI 10.1073/pnas.85.12.4162; PEDERSEN WT, 1991, J MOL BIOL, V219, P231, DOI 10.1016/0022-2836(91)90564-M; PRESCOTT CD, 1991, BIOCHIMIE, V73, P1121, DOI 10.1016/0300-9084(91)90155-T; RAUE HA, 1990, STRUCTURE FUNCTION G, P217; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; SCHROEDER R, 1993, SCIENCE, V260, P1443, DOI 10.1126/science.8502988; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; TATE WP, 1983, J BIOL CHEM, V258, P360; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TATE WP, 1990, RIBOSOME, P393; TATE WP, 1993, TRANSLATIONAL APPARATUS, P253; Yarus M, 1992, TRANSFER RNA PROTEIN, P319	31	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33164	33170						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806547				2022-12-25	WOS:A1994QA63800066
J	KARNAUCHOV, I; CAI, DG; SCHMIDT, I; HERRMANN, RG; KLOSGEN, RB				KARNAUCHOV, I; CAI, DG; SCHMIDT, I; HERRMANN, RG; KLOSGEN, RB			THE THYLAKOID TRANSLOCATION OF SUBUNIT-3 OF PHOTOSYSTEM-I, THE PSAF GENE-PRODUCT, DEPENDS ON A BIPARTITE TRANSIT PEPTIDE AND PROCEEDS ALONG AN AZIDE-SENSITIVE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; NUCLEOTIDE-SEQUENCE; PRECURSOR PROTEIN; PREPROTEIN TRANSLOCASE; CHLOROPLAST GENOME; CHROMOPHYTIC ALGA; LUMENAL PROTEINS; ESCHERICHIA-COLI; PROTON GRADIENT; PLASTID GENOME	Subunit 3 of photosystem I (PSI-3), the product of the nuclear psaF gene, is the docking protein for plastocyanin during photosynthetic electron transport in thylakoid membranes and is synthesized in the cytosol with a transit peptide that resembles structurally the bipartite targeting signals of hydrophilic, lumenal components such as plastocyanin, In organello import experiments performed with the authentic PSI-3 precursor and chimeric polypeptides consisting of residue-correct fusions of transit peptides and mature proteins derived from different plastid proteins demonstrate that the PSI-3 transit peptide is indeed capable of translocating proteins into the thylakoid lumen and that, conversely, mature PSI-3 depends on a bipartite transit peptide for its thylakoid transfer, Of the three recently described translocation/integration pathways for nucleus encoded proteins carrying bipartite transit peptides that are distinct in their physiological requirements and strictly protein-specific, PSI-3, like plastocyanin and the 33-kDa protein of the oxygen evolving complex, is translocated by a pathway that involves stromal factors but no proton gradient across the membrane, It is not affected by saturating amounts of the precursor for the 23-kDa protein of the oxygen-evolving complex that follows the latter route. Thylakoid translocation of PSI-3 is, however, impaired in the presence of sodium azide, which indicates that a homolog to the bacterial SecA protein might be involved in this process suggesting, thus, a prokaryote-like translocation pathway, The azide sensitive factor appears to interact predominantly with the transit peptide of a precursor protein, since chimeras consisting of a presequence from an azide-resistant precursor and a mature part of an azide-sensitive polypeptide are still translocated in the presence of the inhibitor.	UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	University of Munich								BARTLING D, 1990, BOT MAG TOKYO, V2, P119; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CLAUSMEYER S, 1993, J BIOL CHEM, V268, P13869; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; FLACHMANN R, 1993, J BIOL CHEM, V268, P7514; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V895, P167, DOI 10.1016/S0304-4173(87)80002-2; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HAVAUX M, 1991, Z NATURFORSCH C, V46, P1038; HENRY R, 1994, J BIOL CHEM, V269, P10189; Herrmann R. G., 1991, Plant molecular biology 2. Proceedings of a NATO Advanced Study Institute, 14-23 May 1990, Elmau, Germany., P411; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; HULFORD A, 1994, J BIOL CHEM, V269, P3251; JAMES HE, 1989, J BIOL CHEM, V264, P19573; JANSEN T, 1987, FEBS LETT, V216, P234, DOI 10.1016/0014-5793(87)80696-8; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MARGUILES MM, 1989, PLANT SCI, V54, P1; Margulis L., 1993, SYMBIOSIS CELL EVOLU; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OTTO J, 1989, FEBS LETT, V259, P625; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SCARAMUZZI CD, 1992, CURR GENET, V22, P421, DOI 10.1007/BF00352444; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; THEG SM, 1989, J BIOL CHEM, V264, P6730; TJUS SE, 1991, PHOTOSYNTH RES, V27, P209, DOI 10.1007/BF00035842; TYAGI A, 1987, MOL GEN GENET, V207, P288, DOI 10.1007/BF00331591; VALENTIN K, 1993, MOL GEN GENET, V236, P245, DOI 10.1007/BF00277119; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1985, MOL BIOL PHOTOSYNTHE, P141; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901	65	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32871	32878						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806513				2022-12-25	WOS:A1994QA63800026
J	MOK, SS; MASUDA, K; HAUSELMANN, HJ; AYDELOTTE, MB; THONAR, EJMA				MOK, SS; MASUDA, K; HAUSELMANN, HJ; AYDELOTTE, MB; THONAR, EJMA			AGGRECAN SYNTHESIZED BY MATURE BOVINE CHONDROCYTES SUSPENDED IN ALGINATE - IDENTIFICATION OF 2 DISTINCT METABOLIC MATRIX POOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; SUB-POPULATIONS; PROTEOGLYCANS; TURNOVER; BIOSYNTHESIS; CATABOLISM; CULTURES; EXPLANTS	Proteoglycans synthesized by chondrocytes in alginate beads are found in two compartments: the cell-associated matrix and the further removed matrix (Hauselmann, H. J,, Aydelotte M, B,, Schumacher B, L,, Kuettner K, E,, Gitelis, S, Ii,, and Thonar, E, J,-M, A (1992) Matrix 12, 116-129), To study the metabolism of aggrecan in these two compartments, mature bovine articular chondrocytes in alginate beads were pulsed with [S-35]sulfate for 30 min or 16 h on day 7 of culture and then chased in isotope-free medium for up to 21 days, At different times, the two matrix pools were separately isolated, and the S-35-proteoglycans quantified, purified, and characterized, Radiolabeled aggrecan molecules exhibited a very long average half life in the beads (t(1/2) = 95 days), In contrast, small non-aggregating proteoglycans, which made up approximately 4% of the S-35-proteoglycans synthesized, were rapidly lost from the beads (t(1/2) = <24 h), Approximately half the S-35-aggrecan subunits, representing mostly molecules which showed a delay in ability to form aggregates in the presence of exogenous hyaluronan and link protein, spent only a short time (t(1/2) = 4 h) in the cell-associated matrix before moving into the further removed matrix, They exhibited a much longer average half life in the beads than S-35-aggrecan molecules which became resident of the cell-associated matrix (t(1/2) = >95 days versus 15 days), Radiolabeled aggrecan subunits in the two matrix compartments had a similar average hydrodynamic size and polydispersity; importantly, the size of these molecules did not change during the chase period, Catabolism of S-35-aggrecan in the cell-associated matrix was the only significant contributor to the appearance in the medium of partially degraded S-35-aggrecan which had lost the ability to bind to hyaluronan, These results strongly suggest aggrecan molecules which reside in the pericellular and territorial matrix compartments in close proximity to the chondrocytes have a much faster rate of turnover than their counterpart in the interterritorial areas further removed from the cells,	RUSH PRESBYTERIAN ST LUKES MED CTR,RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,RUSH MED COLL,DEPT INTERNAL MED,CHICAGO,IL 60612; UNIV ZURICH HOSP,DEPT RHEUMATOL,CH-8091 ZURICH,SWITZERLAND; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND	Rush University; Rush University; University of Zurich; University Zurich Hospital; University of Bern					NIAMS NIH HHS [1-P50-AR39239] Funding Source: Medline; NIA NIH HHS [AG04736] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004736] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P223, DOI 10.3109/03008208809016809; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; Aydelotte MB, 1986, ARTICULAR CARTILAGE, P235; BARONEVARELAS J, 1991, CONNECT TISSUE RES, V26, P101, DOI 10.3109/03008209109152167; BAYLISS MT, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P487; BAYLISS MT, 1987, ORTHOP T, V11, P289; CAMPBELL MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P275, DOI 10.1016/0003-9861(84)90350-3; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; EYRE DR, 1990, METHODS CARTILAGE RE, P28; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HARDINGHAM TE, 1972, BIOCHEM J, V126, P791, DOI 10.1042/bj1260791; HASCALL VC, 1994, IN PRESS STRUCTURE F; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HAUSELMANN HJ, 1992, MATRIX, V12, P116; HUNZIKER EB, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P183; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; KUETTNER KE, 1990, CARTILAGE CHANGES OS, P3; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; LOHMANDER S, 1977, ARCH BIOCHEM BIOPHYS, V180, P93, DOI 10.1016/0003-9861(77)90012-1; MAROUDAS A, 1985, IN PRESS ORTHOP T; MAROUDAS A, 1992, CONNECT TISSUE RES, V27, P1; MOLLENHAUER HH, 1964, STAIN TECHNOL, V39, P111; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; PETIT B, 1995, IN PRESS ORTHOP T; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; Roughley P J, 1986, Agents Actions Suppl, V18, P19; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P21; SANDY JD, 1989, ARCH BIOCHEM BIOPHYS, V271, P300, DOI 10.1016/0003-9861(89)90280-4; STEVENS RL, 1981, J BIOL CHEM, V256, P2045; THONAR EJMA, 1983, J BIOL CHEM, V258, P1564; THONAR EJMA, 1986, J BIOL CHEM, V261, P2467; VANKAMPEN GPJ, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P281; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3	38	139	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33021	33027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806530				2022-12-25	WOS:A1994QA63800046
J	CHAZENBALK, GD; RAPOPORT, B				CHAZENBALK, GD; RAPOPORT, B			CLEAVAGE OF THE THYROTROPIN RECEPTOR DOES NOT OCCUR AT A CLASSICAL SUBTILISIN-RELATED PROPROTEIN CONVERTASE ENDOPROTEOLYTIC SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; FUNCTIONAL EXPRESSION; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; GRAVES-DISEASE; BINDING; CELLS; CHAIN; DNA; AUTOANTIBODIES	The human thyrotropin receptor (TSHR) undergoes proteolytic cleavage closely upstream to amino acid 317. Between residues 261 and 313 are three clusters of positively charged amino acids, arginines (Arg) and lysines (Lys), which are potential subtilisin-related proprotein convertase sites, We used oligonucleotide-directed mutagenesis to perform conservative amino acid substitutions within these regions (Arg or Lys to glutamine, Gin), Chinese hamster ovary cells stably transfected with mutant receptor cDNA TSHR-CS1 (Gln(261)) and TSHR-CS3 (Gln(290), Gln(313)) bound radiolabeled TSH with an affinity similar to the wild-type TSHR. Mutant cDNA TSHR-CS2 (Gln(312), Gln(291)) and TSHR-CS4 (Gln(261), Gln(290), Gln(291), Gln(312), Gln(313)) did not express a protein on the cell surface capable of specific TSH binding, After covalent cross-linkage of radiolabeled TSH to TSHR-CS1 and TSHR-CS3, the mutant receptors dissociated into two subunits under reducing conditions, The most prominent cluster of basic amino acids in the TSHR extracellular region (residues 287-293) was studied in a second series of mutations designed to eliminate the classical proprotein convertase sites in this region and yet be compatible with TSHR function, All three mutant receptors, TSHR-CS5 (Gln(290)), TSHR-CS6 (Gln(291)), and TSHR-CS7 (Gln(291), Gln(293)) bound TSH with an affinity similar to that of wild type, and none of these amino acid substitutions prevented proteolytic cleavage of the extracellular domains of the TSHR. Thus, cleavage of the TSHR extracellular domain does not involve a classical subtilisin-related proprotein convertase cleavage site, raising the possibility that TSHR cleavage occurs after processing and trafficking of the protein to the plasma membrane.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco	CHAZENBALK, GD (corresponding author), VET ADM MED CTR,THYROID MOLEC BIOL UNIT 111T,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLAND PR, 1982, FEBS LETT, V145, P245, DOI 10.1016/0014-5793(82)80176-2; CHAZENBALK GD, 1990, ENDOCRINOLOGY, V127, P1240, DOI 10.1210/endo-127-3-1240; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DICKINSON CJ, 1992, J BIOL CHEM, V267, P21795; ENDO K, 1978, J CLIN ENDOCR METAB, V46, P734, DOI 10.1210/jcem-46-5-734; ENDO T, 1992, BIOCHEM BIOPH RES CO, V187, P887, DOI 10.1016/0006-291X(92)91280-4; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; GOLDFINE ID, 1974, ENDOCRINOLOGY, V95, P1228, DOI 10.1210/endo-95-5-1228; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOSSFELT H, 1992, P NATL ACAD SCI USA, V895, P3765; LU WY, 1993, J BIOL CHEM, V268, P14583; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; ORGIAZZI J, 1976, J CLIN ENDOCR METAB, V42, P341, DOI 10.1210/jcem-42-2-341; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SMITH BR, 1974, LANCET, V2, P427; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596	32	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32209	32213						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798220				2022-12-25	WOS:A1994PX30400032
J	FAZIO, S; MAROTTI, KR; LEE, YL; CASTLE, CK; MELCHIOR, GW; RALL, SC				FAZIO, S; MAROTTI, KR; LEE, YL; CASTLE, CK; MELCHIOR, GW; RALL, SC			COEXPRESSION OF CHOLESTERYL ESTER TRANSFER PROTEIN AND DEFECTIVE APOLIPOPROTEIN-E IN TRANSGENIC MICE ALTERS PLASMA-CHOLESTEROL DISTRIBUTION - IMPLICATIONS FOR THE PATHOGENESIS OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN LEVELS; FAMILIAL DYSBETALIPOPROTEINEMIA; PHENOTYPE-E3/3; METABOLISM; CYSTEINE; VARIANT	Despite the definite etiologic link between apolipoprotein (ape) E mutations and type III hyperlipoproteinemia (HLP), it is not clear what additional factors are involved in the development of florid hyperlipidemia and how to explain the wide variability in the expression of the hyperlipidemic phenotype in carriers of receptor binding-defective apoE variants, The present study was designed to determine whether the overexpression of cholesteryl ester transfer protein (CETP), a plasma protein that transfers cholesteryl esters hom the high density lipoproteins (HDL) to the very low density lipoproteins (VLDL) and whose activity is increased in hyperlipidemic states, plays a role in the development of hyperlipidemia and beta-VLDL accumulation in type III HLP. We produced double-transgenic mice that co-expressed high levels of simian CETP and either high or low levels of a human receptor binding-defective apoE variant, apoE(Cys-142). We previously reported that apoE(Cys-142) high-expresser mice showed spontaneous hyperlipidemia and accumulation of beta-VLDL, whereas the low-expresser mice showed only a modest increase in VLDL cholesterol. Go-expression of CETP induced a massive transfer of cholesteryl esters from the HDL to the VLDL in both lines of double-transgenic mice. As a result, HDL cholesterol and apoA-I levels were reduced to about 50% of normal, VLDL cholesterol increased 2.5-fold, and the cholesteryl ester content of VLDL reached values similar to those observed in human beta-VLDL. The ratio of defective to normal apoE in VLDL was unaffected by CETP co-expression and was higher in animals expressing high apoE levels, Finally, in spite of an increased accumulation of beta-VLDL in the high-expresser mice, the VLDL of the low-expresser mice maintained pre-beta mobility upon co expression of CETP. The results of this study demonstrate that the ratio of defective to normal apoE on the VLDL, rather than the cholesteryl ester content of VLDL, is the major factor determining the development of severe hyperlipidemia and the formation and accumulation of beta-VLDL in type III HLP.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UPJOHN CO, UPJOHN LABS, KALAMAZOO, MI 49001 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; Pfizer					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; ANDERSON LJ, 1989, J LIPID RES, V30, P1819; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; FAINARU M, 1982, J LIPID RES, V23, P702; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1980, P NATL ACAD SCI-BIOL, V77, P4349, DOI 10.1073/pnas.77.7.4349; HAYEK T, 1993, J CLIN INVEST, V92, P1143, DOI 10.1172/JCI116683; HORIE Y, 1992, J BIOL CHEM, V267, P1962; INNERARITY TL, 1986, LIPOPROTEIN DEFICIEN, P273; KIEFT KA, 1991, J LIPID RES, V32, P859; KINOSHITA M, 1993, J LIPID RES, V34, P261; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P476, DOI 10.1161/01.ATV.11.3.476; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MELCHIOR GW, 1994, J BIOL CHEM, V269, P8044; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; SEIP RL, 1993, ARTERIOSCLER THROMB, V13, P1359, DOI 10.1161/01.ATV.13.9.1359; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1986, J LIPID RES, V27, P361; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518	28	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32368	32372						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798236				2022-12-25	WOS:A1994PX30400054
J	SRIKANTH, S; RADO, TA				SRIKANTH, S; RADO, TA			A 30-BASE PAIR ELEMENT IS RESPONSIBLE FOR THE MYELOID-SPECIFIC ACTIVITY OF THE HUMAN NEUTROPHIL ELASTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYELOPEROXIDASE GENE; CD11B PROMOTER; NF-M; EXPRESSION; PROTEIN; DIFFERENTIATION; CELLS; IDENTIFICATION; PROTOONCOGENE; REGION	Human neutrophil elastase (HNE), a serine protease, is expressed only in the promyelocytic stages of granulocyte maturation. We examined several regions of the promoter for transcriptional activity and report that a 30-base pair (bp) element located between -76 and -106 in the 5'-flanking region of HNE is sufficient for myeloid-specific expression of HNE. Gel shift assays using nuclear extracts from myeloid and non-myeloid cells reveal several myeloid-specific complexes binding to the 30-bp element. Examination of DNA-protein interactions shows that at least two myeloid-specific proteins of 38 and 55 kDa bind to this element. DNase I protection analysis reveals two distinct footprints between -80 to -91 and -94 to -104 within this element. Transient expression studies using deletion constructs of the HNE 5'-flanking region show that the 30-bp element is active in myeloid cells It 562 and U 937 but not in HeLa cells. Internal deletion of this element results in a 60-85% loss of promoter activity in myeloid cells. Additional functional studies also show that a 19-bp region between -112 and -131 contributes to transcriptional activity of the elastase promoter as well.	UNIV ALABAMA,DEPT MED,DIV HEMATOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,DIV HEMATOL,BIRMINGHAM,AL 35294; BIRMINGHAM VET AFFAIRS MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007237] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA07237] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BAGIUS S, 1994, ANN HEMATOL, V68, P125; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHUMAKOV AM, 1993, BLOOD, V82, P30; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAN J, 1991, BIOCHEM BIOPH RES CO, V181, P1462, DOI 10.1016/0006-291X(91)92104-R; HASHINAKA K, 1992, ARCH BIOCHEM BIOPHYS, V293, P40, DOI 10.1016/0003-9861(92)90362-Z; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LEE TC, 1992, BIOTECHNIQUES, V12, P486; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LUBBERT M, 1991, BLOOD, V78, P345; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAI S, 1993, P NATL ACAD SCI USA, V90, P1753; TUCKER KA, 1987, BLOOD, V70, P372; YOSHIMURA K, 1992, BLOOD, V79, P2733; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG WW, 1991, BIOTECHNIQUES, V11, P728; ZIMMER M, 1992, P NATL ACAD SCI USA, V89, P8215, DOI 10.1073/pnas.89.17.8215	43	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32626	32633						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798268				2022-12-25	WOS:A1994PX30400090
J	WEN, W; HAROOTUNIAN, AT; ADAMS, SR; FERAMISCO, J; TSIEN, RY; MEINKOTH, JL; TAYLOR, SS				WEN, W; HAROOTUNIAN, AT; ADAMS, SR; FERAMISCO, J; TSIEN, RY; MEINKOTH, JL; TAYLOR, SS			HEAT-STABLE INHIBITORS OF CAMP-DEPENDENT PROTEIN-KINASE CARRY A NUCLEAR EXPORT SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CYCLIC-AMP; ESCHERICHIA-COLI; GOLGI-COMPLEX; PORE COMPLEX; LOCALIZATION; RNA; OOCYTES; TRANSLOCATION; EXPRESSION	The heat-stable inhibitor of cAMP-dependent protein kinase (PKI) was shown previously to export the kinase catalytic subunit (C) from the nucleus (Fantozzi, D. A., Harootunian, A. T., Wen, W., Taylor, S. S., Feramisco, J. R., Tsien, R. Y., and Meinkoth, J. L. (1994) J. Biol. Chem. 269, 2676-2686), in addition to its ability to inhibit kinase activity. In this study, the mechanism of PKI export is investigated. The injection of a C PHI complex containing both labeled PHI and C-subunit revealed that both proteins exit the nucleus in unison. A fusion protein of C-subunit with glutathione S-transferase (GST) (140 kDa) cannot traverse the nuclear membrane in either direction, but can be exported from the nucleus when complexed with PHI, supporting the presence of a nuclear export signal (NES) in the C.PKI complex. Fusions of PKI alpha with GST (70 kDa) or PKI beta 1 with maltose-binding protein (MBP) (50 kDa) remain effective at exporting complexes with C-subunit. The export of C.PKI is also sensitive to temperature and energy depletion. Taken together, these results demonstrate that export is both energy- and temperature-dependent, but size-independent, consistent with an active signal-mediated export process. GST-PKI exits from the nucleus even in the absence of C-subunit, indicating that the NES resides entirely on PKI, but suggesting that fusion of PKI to GST leads 60 a conformational change that mimics the exposure of the NES caused by the binding of C. Since both PKI alpha and PKI beta 1 can export C-subunit, the predicted export signal is likely to reside on the residues conserved between PKI alpha and PKI beta 1.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; CARR DW, 1992, J BIOL CHEM, V267, P13376; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, PEPT PROT PHOSPH, P1; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; WEN W, 1994, J BIOL CHEM, V269, P8423	41	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32214	32220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798221				2022-12-25	WOS:A1994PX30400033
J	YANG, GY; MERRILL, DC; THOMPSON, MW; ROBILLARD, JE; SIGMUND, CD				YANG, GY; MERRILL, DC; THOMPSON, MW; ROBILLARD, JE; SIGMUND, CD			FUNCTIONAL EXPRESSION OF THE HUMAN ANGIOTENSINOGEN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; CELL-SPECIFIC EXPRESSION; HUMAN RENIN GENE; MESSENGER-RNA; BLOOD-PRESSURE; SMOOTH-MUSCLE; INSITU HYBRIDIZATION; CONVERTING ENZYME; POLYMORPHISM; ELEMENTS	The renin-angiotensin system is a major determinant of arterial pressure and volume homeostasis in mammals through the actions of angiotensin II, the proteolytic digestion product of angiotensinogen. Molecular genetic studies in several human populations have revealed genetic linkage between the angiotensinogen gene and both hypertension and increased plasma angiotensinogen. Transgenic mice were generated with a human angiotensinogen genomic clone to develop an animal model to examine tissue- and cell-specific expression of the gene and to determine if overexpression of angiotensinogen results in hypertension. Human angiotensinogen mRNA was expressed in transgenic mouse liver, kidney, heart, adrenal gland, ovary, brain, and white and brown adipose tissue and, in kidney, was exclusively localized to epithelial cells of the proximal convoluted tubules, Plasma levels of human angiotensinogen were approximately 150-fold higher in transgenic mice than that found normally in human plasma. The blood pressure of mice bearing the human angiotensinogen gene was normal but infusion of a single bolus dose of purified human renin resulted in a transient increase in blood pressure of approximately 30 mm Hg within 2 min. These results suggest that abnormalities in the angiotensinogen gene resulting in increased circulating levels of angiotensinogen could potentially contribute in part to the pathogenesis of essential hypertension.	UNIV IOWA,COLL MED,DEPT MED & PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ANAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OBSTET & GYNECOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048058, R37HL048058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAZIL MK, 1993, J CARDIOVASC PHARM, V22, P897, DOI 10.1097/00005344-199312000-00019; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; BURTON J, 1988, BIOCHIM BIOPHYS ACTA, V952, P8, DOI 10.1016/0167-4838(88)90095-7; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLISON KE, 1989, J CLIN INVEST, V83, P1941, DOI 10.1172/JCI114102; GAILLARDSANCHEZ I, 1990, HUM GENET, V84, P341; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GYURKO R, 1993, REGUL PEPTIDES, V49, P167, DOI 10.1016/0167-0115(93)90438-E; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HOGAN E, 1986, MANIPULATING MOUSE E; HUBNER N, 1994, HYPERTENSION, V23, P797, DOI 10.1161/01.HYP.23.6.797; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LEVENS NR, 1981, CIRC RES, V48, P157, DOI 10.1161/01.RES.48.2.157; LIFTON RP, 1989, HYPERTENSION, V13, P884, DOI 10.1161/01.HYP.13.6.884; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; NAFTILAN AJ, 1989, HYPERTENSION, V14, P614, DOI 10.1161/01.HYP.14.6.614; NAFTILAN AJ, 1989, HYPERTENSION, V13, P706, DOI 10.1161/01.HYP.13.6.706; NISHIMURA M, 1992, HYPERTENSION, V20, P158, DOI 10.1161/01.HYP.20.2.158; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; TAMURA K, 1993, J BIOL CHEM, V268, P15024; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; WARD R, 1990, HYPERTENSION PATHOPH, P81; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	43	110	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32497	32502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798251				2022-12-25	WOS:A1994PX30400072
J	LIU, TC; KOROTCHKINA, LG; HYATT, SL; VETTAKKORUMAKANKAV, NN; PATEL, MS				LIU, TC; KOROTCHKINA, LG; HYATT, SL; VETTAKKORUMAKANKAV, NN; PATEL, MS			SPECTROSCOPIC STUDIES OF THE CHARACTERIZATION OF RECOMBINANT HUMAN DIHYDROLIPOAMIDE DEHYDROGENASE AND ITS SITE-DIRECTED MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; DISULFIDE OXIDOREDUCTASES; HIS450-GLU455 DIAD; MUTATED ENZYMES; WILD-TYPE; MUTAGENESIS	In this paper, we report the overexpression and single-step purification of recombinant wild-type and site-directed mutants of human dihydrolipoamide dehydro genase in Escherichia coli and detailed spectroscopic studies aimed at understanding the catalytic mechanism of this enzyme, One mutation (K37E) has been identified in a patient lacking dihydrolipoamide dehydrogenase activity and has been reported previously (Liu, T,-C,, Kim, H,, Arizmendi, C., Kitano, A, and Patel, M. S. (1993) Proc, Natl, Acad, Sci, USA, 90, 5186-5190), while the other two mutations were previously generated specifically to address the role of the active-site base (His-452) and its ion pair (Glu-457). Circular dichroic and fluorescence spectroscopic data illustrate the role of these amino acids in maintaining the structure and function of human dihydrolipoamide dehydrogenase, While mutant H452Q is severely crippled in catalysis of the physiological reaction, the reverse reaction is affected in the E457Q mutant, The K37E mutant shows very little deviation from the wild-type enzyme.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042885] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42885] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON N, 1988, BIOCHEM J, V256, P741, DOI 10.1042/bj2560741; BENEN J, 1991, EUR J BIOCHEM, V202, P863, DOI 10.1111/j.1432-1033.1991.tb16444.x; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; CAROTHERS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P409, DOI 10.1016/0003-9861(89)90309-3; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; JENTOFT JE, 1992, PROTEINS, V14, P88, DOI 10.1002/prot.340140110; KIKUCHI G, 1982, MOL CELL BIOCHEM, V45, P137; KIM H, 1992, J BIOL CHEM, V267, P5128; KIM HJ, 1991, J BIOL CHEM, V266, P9367; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIU TC, 1993, P NATL ACAD SCI USA, V90, P5186, DOI 10.1073/pnas.90.11.5186; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; OTULAKOWSKI G, 1987, J BIOL CHEM, V262, P17313; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; REED LJ, 1958, J BIOL CHEM, V232, P143; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	24	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15545	15550		10.1074/jbc.270.26.15545	http://dx.doi.org/10.1074/jbc.270.26.15545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797549	hybrid			2022-12-25	WOS:A1995RG53800019
J	MEINNEL, T; BLANQUET, S				MEINNEL, T; BLANQUET, S			MATURATION OF PRE-TRNA(FMET) BY ESCHERICHIA-COLI RNASE-P IS SPECIFIED BY A GUANOSINE OF THE 5'-FLANKING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; PRE-TRANSFER RNAS; CLEAVAGE SITE; ACCEPTOR STEM; M1 RNA; GENE; PRECURSOR; ENZYME; FORMYLTRANSFERASE; RECOGNITION	The C+1/A(+72) base pair at the top of the acceptor stem of Escherichia coli tRNA(fMet) accounts for several of the specialized roles of this tRNA in translation initiation. According to the rules of RNA substrate recognition by RNase P, the C+1/A(+72) pair is likely to disfavor the 5'-maturation of pre-tRNA(fMet). Indeed, in contrast to other E. coli tRNA species, tRNA(fMet) was not properly matured when overproduced from a multicopy expression vector. Half of the recovered tRNA(fMet) retained an extension at the 5' side. Such a defect of tRNA(fMet) processing could be cured by changing bases C+1 and A(+72) by a Watson-Crick base pair or by non-paired bases, provided one of them was a G. It could also be compensated by either (i) overexpression of RNase P or (ii) introduction within the plasmid of one out of the three 5'-flanking sequences naturally occurring in the four E. coli tRNA(fMet) genes. The effect of these flanking sequences on the maturation of tRNA(fMet) could be accounted for by the presence of a G located 2 bases upstream from C+1. Notably, this G is the only residue that is conserved in the 5'-flanking sequences of all four E. coli tRNA(fmet) genes.			MEINNEL, T (corresponding author), ECOLE POLYTECH, BIOCHIM LAB, CNRS, URA 1970, F-91128 PALAISEAU, FRANCE.		Meinnel, Thierry/B-9813-2016	Meinnel, Thierry/0000-0001-5642-8637				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BLANQUET S, 1984, METHOD ENZYMOL, V106, P141; BURKARD U, 1988, J BIOL CHEM, V263, P2447; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1993, BIOCHEMISTRY-US, V32, P7152, DOI 10.1021/bi00079a012; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HAHN CS, 1989, METHOD ENZYMOL, V180, P121; HOLM PS, 1992, NUCLEIC ACIDS RES, V20, P421, DOI 10.1093/nar/20.3.421; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KENRI T, 1994, GENE, V138, P261, DOI 10.1016/0378-1119(94)90821-4; KIRSEBOM LA, 1993, J MOL BIOL, V231, P594, DOI 10.1006/jmbi.1993.1312; KIRSEBOM LA, 1992, NUCLEIC ACIDS RES, V20, P425, DOI 10.1093/nar/20.3.425; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; KOMINE Y, 1991, J BACTERIOL, V173, P1813, DOI 10.1128/jb.173.5.1813-1816.1991; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; KUCHINO Y, 1989, METHOD ENZYMOL, V180, P154; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEVEQUE F, 1991, J BACTERIOL, V173, P7903, DOI 10.1128/jb.173.24.7903-7910.1991; MASSON JM, 1986, GENE, V47, P179, DOI 10.1016/0378-1119(86)90061-2; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MEINNEL T, 1993, J MOL BIOL, V229, P26, DOI 10.1006/jmbi.1993.1005; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1992, NUCLEIC ACIDS RES, V20, P4741, DOI 10.1093/nar/20.18.4741; MILLER HI, 1980, CELL, V20, P711, DOI 10.1016/0092-8674(80)90317-7; MOTAMEDI H, 1984, P NATL ACAD SCI-BIOL, V81, P3959, DOI 10.1073/pnas.81.13.3959; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NAKAMURA K, 1979, CELL, V18, P1109, DOI 10.1016/0092-8674(79)90224-1; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; PACE NR, 1990, J BIOL CHEM, V265, P3587; REILLY RM, 1986, J BIOL CHEM, V263, P2344; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHULMAN LH, 1975, J BIOL CHEM, V250, P542; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SVARD SG, 1992, J MOL BIOL, V227, P1019, DOI 10.1016/0022-2836(92)90518-O; SVARD SG, 1993, NUCLEIC ACIDS RES, V21, P427, DOI 10.1093/nar/21.3.427; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15908	15914		10.1074/jbc.270.26.15908	http://dx.doi.org/10.1074/jbc.270.26.15908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797595	hybrid			2022-12-25	WOS:A1995RG53800071
J	PARK, MS				PARK, MS			EXPRESSION OF HUMAN RAD52 CONFERS RESISTANCE TO IONIZING-RADIATION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENETIC-CONTROL; RECOMBINATION; REPAIR; DNA; YEAST; PROTEIN	Processing of mutagenic DNA damages by the double strand breaks (DSB) in eukaryotes is most likely achieved by multiple pathways, including homologous recombination. Although RAD52 has been shown to be important for DSB repair in yeasts, its role in DSB repair in mammalian cells has not been demonstrated. This study reports for the first time that the overexpression of human RAD52 confers enhanced resistance to gamma-rays and induces homologous intrachromosomal recombination in cultured monkey cells. Recombination frequency synergistically increased by the combination of overexpression of RAD52 and ionizing radiation. These observations suggest that homologous recombination mediated by RAD52 is involved in double-stranded break repair in mammalian cells.			PARK, MS (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,M888,LOS ALAMOS,NM 87545, USA.		Park, Min Sung/HCH-2207-2022					ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; AJIMURA M, 1992, GENETICS, V133, P51; BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BERNSTEIN H, 1985, SCIENCE, V229, P1277, DOI 10.1126/science.3898363; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GAME J, 1983, YEAST GENETICS FUNDA, P105; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY R, 1992, AM TYPE CULTURE COLL, V7, P1; IVANOV EL, 1992, GENETICS, V132, P651; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KUNZ BA, 1981, ANNU REV GENET, V15, P57, DOI 10.1146/annurev.ge.15.120181.000421; LATT SA, 1981, ANNU REV GENET, V15, P11, DOI 10.1146/annurev.ge.15.120181.000303; LUDWIG DL, 1994, SOMAT CELL MOLEC GEN, V20, P11, DOI 10.1007/BF02257482; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; RESNICK MA, 1975, J THEOR BIOL, V59, P97; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959	34	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15467	15470		10.1074/jbc.270.26.15467	http://dx.doi.org/10.1074/jbc.270.26.15467			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797537	hybrid			2022-12-25	WOS:A1995RG53800007
J	PORTER, DJT; SHORT, SA				PORTER, DJT; SHORT, SA			NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE - PRE-STEADY-STATE KINETIC-ANALYSIS OF NATIVE ENZYME AND MUTANT ENZYME WITH AN ALANYL RESIDUE REPLACING GLU-98	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; TRANS-N-DEOXYRIBOSYLASE; ACTIVE-SITE; ESSENTIAL CARBOXYLATE; DEOXYRIBOSYLTRANSFERASE; CRYSTALLIZATION; NUCLEOPHILE; MECHANISM	Nucleoside 2-deoxyribosyltransferase catalyzes cleavage of a 2'-deoxyribosylnucleoside (A) to a nucleobase (P) with deoxyribosylation of the enzyme, Substrates quenched the intrinsic fluorescence of native enzyme (E) and a catalytically inactive mutant enzyme (E98A enzyme), The time courses of these reactions were analyzed in terms of the following scheme where EX is the 2-deoxyribosyl ester of Glu-98. [GRAPHICS] The initial complexes between E and dAdo, dGuo, dIno, and dCyd or those between EX and the corresponding nucleobases were formed in a rapid equilibrium step, Native enzyme and E98A enzyme bound 2'-deoxyribosylnucleosides with similar affinities (k(-1)/k(1)). From a comparison of the time-dependent fluorescence changes associated with the reaction of native enzyme or E98A enzyme with these substrate, the kinetic step for 2-deoxyribosylation of Glu-98 was identified (k(2) and k(-2)). dThd and dUrd quenched the fluorescence of native enzyme in a biphasic process, The late phase of this reaction was associated with 2-deoxyribosylation of Glu-98. The pre-steady-state kinetic constants calculated from fluorescence quenching data for dAdo and Cyt were consistent with the experimental values for the steady-state kinetic coefficients and the equilibrium constant of the reaction.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9306, DOI 10.1021/bi00450a010; CARDINAUD R, 1979, BIOCHIM BIOPHYS ACTA, V568, P339, DOI 10.1016/0005-2744(79)90301-2; COOK WJ, 1990, J BIOL CHEM, V265, P2682; DANZIN C, 1976, EUR J BIOCHEM, V62, P365, DOI 10.1111/j.1432-1033.1976.tb10168.x; DANZIN C, 1974, EUR J BIOCHEM, V48, P255, DOI 10.1111/j.1432-1033.1974.tb03763.x; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOLGUIN J, 1975, EUR J BIOCHEM, V54, P515, DOI 10.1111/j.1432-1033.1975.tb04164.x; HOLGUINH.J, 1972, FEBS LETT, V20, P171, DOI 10.1016/0014-5793(72)80785-3; HUANG MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P133, DOI 10.1016/0003-9861(83)90510-6; HUANG MC, 1981, BIOCHEM PHARMACOL, V30, P2663, DOI 10.1016/0006-2952(81)90535-9; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V534, P102; MACNUTT WS, 1952, BIOCHEM J, V50, P384, DOI 10.1042/bj0500384; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Mooser G., 1992, ENZYMES, P187; PORTER DJT, 1995, J BIOL CHEM, V270, P15551, DOI 10.1074/jbc.270.26.15551; QUARONI A, 1976, J BIOL CHEM, V251, P3250; Segel IH, 1975, ENZYME KINETICS, P54; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9780; UERKVITZ W, 1971, EUR J BIOCHEM, V23, P387, DOI 10.1111/j.1432-1033.1971.tb01632.x; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929	25	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15557	15562		10.1074/jbc.270.26.15557	http://dx.doi.org/10.1074/jbc.270.26.15557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797551	hybrid			2022-12-25	WOS:A1995RG53800021
J	WALLER, GS; OUYANG, G; SWAFFORD, J; VIBERT, P; LOWEY, S				WALLER, GS; OUYANG, G; SWAFFORD, J; VIBERT, P; LOWEY, S			A MINIMAL MOTOR DOMAIN FROM CHICKEN SKELETAL-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAINS; HEAVY-CHAIN; F-ACTIN; SUBFRAGMENT-1; PROTEIN; BINDING; IMAGES; MICROSCOPY; ANTIBODIES; FILAMENT	The myosin head (S1) consists of a wide, globular region that contains the actin- and nucleotide-binding sites and an alpha-helical, extended region that is stabilized by the presence of two classes of Light chains. The essential light chain abuts the globular domain, whereas the regulatory light chain lies near the head-rod junction of myosin. Removal of the essential Light chain by a mild denaturant exposes the underlying heavy chain to proteolysis by chymotrypsin. The cleaved fragment, or ''motor domain'' (MD), migrates as a single band on SDS-polyacrylamide gel electrophoresis, with a slightly greater mobility than S1 prepared by papain or chymotrypsin. Three-dimensional image analysis of actin filaments decorated with MD reveals a structure similar to S1, but shorter by an amount consistent with the absence of a Light chain-binding domain. The actin-activated MgATPase activity of MD is similar to that of S1 in V-max and K-m. But the ability of MD to move actin filaments in a motility assay is considerably reduced relative to S1. We conclude that the globular, active site region of the myosin head is a stable, independently folded domain with intrinsic motor activity, but the coupling efficiency between ATP hydrolysis and movement declines markedly as the light chain binding region is truncated.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University					NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017350, R37AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; FISHER AJ, 1995, BIOPHYS J, V68, pS19; HUANG TG, 1994, J BIOL CHEM, V269, P16493; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LOWEY S, 1993, J BIOL CHEM, V268, P20414; LOWEY S, 1994, MYOLOGY, P485; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORGAN DG, 1992, ULTRAMICROSCOPY, V46, P263, DOI 10.1016/0304-3991(92)90019-G; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; OKAMOTO Y, 1987, J BIOL CHEM, V262, P7951; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIVARAMAKRISHNA.M, 1982, J BIOL CHEM, V257, P1102; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TRYBUS KM, 1994, J CELL BIOL, P963; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1983, J BIOL CHEM, V258, P8876; WAGNER PD, 1979, EUR J BIOCHEM, V99, P385, DOI 10.1111/j.1432-1033.1979.tb13267.x; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P968; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2	35	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15348	15352		10.1074/jbc.270.25.15348	http://dx.doi.org/10.1074/jbc.270.25.15348			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797523	hybrid			2022-12-25	WOS:A1995RE66600075
J	BOBOLA, N; HIRSCH, E; ALBINI, A; ALTRUDA, F; NOONAN, D; RAVAZZOLO, R				BOBOLA, N; HIRSCH, E; ALBINI, A; ALTRUDA, F; NOONAN, D; RAVAZZOLO, R			A SINGLE CIS-ACTING ELEMENT IN A SHORT PROMOTER SEGMENT OF THE GENE ENCODING THE INTERPHOTORECEPTOR RETINOID-BINDING PROTEIN CONFERS TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; IRBP PROMOTER; MESSENGER-RNA; SEQUENCE; REGION; FAMILY; SITE	Interphotoreceptor retinoid-binding protein (IRBP) is the major protein component of the interphotoreceptor matrix, IRBP has a highly restricted tissue-specific expression in retinal photoreceptor cells and in a subgroup of pinealocytes, With the purpose of understanding how transcriptional regulation contributes to the expression of human IRBP, we have studied a short promoter fragment (from -123 to +18, relative to the transcription start site), We demonstrate, by analysis of the expression of the lacZ reporter gene fused to this short promoter fragment in transgenic mice, that it is sufficient to confer tissue-specific expression in retinal photoreceptors and in pinealocytes, DNA/protein binding assays, performed to identify binding sites for tissue-specific trans-acting factors, have shown that an element between -45 and -58 binds a factor present only in nuclear extracts of retinoblastoma derived cell lines, which express IRBP. An element further upstream, between -86 and -106, binds apparently ubiquitous factors, Site-directed mutagenesis was performed to disrupt a GATTAA motif included in the -45 to -58 binding site and a second inverted GATTAA motif present shortly upstream. In transgenic mice bearing the mutated version of the promoter fragment, the expression of the reporter gene was completely abolished, thus suggesting that this element is essential for tissue-specific expression. A GATTAA motif appears in the 5'-flanking regions of several photoreceptor-specific genes, suggesting that this could be the recognition site for a photoreceptor-specific factor.	UNIV GENOA,INST BIOL & GENET,I-16132 GENOA,ITALY; UNIV TURIN,DEPT GENET BIOL & MED CHEM,I-10126 TURIN,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY	University of Genoa; University of Turin; University of Genoa; IRCCS AOU San Martino IST			Hirsch, Emilio/F-4848-2013; Noonan, Douglas M/A-8620-2010	Hirsch, Emilio/0000-0002-9073-6024; Noonan, Douglas M/0000-0001-8058-0719; Albini, Adriana/0000-0002-9624-5103				ADLER AJ, 1985, J BIOL CHEM, V260, P4850; AHMAD I, 1994, J NEUROCHEM, V62, P396; ALBINI A, 1990, NUCLEIC ACIDS RES, V18, P5181, DOI 10.1093/nar/18.17.5181; BAAZAN NG, 1985, J BIOL CHEM, V260, P13677; BORST DE, 1989, J BIOL CHEM, V264, P1115; CHADER GJ, 1989, INVEST OPHTH VIS SCI, V30, P7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FASSINA G, 1993, INT J ONCOL, V2, P745; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRSCH E, 1993, CELL ADHES COMMUN, V1, P203, DOI 10.3109/15419069309097254; HO MTP, 1989, J BIOL CHEM, V264, P928; HOGAN B, 1986, MANIPULATING MOUSE E, P157; INOUYE LN, 1989, EXP EYE RES, V49, P171, DOI 10.1016/0014-4835(89)90087-0; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KUTTY G, 1994, EXP EYE RES, V58, P65, DOI 10.1006/exer.1994.1195; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; LIOU GI, 1989, J BIOL CHEM, V264, P8200; LIOU GI, 1987, SOMAT CELL MOLEC GEN, V13, P315, DOI 10.1007/BF01534925; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NICKERSON JM, 1993, INVEST OPHTH VIS SCI, V34, P830; PFEFFER B, 1983, J CELL PHYSIOL, V117, P333, DOI 10.1002/jcp.1041170308; Sambrook J, 1989, MOL CLONING LABORATO; VANVEEN T, 1986, FEBS LETT, V208, P133, DOI 10.1016/0014-5793(86)81547-2; YOKOYAMA T, 1992, EXP EYE RES, V55, P225, DOI 10.1016/0014-4835(92)90186-V	32	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1289	1294		10.1074/jbc.270.3.1289	http://dx.doi.org/10.1074/jbc.270.3.1289			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836393	hybrid			2022-12-25	WOS:A1995QB15600048
J	KOLLAR, R; PETRAKOVA, E; ASHWELL, G; ROBBINS, PW; CABIB, E				KOLLAR, R; PETRAKOVA, E; ASHWELL, G; ROBBINS, PW; CABIB, E			ARCHITECTURE OF THE YEAST-CELL WALL - THE LINKAGE BETWEEN CHITIN AND BETA(1-]3)-GLUCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCAN; PURIFICATION; ENZYME; OLIGOSACCHARIDES	To isolate the putative linkage region between chitin and beta(1-->3)-glucan, Saccharomyces cerevisiae cell walls were digested with beta(1-->3)-endoglucanase and the reducing ends of the enzyme-resistant glucose chain stubs were labeled by reduction with borotritide, The radioactive material was further digested with exochitinase to remove the bulk of the chitin, and the Liberated oligosaccharides were fractionated on a sizing column, A single peak (compound I) was found to consist of N-acetylglucosamine, glucose, and glucitol residues in the ratio 1:2:1, By digestion with beta-N-acetylglucosaminidase and by NMR spectroscopy, N-acetylglucosamine was identified as the nonreducing terminus, linked to laminaritriitol by a beta(1-->4) bond, Five additional oligosaccharides were recovered, two being analogs of compound I, with 1 or 3 glucose units, respectively; the remaining three were shown to be the reduced analogs of laminaribiose, laminaritriose, and laminaritetraose. The presence of N-acetylglucosamine-containing oligosaccharides arises from the activity of chitinase in cleaving 2 sugar units sequentially in those chains containing an odd number of N-acetylglucosamine residues; correspondingly, oligosaccharides containing only glucose and sorbitol derive from even-numbered chitin chains, a result implying that chitinase can hydrolyze the linkage between N-acetylglucosamine and glucose. It is concluded that the terminal reducing residue of a chitin chain is attached to the nonreducing end of a beta(1-->3)-glucan chain by a beta(1-->4) linkage. Experiments with appropriate mutants showed that synthesis of the chitin combined with glucan is catalyzed by chitin synthetase 3. The timing and possible mechanism of formation of the chitin-glucan linkage is discussed.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NIDDKD,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Robbins, Phillips/0000-0002-5121-1524	NIDDK NIH HHS [DK0016] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; BULAWA CE, 1990, P NATL ACAD SCI USA, V87, P7424, DOI 10.1073/pnas.87.19.7424; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, 1988, MICROBIOL SCI, V5, P370; FLEET GH, 1976, J GEN MICROBIOL, V94, P180, DOI 10.1099/00221287-94-1-180; HARTLAND RP, YEAST, V10, P1591; HORISBERGER M, 1977, ARCH MICROBIOL, V115, P1, DOI 10.1007/BF00427837; KANG MS, 1984, J BIOL CHEM, V259, P4966; KHAN SH, 1994, CARBOHYD RES, V262, P283, DOI 10.1016/0008-6215(94)84185-3; KITAMURA K, 1974, J GEN APPL MICROBIOL, V20, P323, DOI 10.2323/jgam.20.323; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MOL PC, 1987, FEMS MICROBIOL LETT, V41, P95; MOLANO J, 1980, J CELL BIOL, V8, P199; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROBERTS RL, 1982, ANAL BIOCHEM, V127, P402, DOI 10.1016/0003-2697(82)90194-4; ROBERTS RL, 1983, MOL CELL BIOL, V3, P92; SHAW JA, 1991, J CELL BIOL, V114, P11; SIETSMA JH, 1979, J GEN MICROBIOL, V114, P99, DOI 10.1099/00221287-114-1-99; SURARIT R, 1988, J GEN MICROBIOL, V134, P1723; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; VANRINSUM J, 1991, YEAST, V7, P717, DOI 10.1002/yea.320070707; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105; ZLOTNIK H, 1984, J BACTERIOL, V159, P1018, DOI 10.1128/JB.159.3.1018-1026.1984	25	226	231	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1170	1178		10.1074/jbc.270.3.1170	http://dx.doi.org/10.1074/jbc.270.3.1170			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836376	hybrid			2022-12-25	WOS:A1995QB15600031
J	SIMON, A; HELLMAN, U; WERNSTEDT, C; ERIKSSON, U				SIMON, A; HELLMAN, U; WERNSTEDT, C; ERIKSSON, U			THE RETINAL-PIGMENT EPITHELIAL-SPECIFIC 11-CIS RETINOL DEHYDROGENASE BELONGS TO THE FAMILY OF SHORT-CHAIN ALCOHOL DEHYDROGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MEMBRANE-RECEPTOR; BOVINE; IDENTIFICATION; SEQUENCE; CDNA; TRANSPORT; RIBOSOMES; INVITRO	We have isolated and partially characterized a 32-kDa membrane-associated protein (p32), which forms a complex with p63, an abundant membrane protein in bovine retinal pigment epithelium. The sequence of a cDNA clone for p32 revealed an open reading frame encoding 318 amino acid residues. Several hydrophobic regions could be identified, suggesting that p32 is an integral membrane protein. A search of data bases identified p32 as a member of the superfamily of short chain alcohol dehydrogenases. Transcripts for p32 were specifically expressed in retinal pigment epithelium. Overexpression of p32 in Cos cells produced a membrane-bound stereospecific 11-cis retinol dehydrogenase, active in the presence of NAD(+) as cofactor but not in the presence of NADP. We propose that p32 is the stereospecific 11-cis retinol dehydrogenase, which catalyzes the final step in the biosynthesis of 11-cis retinaldehyde, the universal chromophore of visual pigments.	LUDWIG INST CANC RES,CTR BIOMED,UPPSALA BRANCH,S-75122 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research	SIMON, A (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,BOX 240,S-17177 STOCKHOLM,SWEDEN.			Simon, Andras/0000-0002-1018-1891				ADLER AJ, 1982, BIOCHEM BIOPH RES CO, V108, P1601, DOI 10.1016/S0006-291X(82)80091-0; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BLISS AF, 1948, J BIOL CHEM, V172, P165; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIDGES CDB, 1984, RETINOIDS, V2, P125; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; DUESTER G, 1994, EXS, V71, P279; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HELLER J, 1973, J BIOL CHEM, V248, P6308; HELLER J, 1975, J BIOL CHEM, V250, P3613; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; Luu The V, 1989, Mol Endocrinol, V3, P1301; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROSENFELD J, 1992, ANAL BIOCHEM, V15, P173; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P201, DOI 10.1016/0167-4838(93)90182-Q; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZGOMBICKNIGHT M, 1994, J BIOL CHEM, V269, P6790; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8; ZIMMERMAN WF, 1976, EXP EYE RES, V21, P325	35	216	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1107	1112		10.1074/jbc.270.3.1107	http://dx.doi.org/10.1074/jbc.270.3.1107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836368	hybrid			2022-12-25	WOS:A1995QB15600023
J	ACKERMANN, EJ; CONDEFRIEBOES, K; DENNIS, EA				ACKERMANN, EJ; CONDEFRIEBOES, K; DENNIS, EA			INHIBITION OF MACROPHAGE CA2+-INDEPENDENT PHOSPHOLIPASE A(2) BY BROMOENOL LACTONE AND TRIFLUOROMETHYL KETONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; SUICIDE INHIBITION; CELL-LINE; PURIFICATION; SOLUBILIZATION; CHYMOTRYPSIN; U937	A novel Ca2+-independent phospholipase A(2) (PLA(2)) has recently been purified from the murine macrophage-like cell line P388D(1) (Ackermann, E. J., Kempner, E. S., and Dennis, E. A. (1994) J. Biol. Chem. 269, 9227-9233). This enzyme is now shown to be inhibited by palmitoyl trifluoromethyl ketone (PACOCF(3)), arachidonyl trifluoromethyl ketone (AACOCF(3)), and a bromoenol lactone (EEL). Both PACOCF(3) and AACOCF(3) were found to inhibit the macrophage PLA(2) in a concentration-dependent manner, PACOCF(3) was found to be similar to 4-fold more potent than AACOCF(3), with IC50 values of 3.8 mu M (0.0075 mol fraction) and 15 mu M (0.028 mol fraction), respectively. Reaction progress curves in the presence of either inhibitor were found to be linear, and the PACOCF(3).PLA(2) complex rapidly dissociated upon dilution. BEL was also found to inhibit the macrophage PLA(2) in a concentration-dependent manner, with half-maximal inhibition observed at 60 nM after a 5-min preincubation at 40 degrees C, Inhibition was not reversed after extensive dilution of the enzyme into assay buffer, Treatment of the PLA(2) with EEL resulted in a linear, time-dependent inactivation of activity, and the rate of this inactivation was diminished in the presence of PACOCF(3). In addition, PLA(2) treated with [H-3]BEL resulted in the covalent labeling of a major band at M(r) 80,000. Inactivation of the PLA(2) by 5,5'-dithiobis(2-nitrobenzoic acid) prior to treatment with [H-3]BEL resulted in the near complete lack of labeling consistent with covalent irreversible suicide inhibition of the enzyme. The labeling of a M(r) 80,000 band rather than a M(r) 40,000 band upon treatment with [H-3]BEL distinguishes the macrophage Ca2+-independent PLA(2) from a previously identified myocardial Ca2+-independent PLA(2) and provides strong evidence that the M(r) 80,000 protein is the catalytic subunit.	UNIV CALIF SAN DIEGO,REVELLE COLL,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140; Conde-Frieboes, Kilian/0000-0001-5303-4448	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-26171] Funding Source: Medline; NIGMS NIH HHS [GM-20501, GM-51606] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BAEK DJ, 1991, BIOCHEM BIOPH RES CO, V178, P1335, DOI 10.1016/0006-291X(91)91040-J; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BOIVIN J, 1992, TETRAHEDRON LETT, V33, P1285, DOI 10.1016/S0040-4039(00)91602-2; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1983, ENZYMES, P307; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; DURLEY RC, 1992, J LABELLED COMPD RAD, V31, P685, DOI 10.1002/jlcr.2580310907; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; IBRAHIM SA, 1967, BIOCHIM BIOPHYS ACTA, V137, P413, DOI 10.1016/0005-2760(67)90122-1; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; PLESNIAK LA, 1993, BIOCHEMISTRY-US, V32, P5009, DOI 10.1021/bi00070a006; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SILVERMANN RB, 1988, MECHANISM BASED ENZY; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	27	378	387	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					445	450		10.1074/jbc.270.1.445	http://dx.doi.org/10.1074/jbc.270.1.445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814408	hybrid, Green Submitted			2022-12-25	WOS:A1995QA28700070
J	BAJT, ML; GOODMAN, T; MCGUIRE, SL				BAJT, ML; GOODMAN, T; MCGUIRE, SL			BETA(2) (CD18) MUTATIONS ABOLISH LIGAND RECOGNITION BY I-DOMAIN INTEGRINS LFA-1 (ALPHA(L)BETA(2), CD11A/CD18) AND MAC-1 (ALPHA(M)BETA(2), CD11B/CD18)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; COMPLEMENT RECEPTOR TYPE-3; LEUKOCYTE ADHESION GLYCOPROTEIN; FUNCTION ASSOCIATED MOLECULE-1; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; COUNTER-RECEPTOR; EPITHELIAL-CELLS; ICAM-1 CD54; CLONING	The ''I'' domains of the beta(2) (CD18) leukocyte integrins are implicated in ligand binding function. Moreover, rather than recognizing linear peptide sequences, this class of integrins generally recognizes multiple discontinuous sites on immunoglobulin superfamily adhesion receptors. A conserved cluster of oxygenated residues is involved in ligand recognition by beta(1) and beta(3) integrins. In the present study, we evaluated the role of this region in the I domain-containing beta(2) integrins. Recombinant alpha(L) beta(2) (LFA-1, CD11a/CD18) and alpha(M) beta(2) (MAC-1, CD11b/CD18) were expressed on COS cells, and function was assessed by adhesion to ICAM-1 or iC3b, respectively. Alanine substitution at position Asp(134) or Ser(136) in beta(2) produced a complete loss in the capacity of both alpha(L) beta(2) and alpha(M) beta(2) to support cell adhesion. In contrast, substitution at Asp(128) or Ser(138) resulted in loss of beta(2) surface expression when co-transfected with alpha(L) (CD11a) or alpha(M) (CD11b). These data provide the first evidence for involvement of the beta(2) subunit in ligand binding to I domain integrins.			BAJT, ML (corresponding author), UPJOHN CO,UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001, USA.							ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1994, METABOLIC BASIS INHE; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1989, EMBO J, V12, P3759; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V79, P87; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MOYLE M, 1991, J BIOL CHEM, V266, P19650; NILSSON UR, 1993, SCAND J IMMUNOL, V37, P349, DOI 10.1111/j.1365-3083.1993.tb02564.x; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RANDI AM, 1994, J BIOL CHEM, V269, P12395; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHUSTER DE, 1992, P NATL ACAD SCI USA, V89, P9225, DOI 10.1073/pnas.89.19.9225; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WEGNER CD, 1990, SCIENCE, V247, P567; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9	56	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					94	98		10.1074/jbc.270.1.94	http://dx.doi.org/10.1074/jbc.270.1.94			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814426	hybrid			2022-12-25	WOS:A1995QA28700020
J	RANDRIAMAMPITA, C; TSIEN, RY				RANDRIAMAMPITA, C; TSIEN, RY			DEGRADATION OF A CALCIUM INFLUX FACTOR (CIF) CAN BE BLOCKED BY PHOSPHATASE INHIBITORS OR CHELATION OF CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLOSPORINE-A; OKADAIC ACID; CA-2+ ENTRY; STORES; DEPLETION; OSCILLATIONS; MECHANISM; MESSENGER; CELLS	In many cell types, depletion of Ca2+ stores causes activation of Ca2+ influx by a mechanism whose molecular basis remains unclear, We recently described a new messenger that is released by empty Ca2+ stores and that activates Ca2+ influx in heterologous cells (Randriamampita, C. & Tsien, R. Y. (1993) Nature 364, 809-814). This factor, provisionally named CIF (for Ca2+ influx factor), seems to be a small nonprotein factor possessing a phosphate group. Meanwhile Parekh et al, reported that okadaic acid, an inhibitor of protein phosphatases 1 and 2A, potentiates Ca2+ influx in Xenopus oocytes (Parekh, A. B., Terlau, H. and Stuhmer, W. (1993) Nature 364, 814-818). A link between these two observations is presented in this paper, We show that in astrocytoma cells, okadaic acid and cyclosporin A (an inhibitor of calcineurin) both potentiate the Ca2+ elevations due to low doses of CIF, thapsigargin, or carbachol. In lymphocytes, okadaic acid potentiates the Ca2+ elevations due to low doses of phytohemagglutinin and increases the amount of extractable CIF. CIF degradation can be observed in cell-free homogenates of lymphocytes and is prevented by the above phosphatase inhibitors, an effect that can at least partly explain their potentiation of Ca2+ influx. CIF degradation is also prevented by lowering free Ca2+ concentrations, which could be a feedback mechanism to enhance Ca2+ influx when cells are depleted of Ca2+.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	RANDRIAMAMPITA, C (corresponding author), ECOLE NORMALE SUPER,NEUROBIOL LAB,46 RUE ULM,F-75005 PARIS,FRANCE.			Randriamampita, Clotilde/0000-0001-8594-7831	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLOU LM, 1986, ENZYMES, V17, P311; BERLIN RD, 1993, CELL CALCIUM, V144, P379; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DONNADIEU E, 1994, CURR BIOL, V4, P584, DOI 10.1016/S0960-9822(00)00130-5; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	20	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					29	32		10.1074/jbc.270.1.29	http://dx.doi.org/10.1074/jbc.270.1.29			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814389	hybrid			2022-12-25	WOS:A1995QA28700008
J	SAKAKIBARA, J; WATANABE, R; KANAI, Y; ONO, T				SAKAKIBARA, J; WATANABE, R; KANAI, Y; ONO, T			MOLECULAR-CLONING AND EXPRESSION OF RAT SQUALENE EPOXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHOLESTEROL-BIOSYNTHESIS; LIVER MICROSOMES; INHIBITOR; 2,3-OXIDOSQUALENE; SEQUENCES; PROTEINS; ENZYMES; CELLS	Squalene epoxidase (SE) (EC 1.14.99.7) catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway, Rat SE cDNA was isolated by selecting yeast transformants expressing rat cDNA in the presence of terbinafine, an inhibitor specific for fungal SE. The expression of rat SE in the isolated terbinafine resistant clone was confirmed by its survival in the presence of either terbinafine or an inhibitor specific for mammalian SE, NB-598, but not in the presence of both terbinafine and NB-598. Rat SE polypeptide deduced from the nucleotide sequence contains 573 amino acids, and its molecular weight is 63,950 Da. The amino acid sequence reveals one potential transmembrane domain, a hydrophobic segment (Leu(27) to Tyr(43)) in the NH2-terminal region. This region also contains a beta 1-alpha A-beta 2 motif, which is the consensus sequence for an FAD binding domain, suggesting that SE is a flavoenzyme. This deduced rat SE sequence is 30.2% identical to the ERG 1 gene, which encodes SE from an allylamine-resistant Saccharomyces cerevisiae mutant. Expression of a full-length rat SE protein in Escherichia coli confirms this polypeptide as a functional SE. This is the first report of the molecular cloning of mammalian SE.	NIIGATA UNIV,FAC AGR,DEPT AGR CHEM,NIIGATA 95021,JAPAN	Niigata University	SAKAKIBARA, J (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,1-757 ASAHIMACHIDORI,NIIGATA 951,JAPAN.							BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHANG TY, 1979, J BIOL CHEM, V254, P1258; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1993, TRENDS BIOCH SOC, V4, P230; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; GOLLUB EG, 1974, BIOCHEM BIOPH RES CO, V56, P471, DOI 10.1016/0006-291X(74)90866-3; GONZALEZ R, 1979, ARCH BIOCHEM BIOPHYS, V196, P574, DOI 10.1016/0003-9861(79)90310-2; HIDAKA Y, 1990, J LIPID RES, V31, P2087; HORIE M, 1990, J BIOL CHEM, V265, P18075; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V175, P105; NELSON JA, 1981, J BIOL CHEM, V256, P1067; NELSON JA, 1978, J AM CHEM SOC, V100, P4900, DOI 10.1021/ja00483a050; OKAZAKI K, 1991, NUCLEIC ACIDS RES, V18, P6485; ONO T, 1985, METHOD ENZYMOL, V110, P375; ONO T, 1975, J BIOL CHEM, V250, P1571; ONO T, 1982, BIOCHIM BIOPHYS ACTA, V709, P84, DOI 10.1016/0167-4838(82)90424-1; ONO T, 1979, BIOCH ASPECTS NUTRIT, P115; POPJAK G, 1978, P R SOC LOND B BIOL, V232, P273; RICHARD DS, 1989, P NATL ACAD SCI USA, V86, P1421, DOI 10.1073/pnas.86.4.1421; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Rudney Harry, 1993, Current Opinion in Lipidology, V4, P230, DOI 10.1097/00041433-199306000-00009; RYDER NS, 1985, BIOCHEM J, V230, P765, DOI 10.1042/bj2300765; SATOH T, 1990, J LIPID RES, V31, P2095; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; Steinberg D., 1988, ATHEROSCLER REV, V18, P1; TAI HH, 1972, J BIOL CHEM, V247, P3767; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMAMOTO S, 1970, J BIOL CHEM, V245, P1670	34	71	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					17	20		10.1074/jbc.270.1.17	http://dx.doi.org/10.1074/jbc.270.1.17			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814369	hybrid			2022-12-25	WOS:A1995QA28700005
J	LUND, J; TAKAHASHI, N; POUND, JD; GOODALL, M; NAKAGAWA, H; JEFFERIS, R				LUND, J; TAKAHASHI, N; POUND, JD; GOODALL, M; NAKAGAWA, H; JEFFERIS, R			OLIGOSACCHARIDE PROTEIN INTERACTIONS IN IGG CAN MODULATE RECOGNITION BY FC-GAMMA RECEPTORS	FASEB JOURNAL			English	Article						GLYCOSYLATION; HUMAN IGG	EFFECTOR FUNCTIONS; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN-G; BINDING-SITE; CARBOHYDRATE; FRAGMENT; REGION; MOUSE; CELLS	X-ray crystal structures of IgG-Fc provide evidence of extensive noncovalent interactions between the protein and carbohydrate moieties, and glycosylation, at Asn-297 within the Fc, has been shown to be important for effector functions mediated through Fc gamma receptors expressed on leukocytes. We have applied protein engineering in an attempt to define protein/carbohydrate interactions essential to wild-type biological activity. We demonstrate that replacement of Lys-246, Asp-249, and Glu-258, which make contacts with GlcNac and Gal on the outer alpha[1-->6] arm, do not affect recognition of human chimeric IgG3 by human Fc gamma RI and Fc gamma RII. However, replacement of Asp-265, which make contacts with the primary GlcNac sugar residue and is covalently attached to Asn-297, resulted in loss of recognition of both Fc gamma RI and Fc gamma RII. Similarly, replacement of Asp-265 in mouse IgG2b resulted in loss of recognition by mouse Fc gamma RII. These results suggest that noncovalent contacts of Asp-265 with the primary GlcNac residue are important for maintenance of recognition of IgG by Fc gamma receptors whereas contacts with GlcNac and Gal on the alpha[1-->6] arm do not have a measurable effect. This conclusion was supported by experiments in which galactose-deficient and fully galactosylated forms of a human IgG4-Fc fragment were shown to be equivalent in their ability to inhibit superoxide generation by IgG4 stimulated U937 cells.	NAKANO VINEGAR CO LTD,GLYCOLAB,HANDA,AICHI 475,JAPAN		LUND, J (corresponding author), UNIV BIRMINGHAM SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; GILHESPIEMUSKET.A, 1994, J GLYCOBIOL, V4, P485; HINDLEY SA, 1993, BIOCH SOC T, V21; HORWITZ AH, 1988, P NATL ACAD SCI USA, V85, P8678, DOI 10.1073/pnas.85.22.8678; JEFFERIS R, 1990, BIOCHEM J, V268, P529, DOI 10.1042/bj2680529; JEFFERIS R, 1993, PROTEIN ENG ANTIBODY, P115; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LUND J, 1993, MOL IMMUNOL, V30, P741, DOI 10.1016/0161-5890(93)90145-2; LUND J, 1991, J IMMUNOL, V147, P2657; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; LUND J, 1992, MOL IMMUNOL, V29, P633; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PADLAN E, 1991, FC RECEPTORS ACTION; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SUTTON BJ, 1983, BIOCHEM SOC T, V11, P130, DOI 10.1042/bst0110130; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAO MH, 1989, J IMMUNOL, V143, P2595; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347	26	63	189	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					115	119		10.1096/fasebj.9.1.7821750	http://dx.doi.org/10.1096/fasebj.9.1.7821750			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821750				2022-12-25	WOS:A1995QD20200018
J	COX, JA; DURUSSEL, I; COMTE, M; NEF, S; NEF, P; LENZ, SE; GUNDELFINGER, ED				COX, JA; DURUSSEL, I; COMTE, M; NEF, S; NEF, P; LENZ, SE; GUNDELFINGER, ED			CATION-BINDING AND CONFORMATIONAL-CHANGES IN VILIP AND NCS-1, 2 NEURON-SPECIFIC CALCIUM-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; BOVINE BRAIN; S-MODULIN; CA-2+-BINDING PROTEIN; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; NERVOUS-SYSTEM; RAT-BRAIN; RECOVERIN; CALMODULIN	VILIP and NCS-1, neural-specific, 22-kDa Ca2+-binding proteins possessing four EF-hands, were expressed in Escherichia coli to study their divalent cation properties. Flow dialysis (Ca2+ binding) and equilibrium gel filtration (Mg2+ binding) revealed that both recombinant proteins possess only two active metal-binding sites, which can accommodate either Ca2+ or Mg2+. VILIP binds cations without cooperativity with intrinsic affinity constants K'(Ca) of 1.0 x 10(6) M(-1) and K'(Mg) of 4.8 x 10(3) M(-1). Mg2+ antagonizes Ca2+ binding by shifting the isotherms to higher free Ca2+ concentrations without changing their shape. The competition equation yields a K'(Mg, comp) value of 180 M(-1) for both sites. NCS-1 binds two Mg2+ without cooperativity with K'(Mg) of 8.3 x 10(4) M(-1) and two Ca2+ with very strong positive cooperativity (n(H) = 1.96). In the absence of Mg2+ the K'(Cal) and K'(Ca2) values are 8.9 x 10(4) and 1.4 x 10(8) M(-1), respectively, which represent an allosteric increase of 1600-fold. Mg2+ shifts the Ca2+-binding isotherms to higher Ca2+ concentrations, yielding a K'(Mg, comp) value of 800 M(-1) for both sites. Thus VILIP and NCS-1 show three remarkable differences in the Ca2+/Mg2+ binding parameters: 1) VILIP binds Ca2+ with much lower affinity than NCS-1; 2) VILIP binds Ca2+ in a noncooperative way, whereas NCS-1 shows maximal positive cooperativity; 3) in VILIP the Mg2+/Ca2+ antagonism is much weaker than in NCS-1. Conformational changes monitored by Trp fluorescence indicate that the metal-free forms already are highly structured. Ca2+ binding promotes a 20-30% increase of fluorescence in both proteins, but whereas the Mg2+ form of VILIP has the same fluorescence properties as the metal-free form, Mg2+-saturated NCS-1 has those of the Ca2+ form. Near UV difference spectra confirmed that in VILIP the Mg2+ form is very similar to the metal-free form; in NCS-1 it is different, especially in the Tyr region. NCS-1 possesses one unique Cys-38 in EF-hand site I. Its reactivity (k(SH)) toward 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) is the same for the Ca2+- and Mg2+-loaded protein, but k(SH) is 4-fold higher in metal-free NCS-1. VILIP possesses two additional thiols, one of which is inaccessible to DTNB in the native protein. The reactivity of the two accessible thiols is identical in the metal-free and Mg2+ forms and 5-fold higher than in the Ca2+ form. In NCS-1 the accessibility of the hydrophobic matrix to 2-p-toluidinylnaphthalene-6-sulfonate is increased by Ca2+ binding but decreased by Mg2+ binding. In VILIP this accessibility is highest for the metal-free and Mg2+ forms; Ca2+ binding leads to a 2-fold decrease in fluorescence enhancement. Thus, although these two proteins display 57% sequence identity, not only their Ca2+/Mg2+ binding properties but also their Ca2+/Mg2+-induced conformational changes are very different, suggesting that the two proteins play different roles in the cell.	INST NEUROBIOL,DEPT NEUROCHEM & MOLEC BIOL,D-39118 MAGDEBURG,GERMANY	Leibniz Institut fur Neurobiologie (LIN)	COX, JA (corresponding author), UNIV GENEVA,DEPT BIOCHEM,START UNIT,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.		Nef, Serge/AAV-6445-2020	Nef, Serge/0000-0001-5462-0676				Adair GS, 1925, J BIOL CHEM, V63, P529; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; COX JA, 1992, CHIMIA, V46, P159; COX JA, 1990, J BIOL CHEM, V265, P6633; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; Cox JA, 1990, STIMULUS RESPONSE CO, P83; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P6089, DOI 10.1021/bi00074a021; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FONTANA G, 1993, J NEUROCHEM, V60, P843, DOI 10.1111/j.1471-4159.1993.tb03228.x; HANER M, 1984, ANAL BIOCHEM, V138, P229, DOI 10.1016/0003-2697(84)90793-0; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KUDO Y, 1992, NEUROSCIENCE, V50, P619, DOI 10.1016/0306-4522(92)90451-7; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MANALAN AS, 1984, J BIOL CHEM, V259, P2047; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; MCDONALD JR, 1985, BIOCHEM J, V232, P569, DOI 10.1042/bj2320569; MELAMED N, 1993, J NEUROCHEM, V60, P632; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NEF S, 1995, IN PRESS J RECEPT RE, V15; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PAULS TL, 1993, J BIOL CHEM, V268, P20897; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIVOSECCHI R, 1994, J PHYSIOL-LONDON, V474, P223, DOI 10.1113/jphysiol.1994.sp020015; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKAMATSU K, 1992, BIOCHEM BIOPH RES CO, V183, P245, DOI 10.1016/0006-291X(92)91635-4; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; WAISMAN DM, 1983, FEBS LETT, V164, P80; YAMAGATA K, 1990, NEURON, V2, P469	46	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32807	32813						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806504				2022-12-25	WOS:A1994QA63800017
J	ZHU, L; HOPE, TJ; HALL, J; DAVIES, A; STERN, M; MULLEREBERHARD, U; STERN, R; PARSLOW, TG				ZHU, L; HOPE, TJ; HALL, J; DAVIES, A; STERN, M; MULLEREBERHARD, U; STERN, R; PARSLOW, TG			MOLECULAR-CLONING OF A MAMMALIAN HYALURONIDASE REVEALS IDENTITY WITH HEMOPEXIN, A SERUM HEME-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RABBIT HEMOPEXIN; ACID; PURIFICATION; RECEPTOR; IDENTIFICATION; SEQUENCE; CELLS; LIVER	Hyaluronan is the most abundant glycosaminoglycan of the extracellular matrix and is a critical substrate for cellular attachment and locomotion. Little is known about the class of enzymes, termed hyaluronidases, that are responsible for hyaluronan catabolism in mammals. We have determined a partial amino acid sequence from a purified preparation of porcine liver hyaluronidase and have used this information as the basis for cloning complementary DNA that encodes the corresponding protein. When expressed in a recombinant baculovirus system, the protein exhibited hyaluronidase activity in a substrate-gel assay. The deduced sequence of this mammalian hyaluronidase is that of a 459-amino-acid polypeptide bearing four potential N-glycosylation sites as well as a copy of a proposed hyaluronan binding motif. Remarkably, amino acid sequence comparisons and immunologic cross-reactivities strongly suggest that the cloned protein is identical to hemopexin, an abundant, heme-binding serum protein. Although hemopexin has not previously been reported to possess any enzymatic activity, it includes a conserved domain found in collagenases, stromelysins, and other enzymes that metabolize the extracellular matrix. We conclude that hemopexin is the predominant hyaluronidase expressed in mammalian liver.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ORAL & MAXILLOFACIAL SURG, SAN FRANCISCO, CA 94143 USA; CORNELL UNIV, SCH MED, DEPT PEDIAT, NEW YORK, NY 10021 USA; CORNELL UNIV, SCH MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University; Cornell University; Cornell University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30203] Funding Source: Medline; NIGMS NIH HHS [GM43574, GM46765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALTRUDA F, 1988, J MOL EVOL, V27, P102, DOI 10.1007/BF02138368; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONSON NN, 1967, J BIOL CHEM, V242, P437; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BERTOLAMI CN, 1982, J INVEST DERMATOL, V79, P417, DOI 10.1111/1523-1747.ep12530400; DAVIES AH, 1994, BIO-TECHNOL, V12, P47, DOI 10.1038/nbt0194-47; DESALEGU.M, 1967, ARCH BIOCHEM BIOPHYS, V120, P60, DOI 10.1016/0003-9861(67)90598-X; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GOLD EW, 1982, BIOCHEM J, V205, P69, DOI 10.1042/bj2050069; GUNTENHONER MW, 1992, MATRIX, V12, P388, DOI 10.1016/S0934-8832(11)80035-1; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; JOY MB, 1985, BIOCHIM BIOPHYS ACTA, V838, P257, DOI 10.1016/0304-4165(85)90087-X; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KULYK WM, 1987, DEV BIOL, V120, P535, DOI 10.1016/0012-1606(87)90256-9; LAMBERG SI, 1986, J INVEST DERMATOL, V86, P659, DOI 10.1111/1523-1747.ep12275707; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MORGAN WT, 1993, J BIOL CHEM, V268, P6256; MORGAN WT, 1984, J BIOL CHEM, V259, P2001; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112; MUSTER P, 1991, J PROTEIN CHEM, V10, P123, DOI 10.1007/BF01024662; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; ORKIN RW, 1980, J BIOL CHEM, V255, P1036; POLANSKY JR, 1974, SCIENCE, V183, P862, DOI 10.1126/science.183.4127.862; Possee RD., 1992, BACULOVIRUS EXPRESSI; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATOH T, 1994, P NATL ACAD SCI USA, V91, P8423, DOI 10.1073/pnas.91.18.8423; SPENCER HT, 1990, INT J BIOCHEM, V22, P367, DOI 10.1016/0020-711X(90)90139-T; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STANLEY KK, 1986, FEBS LETT, V199, P249, DOI 10.1016/0014-5793(86)80489-6; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKETANI S, 1990, J BIOL CHEM, V265, P13981; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	45	32	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32092	32097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798203				2022-12-25	WOS:A1994PX30400015
J	BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P				BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P			PURIFICATION AND CHARACTERIZATION OF A RAT-LIVER ENZYME THAT HYDROLYZES VALACICLOVIR, THE L-VALYL ESTER PRODRUG OF ACYCLOVIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; PROTEINS; MITOCHONDRIA; CELLS	Valaciclovir is an oral prodrug of the antiherpetic agent acyclovir, An enzyme that hydrolyzes valaciclovir to acyclovir, valaciclovir hydrolase (VACVase), was purified from rat liver and characterized, VACVase was a basic (pI 9.4) protein associated with mitochondria, It was monomeric and had a molecular mass of 29 kDa, Amino acid sequences of six VACVase peptides, including its NH2 terminus (13 amino acids) and accounting for approximately 20% of its complete sequence, were not found in the SwissProt protein data base, VACVase hydrolyzed other amino acid esters of acyclovir in addition to valaciclovir (k(cat)/K-m = 58 mM(-1) s(-1)), with a preference for the L-alanyl (k(cat)/K-m = 226 mM(-1) S-1) and L-methionyl (k(cat)/K-m = 200 mM(-1) S-1) esters. It did not hydrolyze other types of esters or numerous di- and tripeptides and aminoacyl-beta-naphthylamides. Hydrolysis of valaciclovir by VACVase was not inhibited by amastatin, antipain, aprotinin, bestatin, chymostatin, E-64, EDTA, ebelactone A, ebelactone B, elastatinal, leupeptin, pepstatin, or phosphoramidon. It was neither inhibited nor activated by Ca2+, Co2+, Mg2+, Mn2+, or Zn2+. Therefore, this enzyme is not a typical esterase or peptidase and, to our knowledge, it has not been described previously. Its physiological function is not known; however, it may play a significant role in the biotransformation of valaciclovir to acyclovir.	BURROUGHS WELLCOME CO, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	BURNETTE, TC (corresponding author), BURROUGHS WELLCOME CO, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							Adibi S. A., 1981, PHYSL GASTROINTESTIN, V2, P1073; Beauchamp Lilia M., 1993, Drugs of the Future, V18, P619; BEAUCHAMP LM, 1992, ANTIVIR CHEM CHEMOTH, V3, P157, DOI 10.1177/095632029200300305; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnette T. C., 1993, Antiviral Research, V20, P115; BURNETTE TC, 1994, DRUG METAB DISPOS, V22, P60; CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31; DEMIRANDA P, 1994, DRUG METAB DISPOS, V22, P55; DEMIRANDA P, 1994, 34TH INT C ANT AG CH; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Fleischer S, 1974, Methods Enzymol, V31, P6; FREITAS JO, 1981, INT J BIOCHEM, V13, P991, DOI 10.1016/0020-711X(81)90004-5; FRICK L, 1984, COMP BIOCHEM PHYS B, V77, P533, DOI 10.1016/0305-0491(84)90271-2; GROSS M, 1992, J BIOL CHEM, V267, P2080; JACOBSON MA, 1994, ANTIMICROB AGENTS CH, V38, P1534, DOI 10.1128/AAC.38.7.1534; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MEADOWS KC, 1990, PHARMACEUT RES, V7, P299, DOI 10.1023/A:1015890516119; MIRCHEFF AK, 1976, J MEMBRANE BIOL, V28, P309, DOI 10.1007/BF01869703; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; SMITH C, 1993, 33RD INT C ANT AG CH; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TERMIGNONI C, 1991, MOL CELL BIOCHEM, V102, P101; VISSER L, 1972, BIOCHIM BIOPHYS ACTA, V268, P257, DOI 10.1016/0005-2744(72)90223-9; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196; WIEDHAUP K, 1981, TOP PHARM SCI, P307	28	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15827	15831		10.1074/jbc.270.26.15827	http://dx.doi.org/10.1074/jbc.270.26.15827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797586	hybrid			2022-12-25	WOS:A1995RG53800059
J	USDIN, TB; GRUBER, C; BONNER, TI				USDIN, TB; GRUBER, C; BONNER, TI			IDENTIFICATION AND FUNCTIONAL EXPRESSION OF A RECEPTOR SELECTIVELY RECOGNIZING PARATHYROID-HORMONE, THE PTH2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEPTIDE RECEPTOR; PANCREATIC-ISLETS; CYTOSOLIC CALCIUM; KIDNEY-CELLS; PROTEIN; HYPOTHALAMUS; RESPONSES; SECRETION; CLONING; TISSUES	We have identified a G-protein-coupled receptor specifically activated by parathyroid hormone, which we refer to as the PTH2 receptor. Parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP, hypercalcemia of malignancy factor) activate a previously identified PTH/PTHrP receptor, which has a widespread tissue distribution. The PTH2 receptor is much more selective in ligand recognition and appears to have a more specific tissue distribution. It is activated by PTH and not by PTHrP and is particularly abundant in the brain and pancreas.			USDIN, TB (corresponding author), NIMH,CELL BIOL LAB,BLDG 36 RM 3A17,36 CONVENT DR MSC 4090,BETHESDA,MD 20892, USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BLIND E, 1993, EXP CLIN ENDOCRINOL, V101, P150, DOI 10.1055/s-0029-1211222; BOWDEN SJ, 1994, J ENDOCRINOL, V142, P217, DOI 10.1677/joe.0.1420217; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; FADDA GZ, 1988, KIDNEY INT, V33, P1066, DOI 10.1038/ki.1988.112; FADDA GZ, 1993, KIDNEY INT, V43, P554, DOI 10.1038/ki.1993.82; FERGUSON JE, 1992, P NATL ACAD SCI USA, V89, P8384, DOI 10.1073/pnas.89.17.8384; FRASER RA, 1990, ENDOCRINOLOGY, V127, P2517, DOI 10.1210/endo-127-5-2517; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; HARVEY S, 1993, PEPTIDES, V14, P269, DOI 10.1016/0196-9781(93)90041-E; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KONIG M, 1991, Molecular and Cellular Neuroscience, V2, P331, DOI 10.1016/1044-7431(91)90063-T; KURODA T, 1993, PANCREAS, V8, P732, DOI 10.1097/00006676-199311000-00010; Law F, 1994, Adv Nephrol Necker Hosp, V23, P281; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LIN SC, 1993, NATURE, V15, P208; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARTIN TJ, 1993, J INTERN MED, V233, P1, DOI 10.1111/j.1365-2796.1993.tb00638.x; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MATSUI H, 1995, AM J PHYSIOL-REG I, V268, pR21, DOI 10.1152/ajpregu.1995.268.1.R21; Moore DD, 1995, GLOB MOB SURV; MUFF R, 1994, MOL CELL ENDOCRINOL, V100, P35, DOI 10.1016/0303-7207(94)90275-5; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; PANG PKT, 1988, AM J PHYSIOL, V255, pR643, DOI 10.1152/ajpregu.1988.255.4.R643; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHNEIDER H, 1993, EUR J PHARM-MOLEC PH, V246, P149, DOI 10.1016/0922-4106(93)90092-N; SHURTZSWIRSKI R, 1993, HUM REPROD, V8, P107, DOI 10.1093/oxfordjournals.humrep.a137855; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WEAVER DR, 1994, MOL BRAIN RES, V28, P296; 1991, PROGRAM MANUAL WISCO	40	311	332	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15455	15458		10.1074/jbc.270.26.15455	http://dx.doi.org/10.1074/jbc.270.26.15455			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797535	hybrid			2022-12-25	WOS:A1995RG53800004
J	ZHANG, JM; VASILYEVA, E; FENG, Y; FORGAC, M				ZHANG, JM; VASILYEVA, E; FENG, Y; FORGAC, M			INHIBITION AND LABELING OF THE COATED VESICLE V-ATPASE BY 2-AZIDO-[P-32]ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; PROTON PUMP; ESCHERICHIA-COLI; CDNA SEQUENCE; SUBUNIT; (H+)-ATPASE; F1-ATPASE; CLATHRIN; BINDING	Previous studies have indicated that the 73-kDa A subunit of the coated vesicle V-ATPase possesses a nucleotide-binding site essential for activity (Arai, H., Berne, M., Terres, G., Terres, Ii., Puopolo, K., and Forgac, M. (1987) Biochemistry 26, 6632-6638) and have identified a cysteine residue (Cys(254)) whose modification leads to complete loss of activity (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 5817-5822). To further characterize the structure of the nucleotide-binding sites of the V-ATPase, labeling studies using the photoactivated analog 2-azido-[P-32]ATP have been carried out. We have observed that 2-azido-[P-32]ATP is hydrolyzed by the V-ATPase at a rate (at 1 mM) approximately 4-fold lower than observed for ATP, indicating that 2-azido-[P-32]ATP is a good substrate for the V-ATPase. Irradiation of the V-ATPase in the presence of 0.5 mM 2-azido-[P-32]ATP leads to inactivation of V-ATPase activity with a t(1/2) of 56 min, The 73-kDa A subunit, the 58-kDa B subunit, and the 50 kDa subunit of the AP-2 adaptin complex (Myers, M., and Forgac, M. (1993) J. Biol. Chem. 268, 9184-9186) are all labeled in an ATP-protectable manner on irradiation of the purified V-ATPase with 2-azido[P-32]ATP. The time course for inactivation most closely correlates with labeling of the A subunit. Measurement of the stoichiometry of 2-azido-[P-32]ATP incorporation into the A subunit as a function of inactivation indicates that complete loss of activity is obtained on incorporation of 1.2 mol of 2-azido-[P-32]ATP/mol V-ATPase complex. 2-Azido-[32P]ATP labeling indicates that the V-ATPase possesses both rapidly (t(1/2) < 2 min) and slowly (t(1/2) > 2 min) exchangeable nucleotide-binding sites. The A subunit is labeled upon modification of both rapidly and slowly exchangeable sites whereas the B subunit is labeled upon modification of only rapidly exchangeable sites. Inhibition of V-ATPase activity correlates with labeling of the rapidly exchangeable sites. Amino acid sequence analysis of peptides derived from the 2-azido-[P-32]ATP-labeled A subunit indicates labeling of two peptides: a 12-kDa fragment which begins at residue 511 and contains Cys(532) and 3-kDa fragment which begins at residue 233 and contains the glycine-rich loop and Cys(254). Only the 12-kDa fragment is labeled upon modification of the rapidly exchangeable sites. A 12-kDa V-8 peptide, which begins at residue 375 of the B subunit is also labeled by 2-azido-[P-32]ATP under conditions which modify the rapidly exchangeable sites, These results provide further information concerning the nucleotide-binding sites on the V-ATPase A and B subunits. The differences in nucleotide-binding sites between F-and V-ATPases are also discussed.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA	Tufts University					NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1987, P NATLA CAD SCI US, V84, P7515; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1992, J BIOENERG BIOMEMBR, V24, P463, DOI 10.1007/BF00762363; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; LIU Q, 1994, J BIOL CHEM, V269, P31592; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15494	15500		10.1074/jbc.270.26.15494	http://dx.doi.org/10.1074/jbc.270.26.15494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797542	hybrid			2022-12-25	WOS:A1995RG53800012
J	SPECTOR, NL; HARDY, L; RYAN, C; MILLER, WH; HUMES, JL; NADLER, LM; LUEDKE, E				SPECTOR, NL; HARDY, L; RYAN, C; MILLER, WH; HUMES, JL; NADLER, LM; LUEDKE, E			28-KDA MAMMALIAN HEAT-SHOCK PROTEIN, A NOVEL SUBSTRATE OF A GROWTH-REGULATORY PROTEASE INVOLVED IN DIFFERENTIATION OF HUMAN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; COLONY-STIMULATING FACTOR; STRESS PROTEINS; TYROSINE PHOSPHORYLATION; T(15-17) TRANSLOCATION; ACTIN POLYMERIZATION; RAR-ALPHA; KINASE; ARREST	Because of their differentiating effects in neoplastic cells in vitro, the use of retinoids in the treatment of various malignant and premalignant conditions is under investigation, To date, signal transduction pathways involved in retinoid-induced differentiation remain poorly understood. Differentiation of HL-60 cells by all trans-retinoic acid (tRA) is directly mediated by down-regulation of the serine protease myeloblastin (mbn). In this report, we investigate the possibility that the 28-kDa heat shock protein (hsp28), previously linked to differentiation of normal and neoplastic cells including HL-60, may be regulated by mbn, Using NB4 promyelocytic leukemic cells as a differentiative model, we show that tRA induces initial suppression and subsequent up regulation of hsp28 protein, mirroring tRA-induced changes in mbn protein. The progressive reduction in hsp28 mRNA levels in response to tRA suggests that changes in hsp28 protein levels might be posttranscriptionally mediated, raising the possibility that hsp28 may be targeted by mbn. To address this, we developed an assay using purified mbn and recombinant hsp28 and now show that hsp28 is hydrolyzed by mbn but not its homologue, human neutrophil elastase, Moreover, mbn does not indiscriminately hydrolyze other proteins, Identifying hsp28 as a substrate of mbn strongly suggests that hsp28 may be a key component of the tRA signaling pathway involved in regulating cell differentiation.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; JEWISH GEN HOSP, LADY DAVIS INST MED RES, MONTREAL, PQ 4365, CANADA; MERCK & CO INC, BIOCHEM & MOLEC PATHOL, RAHWAY, NJ 07065 USA; AMGEN CORP, THOUSAND OAKS, CA 91320 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Lady Davis Institute; McGill University; Merck & Company; Amgen	SPECTOR, NL (corresponding author), UNIV MIAMI, SCH MED,SYLVESTER COMPREHENS CANC CTR, DIV HEMATOL ONCOL,1475 NW 12TH AVE, D8-4, MIAMI, FL 33136 USA.				NCI NIH HHS [CA-40216-06, IF32CA08954-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216, F32CA008954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KINDASMUGGE I, 1994, CELL GROWTH DIFFER, V5, P777; LABBAYE C, 1993, BLOOD, V81, P475; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MING Z, 1993, J BIOL CHEM, V268, P35; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OKUDA K, 1992, BLOOD, V79, P2880; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RAINES MA, 1992, BLOOD, V79, P3350; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SHIBANUMA M, 1992, BIOCHEM BIOPH RES CO, V187, P1418, DOI 10.1016/0006-291X(92)90460-3; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989; ZHAO S, 1993, BLOOD, V82, pA1962	50	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1003	1006		10.1074/jbc.270.3.1003	http://dx.doi.org/10.1074/jbc.270.3.1003			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836350	hybrid			2022-12-25	WOS:A1995QB15600005
J	CAIRO, G; TACCHINI, L; POGLIAGHI, G; ANZON, E; TOMASI, A; BERNELLIZAZZERA, A				CAIRO, G; TACCHINI, L; POGLIAGHI, G; ANZON, E; TOMASI, A; BERNELLIZAZZERA, A			INDUCTION OF FERRITIN SYNTHESIS BY OXIDATIVE STRESS - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION BY EXPANSION OF THE FREE IRON POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT BINDING-PROTEIN; HEME OXYGENASE; RAT-LIVER; TRANSFERRIN RECEPTOR; GENE-EXPRESSION; MESSENGER-RNAS; HEAVY-SUBUNIT; SKIN FIBROBLASTS; LIGHT-SUBUNIT; METABOLISM	Ferritin, by regulating the ''free'' intracellular iron pool, controls iron-catalyzed generation of reactive oxygen species, but its role in oxidative damage is still unclear. We show that ferritin synthesis is significantly stimulated in the liver of rats subjected to oxidative stress by treatment with phorone, a glutathione-depleting drug, RNA-bandshift assays document reduced activity of iron regulatory factor, in particular of IRF(B), the cytoplasmic protein that post-transcriptionally controls ferritin mRNA translation, Furthermore, Northern blot analysis shows increased accumulation of H and L subunit mRNAs, and nuclear run-on experiments provide evidence of transcriptional activation, Direct measurements of intracellular free iron levels by EPR indicate that the increased ferritin synthesis can be mediated by an expansion of the free iron pool, An early drop of ferritin content after phorone treatment indicates that part of the iron that fuels the free pool might derive from ferritin degradation, Present data seem to suggest that, under conditions of oxidative stress, liver ferritin can represent either a pro- or an anti-oxidant in a time-dependent manner, In fact, its early degradation contributes to expand the intracellular free iron pool that, later on, activates multiple molecular mechanisms to reconstitute ferritin content, thus Limiting the prooxidant challenge of iron.	UNIV MODENA,DIPARTIMENTO SCI BIOMED,I-41100 MODENA,ITALY	Universita di Modena e Reggio Emilia	CAIRO, G (corresponding author), UNIV MILAN,IST PATOL GEN,CTR STUDIO PATOL CELLULARE,CNR,VIA MANGIAGALLI 31,I-20133 MILAN,ITALY.		Cairo, Gaetano/M-5104-2016; Tomasi, Aldo/F-8513-2017; Tacchini, Lorenza/L-1418-2016	Cairo, Gaetano/0000-0002-8147-4720; Tomasi, Aldo/0000-0002-1356-3430; Tacchini, Lorenza/0000-0002-4863-178X				ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; AROSIO P, 1989, IRON IMMUNITY CANCER, P55; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BERGELSON S, 1994, CANCER RES, V54, P36; BERNELLIZAZZERA A, 1966, BIOCHEM J, V100, P114, DOI 10.1042/bj1000114; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CAIRO G, 1991, BIOCHEM J, V275, P813, DOI 10.1042/bj2750813; CAIRO G, 1993, EXP CELL RES, V206, P255, DOI 10.1006/excr.1993.1145; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; Colburn N.H., 1992, BIOL CONSEQUENCES OX, P121; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; GUO B, 1993, FASEB J, V7, pA1084; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; IANNONE A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P290, DOI 10.1016/0304-4165(90)90053-Y; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; MINOTTI G, 1989, CHEM-BIOL INTERACT, V71, P1, DOI 10.1016/0009-2797(89)90087-2; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MUNRO H, 1993, NUTR REV, V51, P65, DOI 10.1111/j.1753-4887.1993.tb03072.x; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; ORRENIUS S, 1988, OXY RADICALS MOL BIO, P327; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; SCHIAFFONATI L, 1990, J CELL PHYSIOL, V143, P79, DOI 10.1002/jcp.1041430110; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; TACCHINI L, 1992, BIOCHIM BIOPHYS ACTA, V1131, P133, DOI 10.1016/0167-4781(92)90067-A; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; WHITE K, 1988, J BIOL CHEM, V263, P8938; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V145, P502, DOI 10.1016/0006-291X(87)91349-0	47	290	300	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					700	703		10.1074/jbc.270.2.700	http://dx.doi.org/10.1074/jbc.270.2.700			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822298	hybrid			2022-12-25	WOS:A1995QB81600032
J	DUA, R; WU, SK; CHO, WH				DUA, R; WU, SK; CHO, WH			A STRUCTURE-FUNCTION STUDY OF BOVINE PANCREATIC PHOSPHOLIPASE A(2) USING POLYMERIZED MIXED LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; ACTIVE-SITE; INTERFACIAL ACTIVATION; VENOM PHOSPHOLIPASE-A2; CRYSTAL-STRUCTURE; MECHANISM; SPECIFICITY; LYSINE-56; PROTEINS; MUTAGENESIS	A new combinatorial approach that includes the genetic variation of protein structure and the chemical modification of phospholipid structure in polymerized mixed liposomes was used to delineate the structure-function relationships in the interfacial catalysis of bovine pancreatic phospholipase A(2) (PLA(2)). Based on previous structural and mutational studies, several bovine PLA(2) mutants were generated in which a positive charge of putatively important lysyl side chains was reversed (K10E, K53E, K56E, and K116E) or neutralized (K56Q and K116Q). Kinetic parameters of bovine wild type and mutant PLA(2)s determined using polymerized mixed liposomes consisting of 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoethanolamine (or -phosphoglycerol) and 1,2-bis[12-(lipoyloxy)dodecanoyl]-sn-glycero-3-phosphoglycerol showed that Lys-53 is involved specifically in the interaction with a substrate bound in the active site. Also, these results showed that Lys-10 and Lys-116 are involved in the interaction of bovine PLA(2) with anionic interfaces but not in the interaction with the active site-bound substrate, In particular, Lys-116 makes more significant contribution than Lys-10 by similar to 1.0 kcal/mol to the binding to anionic interfaces. Most importantly, Lys-56 was shown to participate in the interaction with both the active site-bound substrate and anionic interfaces. These findings establish Lys-56 and Lys-116 as essential residues for the binding of bovine pancreatic PLA(2) to anionic interfaces. Lastly, our structure-function analysis based on the use of polymerized mixed liposomes was further supported by equilibrium binding measurements of these proteins using 1,2-bis[12-(lipoyloxy)dodecanoyl]-sn-glycero-3-phosphoglycerol polymerized liposomes and by kinetic analyses using monomeric substrates, 1,2-dihexanoyl-sn-glycero-3-phosphoethanolamine and -phosphoglycerol.	UNIV ILLINOIS, DEPT CHEM MC111, CHICAGO, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; CHO WH, 1991, METHOD ENZYMOL, V197, P75; CHO WW, 1988, J BIOL CHEM, V263, P11237; CHO WW, 1988, J AM CHEM SOC, V110, P5166, DOI 10.1021/ja00223a043; DENG TL, 1990, GENE, V93, P229, DOI 10.1016/0378-1119(90)90229-K; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1978, J MOL BIOL, V124, P53, DOI 10.1016/0022-2836(78)90146-8; DIJKSTRA BW, 1981, NATURE, V289, P604, DOI 10.1038/289604a0; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P10576, DOI 10.1021/bi00158a021; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P6402, DOI 10.1021/bi00143a007; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KATES M, 1986, TECHNIQUES LIPIDOLOG, P115; KUIPERS OP, 1989, SCIENCE, V244, P82, DOI 10.1126/science.2704992; KUIPERS OP, 1990, PROTEIN ENG, V3, P599, DOI 10.1093/protein/3.7.599; KUIPERS OP, 1989, PROTEIN ENG, V2, P467, DOI 10.1093/protein/2.6.467; LUGTIGHEID RB, 1993, EUR J BIOCHEM, V213, P517, DOI 10.1111/j.1432-1033.1993.tb17789.x; LUGTIGHEID RB, 1993, EUR J BIOCHEM, V216, P519, DOI 10.1111/j.1432-1033.1993.tb18170.x; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; NOEL JP, 1990, J AM CHEM SOC, V112, P3704, DOI 10.1021/ja00165a090; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHEN Z, 1994, BIOCHEMISTRY-US, V33, P11598, DOI 10.1021/bi00204a022; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; TOMASSELLI AG, 1989, J BIOL CHEM, V264, P10041; VANDENBERGH CJ, 1988, EUR J BIOCHEM, V176, P353; VANDERWIELE FC, 1988, BIOCHEMISTRY-US, V27, P1688, DOI 10.1021/bi00405a046; VANDERWIELE FC, 1988, BIOCHEMISTRY-US, V27, P1683, DOI 10.1021/bi00405a045; WELLS MA, 1974, BIOCHEMISTRY-US, V13, P2248, DOI 10.1021/bi00708a002; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WU SK, 1994, ANAL BIOCHEM, V221, P152, DOI 10.1006/abio.1994.1391; WU SK, 1993, BIOCHEMISTRY-US, V32, P13902, DOI 10.1021/bi00213a020; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	41	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					263	268		10.1074/jbc.270.1.263	http://dx.doi.org/10.1074/jbc.270.1.263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814384	hybrid			2022-12-25	WOS:A1995QA28700042
J	MORINO, N; MIMURA, T; HAMASAKI, K; TOBE, K; UEKI, K; KIKUCHI, K; TAKEHARA, K; KADOWAKI, T; YAZAKI, Y; NOJIMA, Y				MORINO, N; MIMURA, T; HAMASAKI, K; TOBE, K; UEKI, K; KIKUCHI, K; TAKEHARA, K; KADOWAKI, T; YAZAKI, Y; NOJIMA, Y			MATRIX/INTEGRIN INTERACTION ACTIVATES THE MITOGEN-ACTIVATED PROTEIN-KINASE, P44(ERK-1) AND P42(ERK-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; CELL-ADHESION; GENE-EXPRESSION; MAP KINASES; T-CELLS; FIBRONECTIN; THREONINE; INSULIN	Cell adhesion to extracellular matrix proteins is a dynamic process leading to dramatic changes in the cell phenotype. Integrins are one of the major receptor families that mediate cell-matrix contact. Evidence that integrins can act as signal transducing molecules has accumulated over the past few years. We report here that p44(erk-1) and p42(erk-2) mitogen-activated protein (MAP) kinases are rapidly phosphorylated on tyrosine residues upon adhesion of human skin fibroblasts to fibronectin or upon cross-linking of beta 1 integrins with antibody. The tyrosine phosphorylation of both kinases is associated with increased enzymatic activity. Pretreatment of the cells with cytochalasin D, which selectively disrupts the network of the actin filaments, completely inhibits this adhesion-mediated MAP kinase activation. Thus, our findings indicate that ligation of beta 1 integrins induces an increase in both tyrosine phosphorylation and enzymatic activity of p44(erk-1) and p42(erk-2) MAP kinases, and that the integrity of the actin cytoskeleton is essential in this process. Since MAP kinase behaves as a convergence point for diverse receptor-initiated signaling events at the plasma membrane, this serine/threonine kinase plays a key role and helps to account for the diversity of integrin-dependent cell functions.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT DERMATOL,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo								AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1987, ANN REV CELL BIOL, V4, P487; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DHAWAN J, 1990, J BIOL CHEM, V265, P9015; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOBE K, 1991, J BIOL CHEM, V266, P24793; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	32	263	265	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					269	273		10.1074/jbc.270.1.269	http://dx.doi.org/10.1074/jbc.270.1.269			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814385	hybrid			2022-12-25	WOS:A1995QA28700043
J	OGIERDENIS, E; COUVINEAU, A; MAORET, JJ; HOURI, JJ; BAUVY, C; DESTEFANIS, D; ISIDORO, C; LABURTHE, M; CODOGNO, P				OGIERDENIS, E; COUVINEAU, A; MAORET, JJ; HOURI, JJ; BAUVY, C; DESTEFANIS, D; ISIDORO, C; LABURTHE, M; CODOGNO, P			A HETEROTRIMERIC G(I3)-PROTEIN CONTROLS AUTOPHAGIC SEQUESTRATION IN THE HUMAN COLON-CANCER CELL-LINE HT-29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							G-PROTEINS; ENTEROCYTIC DIFFERENTIATION; HEPATOCYTIC AUTOPHAGY; ENDOPLASMIC-RETICULUM; ADENYLYL CYCLASE; EPITHELIAL-CELLS; GOLGI MEMBRANES; TRANSPORT; DEGRADATION; INHIBITION	Human colon cancer HT-29 cells exhibit a differentiation dependent autophagic lysosomal pathway that is responsible for the degradation of a pool of newly synthesized N-linked glycoproteins in undifferentiated cells. In the present study, we have investigated the molecular control of this degradative pathway in undifferentiated HT-29 cells. For this purpose, we have modulated the function and expression of the heterotrimeric G-proteins (G(8) and G(i)) in these cells. After pertussis toxin treatment which ADP-ribosylates heterotrimeric G(i)-proteins, we observed an inhibition of autophagic sequestration and the complete restoration of the passage of N-linked glycoproteins through the Golgi complex. In contrast, autophagic sequestration was not reduced by cholera toxin, which acts on heterotrimeric G(s)-proteins. Further insights on the nature of the pertussis toxin-sensitive alpha subunit controlling autophagic sequestration were obtained by cDNA transfections of alpha(i) subunits. Overexpression of the alpha(i3), subunit increased autophagic sequestration and degradation in undifferentiated cells, whereas overexpression of the alpha(i2) subunit, the only other pertussis toxin-sensitive alpha subunit expressed in HT-29 cells, did not alter the rate of autophagy.	FAC XAVIER BICHAT,INSERM,U410,F-75018 PARIS,FRANCE; UNIV TURIN,DIPARTIMENTO MED & ONCOL SPERIMENTALE,GEN PATHOL SEZ,I-10125 TURIN,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Turin			couvineau, alain/T-3466-2019; couvineau, alain/G-3641-2013; Ogier-Denis, Eric/E-5030-2016; LABURTHE, Marc/C-1875-2012; Codogno, Patrice/G-1384-2013; Isidoro, Ciro/J-6063-2016	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; Codogno, Patrice/0000-0002-5492-3180; Isidoro, Ciro/0000-0002-5494-3034; Ogier-Denis, Eric/0000-0002-0057-7593				AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COUVINEAU A, 1992, AM J PHYSIOL, V262, pC1478, DOI 10.1152/ajpcell.1992.262.6.C1478; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORDON PB, 1993, J BIOL CHEM, V268, P26107; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; HIRSIMAKI P, 1983, PATHOBIOLOGY CELL ME, V3, P201; HOFMANN KP, 1993, GTPASES BIOL, V2, P267; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; JARRY A, 1994, EUR J PHARM-MOLEC PH, V267, P95, DOI 10.1016/0922-4106(94)90229-1; KADOWAKI M, 1994, J BIOL CHEM, V269, P3703; LENCER WI, 1990, AM J PHYSIOL, V258, pG96, DOI 10.1152/ajpgi.1990.258.1.G96; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TRUGNAN G, 1991, J BIOL CHEM, V266, P20849; VANDENBERGHE N, 1991, BIOCHEM J, V278, P565, DOI 10.1042/bj2780565; WICE BM, 1985, J BIOL CHEM, V260, P139; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233	40	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					13	16		10.1074/jbc.270.1.13	http://dx.doi.org/10.1074/jbc.270.1.13			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814364	hybrid			2022-12-25	WOS:A1995QA28700004
J	FEHLBAUM, P; BULET, P; MICHAUT, L; LAGUEUX, M; BROEKAERT, WF; HETRU, C; HOFFMANN, JA				FEHLBAUM, P; BULET, P; MICHAUT, L; LAGUEUX, M; BROEKAERT, WF; HETRU, C; HOFFMANN, JA			INSECT IMMUNITY - SEPTIC INJURY OF DROSOPHILA INDUCES THE SYNTHESIS OF A POTENT ANTIFUNGAL PEPTIDE WITH SEQUENCE HOMOLOGY TO PLANT ANTIFUNGAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITIN-BINDING PROTEINS; ANTIMICROBIAL PEPTIDES; L SEEDS; FAMILY; MODEL	In response to a septic injury (pricking with a bacteria-soaked needle) larvae and adults of Drosophila produce considerable amounts of a 44-residue peptide containing 8 cysteines engaged in intramolecular disulfide bridges, The peptide is synthesized in the fat body, a functional homologue of the mammalian liver, and secreted into the blood of the insect. It exhibits potent antifungal activity but is inactive against bacteria, This novel inducible peptide, which we propose to name drosomycin, shows a significant homology with a family of 5-kDa cysteine-rich plant antifungal peptides recently isolated from seeds of Brassicaceae, This finding underlines that plants and insects can rely on similar molecules in their innate host defense.	INST BIOL MOLEC & CELLULAIRE,CNRS,UPR 9022,F-67084 STRASBOURG,FRANCE; CATHOLIC UNIV LEUVEN,FA JANSSENS LAB GENET,B-3001 HEVERLEE,BELGIUM	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; KU Leuven			BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; BULET P, 1993, J BIOL CHEM, V268, P14893; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IJIMA R, 1993, J BIOL CHEM, V268, P12055; KREIL G, 1990, TRENDS BIOCHEM SCI, V15, P23, DOI 10.1016/0968-0004(90)90126-V; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; TAUTZ D, 1989, CHROMOSOMA, V98, P80; TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WICKER C, 1990, J BIOL CHEM, V265, P22493	19	331	360	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33159	33163						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806546				2022-12-25	WOS:A1994QA63800065
J	CHEN, H; SOTTILE, J; OROURKE, KM; DIXIT, VM; MOSHER, DF				CHEN, H; SOTTILE, J; OROURKE, KM; DIXIT, VM; MOSHER, DF			PROPERTIES OF RECOMBINANT MOUSE THROMBOSPONDIN-2 EXPRESSED IN SPODOPTERA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HEPARIN-BINDING PEPTIDES; INDUCED SECRETED PROTEIN; ARG-GLY-ASP; ADHESION RECEPTOR; I REPEATS; ALPHA(V)BETA(5) INTEGRIN; EXTRACELLULAR-MATRIX; CARCINOMA-CELLS; VITRONECTIN	A baculovirus system was used to express full-length recombinant mouse thrombospondin 2 (rTSP2) as a disulfide-bonded homotrimer with an NH2 terminus beginning with Asp(20). rTSP2, like TSP1, was more sensitive to trypsin digestion if depleted of calcium ion. The trypsin digestion pattern of rTSP2 and TSP1 differed in that trypsin cut between the first and second type 1 modules of rTSP2. For bovine aortic endothelial cells adhering to TSP-coated polystyrene plates, reduction after coating caused both TSPs to be much more adhesive; these adhesions were blocked completely by RGDS peptide or antibody to alpha(v) beta(s) integrin. rTSP2 and TSP1 also mediated the adhesion of HT-29 human colon adenocarcinoma cells that carry alpha(v) beta(5) but not alpha(v) beta(3) integrin. Antibody to alpha(v) beta(5) did not inhibit adhesion of HT-29 cells to TSP1 or rTSP2. Rather, adhesion of HT-29 cells was decreased by treatment of TSPs with EDTA, abolished by reduction of the TSPs, and, in the case of rTSP2, blocked by heparin. Adhesion of MG63 cells to both TSPs was complex. Treatment with EDTA enhanced the adhesive activity of rTSP2 but decreased the adhesive activity of TSP1. These results show that TSP2 can be processed and secreted when overexpressed using baculovirus, TSP1 and rTSP2 differ in protease susceptibility in the type 1 module region, and TSP1 and rTSP2 mediate cell adhesion by complex and similar but not identical mechanisms.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA58182] Funding Source: Medline; NHLBI NIH HHS [HL29586, HL49111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049111, P01HL029586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1993, J CELL SCI, V104, P1061; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER JW, 1981, THROMB RES, V22, P267, DOI 10.1016/0049-3848(81)90119-5; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LERCH RA, 1993, NUCLEIC ACIDS RES, V21, P1753, DOI 10.1093/nar/21.8.1753; MARGOSSIAN SS, 1981, J BIOL CHEM, V256, P7495; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSHER DF, 1990, ANNU REV MED, V41, P85; MOSHER DF, 1993, ADV MOL CELL BIOL, V6, P115; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P98; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PELLERIN S, 1993, J BIOL CHEM, V268, P4304; PELLERIN S, 1993, J BIOL CHEM, V268, P18810; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1988, CANCER RES, V48, P6785; SCHREINER C, 1991, CLIN EXP METASTAS, V9, P163, DOI 10.1007/BF01756387; SHINGU T, 1993, GENOMICS, V16, P78, DOI 10.1006/geno.1993.1143; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SONCIN F, 1994, J BIOL CHEM, V269, P8999; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	59	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32226	32232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798222				2022-12-25	WOS:A1994PX30400035
J	FAWCETT, TW; SYLVESTER, SL; SARGE, KD; MORIMOTO, RI; HOLBROOK, NJ				FAWCETT, TW; SYLVESTER, SL; SARGE, KD; MORIMOTO, RI; HOLBROOK, NJ			EFFECTS OF NEUROHORMONAL STRESS AND AGING ON THE ACTIVATION OF MAMMALIAN HEAT-SHOCK FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-DEPENDENT RESPONSE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; PROTEIN INDUCTION; BINDING-ACTIVITY; GENE-EXPRESSION; ADRENAL-CORTEX; FACTOR-II; CELLS; FIBROBLASTS	The mammalian heat shock response has been investigated extensively using tissue culture cells with only a limited amount of information available on animals and intact tissues. The neurohormonal stress response mediated by the hypothalamic-pituitary-adrenal axis leads to the activation of heat shock factor (HSF) in rat adrenal tissue. Here we show through the use of antibodies specific to each member of the HSF family that restraint-induced stress in intact Wistar rats and adrenocorticotropic hormone treatment of hypophysectomized animals leads to the activation of HSF1 monomers to trimers with DNA-binding activity Because HSF1 is also the target factor for metabolic and environmental stress, these data reveal an intersection of pathways leading to HSF1 activation. Comparison of the biochemical properties and levels of HSF1 in the Wistar and Fischer 344 rat strains reveals that HSF1 is constitutively present in an activated DNA-binding state in the adrenals of Fischer 344 rats. During aging, the levels of HSF1 remain constant, yet the transcription factor from aged animals exhibits a decreased ability to bind DNA.	NIA, GENE EXPRESS & AGING SECT, BALTIMORE, MD USA; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Kentucky; Northwestern University								ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANG D, 1991, J BIOL CHEM, V266, P24233; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Baxter JD, 1987, ENDOCRINOL METAB, P511; BLAKE MJ, 1991, P NATL ACAD SCI USA, V88, P9873, DOI 10.1073/pnas.88.21.9873; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIUFFRE KA, 1988, ENDOCRINOLOGY, V122, P306, DOI 10.1210/endo-122-1-306; GOWER DJ, 1989, J NEUROSURG, V70, P605, DOI 10.3171/jns.1989.70.4.0605; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUCE MC, 1992, EXP CELL RES, V202, P9, DOI 10.1016/0014-4827(92)90398-R; MASORO EJ, 1990, HDB BIOL AGING, P72; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PARE WP, 1986, NEUROSCI BIOBEHAV R, V10, P339, DOI 10.1016/0149-7634(86)90017-5; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; UDELSMAN R, 1991, SURGERY, V110, P1125; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WELCH WJ, 1993, PHILOS T ROY SOC B, V339, P327, DOI 10.1098/rstb.1993.0031	35	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32272	32278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798227				2022-12-25	WOS:A1994PX30400041
J	NARANDA, T; MACMILLAN, SE; HERSHEY, JWB				NARANDA, T; MACMILLAN, SE; HERSHEY, JWB			PURIFIED YEAST TRANSLATIONAL INITIATION-FACTOR EIF-3 IS AN RNA-BINDING PROTEIN COMPLEX THAT CONTAINS THE PRT1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; WHEAT-GERM; HELA-CELLS; PURIFICATION; MECHANISM; SYSTEM	Eukaryotic initiation factor-3 (eIF-3) plays a pivotal role in the initiation phase of protein synthesis where it promotes dissociation of 80 S ribosomes into subunits, stabilizes methionyl-tRNA(i) binding to 40 S ribosomal subunits, and is required for mRNA binding. Mammalian eIF-3 is comprised of eight subunits, but no mammalian cDNA encoding these proteins has been cloned and sequenced, nor has the corresponding factor been characterized in yeast. Since many initiation factors are strongly conserved between mammalian and yeast systems, we employed a mammalian assay for initiation, the synthesis of methionyl-puromycin, to detect eIF-3 activity in yeast subcellular fractions. Yeast eIF-3 was purified from the high salt wash of ribosomes by Superose 6 molecular sieve and MonoS ion exchange chromatography. Yeast eIF-3 contains eight subunits with masses of 16, 21, 29, 33, 39, 62, 90, and 135 kilodaltons all of which coelute with an apparent mass of 550 kilodaltons from the Superose 6 column. Immunoblotting shows that the 90-kDa subunit corresponds to the product of the PRT1 gene whose mutant form, prt1-1, exhibits destabilization of methionyl-tRNA(i) binding to 40 S ribosomal subunits. eIF-3, and specifically the 62-kDa subunit, bind to RNA. These biochemical approaches to defining yeast eIF-3 complement genetic methods so far used in characterizing the initiation factors and provide another route to defining the yeast translational machinery.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Benne R, 1979, Methods Enzymol, V60, P15; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; GASIOR E, 1983, METHOD ENZYMOL, V101, P644; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1968, P NATL ACAD SCI USA, V62, P468; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; MOLDAVE K, 1988, GENETICS TRANSLATION, P271; NARANDA T, 1994, J BIOL CHEM, V269, P14465; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; PRAT A, 1990, BIOCHIM BIOPHYS ACTA, V1050, P140, DOI 10.1016/0167-4781(90)90155-U; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SEAL SN, 1983, J BIOL CHEM, V258, P866; SUNDKVIST IC, 1975, J MOL BIOL, V99, P401, DOI 10.1016/S0022-2836(75)80135-5; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	27	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32286	32292						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798228				2022-12-25	WOS:A1994PX30400043
J	SHINGU, T; BORNSTEIN, P				SHINGU, T; BORNSTEIN, P			OVERLAPPING EGR-1 AND SP1 SITES FUNCTION IN THE REGULATION OF TRANSCRIPTION OF THE MOUSE THROMBOSPONDIN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; SERUM RESPONSE ELEMENT; GROWTH-FACTOR; C-FOS; REPRESSES TRANSCRIPTION; BINDING-SITE; 1ST INTRON; CHAIN GENE; EXPRESSION	We have evaluated the basis for the constitutive and serum-regulated expression of the mouse thrombospondin (TSP) gene in both transiently and stably transfected NIH-3T3 cells. Experiments with deleted and mutated mouse promoter/CAT constructs and gel mobility assays demonstrated that an Egr-1 binding site in the proximal promoter, flanked by overlapping GC boxes and an adjacent CC-rich region, functioned to positively regulate the constitutive activity of the gene. These motifs, and their cognate transcription factors, appear to act in concert, with partial redundancy, so that discrete mutations were only partially effective in reducing transcriptional activity. The Egr-1 site corresponds in position to an NF-Y binding site which functions synergistically with a distal serum-response element to mediate the serum response of the human TSP1 gene. However, neither the Egr-1 motif nor the surrounding proximal promoter region upstream from the TATA box participates in the serum response of mouse TSP1. These experiments add support to the growing realization that similar physiologic responses of homologous genes in mouse and man need not utilize similarly placed cis-acting elements.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLEZARDIN P, 1993, THROMBOSPONDIN, P41; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JABOKOWITZ R, 1993, J CELL PHYSL, V157, P24; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KITADAI Y, 1993, CELL GROWTH DIFFER, V4, P291; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LAWLER J, 1986, BLOOD, V67, P1197; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LI XY, 1992, J BIOL CHEM, V267, P8984; Liska Deann J., 1992, Gene Expression, V2, P379; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG ZY, 1992, J BIOL CHEM, V267, P21999	45	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32551	32557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798257				2022-12-25	WOS:A1994PX30400079
J	PORTER, DJT; MERRILL, BM; SHORT, SA				PORTER, DJT; MERRILL, BM; SHORT, SA			IDENTIFICATION OF THE ACTIVE-SITE NUCLEOPHILE IN NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE AS GLUTAMIC-ACID-98	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; ESSENTIAL CARBOXYLATE; ESCHERICHIA-COLI; RNA-POLYMERASE; MECHANISM; DEOXYRIBOSYLTRANSFERASE; ALPHA-2-MACROGLOBULIN; GALACTOSIDASE; FRAGMENTATION; GLYCOSIDASE	2'-FIuoro-2'-deoxyarabinonucleosides are time-dependent inhibitors of nucleoside 2-deoxyribosyltransferase. 2,6-Diamino-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-9H-purine (dFDAP) inhibited the enzyme by formation of a primary complex (K-d = 140 mu M) that isomerized to a secondary complex with a first-order rate constant of 0.2 min(-1). Inhibited enzyme contained stoichiometric amounts of covalently bound 2'-fluoro-2'-deoxyarabinosyl moiety, recovered less than 5% of its activity after storage for a week at 5 degrees C, but regained over 70% of the lost activity by treatment with 600 mu m Ade. 6-Amino-9-(2'-deoxy-2'-fluoro-beta-D-arabinosyl)-9H-purine (dFAdo) was a product of the reactivation reaction. Proteolysis of inhibited enzyme identified a modified fragment that spanned residues 82-107 which could not be sequenced past Gly-96. dFDAP inhibited enzyme and enzyme reacted with normal substrates (i.e. dThd and dAdo) were hydrolyzed between Met-97 and Glu-98 by 0.1 M NaOH, These findings and model studies on the base lability of peptides containing glutamyl esters suggested that the gamma-carboxylate of Glu-98 was esterfied during catalysis. The role of Glu-98 was confirmed by changing this residue to alanine. The spe cific activity of wild-type enzyme was 3 orders of magnitude greater than that of the mutant enzyme. Collectively, chemical modification and mutagenesis studies have identified Glu-98 as the active site nucleophile of nucleoside 2-deoxyribosyltransferase.	WELLCOME RES LABS,DIV BIOANALYT SCI,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BATTERSBY A, 1961, J CHEM SOC, P524, DOI 10.1039/jr9610000524; BATTERSBY AR, 1955, J CHEM SOC, P259, DOI 10.1039/jr9550000259; BATTERSBY AR, 1956, J CHEM SOC, P2076, DOI 10.1039/jr9560002076; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDINAUD R, 1979, BIOCHIM BIOPHYS ACTA, V568, P339, DOI 10.1016/0005-2744(79)90301-2; COOK WJ, 1990, J BIOL CHEM, V265, P2682; DANZIN C, 1976, EUR J BIOCHEM, V62, P365, DOI 10.1111/j.1432-1033.1976.tb10168.x; DANZIN C, 1974, EUR J BIOCHEM, V48, P255, DOI 10.1111/j.1432-1033.1974.tb03763.x; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GORSKI JP, 1980, J BIOL CHEM, V255, P25; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOLGUIN J, 1975, EUR J BIOCHEM, V54, P515, DOI 10.1111/j.1432-1033.1975.tb04164.x; HOLGUINH.J, 1972, FEBS LETT, V20, P171, DOI 10.1016/0014-5793(72)80785-3; HOWARD JB, 1986, J BIOL CHEM, V261, P60; HOWARD JB, 1980, J BIOL CHEM, V255, P7082; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HOWARD JB, 1980, J BIOL CHEM, V265, P3820; HUANG MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P133, DOI 10.1016/0003-9861(83)90510-6; HUANG MC, 1981, BIOCHEM PHARMACOL, V30, P2663, DOI 10.1016/0006-2952(81)90535-9; Jencks W. P., 1973, ENZYMES, V9, P483; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V534, P102; MIAO SC, BIOCHEMISTRY-US, V33, P7027; Miller J. H., 1972, EXPT MOL GENETICS, P433; PORTER DJT, 1995, J BIOL CHEM, V270, P15557, DOI 10.1074/jbc.270.26.15557; QUARONI A, 1976, J BIOL CHEM, V251, P3250; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSH AH, 1958, J BIOL CHEM, V233, P261; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9978; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TULL D, 1991, J BIOL CHEM, V266, P15621; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2622	40	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15551	15556		10.1074/jbc.270.26.15551	http://dx.doi.org/10.1074/jbc.270.26.15551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797550	hybrid			2022-12-25	WOS:A1995RG53800020
J	VALVERDE, V; DELMAS, P; KAGHAD, M; LOISON, G; JARA, P				VALVERDE, V; DELMAS, P; KAGHAD, M; LOISON, G; JARA, P			SECRETION AND MATURATION STUDY OF ENDOTHIAPEPSIN IN SACCHAROMYCES-CEREVISIAE - A FIRST STEP TOWARD IMPROVING ITS SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ENCODING ENDOTHIAPEPSIN; SITE-DIRECTED MUTAGENESIS; CRYPHONECTRIA-PARASITICA; ASPARTIC PROTEINASE; YEAST; CHYMOSIN; TRANSFORMATION; PROPEPTIDE; MUTATION; PROTEASE	The gene encoding endothiapepsin (EAP), an extracellular aspartic proteinase from the filamentous ascomycete Cryphonectria parasitica, was expressed into Saccharomyces cerevisiae, Efficient secretion of an active and correctly processed enzyme was achieved when expressing the entire cDNA encoding prepro-EAP under the control of the galactose inducible GRAP1 yeast promoter, Since three independent, site-directed mutations of EAP, including the substitution of an aspartyl catalytic residue, resulted in the intracellular accumulation of zymogen forms, we assumed that the EAP propeptide was autocatalytically processed. As a prerequisite to further improve the specificity of EAP, we therefore attempted to bypass this self-processing step in three different ways: 1) introduction of a Kex2-like recognition site between the pro and the mature part, 2) deletion of the prosequence (pre-EAP), and 3) co-expression in trans of the pre-EAP with its preprosequence. No improvement in the secretion of mutant enzymes was obtained in any of these experiments. As an alternative, we finally replaced the EAP processing site by the chymosin cleavage sequence of kappa-casein, Such a modification remained efficient in directing the secretion of active EAP only when a putative alpha-helix structural motif was conserved at the C terminus of the pro region.	SANOFI RECH, CTR LABEGE, LABEGE INNOPOLE, F-31676 LABEGE, FRANCE	Sanofi-Aventis								AIKAWA J, 1991, ADV EXP MED BIOL, V306, P233; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CHOI GH, 1993, GENE, V125, P135, DOI 10.1016/0378-1119(93)90320-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIRAMATSU R, 1989, J BIOL CHEM, V264, P16862; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMSA M, 1990, J IND MICROBIOL, V5, P229, DOI 10.1007/BF01569680; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; ORPRAYOON P, 1991, BIOCHEM SOC T, V19, pS265, DOI 10.1042/bst019265s; PITTS JE, 1992, SCAND J CLIN LAB INV, V52, P39, DOI 10.3109/00365519209104653; RAMOS C, 1994, J BIOL CHEM, V269, P7006; RAZANAMPARANY V, 1992, CURR GENET, V21, P455, DOI 10.1007/BF00351655; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINTANI T, 1994, BBA-PROTEIN STRUCT M, V1204, P257, DOI 10.1016/0167-4838(94)90016-7; SUZUKI J, 1990, PROTEIN ENG, V4, P69, DOI 10.1093/protein/4.1.69; SZECSI PB, 1992, SCAND J CLIN LAB INV, V52, P5, DOI 10.3109/00365519209104650; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	28	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15821	15826		10.1074/jbc.270.26.15821	http://dx.doi.org/10.1074/jbc.270.26.15821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797585	hybrid			2022-12-25	WOS:A1995RG53800058
J	KAN, JLC; MORAN, RG				KAN, JLC; MORAN, RG			ANALYSIS OF A MOUSE GENE ENCODING 3 STEPS OF PURINE SYNTHESIS REVEALS USE OF AN INTRONIC POLYADENYLATION SIGNAL WITHOUT ALTERNATIVE EXON USAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE; PHENOL-CHLOROFORM EXTRACTION; MESSENGER-RNA; SEQUENCE REQUIREMENTS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; POLY(A) SITE; TRANSCRIPTION; TRANSFORMYLASE; DROSOPHILA	A single mouse genomic locus encodes proteins catalyzing three steps of purine synthesis, glycinamide ribonucleotide synthetase (GARS), aminoimidazole ribonucleotide synthetase (AIRS), and glycinamide ribo nucleotide formyltransferase (GART). This gene has 22 exons and spans 28 kilobases. The existence of a second genetic locus and closely related pseudogenes was ruled out by Southern analysis, Mouse tissues express two related classes of messages encoded by this single locus: a trifunctional GARS-AIRS-GART mRNA and a monofunctional GARS mRNA. These transcripts used the same set of multiple transcriptional start sites, and both used the same first 10 exons, CCAAT and TATA elements were not found for this locus. Exon 11, which represented the last coding sequence of the GARS domain, was differentially utilized for the two messages, The trifunctional mRNA was generated by splicing exon 11 to exon 12, the first coding sequence for the AIRS domain with subsequent use of a polyadenylation signal at the end of exon 22. Genomic sequence corresponding to the 3'-UTR of the monofunctional GARS mRNA was contiguous with exon 11, so that the smaller message arose from the recognition of one of the multiple polyadenylation signals present within the intron between exons 11 and 12. Hence, polyadenylation of the primary transcript at a position corresponding to an intron of the genomic locus was responsible for the generation of the monofunctional GARS class of mRNAs. This utilization of an intronic polyadenylation site without alternative exon usage is comparable to the mechanism whereby both secreted and membrane bound forms of the immunoglobulin mu heavy chain are made from a single genetic locus.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA 27605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIMI J, 1990, NUCLEIC ACIDS RES, V18, P6665, DOI 10.1093/nar/18.22.6665; ALT FW, 1980, CELL, V20, P381; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HENIKOFF S, 1986, P NATL ACAD SCI USA, V83, P720, DOI 10.1073/pnas.83.3.720; HENIKOFF S, 1983, CELL, V34, P405, DOI 10.1016/0092-8674(83)90374-4; HENIKOFF S, 1987, GENETICS, V117, P711; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P12; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH JM, 1987, J BIOL CHEM, V262, P10565; SMITH JM, 1986, J BIOL CHEM, V261, P632; TSURUSHITA N, 1988, SCIENCE, V239, P494, DOI 10.1126/science.3124268; TSURUSHITA N, 1987, MOL CELL BIOL, V7, P4603; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449	34	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1823	1832		10.1074/jbc.270.4.1823	http://dx.doi.org/10.1074/jbc.270.4.1823			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829519				2022-12-25	WOS:A1995QD20400053
J	KEPPLER, OT; STEHLING, P; HERRMANN, M; KAYSER, H; GRUNOW, D; REUTTER, W; PAWLITA, M				KEPPLER, OT; STEHLING, P; HERRMANN, M; KAYSER, H; GRUNOW, D; REUTTER, W; PAWLITA, M			BIOSYNTHETIC MODULATION OF SIALIC ACID-DEPENDENT VIRUS-RECEPTOR INTERACTIONS OF 2 PRIMATE POLYOMA VIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; LINKED OLIGOSACCHARIDES; BINDING; LECTIN; GLYCOPROTEINS; ANALOGS; HEMAGGLUTININ; GANGLIOSIDES; ERYTHROCYTES; DETERMINANT	Sialic acids are essential components of the cell surface receptors of many microorganisms including viruses, A synthetic, N-substituted D-mannosamine derivative has been shown to act as precursor for structurally altered sialic acid incorporated into glycoconjugates in vivo (Kayser, H., Zeitler, R., Kannicht, C., Grunow, D., Nuck, R., and Reutter, W. (1992) J. Biol. Chem. 267, 16934-16938). In this study we have analyzed the potential of three different sialic acid precursor analogues to modulate sialic acid-dependent virus receptor function on different cells, We show that treatment with these D-mannosamine derivatives can result in the structural modification of about 50% of total cellular sialic acid content, Treatment interfered drastically and specifically with sialic acid-dependent infection of two distinct primate polyoma viruses, Both inhibition (over 95%) and enhancement (up to 7-fold) of virus binding and infection were observed depending on the N-acyl substitution at the C-5 position of sialic acid, These effects were attributed to the synthesis of metabolically modified, sialylated virus receptors, carrying elongated N-acyl groups, with altered binding affinities for virus particles, Thus, the principle of biosynthetic modification of sialic acid by application of appropriate sialic acid precursors to tissue culture or in vivo offers new means to specifically influence sialic acid-dependent ligand-receptor interactions and could be a potent tool to further clarify the biological functions of sialic acid, in particular its N-acyl side chain.	DEUTSCH KREBSFORSCHUNGSZENTRUM,ANGEW TUMORVIROL,D-69120 HEIDELBERG,GERMANY; FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin			Pawlita, Labor/C-9720-2011	Pawlita, Michael/0000-0002-4720-8306				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BROSSMER R, 1993, FEBS LETT, V323, P96, DOI 10.1016/0014-5793(93)81456-A; CLAYSON ET, 1989, J VIROL, V63, P1095, DOI 10.1128/JVI.63.3.1095-1100.1989; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; FRIED H, 1981, VIROLOGY, V10, P188; GARDNER SD, 1971, RECENT ADV CLIN VIRO, P93; GEILEN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P108, DOI 10.1016/0003-9861(92)90551-7; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; Gottschalk A, 1959, VIRUSES, V3, P51; GRUNHOLZ HJ, 1981, CARBOHYD RES, V96, P259, DOI 10.1016/S0008-6215(00)81876-5; HADLEY TJ, 1986, ANNU REV MICROBIOL, V40, P451, DOI 10.1146/annurev.mi.40.100186.002315; HAUN G, 1993, J VIROL, V67, P7482, DOI 10.1128/JVI.67.12.7482-7492.1993; HEERZE LD, 1990, BIOCHEM BIOPH RES CO, V172, P1224, DOI 10.1016/0006-291X(90)91579-H; Howe C, 1972, Adv Virus Res, V17, P1, DOI 10.1016/S0065-3527(08)60746-0; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KAYSER H, 1993, EXPERIENTIA, V49, P885, DOI 10.1007/BF01952603; KELM S, 1992, EUR J BIOCHEM, V205, P147, DOI 10.1111/j.1432-1033.1992.tb16762.x; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; KO HL, 1987, INFECTION, V15, P237, DOI 10.1007/BF01644121; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MENEZES J, 1975, BIOMEDICINE, V22, P276; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; REUTER G, 1994, METHOD ENZYMOL, V230, P168; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SEIF I, 1981, DNA TUMOR VIRUSES MO, P911; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SINIBALDI L, 1990, ARCH VIROL, V113, P291, DOI 10.1007/BF01316682; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TAVAKKOL A, 1990, BIOCHEMISTRY-US, V29, P10684, DOI 10.1021/bi00499a016; TENEBERG S, 1990, FEBS LETT, V263, P10, DOI 10.1016/0014-5793(90)80693-D; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WANG WC, 1988, J BIOL CHEM, V263, P4576; ZURHAUSEN H, 1979, MED MICROBIOL IMMUN, V167, P137, DOI 10.1007/BF02121180	42	148	156	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1308	1314		10.1074/jbc.270.3.1308	http://dx.doi.org/10.1074/jbc.270.3.1308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836396	hybrid			2022-12-25	WOS:A1995QB15600051
J	PEREZPAYA, E; HOUGHTEN, RA; BLONDELLE, SE				PEREZPAYA, E; HOUGHTEN, RA; BLONDELLE, SE			THE ROLE OF AMPHIPATHICITY IN THE FOLDING, SELF-ASSOCIATION AND BIOLOGICAL-ACTIVITY OF MULTIPLE SUBUNIT SMALL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; SECONDARY STRUCTURE; ANTIMICROBIAL ACTIVITIES; AQUEOUS MELITTIN; AMINO-ACIDS; PEPTIDE; STABILITY; HELIX; MODEL; AGGREGATION	The effect that altering amphipathicity has on the folding process and self association of melittin, a small model protein, has been investigated using single amino acid substitutions of lysine 7, a residue distant from the contact residues involved in the hydrophobic core of tetrameric melittin. While substitutions of such a residue were not expected to interfere with the packing process, the largest alterations in the potential overall amphipathicity of melittin were found to prevent the folding into an alpha-helical conformation to occur and, in turn, to prevent the self association. Amphiphathic alpha-helices were found to be a key determining feature in the early folding process of the self association of peptides and protein segments. Those substitutions, which prevented the inducible amphipathic folding ability, were also found to result in a loss in hemolytic and antimicrobial activity. These results, combined with studies of the binding to artificial liposomes and to polysialic acids, indicate that the losses in activity were due to an initial inability to be induced into an amphipathic alpha-helix and to self associate. Ultimately, melittins's self association is proposed to be required to penetrate the carbohydrate barrier in biological membranes.	TORREY PINES INST MOLEC STUDIES, SAN DIEGO, CA 92121 USA	Torrey Pines Institute for Molecular Studies, California					NIGMS NIH HHS [GM 45583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATENBURG AM, 1988, BIOSCIENCE REP, V8, P299, DOI 10.1007/BF01115220; BELLO J, 1982, BIOCHEMISTRY-US, V21, P461, DOI 10.1021/bi00532a007; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BLONDELLE S E, 1991, Peptide Research, V4, P12; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; GOTO Y, 1992, BIOCHEMISTRY-US, V31, P732, DOI 10.1021/bi00118a014; GREENFIELD NJ, 1993, PROTEIN SCI, V2, P1263, DOI 10.1002/pro.5560020809; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOHN E, 1992, BIOPHYS J, V63, P1536, DOI 10.1016/S0006-3495(92)81737-X; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KNOPPEL E, 1979, BIOCHEMISTRY-US, V18, P4177; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEHRMAN SR, 1990, BIOCHEMISTRY-US, V29, P5590, DOI 10.1021/bi00475a025; LIN GSB, 1983, BIOCHIM BIOPHYS ACTA, V732, P683, DOI 10.1016/0005-2736(83)90247-X; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OOMEN RP, 1992, BIOCHEMISTRY-US, V31, P5698, DOI 10.1021/bi00140a003; PEREZPAYA E, 1994, BIOCHEM J, V299, P587, DOI 10.1042/bj2990587; QUAY SC, 1983, BIOCHEMISTRY-US, V22, P695, DOI 10.1021/bi00272a026; QUAY SC, 1985, BIOCHIM BIOPHYS ACTA, V831, P22, DOI 10.1016/0167-4838(85)90144-X; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; STEWART JM, 1993, AMPHIPATHIC HELIX, P21; TAKEDA K, 1991, J AM CHEM SOC, V113, P1040, DOI 10.1021/ja00003a046; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6010; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; TOSTESON MT, 1990, BIOPHYS J, V58, P1367, DOI 10.1016/S0006-3495(90)82483-8; WILCOX W, 1992, PROTEIN SCI, V1, P641, DOI 10.1002/pro.5560010510; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; ZHOU NE, 1992, J BIOL CHEM, V267, P2664	48	88	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1048	1056		10.1074/jbc.270.3.1048	http://dx.doi.org/10.1074/jbc.270.3.1048			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836358	hybrid			2022-12-25	WOS:A1995QB15600013
J	SPRINGMAN, EB; DIKOV, MM; SERAFIN, WE				SPRINGMAN, EB; DIKOV, MM; SERAFIN, WE			MAST-CELL PROCARBOXYPEPTIDASE-A - MOLECULAR MODELING AND BIOCHEMICAL-CHARACTERIZATION OF ITS PROCESSING WITHIN SECRETORY GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-A; 3-DIMENSIONAL STRUCTURE; ACTIVATION SEGMENT; SERINE PROTEASES; INTERNAL-PH; MOUSE; IDENTIFICATION; CLONING; PROTEIN; RAT	Previously, we characterized murine mast cell procarboxypeptidase A (MC-proCPA) as an inactive zymogen, To investigate the mechanisms for this lack of enzymatic activity and the processing of the zymogen to the active form, we now have performed molecular modeling of the tertiary structure of murine MC-proCPA based on the x-ray crystallographic structures of porcine pancreatic procarboxypeptidases A and B. Our model predicts that MC-proCPA retains a high degree of structural similarity to its pancreatic homologues, The globular propeptide physically blocks access to the fully formed active site of the catalytic domain and contains a salt bridge to the substrate-binding region that precludes docking of even small substrates, Based on consideration of the predicted tertiary structure and charge field characteristics of the model, the activation site (between Glu(A94) and Ile(1)) appears to be highly exposed even after MC-proCPA binds to secretory granule proteoglycans, Based on the steady-state levels of MC-proCPA versus IMC-CPA, cycloheximide inhibition of protein synthesis, and brefeldin A blockage of protein sorting, we show that MC-proCPA is processed rapidly in murine mast cell line KiSV-MC14 with a half-life of 26 +/- 5 min (mean +/- S.D., n = 3), and the processing occurs within the secretory granules, The enzyme responsible for this processing may be a thiol protease since treatment of the KiSV-MC14 with 200 mu M E-64d, a selective thiol-protease inhibitor, increases MC-proCPA by 2.7 +/- 0.2-fold (mean +/- S.D., n = 3) within 6 h of application.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,DIV CLIN PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,DIV ALLERGY,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, T32GM007569, P50GM015431] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31273] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM-07569] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; COLL M, 1991, EMBO J, V10, P1; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; GREER J, 1980, J MOL BIOL, V153, P1027; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HANADA K, 1983, PROTEINASE INHIBITOR, P25; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LAGUNOFF D, 1983, EXP CELL RES, V144, P353, DOI 10.1016/0014-4827(83)90414-7; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P2266; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHWARTZ LB, 1982, J IMMUNOL, V128, P1128; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1993, J ALLERGY CLIN IMMUN, V91, P255; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; SPRINGMAN EB, 1994, BIOL MAST CELL PROTE, P169; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; URATA H, 1990, J BIOL CHEM, V265, P22348; UREN JR, 1974, BIOCHEMISTRY-US, V13, P3512, DOI 10.1021/bi00714a016; VARUGHESE KI, 1992, BIOCHEMISTRY-US, V31, P5172, DOI 10.1021/bi00137a012; VENDRELL J, 1992, BIOL CHEM H-S, V373, P387, DOI 10.1515/bchm3.1992.373.2.387; VENDRELL J, 1986, BIOCHEM BIOPH RES CO, V141, P517, DOI 10.1016/S0006-291X(86)80203-0; VENDRELL J, 1990, J BIOL CHEM, V265, P6949; VENSEL WH, 1971, BIOCHIM BIOPHYS ACTA, V250, P395, DOI 10.1016/0005-2744(71)90196-3; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEBER IT, 1990, PROTEINS, V7, P172, DOI 10.1002/prot.340070206; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; YAMAMOTO D, 1990, BIOCHEM BIOPH RES CO, V171, P711, DOI 10.1016/0006-291X(90)91204-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	53	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1300	1307		10.1074/jbc.270.3.1300	http://dx.doi.org/10.1074/jbc.270.3.1300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836395	hybrid			2022-12-25	WOS:A1995QB15600050
J	ZUCKER, SD; GOESSLING, W; GOLLAN, JL				ZUCKER, SD; GOESSLING, W; GOLLAN, JL			KINETICS OF BILIRUBIN TRANSFER BETWEEN SERUM-ALBUMIN AND MEMBRANE-VESICLES - INSIGHT INTO THE MECHANISM OF ORGANIC ANION DELIVERY TO THE HEPATOCYTE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; SURFACE-MEDIATED DISSOCIATION; HEPATIC TRANSPORT; FATTY-ACIDS; ROSE-BENGAL; PHOSPHATIDYLCHOLINE VESICLES; UNCONJUGATED BILIRUBIN; PHOSPHOLIPID-BILAYERS; UNILAMELLAR VESICLES; CELL-SURFACE	Unconjugated bilirubin is transported in the plasma bound primarily to serum albumin, from which it is taken up and metabolized by the liver. To better characterize the mechanism of bilirubin delivery to the hepatocyte, stopped-flow techniques were utilized to study the kinetics of bilirubin transfer between serum albumin and both model phospholipid and native hepatocyte plasma membrane vesicles. The transfer process was best described by a single exponential function, with rate constants of 0.93 +/- 0.04, 0.61 +/- 0.03, and 0.10 +/- 0.01 s(-1) (+/- S.D.) at 25 degrees C for human, rat, and bovine serum albumins, respectively. The observed variations in rate with respect to donor and acceptor concentrations provide strong evidence for the diffusional transfer of free bilirubin. Thermodynamic analysis suggests that the binding site on bovine serum albumin demonstrates higher specificity for the bilirubin molecule than that on human or rat serum albumin, which exhibit similar binding characteristics. Kinetic analysis of bilirubin transfer from rat serum albumin to isolated rat basolateral liver plasma membranes indicates that the delivery of albumin-bound bilirubin to the hepatocyte surface occurs via aqueous diffusion, rather than a collisional process, thereby mitigating against the presence of an ''albumin receptor.''	HARVARD UNIV, CTR DIGEST DIS, BOSTON, MA 02115 USA	Harvard University	ZUCKER, SD (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV GASTROENTEROL, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Zucker, Stephen/AAJ-3359-2020	Zucker, MD, Stephen/0000-0003-1451-905X; Goessling, Wolfram/0000-0001-9972-1569	NIDDK NIH HHS [DK-02047, DK-36887, DK-43955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036887, K11DK002047, R01DK043955] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1989, METHOD ENZYMOL, V174, P58; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEAVEN GH, 1973, EUR J BIOCHEM, V33, P500, DOI 10.1111/j.1432-1033.1973.tb02709.x; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BLAUER G, 1970, J BIOL CHEM, V245, P372; BLITZER BL, 1985, AM J PHYSIOL, V249, pG34, DOI 10.1152/ajpgi.1985.249.1.G34; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BRANCA M, 1983, BIOCHIM BIOPHYS ACTA, V742, P341, DOI 10.1016/0167-4838(83)90320-5; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; Chen R. F., 1973, FLUORESCENCE TECHNIQ; CHEN RF, 1974, ARCH BIOCHEM BIOPHYS, V160, P106, DOI 10.1016/S0003-9861(74)80014-7; COOKE JR, 1969, CLIN CHIM ACTA, V26, P425, DOI 10.1016/0009-8981(69)90070-9; CU A, 1975, J AM CHEM SOC, V97, P2579, DOI 10.1021/ja00842a066; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; DEPIERRE JW, 1988, LIVER BIOL PATHOBIOL, P165; FAERCH T, 1975, ARCH BIOCHEM BIOPHYS, V168, P351, DOI 10.1016/0003-9861(75)90263-5; FLEISCHER AB, 1986, J CLIN INVEST, V77, P964, DOI 10.1172/JCI112397; FORKER EL, 1985, HEPATOLOGY, V5, P1236, DOI 10.1002/hep.1840050630; FORKER EL, 1985, AM J PHYSIOL, V248, pG702, DOI 10.1152/ajpgi.1985.248.6.G702; FORKER EL, 1982, J PHARMACOL EXP THER, V223, P342; FORKER EL, 1985, AM J PHYSIOL, V248, pG709, DOI 10.1152/ajpgi.1985.248.6.G709; FORKER EL, 1981, J CLIN INVEST, V67, P1517, DOI 10.1172/JCI110182; FORKER EL, 1983, J CLIN INVEST, V72, P1764, DOI 10.1172/JCI111136; FRICKER G, 1989, J CLIN INVEST, V84, P876, DOI 10.1172/JCI114248; GLUSHKO V, 1982, BIOCHIM BIOPHYS ACTA, V719, P65, DOI 10.1016/0304-4165(82)90308-7; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; GOLLAN J, 1981, J CLIN INVEST, V67, P1003, DOI 10.1172/JCI110111; GRAY RD, 1978, J BIOL CHEM, V253, P4370; HAHM JS, 1992, J LIPID RES, V33, P1123; HAMILTON JA, 1989, P NATL ACAD SCI USA, V86, P2663, DOI 10.1073/pnas.86.8.2663; HRKAL Z, 1984, INT J BIOCHEM, V16, P799, DOI 10.1016/0020-711X(84)90192-7; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; INOUE M, 1985, J BIOCHEM-TOKYO, V97, P737, DOI 10.1093/oxfordjournals.jbchem.a135113; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; LEE JJ, 1981, PHOTOCHEM PHOTOBIOL, V33, P757, DOI 10.1111/j.1751-1097.1981.tb05486.x; LEVINE RL, 1977, CLIN CHEM, V23, P2292; LIGHTNER DA, 1977, PHOTOCHEM PHOTOBIOL, V26, P427, DOI 10.1111/j.1751-1097.1977.tb07510.x; LIGHTNER DA, 1982, BILIRUBIN CHEM, V1, P2; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; MORGAN DJ, 1985, HEPATOLOGY, V5, P1231, DOI 10.1002/hep.1840050629; MOSELEY RH, 1986, AM J PHYSIOL, V250, pG35, DOI 10.1152/ajpgi.1986.250.1.G35; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; NOY N, 1992, BIOPHYS CHEM, V42, P177, DOI 10.1016/0301-4622(92)85007-Q; NUNES R, 1988, J HEPATOL, V7, P293, DOI 10.1016/S0168-8278(88)80001-1; ONISHI S, 1985, BIOCHEM J, V230, P561, DOI 10.1042/bj2300561; OSTROW JD, 1963, J CLIN INVEST, V42, P1286, DOI 10.1172/JCI104813; PEDERSEN AO, 1977, EUR J BIOCHEM, V72, P213, DOI 10.1111/j.1432-1033.1977.tb11242.x; REED RG, 1977, J BIOL CHEM, V252, P7483; REED RG, 1989, J BIOL CHEM, V264, P9867; ROSEI MA, 1983, EXPERIENTIA, V39, P165, DOI 10.1007/BF01958878; RUBALTELLI FF, 1979, PHOTOCHEM PHOTOBIOL, V29, P991, DOI 10.1111/j.1751-1097.1979.tb07803.x; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; STREMMEL W, 1983, BIOCHIM BIOPHYS ACTA, V756, P20, DOI 10.1016/0304-4165(83)90019-3; TIRIBELLI C, 1993, HEPATOLOGY, V17, P715, DOI 10.1002/hep.1840170428; VANDERSLUIJS P, 1987, HEPATOLOGY, V7, P688; WATSON D, 1962, CLIN SCI, V22, P435; WEISIGER R, 1980, GASTROENTEROLOGY, V79, P1065; WEISIGER R, 1981, SCIENCE, V211, P1048, DOI 10.1126/science.6258226; WEISIGER RA, 1987, J CLIN INVEST, V79, P1070, DOI 10.1172/JCI112920; WEISIGER RA, 1984, HEPATOLOGY, V4, P492, DOI 10.1002/hep.1840040323; WEISIGER RA, 1989, AM J PHYSIOL, V257, pG904, DOI 10.1152/ajpgi.1989.257.6.G904; WEISIGER RA, 1985, P NATL ACAD SCI USA, V82, P1563, DOI 10.1073/pnas.82.5.1563; WEISIGER RA, 1991, AM J PHYSIOL, V261, pG872, DOI 10.1152/ajpgi.1991.261.5.G872; Weisiger Richard A., 1993, P171; WOLKOFF AW, 1987, HEPATOLOGY, V7, P777, DOI 10.1002/hep.1840070427; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; WRIGHT TL, 1987, HEPATOLOGY, V7, P294, DOI 10.1002/hep.1840070214; ZUCKER SD, 1994, J BIOL CHEM, V269, P19262; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020	75	61	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1074	1081		10.1074/jbc.270.3.1074	http://dx.doi.org/10.1074/jbc.270.3.1074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836362	hybrid			2022-12-25	WOS:A1995QB15600017
J	HAN, XY; GALLOWAY, DR				HAN, XY; GALLOWAY, DR			ACTIVE-SITE MUTATIONS OF PSEUDOMONAS-AERUGINOSA EXOTOXIN-A - ANALYSIS OF THE HIS(440) RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; DIPHTHERIA-TOXIN; GLUTAMIC ACID-553; ASPARTIC-ACID; NAD; MUTAGENESIS; MECHANISM; HOMOLOGY; TOXICITY; PROTEIN	Pseudomonas aeruginosa exotoxin A (ETA) is a member of the family of bacterial ADP-ribosylating toxins which use NAD(+) as the ADP-ribose donor, By analogy to diphtheria and pertussis toxins, the His(440) residue of ETA has been proposed to be one of the critical residues within the active site of the toxin. In this study the role of the His(440) residue was explored through site-directed mutagenesis which resulted in the production of ETA proteins containing Ala, Asn, and Phe substitutions at the 440 position, The His(440) substituted ETA proteins were purified and analyzed. All substitutions at the 440 site displayed severely reduced ADP-ribosylation activity (>1000-fold). However, NAD glycohydrolase activity remained intact and in the case of ETAH440N actually increased 10-fold. NAD(+) binding is not affected by substitutions at the 440 site as indicated by similar K-m values for the ETA variants tested. Conformational integrity of the mutant toxins appears to be largely unaffected as assessed by analysis with a conformation-sensitive monoclonal antibody as well as sensitivity to proteinase digestion. In view of the location of His(440) residue within or close to the proposed NAD(+)-binding site, these results suggest that His(440) may be a catalytic residue involved in the transfer of the ADP-ribose moiety to the EF-2 substrate.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NIAID NIH HHS [AI123429-06] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1994, J BIOL CHEM, V269, P6450; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; DOUGLAS CM, 1990, BIOCHEMISTRY-US, V29, P5043, DOI 10.1021/bi00473a007; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; GALLOWAY DR, 1989, J BIOL CHEM, V264, P14869; GALSKI HL, 1988, P NATL ACAD SCI USA, V85, P1922; GUIDIRONTANI C, 1987, MOL MICROBIOL, V1, P67, DOI 10.1111/j.1365-2958.1987.tb00528.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JOHNSON VG, 1994, J BIOL CHEM, V269, P4349; KANDEL J, 1974, J BIOL CHEM, V249, P2088; KESSLER SP, 1992, J BIOL CHEM, V267, P19107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; LUKAC M, 1988, J BIOL CHEM, V263, P6146; MCGOWAN JL, 1991, J BIOL CHEM, V266, P4911; OLSEN RH, 1982, J BACTERIOL, V150, P60, DOI 10.1128/JB.150.1.60-69.1982; Sambrook J, 1989, MOL CLONING LABORATO; WICK MJ, 1990, MOL MICROBIOL, V4, P527, DOI 10.1111/j.1365-2958.1990.tb00620.x; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; WILSON BA, 1992, CURR TOP MICROBIOL, V175, P27; WOZNIAK DJ, 1988, P NATL ACAD SCI USA, V85, P8880, DOI 10.1073/pnas.85.23.8880	33	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					679	684		10.1074/jbc.270.2.679	http://dx.doi.org/10.1074/jbc.270.2.679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822295	hybrid			2022-12-25	WOS:A1995QB81600029
J	COUSTRY, F; MAITY, SN; DECROMBRUGGHE, B				COUSTRY, F; MAITY, SN; DECROMBRUGGHE, B			STUDIES ON TRANSCRIPTION ACTIVATION BY THE MULTIMERIC CCAAT-BINDING FACTOR CBF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MAMMALIAN-CELLS; MOLECULAR-CLONING; SEQUENCE IDENTITY; COLLAGEN PROMOTER; ESCHERICHIA-COLI; B-SUBUNIT; DROSOPHILA; DOMAINS; YEAST	The CGAAT-binding factor CBF is a heteromeric transcription factor that specifically binds to CCAAT sequences in many eukaryotic genes. CBF consists of three subunits, CBF-A, CBF-B, and CBF-C, all three of which are necessary for DNA binding. In this study we examined the transcription activation function of CBF by two different approaches. We first used a heterologous system in which a series of deletion mutations of CBF-B, fused to the bacterial LexA DNA binding domain, were transfected into HeLa cells together with a reporter gene driven by a minimal promoter containing LexA binding sites. These experiments showed that CBF-B needed both a glutamine-rich domain and an adjacent serine/threonine-rich domain to activate the reporter gene optimally. The glutamine-rich domain by itself activated transcription only modestly. We also set up an in vitro transcription reconstituted system in which trans-activation by CBF occurred through a physiological CCAAT motif. Nuclear extracts from NIH 3T3 cells were first depleted of CBF and then complemented with recombinant CBF-B and a highly purified fraction containing native CBF-A and CBF-C. Recombinant full-length CBF-B together with CBF-A and CBF-C activated transcription of several alpha 2(I) collagen gene promoter constructs. We then tested whether in this system the glutamine- and serine/threonine-rich domains of CBF-B were needed for trans activation by CBF. We generated a truncated form of CBF-B that was still able to bind DNA in the presence of CBF-A and CBF-C, Even in the absence of the glutamine- and serine/threonine-rich domains of CBF-B, reconstituted CBF did activate transcription, suggesting that CBF transcriptional activation can also be mediated by the other subunits of CBF or by another transcription factor present in the nuclear extracts that interacts with CBF. Taken together our results suggest a model in which CBF has the potential to activate transcription either through the glutamine- and serine/threonine-rich domains of CBF-B or through the other subunits of CBF or through another component recruited by CBF.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Maity, Sankar/0000-0002-2387-6545	NCI NIH HHS [CA49515] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049515] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; LI XY, 1992, J BIOL CHEM, V267, P8984; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WICKENS MP, 1973, J BIOL CHEM, V253, P2483; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WOOD WM, 1989, J BIOL CHEM, V264, P14840	29	76	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					468	475		10.1074/jbc.270.1.468	http://dx.doi.org/10.1074/jbc.270.1.468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814413	hybrid			2022-12-25	WOS:A1995QA28700074
J	SOUTHWICK, FS				SOUTHWICK, FS			GAIN-OF-FUNCTION MUTATIONS CONFERRING ACTIN-SEVERING ACTIVITY TO HUMAN MACROPHAGE CAP-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CAPPING PROTEIN; GELSOLIN; DOMAINS; MUTAGENESIS; COMPLEX	Nonmuscle cell motility requires marked changes in the consistency and shape of the peripheral cytoplasm. These changes are regulated by a gel-sol transformation of the actin filament network, and actin filament-severing proteins are responsible for network solation. Macrophage Cap G, unlike all other proteins in the gelsolin family, caps but does not sever actin filaments. Two amino acid stretches in Cap G diverge markedly from the severing proteins: (84)LNTLLGE and (124)AFHKTS. Discrete mutations in Cap G have been generated to determine if these amino acid sequences are critical for actin filament severing. Conversion of (84)LNTLLGE to the gelsolin actin-binding helix sequence ((84)LDDYLGG) renders Cap G capable of severing actin filaments (half-maximal severing, 1-2 mu M). Adding a second set of mutations, converting (124)AFHKTS to (124)GFKHV, enhances severing by 10-fold (half-maximal severing, 0.1-0.2 mu M). These experiments support a critical role for these two regions in actin filament severing and showcase the power of gain-of-function mutations in clarifying structure-function relationships.	UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida	SOUTHWICK, FS (corresponding author), UNIV FLORIDA,COLL MED,DEPT MED,DIV INFECT DIS,POB 100277,GAINESVILLE,FL 32610, USA.				NIAID NIH HHS [R01 AI23262, R01 AI023262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRE E, 1988, J BIOL CHEM, V263, P722; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; FUXIN Y, 1991, J BIOL CHEM, V266, P19269; HARTWIG JH, 1991, CURR OPIN CELL BIOL, V3, P353; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; SUN HQ, 1994, J BIOL CHEM, V269, P9473; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	17	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					45	48		10.1074/jbc.270.1.45	http://dx.doi.org/10.1074/jbc.270.1.45			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814409	hybrid			2022-12-25	WOS:A1995QA28700012
J	ZHANG, R; CHEN, LR; VILLERET, V; FROMM, HJ				ZHANG, R; CHEN, LR; VILLERET, V; FROMM, HJ			GLYCINE-122 IS ESSENTIAL FOR COOPERATIVITY AND BINDING OF MG2+ TO PORCINE FRUCTOSE-1,6-BISPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; 2.8-A RESOLUTION; PHOSPHOFRUCTOKINASE; BISPHOSPHATASE; STIMULATOR; AMP; 1,6-BISPHOSPHATASE; 6-PHOSPHATE	Site directed mutagenesis of an amino acid residue in the substrate binding site of porcine fructose-1,6-bisphosphatase was carried out based on the crystal structure of the enzyme (Zhang, Y., Liang, J.-Y., Huang, S., Ke, H., and Lipscomb, W. N. (1993) Biochemistry 32, 1844-1857), A mutant enzyme form of fructose-1,6-bisphosphatase, G122A, was purified and characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, circular dichroism spectrometry (CD), and initial rate kinetics, There were no discernible differences between the secondary structures of the wild-type and the mutant enzyme on the basis of CD data, Altering Gly-122 to alanine caused a significant decrease in the enzyme's activity and affinity for Mg2+. The k(cat) for this mutant enzyme was only about 5% of that of wild-type fructose-1,6-bisphosphatase, and the K-a for Mg2+ was about 20-fold higher than that of the wild-type enzyme, The K-i for AMP was increased 77-fold in the case of the mutant enzyme; however, the Hill coefficient was unaltered, Most importantly, it was observed that replacement of Gly-122 with alanine caused the total loss of cooperativity for Mg2+. It is concluded that Gly-122 is essential for Mg2+ cooperativity and important for binding of Mg2+ and AMP as well as for enzyme activity.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA; HARVARD UNIV, GIBBS CHEM LAB, CAMBRIDGE, MA 02138 USA	Iowa State University; Harvard University				Villeret, Vincent/0000-0003-4504-056X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM006920, R01GM006920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM06920] Funding Source: Medline; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC PA, 1978, P NATL ACAD SCI USA, V75, P2185, DOI 10.1073/pnas.75.5.2185; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHEN LR, 1993, ARCH BIOCHEM BIOPHYS, V307, P350, DOI 10.1006/abbi.1993.1599; CHEN M, 1994, J BIOL CHEM, V269, P5554; ELMAGHRABI MR, 1993, J BIOL CHEM, V268, P9466; GANSON NJ, 1982, BIOCHEM BIOPH RES CO, V108, P233, DOI 10.1016/0006-291X(82)91856-3; Gomori G, 1943, J BIOL CHEM, V148, P139; HERS HG, 1982, BIOCHEM J, V206, P1; HUBERT E, 1970, ARCH BIOCHEM BIOPHYS, V138, P590, DOI 10.1016/0003-9861(70)90385-1; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; KREBS HA, 1963, ADV ENZYME REGUL, V1, P385; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIANG JY, 1992, OCT P RA WELCH F C C; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; MCGILVERY RW, 1964, FRUCTOSE 1 6 DIPHOSP, P3; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PONTREMODI S, 1907, METHOD ENZYMOL, V42, P369; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; UNDERWOOD AH, 1965, BIOCHEM J, V95, P767, DOI 10.1042/bj0950767; VANSCHAFTINGEN E, 1980, BIOCHEM BIOPH RES CO, V96, P1524; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	34	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					54	58		10.1074/jbc.270.1.54	http://dx.doi.org/10.1074/jbc.270.1.54			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814419	hybrid			2022-12-25	WOS:A1995QA28700014
J	BARRY, J; ALBERTS, B				BARRY, J; ALBERTS, B			PURIFICATION AND CHARACTERIZATION OF BACTERIOPHAGE-T4 GENE-59 PROTEIN - A DNA HELICASE ASSEMBLY PROTEIN INVOLVED IN DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; RNA PRIMER SYNTHESIS; PRIMASE-HELICASE; ACCESSORY PROTEINS; 45 PROTEINS; LAMBDA-P; FACTOR-C; INVITRO; POLYMERASE; RECOMBINATION	The T4 bacteriophage gene 59 protein is required for normal T4 DNA replication. We have purified this protein to homogeneity in two steps and show that it binds both to single-stranded DNA and to the T4 gene 32 protein, a DNA single strand binding protein. In in vitro assays, covering DNA with 32 protein makes this DNA inaccessible to the 41 protein, the highly processive DNA helicase, that associates with the T4 DNA primase (gene 61 protein) to form an active primosome. However, the 59 protein brings about the rapid assembly of 41 protein onto single stranded DNA, even if this DNA is covered with 32 protein. The 59 protein is therefore a DNA helicase assembly protein. The observed requirements for the 59 protein in in vivo T4 DNA replication are explained by there being two alternative pathways for loading the 41 protein onto a replication fork at early times of T4 DNA synthesis, with only a 59 protein-mediated pathway remaining operative for the recombination-mediated replication that dominates later in infection (Barry, J., and Alberts, B. M. (1994) J. Biol. Chem. 269, 33063-33068).	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIGMS NIH HHS [GM24020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024020, R37GM024020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1980, MECHANISTIC STUDIES, P449; ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ALLEN GC, 1993, CELL, V74, P713, DOI 10.1016/0092-8674(93)90518-U; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BARRY J, 1994, J BIOL CHEM, V269, P33063; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BURKE RL, 1985, J BIOL CHEM, V260, P1711; Carpousis A. J., 1994, P176; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; DANNENBERG R, 1983, J VIROL, V45, P813, DOI 10.1128/JVI.45.2.813-831.1983; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GOLD L, 1976, J BIOL CHEM, V251, P7251; HACKER K, 1989, J CELL BIOCHEM, V13, P87; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HAHN S, 1986, NUCLEIC ACIDS RES, V14, P9311, DOI 10.1093/nar/14.23.9311; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; KNOPF KW, 1977, EUR J BIOCHEM, V73, P33, DOI 10.1111/j.1432-1033.1977.tb11289.x; KORNBERG A, 1991, COLD SH Q B, V56, P275; KRISCH HM, 1981, J MOL BIOL, V148, P199, DOI 10.1016/0022-2836(81)90535-0; Kutter E., 1983, BACTERIOPHAGE T4, P277; Kutter Elizabeth, 1994, P491; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1979, COLD SPRING HARB SYM, V43, P469, DOI 10.1101/SQB.1979.043.01.053; LIU CC, 1981, J BIOL CHEM, V256, P2821; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUELLER R, 1991, THESIS RUH U BOCHUM; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SELICK HE, 1988, J BIOL CHEM, V263, P11336; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SILVER LL, 1982, J BIOL CHEM, V257, P1696; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; SPICER EK, 1988, J BIOL CHEM, V263, P7478; SPICER EK, 1983, BACTERIOPHAGE T4, P291; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WOOD WB, 1976, BACTERIOL REV, V40, P847, DOI 10.1128/MMBR.40.4.847-868.1976; WU JR, 1984, J VIROL, V52, P1028, DOI 10.1128/JVI.52.3.1028-1031.1984; WU R, 1974, VIROLOGY, V59, P108, DOI 10.1016/0042-6822(74)90209-8; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	78	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33049	33062						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806533				2022-12-25	WOS:A1994QA63800050
J	GARDNER, K; MOORE, TC; DAVISSMYTH, T; KRUTZSCH, H; LEVENS, D				GARDNER, K; MOORE, TC; DAVISSMYTH, T; KRUTZSCH, H; LEVENS, D			PURIFICATION AND CHARACTERIZATION OF A MULTICOMPONENT AP-1 JUND COMPLEX FROM T-CELLS - DEPENDENCE ON A SEPARATE CELLULAR FACTOR FOR ENHANCED DNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR AP-1; APE LEUKEMIA-VIRUS; FOS-JUN; GENE-EXPRESSION; LYMPHOCYTES-T; HETERODIMER FORMATION; SIGNAL TRANSDUCTION; INTERLEUKIN-2 GENE; MOLECULAR-CLONING	TAP-1 (T-cell AP-1) is a previously identified DNA-binding activity that is rapidly induced in activated T cells in the absence of protein synthesis, This activity has been purified over 2,000-fold from the T-cell line MLA144. Purified TAP-1 is a multicomponent complex composed of 38-kDa and 43-kDa junD polypeptides in association with a separate factor(s), distinct from fos, that partly dissociate from the complex during affinity purification but is required for full TAP-1 DNA-binding activity. When reconstituted with TAP-1, this partly dissociated component strongly enhances the DNA-binding activity of the TAP-1 complex. W-cross linking analysis identifies the dissociable component of the TAP-1 complex as a separate class of low molecular mass (23-29-kDa) DNA-binding polypeptide(s). 23-29-kDa polypeptides have been partially purified from nuclear extracts derived from MLA144 that enhance TAP-1 DNA-binding activity over 100-fold and increase its contacts with flanking DNA sequence. These results define TAP-1 as a distinct AP-l junD-containing complex in T cells whose DNA-binding activity is regulated by the interaction of distinct and separate cellular factor(s).			GARDNER, K (corresponding author), NCI,PATHOL LAB,BLDG 10,RM 2N212,BETHESDA,MD 20892, USA.		Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; AUWERX J, 1992, ONCOGENE, V7, P2271; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURDACH S, 1991, J CLIN INVEST, V87, P2114, DOI 10.1172/JCI115242; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CHAUHAN D, 1993, BLOOD, V81, P1540; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MORGAN IM, 1992, CELL PROLIFERAT, V25, P205, DOI 10.1111/j.1365-2184.1992.tb01395.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NAKAGAWA TY, 1986, P NATL ACAD SCI USA, V83, P2007, DOI 10.1073/pnas.83.7.2007; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; QUINN JP, 1989, MOL CELL BIOL, V9, P4713, DOI 10.1128/MCB.9.11.4713; QUINN JP, 1989, J VIROL, V63, P1737, DOI 10.1128/JVI.63.4.1737-1742.1989; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROSENSTREICH DL, 1979, J IMMUNOL, V123, P1749; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUNG SSJ, 1991, J IMMUNOL, V147, P2047; SWANSON MS, 1987, MOL CELL BIOL, V7, P171; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	74	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32963	32971						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806526				2022-12-25	WOS:A1994QA63800039
J	CALABRESI, L; VECCHIO, G; LONGHI, R; GIANAZZA, E; PALM, G; WADENSTEN, H; HAMMARSTROM, A; OLSSON, A; KARLSTROM, A; SEJLITZ, T; AGELAND, H; SIRTORI, CR; FRANCESCHINI, G				CALABRESI, L; VECCHIO, G; LONGHI, R; GIANAZZA, E; PALM, G; WADENSTEN, H; HAMMARSTROM, A; OLSSON, A; KARLSTROM, A; SEJLITZ, T; AGELAND, H; SIRTORI, CR; FRANCESCHINI, G			MOLECULAR CHARACTERIZATION OF NATIVE AND RECOMBINANT APOLIPOPROTEIN A-I-MILANO DIMER - THE INTRODUCTION OF AN INTERCHAIN DISULFIDE BRIDGE REMARKABLY ALTERS THE PHYSICOCHEMICAL PROPERTIES OF APOLIPOPROTEIN-A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; ESCHERICHIA-COLI; SELF-ASSOCIATION; APOA-I; DOMAINS; PLASMA; CONFORMATION; PROTEINS; EFFLUX	The disulfide-linked dimer of apolipoprotein A-I-Milano (A-I-M/A-I-M), a natural Arg(173) --> CYS variant of apoA-I, was purified from carriers' plasma and produced in Escherichia coli. The recombinant A-I-M/A-I-M is identical to native A-I-M/A-I-M, by mass spectrometry, SDS-polyacrylamide gel electrophoresis, and isoelectric focusing. Lipid-free A-I-M/A-I-M undergoes concentration-dependent self-association similar to apoA-I, but at all concentrations apoA-I is more self-associated than A-I-M/A-I-M. Farultraviolet CD spectra of A-I-M/A-I-M reveal a highly alpha-helical structure predicted to be similar to 65% in the lipid-free and similar to 78% in the lipid-associated states, versus 43 and 73% for apoA-I. A significant loss of alpha-helix occurs below pH 3.5 and above pH 10 in both apoA-I and A-I-M/A-I-M; A-I-M/A-I-M constantly shows a higher alpha-helical content than apoA-I over the entire pH range (1.7-12.8), suggesting that hydrophobic forces stabilize the interaction between the two A-I-M chains. Indeed, and differently from apoA-I, the alpha-helical content of A-I-M/A-I-M is minimally affected by solvent ionic strength. The aromatic side chains in both Lipid-free and lipid-bound A-I-M/A-I-M are immobilized in a more asymmetric and hydrophobic environment than in Lipid-free apoA-I, the conformation ofA-I(M)A-I-M, being instead similar to that achieved by apoA-I following interaction with lipids. The present findings prove that rA-I-M/A-I-M is structurally identical to the native protein; the conformation of A-I-M/IA-I-M is remarkably different fi om that of apoA-I, thus possibly explaining some of the peculiar functional properties of the apoA-I-Milano dimer.	UNIV MILAN,INST PHARMACOL SCI,CTR E GROSSI PUOLETTI,I-20133 MILAN,ITALY; CNR,IST CHIM ORMONI,I-20133 MILAN,ITALY; PHARMACIA BIOSCI CTR,S-11287 STOCKHOLM,SWEDEN; PHARMACIA THERAPEUT,S-11287 STOCKHOLM,SWEDEN	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Pfizer			Sirtori, Cesare/F-4658-2012	FRANCESCHINI, GUIDO/0000-0003-2687-1771; Calabresi, Laura/0000-0001-5042-9532				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BANKA CL, 1994, J BIOL CHEM, V269, P10288; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN SH, 1986, HUMAN APOLIPROTEIN M, P99; CHMIELEWSKA J, 1993, P INT S LIPID TRIAD, P41; DALTON MB, 1993, J BIOL CHEM, V268, P19274; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORSBERG G, 1989, Biofactors, V2, P105; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; FRANCESCHINI G, 1982, J BIOL CHEM, V257, P9926; FRANCESCHINI G, 1981, METABOLISM, V30, P502, DOI 10.1016/0026-0495(81)90188-8; FRANCESCHINI G, 1990, J BIOL CHEM, V265, P12224; FRANCESCHINI G, 1985, J BIOL CHEM, V260, P6321; GIANAZZA E, 1986, ELECTROPHORESIS, V7, P76, DOI 10.1002/elps.1150070205; GLOMSET JA, 1968, J LIPID RES, V9, P155; GUALANDRI V, 1985, AM J HUM GENET, V37, P1083; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; ISACCHI A, 1989, GENE, V81, P129, DOI 10.1016/0378-1119(89)90343-0; JACKSON RL, 1972, BIOCHEM BIOPH RES CO, V49, P1444, DOI 10.1016/0006-291X(72)90501-3; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; KISS RS, 1993, BIOCHEMISTRY-US, V32, P7872, DOI 10.1021/bi00082a006; LEROY A, 1994, BBA-LIPID LIPID MET, V1212, P285, DOI 10.1016/0005-2760(94)90202-X; LUX SE, 1972, J BIOL CHEM, V247, P2598; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MENG QH, 1993, J BIOL CHEM, V268, P16966; ORAM JF, 1993, ATHER REV, V24, P87; PIETERS MN, 1993, BIOCHEM J, V292, P819, DOI 10.1042/bj2920819; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROMA P, 1993, J CLIN INVEST, V91, P1445, DOI 10.1172/JCI116349; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYAN RO, 1993, J BIOL CHEM, V268, P1505; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SIRTORI CR, 1993, HUMAN APOLIPOPROTEIN, V3, P121; STONE WL, 1975, J BIOL CHEM, V250, P8045; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; SWANEY JB, 1976, BIOCHEM BIOPH RES CO, V71, P636, DOI 10.1016/0006-291X(76)90835-4; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2508; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; ZANNIS VI, 1980, J BIOL CHEM, V255, P8612	53	81	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32168	32174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798214				2022-12-25	WOS:A1994PX30400026
J	WU, CB; SEIBERT, FS; KO, K				WU, CB; SEIBERT, FS; KO, K			IDENTIFICATION OF CHLOROPLAST ENVELOPE PROTEINS IN CLOSE PHYSICAL PROXIMITY TO A PARTIALLY TRANSLOCATED CHIMERIC PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TRANSIT PEPTIDE; IMPORT APPARATUS; MEMBRANE-PROTEIN; OUTER-MEMBRANE; BINDING; LOCALIZATION; HSP70; MITOCHONDRIA; POLYPEPTIDES	Translocation intermediates of the chimeric protein precursor Oee1-Dhfr mere generated and used to identify envelope components in close proximity to the arrested precursor. The translocation of Oee1-Dhfr across the chloroplast envelope can be arrested at low ATP levels or by prebinding the fusion precursor with anti-Dhfr IgGs. The arrested Oeel-Dhfr precursors appear to span both the outer and inner envelope membranes. Translocational arrest of Oee1-Dhfr by low ATP levels was reversible, and import was restored upon resupplementation with higher ATP levels. Chemical cross-linking and co-immunoprecipitation with monospecific antibodies indicate that two outer envelope membrane proteins (Com44 and Com70) and at least one inner envelope protein (Cim44 and Cim97) were found to be in close proximity to Oee1-Dhfr during translocation. The Com70 protein was further studied and additional evidence for its role in chloroplast protein import is presented.	QUEENS UNIV, DEPT BIOL, KINGSTON K7L 3N6, ON, CANADA	Queens University - Canada								AMIRSHAPIRA D, 1990, P NATL ACAD SCI USA, V87, P374; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUA NH, 1982, METHODS CHLOROPLAST, P1063; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DELLACIOPPA G, 1988, EMBO J, V7, P1299, DOI 10.1002/j.1460-2075.1988.tb02944.x; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HINZ G, 1988, EUR J BIOCHEM, V175, P649, DOI 10.1111/j.1432-1033.1988.tb14241.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; JOYARD J, 1983, J BIOL CHEM, V258, P1; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KO K, 1992, J BIOL CHEM, V267, P13910; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1993, FEBS LETT, V332, P277, DOI 10.1016/0014-5793(93)80649-F; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; MARSHALL JS, 1992, PLANT PHYSIOL, V100, P1048, DOI 10.1104/pp.100.2.1048; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PFISTERER J, 1982, EUR J BIOCHEM, V126, P143, DOI 10.1111/j.1432-1033.1982.tb06758.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SUTTON A, 1987, EUR J BIOCHEM, V164, P571, DOI 10.1111/j.1432-1033.1987.tb11165.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WU CB, 1993, J BIOL CHEM, V268, P19384; YALOVSKY S, 1992, P NATL ACAD SCI USA, V89, P5616, DOI 10.1073/pnas.89.12.5616	48	102	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32264	32271						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798226				2022-12-25	WOS:A1994PX30400040
J	MIELE, C; FORMISANO, P; SOHN, KJ; CARUSO, M; PIANESE, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F				MIELE, C; FORMISANO, P; SOHN, KJ; CARUSO, M; PIANESE, M; PALUMBO, G; BEGUINOT, L; BEGUINOT, F			DECREASED PHOSPHORYLATION OF MUTANT INSULIN-RECEPTOR BY PROTEIN-KINASE-C AND PROTEIN-KINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; THREONINE 1336; BETA-SUBUNIT; AUTOPHOSPHORYLATION; MUTATION; SITES; CELLS; DNA; ACTIVATION; INVITRO	We have recently reported that the Arg(1152) --> Gln insulin receptor mutation (QR single mutant) alters a conserved motif (RK motif) immediately next to the hey tyrosine phosphorylation sites (Tyr(1146), Tyr(1150) Tyr(1151)) of the receptor and constitutively activates its kinase and metabolic signaling. To investigate further the function of the RK motif, we have expressed two additional mutant insulin receptors: a single mutant, in which the second basic residue in the RR motif (Lys(1153)) was substituted (RA mutant); and a double mutant, in which both the Arg and the Lye residues were replaced with noncharged amino acids (QA mutant). As compared with the transfected wild-type receptors (WT), both the single and the double mutant receptors were normally synthetized and transported to the plasma membrane and bound insulin normally, Whereas the double mutant receptor exhibited preserved insulin-dependent autophosphorylation, kinase activity, and a-deoxyglucose uptake, all of these functions were grossly impaired in the two single mutant receptors, Two-dimensional analysis of tryptic phosphopeptides from receptor beta-subunits revealed that decreased autophosphorylation of the single mutant receptors mainly involved regulatory Tyr(1150,1151) and carboxyl-terminal Tyr(1316,1322). At variance with the insulin-stimulated, insulin-independent tyrosine kinase activity toward poly(Glu-Tyr) 4:1 was increased 3-fold in both the double and the single mutants. Ah mutant receptors induced a 2-fold increase in basal 2-deoxyglucose uptake in NIH-3T3 cells, Treatment of WT transfected cells with 12-O-tetradecanoyl-phorbol-13-acetate or 8-bromo-cAMP increased insulin receptor phosphorylation by 3-fold. No phosphorylation was observed in cells expressing the two single or the double mutant receptor, Consistently, purified preparations of PKC and PKA phosphorylated the WT but not the mutant receptors in vitro. A 17-amino acid synthetic peptide encoding the receptor sequence surrounding the RR. motif inhibited phosphorylation of WT insulin receptors by both protein kinases A and C. A mutant peptide in which the RR sequence was replaced by QK (to mimic the mutation in the QK receptor) exhibited no inhibitory effect, Thus, the RK insulin receptor moth is required for insulin receptor phosphorylation by protein kinases C and A and may modulate insulin-independent receptor activity, The RK motif may also have an important structural role in allowing normal insulin regulation of the kinase.	UNIV NAPLES,FAC MED,SCH MED,CONSIGLIO NAZL RIC,CTR ENDOCRINOL & ONCOL SPERIME,I-80131 NAPLES,ITALY; HOSP SAN RAFFAELE,CONSIGLIO NAZL RIC,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CONSIGLIO NAZL RIC,DIPARTIMENTO RICERCA BIOL & TECNOL,MOLEC ONCOL LAB,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Formisano, Pietro/J-4237-2018; Palumbo, Giuseppe/N-3136-2016	Palumbo, Giuseppe/0000-0001-9380-8436; Formisano, Pietro/0000-0001-7020-6870				AHN J, 1993, J BIOL CHEM, V268, P16839; Battey, 1986, BASIC METHODS MOL BI; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CZECH M P, 1985, Diabetes Metabolism Reviews, V1, P33; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELIN K, 1991, ONCOGENE, V6, P825; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HUBBARD SR, 1995, NATURE, V372, P22; KARASIK A, 1990, J BIOL CHEM, V265, P10226; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MCDONALD NQ, 1995, STRUCTURE, V3, P1, DOI 10.1016/S0969-2126(01)00129-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETRUZZIELLO A, 1993, J CLIN ENDOCR METAB, V77, P409, DOI 10.1210/jc.77.2.409; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WHITE MF, 1994, J BIOL CHEM, V269, P1	36	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15844	15852		10.1074/jbc.270.26.15844	http://dx.doi.org/10.1074/jbc.270.26.15844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797589	hybrid			2022-12-25	WOS:A1995RG53800062
J	OLIVES, B; MATTEI, MG; HUET, M; NEAU, P; MARTIAL, S; CARTRON, JP; BAILLY, P				OLIVES, B; MATTEI, MG; HUET, M; NEAU, P; MARTIAL, S; CARTRON, JP; BAILLY, P			KIDD BLOOD-GROUP AND UREA TRANSPORT FUNCTION OF HUMAN ERYTHROCYTES ARE CARRIED BY THE SAME PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELLS; MONOCLONAL-ANTIBODY; SOLUTE PERMEABILITY; WATER; EXPRESSION; ANTIGEN; LINKAGE	The gene encoding the urea transporter of human erythrocytes (HUT11 clone) has been cloned recently (Olives, B,, Neau, P,, Bailly, P,, Hediger, M. A., Rousselet, G,, Cartron, J, P,, and Ripoche, P, (1994) J, Biol, Chem, 269, 31649-31652), Now, this gene has been assigned to chromosome 18q12-q21 by in situ hybridization, as also found for the Kidd (Jk) blood group locus, In coupled transcription-translation assays, the HUT11 cDNA directed the synthesis of a 36-kDa protein which was immunoprecipitated by a human anti-Jk(3) antibody produced by immunized Jk(a-b-) donors whose red cells lack Kidd antigens, The anti-Jk(3) antibody also immunoprecipitated a protein material of 46-60 kDa from all red cell membranes, except those from Jk(a-b-) cells, After N-glycanase digestion the 46-60-kDa component was reduced to 36 kDa, A rabbit antibody raised against the predicted NH,-terminal amino-acids of the HUT11 protein reacted on immunoblots with a 46-60-kDa component present in all human erythrocytes except those from Jk(a-b-) individuals, Jk(a-b-) red cells lack the Kidd/urea transport protein and have a selective defect of the urea transport capacity, but a normal water permeability and aquaporin-associated Colton blood group antigens, These findings indicate that the erythrocyte urea transporter is encoded by the Kidd locus and may have implications for the biology of urea transporters and their tissue specific regulation.	INST NATL TRANSFUS SANGUINE,INSERM,U76,F-75015 PARIS,FRANCE; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE 05,FRANCE; CEA SACLAY,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CEA; UDICE-French Research Universities; Universite Paris Saclay			Martial, Sonia/L-8270-2019	Martial, Sonia/0000-0002-6732-0936				BLOY C, 1987, BLOOD, V69, P1491; BRAHM J, 1983, J GEN PHYSIOL, V82, P1, DOI 10.1085/jgp.82.1.1; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CHAUDHURI A, 1995, BLOOD, V85, P615, DOI 10.1182/blood.V85.3.615.bloodjournal853615; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; FROHLICH O, 1991, AM J PHYSIOL, V260, pC778, DOI 10.1152/ajpcell.1991.260.4.C778; GEITVIK GA, 1987, HUM GENET, V77, P205, DOI 10.1007/BF00284470; GILLIN AG, 1993, SEMIN NEPHROL, V13, P146; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HASEGAWA H, 1993, AM J PHYSIOL, V265, pC514, DOI 10.1152/ajpcell.1993.265.2.C514; HEATON DC, 1982, TRANSFUSION, V22, P70, DOI 10.1046/j.1537-2995.1982.22182154224.x; HODGE SE, 1981, LANCET, V2, P893; HUNTER FR, 1970, BIOCHIM BIOPHYS ACTA, V211, P216, DOI 10.1016/0005-2736(70)90094-5; KNEPPER MA, 1990, AM J PHYSIOL, V259, pF393, DOI 10.1152/ajprenal.1990.259.3.F393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATRON F, 1987, BIOCHEM J, V247, P757, DOI 10.1042/bj2470757; LECLAIR K, 1981, J IMMUNOL METHODS, V41, P137, DOI 10.1016/0022-1759(81)90237-4; MACEY RI, 1988, AM J PHYSIOL, V254, pC669, DOI 10.1152/ajpcell.1988.254.5.C669; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MARTIAL S, 1991, ANAL BIOCHEM, V197, P296, DOI 10.1016/0003-2697(91)90395-A; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; OLIVES B, 1994, J BIOL CHEM, V269, P31649; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; ROUSSELET G, 1995, FASEB J, V9, P563; SANDS JM, 1992, J AM SOC NEPHROL, V2, P1689; SINOR LT, 1987, MED LAB SCI, V44, P294; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	31	128	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15607	15610		10.1074/jbc.270.26.15607	http://dx.doi.org/10.1074/jbc.270.26.15607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797558	hybrid, Green Submitted			2022-12-25	WOS:A1995RG53800028
J	SCHMITZ, ML; SILVA, MAD; BAEUERLE, PA				SCHMITZ, ML; SILVA, MAD; BAEUERLE, PA			TRANSACTIVATION DOMAIN-2 (TA(2)) OF P65 NF-KAPPA-B - SIMILARITY TO TA(1) AND PHORBOL ESTER-STIMULATED ACTIVITY AND PHOSPHORYLATION IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; DNA-BINDING; ENHANCER ELEMENT; MAMMALIAN-CELLS; FACTOR-TFIIB; C-REL; ALPHA; PROTEIN; EXPRESSION; MECHANISM	The p65 subunit of the inducible transcription factor NF-kappa B contains at least two strong transactivation domains (TADs) within its C terminus. The first domain, TA(1), is contained within the last 30 amino acids of p65, whereas TA(2) comprises the adjacent 90 amino acids. In this study, squelching experiments revealed that both TADs of p65, as well as the related subunit c-Rel, compete for the same cofactor(s) mediating transactivation. Both TADs of p65 share a common sequence motif, which is evolutionarily conserved and displays a remarkable degree of spatial organization when aligned on an cu-helical surface. The functional importance of the common sequence motif was confirmed by deletion analysis of TA(2). Within the conserved sequence motif, a 7-amino-acid repeat was noted. Idealized heptad repeats fused to the DNA binding domain of Gal4 were transcriptionally active, but only as multimers. Phosphorylation and transcriptional activity of a defined region within the TA(2) domain was found to be stimulated by phorbol ester treatment of cells. In contrast, TA(1) was constitutively phosphorylated, and its activity did not significantly respond to phorbol ester stimulation. The stimulatory effect of phorbol ester on transcription of the TA(2) domain was completely blocked by the protein kinase C inhibitor. These data suggest that protein kinase C has a dual effect on NF-kappa B activity, It not only causes removal of I kappa B-alpha from cytoplasmic NF-KB but also augments the transactivation potential of activated nuclear NF-kappa B.			SCHMITZ, ML (corresponding author), UNIV FREIBURG,INST BIOCHEM,HERMANN HERDER STR 7,D-79104 FREIBURG,GERMANY.		Silva, Marcos/C-7260-2015; Schmitz, M. Lienhard/D-9328-2017; Silva Ferraz, Marcos/X-9172-2018; Ferraz, Marcos A.S. Silva/ABG-4813-2020	Schmitz, M. Lienhard/0000-0002-6984-7192; Silva Ferraz, Marcos/0000-0001-6898-9132; Ferraz, Marcos A.S. Silva/0000-0001-6898-9132				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHMITZ ML, 1995, IN PRESS IMMUNOBIOLO; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SIGLER PB, 1988, NATURE, V331, P210; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TIJIAN R, 1994, CELL, V77, P5; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	56	148	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15576	15584		10.1074/jbc.270.26.15576	http://dx.doi.org/10.1074/jbc.270.26.15576			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797554	hybrid			2022-12-25	WOS:A1995RG53800024
J	SOHAL, RS; AGARWAL, A; AGARWAL, S; ORR, WC				SOHAL, RS; AGARWAL, A; AGARWAL, S; ORR, WC			SIMULTANEOUS OVEREXPRESSION OF COPPER-CONTAINING AND ZINC-CONTAINING SUPEROXIDE-DISMUTASE AND CATALASE RETARDS AGE-RELATED OXIDATIVE DAMAGE AND INCREASES METABOLIC POTENTIAL IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATIVE DISEASES; OXYGEN RADICALS; DNA-DAMAGE; 8-HYDROXY-2'-DEOXYGUANOSINE; URINE	The objective of this study was to elucidate the nature of the mechanisms by which overexpression of copper- and zinc-containing superoxide dismutase (Cu,Zn-SOD) and catalase extends life span of Drosophila melanogaster. Experimental flies containing single extra doses of Drosophila Cu,Zn-SOD and catalase genes were compared with appropriate controls at different ages, Overexpression of Cu,Zn SOD and catalase caused a retardation in the accumulation of 8-hydroxydeoxyguanosine during aging and in response to the exposure of live flies to x-rays, The age related loss of glucose-6-phosphate dehydrogenase activity (Glu-6-P dehydrogenase) and the increase in the rate of mitochondrial H2O2 generation were less steep in the experimental than control flies, The rate of in vivo oxygen consumption in the latter two-thirds of life span was higher in the experimental than in the control flies, Furthermore, the metabolic potential, or the total amount of oxygen consumed during an average life span, was about 30% greater in the experimental than the control flies, Altogether, results of this study indicate that overexpression of Cu,Zn-SOD and catalase ameliorates the age-related accumulation of molecular oxidative damage and susceptibility to such damage in response to acute oxidative stress while prolonging the metabolic life of flies, The concept that oxidative stress is a causal factor in the aging process is supported.			SOHAL, RS (corresponding author), SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275, USA.				NATIONAL INSTITUTE ON AGING [R01AG008459] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG8459] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL S, 1993, BIOCHEM BIOPH RES CO, V194, P1203, DOI 10.1006/bbrc.1993.1950; AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Beutler E., 1971, RED CELL METABOLISM; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; MCARTHUR MC, 1982, J GERONTOL, V37, P268, DOI 10.1093/geronj/37.3.268; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1993, AGING-CLIN EXP RES, V5, P3, DOI 10.1007/BF03324120; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1992, FREE RADICALS AGING, P64; WOOD FE, 1980, INSECT BIOCHEM, V10, P95, DOI 10.1016/0020-1790(80)90044-X	25	193	203	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15671	15674		10.1074/jbc.270.26.15671	http://dx.doi.org/10.1074/jbc.270.26.15671			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797567	hybrid			2022-12-25	WOS:A1995RG53800038
J	PAUL, S; LI, L; KALAGA, R; WILKINSSTEVENS, P; STEVENS, FJ; SOLOMON, A				PAUL, S; LI, L; KALAGA, R; WILKINSSTEVENS, P; STEVENS, FJ; SOLOMON, A			NATURAL CATALYTIC ANTIBODIES - PEPTIDE-HYDROLYZING ACTIVITIES OF BENCE-JONES PROTEINS AND V-L FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; LIGHT-CHAINS; LAMBDA-CHAIN; AUTOANTIBODIES; SITES; IMMUNOGLOBULINS; BINDING; MYELOMA; SERUM; CELLS	Monoclonal human light chains, i.e. Pence Jones proteins, and their recombinant variable fragments (V-L) were screened for proteolytic activity using peptide-methylcoumarinamide (peptide-MCA) conjugates and vasoactive intestinal polypeptide (VIP) as substrates. Sixteen of 21 Pence Jones proteins and one of three V-L fragments were capable of detectable cleavage of one or more substrates. The magnitude and kinetic characteristics of the activity varied with different substrates. Among the peptide-MCA substrates, the presence of tripeptide or tetrapeptide moieties with a basic residue at the scissile bond generally favored expression of the activity. The influence of N-terminal flanking residue recognition was evident from differing values of K-m and k(cat) (turnover number) observed using different Arg-containing peptide-MCA substrates. Different light chains displayed different kinetic parameters for the same substrate, suggesting unique catalytic sites. Hydrolysis of VIP was characterized by nanomolar Michaelis-Menten constants (K-m), suggesting comparatively high affinity recognition of this peptide, The 25-kDa monomer and the 50-kDa dimer forms of one light chain preparation were resolved by gel filtration in 6 M guanidine hydrochloride, Following renaturation, the monomer displayed 51-fold greater peptide-MCA-hydrolyzing activity than the dimer. A renatured V-L domain prepared by gel filtration in 6 M guanidine hydrochloride displayed VIP-hydrolyzing activity in the 12.5-kDa peak fractions. These results provide evidence for the proteolytic activity of certain human light chains and imply that this phenomenon may have a pathophysiological significance.	ARGONNE NATL LAB,ARGONNE,IL 60439; UNIV TENNESSEE,MED CTR,KNOXVILLE,TN 37920; HUMAN IMMUNOL & CANC PROGRAM,KNOXVILLE,TN 37920	United States Department of Energy (DOE); Argonne National Laboratory; University of Tennessee System; University of Tennessee Health Science Center	PAUL, S (corresponding author), UNIV NEBRASKA,MED CTR,DEPT ANESTHESIOL,600 S 42ND ST,OMAHA,NE 68198, USA.				NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043757] Funding Source: NIH RePORTER; NCI NIH HHS [CA10056] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline; NIDDK NIH HHS [DK43757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG CH, 1985, BIOCHEMISTRY-US, V24, P4890, DOI 10.1021/bi00339a025; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1962, J EXP MED, V116, P207; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FINCH RJ, 1989, J IMMUNOL, V142, P1977; GAO QS, 1994, J BIOL CHEM, V269, P32389; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jones H. B., 1848, PHILOS T R SOC LOND, V138, P55; JONSSON V, 1992, J INTERN MED, V232, P185, DOI 10.1111/j.1365-2796.1992.tb00570.x; JONSSON V, 1988, ACTA MED SCAND, V223, P255; KIMATA H, 1993, J IMMUNOL, V150, P4630; LI L, 1994, J IMMUNOL, V154, P3328; MAHANA W, 1994, SCAND J IMMUNOL, V39, P107, DOI 10.1111/j.1365-3083.1994.tb03347.x; MATHEW RC, 1992, J IMMUNOL, V148, P3572; MODY R, 1994, INT J PEPT PROT RES, V44, P441; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; NELSON M, 1992, BRIT J HAEMATOL, V81, P223, DOI 10.1111/j.1365-2141.1992.tb08211.x; NODA Y, 1994, BIOPOLYMERS, V34, P217, DOI 10.1002/bip.360340208; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1985, BIOCHEM BIOPH RES CO, V130, P479, DOI 10.1016/0006-291X(85)90442-5; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SMITH GD, 1977, ANAL BIOCHEM, V79, P643, DOI 10.1016/0003-2697(77)90451-1; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, 1994, J IMMUNOL, V153, P5121; THOMAS NR, 1994, APPL BIOCHEM BIOTECH, V47, P345, DOI 10.1007/BF02787945; TILLYER CR, 1991, J CLIN PATHOL, V44, P466, DOI 10.1136/jcp.44.6.466; WILKINSSTEVENS P, 1995, PROTEIN SCI, V4, P421	34	116	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15257	15261		10.1074/jbc.270.25.15257	http://dx.doi.org/10.1074/jbc.270.25.15257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797511	hybrid			2022-12-25	WOS:A1995RE66600062
J	ELLIS, TJ; WAGNER, GF				ELLIS, TJ; WAGNER, GF			POSTTRANSCRIPTIONAL REGULATION OF THE STANNIOCALCIN GENE BY CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; ISOLATED EEL GILL; RAINBOW-TROUT; INSULIN-BIOSYNTHESIS; ANGUILLA-ROSTRATA; PANCREATIC-ISLETS; PROTEIN-SYNTHESIS; SALMO-GAIRDNERI; AMERICAN EELS; COHO SALMON	Stanniocalcin (STC) is a Ca2+-regulating hormone produced by the corpuscles of Stannius in bony fish. Calcium has been shown to stimulate STC synthesis at multiple levels including the level of gene expression. The purpose of this study was to determine the effects of Ca2+ on STC mRNA stability, The half-life of STC mRNA was measured in primary cultured trout corpuscles of Stannius cells maintained in either normal (1.2 mm) or high (1.9 mM) levels of extracellular calcium and treated with the transcriptional inhibitor alpha-amanitin. In cells maintained in 1.2 mM Ca2+, STC mRNA levels decreased progressively over time with an estimated half-life of similar to 71 h. However, message levels remained unchanged for up to 4 days in cells maintained in 1.9 mM Ca2+, indicating that the transcript had been stabilized in response to Ca2+ stimulation. Blocking transcription prior to exposing cells to high Ca2+ did not alter the stabilizing effects of the cation, indicating that synthesis and processing of the mRNA transcript were not involved in message stabilization. Inhibiting protein synthesis with cycloheximide also had no influence on the stabilizing effects of high calcium, The experiments involving cycloheximide further suggested that the mechanism of mRNA stabilization involved protein-nucleic acid interactions in the cytoplasm, whereby the polysomal complex protected the mRNA from degradation, These data demonstrate that the stimulatory effect of Ca2+ on STC gene expression is due, in part, to mRNA stabilization.	UNIV WESTERN ONTARIO, FAC MED, DEPT PHYSIOL, LONDON, ON N6A 5C1, CANADA	Western University (University of Western Ontario)								AHMAD N, 1990, ARCH BIOL, V101, P285; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267, DOI 10.1128/MCB.8.6.2267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FENWICK JC, 1991, GEN COMP ENDOCR, V82, P459, DOI 10.1016/0016-6480(91)90321-V; FENWICK JC, 1974, J EXP ZOOL, V188, P125, DOI 10.1002/jez.1401880112; FLEMING WR, 1973, AM ZOOL, V73, P793; FONTAINE M, 1964, CR ACAD SCI D NAT, V529, P875; Garrett FD, 1942, J MORPHOL, V70, P41, DOI 10.1002/jmor.1050700104; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; HAWA NS, 1993, J MOL ENDOCRINOL, V10, P43, DOI 10.1677/jme.0.0100043; KRISHNAMURTHY VG, 1976, INT REV CYTOL, V46, P177, DOI 10.1016/S0074-7696(08)60992-4; LU MQ, 1994, AM J PHYSIOL-REG I, V267, pR1356, DOI 10.1152/ajpregu.1994.267.5.R1356; MILLIKEN CE, 1990, GEN COMP ENDOCR, V77, P416, DOI 10.1016/0016-6480(90)90232-B; MOULAND AJ, 1991, ENDOCRINOLOGY, V128, P441, DOI 10.1210/endo-128-1-441; NAVEHMANY T, 1989, ENDOCRINOLOGY, V125, P275, DOI 10.1210/endo-125-1-275; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; NEILSEN DA, 1985, J BIOL CHEM, V250, P6134; OBRIG TG, 1971, J BIOL CHEM, V246, P174; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SO YP, 1979, GEN COMP ENDOCR, V37, P143, DOI 10.1016/0016-6480(79)90101-1; SO YP, 1977, J EXP ZOOL, V200, P259, DOI 10.1002/jez.1402000207; Stannius H, 1839, ARCH ANAT PHYSIOL, V6, P97; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WAGNER GF, 1992, MOL CELL ENDOCRINOL, V90, P7, DOI 10.1016/0303-7207(92)90095-N; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; WAGNER GF, 1994, MOL CELL ENDOCRINOL, V99, P315, DOI 10.1016/0303-7207(94)90023-X; WAGNER GF, 1989, MOL CELL ENDOCRINOL, V62, P31, DOI 10.1016/0303-7207(89)90110-X; WAGNER GF, 1988, GEN COMP ENDOCR, V72, P237, DOI 10.1016/0016-6480(88)90206-7; WAGNER GF, 1985, CAN J ZOOL, V63, P2778, DOI 10.1139/z85-414; WAGNER GF, 1993, MOL CELL ENDOCRINOL, V93, P185, DOI 10.1016/0303-7207(93)90122-Z; Wagner Graham F., 1993, Biochemistry and Molecular Biology of Fishes, V2, P419; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590	40	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1960	1965		10.1074/jbc.270.4.1960	http://dx.doi.org/10.1074/jbc.270.4.1960			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829534				2022-12-25	WOS:A1995QD20400071
J	GRABCZYK, E; FISHMAN, MC				GRABCZYK, E; FISHMAN, MC			A LONG PURINE-PYRIMIDINE HOMOPOLYMER ACTS AS A TRANSCRIPTIONAL DIODE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; HOMOPURINE-HOMOPYRIMIDINE SEQUENCES; H-DNA; SUPERCOILED DNA; FORMING OLIGONUCLEOTIDES; MIRROR REPEATS; RNA; BINDING; TEMPLATE; REGION	Polypurine-polypyrimidine (R.Y) sequences have the unusual ability to form DNA triple helices. Such tracts are overrepresented upstream of eukaryotic genes, although a function there has not been clear. We report that transcription in vitro into one such upstream R.Y tract in the direction that makes a predominantly purine RNA is effectively blocked by formation of an intramolecular triple helix. The tripler is triggered by transcription and stabilized by the binding of nascent purine RNA to the template. Transcription in the opposite direction is not restricted. Polypurine-polypyrimidine DNA may provide a dynamic and selective block to transcription without the aid of accessory proteins.	MASSACHUSETTS GEN HOSP E, DEV BIOL LAB, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP E, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEHE MJ, 1987, BIOCHEMISTRY-US, V26, P7870, DOI 10.1021/bi00398a050; BELOTSERKOVSKII BP, 1992, NUCLEIC ACIDS RES, V20, P1903, DOI 10.1093/nar/20.8.1903; BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DICKSON KR, 1989, GENE, V84, P197, DOI 10.1016/0378-1119(89)90156-X; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GEE JE, 1992, J BIOL CHEM, V267, P11163; GORDON CN, 1968, BIOCHIM BIOPHYS ACTA, V155, P305, DOI 10.1016/0005-2787(68)90363-8; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KANG S, 1992, J BIOL CHEM, V267, P20887; KLYSIK J, 1992, J BIOL CHEM, V267, P17430; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOLLER T, 1974, BIOPOLYMERS, V13, P995, DOI 10.1002/bip.1974.360130514; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MURCHIE AIH, 1987, NUCLEIC ACIDS RES, V15, P9641, DOI 10.1093/nar/15.23.9641; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; PILCH DS, 1990, NUCLEIC ACIDS RES, V18, P5743, DOI 10.1093/nar/18.19.5743; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; STAVNEZER J, 1991, NATURE, V351, P447, DOI 10.1038/351447b0; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	43	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1791	1797		10.1074/jbc.270.4.1791	http://dx.doi.org/10.1074/jbc.270.4.1791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829515	hybrid			2022-12-25	WOS:A1995QD20400049
J	JARVIS, JA; RYAN, MT; HOOGENRAAD, NJ; CRAIK, DJ; HOJ, PB				JARVIS, JA; RYAN, MT; HOOGENRAAD, NJ; CRAIK, DJ; HOJ, PB			SOLUTION STRUCTURE OF THE ACETYLATED AND NONCLEAVABLE MITOCHONDRIAL TARGETING SIGNAL OF RAT CHAPERONIN-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTERPROTON DISTANCE RESTRAINTS; PROTEIN SECONDARY STRUCTURE; ALDEHYDE DEHYDROGENASE; LIVER MITOCHONDRIA; NMR-SPECTROSCOPY; CHEMICAL-SHIFT; BETA-SUBUNIT; HELIX DIPOLE; AMINO-ACIDS	Chaperonin 10 (Cpn10) is one of only a few mitochondrial matrix proteins synthesized without a cleavable targeting signal. Using a truncated form of Cpn10 and synthetic peptides in mitochondrial import assays, we show that the N-terminal region is both necessary and sufficient for organellar targeting in vitro. To elucidate the structural features of this topogenic signal, peptides representing residues 1-25 of rat Cpn10 were synthesized with and without the naturally occurring N-terminal acetylation, H-1 NMR spectroscopy in 20% CF3CH2OH, H2O showed that both peptides assume a stable helix-turn-helix moth and are highly amphiphilic in nature, Chemical shift and coupling constant data revealed that the N-terminal helix is stabilized by N-acetylation, whereas NOE and exchange studies were used to derive a three dimensional structure for the acetylated peptide. These findings are discussed with respect to a recent model predicting that targeting sequences forming a continuous alpha-helix of more than 11 residues cannot adopt a conformation necessary for proteolysis by the matrix located signal peptidases (Hammen, P. K., Gorenstein, D. G., and Weiner, H, (1994) Biochemistry 33, 8610-8617).	LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; MONASH UNIV,SCH PHARMACEUT CHEM,PARKVILLE,VIC 3052,AUSTRALIA	La Trobe University; Monash University			Ryan, Michael/X-2152-2019; Ryan, Michael T/C-6673-2011; Hoj, Peter B/E-8526-2011; Craik, David/B-1695-2010; Hoogenraad, Nicholas J/C-7505-2011	Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; Craik, David/0000-0003-0007-6796; 				AMAYA Y, 1988, J BIOL CHEM, V263, P14463; ARAKAWA H, 1990, J BIOCHEM-TOKYO, V107, P160, DOI 10.1093/oxfordjournals.jbchem.a123001; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN JL, 1976, J BIOL CHEM, V251, P1009; BRUCH MD, 1992, BIOCHIM BIOPHYS ACTA, V1159, P81, DOI 10.1016/0167-4838(92)90078-R; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ENDO T, 1989, J BIOCHEM, V106, P396, DOI 10.1093/oxfordjournals.jbchem.a122864; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOYT DW, 1991, J BIOL CHEM, V266, P21693; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LINGELBACH KR, 1986, EUR J BIOCHEM, V161, P19, DOI 10.1111/j.1432-1033.1986.tb10119.x; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MATSUSHITA Y, 1993, EUR J BIOCHEM, V214, P577, DOI 10.1111/j.1432-1033.1993.tb17956.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PAK YK, 1990, J BIOL CHEM, V265, P14298; PERALTA D, 1993, EUR J BIOCHEM, V211, P881, DOI 10.1111/j.1432-1033.1993.tb17621.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD AG, 1975, J MAGN RESON, V19, P250, DOI 10.1016/0022-2364(75)90073-6; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; RYAN MT, 1994, FEBS LETT, V337, P152, DOI 10.1016/0014-5793(94)80263-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; THORNTON K, 1993, J BIOL CHEM, V268, P19906; VENKATACHALAPATHI, 1993, PROTEINS, V15, P349; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WANG Y, 1993, J BIOL CHEM, V268, P4759; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZARDENETA G, 1992, J BIOL CHEM, V267, P24193	49	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1323	1331		10.1074/jbc.270.3.1323	http://dx.doi.org/10.1074/jbc.270.3.1323			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836398	hybrid			2022-12-25	WOS:A1995QB15600053
J	CHANG, MS; MCNINCH, J; BASU, R; SHUTTER, J; HSU, RY; PERKINS, C; MAR, V; SUGGS, S; WELCHER, A; LI, L; LU, H; BARTLEY, T; HUNT, P; MARTIN, F; SAMAL, B; BOGENBERGER, J				CHANG, MS; MCNINCH, J; BASU, R; SHUTTER, J; HSU, RY; PERKINS, C; MAR, V; SUGGS, S; WELCHER, A; LI, L; LU, H; BARTLEY, T; HUNT, P; MARTIN, F; SAMAL, B; BOGENBERGER, J			CLONING AND CHARACTERIZATION OF THE HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (MGDF) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACUTE NONLYMPHOCYTIC LEUKEMIA; PROMOTER REGION; CHROMOSOME-3; SEQUENCE; ENCODES	The megakaryocyte growth and development factor (MGDF) is a cytokine that regulates megakaryocyte development and is a ligand for the MPL receptor, In this study, we describe the genomic structure of the human MGDF gene. The MGDF gene was found to consist of seven exons and six introns spanning 8 kilobases. The protein is encoded by exons 3 through 7. The human MGDF gene has been mapped to chromosome 3q26.3. In addition to the previously described full-length cDNA, two cDNA variants were isolated from human fetal liver. Comparison of these two cDNA sequences with the genomic sequence indicates that they arise by differential splicing.			CHANG, MS (corresponding author), AMGEN INC, DEPT DEV BIOL, 14-1-B-219, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.		Samal, Babru/ABE-5931-2020; Samal, Babru B/C-5563-2008					BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BERNSTEIN R, 1982, BLOOD, V60, P613; CHANG MS, 1994, BLOOD, V83, P3199; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; HALLETT JM, 1989, BRIT J HAEMATOL, V71, P291, DOI 10.1111/j.1365-2141.1989.tb04269.x; HANNINK M, 1990, ONCOGENE, V5, P1843; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JORCYK CL, 1991, ONCOGENE, V6, P523; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MAZUR E, 1985, EXP HEMATOL, V13, P1165; MCDONALD TP, 1975, BIOCHEM MED METAB B, V13, P101, DOI 10.1016/0006-2944(75)90145-3; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; ODELL TT, 1961, P SOC EXP BIOL MED, V108, P428; OGATA K, 1990, INT J CELL CLONING, V8, P103, DOI 10.1002/stem.5530080710; PINTADO T, 1985, CANCER, V55, P535, DOI 10.1002/1097-0142(19850201)55:3<535::AID-CNCR2820550311>3.0.CO;2-4; ROWLEY JD, 1976, BLOOD, V47, P705	21	84	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					511	514		10.1074/jbc.270.2.511	http://dx.doi.org/10.1074/jbc.270.2.511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822271	hybrid			2022-12-25	WOS:A1995QB81600003
J	DANIELSEN, E; BAUER, R; HEMMINGSEN, L; ANDERSEN, ML; BJERRUM, MJ; BUTZ, T; TROGER, W; CANTERS, GW; HOITINK, CWG; KARLSSON, G; HANSSON, O; MESSERSCHMIDT, A				DANIELSEN, E; BAUER, R; HEMMINGSEN, L; ANDERSEN, ML; BJERRUM, MJ; BUTZ, T; TROGER, W; CANTERS, GW; HOITINK, CWG; KARLSSON, G; HANSSON, O; MESSERSCHMIDT, A			STRUCTURE OF METAL SITE IN AZURIN, MET(121) MUTANTS OF AZURIN, AND STELLACYANIN INVESTIGATED BY CD-111M PERTURBED-ANGULAR-CORRELATION (PAC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-QUADRUPOLE INTERACTION; BLUE COPPER PROTEINS; PSEUDOMONAS-AERUGINOSA; COORDINATION GEOMETRY; CORRELATION SPECTROSCOPY; CRYSTAL-STRUCTURE; CADMIUM; MODEL; REDUCTION; COMPLEXES	The geometries of the metal sites in cadmium-substituted azurins have been investigated by Cd-111m perturbed angular correlation (PAC), The study includes wild type azurin as well as Met(121) mutants of azurin, where methionine has been substituted by Ala, Asn, Asp, Gin, Glu, and Leu. The nuclear quadrupole interaction of wild type azurin analyzed in the angular overlap model is well described as coordination of His(46), His(117), and Cys(112) and cannot be described by coordination of Met(121) and/or Gly(45). For most of the mutants, there exist two coordination geometries of the cadmium ion, With the exception of the Gau and Asp mutants, one of the conformations is similar to the wild type conformation. The other coordination geometries are either best described by a coordinating water molecule close to the original methionine position or by coordination by the substituting amino acid, These experiments show that even though the methionine does not coordinate it plays an important role for the geometry of the metal site. The nuclear quadrupole interaction of stellacyanin was also measured, The value resembles the most prominent nuclear quadrupole interaction of the Met(121) --> Gin mutant of Alcaligenes denitrificans azurin, indicating that the structures of the two metal sites are similar.	ROYAL VET & AGR UNIV,DEPT CHEM,DK-1871 FREDERIKSBERG C,DENMARK; UNIV LEIPZIG,FAC PHYS & GEOSCI,O-7010 LEIPZIG,GERMANY; LEIDEN UNIV,LEIDEN INST CHEM,2300 RA LEIDEN,NETHERLANDS; CHALMERS UNIV TECHNOL,S-41390 GOTHENBURG,SWEDEN; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	University of Copenhagen; Leipzig University; Leiden University; Leiden University - Excl LUMC; Chalmers University of Technology; Max Planck Society	DANIELSEN, E (corresponding author), ROYAL VET & AGR UNIV,DEPT MATH & PHYS,THORVALDSENSVEJ 40,DK-1871 FREDERIKSBERG C,DENMARK.		Hansson, Orjan/D-1282-2009; Hemmingsen, Lars/A-6780-2015; Messerschmidt, Albrecht/A-8337-2008; Hemmingsen, Lars/AAD-1318-2020; Karlsson, Göran/E-8686-2011	Hemmingsen, Lars/0000-0002-1823-3035; Hemmingsen, Lars/0000-0002-1823-3035; 				ADMAN ET, 1978, J MOL BIOL, V123, P35, DOI 10.1016/0022-2836(78)90375-3; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BAUER R, 1991, ACTA CHEM SCAND, V45, P593, DOI 10.3891/acta.chem.scand.45-0593; BAUER R, 1979, J CHEM PHYS, V70, P4117, DOI 10.1063/1.438036; BAUER R, 1991, EUR BIOPHYS J, V20, P215, DOI 10.1007/BF00183458; BAUER R, 1988, HYPERFINE INTERACT, V39, P203, DOI 10.1007/BF02394319; BAUER R, 1985, Q REV BIOPHYS, V18, P1, DOI 10.1017/S0033583500004972; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P315; BUTZ T, 1989, NUCL INSTRUM METH A, V284, P417, DOI 10.1016/0168-9002(89)90311-2; Cantor CR, 1980, BIOPHYSICAL CHEM 2, P461; DANIELSEN E, 1992, HYPERFINE INTERACT, V62, P311; FIELDS BA, 1991, J MOL BIOL, V222, P1053, DOI 10.1016/0022-2836(91)90593-U; FRAUENFELDER H, 1965, ALPHA BETA GAMMA RAY, V2, P97; Gray H. B., 1983, COMMENTS INORG CHEM, V2, P203; GRUFF ES, 1990, J AM CHEM SOC, V112, P1245, DOI 10.1021/ja00159a054; HAAS H, 1973, J CHEM PHYS, V58, P3339, DOI 10.1063/1.1679661; KARLSSON BG, 1989, FEBS LETT, V253, P99, DOI 10.1016/0014-5793(89)80938-X; KARLSSON BG, 1991, PROTEIN ENG, V4, P343, DOI 10.1093/protein/4.3.343; KARLSSON G, 1993, THESIS CHALMERS U TE; LOWERY MD, 1992, INORG CHIM ACTA, V200, P233; MURATA M, 1982, P NATL ACAD SCI-BIOL, V79, P6434, DOI 10.1073/pnas.79.21.6434; MURPHY LM, 1993, BIOCHEMISTRY-US, V32, P1965, DOI 10.1021/bi00059a013; NAR H, 1992, EUR J BIOCHEM, V205, P1123, DOI 10.1111/j.1432-1033.1992.tb16881.x; NAR H, 1991, J MOL BIOL, V221, P765, DOI 10.1016/0022-2836(91)80173-R; NAR H, 1992, THESIS TU MUNICH; PASCHER T, 1993, EUR J BIOCHEM, V212, P289, DOI 10.1111/j.1432-1033.1993.tb17661.x; REINHAMM.B, 1970, BIOCHIM BIOPHYS ACTA, V205, P35, DOI 10.1016/0005-2728(70)90059-9; ROMERO A, 1993, J MOL BIOL, V229, P1007, DOI 10.1006/jmbi.1993.1101; SANTOS RA, 1991, J AM CHEM SOC, V113, P469, DOI 10.1021/ja00002a014; SHEPARD WEB, 1990, J AM CHEM SOC, V112, P7817, DOI 10.1021/ja00177a065; VITTAL JJ, 1993, INORG CHEM, V32, P791, DOI 10.1021/ic00058a007; WHITLOW SH, 1975, ACTA CRYSTALLOGR B, V31, P2531, DOI 10.1107/S0567740875008035	33	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					573	580		10.1074/jbc.270.2.573	http://dx.doi.org/10.1074/jbc.270.2.573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822282	hybrid			2022-12-25	WOS:A1995QB81600014
J	SHAPIRO, MJ; PANOMITROS, D; KOSHLAND, DE				SHAPIRO, MJ; PANOMITROS, D; KOSHLAND, DE			INTERACTIONS BETWEEN THE METHYLATION SITES OF THE ESCHERICHIA-COLI ASPARTATE RECEPTOR-MEDIATED BY THE METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIERARCHICAL PROTEIN-PHOSPHORYLATION; ACCEPTING CHEMOTAXIS PROTEINS; BACTERIAL SENSING SYSTEM; SENSORY TRANSDUCTION; GENE-PRODUCT; ADAPTATION; IDENTIFICATION; METHYLESTERASE; ESTERIFICATION	Mutations made at and near the methylation sites of the Escherichia coli aspartate receptor were found to affect the methylation rates of the remaining methylation sites. The results supported a model in which the methyltransferase enzyme contacts a residue seven amino acids to the C terminus of a site being methylated. The presence of a negatively charged residue at that position inhibits methylation, whereas a neutral residue has no effect. Methylation sites in the wild type receptor may also influence the methylation of other sites which are 7 residues away through a physical contact with the methyltransferase.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARKE S, 1979, J BIOL CHEM, V254, P9695; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KEHRY MR, 1982, J BIOL CHEM, V257, P378; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; NOWLIN DM, 1988, PROTEINS, V3, P102, DOI 10.1002/prot.340030205; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SHAPIRO MJ, 1994, J BIOL CHEM, V269, P11054; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; TERWILLIGER TC, 1986, P NATL ACAD SCI USA, V83, P6707, DOI 10.1073/pnas.83.18.6707; TERWILLIGER TC, 1983, J BIOL CHEM, V258, P9608; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; WANG EA, 1980, P NATL ACAD SCI-BIOL, V77, P7157, DOI 10.1073/pnas.77.12.7157; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987	24	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					751	755		10.1074/jbc.270.2.751	http://dx.doi.org/10.1074/jbc.270.2.751			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822306	hybrid			2022-12-25	WOS:A1995QB81600040
J	SMERZBERTLING, C; DUSCHL, A				SMERZBERTLING, C; DUSCHL, A			BOTH INTERLEUKIN-4 AND INTERLEUKIN-13 INDUCE TYROSINE PHOSPHORYLATION OF THE 140-KDA SUBUNIT OF THE INTERLEUKIN-4 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GAMMA-CHAIN; IL-2 RECEPTOR; CELL-LINE; PROLIFERATIVE ACTIVITY; FUNCTIONAL COMPONENT; HEMATOPOIETIC-CELLS; B-CELLS; PROTEIN; BINDING	We have investigated tyrosine phosphorylation of cellular proteins induced by interleukin (IL) 4 and compared it with the effects of three related cytokines, IL-2, IL-7, and IL-13. We show here that both IL-4 and IL-13 stimulate tyrosine phosphorylation of the 140-kDa IL-4 receptor subunit, which suggests that this receptor protein is used by both cytokines. Receptor phosphorylation induced by IL-13 was both weaker and slower than with IL-4. Stimulation of cells with IL-2 and IL-7 induced identical phosphorylation patterns to each other but not phosphorylation of the 140-kDa IL-4 receptor subunit. The only signal appearing upon stimulation with any of the four cytokines was the weak phosphorylation of an unidentified protein of 160 kDa. SH2 domains of p56(lck) and p59(fyn) precipitated the same proteins as anti-phosphotyrosine antibodies after IL-4 stimulation, which suggests that a src-type kinase may be involved in signal transduction through the IL-4 receptor.	THEODOR BOVERI INST BIOWISSENSCH, D-97074 WURZBURG, GERMANY				Duschl, Albert/E-5872-2011	Duschl, Albert/0000-0002-7034-9860				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Duschl A, 1992, Eur Cytokine Netw, V3, P97; GATELY MK, 1991, J IMMUNOL, V147, P874; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IZUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992, DOI 10.1006/bbrc.1993.1147; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KEEGAN AD, 1994, J LEUKOCYTE BIOL, V55, P272, DOI 10.1002/jlb.55.2.272; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KOHLER I, 1994, EUR J IMMUNOL, V345, P187; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PAUL WE, 1991, BLOOD, V77, P1859; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; RUFFJAMISON S, 1993, J IMMUNOL, V150, P3389; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	56	122	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					966	970		10.1074/jbc.270.2.966	http://dx.doi.org/10.1074/jbc.270.2.966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822337	hybrid			2022-12-25	WOS:A1995QB81600072
J	VOGT, A; QIAN, YM; BLASKOVICH, MA; FOSSUM, RD; HAMILTON, AD; SEBTI, SM				VOGT, A; QIAN, YM; BLASKOVICH, MA; FOSSUM, RD; HAMILTON, AD; SEBTI, SM			A NONPEPTIDE MIMETIC OF RAS-CAAX - SELECTIVE-INHIBITION OF FARNESYLTRANSFERASE AND RAS PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE INHIBITORS; MEMBRANE ASSOCIATION; P21RAS; FARNESYL; TRANSFORMATION; CELLS; PEPTIDOMIMETICS; TRANSFERASE; TERMINUS	Cysteine farnesylation of the carboxyl-terminal tetrapeptide CAAX (C = Cys, A = Leu, ne, or Val, X = Met or Ser) of the oncogene product Ras is required for its malignant transformation activity. As a consequence farnesyltransferase (FTase), the enzyme responsible for this lipid modification, has become one of the most sought-after targets for anticancer drug development. We have recently designed peptide mimics of the COOH-terminal Cys-Val-Ile-Met of K-B-Ras where the dipeptide Val-ne was replaced by aminobenzoic acid derivatives. Although these peptidomimetics are potent inhibitors of FTase in vitro, they retain several undesirable peptide features that hamper their use in vivo. We report here the design, synthesis, and biological activity of the first non-peptide mimetics of CAAX where the tripeptide AAX was replaced by biphenyl derivatives, (R)-4-[N-(3-mercapto-2-aminopropyl)]amino-3'-carboxybiphenyl, where the cysteine is linked to the biphenyl derivative through a secondary amine, contains no amino acids, lacks peptidic features, and has no hydrolyzable bonds. This peptidomimetic is a potent inhibitor of FTase in vitro (IC50 = 50-150 nM) and disrupts Ras processing in whole cells. Furthermore, this non-peptide mimetic of CAAX is highly selective for FTase (666-fold) relative to the closely related geranylgeranyl-transferase I. This selectivity is also respected in vivo since the processing of has but not the geranylgeranylated Rap1A was disrupted in whole cells. Structure activity relationship studies revealed that FTase recognition and inhibitory potency of CAAX peptidomimetics require free thiol and carboxylate groups separated by a hydrophobic moiety, and that precise positioning of these functional groups must correspond to that of the parent CAAX. The true CAAX peptidomimetic described in this manuscript has several desirable features for further develop ment as a potential anticancer agent. It is not metabolically inactivated by FTase, does not require a prodrug strategy for inhibition in vivo, and is selective for farnesylation relative to geranylgeranylation.	UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NIGAM M, 1993, J BIOL CHEM, V268, P20695; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; QIAN YM, 1994, BIOORG MED CHEM LETT, V4, P2579, DOI 10.1016/S0960-894X(01)80287-0; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; WATANABE T, 1992, SYNLETT, V3, P207; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	34	110	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					660	664		10.1074/jbc.270.2.660	http://dx.doi.org/10.1074/jbc.270.2.660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822292	hybrid			2022-12-25	WOS:A1995QB81600026
J	BURKE, JR; GREGOR, KR; TRAMPOSCH, KM				BURKE, JR; GREGOR, KR; TRAMPOSCH, KM			MECHANISM OF INHIBITION OF HUMAN NONPANCREATIC SECRETED PHOSPHOLIPASE A(2) BY THE ANTIINFLAMMATORY AGENT BMS-181162	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHRITIC SYNOVIAL-FLUID; INTERFACIAL CATALYSIS; COMPETITIVE INHIBITORS; SCOOTING MODE; EXTRACELLULAR PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; ANTIINFLAMMATORY ACTIVITY; SUBSTRATE SPECIFICITIES; KINETIC-ANALYSIS; VESICLES	Many important mediators of inflammation result from the liberation of free arachidonic acid from phospholipid pools which is thought to result from the action of phospholipase A(2) (PLA(2)), It is believed, therefore, that the inhibition of PLA(2) would be an important treatment in many inflammatory disease states, The anti-inflammatory agent BMS-181162 (4-(3'-carboxyphenyl)-3,7-dimethyl-9-(2'',6'',6''-trimethyl-1''-cyclohexenyl)-2Z,4E,6E,8E-nonatetraenoic acid) selectively inhibits PLA(2) and has been shown to block arachidonic acid release in whole cells, The mechanism of inhibition of human nonpancreatic-secreted PLA(2) by BMS-181162 is investigated in this paper, A scooting mode assay in which the enzyme is irreversibly bound to vesicles of 1,2-dimyristoyl-sn-glycero-3-phosphomethanol containing 5 mol % of 1-palmitoyl-2-[1-C-14]arachidonoyl-sn-glycero-3-phosphocholine, was used to characterize the inhibition, With this assay system, BMS-181162 inhibited the enzyme in a dose-dependent manner, Compounds which inhibit in the scooting mode have been shown to be competitive inhibitors in the interface (Gelb, M, H., Berg, O., and Jain, M, K, (1991) Curr. Op, Struct, Biol, 1, 836-843), This was verified by demonstrating that the inhibition was not due to the desorption of the enzyme from the lipid-water interface, Additionally, the compound did not measurably affect the rate of association onto the vesicles, Therefore, the inhibition was not the result of a modulation of the bilayer morphology nor an interaction with the interfacial binding site on the enzyme, The degree of inhibition was dependent on the reaction volume which indicates that the inhibitor is only partially partitioned into the bilayer, After compensating for this partitioning, the dose-dependent inhibition could be defined by kinetic equations describing competitive inhibition at the interface, The equilibrium dissociation constant for the inhibitor bound to the enzyme at the interface (K-I*) was determined to be 0.013 mol fraction, thus demonstrating that BMS-181162 represents a novel structural class of tight-binding competitive inhibitors of human nonpancreatic secreted PLA(2). Using Escherichia coli membranes as substrate, to which the enzyme binds to the interface reversibly, the inhibition showed a nonclassical kinetic pattern which is also consistent with a partial partitioning of the inhibitor into the bilayer, This was verified by a direct measurement of the amount of inhibitor remaining in solution, The implications for in vivo efficacy which result from this mechanism are discussed.			BURKE, JR (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, DERMATOL DISCOVERY RES, 100 FOREST AVE, BUFFALO, NY 14213 USA.							BASSOLINOKLIMAS D, 1993, BIOCHEMISTRY-US, V32, P12624, DOI 10.1021/bi00210a010; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; CROWL R, 1990, ADV EXP MED BIOL, V279, P173; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; DIEZ E, 1992, J BIOL CHEM, V267, P18342; GELB MH, 1992, BIOORG MED CHEM LETT, V2, P1335, DOI 10.1016/S0960-894X(00)80508-9; Gelb MH, 1991, CURR OPIN STRUC BIOL, V1, P836, DOI 10.1016/0959-440X(91)90187-X; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; Jain M K, 1992, Mediators Inflamm, V1, P85, DOI 10.1155/S0962935192000164; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P11319, DOI 10.1021/bi00093a008; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1985, BIOCHIM BIOPHYS ACTA, V814, P319, DOI 10.1016/0005-2736(85)90451-1; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LEMAHIEU RA, 1993, J MED CHEM, V36, P3029, DOI 10.1021/jm00072a025; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; RAGHUPATHI R, 1987, FASEB J, V46, P1945; RECKLIES AD, 1991, ARTHRITIS RHEUM, V34, P1106, DOI 10.1002/art.1780340906; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCRUTTON MC, 1965, J BIOL CHEM, V240, P3714; Segel I. H., 1975, ENZYME KINETICS, pxxii; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STEFANSKI E, 1986, J BIOCHEM-TOKYO, V100, P1297, DOI 10.1093/oxfordjournals.jbchem.a121836; TRAMPOSCH KM, 1992, BIOCHEM BIOPH RES CO, V189, P272, DOI 10.1016/0006-291X(92)91554-4; TRAMPOSCH KM, 1994, IN PRESS J PHARM EXP; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1988, AGENTS ACTIONS, V24, P320, DOI 10.1007/BF02028289; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WONG PYK, 1990, ADV EXP MED BIOL, V275; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024	41	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					274	280		10.1074/jbc.270.1.274	http://dx.doi.org/10.1074/jbc.270.1.274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814386	hybrid			2022-12-25	WOS:A1995QA28700044
J	DUSTIN, ML; BARANSKI, TJ; SAMPATH, D; KORNFELD, S				DUSTIN, ML; BARANSKI, TJ; SAMPATH, D; KORNFELD, S			A NOVEL MUTAGENESIS STRATEGY IDENTIFIES DISTANTLY SPACED AMINO-ACID-SEQUENCES THAT ARE REQUIRED FOR THE PHOSPHORYLATION OF BOTH THE OLIGOSACCHARIDES OF PROCATHEPSIN-D BY N-ACETYLGLUCOSAMINE 1-PHOSPHOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; PROTEIN RECOGNITION DETERMINANTS; HUMAN CATHEPSIN-D; CRYSTAL-STRUCTURES; TARGETING SIGNAL; RECEPTOR; BINDING; CELLS; CDNA; GLYCOPROTEINS	A novel combinatorial mutagenesis strategy (shuffle mutagenesis) was developed to identify sequences in the propiece and amino lobe of cathepsin D which direct oligosaccharide phosphorylation by UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine l-phosphotransferase. Propiece restriction fragments and oligonucleotide cassettes corresponding to 13 regions of the cathepsin D and glyco pepsinogen amino lobes were randomly shuffled together to generate a large library of chimeric molecules, The library was inserted into an expression vector encoding the carboxyl lobe of cathepsin D with a carboxyl-terminal myc epitope and a CD8 transmembrane extension. Transfected COS1 cells expressing the membrane-anchored forms of the cathepsin D/glycopepsinogen chimeras at the cell surface were selected with solid phase mannose 6-phosphate receptor or an antibody to the myc epitope, Plasmids were rescued in Escherichia coli and sequenced by hybridization to the original oligonucleotide cassettes. Two regions of the cathepsin D amino lobe (segments 7 and 12) were found to contribute to proper folding, surface expression, and selective phosphorylation of the carboxyl lobe oligosaccharide. Two different cathepsin D regions (the propiece and segment 5) cooperated with a previously identified recognition element in the carboxyl lobe to allow efficient phosphorylation of both the amino and carboxyl lobe oligosaccharides. Three general models for extending the catalytic reach of N-acetylglucosamine l-phosphotransferase to widely spaced oligosaccharides are presented.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL)			Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389	NCI NIH HHS [CA 08759] Funding Source: Medline; NIGMS NIH HHS [GM-07200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARTSUCK JA, 1992, PROTEINS, V13, P1, DOI 10.1002/prot.340130102; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MANIATIS T, 1987, MOL CLONING; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Montreuil J, 1980, Adv Carbohydr Chem Biochem, V37, P157; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; POSNER RG, 1992, BIOCHEMISTRY-US, V31, P5350, DOI 10.1021/bi00138a015; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; SALI A, 1992, PROTEINS, V12, P158, DOI 10.1002/prot.340120209; VARKI A, 1983, J BIOL CHEM, V258, P2808; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167	29	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					170	179		10.1074/jbc.270.1.170	http://dx.doi.org/10.1074/jbc.270.1.170			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814370	hybrid			2022-12-25	WOS:A1995QA28700030
J	KARNS, LR; KARIYA, K; SIMPSON, PC				KARNS, LR; KARIYA, K; SIMPSON, PC			M-CAT, CARG, AND SP1 ELEMENTS ARE REQUIRED FOR ALPHA(1)-ADRENERGIC INDUCTION OF THE SKELETAL ALPHA-ACTIN PROMOTER DURING CARDIAC MYOCYTE HYPERTROPHY - TRANSCRIPTIONAL ENHANCER FACTOR-I AND PROTEIN-KINASE-C AS CONSERVED TRANSDUCERS OF THE FETAL PROGRAM IN CARDIAC GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; HEAVY-CHAIN GENE; RAT-HEART MYOCYTES; TROPONIN-T-GENE; BINDING-FACTOR; MUSCLE-CELLS; STIMULATED HYPERTROPHY; PRESSURE-OVERLOAD; MYOCARDIAL-CELLS; MESSENGER-RNAS	Induction of the fetal isogenes skeletal alpha-actin (skACT) and beta-myosin heavy chain (beta-MHC) is characteristic of cardiac growth in many models, suggesting a conserved signaling pathway. However, divergent regulation has also been observed. beta-Protein kinase C (PKC) and transcriptional enhancer factor-1 (TEF-1) are involved in induction of beta-MHC in alpha(1)-adrenergic stimulated hypertrophy of cultured cardiac myocytes (Kariya, K., Farrance, I. K. G., and Simpson, P. C. (1993) J. Biol. Chem. 268, 26658-26662; Kariya, K., Karns, L. R., and Simpson, P. C. (1994) J. Biol. Chem. 269, 3775-3782). In the present study, we asked whether the skACT promoter used the same mechanism. A mouse skACT promoter fragment (-113/-46) was induced by both alpha(1)-adrenergic stimulation and co-transfection of activated beta-PKC, and contained three required DNA sequence elements: M-CAT, CArG, and Sp1. The skACT M-CAT element bound TEF-1 in cardiac myocytes. Thus the skACT and beta-MHC promoters both require a TEF-1 binding site for activation by alpha(1)-adrenerse stimulation, but differ in that skACT also requires a CArG box. These results provide a potential molecular basis for divergent regulation of the fetal program, and also imply that PKC and TEF-1 are conserved transducers for this program during cardiac growth.	VET AFFAIRS MED CTR, DIV CARDIOL, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, RES SERV, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031113] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL031113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAGI T, 1993, J BIOL CHEM, V268, P27176; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; ASANTE EA, 1994, TRANSGENIC RES, V3, P59, DOI 10.1007/BF01976028; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CARRIER L, 1992, CIRC RES, V70, P999, DOI 10.1161/01.RES.70.5.999; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; DELEON JR, 1994, P NATL ACAD SCI USA, V91, P519, DOI 10.1073/pnas.91.2.519; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARIYA K, 1994, CIRCULATION, V90, P580; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; RINDT H, 1993, J BIOL CHEM, V268, P5332; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHWARTZ K, 1993, J AM COLL CARDIOL, V22, pA30, DOI 10.1016/0735-1097(93)90459-E; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; SOULEZ M, 1993, BIOCHEM BIOPH RES CO, V195, P400, DOI 10.1006/bbrc.1993.2057; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VONHARSDORF R, 1993, CIRC RES, V72, P688, DOI 10.1161/01.RES.72.3.688; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	58	159	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					410	417		10.1074/jbc.270.1.410	http://dx.doi.org/10.1074/jbc.270.1.410			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814403	hybrid			2022-12-25	WOS:A1995QA28700065
J	TOLSTRUP, AB; BEJDER, A; FLECKNER, J; JUSTESEN, J				TOLSTRUP, AB; BEJDER, A; FLECKNER, J; JUSTESEN, J			TRANSCRIPTIONAL REGULATION OF THE INTERFERON-GAMMA-INDUCIBLE TRYPTOPHANYL-TRANSFER-RNA SYNTHETASE INCLUDES ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; CHAIN-RELEASE FACTOR; SIGNAL-TRANSDUCTION PATHWAY; DNA-BINDING PROTEINS; MUTANT-CELL LINE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; GENE-EXPRESSION; GROWTH-FACTOR; INDOLEAMINE 2,3-DIOXYGENASE	We have investigated the transcriptional control elements of the human interferon (IFN)-gamma-induced tryptophanyl-tRNA synthetase (hWRS) gene and characterized the transcripts. Transcription leads to a series of mRNAs with different combinations of the first exons. The full-length mRNA codes for a 55-kDa protein (hWRS), but a mRNA lacking exon II is present in almost as high amounts as the full-length transcript. This alternatively spliced mRNA is probably translated into a 48-kDa protein starting from Met(48) in exon III. The predicted 48-kDa protein corresponds exactly to an IFN-gamma-inducible protein previously detected by two-dimensional gel electrophoresis. By isolation of genomic clones and construction of plasmids containing hWRS promoter fragments fused to the secreted alkaline phosphatase reporter gene we have mapped a promoter region essential for IFN-mediated gene activation. This region contains IFN stimulated response elements (ISRE) as well as a Y-box and a gamma-activated sequence (GAS) element. IFN-gamma inducibility of hWRS depends on ongoing protein synthesis, suggesting that so far undescribed scribed transcription factors apart from the latent GAS-binding protein p91 contribute to gene activation. This could be interferon-regulatory factor-1, which binds ISRE elements.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK	Aarhus University								Baron S, 1992, INTERFERON PRINCIPLE; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; CELIS JE, 1987, LEUKEMIA, V12, P800; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEMAEYER E, 1991, CYTOKINE HDB, P215; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLECKNER J, 1995, IN PRESS CYTOKINE, V7; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; FROLOVA LY, 1993, GENE, V128, P237, DOI 10.1016/0378-1119(93)90568-N; FROLOVA LY, 1993, EMBO J, V12, P4013; FROLOVA LY, 1993, EUR J BIOCHEM, V212, P457, DOI 10.1111/j.1432-1033.1993.tb17682.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GUPTA SL, 1992, INTERFERON PRINCIPLE, P193; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KISSELEV L, 1993, TRENDS BIOCHEM SCI, V18, P263, DOI 10.1016/0968-0004(93)90178-P; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE CC, 1990, P NATL ACAD SCI USA, V87, P3508, DOI 10.1073/pnas.87.9.3508; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OZES ON, 1994, J INTERFERON RES, V14, P25, DOI 10.1089/jir.1994.14.25; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	57	94	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					397	403		10.1074/jbc.270.1.397	http://dx.doi.org/10.1074/jbc.270.1.397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814400	hybrid			2022-12-25	WOS:A1995QA28700063
J	CAMADRO, JM; THOME, F; BROUILLET, N; LABBE, P				CAMADRO, JM; THOME, F; BROUILLET, N; LABBE, P			PURIFICATION AND PROPERTIES OF PROTOPROPHYRINOGEN OXIDASE FROM THE YEAST SACCHAROMYCES-CEREVISIAE - MITOCHONDRIAL LOCATION AND EVIDENCE FOR A PRECURSOR FORM OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHENYL ETHER HERBICIDES; MURINE PROTOPORPHYRINOGEN OXIDASE; MICROBIAL HEME SYNTHESIS; COPROPORPHYRINOGEN OXIDASE; ACIFLUORFEN-METHYL; LATE STEP; CELLULAR-LOCALIZATION; DESULFOVIBRIO-GIGAS; ENZYMIC CONVERSION; BARLEY ORGANELLES	Protoporphyrinogen oxidase, the molecular target of diphenylether-type herbicides, was purified to homogeneity from yeast mitochondrial membranes and found to be a 55-kDa polypeptide with a pI of 8.5 and a specific activity of 40,000 nmol of protoporphyrin/h/mg of protein at 30 degrees C. The Michaelis constant (K-m) for protoporphyrinogen IX was 0.1 mu M. Due to the high affinity of the enzyme toward oxygen, the K-m for oxygen could only be approximated to 0.5-1.5 mu M. The purified enzyme contained a flavin as cofactor. Studies with rabbit antibodies to yeast protoporphyrinogen oxidase showed that the enzyme is synthesized as a high molecular weight precursor (58 kDa) that is rapidly converted in vivo to the mature (55 kDa) membrane bound form. Protoporphyrinogen oxidase activity was found only in purified yeast mitochondrial inner membrane (not in the outer membrane). Acifluorfen-methyl, a potent diphenylethertype herbicide, competitively inhibited the purified enzyme (K-i = 10 nM), The mixed inhibition by acifluorfenmethyl previously reported for the membrane-bound protoporphyrinogen oxidase (Camadro, J. M., Matringe, M., Scalla, R., and Labbe, P. (1991) Biochem. J. 277, 17-21) was shown to be related to partial proteolysis of the enzyme.			CAMADRO, JM (corresponding author), INST JACQUES MONOD, DEPT MICROBIOL, BIOCHIM PORPHYRINES LAB, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.			Camadro, Jean-Michel/0000-0002-8549-2707				AKAGI T, 1993, Z NATURFORSCH C, V48, P345; CAMADRO JM, 1985, ARCH BIOCHEM BIOPHYS, V242, P206, DOI 10.1016/0003-9861(85)90494-1; CAMADRO JM, 1991, BIOCHEM J, V277, P17, DOI 10.1042/bj2770017; CAMADRO JM, 1982, BIOCHEM BIOPH RES CO, V106, P724, DOI 10.1016/0006-291X(82)91771-5; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; CERLETTI P., 1971, Methods in Enzymology, V18B, P285, DOI 10.1016/S0076-6879(71)18090-1; DAILEY HA, 1987, BIOCHEMISTRY-US, V26, P2697, DOI 10.1021/bi00384a007; DEYBACH JC, 1985, EUR J BIOCHEM, V149, P431, DOI 10.1111/j.1432-1033.1985.tb08943.x; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; ELDER GH, 1978, BIOCHEM J, V172, P345, DOI 10.1042/bj1720345; FALK JE, 1964, PORPHYRINS METALLOPO, V2, P162; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; HAID A, 1983, METHOD ENZYMOL, V96, P192; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1990, ARCH BIOCHEM BIOPHYS, V280, P369, DOI 10.1016/0003-9861(90)90344-X; JACOBS JM, 1991, PLANT PHYSIOL, V97, P197, DOI 10.1104/pp.97.1.197; JACOBS JM, 1977, BIOCHEM BIOPH RES CO, V78, P429, DOI 10.1016/0006-291X(77)91272-4; JACOBS NJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P540, DOI 10.1016/0304-4165(78)90328-8; JACOBS NJ, 1989, BIOCHEM BIOPH RES CO, V161, P790, DOI 10.1016/0006-291X(89)92669-7; JACOBS NJ, 1976, BIOCHIM BIOPHYS ACTA, V449, P1, DOI 10.1016/0005-2728(76)90002-5; JACOBS NJ, 1977, BIOCHIM BIOPHYS ACTA, V459, P141, DOI 10.1016/0005-2728(77)90017-2; JACOBS NJ, 1975, BIOCHEM BIOPH RES CO, V65, P435, DOI 10.1016/S0006-291X(75)80112-4; JONES C, 1984, J CHEM SOC PERK T 1, P2625, DOI 10.1039/p19840002625; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KLEMM DJ, 1985, J BACTERIOL, V164, P316, DOI 10.1128/JB.164.1.316-320.1985; KOZIOL J., 1971, Methods in Enzymology, V18B, P253, DOI 10.1016/S0076-6879(71)18089-5; KRIJT J, 1993, ARCH TOXICOL, V67, P255, DOI 10.1007/BF01974344; KRIJT J, 1992, PESTIC BIOCHEM PHYS, V42, P180, DOI 10.1016/0048-3575(92)90064-7; LABBE P, 1971, BIOCHIMIE, V53, P1001, DOI 10.1016/S0300-9084(71)80068-8; LABBE P, 1985, ANAL BIOCHEM, V149, P248, DOI 10.1016/0003-2697(85)90502-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HJ, 1993, PLANT PHYSIOL, V102, P881, DOI 10.1104/pp.102.3.881; LEHNEN LP, 1990, PESTIC BIOCHEM PHYS, V37, P239, DOI 10.1016/0048-3575(90)90130-T; LYDON J, 1988, PESTIC BIOCHEM PHYS, V31, P74, DOI 10.1016/0048-3575(88)90031-4; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MATRINGE M, 1987, P BR CROP PROT C B, V9, P981; MILLER MJ, 1979, P NATL ACAD SCI USA, V76, P5222, DOI 10.1073/pnas.76.10.5222; NANDIHALLI UB, 1992, PESTIC BIOCHEM PHYS, V43, P193, DOI 10.1016/0048-3575(92)90033-V; OHANIANCE L, 1966, BIOCHIM BIOPHYS ACTA, V128, P228, DOI 10.1016/0926-6593(66)90170-6; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; POULSON R, 1976, J BIOL CHEM, V251, P3730; POULSON R, 1975, J BIOL CHEM, V250, P1269; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; SANDMANN G, 1988, Z NATURFORSCH C, V43, P699; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; URBANGRIMAL D, 1981, MOL GEN GENET, V183, P85, DOI 10.1007/BF00270144; URBANGRIMAL D, 1986, EUR J BIOCHEM, V156, P511, DOI 10.1111/j.1432-1033.1986.tb09610.x; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WITKOWSKI DA, 1988, PLANT PHYSIOL, V87, P632, DOI 10.1104/pp.87.3.632; WITKOWSKI DA, 1989, PLANT PHYSIOL, V90, P1239, DOI 10.1104/pp.90.4.1239; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	60	53	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32085	32091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798202				2022-12-25	WOS:A1994PX30400014
J	CHARLESWORTH, A; ROZENGURT, E				CHARLESWORTH, A; ROZENGURT, E			THAPSIGARGIN AND DI-TERT-BUTYLHYDROQUINONE INDUCE SYNERGISTIC STIMULATION OF DNA-SYNTHESIS WITH PHORBOL ESTER AND BOMBESIN IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PASTEURELLA-MULTOCIDA TOXIN; INTRACELLULAR CA-2+ STORES; GROWTH-FACTOR; PLASMA-MEMBRANE; TUMOR PROMOTER; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; INOSITOL PHOSPHATE; MITOGENIC SIGNAL	The specific inhibitors of the endoplasmic reticulum Ca2+ pump, thapsigargin and 2,5-di-tert-butylhydroquinone (DBHQ), stimulated reinitiation of DNA synthesis in synergy with either phorbol 12,13-dibutyrate or bombesin in Swiss 3T3 cells. Maximum stimulation was achieved at 0.5 nM thapsigargin and 7.5 mu M DBHQ. Kinetics of [H-3]thymidine incorporation were consistent with exit from G(0) and entry into S phase. Autoradiography of labeled nuclei showed that the increase in [H-3]thymidine incorporation was due to an increase in the proportion of cells entering into DNA synthesis. Down-regulation or selective inhibition of protein kinase C abolished this synergistic stimulation of DNA synthesis. Thapsigargin and DBHQ and did not potentiate protein kinase C-mediated signals such as direct phosphorylation of myristoylated alanine-rich C-kinase substrate, activation of mitogen-activated protein kinase, and tyrosine phosphorylation of bands 110,000-130,000 and 70,000-80,000. Thapsigargin and DBHQ caused a marked reduction in the ability of bombesin to induce a rapid and transient increase in intracellular Ca2+ via depletion of total cellular Ca2+, measured by Ca-45(2+) content. The synergistic stimulation of DNA synthesis by DBHQ and phorbol 12,13-dibutyrate was dependent on a high concentration of extracellular Ca2+ (ED(50) = 410 mu M) and was preferentially inhibited by the inhibitor of Ca2+ influx econozole. This suggests a role for Ca2+ entry in growth control. This is the first time that either thapsigargin or DBHQ has been shown to stimulate the reinitiation of DNA synthesis in any target cell.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BREITTMAYER JP, 1993, CELL IMMUNOL, V152, P143, DOI 10.1006/cimm.1993.1274; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; DICKER P, 1978, NATURE, V276, P723, DOI 10.1038/276723a0; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARA F, 1985, BIOCHEM BIOPH RES CO, V130, P646, DOI 10.1016/0006-291X(85)90466-8; VOSTAL JG, 1993, BIOCHEM J, V295, P525, DOI 10.1042/bj2950525; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	59	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32528	32535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798254				2022-12-25	WOS:A1994PX30400076
J	FIOL, CJ; WILLIAMS, JS; CHOU, CH; WANG, QM; ROACH, PJ; ANDRISANI, OM				FIOL, CJ; WILLIAMS, JS; CHOU, CH; WANG, QM; ROACH, PJ; ANDRISANI, OM			A SECONDARY PHOSPHORYLATION OF CREB(341) AT SER(129) IS REQUIRED FOR THE CAMP-MEDIATED CONTROL OF GENE-EXPRESSION - A ROLE OF GLYCOGEN-SYNTHASE KINASE-3 IN THE CONTROL OF GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; RAT SOMATOSTATIN GENE; AMP RESPONSE ELEMENT; NUCLEAR-PROTEIN; FACTOR CREB; TRANSCRIPTION; PROMOTER; PEPTIDE; CELLS	The cAMP-dependent protein kinase (PKA) phosphorylates CREB(327/341) at a single serine residue, Ser(119/133), respectively, Phosphorylation at this site creates the sequence motif SXXXS(P), a consensus site of the glycogen synthase kinase-3 (GSK-3) enzyme (Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W., and Roach, P. J. (1987) J. Biol, Chem, 262, 14042-14048), We examined the phosphorylation of CREB at the SXXXS(P) consensus site and its role in CREB transactivation to cAMP induction, Neither isoform of the GSK-3 enzyme (GSK-3 alpha or beta) utilizes CREE as its substrate unless CREB is already phosphorylated at Ser(119/133). A 13-amino acid peptide containing the sequence surrounding Ser(119/133) was phosphorylated by GSK-3, at Ser(115/129), only after the primary phosphorylation of the peptide by PKA (at Ser(119/133)), suggesting that Ser(115/129) is a GSK-3 phosphoacceptor site, Mutant CREB(327/341) proteins containing Ser-->Ala substitutions confirmed Ser(115/129) as the only GSK-3 phosphorylation site, Transfection assays of wild type and mutant Gal4-CREB fusion proteins in PC12 cells demonstrated that Ser-->Ala substitution of residue 129 of CREB(341) impairs the transcriptional response to cAMP induction, Analogous mutation in CREB(327) results in 70% decrease in its transactivation response to cAMP. In undifferentiated F9 cells, which are refractory to cAMP induction, transfected GSK-3 beta kinase induces a 60-fold increase in cyclic AMP response element-dependent transcription, mediated via the endogenous CREB protein, We propose that the hierarchical phosphorylation at the PRA and GSK-3 sites of CREB are essential for cAMP control of CREB.	PURDUE UNIV,SCH VET MED,DEPT PHYSIOL & PHARMACOL,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis				Andrisani, Ourania/0000-0002-6230-0303	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK044533, R01DK027221, R29DK044533] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221, DK44533] Funding Source: Medline; PHS HHS [NTP1246] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MEEK DW, 1992, BIOCHEM J, V287, P1; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PARK IK, 1991, FASEB J, V5, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WANG QM, 1994, J BIOL CHEM, V269, P14566; WANG QM, 1994, ANAL BIOCHEM, V220, P397, DOI 10.1006/abio.1994.1356; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	35	248	252	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32187	32193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798217				2022-12-25	WOS:A1994PX30400029
J	HIASA, H; MARIANS, KJ				HIASA, H; MARIANS, KJ			TOPOISOMERASE-III, BUT NOT TOPOISOMERASE-I, CAN SUPPORT NASCENT CHAIN ELONGATION DURING THETA-TYPE DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PBR322 DNA; GYRASE; STRAND; DECATENATION; CHROMOSOME; ORIGIN	Topoisomerase III, but not topoisomerase I, could, in the absence of DNA gyrase, support bidirectional DNA replication in an oriC plasmid DNA replication system reconstituted with purified proteins. The initial rate of DNA synthesis and the efficiency of nascent chain elongation showed that topoisomerase III-stimulated DNA replication was as efficient as gyrase-stimulated DNA replication. In addition, topoisomerase III was also able, in the absence of DNA gyrase, to decatenate the replicating daughter DNA molecules to form monomer product. Thus, of the four topoisomerases in Escherichia coli, three, topoisomerases III and IV and DNA gyrase, can support nascent chain elongation, whereas only two, topoisomerases III and IV can topologically resolve the daughter molecules.			HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BOHK JJ, 1983, GENE, V24, P265; FILUTOWICZ M, 1982, MOL GEN GENET, V191, P282; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1994, J BIOL CHEM, V269, P2093; KATO J, 1992, J BIOL CHEM, V267, P25676; KEUZER KN, 1979, J BACTERIOL, V140, P424; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030	23	64	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32655	32659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798272				2022-12-25	WOS:A1994PX30400094
J	WIKNER, C; MESHALKINA, L; NILSSON, U; NIKKOLA, M; LINDQVIST, Y; SUNDSTROM, M; SCHNEIDER, G				WIKNER, C; MESHALKINA, L; NILSSON, U; NIKKOLA, M; LINDQVIST, Y; SUNDSTROM, M; SCHNEIDER, G			ANALYSIS OF AN INVARIANT COFACTOR-PROTEIN INTERACTION IN THIAMIN DIPHOSPHATE-DEPENDENT ENZYMES BY SITE-DIRECTED MUTAGENESIS - GLUTAMIC-ACID-418 IN TRANSKETOLASE IS ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; BAKERS-YEAST; GENE; DNA; PYROPHOSPHATE; COLLECTION; DETECTOR; PLASMID	A homologous expression system and a purification protocol for pure, highly active recombinant yeast transketolase have been developed. The invariant transketolase residue Glu(418), which forms a hydrogen bond to the N-1' nitrogen atom of the pyrimidine ring of the cofactor thiamin diphosphate has been replaced by glutamine and alanine. Crystallographic analyses of the mutants show that these amino acid substitutions do not induce structural changes beyond the site of mutation. In both cases, the cofactor binds in a manner identical to the wild-type enzyme. Significant differences in the CD spectra of the mutant transketolases compared with the spectrum of wild-type enzyme indicate differences in the electron distribution of the aminopyrimidine ring of the cofactor. The E418Q mutant shows 2% and the E418A mutant shows about 0.1% of the catalytic activity of wild-type enzyme. The affinities of the mutant enzymes for thiamin diphosphate are comparable with wild-type transketolase, The hydrogen bond between the coenzyme and the side chain of Glu(418) is thus not required for coenzyme binding but essential for catalytic activity. The results demonstrate the functional importance of this interaction and support the molecular model for cofactor deprotonation, the first step in enzymatic thiamin catalysis.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT BIOL MOLEC,S-75124 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Meshalkina, Ludmilla/D-8448-2012; Lindqvist, Ylva/F-9009-2010	Schneider, Gunter/0000-0003-0622-5713; Lindqvist, Ylva/0000-0003-3162-8661				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CALDWELL GA, 1993, PROMEGA NOTES, V44, P6; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; ELODI P, 1956, Acta Physiol Acad Sci Hung, V9, P339; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; GOLBIK R, 1991, BIOORG CHEM, V19, P10, DOI 10.1016/0045-2068(91)90039-R; HEINRICH CP, 1972, BIOCHEM BIOPH RES CO, V49, P1427, DOI 10.1016/0006-291X(72)90498-6; HEINRICH PC, 1972, EUR J BIOCHEM, V30, P533, DOI 10.1111/j.1432-1033.1972.tb02124.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN F, 1982, ANN NY ACAD SCI, V378, P14; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KONIG S, 1994, J BIOL CHEM, V269, P10879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; LINDQVIST Y, 1993, CURR OPIN STRUC BIOL, V3, P896, DOI 10.1016/0959-440X(93)90153-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; NILSSON U, 1993, FEBS LETT, V326, P145, DOI 10.1016/0014-5793(93)81779-Y; OSAWA T, 1972, CHEM PHARM BULL, V20, P2715; Racker E, 1961, ENZYMES, V5, P397; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAITOU S, 1974, FEBS LETT, V40, P114, DOI 10.1016/0014-5793(74)80906-3; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SCHAAFFGERSTENSCHLAGER I, 1993, EUR J BIOCHEM, V217, P487, DOI 10.1111/j.1432-1033.1993.tb18268.x; SCHELLENBERGER A, 1965, H-S Z PHYSIOL CHEM, V343, P189; SCHELLENBERGER A, 1967, ANGEW CHEM INT EDIT, V6, P1024, DOI 10.1002/anie.196710241; SCHNEIDER G, 1989, J BIOL CHEM, V264, P21619; SCHNEIDER G, 1993, BIOORG CHEM, V21, P109, DOI 10.1006/bioo.1993.1012; SHERMAN F, 1986, METHODS YEAST GENETI, P164; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TIKHOMIROVA NK, 1990, BIOCHEM INT, V22, P31; VILLAFRANCA BL, 1971, J BIOL CHEM, V246, P3126; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1979, SERC4 DAR LAB COLL C	46	108	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32144	32150						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798210				2022-12-25	WOS:A1994PX30400022
J	VOGEL, WK; MOSSER, VA; BULSECO, DA; SCHIMERLIK, MI				VOGEL, WK; MOSSER, VA; BULSECO, DA; SCHIMERLIK, MI			PORCINE M2 MUSCARINIC ACETYLCHOLINE RECEPTOR-EFFECTOR COUPLING IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE INHIBITION; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; PHOSPHOINOSITIDE TURNOVER; PHOSPHOLIPID TURNOVER; CHICK HEART; BINDING; PROTEIN; BRAIN; ACTIVATION	The relationship between porcine ma muscarinic receptor coupling to inhibition of cAMP formation and stimulation of phosphatidylinositol metabolism in Chinese hamster ovary cells was examined. Reduction of the number of receptors per cell with the slowly dissociating antagonist (-)-quinuclidinyl benzilate caused a decrease in maximal response with no effect on EC(50) for coupling to phosphatidylinositol metabolism. Inhibition of cAMP formation showed the opposite dependence with no effect on maximal response but an increase in EC(50) value as receptor density decreased, Pilocarpine appeared to be a partial agonist at low cell receptor density but displayed full agonism at higher receptor density. These results are compatible with a two-state model describing m2 muscarinic receptor acting via two different G proteins, This model is compatible with ob servations of negative antagonism where antagonists stimulated cAMP formation in adenylyl cyclase inhibition assays, and can also be used to estimate receptor affinities for G proteins in systems which display negative antagonism.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, ENVIRONM HLTH SCI CTR, CORVALLIS, OR 97331 USA	Oregon State University; Oregon State University				Vogel, Walter/0000-0002-5663-6660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23632] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1987, SCIENCE, V237, P1628; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; COSTA T, 1992, MOL PHARMACOL, V41, P549; DAI YS, 1993, AM J PHYSIOL, V265, pG1122, DOI 10.1152/ajpgi.1993.265.6.G1122; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELHAYE M, 1984, N-S ARCH PHARMACOL, V325, P170, DOI 10.1007/BF00506197; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; EHLERT FJ, 1985, MOL PHARMACOL, V28, P410; FISHER SK, 1984, J NEUROCHEM, V43, P1171, DOI 10.1111/j.1471-4159.1984.tb12858.x; FISHER SK, 1983, J BIOL CHEM, V258, P7358; FURCHGOTT RF, 1964, ANNU REV PHARMACOL, V4, P21, DOI 10.1146/annurev.pa.04.040164.000321; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEE W, 1990, J PHARMACOL EXP THER, V252, P482; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MUKAI H, 1992, J BIOL CHEM, V267, P16237; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHIMERLIK MI, 1980, BIOCHEMISTRY-US, V19, P3407, DOI 10.1021/bi00556a001; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; TOTA MR, 1990, MOL PHARMACOL, V37, P996; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037; YOCCA FD, 1992, MOL PHARMACOL, V41, P1066	42	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15485	15493		10.1074/jbc.270.26.15485	http://dx.doi.org/10.1074/jbc.270.26.15485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797541	hybrid			2022-12-25	WOS:A1995RG53800011
J	YU, H; SUCHARD, SJ; NAIRN, R; JOVE, R				YU, H; SUCHARD, SJ; NAIRN, R; JOVE, R			DISSOCIATION OF MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION FROM THE OXIDATIVE BURST IN DIFFERENTIATED HL-60 CELLS AND HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST; TYROSINE PHOSPHORYLATION; THREONINE KINASE; MAP KINASES; INHIBITION; RAF; STIMULATION; SPECIFICITY; LEUKOCYTES; OXIDASE	In human polymorphonuclear leukocytes (PMNs), mitogen-activated protein kinases (MAPKs), also known as extracellular signal-regulated kinases (Erks), are activated within minutes upon stimulation with either chemoattractant formyl-Met-Leu-Phe (fMLP) or phorbol 12-myristate 13-acetate (PMA), This activation of MAPKs coincides with the formation of superoxide anion, which occurs through the activation of a multiple-component NADPH oxidase pathway, MAPKs have thus been suggested to be involved in signal transduction leading to the oxidative burst, To investigate whether MAPK activation plays a central role in the oxidative burst, we evaluated the effect of cAMP on MAPK activation induced by fMLP and PMA. cAMP inhibits many PMN functional responses, including the oxidative burst, and has recently been shown to reduce growth factor- and PMA induced MAPK activities in a variety of cells, We found that in differentiated, neutrophil-like HL-60 cells, while cAMP reduced PMA-induced MAPK activation, it had no effect on fMLP-induced MAPK activation, Despite the presence of unchanged levels of activated MAPKs, the fMLP-induced oxidative burst was substantially diminished by cAMP. By contrast, O-2(-) production induced by PMA remained the same even though MAPK activation was inhibited, In PMNs, although the levels of O-2(-) induced by either 10 ng/ml or 100 ng/ml PMA were similar, only 100 ng/ml could stimulate MAPK activation, suggesting that the oxidative burst could occur in the absence of detectable activation of MAPKs. As in HL-60 cells, cAMP inhibited the O-2(-) production in fMLP-stimulated PMNs but had no effect on MAPK activity, These results demonstrate that, while MAPK activation coincides with PMN activation, it can be dissociated from the oxidative burst.	UNIV MICHIGAN,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	YU, H (corresponding author), UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,5812 MED SCI 2,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline; NHLBI NIH HHS [HL53074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDREWS PC, 1983, BLOOD, V61, P333; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V884, P54; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V882, P57, DOI 10.1016/0304-4165(86)90055-3; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CURNUTTE JT, 1979, J CLIN INVEST, V63, P637, DOI 10.1172/JCI109346; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FANTONE JC, 1984, BIOCHIM BIOPHYS ACTA, V804, P265, DOI 10.1016/0167-4889(84)90129-0; FANTONE JC, 1984, AM J PATHOL, V115, P9; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LEVY R, 1990, J IMMUNOL, V145, P2595; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEWBURGER PE, 1984, J BIOL CHEM, V259, P3771; PARSONS WJ, 1988, MOL PHARMACOL, V33, P441; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; THOMPSON HL, 1993, BIOCHEM J, P483; TORRES M, 1993, J IMMUNOL, V150, P1563; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WELLS JN, 1975, MOL PHARMACOL, V11, P775; WORTHON GS, 1994, J CLIN INVEST, V84, P815; WU J, 1992, BIOCHEM SOC T, V20, P675, DOI 10.1042/bst0200675; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	42	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15719	15724		10.1074/jbc.270.26.15719	http://dx.doi.org/10.1074/jbc.270.26.15719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797573	hybrid			2022-12-25	WOS:A1995RG53800045
J	SRINIVASAN, M; KALOUSEK, F; CURTHOYS, NP				SRINIVASAN, M; KALOUSEK, F; CURTHOYS, NP			IN-VITRO CHARACTERIZATION OF THE MITOCHONDRIAL PROCESSING AND THE POTENTIAL FUNCTION OF THE 68-KDA SUBUNIT OF RENAL GLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-DEPENDENT GLUTAMINASE; PURIFIED PRECURSOR PROTEIN; RAT-KIDNEY; INTERMEMBRANE SPACE; PEPTIDASE; IMPORT; LIVER; CELLS; TRANSLOCATION; BIOSYNTHESIS	Rat renal mitochondrial glutaminase (GA) is initially synthesized in primary cultures of proximal tubule cells as a 74-kDa precursor and is processed via a 72-kDa intermediate to generate a heterotetrameric enzyme which contains three 66-kDa subunits and one 68-kDa subunit (Perera, S. Y., Chen, T. C., and Curthoys, N. P. (1990) J. Biol. Chem. 265, 17764-17770). The two mature subunits may be derived by either of two possible mechanisms: 1) alternative proteolytic processing or 2) initial synthesis of the 66-kDa subunit followed by its covalent modification to generate the 68-kDa subunit. An in vitro system was utilized to further characterize this unique processing pathway and to investigate the potential function of the 68-kDa subunit, In vitro transcription and translation of the GA cDNA yields a single 74-kDa precursor, Upon incubation with isolated rat liver mitochondria, the precursor is translocated into the mitochondria and processed via a 72-kDa intermediate to yield a 3:1 ratio of the 66- and 68-kDa subunits, respectively, The kinetics of the in vitro processing reaction also closely approximate the kinetics observed in cultured cells, Mitochondrial processing is blocked by o-phenanthroline, an inhibitor of the matrix processing peptidase (MPP), The 72-amino acid presequence of the 66-kDa subunit contains a large proportion of basic amino acids, Two-dimensional gel electrophoresis of mature GA established that the 68-kDa subunit is slightly more basic than the 66-kDa subunit, In addition, incubation of the 74-kDa precursor with purified MPP yields equimolar amounts of the two mature peptides, A cDNA construct, p Delta GA, was created which lacks the nucleotides that encode the amino acid residues 32 through 72 of GA, When transcribed and translated in vitro, p Delta GA yields a 70-kDa precursor, This precursor is processed by mitochondria to a single mature subunit with a M of 66 kDa. This observation suggests that the 68-kDa subunit is not produced by covalent modification of the 66-kDa subunit and further supports the conclusion that the two mature subunits of GA are produced by alternative processing reactions which can be catalyzed by MPP, However, the yield of products obtained in intact mitochondria may be determined by some unidentified accessory factor, Submitochondrial fractionation of imported GA and Delta GA precursors suggest that the 68-kDa subunit may function to retain the mature GA within the mitochondrial matrix.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06520	Colorado State University; Yale University					NIDDK NIH HHS [DK-09527, DK-37124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN WJ, 1987, J BIOL CHEM, V262, P15605; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; CURTHOYS NP, 1974, J BIOL CHEM, V249, P3261; CURTHOYS NP, 1976, ARCH BIOCHEM BIOPHYS, V172, P162, DOI 10.1016/0003-9861(76)90062-X; CURTHOYS NP, 1988, PH HOMEOSTASIS MECHA, P323; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASER WG, 1985, BIOCHEM J, V229, P399, DOI 10.1042/bj2290399; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KALOUSEK F, 1993, TRENDS BIOCHEM SCI, V18, P249, DOI 10.1016/0968-0004(93)90174-L; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERERA SY, 1990, J BIOL CHEM, V265, P17764; PERERA SY, 1991, BIOCHEM J, V273, P265, DOI 10.1042/bj2730265; PERERA SY, 1989, THESIS U PITTSBURGH; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SCHOOLWERTH AC, 1980, J BIOL CHEM, V255, P3403; SHAPIRO RA, 1987, BIOCHEM J, V242, P743, DOI 10.1042/bj2420743; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SRINIVASAN M, 1995, J BIOL CHEM, V270, P1191, DOI 10.1074/jbc.270.3.1191; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAYASARATHY C, 1989, J BIOL CHEM, V264, P7772	36	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1185	1190		10.1074/jbc.270.3.1185	http://dx.doi.org/10.1074/jbc.270.3.1185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836378	hybrid			2022-12-25	WOS:A1995QB15600033
J	HOLNESS, CL; BATES, PA; LITTLER, AJ; BUCKLEY, CD; MCDOWALL, A; BOSSY, D; HOGG, N; SIMMONS, DL				HOLNESS, CL; BATES, PA; LITTLER, AJ; BUCKLEY, CD; MCDOWALL, A; BOSSY, D; HOGG, N; SIMMONS, DL			ANALYSIS OF THE BINDING-SITE ON INTERCELLULAR-ADHESION MOLECULE-3 FOR THE LEUKOCYTE INTEGRIN LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN CD4; CRYSTAL-STRUCTURE; COUNTER-RECEPTOR; ICAM-1 CD54; LFA-1; EXPRESSION; CLONING; RESOLUTION; DISTINCT	Intercellular adhesion molecule 3 (ICAM-3, CD50) is a member of the immunoglobulin superfamily and is a constitutively expressed ligand for the leukocyte integrin LFA-1 (CD11a/CD18). ICAM-3 is expressed at high levels by all resting leukocyte populations and antigen presenting cells and is a major ligand for LFA-1 in the resting immune system. ICAM-3 is a signal transducer and may play a hey role in initiating immune responses. Mutant ICAM-3 Fc-chimeric proteins were quantitatively analyzed for their ability to bind COS cells expressing human LFA-1. The LFA-1-binding site on ICAM-3 is located in the N-terminal 2 Ig domains. Domains 3-5 do not significantly contribute to adhesion. The binding site has been further resolved by rational targeting of. 14 point mutations throughout domains 1 and 2, coupled with modeling studies. Within domain 1 a cluster of residues (Glu(37), Leu(66), Ser(68), and Gln(75)), that are predicted to lie on the CC'FG face of the Ig fold, play a dominant role in LFA-1 binding.	JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND, CELL ADHESION LAB, OXFORD OX3 9DU, ENGLAND; IMPERIAL CANC RES FUND, LEUKOCYTE ADHESION LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, BIOMOLEC MODELLING LAB, LONDON WC2A 3PX, ENGLAND	University of Oxford; Cancer Research UK; Cancer Research UK				McDowall, Alison/0000-0003-2018-1462; Bates, Paul/0000-0003-0621-0925				ACEVEDO A, 1993, AM J PATHOL, V143, P774; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BOSSY D, 1994, IN PRESS EUR J IMMUN; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CID MC, 1994, EUR J IMMUNOL, V24, P1377, DOI 10.1002/eji.1830240621; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOUSSISANAGNOSTOPOULOU I, 1993, AM J PATHOL, V143, P1040; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GARRETT TPJ, 1993, J MOL BIOL, V234, P763, DOI 10.1006/jmbi.1993.1625; HAMMOND L, 1993, GENBANK RELEASE 80 0; HERNANDEZCASELLES T, 1993, EUR J IMMUNOL, V23, P2799, DOI 10.1002/eji.1830231112; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONG X, 1992, J IMMUNOL, V149, P2650; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; KITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1131, P108, DOI 10.1016/0167-4781(92)90107-B; Klickstein L. B., 1993, Tissue Antigens, V42, P270; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6	56	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					877	884		10.1074/jbc.270.2.877	http://dx.doi.org/10.1074/jbc.270.2.877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822326	hybrid, Green Published			2022-12-25	WOS:A1995QB81600060
J	WANG, SK; KUSSIE, P; DENG, LP; TALL, A				WANG, SK; KUSSIE, P; DENG, LP; TALL, A			DEFECTIVE BINDING OF NEUTRAL LIPIDS BY A CARBOXYL-TERMINAL DELETION MUTANT OF CHOLESTERYL ESTER TRANSFER PROTEIN - EVIDENCE FOR A CARBOXYL-TERMINAL CHOLESTERYL ESTER BINDING-SITE ESSENTIAL FOR NEUTRAL LIPID TRANSFER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; HUMAN-PLASMA; MONOCLONAL-ANTIBODY; PHOSPHOLIPIDS; PURIFICATION; MUTATION; GENE	The plasma cholesteryl ester transfer protein (CETP, 476 amino acids) transfers cholesteryl ester (CE) from high density lipoprotein (HDL) to triglyceride-rich lipoproteins and plays a major role in HDL catabolism. Using deletional and site-directed mutagenesis, we previously showed that the carboxyl terminus of human CETP comprises the epitope of a neutralizing monoclonal antibody and is necessary for neutral lipid transfer activity, To assess the nature of the involvement of the COOH terminus in cholesteryl ester transfer activity, we characterized a deletion mutant of CETP lacking amino acid residues 470-475 in terms of CE transfer kinetics, association with HDL, and capacity to bind CE, triglyceride (TG), and phosphatidylcholine (PC), Kinetic analysis indicated a major catalytic defect of the deletion mutant, as shown by markedly decreased maximum cholesteryl ester transfer activities (apparent V-max) for donor (HDL) and acceptor (low density lipoprotein (LDL)) lipoproteins but there were no significant changes of concentrations of the donor and acceptor at 50% V-max (apparent K-m). The binding of CETP to HDL, as determined by native gel electrophoresis, was similar for wild-type and mutant protein, When egg PC/CE vesicles were incubated with wild type CETP and then separated by gel filtration chromatography, there was maximum binding of about 1 mol of CE/mol of CETP, Under similar conditions the mutant CETP bound 0.09-0.37 mol of CE/mol of protein, Similarly, when egg PC/TG vesicles were incubated with the CETP proteins, there was a maximum binding of 0.5 mol of triglyceride/mol of wild-type CETP, whereas there was only 0.00-0.07 mol of TG/mol of deletion mutant, The binding of phosphatidylcholine was similar for wild type and the deletion mutant. The studies suggest that amino acids 470-475 (forming part of a COOH-terminal amphipathic helix) are involved in CE and TG binding by CETP but are not required either for the binding of PC by CETP or the association of CETP with HDL. The COOH terminus of CETP may comprise a neutral lipid binding site directly involved in the lipid transfer mechanism.	COLUMBIA UNIV, DEPT MED, DIV MOLEC MED, NEW YORK, NY 10032 USA	Columbia University	WANG, SK (corresponding author), SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA.		Tall, Alan/AAT-8528-2021					AGELLON LB, 1991, J BIOL CHEM, V266, P10796; AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BARTER PJ, 1980, J LIPID RES, V21, P238; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Cleland W W, 1979, Methods Enzymol, V63, P103; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GLOMSET JA, 1968, J LIPID RES, V9, P155; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HESLER CB, 1987, J BIOL CHEM, V262, P2275; IHM J, 1982, J LIPID RES, V27, P361; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MATRUNAGA A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P131; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; OHNISHI T, 1990, J LIPID RES, V31, P397; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; STEVENSON SC, 1993, BIOCHEMISTRY-US, V32, P5121, DOI 10.1021/bi00070a021; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; WANG SK, 1993, J BIOL CHEM, V268, P1955; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	30	40	43	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					612	618		10.1074/jbc.270.2.612	http://dx.doi.org/10.1074/jbc.270.2.612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822286	hybrid			2022-12-25	WOS:A1995QB81600019
J	PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A				PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A			PHOSPHORYLATION OF A SPECIFIC CDK SITE IN E2F-1 AFFECTS ITS ELECTROPHORETIC MOBILITY AND PROMOTES PRB-BINDING IN-VITRO	ONCOGENE			English	Article						E2F; PRB; CYCLIN; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; COMPLEX-FORMATION; TRANS-ACTIVATION; S-PHASE; EXPRESSION; P107; RB	The E2F transcription factor family participates in growth control presumably through transcriptional activation of genes that promote entry into S phase. E2F activity is believed to be controlled across the cell cycle by association with various cellular proteins, including the product of the retinoblastoma gene (pRB). We find that E2F-1 proteins are heterogeneously phosphorylated in insect cells, as a result of which they migrate as a doublet on SDS-polyacrylamide gels. This electrophoretic shift is shown to be dependent upon specific phosphorylation of E2F-1 on serine-375 (S375), near the pRB-binding site. Phosphorylation on S375 also occurs in human cells. E2F-1 was most efficiently phosphorylated on this residue by cyclin A/cdc2 kinase, and to a lesser extent by cyclin A/cdk2, irrespective of the presence of the pRB-related p107 protein. Phosphorylation of E2F-1 on S375 greatly enhanced its affinity of PRE in vitro. These results suggest a novel way of regulating E2F-1 activity, namely by cell-cycle-dependent phosphorylation of this transcription factor.	LEIDEN UNIV, DEPT MOLEC CARCINOGENESIS, SYLVIUS LAB, 2333 AL LEIDEN, NETHERLANDS; MASSACHUSETTS GEN HOSP E, CTR CANC, BOSTON, MA 02129 USA	Leiden University; Leiden University - Excl LUMC			Helin, Kristian/K-2526-2019; Peeper, Daniel/AAA-2430-2020; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PEEPER DS, 1992, VIROLOGY, V190, P733, DOI 10.1016/0042-6822(92)90911-8; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Summers MD, 1987, TEXAS AGR EXPT STATI; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	60	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824278				2022-12-25	WOS:A1995QA98000006
J	KURLANDSKY, SB; XIAO, JH; DUELL, EA; VOORHEES, JJ; FISHER, GJ				KURLANDSKY, SB; XIAO, JH; DUELL, EA; VOORHEES, JJ; FISHER, GJ			BIOLOGICAL-ACTIVITY OF ALL-TRANS RETINOL REQUIRES METABOLIC CONVERSION TO ALL-TRANS-RETINOIC ACID AND IS MEDIATED THROUGH ACTIVATION OF NUCLEAR RETINOID RECEPTORS IN HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; CULTURED HUMAN KERATINOCYTES; HUMAN-SKIN KERATINOCYTES; BINDING-PROTEIN; VITAMIN-A; X-RECEPTORS; TERMINAL DIFFERENTIATION; RESPONSE ELEMENT; MOUSE EPIDERMIS; SERTOLI CELLS	The biological activity of all trans retinol, in human keratinocytes, was investigated through metabolic and functional analyses that assessed the capacity for retinol uptake and metabolism and the mechanism of retinol-induced activation of gene transcription, Human keratinocytes converted all-trans retinol predominantly to retinyl esters, which accounted for 60 and 90% of cell associated radiolabel after a 90-min pulse and a 48-h chase, respectively. Human keratinocytes also metabolized all-trans retinol to low levels of all-trans retinoic acid (11.47-131.3 ng/mg of protein) in a dose-dependent manner, between 0.3 and 10 mu M added retinol. Small amounts of 13-cis retinoic acid (5.47-8.62 ng/mg of protein) were detected, but 9-cis retinoic acid was detected only when keratinocytes were incubated with radiolabeled retinol, There was no accumulation of the oxidized catabolic metabolites 4-hydroxy- or 4-oxoretinoic acid; however, 5,6-epoxy retinoic acid was detected at pharmacological levels (10 and 30 mu M) of added retinol, Biological activity of retinol was assessed through analysis of two known retinoic acid-mediated responses: 1) reduction of type I epidermal transglutaminase and 2) activation of a retinoic acid receptor-dependent reporter gene, beta RARE(3)-tk-CAT. Both all-trans retinol and all-trans retinoic acid reduced type I epidermal transglutaminase in a dose-dependent manner; however, the ED(50) for all-trans retinol (10 nM) was 10 times greater than for all-trans retinoic acid (1 nM). All-trans retinol also stimulated beta RARE(3)-tk-CAT reporter gene activity in a dose-dependent manner, Half-maximal induction was observed at 30 nM retinol, which was again 10-fold greater than observed with all-trans retinoic acid, Cotransfection of human keratinocytes with expression vectors for dominant negative mutant retinoic acid and retinoid X receptors reduced retinol-induced beta RARE(3)-tk-CAT reporter gene activation by 80%. Inhibition of conversion of ah-trans retinol or all-trans retinaldehyde to all-traits retinoic acid by citral reduced beta RARE(3)-tk-CAT activity 98 and 86%, respectively, These data demonstrate that retinol-induced responses in human keratinocytes are mediated by its tightly regulated conversion to retinoic acid, which functions as a ligand to activate nuclear retinoic acid receptors.	UNIV MICHIGAN, MED CTR, DEPT DERMATOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007197] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07197-18] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ASTROM A, 1991, J BIOL CHEM, V266, P17662; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BORENFREUND E, 1981, J TISSUE CULTURE MET, V9, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CONNOR MJ, 1988, CANCER RES, V48, P7038; CREEK KE, 1993, J NUTR, V123, P356, DOI 10.1093/jn/123.suppl_2.356; CREEK KE, 1989, J INVEST DERMATOL, V92, P283, DOI 10.1111/1523-1747.ep12276867; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; ESKILD W, 1988, BIOCHEM BIOPH RES CO, V152, P1504, DOI 10.1016/S0006-291X(88)80456-X; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FOGH K, 1993, ARCH BIOCHEM BIOPHYS, V300, P751, DOI 10.1006/abbi.1993.1104; FROLIK CA, 1984, RETINOIDS, V2, P177; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIUDICE GJ, 1990, METHOD ENZYMOL, V190, P18; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GRIFFITHS CEM, 1992, J INVEST DERMATOL, V99, P283, DOI 10.1111/1523-1747.ep12616626; Groenendijk G W, 1980, Methods Enzymol, V67, P203; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODAM JR, 1991, J INVEST DERMATOL, V97, P298, DOI 10.1111/1523-1747.ep12480562; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; JETTEN AM, 1990, J INVEST DERMATOL, V95, pS44, DOI 10.1111/1523-1747.ep12505757; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KLIGMAN AM, 1993, J AM ACAD DERMATOL, V29, P25, DOI 10.1016/0190-9622(93)70147-L; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MICHEL S, 1991, ANAL BIOCHEM, V192, P232, DOI 10.1016/0003-2697(91)90213-D; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; Ong David E., 1994, P283; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; ROLLMAN O, 1993, BIOCHEM J, V293, P675, DOI 10.1042/bj2930675; RUSH MG, 1991, ENDOCRINOLOGY, V129, P705, DOI 10.1210/endo-129-2-705; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIEGENTHALER G, 1990, METHOD ENZYMOL, V189, P530; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SIEGENTHALLER G, 1989, PHARM RETINOIDS SKIN, V3, P52; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; TALWAR HS, 1993, J INVEST DERMATOL, V100, P800, DOI 10.1111/1523-1747.ep12476615; TANG GW, 1990, J LIPID RES, V31, P175; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; TORMA H, 1990, METHOD ENZYMOL, V190, P210; TORMA H, 1991, SKIN PHARMACOL, V4, P154; WANG XD, 1993, J NUTR, V123, P1277, DOI 10.1093/jn/123.7.1277	64	100	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32821	32827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806506				2022-12-25	WOS:A1994QA63800019
J	ZHAO, LJ; WANG, LL; MUKHERJEE, S; NARAYAN, O				ZHAO, LJ; WANG, LL; MUKHERJEE, S; NARAYAN, O			BIOCHEMICAL-MECHANISM OF HIV-1 VPR FUNCTION - OLIGOMERIZATION MEDIATED BY THE N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRION-ASSOCIATED PROTEIN; DNA-BINDING; PRODUCTIVE INFECTION; HUMAN MACROPHAGES; TYPE-1; GENE; ENCODES; REGION; CELLS	The human immunodeficiency virus, type 1 (HIV-1) genome encodes a 15-kDa accessory gene product, Vpr, that is essential for virus replication in primary monocytes/macrophages. Being present in the virion, Vpr is believed to function in the early phases of HIV-1 replication, including nuclear migration of the pre-integration complex and/or transcription of the provirus genome. By gel filtration analysis of highly purified Vpr protein and its mutants, we demonstrate that HIV-1 Vpr exists as an oligomer, The N-terminal domain of Vpr (amino acids (aa) 1-42) is sufficient for oligomerization; however deletion of aa 36-76 from Vpr disrupts oligomerization, suggesting that aa 36-42 are critical for Vpr oligomerization, As a result of Vpr oligomerization, basic aa residues within Vpr aa 1-73 are highly resistant to trypsin digestion, while those within Vpr aa 74-96 are easily accessible, Mutations within the leucine-/isoleucine-rich domain (aa 60-81), which was previously identified to be involved in Vpr interaction with a host cellular protein, rendered Arg(62) more susceptible to trypsin digestion, Thus, the Vpr oligomeric structure must be extended into this domain. These results suggest a novel feature of HIV-1 Vpr that may be important for its functions.			ZHAO, LJ (corresponding author), UNIV KANSAS,MED CTR,MARION MERRELL DOW FDN,DEPT MICROBIOL MOLEC GENET & IMMUNOL,VIRAL PATHOG,KANSAS CITY,KS 66160, USA.				NCRR NIH HHS [RR06753] Funding Source: Medline; NINDS NIH HHS [NS32203] Funding Source: Medline; PHS HHS [A129382] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032203] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BALOTTA C, 1993, J VIROL, V67, P4409, DOI 10.1128/JVI.67.7.4409-4414.1993; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LORI F, 1992, J VIROL, V66, P5553, DOI 10.1128/JVI.66.9.5553-5560.1992; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	35	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32131	32137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798208				2022-12-25	WOS:A1994PX30400020
J	SUTHERLAND, C; OBRIEN, RM; GRANNER, DK				SUTHERLAND, C; OBRIEN, RM; GRANNER, DK			PHOSPHATIDYLINOSITOL 3-KINASE, BUT NOT P70/P85 RIBOSOMAL S6 PROTEIN-KINASE, IS REQUIRED FOR THE REGULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK) GENE-EXPRESSION BY INSULIN - DISSOCIATION OF SIGNALING PATHWAYS FOR INSULIN AND PHORBOL ESTER REGULATION OF PEPCK GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION; ACTIVATION; SEQUENCE; 3,4,5-TRISPHOSPHATE; ASSOCIATION; INHIBITION; DOMAINS	Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the rate limiting step in hepatic gluconeogenesis. Glucagon (via the second messenger cAMP) and glucocorticoids stimulate the transcription of the PEPCK gene, whereas insulin and phorbol esters inhibit, in a dominant fashion, these effects, Wortmannin, an inhibitor of phosphatidylinositol 3-kinase, prevents the stimulation of glycogen synthesis, glucose transport, mitogen-activated protein kinase, and p70/p85 ribosomal S6 protein kinase by insulin, We now show that wortmannin can also block the inhibition of glucocorticoid- and cAMP-stimulated PEPCK gene expression by insulin, PEPCK-chloramphenico1 acetyltransferase fusion gene experiments demonstrate that wortmannin blocks an activity that is required for insulin signaling to elements within the PEPCK promoter. Phorbol esters mimic the action of insulin on the regulation of PEPCK gene expression, but wortmannin does not block the effect of these agents, Thus, phosphatidylinositol 3-kinase is required for the regulation of PEPCK gene expression by insulin, but not by phorbol esters, The immunosuppressant rapamycin, a potent inhibitor of insulin or phorbol. ester stimulation of p70/p85 ribosomal S6 protein kinase, has no significant effect on the regulation of PEPCK gene expression by insulin or phorbol esters. Thus, p70/p85 ribosomal S6 protein kinase does not have a role in signaling to the PEPCK promoter by insulin or phorbol esters.	VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University				Sutherland, Calum/0000-0003-4398-7434	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, P30DK020593, P60DK020593, R37DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35107, DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEALE EG, 1985, J BIOL CHEM, V260, P748; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOU T, 1991, MOL CELL ENDOCRINOL, V75, P181, DOI 10.1016/0303-7207(91)90159-P; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENTON RM, 1986, ADV CYCLIC NUCLEOTID, V20, P289; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FILLAT C, 1993, FEBS LETT, V318, P287, DOI 10.1016/0014-5793(93)80530-8; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GOULD GW, 1994, J BIOL CHEM, V269, P26622; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; MOLERO C, 1992, EXP CELL RES, V200, P295, DOI 10.1016/0014-4827(92)90175-8; MYUERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1994, BIOCHEM J, V303, P737, DOI 10.1042/bj3030737; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TOKER A, 1994, J BIOL CHEM, V269, P32358; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	55	146	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15501	15506		10.1074/jbc.270.26.15501	http://dx.doi.org/10.1074/jbc.270.26.15501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797543	hybrid			2022-12-25	WOS:A1995RG53800013
J	TOGAWA, K; ISHIGURO, T; KAYA, S; SHIMADA, A; IMAGAWA, T; TANIGUCHI, K				TOGAWA, K; ISHIGURO, T; KAYA, S; SHIMADA, A; IMAGAWA, T; TANIGUCHI, K			REVERSIBLE PHOSPHORYLATION OF BOTH TYR(7) AND TYR(10) IN THE ALPHA-CHAIN OF PIG STOMACH H+,K+-ATPASE BY A MEMBRANE-BOUND KINASE AND A PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; CDNA CLONING; GASTRIC (H+; SEQUENCE; SUBUNIT; NA+,K+-ATPASE; PARIETAL; HISTAMINE; CLEAVAGE; PROTEINS	When pig stomach membrane H+,K+-ATPase preparations were incubated with [gamma-P-32]ATP and Mg2+ with vanadate, P-32 was incorporated into the oc chain of H+,K+-ATPase to a steady-state level of approximately 0.7 mol of phosphotyrosine (Tyr(P))/mol of phosphoenzyme intermediates. The addition of a membrane H+,K+ ATPase preparation with Mg2+ accelerated the liberation of P-32 from Tyr(P) residues in the alpha-chain, Mild tosylphenylalanyl chloromethyl ketone-trypsin treatment solubilized P-32-containing peptides from the ct-chain almost completely. A reverse-phase column chromatography of the supernatant gave two peaks of P-32-peptide with similar total radioactivities. The amino acid sequence of both peaks was shown to be Gly Lys Ala-Glu-Asn-Tyr-Glu-Leu-Tyr-Gln-, which is consistent with the amino-terminal sequence of the alpha-chain of H+,K+-ATPase deduced from cDNA from pig stomach except that the initial Met was absent. The comparison of the recovery of amino acid from each Edman cycle showed that the phosphorylation of Tyr(10) occurred preceding the phosphorylation of Tyr(7). These data and others suggested the presence of a novel membrane-bound enzyme system to participate in reversible phosphorylation of both Tyr residues in the alpha-chain of H+,K+-ATPase.	HOKKAIDO UNIV,FAC SCI,GRAD SCH SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Imagawa, Toshiaki/A-4255-2012					BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CARLSSON T, 1979, ACTA CHEM SCAND B, V33, P607, DOI 10.3891/acta.chem.scand.33b-0607; CHANG H, 1977, BIOCHIM BIOPHYS ACTA, V464, P313, DOI 10.1016/0005-2736(77)90006-2; CHEW CS, 1986, BIOCHIM BIOPHYS ACTA, V888, P116, DOI 10.1016/0167-4889(86)90077-7; CHEW CS, 1980, AM J PHYSIOL, V238, pG312, DOI 10.1152/ajpgi.1980.238.4.G312; EGUCHI H, 1993, BIOCHEM BIOPH RES CO, V196, P294, DOI 10.1006/bbrc.1993.2248; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1986, BIOCHEM BIOPH RES CO, V138, P185, DOI 10.1016/0006-291X(86)90264-0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SOLL AH, 1979, AM J PHYSIOL, V237, pE444, DOI 10.1152/ajpendo.1979.237.5.E444; TSUNODA Y, 1993, AM J PHYSIOL, V264, pG351, DOI 10.1152/ajpgi.1993.264.2.G351	22	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15475	15478		10.1074/jbc.270.26.15475	http://dx.doi.org/10.1074/jbc.270.26.15475			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797539	hybrid			2022-12-25	WOS:A1995RG53800009
J	ZIEMIENOWICZ, A; ZYLICZ, M; FLOTH, C; HUBSCHER, U				ZIEMIENOWICZ, A; ZYLICZ, M; FLOTH, C; HUBSCHER, U			CALF THYMUS HSC70 PROTEIN PROTECTS AND REACTIVATES PROKARYOTIC AND EUKARYOTIC ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; STRESS PROTEINS; DNA-REPLICATION; RNA-POLYMERASE; MOLECULAR CHAPERONES; BINDING-SPECIFICITY; PEPTIDE-BINDING; ATP HYDROLYSIS; HSP70	The heat-shock 70 protein (Hsp 70) chaperone family is very conserved and its prokaryotic homologue, the DnaK protein, is assumed to form one of the cellular systems for the prevention and restoration of heat-induced protein denaturation. By using anti-DnaK antibodies we purified the DnaK homologue heat-shock cognate protein (Hsc70) from calf thymus to apparent homogeneity, This protein was classified as an eukaryotic Hsc70, since (i) monoclonal antibodies against eukaryotic Hsc70 recognized it, (ii) its amino terminal sequence showed strong homology to Hsp70s from eukaryotes and, (iii) it had an intrinsic weak ATPase activity that was stimulated by various peptide substrates, We show that this calf thymus Hsc70 protein protected calf thymus DNA polymerases alpha and epsilon as well as Escherichia coli DNA polymerase III and RNA polymerase from heat inactivation and could reactivate these heat-inactivated enzymes in an ATP-hydrolysis dependent manner, likely leading to the dissociation of aggregates formed during heat inactivation, In contrast to this, DnaK protein was exclusively able to protect and to reactivate the enzymes from E. coli but not from eukaryotic cells, Finally, the addition of calf thymus DnaJ cochaperone homologue reduced the amount of Hsc70 required for reactivation at least 10-fold.	UNIV ZURICH,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; UNIV GDANSK,DEPT BIOL MOLEC,DIV BIOPHYS,PL-80822 GDANSK,POLAND	University of Zurich; Fahrenheit Universities; University of Gdansk								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V129, P95; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISER T, 1991, J BIOL CHEM, V266, P10420; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	35	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15479	15484		10.1074/jbc.270.26.15479	http://dx.doi.org/10.1074/jbc.270.26.15479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797540	Green Accepted, hybrid			2022-12-25	WOS:A1995RG53800010
J	GLOVER, S; BAYBURT, T; JONAS, M; CHI, E; GELB, MH				GLOVER, S; BAYBURT, T; JONAS, M; CHI, E; GELB, MH			TRANSLOCATION OF THE 85-KDA PHOSPHOLIPASE A(2) FROM CYTOSOL TO THE NUCLEAR-ENVELOPE IN RAT BASOPHILIC LEUKEMIA-CELLS STIMULATED WITH CALCIUM IONOPHORE OR IGE/ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONATE-MOBILIZING PHOSPHOLIPASE-A2; MOUSE PERITONEAL-MACROPHAGES; PRODUCT-CONTAINING VESICLES; MEMBRANE ASSOCIATION; ACID RELEASE; MAST-CELLS; HYDROLYZING PHOSPHOLIPASE-A2; SUBSTRATE SPECIFICITIES; HUMAN PLATELETS	The rat mast cell line RBL-2H3,1 contains an 85-kDa cytosolic phospholipase A(2) (cPLA(2)) that is very likely involved in liberating arachidonate from membrane phospholipid for the synthesis of eicosanoids following stimulation with either calcium ionophore or IgE/antigen. In this study, the intracellular location of cPLA(2) was determined using immunofluorescence microscopy and immuno-goId electron microscopy. In nonstimulated cells, cPLA(2) is distributed throughout the cytosol and is excluded from the nucleoplasm. Following cell activation with calcium ionophore, most of the cPLA(2) translocates to the nuclear envelope, and the enzyme remains there during the entire period that ionophore is present. With IgE/antigen stimulation for 5 min, approximately 20-30% of the cPLA(2) translocates to the nuclear envelope, and after 30 min of stimulation, most of the enzyme returns to the cytosol. Measurement of intracellular calcium using the dye Fura-2/AM shows that the level of calcium rises immediately after antigen is added, remains high for about 30 s, and then declines back to resting levels. Activation with calcium ionophore produces a 10-fold larger release of arachidonate than does stimulation with IgE/antigen. Thus, the results suggest that the extent of membrane binding of cPLA(2) correlates with the release of arachidonate and that the site of arachidonate liberation is the nuclear envelope where many of the enzymes that oxygenate this fatty acid are located.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017758] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL50040] Funding Source: Medline; NIAID NIH HHS [AI17758] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BINGHAM BR, 1994, J BIOL CHEM, V269, P19300; BOLE DG, 1989, J HISTOCHEM CYTOCHEM, V37, P1817, DOI 10.1177/37.12.2685110; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHI EY, 1982, LAB INVEST, V47, P579; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOD BJ, 1968, BIOCHIM BIOPHYS ACTA, V150, P397, DOI 10.1016/0005-2736(68)90138-7; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FONTEH AN, 1994, J IMMUNOL, V154, P5438; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; ISHIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1084, P53, DOI 10.1016/0005-2760(91)90055-M; ITO T, 1988, J CELL BIOL, V107, P929, DOI 10.1083/jcb.107.3.929; KEENAN TW, 1970, BIOCHIM BIOPHYS ACTA, V203, P547, DOI 10.1016/0005-2736(70)90191-4; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAUSE H, 1991, EUR J BIOCHEM, V199, P3555; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEI ZM, 1992, ENDOCRINOLOGY, V130, P861, DOI 10.1210/en.130.2.861; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCGIVNEY A, 1981, ARCH BIOCHEM BIOPHYS, V212, P572, DOI 10.1016/0003-9861(81)90400-8; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL DE, 1991, PROSTAG LEUKOTR ESS, V43, P1, DOI 10.1016/0952-3278(91)90125-O; MONK PN, 1993, RECEPTOR, V3, P77; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NAKATANI Y, 1994, BIOL PHARM BULL, V17, P47; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NATSUI K, 1991, BIOCHIM BIOPHYS ACTA, V1085, P241, DOI 10.1016/0005-2760(91)90100-V; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OKANO Y, 1985, BIOCHEM BIOPH RES CO, V127, P726, DOI 10.1016/S0006-291X(85)80003-6; OROURKE AM, 1992, MOL IMMUNOL, V29, P1299, DOI 10.1016/0161-5890(92)90166-U; ORTEGA E, 1989, EUR J IMMUNOL, V19, P2251, DOI 10.1002/eji.1830191211; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; REHFELDT W, 1991, BIOCHEM J, V276, P631, DOI 10.1042/bj2760631; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SAHARA N, 1990, J HISTOCHEM CYTOCHEM, V38, P975, DOI 10.1177/38.7.1693935; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STEINER MR, 1991, ARCH BIOCHEM BIOPHYS, V286, P293, DOI 10.1016/0003-9861(91)90043-I; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TANAKA Y, 1991, CHEM PHARM BULL, V39, P2072; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1989, FEBS LETT, V244, P51, DOI 10.1016/0014-5793(89)81160-3; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; XING MZ, 1994, J BIOL CHEM, V269, P3117; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; ZOR U, 1991, BIOCHIM BIOPHYS ACTA, V1091, P385, DOI 10.1016/0167-4889(91)90204-B; ZOR U, 1990, BIOCHIM BIOPHYS ACTA, V1091, P385	74	315	318	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15359	15367		10.1074/jbc.270.25.15359	http://dx.doi.org/10.1074/jbc.270.25.15359			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797525	hybrid			2022-12-25	WOS:A1995RE66600077
J	TEDESCHI, G; CHEN, S; MASSEY, V				TEDESCHI, G; CHEN, S; MASSEY, V			DT-DIAPHORASE - REDOX POTENTIAL, STEADY-STATE, AND RAPID REACTION STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE ACCEPTOR OXIDOREDUCTASE; RAT-LIVER; ONE-ELECTRON; MECHANISM; REDUCTION; SYSTEMS; NAD(P)H; GLUTATHIONE; DIAZIQUONE; CELLS	NAD(P)H:quinone oxidoreductase (DT-diaphorase) appears to be a 2-electron transfer flavoprotein, which catalyzes the conversion of quinones into hydroquinones. Upon photoreduction in the presence of dimethylformamide, the enzyme forms a red semiquinone. In the absence of dimethylformamide, only 10% of the radical form is thermodynamically stabilized. This indicates a redox potential of the enzyme-bound semiquinone/reduced flavin couple that is higher than the midpoint potential for the oxidized flavin/semiquinone couple, The 2-electron redox potential was determined to be -159 +/- 3 mV at 25 degrees C, pH 7.0, In the presence of benzoquinone or 3-aminopyridine adenine dinucleotide phosphate, as NADPH analogue, there is no change in the redox properties of the enzyme flavin. A significant decrease is observed in the presence of the competitive inhibitor dicumarol (E(m) = -234 +/- 2 mV at pH 7.0). The reaction mechanism of the flavoprotein has been investigated by steady-state and stopped-flow kinetic methods using NADPH, NADH, deamino-NADPH, and 3-acetylpyridine adenine dinucleotide reduced form (APADH) as electron donors and K3Fe(CN)(6), 4,5-dihydro-4,5-dioxo-1H-pyrrolo-[2,3-f]quinoline-2,7,9-tricarboxylic acid (PQQ), and 2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone (AZQ) as electron accepters in 50 mM phosphate buffer, pH 7.0, 25 degrees C. No evidence could be obtained to indicate that semiquinoid intermediates play a part in the catalytic mechanism of DT-diaphorase with quinones as accepters. The rates of the reduction by NADPH, NADH, deamino-NADPH, and APADH (1.3 x 10(9), 8.8 x 10(8), 8.3 x 10(8) and 9.8 x 10(6) M(-1) min(-1), respectively) as well as the rates of the reoxidation by PQQ and AZQ (9 x 10(4) and 2.8 x 10(6) M(-1) min(-1), respectively) are directly proportional to substrate concentration, and there is no evidence of the formation of enzyme-substrate complexes. If such complexes do indeed exist, the affinity of the enzyme for substrate must be extremely low. Using K3Fe(CN)(6) as electron acceptor, the rate of oxidation of fully reduced enzyme is 4.6 x 10(7) M(-1) min(-1) and it is accurately proportional to ferricyanide concentration. This rate represents that of flavin semiquinone formation, with the subsequent oxidation of the semiquinone being much faster, since no spectral evidence for semiquinone formation could be obtained. Studies were also conducted attempting to use apo-DT-diaphorase reconstituted with PQQ as coenzyme. The lack of activity toward AZQ, K3Fe(CN)(6), and menadione suggests that DT-diaphorase can use PQQ only as electron acceptor and not as redox cofactor.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope			Tedeschi, Gabriella/I-6247-2017	Tedeschi, Gabriella/0000-0003-2082-6443	NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BLANKENHORN G, 1976, EUR J BIOCHEM, V67, P67, DOI 10.1111/j.1432-1033.1976.tb10634.x; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; BRUNMARK A, 1988, FREE RADICAL BIO MED, V5, P133, DOI 10.1016/0891-5849(88)90076-7; BUFINTON GD, 1988, BIOCHEM J, V257, P561; BUTLER J, 1987, BIOCHIM BIOPHYS ACTA, V925, P144, DOI 10.1016/0304-4165(87)90103-6; CHEN HH, 1992, BIOCHEM J, V284, P855, DOI 10.1042/bj2840855; CHEN S, 1994, PROTEIN SCI, V3, P51; CHEN SU, 1992, MOL PHARMACOL, V42, P545; Clark W.M., 1960, OXIDATION REDUCTION, P184; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; DEFLORA S, 1985, CANCER RES, V45, P3188; DODD NJF, 1984, BIOCHEM PHARMACOL, V33, P379, DOI 10.1016/0006-2952(84)90229-6; DUINE JA, 1990, TRENDS BIOCHEM SCI, V15, P96, DOI 10.1016/0968-0004(90)90189-I; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FULTZ ML, 1982, ANAL CHIM ACTA, V140, P1, DOI 10.1016/S0003-2670(01)95447-9; HOSODA S, 1974, J BIOL CHEM, V249, P6416; HUANG MT, 1979, J BIOL CHEM, V254, P3930; HUANG MT, 1978, BIOCHEM BIOPH RES CO, V83, P1253, DOI 10.1016/0006-291X(78)91356-6; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1969, J BIOL CHEM, V244, P3999; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MCWHIRTER RB, 1990, BIOCHEMISTRY-US, V269, P6919; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Muller OH, 1942, J BIOL CHEM, V145, P425; NISHIGORI H, 1989, LIFE SCI, V45, P593, DOI 10.1016/0024-3205(89)90044-1; ORDONEZ ID, 1992, BIOCHEM J, V286, P481, DOI 10.1042/bj2860481; PROCHASKA HJ, 1991, OXIDATIVE STRESS OXI, P195; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P167, DOI 10.1016/0006-2952(92)90274-M; SIEGEL D, 1990, CANCER RES, V50, P7293; SUGIMURA T, 1966, CANCER RES, V26, P1717; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V964, P175, DOI 10.1016/0304-4165(88)90164-X	36	96	98	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1198	1204		10.1074/jbc.270.3.1198	http://dx.doi.org/10.1074/jbc.270.3.1198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836380	hybrid			2022-12-25	WOS:A1995QB15600035
J	BOGDANOV, M; DOWHAN, W				BOGDANOV, M; DOWHAN, W			PHOSPHATIDYLETHANOLAMINE IS REQUIRED FOR IN-VIVO FUNCTION OF THE MEMBRANE-ASSOCIATED LACTOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCHEMICAL PROTON GRADIENT; PHOSPHOLIPID-COMPOSITION; ACIDIC PHOSPHOLIPIDS; ACTIVE-TRANSPORT; INNER MEMBRANES; VESICLES; CARRIER; TRANSLOCATION; PROTEIN; PHOSPHATIDYLGLYCEROL	Experiments with mutant Escherichia coli cells lacking phosphatidylethanolamine (PE) as a membrane component (DeChavigny, A., Heacock, P. N., and Dowhan, W. (1991) J. Biol. Chem. 266, 5323-5332) were carried out to establish whether or not PE is necessary for full function of the lac permease in vivo. The V-max for active transport of both lactose (in cells lacking beta-galactosidase, lacZ) and the unhydrolyzable lactose analog, methyl-beta-D-galactopyranoside (TMG), by mutant cells lacking PE was reduced 5-10-fold relative to cells containing PE, while the K-m for the uptake of both substrates was the same in both types of cells, The low rate of TMG and lactose uptake by PE-deficient cells was unaffected by the presence of a protonophore (uncoupler) and for TMG uptake was on the order of the greatly reduced rate of uptake in uncoupler-treated cells containing PE, The rate of entry of lactose into lacZ(+) derivatives of both types of cells, as a measure of facilitated diffusion, was nearly the same. The K-m for lactose (lacZ cells) and TMG transport in PE-deficient cells was unaffected by the presence of an uncoupler which had a small effect on V-max. In PE-containing cells these kinetic parameters for TMG transport were reduced by an uncoupler to the level found with PE-deficient cells while an uncoupler reduced lactose uptake by PE-containing (lacZ) cells to below measureable levels. Inverted membrane vesicles made from both types of cells could be loaded with TMG, but energizing TMG-loaded vesicles by ATP only induced rapid, uphill, permease-dependent efflux of TMG from PE-containing vesicles, The decrease in apparent active transport activity of cells with no PE was not due to a change in membrane permeability, to a reduced Delta(mu H+) (proton electrochemical gradient) across the cell membrane, or to a reduced level of membrane-associated lac permease protein, These results suggest that in the absence of PE the Iac permease cannot couple substrate uptake to Delta(mu H+) in order to effect accumulation of substrate and as a result only carries out facilitated diffusion.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System			Bogdanov, Mikhail/J-3695-2017		NIGMS NIH HHS [GM 20478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020478, R01GM020478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BOGDANOV M, 1994, FASEB J, V8, pA1449; BOGDANOV M, 1993, FASEB J, V7, pA1141; BOGDANOV M, 1986, DOKLADY BIOCH, V288, P200; BRABETZ W, 1993, J BACTERIOL, V175, P7488, DOI 10.1128/JB.175.22.7488-7491.1993; CHEN CC, 1984, J BIOL CHEM, V259, P150; CONSLER TG, 1991, BIOCHEMISTRY-US, V30, P1291, DOI 10.1021/bi00219a019; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; DOWHAN W, 1992, METHOD ENZYMOL, V209, P7; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; FISCHER W, 1978, BIOCHIM BIOPHYS ACTA, V528, P288, DOI 10.1016/0005-2760(78)90018-8; GHAZI A, 1981, BIOCHIM BIOPHYS ACTA, V645, P305; HAWROT E, 1978, J BIOL CHEM, V253, P8213; INTVELD G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P250, DOI 10.1016/0005-2736(92)90037-M; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P627; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LANCASTER JR, 1977, J BIOL CHEM, V252, P7657; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MALONEY PC, 1975, METHODS MEMBRANE BIO, V5, P1; Maniatis T., 1982, MOL CLONING; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MILEYKOVSKAYA EI, 1993, J BIOL CHEM, V268, P24824; Miller J.H., 1972, EXPT MOL GENETICS; MINNIKIN DE, 1971, BIOCHEM J, V124, P447, DOI 10.1042/bj1240447; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P854, DOI 10.1021/bi00624a007; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; Rilfors L, 1984, MEMBRANE FLUIDITY, P205; ROBERTSON DE, 1980, BIOCHEMISTRY-US, V19, P5692, DOI 10.1021/bi00566a005; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Seto-Young D, 1985, J MEMBRANE BIOL, V84, P256; SMITH TF, 1971, J MOL BIOL, V59, P273, DOI 10.1016/0022-2836(71)90051-9; URATANI Y, 1986, J BIOL CHEM, V261, P5450; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WILSON DM, 1985, MEMBRANE BIOCHEM, V5, P269, DOI 10.3109/09687688509150282	44	121	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					732	739		10.1074/jbc.270.2.732	http://dx.doi.org/10.1074/jbc.270.2.732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822303	hybrid			2022-12-25	WOS:A1995QB81600037
J	NALDINI, L; VIGNA, E; BARDELLI, A; FOLLENZI, A; GALIMI, F; COMOGLIO, PM				NALDINI, L; VIGNA, E; BARDELLI, A; FOLLENZI, A; GALIMI, F; COMOGLIO, PM			BIOLOGICAL ACTIVATION OF PRO-HGF (HEPATOCYTE GROWTH-FACTOR) BY UROKINASE IS CONTROLLED BY A STOICHIOMETRIC REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BOUND UROKINASE; FACTOR SCATTER FACTOR; HUMAN-MELANOMA CELLS; C-MET PROTOONCOGENE; SINGLE CHAIN FORM; PLASMINOGEN-ACTIVATOR; MOLECULAR-CLONING; EPITHELIAL-CELLS; TYROSINE KINASE; HEPATOPOIETIN-A	Hepatocyte growth factor (HGF) is a paracrine inducer of morphogenesis and invasive growth in epithelial and endothelial cells. HGF is secreted by mesenchymal cells as an inactive precursor (pro-HGF). The crucial step for HGF activation is the extracellular hydrolysis of the Arg(494)-Val(495) bond, which converts pro-HGF into alpha beta-HGF, the high-affinity ligand for the Met receptor. We previously reported that the urokinase-type plasminogen activator (uPA) activates pro-HGF in vitro. We now show that this is a stoichiometric reaction, and provide evidence for its occurrence in tissue culture. Activation involves the formation of a stable complex between pro-HGF and uPA. This complex was isolated from the in vitro reaction of pure uPA with recombinant pro-HGF, as well as from the membrane of target cells, after sequential addition of uPA and pro-HGF. On the cell membrane, the uPA HGF complex was bound to the Met receptor. Monocytic cell lines, and primary monocytes after adhesion, activated efficiently pro-HGF both on their surface and in the culture medium. This activation was inhibited by anti-catalytic anti-uPA antibodies, and occurred by a stoichiometric reaction. The stoichiometry of the activation reaction suggests that the biological effects of HGF can be titrated in vivo by the level of uPA activity. Adequate amounts of uPA can be locally provided by the macrophages, which would condition the tissue microenvironment by rendering HGF bioavailable to its target cells.			NALDINI, L (corresponding author), UNIV TURIN, SCH MED, DEPT BIOMED SCI & ONCOL, CORSO MASSIMO AZEGLIO 52, I-10126 TURIN, ITALY.		Galimi, Francesco/J-4238-2012; Naldini, Luigi/E-9083-2012; BARDELLI, Alberto/J-9721-2018	Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070; NALDINI, Luigi/0000-0002-7835-527X; Vigna, Elisa/0000-0001-9787-5732; Follenzi, Antonia/0000-0001-9780-300X				APPELLA E, 1987, J BIOL CHEM, V262, P4437; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; ELLIS V, 1991, J BIOL CHEM, V266, P12752; FRANCO P, 1992, J BIOL CHEM, V267, P19369; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALIMI F, 1993, STEM CELLS, V11, P22; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HEARING VJ, 1988, CANCER RES, V48, P1270; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KASAI S, 1985, J BIOL CHEM, V260, P2382; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; LIU C, 1992, ONCOGENE, V7, P181; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PONZETTO C, 1991, ONCOGENE, V6, P553; PYKE C, 1991, AM J PATHOL, V138, P1059; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOLF HK, 1991, HEPATOLOGY, V14, P488, DOI 10.1016/0270-9139(91)90188-2; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	81	227	234	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					603	611		10.1074/jbc.270.2.603	http://dx.doi.org/10.1074/jbc.270.2.603			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822285	hybrid			2022-12-25	WOS:A1995QB81600018
J	STULL, TL; HYUN, L; SHARETZSKY, C; WOOTEN, J; MCCAULEY, JP; SMITH, AB				STULL, TL; HYUN, L; SHARETZSKY, C; WOOTEN, J; MCCAULEY, JP; SMITH, AB			PRODUCTION AND OXIDATION OF INDOLE BY HAEMOPHILUS-INFLUENZAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; HEMOPHILUS-INFLUENZAE; NITRATE ASSIMILATION; GENES; REDUCTASE	During growth in high concentrations of iron nitrate, H. influenzae produces compounds reactive in biochemical assays for hydroxamates. Mixing experiments established that nitrate was responsible for inducing these compounds, Analysis by H-1 and C-13 NMR and high resolution mass spectrometry identified the active species as 2,2-bis(3'-indolyl)indoxyl. Bacterial production of the latter compound has been previously observed only in Pseudomonas aureofaciens. A mutant defective in the production of 2,2-bis(3'-indolyl)indoxyl was constructed by marker insertion, The formation of indole and 2,2-bis(3'-indolyl)indoxyl was quantitated by reverse-phase high pressure liquid chromatography during growth in high concentrations of nitrate. The mutant produced high concentrations of indole, but only minimal amounts of 2,2-bis(3'-indolyl)indoxyl, and also proved to be defective in nitrate reduction, These data suggest that indole may function as an electron donor for nitrate reductase in H. influenzae.	MED COLL PENN, DEPT PEDIAT, PHILADELPHIA, PA 19129 USA; MED COLL PENN, DEPT MICROBIOL IMMUNOL, PHILADELPHIA, PA 19129 USA; UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	Drexel University; Drexel University; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029611, R56AI029611] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29611] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER HE, 1953, J EXP MED, V97, P17, DOI 10.1084/jem.97.1.17; [Anonymous], 1984, COMPREHENSIVE HETERO; ATKIN CL, 1968, BIOCHEMISTRY-US, V7, P3734, DOI 10.1021/bi00850a054; CALI BM, 1989, J BACTERIOL, V171, P2666, DOI 10.1128/jb.171.5.2666-2672.1989; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAPDEVIELLE P, 1993, TETRAHEDRON LETT, V34, P2953, DOI 10.1016/S0040-4039(00)60490-2; Conn HJ, 1936, J BACTERIOL, V31, P225, DOI 10.1128/JB.31.3.225-233.1936; CRAWFORD IP, 1975, BACTERIOL REV, V39, P87, DOI 10.1128/MMBR.39.2.87-120.1975; CSAKY TZ, 1948, ACTA CHEM SCAND, V2, P450, DOI 10.3891/acta.chem.scand.02-0450; ENOCH HG, 1974, BIOCHEM BIOPH RES CO, V61, P1234, DOI 10.1016/S0006-291X(74)80416-X; GIBSON F, 1969, BIOCHIM BIOPHYS ACTA, V192, P175, DOI 10.1016/0304-4165(69)90353-5; GODFREY C, 1987, BIOCHEM J, V243, P241, DOI 10.1042/bj2430241; Hamill R, 1967, Antimicrob Agents Chemother (Bethesda), V7, P388; JETER RM, 1984, J BACTERIOL, V157, P673, DOI 10.1128/JB.157.2.673-677.1984; KRONE WJA, 1985, A VAN LEEUW J MICROB, V51, P203, DOI 10.1007/BF02310013; LAWLOR KM, 1984, J BACTERIOL, V160, P266, DOI 10.1128/JB.160.1.266-272.1984; MOAT AG, 1988, MICROBIAL PHYSL, P251; Neilands J B, 1990, Adv Inorg Biochem, V8, P63; NOHNO T, 1989, NUCLEIC ACIDS RES, V17, P2947, DOI 10.1093/nar/17.8.2947; OWEN RJ, 1987, NUCLEIC ACIDS RES, V15, P3631, DOI 10.1093/nar/15.8.3631; PIDCOCK KA, 1988, INFECT IMMUN, V56, P721, DOI 10.1128/IAI.56.4.721-725.1988; SHARETZSKY C, 1991, J BACTERIOL, V173, P1561, DOI 10.1128/jb.173.4.1561-1564.1991; SIAS SR, 1980, J GEN MICROBIOL, V118, P229; STEINHART WL, 1968, J BACTERIOL, V96, P1718, DOI 10.1128/JB.96.5.1718-1724.1968; STULL TL, 1984, INFECT IMMUN, V46, P787, DOI 10.1128/IAI.46.3.787-796.1984; WILLIAMS PH, 1979, INFECT IMMUN, V26, P925, DOI 10.1128/IAI.26.3.925-932.1979; WITKOP B, 1947, LIEBIGS ANN CHEM, V558, P98; WITKOP B, 1951, J AM CHEM SOC, V73, P713, DOI 10.1021/ja01146a066	28	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					5	8		10.1074/jbc.270.1.5	http://dx.doi.org/10.1074/jbc.270.1.5			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814418	hybrid			2022-12-25	WOS:A1995QA28700002
J	WHITELEGGE, JP; KOO, D; DINER, BA; DOMIAN, I; ERICKSON, JM				WHITELEGGE, JP; KOO, D; DINER, BA; DOMIAN, I; ERICKSON, JM			ASSEMBLY OF THE PHOTOSYSTEM-II OXYGEN-EVOLVING COMPLEX IS INHIBITED IN PSBA SITE-DIRECTED MUTANTS OF CHLAMYDOMONAS-REINHARDTII - ASPARTATE-170 OF THE D1 POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; MANGANESE-STABILIZING PROTEIN; RIBOSOMAL-RNA GENES; CHLOROPLAST TRANSFORMATION; NUCLEAR TRANSFORMATION; O2 EVOLUTION; D2 PROTEIN; MEMBRANES; BINDING; YIELD	Photosystem II catalyzes the photooxidation of water to molecular oxygen, providing electrons to the photosynthetic electron transfer chain. The D1 and D2 chloroplast encoded reaction center polypeptides bind cofactors essential for Photosystem II function. Transformation of the chloroplast genome of the eukaryotic green alga Chlamydomonas reinhardtii has allowed us to engineer site-directed mutants in which aspartate residue 170 of D1 is replaced by histidine (D170H), asparagine (D170N), threonine (D170T), or proline (D170P). Mutants D170T and D170P are completely deficient in oxygen evolution, but retain normal (D170T) or 50% (D170P) levels of Photosystem II reaction centers. D170H and D170N accumulate wild-type levels of PSII centers, yet evolve oxygen at rates approximately 45% and 15% those of control cells, respectively. Kinetic analysis of chlorophyll fluorescence in the mutants reveals a specific defect in electron donation to the reaction center. Measurements of oxygen flash yields in D170H show, however, that those reaction centers capable of evolving oxygen function normally. We conclude that aspartate residue 170 of the D1 polypeptide plays a critical role in the initial binding of manganese as the functional chloroplast oxygen-evolving complex is assembled.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; DUPONT CO INC,DEPT CENT RES & DEV,WILMINGTON,DE 19880; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; DuPont; University of California System; University of California Los Angeles					NCRR NIH HHS [S07-RR07009-26RR] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007009] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSSON B, 1987, LIGHT REACTIONS, P379; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BLOWERS AD, 1989, PLANT CELL, V1, P123, DOI 10.1105/tpc.1.1.123; BLUBAUGH DJ, 1991, BIOCHEMISTRY-US, V30, P7586, DOI 10.1021/bi00244a030; BLUBAUGH DJ, 1990, BIOCHEMISTRY-US, V29, P5109, DOI 10.1021/bi00473a016; BOCKHOLT R, 1991, FEBS LETT, V294, P59, DOI 10.1016/0014-5793(91)81343-7; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BOSCHETTI A, 1985, BIOCHIM BIOPHYS ACTA, V810, P12, DOI 10.1016/0005-2728(85)90201-4; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; BUTLER WL, 1973, BIOCHIM BIOPHYS ACTA, V292, P140, DOI 10.1016/0005-2728(73)90258-2; CHUA NH, 1977, J CELL BIOL, V74, P441, DOI 10.1083/jcb.74.2.441; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CRITCHLEY C, 1985, BIOCHIM BIOPHYS ACTA, V811, P33, DOI 10.1016/0304-4173(85)90004-7; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEROSE VJ, 1991, BIOCHEMISTRY-US, V30, P1335, DOI 10.1021/bi00219a025; DINER BA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P134, DOI 10.1016/0005-2728(92)90196-9; DINER BA, 1988, J BIOL CHEM, V263, P8972; Diner BA, 1991, CURR OPIN STRUC BIOL, V1, P546, DOI 10.1016/S0959-440X(05)80076-4; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; ERICKSON JM, 1992, PHOTOSYSTEMS STRUCTU, P101; ERICKSON JM, 1992, CURRENT RES PHOTOSYN, V3, P421; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; FICHOT O, 1990, NUCLEIC ACIDS RES, V18, P6162, DOI 10.1093/nar/18.20.6162; FORBUSH B, 1971, PHOTOCHEM PHOTOBIOL, V14, P307, DOI 10.1111/j.1751-1097.1971.tb06175.x; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P105, DOI 10.1007/BF00030070; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1989, GENETICS, V123, P281; HEISS S, 1992, PHOTOSYNTH RES, V34, P311, DOI 10.1007/BF00033448; HORTON P, 1992, METHODS PLANT BIOCH, V4, P259; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; JOHANNINGMEIER U, 1987, FEBS LETT, V211, P221, DOI 10.1016/0014-5793(87)81440-0; Joliot P., 1975, BIOENERG PHOTOSYNTH, P387; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERS A, 1992, J BIOL CHEM, V267, P17494; MARDER JB, 1987, PLANT MOL BIOL, V9, P325, DOI 10.1007/BF00014907; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1990, P NATL ACAD SCI USA, V87, P2087, DOI 10.1073/pnas.87.6.2087; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; METZ JG, 1980, FEBS LETT, V114, P61, DOI 10.1016/0014-5793(80)80861-1; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; MIYAOTOKUTOMI M, 1992, BIOCHEMISTRY-US, V31, P526, DOI 10.1021/bi00117a032; MONOD C, 1994, EMBO J, V13, P2747, DOI 10.1002/j.1460-2075.1994.tb06568.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEWMAN SM, 1990, GENETICS, V126, P875; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1992, PLANT PROTEIN ENG, P93; OETTMEIER W, 1992, PHOTOSYSTEMS STRUCTU, P349; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; PALMER JD, 1983, NATURE, V301, P92, DOI 10.1038/301092a0; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P220; PRZIBILLA E, 1991, PLANT CELL, V2, P169; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; Rochaix JD, 1992, CURR OPIN GENET DEV, V2, P785, DOI 10.1016/S0959-437X(05)80140-6; ROFFEY RA, 1994, BBA-BIOENERGETICS, V1185, P257, DOI 10.1016/0005-2728(94)90240-2; ROFFEY RA, 1991, P NATL ACAD SCI USA, V88, P9122, DOI 10.1073/pnas.88.20.9122; RUFFLE SV, 1991, PHOTOSYNTH RES, V34, P287; Rutherford A.W., 1992, PHOTOSYSTEMS STRUCTU, P179; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD JC, 1993, METHOD ENZYMOL, V217, P483; SCHRADER S, 1992, PLANT MOL BIOL, V10, P251; SCHREIBER U, 1986, PHOTOSYNTH RES, V9, P261, DOI 10.1007/BF00029749; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; STEWART AC, 1985, BIOCHIM BIOPHYS ACTA, V808, P353, DOI 10.1016/0005-2728(85)90145-8; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; TAKAHASHI Y, 1994, PLANT MOL BIOL, V5, P779; TAMURA N, 1987, BIOCHIM BIOPHYS ACTA, V890, P179, DOI 10.1016/0005-2728(87)90019-3; TANG XS, 1990, FEBS LETT, V273, P257, DOI 10.1016/0014-5793(90)81098-9; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TISCHER W, 1977, BIOCHIM BIOPHYS ACTA, V460, P113, DOI 10.1016/0005-2728(77)90157-8; TREBST A, 1991, HERBICIDE RESISTANCE IN WEEDS AND CROPS, P145; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VERMAAS W, 1990, BIOCHEMISTRY-US, V29, P5325, DOI 10.1021/bi00474a017; VERMAAS WFJ, 1992, PHOTOSYSTEMS STRUCTU, P231; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8; WURTZ EA, 1979, MOL GEN GENET, V170, P235, DOI 10.1007/BF00267056	98	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					225	235		10.1074/jbc.270.1.225	http://dx.doi.org/10.1074/jbc.270.1.225			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814379	hybrid			2022-12-25	WOS:A1995QA28700038
J	KUDEROVA, A; TANHA, J; LEE, JS				KUDEROVA, A; TANHA, J; LEE, JS			CHARACTERIZATION OF 4 NUCLEIC ACID-BINDING SINGLE-CHAIN FV-FRAGMENTS BY DIRECT AND COMPETITIVE SOLID-PHASE RADIOIMMUNOASSAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; INCLUSION-BODIES; RNA-POLYMERASE; STRANDED-DNA; EXPRESSION; PROTEINS; FAB; RENATURATION; PURIFICATION	The heavy- and light-chain variable region genes of four different nucleic acid-binding antibodies (Jel 274 and Jel 72 (specific for duplex DNA), Jel 103 (specific for poly(rI)), and Jel 318 (specific for DNA triplexes)) were cloned. Single-chain Fv fragments (scFv) in which the heavy and light chains were joined by a linker were constructed by polymerase chain reaction. The linker of 21 amino acids also served as a tag since it consisted of a repeating heptapeptide that was recognized by a specific antipeptide antibody. scFv were expressed in the cytoplasm of Escherichia coli as inclusion bodies. After purification and renaturation, a cross-linking assay was used to demonstrate that >90% of scFv were in the form of monomers. The specificity of scFv was analyzed by both direct and competitive solid-phase radioimmunoassays. scFv.103 retained its specificity for poly(rI), whereas the other three scFv still bound the original antigen, but subtle changes in the overall specificity were noted. Thus, in some cases, the conformation of the binding site may be different in the context of an scFv compared with the original IgG.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON,SK S7N 0W0,CANADA	University of Saskatchewan			Kuderova, Alena/E-3627-2012					AGAZIE YM, 1994, J BIOL CHEM, V269, P7019; ANAND NN, 1991, J BIOL CHEM, V266, P21874; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BETTER M, 1988, SCIENCE, V240, P1040; BOWDEN GA, 1991, BIO-TECHNOL, V9, P725, DOI 10.1038/nbt0891-725; BRAUN RP, 1986, MOL IMMUNOL, V23, P685, DOI 10.1016/0161-5890(86)90107-0; BRAUN RP, 1986, NUCLEIC ACIDS RES, V14, P5049, DOI 10.1093/nar/14.12.5049; BRIGIDO MM, 1993, J IMMUNOL, V150, P469; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; ESIG NA, 1993, J MOL BIOL, V231, P897; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; GIVOL D, 1991, MOL IMMUNOL, V28, P1379, DOI 10.1016/0161-5890(91)90040-Q; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1982, BIOCHEMISTRY-US, V21, P4940, DOI 10.1021/bi00263a017; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LEE JS, 1984, BIOCHEMISTRY-US, V23, P3277, DOI 10.1021/bi00309a024; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MOL CD, 1994, J BIOL CHEM, V269, P3615; MOL CD, 1994, J BIOL CHEM, V269, P3605; MONTESANO L, 1982, BIOCHEM BIOPH RES CO, V109, P7, DOI 10.1016/0006-291X(82)91558-3; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; POKKULURI PR, 1994, IN PRESS J MOL BIOL; POLYMENIS M, 1994, J IMMUNOL, V152, P5318; POWER BE, 1992, GENE, V113, P95, DOI 10.1016/0378-1119(92)90674-E; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; STOLLAR BD, 1991, MOL IMMUNOL, V28, P1399, DOI 10.1016/0161-5890(91)90042-I; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; STOLLAR BD, 1981, CLIN IMMUNOL ALLERGY, V1, P243; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABUR S, 1985, P NATL ACAD SCI USA, V82, P1074; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0	42	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32957	32962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806525				2022-12-25	WOS:A1994QA63800038
J	LIU, GH; PESSAH, IN				LIU, GH; PESSAH, IN			MOLECULAR INTERACTION BETWEEN RYANODINE RECEPTOR AND GLYCOPROTEIN TRIADIN INVOLVES REDOX CYCLING OF FUNCTIONALLY IMPORTANT HYPERREACTIVE SULFHYDRYLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; RABBIT SKELETAL-MUSCLE; CA-2+ RELEASE; CA2+ RELEASE; FOOT PROTEIN; LOCALIZATION; OXIDATION; COMPLEX; CDNA	The fluorogenic maleimide 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) has been shown to selectively form Michael adducts with hyperreactive sulfhydryls on the skeletal sarcoplasmic reticulum (SR) ryanodine receptor (RyR1) and triadin which are essential for normal Ca2+ channel function (Liu, G., Abramson, J, J,, Zable, A. C,, and Pessah, I. N, (1994) Mel. Pharmacol, 45, 189-200), The present report demonstrates a functionally important interaction between RyR1 and triadin which involves, in part, redox cycling of hyperreactive sulfhydryls in response to channel activation and inactivation, Nanomolar CPM is shown to selectively label RyR1 and triadin only in the presence of Ca2+ channel inhibitors (Mg2+, neomycin, ruthenium red, or anti-triadin antibody), Treatment of SR with channel activators (micromolar Ca2+, nanomolar ryanodine, or millimolar caffeine), 1) slows CPM labeling kinetics >10-fold, 2) negates CPM labeling of channel-associated sulfhydryls, and 3) stabilizes a high molecular weight complex (HMWC) which appears on nonreducing SDS-polyacrylamide gel electrophoresis gels, The HMWC is positively identified as RyR1 and triadin by Western blot and immunoprecipitation analyses, High-affinity [H-3]ryanodine-binding sites are immunoprecipitated by either anti-RyR1 or anti-triadin antibody dose dependently, 1,4-Naphthoquinone (less than or equal to 40 pmol/mu g protein) selectively oxidizes hyperreactive sulfhydryls on RyR1 and triadin, induces Ca2+ efflux from SR, and stabilizes the HMWC. The HMWC is reduced by beta-mercaptoethanol or dithiothreitol into its component RyR1 and triadin protomers, The results provide direct evidence for the existence of a functionally important complex between RyR1 and triadin whose stability is determined by the redox state of hyperreactive sulfhydryl moieties which are allosterically regulated by physiological and pharmacological channel ligands, The present results suggest a possible molecular mechanism by which localized transient changes in the redox state within the RyR1 triadin complex can signal information across the SE membrane.	UNIV CALIF DAVIS, SCH VET MED, DEPT MOLEC BIOSCI, DIV PHARMACOL & TOXICOL, DAVIS, CA 95616 USA	University of California System; University of California Davis			Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005002, R01ES005002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05002, ES05707] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRANDT NR, 1993, J MEMBRANE BIOL, V131, P219, DOI 10.1007/BF02260110; BRANDT NR, 1992, FEBS LETT, V299, P57, DOI 10.1016/0014-5793(92)80100-U; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHIESI M, 1988, BIOCHEM BIOPH RES CO, V154, P1, DOI 10.1016/0006-291X(88)90641-9; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; FLUCHER BE, 1993, J CELL BIOL, V123, P1161, DOI 10.1083/jcb.123.5.1161; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAYARAMAN T, 1992, J BIOL CHEM, V49, P467; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOSHITA M, 1993, EXPERIENTIA, V49, P282, DOI 10.1007/BF01923402; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU GH, 1994, MOL PHARMACOL, V45, P189; LIU GH, 1990, JPN J PHYSL; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; LU XY, 1994, J BIOL CHEM, V269, P6511; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; MACK MM, 1994, J BIOL CHEM, V269, P23236; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MIYAMOTO H, 1982, J MEMBRANE BIOL, V66, P193, DOI 10.1007/BF01868494; OHKUSA T, 1991, J BIOCHEM-TOKYO, V109, P609, DOI 10.1093/oxfordjournals.jbchem.a123428; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SIPPEL TO, 1981, J HISTOCHEM CYTOCHEM, V29, P314, DOI 10.1177/29.2.7019305; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	44	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33028	33034						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806531				2022-12-25	WOS:A1994QA63800047
J	CAI, DY; KLINMAN, JP				CAI, DY; KLINMAN, JP			EVIDENCE FOR A SELF-CATALYTIC MECHANISM OF 2,4,5-TRIHYDROXYPHENYLALANINE QUINONE BIOGENESIS IN YEAST COPPER AMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVE-SITE; COORDINATION CHEMISTRY; SUBSTRATE; COFACTOR; EXCHANGE; WATER; STATE	Copper amine oxidases are representative of a new class of redox enzymes that contain a peptide-bound quinone cofactor, generated by posttranslational modification of amino acid side chain(s). We have investigated the mechanism for the biogenesis of 2,4,5-trihydroxyphenylalanine quinone (TPQ) in amine oxidase with two site-specific mutants of the yeast methylamine oxidase, Our results show that the capacity for TPQ formation in vivo is abolished when a putative ligand to copper, His-456, is changed to Asp; this H456D mutant binds copper at a low level (similar to 4.1%), relative to the wildtype protein, In contrast, altering the active site consensus sequence that contains the precursor tyrosine does not affect TPQ production. The data implicate a self-catalysis mechanism for TPQ biogenesis, in which the protein-bound copper plays a key role, We propose that the minimal information required for TPQ biogenesis lies in a structural motif consisting of the copper site and the precursor tyrosine.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; COLLISON D, 1989, BIOCHEM J, V264, P663, DOI 10.1042/bj2640663; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DOOLEY DM, 1991, J AM CHEM SOC, V113, P754, DOI 10.1021/ja00003a004; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1989, J AM CHEM SOC, V111, P102, DOI 10.1021/ja00183a018; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; MCCRACKEN J, 1992, J AM CHEM SOC, V114, P3715, DOI 10.1021/ja00036a021; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; PAZ MA, 1991, J BIOL CHEM, V266, P689; SCOTT RA, 1985, J AM CHEM SOC, V107, P4348, DOI 10.1021/ja00300a055; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	21	133	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32039	32042						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798196				2022-12-25	WOS:A1994PX30400005
J	JOCKERS, R; LINDER, ME; HOHENEGGER, M; NANOFF, C; BERTIN, B; STROSBERG, AD; MARULLO, S; FREISSMUTH, M				JOCKERS, R; LINDER, ME; HOHENEGGER, M; NANOFF, C; BERTIN, B; STROSBERG, AD; MARULLO, S; FREISSMUTH, M			SPECIES-DIFFERENCE IN THE G-PROTEIN SELECTIVITY OF THE HUMAN AND BOVINE A(1)-ADENOSINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; A1 ADENOSINE RECEPTORS; BETA-GAMMA-SUBUNITS; ESCHERICHIA-COLI; ALPHA-SUBUNITS; MOLECULAR-CLONING; HUMAN BRAIN; ADRENERGIC-RECEPTORS; RADIOLIGAND BINDING; 2 FORMS	The purified bovine brain A(1)-adenosine receptor has previously been shown to discriminate among closely related G protein alpha-subunits. To obtain analogous information for the human receptor, the cDNA coding for the human A(1)-adenosine receptor was inserted into a plasmid placing the synthesis of the receptor protein under the control of the MalE promoter, Following induction by maltose, active receptor accumulated in Escherichia coli membranes, Binding of the antagonist 8-[H-3]cyclopentyl-1,3-dipropylxanthine to E. coli membranes (K-D similar to 2 nM, B-max similar to 0.2-0.4 pmol/mg) showed the appropriate pharmacological profile, Incubation of E. coli membranes with purified G(o,i)-reconstituted guanine nucleotide-sensitive high affinity binding of the agonist (-)[I-125] N-6-3-(iodo-4-hydroxyphenylisopropyl) adenosine to the receptor (K-D similar to 1 nM), In the presence of purified beta gamma-subunit, the recombinant receptor interacted equally well with the recombinant G protein alpha-subunits G(i alpha-1), G(i alpha-2), G(i alpha-3), G(o alpha) displayed a lower affinity for the receptor while G(5 alpha) was inactive, Parallel experiments were carried out in bovine and human brain membranes pretreated with N-ethylmaleimide to inactivate the endogenous G(o)/G(i) proteins; G(i alpha-3) was most potent in reconstituting I-125-HPIA binding to bovine membranes, while G(i alpha-1), G(i alpha-2), and G(o alpha) displayed similar affinities, However, in human membranes, G(i alpha-1), G(i alpha-2), and G(i alpha-3), were equipotent and high concentrations of G(o alpha) were required to promote I-125-HPIA binding. These observations show (i) that functional human A(1)-adenosine receptors were synthesized in E. coli; (ii) that the pattern of G protein coupling is identical, for the recombinant human A(1)-receptor and its counterpart in the native membrane; (iii) and that species differences between bovine and human receptor exist not only in their pharmacological profile but also in their G protein specificity suggesting that species homologues of receptors may use different signaling mechanisms.	UNIV VIENNA,INST PHARMACOL,A-1090 VIENNA,AUSTRIA; INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE; WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	University of Vienna; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL)			Marullo, Stefano/C-6142-2008; Jockers, Ralf/P-2272-2017; Linder, Maurine/AAU-9999-2021; Hohenegger, Martin/AAF-6479-2020; Jockers, Ralf/Q-2100-2019	Marullo, Stefano/0000-0001-9604-9973; Jockers, Ralf/0000-0002-4354-1750; Linder, Maurine/0000-0003-2202-9712; Jockers, Ralf/0000-0002-4354-1750; Freissmuth, Michael/0000-0001-9398-1765; Hohenegger, Martin/0000-0001-6537-9574; nanoff, christian/0000-0002-8857-2470	NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTIN B, 1992, J BIOL CHEM, V267, P8200; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; ENSEN CJ, 1994, MOL PHARMACOL, V45, P294; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; FREISSMUTH M, 1991, BIOCHEM J, V275, P651, DOI 10.1042/bj2750651; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FREISSMUTH M, 1987, N-S ARCH PHARMACOL, V335, P438, DOI 10.1007/BF00165560; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GALEN PJM, 1991, MED RES REV, V12, P423; GARWINS P, 1992, J BIOL CHEM, V267, P16081; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; INUIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KLOTZ KN, 1991, N-S ARCH PHARMACOL, V343, P196, DOI 10.1007/BF00168610; LEE E, 1992, J BIOL CHEM, V267, P1212; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1984, MOL PHARMACOL, V26, P414; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LINDER ME, 1994, METHOD ENZYMOL, V237, P254; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MARULLO S, 1989, BIO-TECHNOL, V7, P923, DOI 10.1038/nbt0989-923; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUNSHI R, 1990, MOL PHARMACOL, V38, P170; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NAKATA H, 1992, EUR J BIOCHEM, V206, P171, DOI 10.1111/j.1432-1033.1992.tb16914.x; NAKATA H, 1989, J BIOL CHEM, V264, P16545; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STILES GL, 1992, J BIOL CHEM, V267, P6451; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	53	99	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32077	32084						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798201				2022-12-25	WOS:A1994PX30400013
J	MOREN, A; OLOFSSON, A; STENMAN, G; SAHLIN, P; KANZAKI, T; CLAESSONWELSH, L; TENDIJKE, P; MIYAZONO, K; HELDIN, CH				MOREN, A; OLOFSSON, A; STENMAN, G; SAHLIN, P; KANZAKI, T; CLAESSONWELSH, L; TENDIJKE, P; MIYAZONO, K; HELDIN, CH			IDENTIFICATION AND CHARACTERIZATION OF LTBP-2, A NOVEL LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; MARFAN-SYNDROME; TGF-BETA; HUMAN-PLATELETS; FIBRILLIN GENES; MESSENGER-RNA; RECEPTOR; FACTOR-BETA-1; EXPRESSION; SECRETION	Latent transforming growth factor-beta (TGF-beta)-binding protein (LTBP) is a component of the latent TGF-beta complex in human platelets. LTBP is composed of two different cysteine-rich repeat sequences, i.e. epidermal growth factor (EGF)-like repeats and a repeat containing 8 cysteine residues. The overall structure of LTBP is similar to those of the microfibrillar proteins fibrillin-1 and fibrillin-2. Here we report the identification of a novel protein termed LTBP-2, which is structurally related to LTBP. cDNA for LTBP-2 was obtained from human foreskin fibroblast cDNA libraries using a fragment of the LTBP cDNA as a probe. LTBP-2 is composed of 20 EGF-like repeats and four copies of the 8-cysteine repeat. The amino acid sequence of LTBP-2 is 41% identical to that of LTBP and 25% identical to that of fibrillin-1. LTBP-2 is synthesized as a 240-kDa protein by human foreskin fibroblasts and also by COS cells transfected with the isolated LTBP-2 cDNA Similar to LTBP, a considerable part of LTBP-2 was found to be associated with extracellular matrix. Co-transfection of cDNAs for LTBP-2 and TGF-beta 1 revealed that LTBP-2 forms a high molecular weight complex with the TGF-beta 1 precursor. The LTBP-S gene was assigned to chromosome 14q24. These results indicate that different forms of latent TGF-beta complexes occur and suggest that the different associated proteins may function to target the complexes to specific sites.	LUDWIG INST CANC RES, CTR BIOMED, S-75124 UPPSALA, SWEDEN; SAHLGRENS UNIV HOSP, DEPT PATHOL, CANC GENET LAB, S-41345 GOTHENBURG, SWEDEN	Ludwig Institute for Cancer Research; Sahlgrenska University Hospital			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Claesson-Welsh, Lena/0000-0003-4275-2000				BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COLOSETTI P, 1993, FEBS LETT, V320, P140, DOI 10.1016/0014-5793(93)80079-A; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DAVIS C G, 1990, New Biologist, V2, P410; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIZOI T, 1993, CANCER RES, V53, P183; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STENMAN G, 1994, CYTOGENET CELL GENET, V66, P117, DOI 10.1159/000133680; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TENDIJKE P, 1988, ONCOGENE, V3, P721; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WALTENBERGER J, 1993, AM J PATHOL, V142, P71; YAMAZAKI M, 1994, AM J PATHOL, V144, P221; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	42	162	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32469	32478						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798248				2022-12-25	WOS:A1994PX30400069
J	TORRE, E; MCNIVEN, MA; URRUTIA, R				TORRE, E; MCNIVEN, MA; URRUTIA, R			DYNAMIN-1 ANTISENSE OLIGONUCLEOTIDE TREATMENT PREVENTS NEURITE FORMATION IN CULTURED HIPPOCAMPAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; REVERSIBLE BLOCKAGE; GTPASE; PROTEINS; MICROTUBULES; ENDOCYTOSIS; DOMAINS; SHIBIRE	Dynamin 1 (D100) is a microtubule-activated GTPase that is believed to play a role in the early steps of receptor-mediated endocytosis. Previous studies on the characterization of the Drosophila dynamin gene homolog, known as shibire, suggest that this protein may also participate in the formation of neuronal processes. To understand the role of rat brain dynamin 1 in neuronal morphogenesis, we correlated the intracellular levels of dynamin with the formation of neurites in rat hippocampal neurons and neuroblastoma N1E-115 cells in vitro. Quantitative Western and Northern blot analyses show that dynamin levels increase during neurite formation in both the hippocampal neurons and N1E-115 cells and decrease in N1E-115 cells during serum-induced neurite retraction. Furthermore, using antisense technology, we investigated the effect of decreased intracellular levels of dynamin on neurite formation in cultured embryonic hippocampal neurons. Antisense oligonucleotides against sequences surrounding the initiation codon of the rat brain dynamin gene (D100) reduce the intracellular levels of dynamin by approximately 90% and impair the formation of the minor and axon-like processes in a dose-dependent manner. Taken together, these results suggest that dynamin-mediated processes are necessary for normal neuronal morphogenesis.	MAYO CLIN & MAYO FDN,DEPT MOLEC NEUROSCI,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905; UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908	Mayo Clinic; Mayo Clinic; University of Virginia					NIAAA NIH HHS [AA09227] Funding Source: Medline; NIDDK NIH HHS [DK 44650] Funding Source: Medline; NINDS NIH HHS [1R29 NS 32882-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044650, R29DK044650, R01DK044650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009227] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Banker G., 1991, CULTURING NERVE CELL; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANSEN SH, 1991, EXP CELL RES, V199, P19; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KIM YT, 1987, J NEUROSCI, V7, P3245; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH HN, 1993, J NEUROSCI, V13, P4282; MASUR S, 1989, J NEUROGENET, V6, P191; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; PRASAD KN, 1975, BIOL REV, V50, P129, DOI 10.1111/j.1469-185X.1975.tb01055.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773	37	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32411	32417						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798241				2022-12-25	WOS:A1994PX30400060
J	TAKAHASHI, S; SUZUKI, J; KOHNO, M; OIDA, K; TAMAI, T; MIYABO, S; YAMAMOTO, T; NAKAI, T				TAKAHASHI, S; SUZUKI, J; KOHNO, M; OIDA, K; TAMAI, T; MIYABO, S; YAMAMOTO, T; NAKAI, T			ENHANCEMENT OF THE BINDING OF TRIGLYCERIDE-RICH LIPOPROTEINS TO THE VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BY APOLIPOPROTEIN-E AND LIPOPROTEIN-LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT ATHEROSCLEROTIC LESIONS; MOUSE PERITONEAL-MACROPHAGES; CHOLESTERYL ESTER SYNTHESIS; CULTURED HUMAN FIBROBLASTS; SMOOTH-MUSCLE CELLS; FAMILIAL HYPERCHOLESTEROLEMIA; HEPARAN-SULFATE; MEDIATED UPTAKE; APOPROTEIN-E; FOAM CELLS	The low density lipoprotein (LDL) receptor plays a crucial role in cholesterol metabolism, A related protein, designated the very low density lipoprotein (VLDL) receptor, that specifically binds apolipoprotein (ape) E has recently been characterized and shown to be expressed in heart, muscle and adipose tissue and the human monocyte-macrophage cell line THP-1, The VLDL receptor binds and internalizes VLDL and intermediate density lipoprotein from Watanabe heritable hyperlipidemic (WHHL) rabbits as well as beta-migrating VLDL from cholesterol-fed rabbits but not LDL from WHHL rabbits, Chinese hamster ovary (CHO) cells transfected with the rabbit VLDL receptor cDNA have now been shown to bind or internalize VLDL (d < 1.006 g/ml) isolated from fasted normolipidemic human subjects with lower affinity than WHHL-VLDL or rabbit beta-VLDL, However, binding and internalization were markedly enhanced when fasted human VLDL was preincubated with either recombinant human apoE (3/3) or lipoprotein lipase (LPL) in CHO cells overexpressing the rabbit or human VLDL receptor, CHO cells transfected with both the rabbit VLDL receptor cDNA and the human LPL cDNA effectively bound, internalized, and degraded fasted human VLDL without pretreatment. Treatment of heparinase reduced the effect of LPL-mediated binding at 4 degrees C, but the inhibitory effect was lower at 37 degrees C, Pseudomonas LPL also enhanced the binding of human fasted VLDL to the VLDL receptor at 37 degrees C in CHO cells overexpressing the human VLDL receptor, Taken together, LPL causes the enhancement of triglyceride-rich lipoproteins binding to the VLDL receptor via both the formation of bridge between lipoproteins and heparan sulfate proteoglycans and its lipolytic effect, Ligand blot analysis showed that the apparent molecular mass of the VLDL receptor is 118 kDa, which is smaller than that of the LDL receptor, These results indicate that the VLDL receptor recognizes both triglyceride-rich lipoproteins that are also relatively rich in apoE, as well as the remnants of triglyceride-rich lipoproteins after catabolism and the interaction with heparan sulfate proteoglycans by LPL, The VLDL receptor may thus function as a receptor for remnants of triglyceride-rich lipoproteins in extrahepatic tissues.	TOHOKU UNIV,CTR GENE RES,SENDAI,MIYAGI 981,JAPAN	Tohoku University	TAKAHASHI, S (corresponding author), FUKUI MED SCH,DEPT INTERNAL MED 3,MATSUOKA,FUKUI 91011,JAPAN.							BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVER.G, 1991, EUR J BIOCHEM, V106, P557; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO P, 1992, BIOCHEM BIOPH RES CO, V183, P514, DOI 10.1016/0006-291X(92)90512-J; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; FLEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOTODA T, 1989, NUCLEIC ACIDS RES, V17, P2351, DOI 10.1093/nar/17.6.2351; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFMANN SL, 1989, J BIOL CHEM, V264, P8260; IKEDA Y, 1990, J LIPID RES, V31, P1911; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAWAMURA M, 1994, ARTERIOSCLER THROMB, V14, P235, DOI 10.1161/01.ATV.14.2.235; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KITA T, 1986, J CLIN INVEST, V77, P1460, DOI 10.1172/JCI112458; KOKUSHO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1743, DOI 10.1080/00021369.1982.10865342; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRAEMER FB, 1983, J BIOL CHEM, V258, P2190; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LINDQVIST P, 1983, J BIOL CHEM, V258, P9086; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MAHLEY RW, 1980, J LIPID RES, V21, P970; MAHLEY RW, 1979, ATHER REV, V5, P1; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NOZAKI S, 1984, CLIN CHEM, V30, P748; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; OKA K, 1994, EUR J BIOCHEM, V244, P975; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SHIBUI T, 1991, J BIOTECHNOL, V17, P109, DOI 10.1016/0168-1656(91)90002-D; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANLENTEN BJ, 1985, J BIOL CHEM, V260, P8783; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINDLER E, 1985, J LIPID RES, V26, P556; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143	60	203	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15747	15754		10.1074/jbc.270.26.15747	http://dx.doi.org/10.1074/jbc.270.26.15747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797576	hybrid			2022-12-25	WOS:A1995RG53800049
J	CHAZENBALK, GD; RAPOPORT, B				CHAZENBALK, GD; RAPOPORT, B			EXPRESSION OF THE EXTRACELLULAR DOMAIN OF THE THYROTROPIN RECEPTOR IN THE BACULOVIRUS SYSTEM USING A PROMOTER ACTIVE EARLIER THAN THE POLYHEDRIN PROMOTER - IMPLICATIONS FOR THE EXPRESSION OF FUNCTIONAL HIGHLY GLYCOSYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; SITE-DIRECTED MUTAGENESIS; TSH RECEPTOR; INSECT CELLS; RADIORECEPTOR ASSAY; HORMONE RECEPTOR; GRAVES-DISEASE; BINDING; AUTOANTIBODIES; REGION	Conventional baculovirus vectors that utilize the very late polyhedrin promoter have not proved successful for expressing a thyrotropin (TSH) receptor capable of ligand and Graves' disease autoantibody binding comparable to the receptor produced in mammalian cells. Because of the clinical importance of high level expression of this protein, we reassessed the baculovirus system using a new transfer vector (pAcMP3) containing the late basic protein promoter, which functions earlier than the classical polyhedrin promoter. Maximal synthesis of the [S-35]methionine labeled TSH receptor extracellular domain, affinity-purified using a 6-histidine tag, occurred earlier (1 day after insect cell infection) than with a vector (pVL1393) containing the polyhedrin promoter. The pAcMP3-derived TSH receptor extracellular domain was larger (similar to 68 kDa) than the pVL1393-derived protein (similar to 63 kDa). Only the 68-kDa product was secreted, albeit in trace amounts detectable only by pre cursor labeling. Enzymatic deglycosylation reduced both 68- and 63-kDa cellular proteins to similar to 54 kDa, indicating that the pAcMP3 vector generated a protein with greater carbohydrate content. However, despite its greater degree of glycosylation, most of the 68-kDa protein remained within the cell, almost entirely in the particulate fraction. Remarkably, the trace amounts of 68-kDa receptor protein affinity-purified from the soluble cytosolic fraction of infected insect cells completely neutralized TSH receptor autoantibodies in patients' sera and partly inhibited TSH binding. In conclusion, a baculovirus vector with a promoter active earlier than the conventional polyhedrin promoter generates a more glycosylated and functional TSH receptor extracellular domain protein, albeit at low levels. These data carry important implications for the expression by baculovirus vectors of functional, highly glycosylated proteins.	VET ADM MED CTR,THYROID MOLEC BIOL UNIT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHRISTOPHE S, 1993, BIOCHEM BIOPH RES CO, V196, P402, DOI 10.1006/bbrc.1993.2263; FILETTI S, 1991, J CLIN ENDOCR METAB, V72, P1096, DOI 10.1210/jcem-72-5-1096; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HARFST E, 1992, MOL CELL ENDOCRINOL, V83, P117, DOI 10.1016/0303-7207(92)90152-V; HARFST E, 1994, MOL CELL ENDOCRINOL, V102, P77, DOI 10.1016/0303-7207(94)90100-7; HARFST E, 1992, J MOL ENDOCRINOL, V9, P227, DOI 10.1677/jme.0.0090227; HARFST E, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90273-6; HUANG GC, 1992, J MOL ENDOCRINOL, V8, P137, DOI 10.1677/jme.0.0080137; HUANG GC, 1993, J MOL ENDOCRINOL, V10, P127, DOI 10.1677/jme.0.0100127; JARVIS DL, 1993, J BIOL CHEM, V268, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XB, 1993, J BIOL CHEM, V268, P1513; LOOSFELT H, 1992, P NATL ACAD SCI USA, V895, P3765; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARKER EM, 1991, J BIOL CHEM, V266, P519; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETAJAREPO UE, 1993, BIOCHEM J, V292, P839, DOI 10.1042/bj2920839; REILANDER H, 1991, FEBS LETT, V2, P441; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEETHARAMAIAH GS, 1993, AUTOIMMUNITY, V14, P315, DOI 10.3109/08916939309079234; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; SHEWRING G, 1982, CLIN ENDOCRINOL, V17, P409, DOI 10.1111/j.1365-2265.1982.tb01607.x; SHI YF, 1993, THYROID, V3, P129, DOI 10.1089/thy.1993.3.129; SISSOM J, 1994, BIOCHEM J, V261, P119; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI O, 1991, BIOCHEM BIOPH RES CO, V179, P319, DOI 10.1016/0006-291X(91)91372-J; VASUDEVAN S, 1991, FEBS LETT, V283, P52, DOI 10.1016/0014-5793(91)80551-D; ZHANG R, 1991, BIOCHEM BIOPH RES CO, V181, P804, DOI 10.1016/0006-291X(91)91261-A	35	73	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1543	1549		10.1074/jbc.270.4.1543	http://dx.doi.org/10.1074/jbc.270.4.1543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829482	hybrid			2022-12-25	WOS:A1995QD20400012
J	MUTERO, A; CAMP, S; TAYLOR, P				MUTERO, A; CAMP, S; TAYLOR, P			PROMOTER ELEMENTS OF THE MOUSE ACETYLCHOLINESTERASE GENE - TRANSCRIPTIONAL REGULATION DURING MUSCLE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; CREATINE-KINASE ENHANCER; DNA-BINDING; UNTRANSLATED REGIONS; MYOGENIC FACTORS; CHAIN GENE; EXPRESSION; RECEPTOR; MYOD; PROTEIN	The increase in acetylcholinesterase expression during muscle differentiation from myoblasts to myotubes was shown previously to reflect primarily a greater stability of the messenger RNA (mRNA). Here, we investigate the regulation of the acetylcholinesterase gene during early determination of the muscle phenotype. (i) We employ myogenic transcription factors to transform non-muscle cells into myoblasts in order to assess the role of the myogenic transcription factors in this regulation. (ii) We analyze the Ache promoter region by deletion analysis, point mutagenesis, and gel mobility shift assays, The myogenic transcription factors do not accelerate transcription of the Ache gene in spite of the presence of E-boxes at -335 base pairs from the start of transcription and in the first intron, and they are not able to trigger stabilization of the Ache mRNA when constitutively expressed in 10T1/2 fibroblasts. A GC-rich region (at -105 to -59 base pairs from the start of transcription) containing overlapping binding sites for the transcription factors Sp1 and Egr-1 is essential for promoter activity, Mutation of the Sp1 sites dramatically reduces the promoter activity while mutation of the Egr-1 sites has little effect. Sp1 and Egr-1 compete for binding to overlapping sites and an increase in Egr-1 decreases the expression of the Ache gene.			MUTERO, A (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVANS S, 1987, J BIOL CHEM, V262, P4911; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANS MS, 1994, J BIOL CHEM, V269, P14170; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LI Y, 1993, J BIOL CHEM, V268, P3563; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MERLIE JP, 1989, NATURE, V317, P86; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POLLWEIN P, 1993, BIOCHEM BIOPH RES CO, V190, P637, DOI 10.1006/bbrc.1993.1096; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SALMON AM, 1992, NEUROREPORT, V3, P973, DOI 10.1097/00001756-199211000-00006; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	59	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1866	1872		10.1074/jbc.270.4.1866	http://dx.doi.org/10.1074/jbc.270.4.1866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829523	hybrid			2022-12-25	WOS:A1995QD20400058
J	PERELROIZEN, I; CARLIER, MF; PANTALONI, D				PERELROIZEN, I; CARLIER, MF; PANTALONI, D			BINDING OF BIVALENT CATION AND NUCLEOTIDE TO G-ACTIN IN THE PRESENCE OF PROFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT METAL-ION; LOW-AFFINITY SITES; ACANTHAMOEBA PROFILIN; MONOMERIC ACTIN; F-ACTIN; ATP; FILAMENT; EXCHANGE; THYMOSIN-BETA-4; MECHANISM	The effect of profilin, a G-actin binding protein, on the mechanism of exchange of the tightly bound metal ion and nucleotide on G-actin, has been investigated, 1) In low ionic strength buffer, profilin increases the rates of Ca2+ and Mg2+ dissociation from G-actin 250- and 50-fold, respectively, On the profilin-actin complex as well as on G-actin alone, nucleotide exchange is dependent on the concentration of divalent metal ion and is kinetically limited, at low concentration of metal ion, by the dissociation of the metal ion, 2) Under physiological ionic conditions, nucleotide exchange on G-actin is 1 order of magnitude faster than at low ionic strength. The rate of MgATP dissociation is increased by profilin from 0.05 s(-1) to 2 s(-1), the rate of MgADP dissociation is increased from 0.2 s(-1) to 24 s(-1). The dependences of the exchange rates on profilin concentration are consistent with a high affinity (5 x 10(6) to 10(7) M(-1)) of profilin for ATP G-actin, and a 20-fold lower affinity for ADP-G-actin, Profilin binding to actin lowers the affinity of metal-nucleotide by about 1 order of magnitude, These results restrain the possible roles of profilin in actin assembly in vivo.			PERELROIZEN, I (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							ATTRI AK, 1991, J BIOL CHEM, V266, P6815; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1986, J BIOL CHEM, V261, P778; CARLIER MF, 1991, J BIOL CHEM, V266, P1; ESTES JE, 1987, J BIOL CHEM, V262, P4952; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; FRIEDEN C, 1982, J BIOL CHEM, V257, P2882; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GERSHMAN LC, 1991, J BIOL CHEM, V266, P76; GERSHMAN LC, 1986, BIOCHEM BIOPH RES CO, V135, P607, DOI 10.1016/0006-291X(86)90036-7; GOLDSCHMIDTCLER.PJ, 1991, J CELL BIOL, V113, P1081; GOLDSCHMIDTCLER.PJ, 1992, MOL BIOL CELL, V3, P1015; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; KABSCH W, NATURE, V347, P37; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; Maciver S. K., 1993, Molecular Biology of the Cell, V4, p152A; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MOCKRIN SC, 1990, BIOCHEMISTRY-US, V19, P5359; NACHMIAS VT, 1990, CURR OPIN CELL BIOL, V5, P56; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SAFER D, 1991, J BIOL CHEM, V266, P4029; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELDEN LA, 1989, J BIOL CHEM, V264, P9271; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT J, 1993, CELL, V75, P836; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TSENG PCH, 1984, J CELL BIOL, V98, P214, DOI 10.1083/jcb.98.1.214; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7759, DOI 10.1021/bi00420a026	47	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1501	1508		10.1074/jbc.270.4.1501	http://dx.doi.org/10.1074/jbc.270.4.1501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829477	hybrid			2022-12-25	WOS:A1995QD20400006
J	REZZONICO, R; PONZIO, G; LOUBAT, A; LALLEMAND, D; PROUDFOOT, A; ROSSI, B				REZZONICO, R; PONZIO, G; LOUBAT, A; LALLEMAND, D; PROUDFOOT, A; ROSSI, B			2 DISTINCT SIGNALING PATHWAYS ARE INVOLVED IN THE CONTROL OF THE BIPHASIC JUNB TRANSCRIPTION INDUCED BY INTERLEUKIN-6 IN THE B-CELL HYBRIDOMA-7TD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-II; DNA-BINDING ACTIVITY; PLASMACYTOMA GROWTH-FACTOR; C-JUN; RESPONSE ELEMENT; TYROSINE KINASE; GENE-TRANSCRIPTION; CYCLE PROGRESSION; NUCLEAR FACTOR; MESSENGER-RNA	We have measured the level of junB mRNA in the B hybridoma cell line 7TD1, under interleukin-6 (IL-6) stimulation. IL-6 increases junB mRNA in a biphasic fashion, The first early-induced peak was transient and likely corresponds to the well documented typical junB mRNA, stimulated in response to numerous growth factors, including IL-6, At variance, the second peak which has never been reported previously, lasted several hours, As a consequence of its effect on junB mRNA, IL-6 stimulated, in a biphasic fashion, the nuclear accumulation of the JunB protein, In this study, we demonstrated that IL-6 regulation occurred exclusively at the transcriptional level and that the bimodal increase of junB mRNA and JunB protein can be accounted for by a biphasic stimulation of junB transcription. Furthermore, our data point to two major differences between the mechanism of control of the early and the late IL-6-induced junB transcription waves. First, cycloheximide strongly potentiated the transcription of the second wave, whereas it failed to affect the early-induced burst, Second, tyrphostin, a tyrosine kinase inhibitor, impaired the expression of the first but not the second junB mRNA peak, Conversely, genistein, another tyrosine kinase inhibitor, totally abolished the expression of the second peak of junB mRNA whereas it did not affect the expression of the first peak. Altogether these data indicate that, in 7TD1 cells, IL-6 controls junB transcription in a biphasic fashion by means of two separate transduction pathways.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			lallemand, dominique/O-7445-2017; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016	lallemand, dominique/0000-0002-0212-7342; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641				AGBOTOUNOU WK, 1994, BIOCHEM PHARMACOL, V48, P505, DOI 10.1016/0006-2952(94)90280-1; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANAFI M, 1992, J BIOL CHEM, V267, P4518; ANDUS T, 1987, FEBS LETT, V221, P18, DOI 10.1016/0014-5793(87)80344-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARTER R, 1991, ONCOGENE, V6, P229; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KITABAYASHI I, 1993, J BIOL CHEM, V266, P14482; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; OFFIR R, 1990, NATURE, V348, P78; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; PULVERER BJ, 1993, ONCOGENE, V8, P407; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAI Y, 1988, J IMMUNOL, V140, P508; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; UYTTENHOVE C, 1988, J EXP MED, V167, P1417, DOI 10.1084/jem.167.4.1417; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	56	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1261	1268		10.1074/jbc.270.3.1261	http://dx.doi.org/10.1074/jbc.270.3.1261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836389	hybrid			2022-12-25	WOS:A1995QB15600044
J	MARFATIA, SM; LUE, RA; BRANTON, D; CHISHTI, AH				MARFATIA, SM; LUE, RA; BRANTON, D; CHISHTI, AH			IDENTIFICATION OF THE PROTEIN 4.1 BINDING INTERFACE ON GLYCOPHORIN-C AND GLYCOPHORIN-P55, A HOMOLOG OF THE DROSOPHILA DISKS-LARGE TUMOR-SUPPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; SEPTATE JUNCTIONS; ERYTHROCYTE; GENE; SKELETON; STABILITY; CONTAINS; LINKAGE; KINASE; DOMAIN	Protein 4.1 is the prototype of a family of proteins that include ezrin, talin, brain tumor suppressor merlin, and tyrosine phosphatases, All members of the protein 4.1 superfamily share a highly conserved N-terminal 30-kDa domain whose biological function is poorly understood. It is believed that the attachment of the cytoskeleton to the membrane may be mediated via this 30-kDa domain, a function that requires formation of multiprotein complexes at the plasma membrane, In this investigation, synthetically tagged peptides and bacterially expressed proteins were used to map the protein 4.1 binding site on human erythroid glycophorin C, a transmembrane glycoprotein, and on human erythroid p55, a palmitoylated peripheral membrane phosphoprotein. The results show that the 30-kDa domain of protein 4.1 binds to a 12-amino acid segment within the cytoplasmic domain of glycophorin C and to a positively charged, 39-amino acid motif in p55, Sequences similar to this charged motif are conserved in other members of the p55 superfamily, including the Drosophila discs-large tumor suppressor protein, Our data provide new insights into how protein 4.1, glycophorin C, p55, and their non-erythroid homologues, interact with the cytoskeleton to exert their physiological effects.	TUFTS UNIV,SCH MED,ST ELIZABETH MED RES,DEPT BIOMED RES,BOSTON,MA 02135; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	St. Elizabeth's Medical Center; Tufts University; Harvard University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, R01HL017411, R01HL051445, R56HL051445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17411, HL51445, HL37462] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANDERSON RA, 1989, RED BLOOD CELL MEMBR, P187; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; CHASIS JA, 1992, BLOOD, V80, P1869; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLIN Y, 1986, J BIOL CHEM, V261, P229; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; CORREAS I, 1986, J BIOL CHEM, V261, P3310; FEHON RG, 1994, DEVELOPMENT, V120, P545; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KIM CLV, 1989, J BIOL CHEM, V264, P20407; KISTNER U, 1993, J BIOL CHEM, V268, P4580; LETO TL, 1984, J BIOL CHEM, V259, P4603; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LING E, 1988, J BIOL CHEM, V263, P2209; LOWINGER L, 1988, EMBO J, V7, P2301; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; REID ME, 1987, BLOOD, V69, P1068; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	38	170	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					715	719		10.1074/jbc.270.2.715	http://dx.doi.org/10.1074/jbc.270.2.715			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822301	hybrid			2022-12-25	WOS:A1995QB81600035
J	NORRIS, FA; UNGEWICKELL, E; MAJERUS, PW				NORRIS, FA; UNGEWICKELL, E; MAJERUS, PW			INOSITOL HEXAKISPHOSPHATE BINDS TO CLATHRIN ASSEMBLY PROTEIN 3(AP-3/AP180) AND INHIBITS CLATHRIN CAGE ASSEMBLY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE RECEPTOR; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; COATED VESICLES; BRAIN; NP185; AP-2	We have isolated an inositol hexakisphosphate binding protein from rat brain by affinity elution chromatography from Mono S cation exchange resin using 0.1 mM inositol hexakisphosphate (InsP(6)). The amino acid sequences of six tryptic peptides from the protein were identical to the sequences predicted from the cDNA encoding a previously isolated protein designated as AP-3 or AP180. This protein is localized in nerve endings and promotes assembly of clathrin into coated vesicles. The isolated protein-bound InsP(6) with a dissociation constant of 1.2 mu M and a stoichiometry of 0.9 mel of InsP(6) bound/mol of AP-3. Recombinant AP-3 expressed in Escherichia coli also bound InsP(6) with a similar affinity. InsP(6) inhibited clathrin cage assembly mediated by AP-3, in an in vitro assay, but had little effect AP-3 binding to preformed cages. We speculate that InsP(6) and perhaps highly phosphorylated inositol lipids may play a role in coated vesicle formation.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	NORRIS, FA (corresponding author), WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, T32HL007088, P50HL014147, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14147, HL16634, HL07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECK KA, 1991, J BIOL CHEM, V266, P4442; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MARTIN JB, 1987, BIOCHIM BIOPHYS ACTA, V931, P16, DOI 10.1016/0167-4889(87)90045-0; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; PITTET D, 1989, J BIOL CHEM, V264, P18489; RAWAL N, 1992, BIOCHEM J, V287, P929, DOI 10.1042/bj2870929; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; ZHOU SB, 1992, J NEUROSCI, V12, P2144; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	24	101	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					214	217		10.1074/jbc.270.1.214	http://dx.doi.org/10.1074/jbc.270.1.214			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814377	hybrid			2022-12-25	WOS:A1995QA28700036
J	KIESS, M; GILL, RM; HAMEL, PA				KIESS, M; GILL, RM; HAMEL, PA			EXPRESSION OF THE POSITIVE REGULATOR OF CELL-CYCLE PROGRESSION, CYCLIN D3, IS INDUCED DURING DIFFERENTIATION OF MYOBLASTS INTO QUIESCENT MYOTUBES	ONCOGENE			English	Article						CYCLINS; MYOBLAST DIFFERENTIATION; CELL CYCLE; KINASES	RETINOBLASTOMA PROTEIN; CANDIDATE ONCOGENE; PUTATIVE ONCOGENE; DEPENDENT KINASE; DNA-REPLICATION; PRAD1/CYCLIN D1; MYOGENIN GENE; G1 PHASE; MUSCLE; FIBROBLASTS	L(6) cells are committed skeletal muscle precursors which can be induced to differentiate into multinucleated, terminally differentiated myotubes. Upon differentiation, these immature skeletal myotubes enter a quiescent state and are unable to reenter the cell cycle. We have examined expression of a series of genes involved in regulation of progression through the G(1)/S boundary in undifferentiated L(6) cells and during terminal differentiation of L(6) myoblasts. While no change in the level of cyclin D1 transcript and a transient increase in cyclin D2 transcript were observed, a large increase in cyclin D3 expression was found. Immunohistochemistry demonstrated strong staining for cyclin D3 protein in the nuclei of the multinucleated myotubes from 4 independent myoblast cell lines; L(6), L(8), G(8) and C2C12. Immunoprecipitation confirmed a greater than 20-fold increase in the levels of cyclin D3 protein in the differentiated L(6) myotubes as well as its association with a number of proteins. Western assays demonstrated, further, that cyclin D3 was complexed with the cyclin dependent-kinases, cdk2 and cdk4, in differentiated L(6) cells. However, while kinase activity specific for a GST-pRB fusion protein was seen for cyclin D3-containing complexes isolated from undifferentiated cells, the high levels of cyclin D3 in the differentiated myotubes had no associated kinase activity. These data demonstrate that cyclin D3 may also have a function in terminally differentiated, quiescent cells. The lack of cyclin D3-associated kinase activity and its association with a number of different proteins suggest that cyclin D3 may regulate the function of other proteins by direct interaction with these factors.	UNIV TORONTO, DEPT CELLULAR & MOLEC PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDO T, 1989, CELLULAR MOL BIOL MU; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MONTARRAS D, 1991, NEW BIOL, V3, P592; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, 9TH ANN M ONC FRED, P7; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAFFE D, 1973, COLD SPRING HARB SYM, V37, P543, DOI 10.1101/SQB.1973.037.01.065; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	58	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					159	166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824268				2022-12-25	WOS:A1995QA98000018
J	CLAUS, P; SCHULZE, E; WISNIEWSKI, JR				CLAUS, P; SCHULZE, E; WISNIEWSKI, JR			INSECT PROTEINS HOMOLOGOUS TO MAMMALIAN HIGH-MOBILITY GROUP PROTEINS-I/Y (HMG-I/Y) - CHARACTERIZATION AND BINDING TO LINEAR AND 4-WAY JUNCTION DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CHROMOSOMAL PROTEIN; DROSOPHILA-MELANOGASTER; PREFERENTIAL BINDING; SATELLITE DNA; BASE-PAIRS; HISTONE H1; CDNAS; CHROMATIN; DOMAINS	A chromosomal high mobility group (HMG) protein from an epithelial cell line of Chironomus tentans (Diptera) was purified to homogeneity and chemically characterized. cDNA clones encoding this protein were isolated and sequenced. The deduced amino acid sequence revealed a high similarity to HMG protein I of mammalia. This insect protein has therefore been designated cHMGI. It has a deduced molecular mass of 10,371 kDa and appears to be a product of a single gene copy. Similarly to mammalian HMGI/Y proteins the insect cHMGI protein has three putative DNA-binding motifs with a sequence K/RXRGRP that are each encoded by one exon of the gene. Using synthetic peptides we have shown that the first and the second moth are necessary for high-affinity binding of the protein to DNA. Protein cHMGI binds preferentially to AT-rich DNA with a half-saturation value of 1.1 nM. Both cHMGI and human HMGI proteins recognize specifically a four-way junction DNA. We have also purified a related protein with similar physico-chemical properties from Drosophila melanogaster It, cells. The identification and characterization of HMGI proteins in insects with polytene chromosomes and with the cytologic and genetic potential of Chironomus and Drosophila opens new possibilities for studying function(s) of this group of chromosomal proteins.	UNIV GOTTINGEN,ZOOL INST ENTWICKLUNGSBIOL,DEPT ZOOL DEV BIOL 3,D-37073 GOTTINGEN,GERMANY	University of Gottingen			Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445				ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Echalier G., 1976, INVERTEBRATE TISSUE, P131, DOI [10.1016/B978-0-12-429740-1.50014-X, DOI 10.1016/B978-0-12-429740-1.50014-X]; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; HAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P577, DOI 10.1093/oxfordjournals.jbchem.a122707; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KARLSON JR, 1989, BIOCHEM BIOPH RES CO, V158, P646, DOI 10.1016/0006-291X(89)92770-8; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSMAN D, 1986, J BIOL CHEM, V261, P6082; LAUX T, 1991, NUCLEIC ACIDS RES, V19, P4768, DOI 10.1093/nar/19.17.4768; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LUND T, 1987, BIOCHEM BIOPH RES CO, V146, P725, DOI 10.1016/0006-291X(87)90589-4; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MCGINNIS W, 1983, CELL, V34, P75, DOI 10.1016/0092-8674(83)90137-X; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NICOLAS RH, 1982, HMG CHROMOSOMAL PROT, P41; NIETOSOTELO J, 1994, PLANT CELL, V6, P287, DOI 10.1105/tpc.6.2.287; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; REECK GR, 1982, NATURE, V300, P76, DOI 10.1038/300076a0; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROTH SY, 1987, NUCLEIC ACIDS RES, V15, P8112, DOI 10.1093/nar/15.19.8112; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT ER, 1981, FEBS LETT, V129, P21, DOI 10.1016/0014-5793(81)80745-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TJADEN G, 1994, PLANT CELL, V6, P107, DOI 10.1105/tpc.6.1.107; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; WISNIEWSKI JR, 1994, IN PRESS EUR J BIOCH; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZWEIDLER A, 1972, Federation Proceedings, V31, P926	50	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33042	33048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806532				2022-12-25	WOS:A1994QA63800049
J	CLERK, A; BOGOYEVITCH, MA; ANDERSSON, MB; SUGDEN, PH				CLERK, A; BOGOYEVITCH, MA; ANDERSSON, MB; SUGDEN, PH			DIFFERENTIAL ACTIVATION OF PROTEIN-KINASE-C ISOFORMS BY ENDOTHELIN-1 AND PHENYLEPHRINE AND SUBSEQUENT STIMULATION OF P42 AND P44 MITOGEN-ACTIVATED PROTEIN-KINASES IN VENTRICULAR MYOCYTES CULTURED FROM NEONATAL RAT HEARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; CARDIAC GENE-TRANSCRIPTION; ATRIAL-NATRIURETIC-FACTOR; PHORBOL ESTERS; MYOCARDIAL-CELLS; PHOSPHOINOSITIDE HYDROLYSIS; ADRENERGIC-STIMULATION; SMOOTH-MUSCLE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE	The translocation of protein kinase C (PKC) isoforms PKC-alpha, PKC-delta, PKC-epsilon, and PKC-zeta from soluble to particulate fractions was studied in ventricular cardiomyocytes cultured from neonatal rats, Endothelin-1 (ET-1) caused a rapid, ET(A) receptor-mediated translocation of PKC-delta and PKC-epsilon (complete in 0.5-1 min). By 3-5 min, both isoforms were returning to the soluble fraction, but a greater proportion of PKC-epsilon remained associated with the particulate fraction, The EC(50) of translocation for PKC-delta was 11-15 nM ET-1 whereas that for PKC-epsilon was 1.4-1.7 nM. Phenylephrine caused a rapid translocation of PKC-epsilon (EC(50) = 0.9 mu M), but the proportion lost from the soluble fraction was less than with ET-1. Translocation of PKC-delta was barely detectable with phenylephrine. Neither agonist caused any consistent translocation of PKC-alpha or PKC-zeta. Activation of p42 and p44 mitogen-activated protein kinase (MAPK) by ET-1 or phenylephrine followed more slowly (complete in 3-5 min), Phosphorylation of p42-MAPK occurred simultaneously with its activation, The proportion of the total p42-MAPK pool phosphorylated in response to ET-1 (50%) was greater than with phenylephrine (20%), In addition to activation of MAPK, an unidentified p85 protein kinase was activated by ET-1 in the soluble fraction whereas an unidentified p58 protein kinase was activated in the particulate fraction.	UNIV LONDON, NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND	Imperial College London; University of London				Bogoyevitch, Marie/0000-0001-9745-3716; Clerk, Angela/0000-0002-5658-0708	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHURCH DJ, 1993, BIOCHEM J, V290, P477, DOI 10.1042/bj2900477; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; HA KS, 1993, J BIOL CHEM, V268, P10534; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HIRATA Y, 1989, BIOCHEM BIOPH RES CO, V160, P1438, DOI 10.1016/S0006-291X(89)80165-2; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KHALIL RA, 1991, CIRC RES, V69, P1626, DOI 10.1161/01.RES.69.6.1626; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; KRAMER BK, 1992, CIRCULATION, V85, P350, DOI 10.1161/01.CIR.85.1.350; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LAZOU A, 1994, AM J PHYSIOL, V267, pH970, DOI 10.1152/ajpheart.1994.267.3.H970; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, J CARDIOVASC PHARM, V17, pS20, DOI 10.1097/00005344-199117002-00005; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MISCHAK H, 1993, FEBS LETT, V326, P51, DOI 10.1016/0014-5793(93)81759-S; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKUMURA K, 1990, MOL CELL BIOCHEM, V93, P173; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; POGGIOLI J, 1986, FEBS LETT, V206, P292, DOI 10.1016/0014-5793(86)80999-1; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; PUCEAT M, 1994, PROTEIN KINASE C, P249; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOZERI O, 1992, ONCOGENE, V7, P2259; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STEINBERG SF, 1987, ENDOCRINOLOGY, V120, P1889, DOI 10.1210/endo-120-5-1889; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TAKANASHI M, 1991, N-S ARCH PHARMACOL, V343, P669; TERZIC A, 1993, PHARMACOL REV, V45, P147; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANHEUGTEN HAA, 1993, J MOL CELL CARDIOL, V25, P41, DOI 10.1006/jmcc.1993.1006; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOODCOCK EA, 1987, CIRC RES, V61, P625, DOI 10.1161/01.RES.61.5.625	96	255	258	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32848	32857						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806510				2022-12-25	WOS:A1994QA63800023
J	MODIANO, JF; DOMENICO, J; SZEPESI, A; LUCAS, JJ; GELFAND, EW				MODIANO, JF; DOMENICO, J; SZEPESI, A; LUCAS, JJ; GELFAND, EW			DIFFERENTIAL REQUIREMENTS FOR INTERLEUKIN-2 DISTINGUISH THE EXPRESSION AND ACTIVITY OF THE CYCLIN-DEPENDENT KINASES CDK4 AND CDK2 IN HUMAN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; NF-KAPPA-B; GENE-EXPRESSION; PHORBOL ESTERS; PROTEIN-KINASE; GROWTH-FACTOR; NUCLEAR PROTEINS; CYCLOSPORINE-A; ACTIVATION; RECEPTOR	We examined the expression and activity of Cdk4 and Cdk2 in resting, competent, and proliferating normal human T cells, Expression of Cdk4 but not of Cdk2 was induced in competent T cells independent of an IL-2 signal, This up-regulation of Cdk4 mRNA and protein was resistant to the immunosuppressant drugs cyclosporin A (CsA) and FK506, A further increase in Cdk4 expression was seen upon stimulation of competent T cells by IL 2, as was de novo expression of Cdk2. Cyclin D2, a Cdk4 partner, showed similar patterns of regulation as Cdk4, The increases in Cdk4 and cyclin D2 expression seen in competent T cells were functionally significant since Cdk4 immunoprecipitates from these cells phosphorylated recombinant RE protein in vitro, Despite the lack of an increase in the expression of Cdk2, a small pool of pre-existing Cdk2 protein detected in resting T cells could be activated upon induction of competence, These data demonstrate that 1) the signals that lead to induction of competence in T cells stimulate an IL-Q-independent and CsA resistant phase of Cdk4 and cyclin D2 expression, Cdk4 kinase activity, and Cdk2 kinase activity, and 2) IL-2 stimulates a second phase of Cdk4 and cyclin D2 expression and de novo expression of Cdk2 in these cells, The data show that the expression and activity of these major cell cycle regulatory proteins are controlled differentially by growth factors and indicate a role for Cdk4 and cyclin D2 in T cell cycle entry and/or early G(1) progression and for Cdk2 in later G(1) progression and G(1)/S transition.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA	National Jewish Health			MODIANO, JAIME/K-3583-2019	MODIANO, JAIME/0000-0001-6398-7648	NHLBI NIH HHS [HL-09154, P0I-HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GELFAND EW, 1989, ADV REGULATION CELL, V1, P119; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HORI T, 1987, BLOOD, V70, P1069; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KERN JA, 1986, J IMMUNOL, V137, P764; KUMAGAI N, 1988, J IMMUNOL, V141, P3747; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MERIDA I, 1991, J IMMUNOL, V147, P2202; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MODIANO JF, 1991, J BIOL CHEM, V266, P10552; MODIANO JF, 1988, J CELL PHYSIOL, V135, P451, DOI 10.1002/jcp.1041350312; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; OR R, 1992, CLIN IMMUNOL IMMUNOP, V64, P210, DOI 10.1016/0090-1229(92)90202-Y; REED JC, 1985, J IMMUNOL, V135, P2478; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REED SI, 1991, COLD SH Q B, V56, P61; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; TERADA N, 1992, J BIOL CHEM, V267, P21207; TERADA N, 1994, GROWTH FACTOR SIGNAL; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Weiss A, 1991, Semin Immunol, V3, P313; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WINSTON JT, 1991, J CELL BIOCHEM, V47, P79, DOI 10.1002/jcb.240470110; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133	46	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32972	32978						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806527				2022-12-25	WOS:A1994QA63800040
J	HARTZOG, PE; CAIN, BD				HARTZOG, PE; CAIN, BD			2ND-SITE SUPPRESSOR MUTATIONS AT GLYCINE-218 AND HISTIDINE-245 IN THE A SUBUNIT OF F1F0 ATP SYNTHASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; A-SUBUNIT; PROTON TRANSLOCATION; ALPHA-SUBUNIT; MUTAGENIC ANALYSIS; F0F1-ATPASE; PORE; F0; F1FO-ATPASE; REGION	The a-like subunits of F1F0 ATP synthases share primary structural homology in two segments near their carboxyl termini, However, the amino acids at the functionally important positions occupied by a(Gly-218) and a(His-245) in Escherichia coli vary depending upon organism and organelle, The a(G218-->D,H245-->G) and a(G218-->K,H245-->G) double mutations were constructed in the E. coli uncB(a) gene to model the chloroplast ATPase IV subunit and alkaliphilic bacterial a subunit, respectively. Strains carrying each of the single mutations, a(G218-->D), a(G218-->K), and a(H245-->G), had marked reductions in F1F0 ATP synthase function. The a(G218-->K) mutation was alone sufficient to virtually eliminate enzyme function, Membranes prepared from the a(G218-->D) mutant exhibited increased levels of ATP hydrolysis activity without a corresponding increase in active proton transport, suggesting a mechanistic uncoupling of catalytic activity and proton translocation, However, much of the lost F1F0 ATP synthase activity was restored in the a(G218-->D,H245-->G) and a(G218-->K,H245-->G) double mutant strains demonstrating that these mutations act as mutual intragenic second-site suppressors. The evidence is consistent with a close spatial interaction between a(Gly-218) and a(His-245).	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIGMS NIH HHS [GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1985, J BIOL CHEM, V260, P1207; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cross RL, 1992, MOL MECHANISMS BIOEN, P317; EYA S, 1988, J BIOL CHEM, V263, P10056; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HOWITT SM, 1993, BIOCHIM BIOPHYS ACTA, V1144, P17, DOI 10.1016/0005-2728(93)90025-B; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; Miller J. H., 1972, EXPT MOL GENETICS, P431; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STACK AE, 1994, J BACTERIOL, V176, P540, DOI 10.1128/JB.176.2.540-542.1994; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; WANG S, 1994, J BIOL CHEM, V269, P3095	35	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32313	32317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798232				2022-12-25	WOS:A1994PX30400047
J	INOUE, T; KIMURA, T; AZUMA, C; INAZAWA, J; TAKEMURA, M; KIKUCHI, T; KUBOTA, Y; OGITA, K; SAJI, F				INOUE, T; KIMURA, T; AZUMA, C; INAZAWA, J; TAKEMURA, M; KIKUCHI, T; KUBOTA, Y; OGITA, K; SAJI, F			STRUCTURAL ORGANIZATION OF THE HUMAN OXYTOCIN RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; DNA-BINDING; EXPRESSION; RAT; PREGNANCY; PROTEINS; UTERUS; HYBRIDIZATION	We isolated and charactarized the human oxytocin receptor gene, Southern blots indicated that the human genome has a single copy of the gene, Chromosomal localization by fluorescence in situ hybridization also showed that the gene was a single copy, assigned to 3p26,2 of the human chromosome, The gene spans approximately 17 kilobases and contains 3 introns and 4 exons, Exons 1 and 2 correspond to the 5'-non-coding region, followed by exons 3 and 4 encoding the amino acids of the receptor, Intron 3, which is the largest at 12 kilobases, separates the coding region immediately after the putative sixth transmembrane-spanning domain. The transcription start sites, demonstrated by primer extension analysis, lie 618 and 621 base pairs upstream of the methionine initiation codon, Near these putative transcription start sites, we found a TATA-like motif and a potential SP-l binding site at about 30 and 65 base pairs, respectively. We also found other known binding sites of transcription regulating factors, such as AP-1, AP-2, GATA-1, Myb, nucleofactor-interleukin 6 binding consensus sequence, and an acute phase reactant-responsive element. No estrogen-responsive element was observed except three half-palindromic estrogen-responsive element motifs. Our findings of the oxytocin receptor gene structure should help to elucidate the mechanism by which the gene expression is induced drastically at parturition in the uterus and how the gene is regulated in other organs such as the mammary gland or central nervous system.	OSAKA UNIV, SCH MED, DEPT OBSTET & GYNECOL, SUITA, OSAKA 565, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KYOTO 602, JAPAN	Osaka University; Kyoto Prefectural University of Medicine								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGIOLAS A, 1991, NEUROSCI BIOBEHAV R, V15, P217, DOI 10.1016/S0149-7634(05)80002-8; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DAWOOD MY, 1979, J CLIN ENDOCR METAB, V49, P429, DOI 10.1210/jcem-49-3-429; FUCHS AR, 1984, AM J OBSTET GYNECOL, V150, P734, DOI 10.1016/0002-9378(84)90677-X; GUYTON AC, 1991, TXB MED PHYSL, P915; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOLTORF AP, 1989, ENDOCRINOLOGY, V125, P2612, DOI 10.1210/endo-125-5-2612; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KIMURA T, 1992, J STEROID BIOCHEM, V42, P253, DOI 10.1016/0960-0760(92)90127-5; LEAKE RD, 1981, J CLIN ENDOCR METAB, V53, P730, DOI 10.1210/jcem-53-4-730; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MANN EA, 1991, J BIOL CHEM, V266, P16931; NUSING RM, 1993, J BIOL CHEM, V268, P25253; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; ROMERO R, 1993, PRETERM BIRTH CAUSES, P97; RUZYCKY AL, 1988, CAN J PHYSIOL PHARM, V66, P10, DOI 10.1139/y88-002; SAMBROOK J, 1992, MOL CLONING LABORATO; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; SOLOFF MS, 1974, J BIOL CHEM, V249, P1376; TAKEMURA M, 1994, J CLIN INVEST, V93, P2319, DOI 10.1172/JCI117236; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YOSHIMURA R, 1993, ENDOCRINOLOGY, V133, P1239, DOI 10.1210/en.133.3.1239	36	210	214	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32451	32456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798245				2022-12-25	WOS:A1994PX30400066
J	TANAKA, Y; TAO, W; BLANCHARD, JS; HEHRE, EJ				TANAKA, Y; TAO, W; BLANCHARD, JS; HEHRE, EJ			TRANSITION-STATE STRUCTURES FOR THE HYDROLYSIS OF ALPHA-D-GLUCOPYRANOSYL FLUORIDE BY RETAINING AND INVERTING REACTIONS OF GLYCOSYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL FLUORIDE; CARBOHYDRASE ACTION; MECHANISM; GLUCOSIDASE; GLUCOAMYLASE; GLUCANASES; TREHALASE; ENZYME; SCOPE	Secondary tritium and primary C-14 kinetic isotope effects were measured for the hydrolysis of alpha-D-glucopyranosyl fluoride catalyzed by sugar beet seed alpha-D-glucosidase, forming alpha-D-glucose, and by Rhizopus niveus glucoamylase forming beta-D-glucose. The data provided a novel opportunity to model and directly compare the transition state structures for the hydrolysis of a substrate promoted with retention or inversion of configuration according to the enzyme catalyst. The isotope effects for the reaction catalyzed by each enzyme are most consistent with an S(N)1 rather than an S(N)2 mechanism, The modeled transition state structures for the hydrolysis promoted by the alpha-glucosidase and the glucoamylase both bear significant oxocarbonium ion character, with the D-glucosyl residue having a flattened C-4(1) conformation and a C-1-O-5 bond order of 1.92, even though opposite D-glucose anomers were produced from the substrate. The transition states show some modest differences, but their general similarity strongly suggests that the stereochemical outcome of glycosylase reactions does not predict the transition state structure, nor does the transition state structure of such reactions predict the stereochemical outcome. The results support previously reported evidence for the separate topological control of product configuration by protein structures in these and other glycosylases.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Tanaka, Yoshimasa/0000-0002-5024-0614	NIGMS NIH HHS [GM 33449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANAIT NS, 1991, J AM CHEM SOC, V113, P7951, DOI 10.1021/ja00021a021; BARNETT JEG, 1971, BIOCHEM J, V123, P607, DOI 10.1042/bj1230607; CHIBA S, 1978, AGR BIOL CHEM TOKYO, V42, P241, DOI 10.1080/00021369.1978.10862964; CHIBA S, 1979, J BIOCHEM-TOKYO, V85, P1135; CHIBA S, 1988, BIOCHEMISTRY-US, V27, P1564, DOI 10.1021/bi00405a025; CHIBA S, 1988, HDB AMYLASES RELATED, P112; CHU SSC, 1968, ACTA CRYSTALL B-STRU, VB 24, P830, DOI 10.1107/S0567740868003250; Cleland W W, 1979, Methods Enzymol, V63, P103; COGOLI A, 1975, J BIOL CHEM, V250, P7802; EVELEIGH DE, 1969, CARBOHYD RES, V10, P87, DOI 10.1016/S0008-6215(00)81090-3; FERRIER WG, 1962, ACTA CRYSTALLOGR, V16, P1023; HEHRE EJ, 1990, CARBOHYD RES, V198, P123, DOI 10.1016/0008-6215(90)84282-Y; HEHRE EJ, 1979, J BIOL CHEM, V254, P5942; HEHRE EJ, 1969, ARCH BIOCHEM BIOPHYS, V135, P75, DOI 10.1016/0003-9861(69)90518-9; HEHRE EJ, 1982, BIOCHEMISTRY-US, V21, P3090, DOI 10.1021/bi00256a009; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10799; IGAKI S, 1989, ANN M JAP AGR SOC NI, P292; KASUMI T, 1987, BIOCHEMISTRY-US, V26, P3010, DOI 10.1021/bi00385a009; KERR JA, 1985, CRC HDB CHEM PHYSICS, pF165; KITA A, 1984, APR ANN M JAP AGR CH, P545; KITAHATA S, 1981, J BIOL CHEM, V256, P6017; KONSTANTINIDIS A, 1991, BIOCHEM J, V279, P587, DOI 10.1042/bj2790587; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LIU W, 1991, BIOCHEMISTRY-US, V30, P1419, DOI 10.1021/bi00219a036; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MATSUI H, 1989, J BIOL CHEM, V264, P8714; MATSUI H, 1993, CARBOHYD RES, V250, P45, DOI 10.1016/0008-6215(93)84153-W; NAKANO M, 1989, CARBOHYD RES, V194, P139, DOI 10.1016/0008-6215(89)85013-X; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; PARKIN DW, 1991, BIOCHEMISTRY-US, V30, P4586, DOI 10.1021/bi00232a032; SIMS LB, 1984, ISOTOPES ORGANIC CHE, V6, P161; SIMS LB, 1974, SPECIAL PUBLICATION, V1; SIMS LB, 1977, 337 IND U QUANT CHEM; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STERN MJ, 1971, J CHEM PHYS, V55, P2007, DOI 10.1063/1.1676366; TSUJISAKA Y, 1960, B OSAKA MUNICIPAL TE, V23, P1; Wilson E. B., 1955, MOL VIBRATIONS; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; AMPAC506 QUANT CHEM	40	69	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32306	32312						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798231				2022-12-25	WOS:A1994PX30400046
J	AKASHI, M; HACHIYA, M; PAQUETTE, RL; OSAWA, Y; SHIMIZU, S; SUZUKI, G				AKASHI, M; HACHIYA, M; PAQUETTE, RL; OSAWA, Y; SHIMIZU, S; SUZUKI, G			IRRADIATION INCREASES MANGANESE SUPEROXIDE-DISMUTASE MESSENGER-RNA LEVELS IN HUMAN FIBROBLASTS - POSSIBLE MECHANISMS FOR ITS ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR GENE-EXPRESSION; LONG TERMINAL REPEAT; IONIZING-RADIATION; MESSENGER-RNA; PHORBOL ESTER; INTERLEUKIN-1 PRECURSOR; NUCLEOTIDE-SEQUENCE; OXYGEN RADICALS; GM-CSF	Irradiation induces the production of superoxide radicals (O O-2)((radical) (anion)), which play an important causative role in radiation damage. Manganese superoxide dismutase (MnSOD) is a mitochondrial enzyme involved in scavenging O-2((radical) (anion)). This study examined MnSOD gene regulation by irradiation in WI38 human fibroblasts. Unstimulated fibroblasts constitutively expressed MnSOD activity and mRNA; irradiation markedly increased MnSOD activity and mRNA levels. The increase in MnSOD transcripts by irradiation was both time- and dose dependent. WI38 fibroblasts constitutively produce low levels of interleukin-1 (IL-1). The induction of MnSOD mRNA by irradiation was partially blocked by anti-IL-1 antibodies, and treatment of cells with IL-1 also increased MnSOD mRNA levels. Inhibition of the cyclo-oxygenase pathway with indomethacin augmented the induction MnSOD mRNA by irradiation and prostaglandin E(2) inhibited the accumulation of MnSOD mRNA by irradiation. Transcriptional run-on analysis showed that irradiation increased the rate of MnSOD transcription 2-fold. Stability studies of MnSOD mRNA in these cells showed that the half-life increased from <1.5 h in unirradiated cells to >4 h in irradiated cells. These results suggest that induction of the MnSOD gene after irradiation is regulated, at least in part, by IL-1 production and that increased levels of MnSOD transcripts also occur through a pathway of endogenous prostaglandin E(2) production. Our data indicate that the increase in MnSOD mRNA observed after irradiation occurs through both transcriptional and post-transcriptional mechanisms.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	AKASHI, M (corresponding author), NATL INST RADIOL SCI,DIV RADIAT HLTH,INAGE KU,4-9-1 ANAGAWA,CHIBA 263,JAPAN.							AKASHI M, 1994, BLOOD, V83, P3182; AKASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P986, DOI 10.1016/0006-291X(92)92301-D; AKASHI M, 1989, BLOOD, V74, P2383; AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; AKASHI M, 1992, HEMATOLOGY BLOOD TRA, P83; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAVARD C, 1990, J CLIN INVEST, V86, P1369, DOI 10.1172/JCI114849; CLARK IA, 1985, MED RES REV, V5, P297, DOI 10.1002/med.2610050303; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P211; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DAVIES KJA, 1983, FEBS LETT, V153, P227, DOI 10.1016/0014-5793(83)80153-7; DAVIES KJA, 1985, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUJII J, 1991, J BIOL CHEM, V266, P23142; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HACHIYA M, 1994, EXP CELL RES, V214, P343, DOI 10.1006/excr.1994.1266; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P10; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HARRIS CA, 1990, J IMMUNOL, V147, P149; HARTMAN JR, 1988, Patent No. 881048805; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND SL, 1984, RADIAT RES, V100, P115, DOI 10.2307/3576527; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MELTZER MS, 1977, J IMMUNOL, V118, P77; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; TANIGUCHI N, 1992, ADV CLIN CHEM, V29, P1, DOI 10.1016/S0065-2423(08)60221-8; VALERIE K, 1987, NATURE, V333, P78; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WESLEY MB, 1979, P NATL ACAD SCI USA, V76, P1967; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1992, TUMOR NECROSIS FACTO, P473; YAMATO K, 1989, J CELL PHYSIOL, V139, P610, DOI 10.1002/jcp.1041390322; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512	57	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15864	15869		10.1074/jbc.270.26.15864	http://dx.doi.org/10.1074/jbc.270.26.15864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797591	hybrid			2022-12-25	WOS:A1995RG53800065
J	DONG, LJ; HSIEH, JC; CHUNG, AE				DONG, LJ; HSIEH, JC; CHUNG, AE			2 DISTINCT CELL ATTACHMENT SITES IN ENTACTIN ARE REVEALED BY AMINO-ACID SUBSTITUTIONS AND DELETION OF THE RGD SEQUENCE IN THE CYSTEINE-RICH EPIDERMAL GROWTH-FACTOR REPEAT-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN ENTACTIN; COLLAGEN TYPE-IV; PHENOTYPIC SELECTION; ADHESION; PROTEINS; INTEGRIN; MUTAGENESIS; RECEPTORS; LAMININ; BINDING	The basement membrane glycoprotein, entactin, has previously been shown to promote cell attachment and chemotaxis. We have constructed a panel of glutathione S-transferase fusion proteins that encompasses the four major structural domains of entactin, G1, G2, E, and G3. These proteins have been synthesized in bacteria and purified by affinity chromatography, The connecting stalk of entactin, E, which contains four cysteine-rich EGF homology repeats and the integrin receptor RGD recognition sequence, has been modified by deletion of the RGD sequence and substituting glutamic acid for aspartic acid. Attachment assays reveal that the RGD sequence is one of the major cell attachment sites in entactin and that this sequence is recognized by the alpha(v) beta(3) integrin receptor, Analysis of cell attachment on mutant forms of full-length entactin expressed in the baculovirus expression system revealed a second attachment site that was independent of the RGD sequence. This second site was localized to a peptide of 39 amino acid residues in the second globular G2 domain of entactin. This peptide represents a cysteine-rich EGF repeat, Inhibition of cell attachment by anti-integrin receptor antibodies indicates that the second attachment site is recognized by a member of the beta(1) family of integrin receptors, possibly alpha(3) beta(1).	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NIGMS NIH HHS [GM-25690] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025690] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHUNG AE, 1993, KIDNEY INT, V43, P13, DOI 10.1038/ki.1993.4; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GRESHAM HD, 1993, MOL BIOL CELL S, V4, P285; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HSIEH JC, 1994, BIOCHEM BIOPH RES CO, V199, P1509, DOI 10.1006/bbrc.1994.1402; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO T, 1990, J BIOL CHEM, V265, P5188; WU CY, 1991, J BIOL CHEM, V266, P18802; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YELIAN FD, 1993, J CELL BIOL, V121, P923, DOI 10.1083/jcb.121.4.923	30	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15838	15843		10.1074/jbc.270.26.15838	http://dx.doi.org/10.1074/jbc.270.26.15838			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797588	hybrid			2022-12-25	WOS:A1995RG53800061
J	MORISHIMAKAWASHIMA, M; HASEGAWA, M; TAKIO, K; SUZUKI, M; YOSHIDA, H; TITANI, K; IHARA, Y				MORISHIMAKAWASHIMA, M; HASEGAWA, M; TAKIO, K; SUZUKI, M; YOSHIDA, H; TITANI, K; IHARA, Y			PROLINE-DIRECTED AND NON-PROLINE-DIRECTED PHOSPHORYLATION OF PHF-TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; MICROTUBULE-ASSOCIATED PROTEIN; ALZHEIMER-LIKE STATE; GLYCOGEN-SYNTHASE KINASE-3; FETAL-TYPE PHOSPHORYLATION; SENILE PLAQUE NEURITES; NEUROFIBRILLARY TANGLES; DISEASE BRAIN; ABNORMAL PHOSPHORYLATION; NEUROPIL THREADS	To gain insight into the abnormal phosphorylation of PHF-tau, we have determined the phosphorylation sites by identifying phosphopeptides by means of ion spray mass spectrometry followed by sequencing of ethane-thiol-modified peptides. Nineteen sites have been identified; all but Ser-262 are localized to the amino- and carboxyl-terminal flanking regions of the microtubule binding domain, Eleven sites correspond to fetal type sites. Unexpectedly, 10 are non-proline-directed, whereas the others are proline-directed. Thus, the abnormal phosphorylation of PHF-tau can be considered to consist of fetal type phosphorylation and additional pro line-directed and non-proline directed phosphorylation. This non-fetal type phosphorylation may provide PHF-tau with the unusual characteristics.	UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT NEUROPATHOL,BUNKYO KU, TOKYO 113, JAPAN; RIKEN, INST PHYS & CHEM RES, DIV BIOMOLEC CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN; RIKEN, INST PHYS & CHEM RES, BIODESIGN RES GRP, WAKO, SAITAMA 35101, JAPAN; FUJITA HLTH UNIV, SCH MED, INST COMPREHENS MED SCI, DIV BIOMED POLYMER SCI, TOYOAKE, AICHI 47011, JAPAN	University of Tokyo; RIKEN; RIKEN; Fujita Health University								ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BAUM L, 1992, BRAIN RES, V573, P126, DOI 10.1016/0006-8993(92)90121-O; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; IWATSUBO T, 1992, AM J PATHOL, V140, P277; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P25922; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; LU Q, 1993, J NEUROSCI, V13, P508; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; PERRY G, 1991, J NEUROSCI, V11, P1748; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TERRY RD, 1981, ANN NEUROL, V10, P184, DOI 10.1002/ana.410100209; TROJANOWSKI JQ, 1993, BRAIN RES, V618, P333, DOI 10.1016/0006-8993(93)91286-2; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YANG SD, 1993, J NEUROCHEM, V61, P1742, DOI 10.1111/j.1471-4159.1993.tb09811.x; YANG SD, 1993, BIOCHEM BIOPH RES CO, V197, P400, DOI 10.1006/bbrc.1993.2493; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	72	519	540	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					823	829		10.1074/jbc.270.2.823	http://dx.doi.org/10.1074/jbc.270.2.823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822317	hybrid			2022-12-25	WOS:A1995QB81600051
J	MUTA, T; SEKI, N; TAKAKI, Y; HASHIMOTO, R; ODA, T; IWANAGA, A; TOKUNAGA, F; IWANAGA, S				MUTA, T; SEKI, N; TAKAKI, Y; HASHIMOTO, R; ODA, T; IWANAGA, A; TOKUNAGA, F; IWANAGA, S			PURIFIED HORSESHOE-CRAB FACTOR-G - RECONSTITUTION AND CHARACTERIZATON OF THE (1-]3)-BETA-D-GLUCAN-SENSITIVE SERINE-PROTEASE CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; FACTOR-C; PROCLOTTING ENZYME; LIMULUS-POLYPHEMUS; CDNA CLONING; BOMBYX-MORI; FACTOR-B; PURIFICATION; COAGULATION; ACTIVATION	Horseshoe crab hemocyte lysate responds to (1-->3)-beta-D-glucans, initiating an enzymatic cascade, which culminates in clot formation,We have purified to homogeneity the serine protease zymogen factor G, which is directly activated by (1-->3)-beta-D-glucans and which initiates the hemolymph clotting cascade, Factor G is a heterodimeric protein composed of two noncovalently associated subunits alpha (72 kDa) and beta (37 kDa), In the presence of (1-->3)-beta-D-glucans such as curdlan and paramylon, factor G is autocatalytically activated to an active serine protease named factor ($) over bar G. This activation is accompanied by limited proteolysis of both subunits: the 72-kDa subunit a is cleaved to 55-kDa and 17-kDa fragments, and the 37-kDa subunit beta is shortened to 34 kDa. Longer incubations with (1-->3)-beta-D-glucans result in cleavage of the 55-kDa fragment to 46 kDa and the 34-kDa fragment to 32 kDa, with concomitant loss of amidase activity. Reconstitution experiments using purified proteins participating in the hemolymph clotting cascade demonstrate that factor ($) over bar is capable of activating proclotting enzyme directly, resulting in the conversion of coagulogen to coagulin gel. Thus, purified factor G is shown to be the primary initiator of the (1-->3)-beta-D-glucan-sensitive coagulation pathway in the horseshoe crab hemocyte lysate.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT BIOL MOLEC,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University				Tokunaga, Fuminori/0000-0003-3626-9119				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ASHIDA M, 1981, INSECT BIOCHEM, V11, P57, DOI 10.1016/0020-1790(81)90041-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; DUVIC B, 1990, J BIOL CHEM, V265, P9327; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIURA Y, 1993, SEIKAGAKU, V65, P924; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA S, 1982, J BIOCHEM, V92, P781, DOI 10.1093/oxfordjournals.jbchem.a133990; NAKAMURA S, 1976, J BIOCHEM, V80, P1011, DOI 10.1093/oxfordjournals.jbchem.a131357; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PEARSON FC, 1984, ARTIF ORGANS, V8, P291, DOI 10.1111/j.1525-1594.1984.tb04293.x; SEKI N, 1994, J BIOL CHEM, V269, P1670; SELJELID R, 1981, EXP CELL RES, V131, P121, DOI 10.1016/0014-4827(81)90413-4; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; SODERHALL K, 1983, COMP BIOCHEM PHYS B, V74, P221, DOI 10.1016/0305-0491(83)90003-2; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; SODERHALL K, 1985, BIOL BULL-US, V169, P661, DOI 10.2307/1541308; STONE BA, 1992, CHEM BIOL 1 RIGHT AR; SUGO T, 1985, EUR J BIOCHEM, V146, P43, DOI 10.1111/j.1432-1033.1985.tb08617.x; TANAKA H, 1970, J GEN APPL MICROBIOL, V16, P39, DOI 10.2323/jgam.16.1_39; TANAKA S, 1991, CARBOHYD RES, V218, P167, DOI 10.1016/0008-6215(91)84095-V; Whistler R L, 1976, Adv Carbohydr Chem Biochem, V32, P235	38	62	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					892	897		10.1074/jbc.270.2.892	http://dx.doi.org/10.1074/jbc.270.2.892			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822328	hybrid			2022-12-25	WOS:A1995QB81600062
J	WANGE, RL; ISAKOV, N; BURKE, TR; OTAKA, A; ROLLER, PP; WATTS, JD; AEBERSOLD, R; SAMELSON, LE				WANGE, RL; ISAKOV, N; BURKE, TR; OTAKA, A; ROLLER, PP; WATTS, JD; AEBERSOLD, R; SAMELSON, LE			F-2(PMP)(2)-TAM-ZETA(3), A NOVEL COMPETITIVE INHIBITOR OF THE BINDING OF ZAP-70 TO THE T-CELL ANTIGEN RECEPTOR, BLOCKS EARLY T-CELL SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-CHAIN; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; SH2 DOMAINS; ACTIVATION; PROTEIN; KINASE; CD3-EPSILON; STIMULATION; RESIDUES	Signaling by the T cell antigen receptor (TCR) is mediated by 17-residue tyrosine-based activation motifs (TAM) present in the cytoplasmic tails of the TCR zeta and CD3 chains. TAMs become tyrosine-phosphorylated upon TCR stimulation, creating a high affinity binding site for the tandem SH2 domains of ZAP-70. In permeabilized T cells, the association of TCR and ZAP-70 was inhibited by a protein tyrosine phosphatase (PTPase)resistant TAM peptide analog, in which difluorophosphonomethyl phenylalanyl (F(2)Pmp) residues replaced phosphotyrosine. Inhibition of this association prevented TCR-stimulated tyrosine phosphorylation of ZAP-70 and reduced ZAP-70 kinase activity to basal levels. The reduction in ZAP-70 activity coincided with reduced tyrosine phosphorylation of a number of substrates. Such PTPase-resistant peptides, capable of disrupting SH2 domain-mediated protein-protein interactions, should prove useful in further dissection of multiple signaling pathways and may serve as models for rationally designed chemotherapeutic agents for the treatment of autoimmune and neoplastic disorders.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, DCT, DTP, MED CHEM LAB, BETHESDA, MD 20892 USA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of British Columbia			Burke, Terrence R/N-2601-2014; Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572; Isakov, Noah/0000-0002-1412-0957; Burke, Terrence/0000-0001-9925-8586				BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BURKE TR, 1993, TETRAHEDRON LETT, V34, P4125, DOI 10.1016/S0040-4039(00)60508-7; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1994, J IMMUNOL, V152, P4758; CONTI A, 1993, J BIOL CHEM, V268, P783; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HARRISON ML, 1994, J BIOL CHEM, V269, P955; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; ISAKOV N, 1995, IN PRESS J EXP MED, P95; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, J IMMUNOL, V144, P1591; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OTAKA A, 1993, TETRAHEDRON LETT, V34, P7039, DOI 10.1016/S0040-4039(00)61591-5; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SMYTH MS, 1994, TETRAHEDRON LETT, V35, P551, DOI 10.1016/S0040-4039(00)75835-7; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	86	95	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					944	948		10.1074/jbc.270.2.944	http://dx.doi.org/10.1074/jbc.270.2.944			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822334	hybrid			2022-12-25	WOS:A1995QB81600069
J	ZACHARIAS, U; XU, YC; HAGEGE, J; SRAER, JD; BRASS, LF; RONDEAU, E				ZACHARIAS, U; XU, YC; HAGEGE, J; SRAER, JD; BRASS, LF; RONDEAU, E			THROMBIN, PHORBOL ESTER, AND CAMP REGULATE THROMBIN RECEPTOR PROTEIN AND MESSENGER-RNA EXPRESSION BY DIFFERENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MESANGIAL CELLS; HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC-RECEPTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; CROSS-REGULATION; DOWN-REGULATION	Human mesangial cells have been used to study the regulation of thrombin receptor protein and mRNA expression during cross-talk between different signal transduction pathways. Persistent activation of thrombin receptor by thrombin led to homologous down-regulation of thrombin receptor protein, However, thrombin receptor mRNA expression was not affected, suggesting that increased receptor degradation is responsible for homologous down-regulation. Chronic activation of protein kinase C by phorbol 12-myristate 13-acetate (PMA) and of adenylylcyclase by prostaglandin E1 (PGE1) resulted in heterologous down-regulation of thrombin receptor protein. In contrast to thrombin, PMA and PGE1 reduced in parallel thrombin receptor mRNA levels to 51% and 24% of control, respectively, indicating that heterologous downregulation of thrombin receptor protein is, at least in part, due to inhibition of receptor mRNA expression. The mechanisms of heterologous down-regulation of thrombin receptor protein have been studied in detail and compared to homologous down-regulation. PMA induced down-regulation was completely blocked by GF 109 203 X, an inhibitor of protein kinase C. However, the loss of thrombin receptor induced by thrombin was not prevented by GF 109 203 X, indicating that homologous regulation is not dependent on protein kinase C activation. The heterologous effect of PGE1 was mimicked by 8-bromo-cAMP, isobutylmethylxanthine, and forskolin, suggesting that an increase in intracellular cAMP level is involved in heterologous regulation, Interestingly, heterologous down regulation induced by PGE1 seems not to require previous internalization of thrombin receptor. These data indicate that thrombin receptor protein and mRNA expression can be regulated in homologous and heterologous ways by different mechanisms.	HOP TENON, INSERM, U64, F-75020 PARIS, FRANCE; HOP TENON, ASSOC CLAUDE BERNARD, F-75020 PARIS, FRANCE; UNIV PENN, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Pennsylvania			Zacharias, Ute/AAS-4998-2020					BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLUCCI WS, 1986, CIRC RES, V58, P393, DOI 10.1161/01.RES.58.3.393; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HE CJ, 1992, J CELL PHYSIOL, V150, P475, DOI 10.1002/jcp.1041500307; HILL SJ, 1989, CELL SIGNAL, V1, P135, DOI 10.1016/0898-6568(89)90002-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ISHII K, 1994, J BIOL CHEM, V269, P1125; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; KANFER A, 1991, INT YB NEPHROLOGY, P3; KANTHOU C, 1992, FEBS LETT, V314, P143, DOI 10.1016/0014-5793(92)80961-F; LACAVE R, 1989, KIDNEY INT, V35, P806, DOI 10.1038/ki.1989.56; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LEE NH, 1993, J BIOL CHEM, V268, P7949; LEE NH, 1994, J BIOL CHEM, V269, P4291; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MARI B, 1994, J BIOL CHEM, V269, P8517; MEULDERS Q, 1992, KIDNEY INT, V42, P327, DOI 10.1038/ki.1992.293; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NEVEU I, 1993, J NEUROCHEM, V60, P858, DOI 10.1111/j.1471-4159.1993.tb03230.x; PORT JD, 1992, J BIOL CHEM, V267, P24103; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; RENNICK RE, 1993, EUR J PHARMACOL, V230, P367, DOI 10.1016/0014-2999(93)90575-3; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; ZACHARIAS U, 1993, FEBS LETT, V334, P225, DOI 10.1016/0014-5793(93)81716-D; ZACHARIAS U, 1994, IN PRESS EXP CELL RE; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					545	550		10.1074/jbc.270.2.545	http://dx.doi.org/10.1074/jbc.270.2.545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822278	hybrid			2022-12-25	WOS:A1995QB81600010
J	SAKURABA, H; NOGUCHI, T				SAKURABA, H; NOGUCHI, T			ALCOHOL-NAD(+) OXIDOREDUCTASE IS PRESENT IN RAT-LIVER PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SJOGREN-LARSSON SYNDROME; FATTY ALCOHOL; CULTURED FIBROBLASTS; OXIDATION; DEHYDROGENASE; ACIDS; METABOLISM	Alcohol:NAD(+) oxidoreductase was found in the peroxisomes of animal liver for the first time as follows. The distribution of alcohol:NAD(+) oxidoreductase activity with nonanol as substrate in the light mitochondrial fraction (peroxisome-enriched fraction) of rat liver was examined by centrifugation in a sucrose density gradient. Most of the enzyme activity was localized in the mitochondria, with some activity in the peroxisomes. The administration of clofibrate, a peroxisome proliferator, to rats resulted in a marked increase of the enzyme activity in the peroxisomes, but not in the mitochondria. The enzyme was found to be located in the matrix of the peroxisomes. The evidence was obtained that the enzyme differed from alcohol dehydrogenases and alcohol oxidizing systems found previously. The enzyme activity was not affected by pyrazole, an inhibitor of alcohol dehydrogenase and sodium azide, an inhibitor of catalase. The enzyme was NAD(+)-dependent and oxidized straight chain aliphatic alcohols with a variety of carbon chains (C-2-C-18), showing the maximum on nonanol. K-m values toward these aliphatic alcohols decreased with increasing chain length. The major reaction product was identified as the carboxylic acid by using high performance liquid chromatography.	KYUSHU DENT COLL, DEPT BIOCHEM, KITAKYUSHU 803, FUKUOKA, JAPAN	Kyushu Dental University								Aebi H., 1974, METHODS ENZYMATIC AN, P673, DOI [10.1016/B978-0-12-091302-2.50032-3, DOI 10.1016/B978-0-12-091302-2.50032-3]; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; BONNICHSEN RK, 1955, METHOD ENZYMOL, V1, P495, DOI 10.1016/0076-6879(55)01083-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CHANCE B, 1971, BIOCHEM J, V122, P225, DOI 10.1042/bj1220225; CHANCE B, 1977, ALCOHOL ALDEHYDE MET, P261; DONALDSO.RP, 1972, ARCH BIOCHEM BIOPHYS, V152, P199, DOI 10.1016/0003-9861(72)90208-1; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HSIEH B, 1976, J BIOL CHEM, V251, P4408; Lazarow P B, 1981, Methods Enzymol, V72, P315; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LEE T, 1979, J BIOL CHEM, V254, P2892; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; NICHOLLS P, 1964, BIOCHEM J, V90, P331, DOI 10.1042/bj0900331; PIETRUSZKO R, 1979, BIOCH PHARMACOLOGY E, V1, P87; RIZZO WB, 1988, J CLIN INVEST, V81, P738, DOI 10.1172/JCI113379; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SHAIKH B, 1978, ANAL BIOCHEM, V85, P47, DOI 10.1016/0003-2697(78)90272-5; THEORELL H, 1969, ACTA CHEM SCAND, V23, P255, DOI 10.3891/acta.chem.scand.23-0255; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x	27	19	19	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					37	40		10.1074/jbc.270.1.37	http://dx.doi.org/10.1074/jbc.270.1.37			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814397	hybrid			2022-12-25	WOS:A1995QA28700010
J	HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J				HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J			MODULATION BY COPPER OF P53 CONFORMATION AND SEQUENCE-SPECIFIC DNA-BINDING - ROLE FOR CU(II) CU(I) REDOX MECHANISM	ONCOGENE			English	Article						P53; REGULATION; REDOX; COPPER; DNA BINDING	TUMOR-SUPPRESSOR P53; GENE-EXPRESSION; WILD-TYPE; MALTOSE-BINDING; METAL-IONS; PROTEIN; FORMS; HYDROQUINONE; COMPLEXES; OXIDATION	The tumor suppressor protein p53 is a metal-binding transcription factor whose conformation and function are altered by mutation in cancers. Using murine p53 translated in vitro, we report here that concentrations of copper within the physiological range (< 30 mu M) alter the conformation of wild-type p53 and inhibit sequence-specific DNA-binding. Direct binding of copper to p53 in the form of Cu(I) was demonstrated by Electron Spin Resonance using a purified recombinant protein containing residues 1-343 of murine wild-type p53 fused to E. coli maltose binding protein. Moreover, protection against the effect of Cu(II) sulfate was achieved by the Cu(I)-specific chelator bathocuproinedisulfonic acid but not by scavengers of reactive oxygen species, suggesting that alteration of p53 by copper depends upon a Cu(II)/Cu(I) redox mechanism, but does not require the production of reactive oxygen species. Thus copper at physiological concentrations can interact with wild-type p53 and affect its DNA-binding capacity.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	HAINAUT, P (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davies, Michael J/H-4939-2011; Hainaut, Pierre/B-6018-2012; Davies, Michael/GWV-2527-2022; Davies, Michael/AGX-9184-2022	Davies, Michael J/0000-0002-5196-6919; Hainaut, Pierre/0000-0002-1303-1610; Davies, Michael/0000-0002-5196-6919				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CANTOR KP, 1966, P NATL ACAD SCI USA, V55, P642, DOI 10.1073/pnas.55.3.642; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; Goodman BA, 1970, ADV INORG CHEM RAD, V13, P135, DOI DOI 10.1016/S0065-2792(08)60336-2; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Jameson R. F, 1981, MET IONS BIOL SYST, V12, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LI YB, 1993, CARCINOGENESIS, V14, P1303, DOI 10.1093/carcin/14.7.1303; LI YB, 1993, ARCH BIOCHEM BIOPHYS, V300, P346, DOI 10.1006/abbi.1993.1047; MARGALIOTH EJ, 1983, CANCER, V52, P868, DOI 10.1002/1097-0142(19830901)52:5<868::AID-CNCR2820520521>3.0.CO;2-K; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, MET IONS BIOL SYST, V25, P105; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POSWILLO DE, 1971, NATURE, V231, P447, DOI 10.1038/231447a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SRINIVASAN R, 1993, CANCER RES, V53, P5361; WACKER WEC, 1959, J BIOL CHEM, V234, P3257; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575	38	84	84	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824276				2022-12-25	WOS:A1995QA98000004
J	DONNADIEU, E; TRAUTMANN, A; MALISSEN, M; TRUCY, J; MALISSEN, B; VIVIER, E				DONNADIEU, E; TRAUTMANN, A; MALISSEN, M; TRUCY, J; MALISSEN, B; VIVIER, E			RECONSTITUTION OF CD3-ZETA COUPLING TO CALCIUM MOBILIZATION VIA GENETIC COMPLEMENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; ZETA-CHAIN; CYTOPLASMIC TAIL; LYMPHOCYTES-T; ACTIVATION; MESSENGER; PHOSPHORYLATION; HYBRIDOMAS	The integrity of the T cell receptor complex (CD3-TCR) transduction machinery is central to T cell development and to T cell effector function, Molecular dissection of the multimeric CD3-TCR complex revealed that at least two associated polypeptides, CD3 zeta and CD3 epsilon, autonomously couple antigenic recognition event to early and late events of the intracytoplasmic activation cascade, A 18-amino acid motif based on a tandem YXXL stretch, the activation receptor homology sequence 1 (ARH-1) motif, is necessary and sufficient to the transducing properties of both CD3 zeta and CD3 epsilon. Stimulation of chimeric molecules made of ecto- and transmembrane domains of various cell surface proteins and intracytoplasmic domains of CD3 epsilon or CD3 zeta leads to an increase in the intracellular Ca2+ concentration ([Ca2+](i)) in Jurkat cells, We describe here that a similar CD25/zeta chimeric molecule was unable to induce a detectable [Ca2+](i) rise upon CD25 cross-linking once expressed in the murine thymoma BW-. A Ca2+ influx could, however, be triggered in BW- cells by thapsigargin, i.e. following depletion of Ca2+ stores, Somatic cell hybrids made from BW- and either thymocytes or mature lymph node T cells reconstituted the coupling of CD3 zeta to the Ca2+ signal via an ARH-1 motif-dependent pathway, However, pervanadate-induced Ca2+ mobilization, a phenomenon attributed to tyrosine phosphorylation, was impaired in BW- cells and reconstituted in hybridomas, In contrast to the Ca2+ response, IL-2 production was induced in both BW- and hybrids cells, which ques-tions the functional relevance of [Ca2+](i) augmentation in T cell activation, In conclusion, the properties of the BW- thymoma, which define a novel group of CD3 zeta transduction cell mutants, as well as its complementation by somatic cell fusion demonstrate that this cell line represents a useful model to dissect the signaling pathway that couples CD3 zeta to Ca2+ mobilization by genetic reconstitution.	FAC SCI LUMINY,CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 09,FRANCE; ECOLE NORMALE SUPER,NEUROBIOL LAB,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Malissen, Bernard/AAK-4659-2020; Vivier, Eric/F-8939-2010; Donnadieu, Emmanuel/P-4566-2017	Vivier, Eric/0000-0001-7022-8287; Malissen, Marie/0000-0003-2331-1445				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; DONNADIEU E, 1993, PFLUG ARCH EUR J PHY, V424, P448, DOI 10.1007/BF00374907; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HOEVELER A, 1993, MOL IMMUNOL, V30, P755, DOI 10.1016/0161-5890(93)90147-4; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MILLS GB, 1985, J IMMUNOL, V134, P1640; MOINGEON P, 1992, P NATL ACAD SCI USA, V89, P1492, DOI 10.1073/pnas.89.4.1492; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1992, COLD SPRING HARB SYM, V67, P107; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WHITE J, 1989, J IMMUNOL, V143, P1822	40	18	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32828	32834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806507				2022-12-25	WOS:A1994QA63800020
J	MOHAN, S; KELLY, TM; EVELAND, SS; RAETZ, CRH; ANDERSON, MS				MOHAN, S; KELLY, TM; EVELAND, SS; RAETZ, CRH; ANDERSON, MS			AN ESCHERICHIA-COLI GENE (FABZ) ENCODING (3R)-HYDROXYMYRISTOYL ACYL CARRIER PROTEIN DEHYDRASE - RELATION TO FABA AND SUPPRESSION OF MUTATIONS IN LIPID A BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; BETA-HYDROXYDECANOYLTHIOESTER DEHYDRASE; UDP-N-ACETYLGLUCOSAMINE; ENDOTOXIN BIOSYNTHESIS; PHOSPHOLIPID-SYNTHESIS; THIOESTER DEHYDRASE; SEQUENCE-ANALYSIS; 1ST STEP; ACYLTRANSFERASE; STRAINS	Escherichia coli strain SM101 harbors a temperature-sensitive allele (lpxA2) of the gene encoding UDP-GlcNAc acyltransferase (the first enzyme of the lipid A pathway), SM101 is temperature-sensitive for lipid A biosynthesis and growth, To determine whether or not E. coli mutants lacking lipid A can be isolated, we examined temperature-resistant revertants of SM101, All regained the ability to synthesize lipid A. However, some were not true revertants but had acquired mutations in a neighboring gene (orf17), while retaining the original lpxA2 lesion, Cell extracts of such revertants displayed 2-5 fold reductions in the specific activity of (3R)-hydroxymyristoyl-ACP dehydrase, Wild-type cells that overproduced the protein encoded by orf17 overproduced (3R)-hydroxymyristoyl-ACP dehydrase activity as much as 170-fold, suggesting that orf17 is the structural gene for the dehydrase. The proposed function of orf17 is further supported by its sequence similarity to fabA, the structural gene for (3R)-hydroxydecanoyl dehydrase of E. coli. We suggest that bypass of the lpxA2 phenotype by mutations in orf17 may be due to an increased (3R)-hydroxymyristoyl-ACP pool. The orf17 gene (which we now designate fabZ) is not regulated by fadR, However, orf17 may be related to sefA, a suppressor of certain lesions in the cell division/lipid A biosynthesis gene, envA.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065	Merck & Company								ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BIRGE CH, 1967, BIOCHEM BIOPH RES CO, V29, P808, DOI 10.1016/0006-291X(67)90291-4; BIRGE CH, 1972, J BIOL CHEM, V247, P4930; BLOCH K, 1970, ENZYMES, V5, P441; BURKS C, 1992, NUCLEIC ACIDS RES, V20, P2065, DOI 10.1093/nar/20.suppl.2065; COLEMAN J, 1986, J BACTERIOL, V170, P1268; CRONAN JE, 1972, J BACTERIOL, V112, P206, DOI 10.1128/JB.112.1.206-211.1972; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; FOSTER SJ, 1993, FEMS MICROBIOL LETT, V110, P295, DOI 10.1016/0378-1097(93)90118-L; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GANONG BR, 1982, J BIOL CHEM, V257, P389; GHUYSEN JM, 1968, COMPREHENSIVE BIOC A, V26, P53; GRUNDSTROM T, 1980, J BACTERIOL, V144, P884; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HIRVAS L, 1990, BIOCHEM BIOPH RES CO, V173, P53, DOI 10.1016/S0006-291X(05)81020-4; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; KASSLR, 1967, P NATL ACAD SCI USA, V58, P1138; KELLY TM, 1993, J BIOL CHEM, V268, P19866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Maniatis T., 1982, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Miller JH, 1972, EXPT MOL GENETICS, P201; NORMARK S, 1976, J BACTERIOL, V128, P401, DOI 10.1128/JB.128.1.401-412.1976; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POSTBEITTENMILL.D, 1991, J BIOL CHEM, V266, P1858; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SCHWAB JM, 1986, J CHEM SOC CHEM COMM, P357, DOI 10.1039/c39860000357; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5309, DOI 10.1021/ja00277a041; SCHWAB JM, 1984, J AM CHEM SOC, V106, P7217, DOI 10.1021/ja00335a060; SHAW EI, 1994, GENE, V140, P109, DOI 10.1016/0378-1119(94)90739-0; SILBERT DF, 1975, ANNU REV BIOCHEM, V44, P315, DOI 10.1146/annurev.bi.44.070175.001531; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; YOUNG K, 1993, FED PROC, V7, P1252	47	117	128	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32896	32903						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806516				2022-12-25	WOS:A1994QA63800029
J	RAHUEL, C; ELOUET, JF; CARTRON, JP				RAHUEL, C; ELOUET, JF; CARTRON, JP			POSTTRANSCRIPTIONAL REGULATION OF THE CELL-SURFACE EXPRESSION OF GLYCOPHORIN-A, GLYCOPHORIN-B, AND GLYCOPHORIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; MESSENGER-RNA; STRUCTURAL ORGANIZATION; MAMMALIAN-CELLS; CDNA CLONES; K562 CELLS; PROMOTER; SEQUENCE; LINE; ELEMENTS	GYPA, GYPB, and GYPE represent a small gene family localized on chromosome 4q28-q31 that encodes the major red cell membrane glycophorins, GPA and GPB, and a new but as yet uncharacterized glycoprotein, GPE. There are 3-4 times more copies of GPA as compared with GPB on human erythrocytes (10(6) versus 2 x 10(5) copies/cell), whereas GPE is absent or poorly represented, Whether these quantitative differences reflect a transcriptional or post-transcriptional regulation was investigated, We found the functional activities of the glycophorin promoters to be similar, as shown by DNase I footprinting, gel retardation, methylation interference, and deletion analysis, Run-on analysis indicated that the transcription rate of each glycophorin gene in K562 cells was also very similar. However, large differences in mRNA decay were found in actinomycin-treated K562 cells, GPA transcripts were very stable (at least 24 h), whereas GPB transcripts were severely reduced after 17 h, The GPE transcripts were barely detectable and disappeared completely after 1 h. These results suggest that a difference in stability of the GPA, GPB, and GPE transcripts rather than a transcriptional regulation may predominantly account for the different levels of glycophorin expression on erythrocytes.	INST NATL TRANSFUS SANGUINE,INSERM,U76,F-75015 PARIS,FRANCE; INSERM,U91,CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)								ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BLANCHARD D, 1990, Transfusion Medicine Reviews, V4, P170, DOI 10.1016/S0887-7963(90)70263-5; CARTRON J-P, 1992, Transfusion Medicine Reviews, V6, P63, DOI 10.1016/S0887-7963(92)70158-8; CARTRON JP, 1992, PROTEIN BLOOD GROUP, P101; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIN Y, 1986, J BIOL CHEM, V261, P229; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FUKUDA M, 1984, CELL SURFACE GLYCOPR, P183; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; GAHMBERG CG, 1979, J BIOL CHEM, V254, P7442; GARDNER B, 1989, IMMUNOLOGY, V68, P283; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMID J, 1990, NUCLEIC ACIDS RES, V18, P5829, DOI 10.1093/nar/18.19.5829; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LEONARD M, 1993, BLOOD, V82, P1071; LITTAUER UZ, 1982, PROG NUCLEIC ACID RE, V27, P53, DOI 10.1016/S0079-6603(08)60597-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MORLE F, 1992, BLOOD, V79, P3094; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; ONDA M, 1994, J BIOL CHEM, V269, P13013; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; RAHUEL C, 1989, GENE, V85, P471, DOI 10.1016/0378-1119(89)90441-1; RAICH N, 1993, STEM CELLS, V11, P95, DOI 10.1002/stem.5530110204; SAMBROOK J, 1989, MOL CLONING LABORATO, P1420; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SIEBERT PD, 1986, J BIOL CHEM, V261, P2433; SILVER RE, 1987, ARCH BIOCHEM BIOPHYS, V256, P285, DOI 10.1016/0003-9861(87)90448-6; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	53	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32752	32758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806496				2022-12-25	WOS:A1994QA63800009
J	DESJARDINS, M; CELIS, JE; VAN MEER, G; DIEPLINGER, H; JAHRAUS, A; GRIFFITHS, G; HUBER, LA				DESJARDINS, M; CELIS, JE; VAN MEER, G; DIEPLINGER, H; JAHRAUS, A; GRIFFITHS, G; HUBER, LA			MOLECULAR CHARACTERIZATION OF PHAGOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; PLASMA-MEMBRANE; CELLS; MACROPHAGES; TRANSPORT; CLATHRIN; BINDING; IDENTIFICATION; TRANSLOCATION; PHAGOCYTOSIS	The transformation of newly formed phagosomes into mature phagolysosomes is a process that involves a complex series of interactions between phagosomes and other vacuolar organelles. The machinery required by phagosomes to mediate these interactions is poorly understood. In this study, we allowed human and various rodent cells to take up latex beads whose density facilitates a simple purification of phagosomes using discontinuous sucrose gradients. With this system, we initiated a systematic study of phagosome proteins using two-dimensional gel electrophoresis and the currently available two-dimensional gel protein data bases. By this approach, we were able to recognize a group of polypeptides associated with mouse J774 phagosomes-phagolysosomes including annexin II, annexin VI, the beta-1 and beta-2 subunits of trimeric G proteins, and a group of actin-binding proteins. While the amount of annexin II associated to phagosomes was similar at all times of latex internalization, the levels of annexin VI were higher on late phagosomes. Phospholipid analysis of J774 phagosomes isolated at early and late time points during phagolysosome formation also revealed significant differences in their lipid composition. In the human phagosomes, we resolved over 200 polypeptides on the two-dimensional gels. These included the proteins described in the mouse, as well as 32 polypeptides that were found to be highly enriched in phagosomes, 15 of which are not present in the current data bases. The results demonstrate that the use of latex bead phagosomes is a powerful system to identify key molecules involved in phagolysosome biogenesis.	DANISH CTR HUMAN GENOME RES, DK-8000 AARHUS C, DENMARK; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Aarhus University; Utrecht University	DESJARDINS, M (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Huber, Lukas Alfons/AAM-3499-2021; van Meer, Gerrit/AAH-1560-2021	Desjardins, Michel/0000-0002-5684-5980; van Meer, Gerrit/0000-0002-5976-6436; Huber, Lukas Alfons/0000-0003-1116-2120				AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; BROWN EJ, 1987, J IMMUNOL, V139, P3777; CELIS JE, 1993, J ELECTROPH, V14, P1091; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNSTER LM, 1994, VIROLOGY, V198, P265, DOI 10.1006/viro.1994.1029; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVANS WH, 1985, BIOCHEM J, V232, P33, DOI 10.1042/bj2320033; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; HONING S, 1994, J CELL SCI, V107, P1185; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JACKLE S, 1994, J BIOL CHEM, V269, P1026; JAHRAUS A, 1994, J CELL SCI, V107, P145; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MCMURRAY WC, 1972, ANNU REV BIOCHEM, V41, P129, DOI 10.1146/annurev.bi.41.070172.001021; MULLER WA, 1983, J CELL BIOL, V96, P29, DOI 10.1083/jcb.96.1.29; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; PIZON V, 1994, J CELL SCI, V107, P1661; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; ZHANG LS, 1992, CANCER RES, V52, P4634	48	226	230	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32194	32200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798218				2022-12-25	WOS:A1994PX30400030
J	VILLENA, JA; MARTIN, I; VINAS, O; CORMAND, B; IGLESIAS, R; MAMPEL, T; GIRALT, M; VILLARROYA, F				VILLENA, JA; MARTIN, I; VINAS, O; CORMAND, B; IGLESIAS, R; MAMPEL, T; GIRALT, M; VILLARROYA, F			ETS TRANSCRIPTION FACTORS REGULATE THE EXPRESSION OF THE GENE FOR THE HUMAN MITOCHONDRIAL ATP SYNTHASE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ENHANCER-BINDING PROTEIN; LONG TERMINAL REPEAT; OXIDATIVE-PHOSPHORYLATION; PROMOTER SEQUENCES; DIFFERENTIAL EXPRESSION; MAMMALIAN-CELLS; NUCLEAR GENES; RAT-LIVER; IV GENE	Elements responsible for the transcriptional activity of the human ATP synthase beta-subunit (ATPsyn beta) gene promoter have been studied through transient expression in HepG2 hepatoma cells of a CAT gene connected with various 5'-deletion mutants of the 5'-flanking region, Promoter activity was mostly dependent upon a single CCAAT motif as well as a nearby Ets domain binding region. This last region contains two sites that bind Ets-related proteins present in liver nuclear extracts as well as recombinant purified Ets-1 protein. The ATPsyn beta promoter was trans-activated by Ets-1 and Ets-2 expression vectors, and this effect was lost when the Ets binding region was deleted, The Ets binding region of the ATPsyn beta promoter increased basal expression and conferred Ets-1- and Ets-2-dependent trans-activation to the herpes symplex thymidine kinase minimal promoter, A double-point mutation of the main Ets-binding site, which suppresses Ets binding, blocks Ets-dependent trans-activation. It is concluded that the gene for the mitochondrial ATPsyn beta is a target of transcriptional activation by members of the Ets family of transcription factors, It is suggested that Ets transcription factors may be involved in the enhanced expression of the ATPsyn beta gene in highly proliferating cells and in the coordinate transcription of nuclear genes for mitochondrial proteins.	UNIV BARCELONA,DEPT BIOQUIM & FISIOL,UNITAT BIOQUIM & BIOL MOLEC B,E-08071 BARCELONA,SPAIN	University of Barcelona			Mampel, Teresa/C-5571-2017; Villarroya, Francesc/K-4357-2014; Iglesias, Roser/C-5561-2017; Villena, Josep A/H-1597-2015; Cormand, Bru/H-5338-2015; Giralt, Marta/A-4756-2013	Iglesias, Roser/0000-0002-7107-8097; Cormand, Bru/0000-0001-5318-4382; Giralt, Marta/0000-0001-7968-4190; Villena, Josep A/0000-0002-2200-2985; Villarroya, Francesc/0000-0003-1266-9142				ASANO M, 1990, J VIROL, V64, P5927, DOI 10.1128/JVI.64.12.5927-5938.1990; ASCIONE R, 1992, INT J ONCOL, V1, P631; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; FABRIZI GM, 1992, GENE, V119, P307, DOI 10.1016/0378-1119(92)90288-Z; FARRELL LB, 1987, BIOCHEM BIOPH RES CO, V144, P1257, DOI 10.1016/0006-291X(87)91446-X; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GLAICHENHAUS N, 1986, EMBO J, V5, P1251; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; LUCIAKOVA K, 1992, EUR J BIOCHEM, V207, P253, DOI 10.1111/j.1432-1033.1992.tb17045.x; LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x; NAGINO M, 1989, CANCER RES, V49, P4913; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHTA S, 1988, J BIOL CHEM, V263, P11257; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	50	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32649	32654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798271				2022-12-25	WOS:A1994PX30400093
J	GRABER, P; PROUDFOOT, AEI; TALABOT, F; BERNARD, A; MCKINNON, M; BANKS, M; FATTAH, D; SOLARI, R; PEITSCH, MC; WELLS, TNC				GRABER, P; PROUDFOOT, AEI; TALABOT, F; BERNARD, A; MCKINNON, M; BANKS, M; FATTAH, D; SOLARI, R; PEITSCH, MC; WELLS, TNC			IDENTIFICATION OF KEY CHARGED RESIDUES OF HUMAN INTERLEUKIN-5 IN RECEPTOR-BINDING AND CELLULAR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-5; COLONY-STIMULATING FACTOR; HUMAN GROWTH-HORMONE; GM-CSF; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION	Interleukin-5 (IL-5) is a cytokine that plays a major role in the differentiation and activation of eosinophils. In order to identify which charged residues of human IL-5 are important in binding to its receptor and subsequent cellular activation, we have systematically replaced all of the clusters of charged amino acids with alanine residues. The mutants have been expressed in Escherichia coli, renatured, and purified. They were assayed for ability to cause proliferation of the erythro-leukaemic cell line TF-1 and the up-regulation of eosinophil adhesion to ICAM-1. In addition, we studied receptor binding using either immobilized recombinant IL-5 receptor alpha-chain or the alpha/beta-receptor complex expressed on TF-2 cells. The key charged residue is Glu-12. This residue is in an identical position to those previously identified in IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) involved in binding to the receptor beta-chain. The alpha-chain binding site is shown to involve the side chains Arg-90 and Glu-109, located in the second beta sheet and after the end of the fourth helix, respectively. It is unique to IL-5 and does not occur in IL-3 or GM-CSF. Understanding the topology of the interaction of IL-5 with its receptor chains will help in the search for rationally designed antagonists of IL-5 function.	GLAXO INST MOLEC BIOL SA,CH-1228 GENEVA,SWITZERLAND; GLAXO RES & DEV,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline; GlaxoSmithKline			Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Wells, Timothy/0000-0001-9796-847X				BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; COLLINS L, 1988, P NATL ACAD SCI USA, V85, P7709, DOI 10.1073/pnas.85.20.7709; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1993, EUR J BIOCHEM, V212, P751, DOI 10.1111/j.1432-1033.1993.tb17714.x; GRENFELL S, 1991, BIOCHEM J, V280, P111, DOI 10.1042/bj2800111; HASSELL AM, 1993, J MOL BIOL, V229, P1150, DOI 10.1006/jmbi.1993.1110; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HERCUS TR, 1994, BLOOD, V83, P3500; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KODAMA S, 1991, BIOCHEM BIOPH RES CO, V178, P514, DOI 10.1016/0006-291X(91)90137-V; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1992, EMBO J, V11, P3137; LEATHERBARROW RJ, 1992, GRAFIT VERSION 3 01; LOKKER NA, 1991, EMBO J, V10, P2125, DOI 10.1002/j.1460-2075.1991.tb07746.x; LOPEZ AF, 1992, P NATL ACAD SCI USA, V89, P11842, DOI 10.1073/pnas.89.24.11842; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MOKS T, 1987, BIOTECHNOLOGY, V5, P37; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAKATSU K, 1992, CURR OPIN IMMUNOL, V4, P299, DOI 10.1016/0952-7915(92)90080-X; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; WEIR MP, 1988, BIOCHEMISTRY-US, V27, P6883, DOI 10.1021/bi00418a034; ZURAWSKI SM, 1989, EMBO J, V8, P2583, DOI 10.1002/j.1460-2075.1989.tb08397.x	43	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15762	15769		10.1074/jbc.270.26.15762	http://dx.doi.org/10.1074/jbc.270.26.15762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797578	hybrid			2022-12-25	WOS:A1995RG53800051
J	KAUFMAN, DL; KEITH, DE; ANTON, B; TIAN, J; MAGENDZO, K; NEWMAN, D; TRAN, TH; LEE, DS; WEN, C; XIA, YR; LUSIS, AJ; EVANS, CJ				KAUFMAN, DL; KEITH, DE; ANTON, B; TIAN, J; MAGENDZO, K; NEWMAN, D; TRAN, TH; LEE, DS; WEN, C; XIA, YR; LUSIS, AJ; EVANS, CJ			CHARACTERIZATION OF THE MURINE MU-OPIOID RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; RAT-BRAIN; CLONING; CDNA; AUTORADIOGRAPHY; MOUSE; DNA	The analgesic and addictive properties of morphine and other opioid drugs are thought to result from their interaction with mu opioid receptors, Using a delta opioid receptor cDNA as a probe, we have isolated a murine mu opioid receptor cDNA clone (mMOR), Stable expression of mMOR in Chinese hamster ovary cells conferred high binding affinity for mu receptor ligands including morphine and [D-Ala(2),N-methyl-Phe(4),Gly(5)-ol]-enkephalin and low affinity for delta and kappa preferring ligands, Treatment of these cell lines with morphine and other mu agonists inhibited forskolin-induced cAMP accumulation, demonstrating a functional coupling of mMOR to the inhibition of adenylate cyclase, The predicted amino acid sequence of mMOR shares approximate to 55% overall amino acid identity with the delta receptor and approximate to 97% identity with the recently reported rat mu opioid receptor, Expression of the mu receptor in mouse brain as revealed by in situ hybridization parallels the reported pattern of distribution of mu-selective ligand binding sites, Chromosomal localization (to mouse chromosome 10) and Southern analysis are consistent with a single mu opioid receptor gene in the mouse genome, suggesting that the various pharmacologically distinct forms of the mu receptor arise from alternative splicing, post-translational events, or from a highly divergent gene(s).	UNIV CALIF LOS ANGELES,NPI,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC & MED PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042488, R01HL042488, P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL42488] Funding Source: Medline; NIDA NIH HHS [P50 DA005010, DA05010] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; BELKNAP JK, 1990, BEHAV GENET, V20, P333, DOI 10.1007/BF01067800; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; CHEN Y, 1993, MOL PHARMACOL, V44, P8; DIETRICH W, 1992, GENETICS, V131, P423; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LOGEL J, 1992, BIOTECHNIQUES, V13, P604; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; MANSOUR A, 1987, J NEUROSCI, V7, P2445; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; MINAMI M, 1994, NEUROSCI RES, V18, P315, DOI 10.1016/0168-0102(94)90167-8; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARIF NA, 1989, PEPTIDES, V10, P499, DOI 10.1016/0196-9781(89)90135-6; TEMPEL A, 1987, P NATL ACAD SCI USA, V84, P4308, DOI 10.1073/pnas.84.12.4308; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; WOLLEMANN M, 1990, J NEUROCHEM, V54, P1095, DOI 10.1111/j.1471-4159.1990.tb01934.x; ZASTAWNY RL, 1994, J NEUROCHEM, V62, P2099	27	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15877	15883		10.1074/jbc.270.26.15877	http://dx.doi.org/10.1074/jbc.270.26.15877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797593	hybrid			2022-12-25	WOS:A1995RG53800067
J	TRIEU, VN; MCCONATHY, WJ				TRIEU, VN; MCCONATHY, WJ			A 2-STEP MODEL FOR LIPOPROTEIN(A) FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSING HUMAN APOLIPOPROTEIN(A); B-CONTAINING LIPOPROTEINS; PLASMA; LP(A); ASSOCIATION; PLASMINOGEN; CYSTEINE; DISEASE; BINDING	Lipoprotein(a) (Lp(a)), a risk factor for coronary artery disease, is a LDL-like particle with apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B (apoB), the main protein component of LDL. Apo(a) is highly homologous to plasminogen and its gene probably arose by duplication of the plasminogen gene. It has many repeats of kringle- 4-like domain, classified as type 1 through type 10 (T1-T10). T9 is responsible for the covalent linkage between apo(a) and LDL. However, we found that T9 has no affinity for LDL. Therefore, an initial noncovalent interaction between apo(a) and LDL is necessary to bring T9 and LDL together. T6 and possibly T7 of apo(a) were identified as the kringles which mediate this initial interaction. With these findings, a two step model for Lp(a) formation is proposed. This model should be useful in the design of Lp(a) formation inhibitors. These inhibitors are potential anti-hyperlipoprotein(a) drugs.	UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM,FT WORTH,TX 76107	University of North Texas System; University of North Texas Health Science Center	TRIEU, VN (corresponding author), UNIV N TEXAS,HLTH SCI CTR,DEPT MED,DIV CLIN RES,3500 CAMP BOWIE BLVD,FT WORTH,TX 76107, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046967] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLEMAN RD, 1990, BIOCHIM BIOPHYS ACTA, V1037, P129, DOI 10.1016/0167-4838(90)90111-R; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DURRINGTON PN, 1988, LANCET, V1, P1070; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FRANK S, 1994, BIOCHEM J, V304, P27, DOI 10.1042/bj3040027; FRANK S, 1994, BIOCHEMISTRY-US, V33, P12329, DOI 10.1021/bi00206a041; GABEL B, 1994, FEBS LETT, V350, P71; GUEVARA J, 1993, BIOPHYS J, V64, P686, DOI 10.1016/S0006-3495(93)81428-0; GURAKAR A, 1985, ATHEROSCLEROSIS, V57, P293, DOI 10.1016/0021-9150(85)90041-3; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; LAW A, 1990, J LIPID RES, V31, P1109; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STEYRER E, 1994, J CLIN INVEST, V94, P2330, DOI 10.1172/JCI117598; TREXLER M, 1983, FEBS LETT, V154, P311, DOI 10.1016/0014-5793(83)80173-2; TRIEU VN, 1995, BIOCHEM J, V307, P17, DOI 10.1042/bj3070017; TRIEU VN, 1990, BIOCHEMISTRY-US, V29, P5919, DOI 10.1021/bi00477a006; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; TRIEU VN, 1995, IN PRESS BIOCH J; VANDERHOEK YY, 1994, CAN J PHYSIOL PHARM, V72, P304, DOI 10.1139/y94-046; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; YE SQ, 1988, J BIOL CHEM, V263, P6337	29	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15471	15474		10.1074/jbc.270.26.15471	http://dx.doi.org/10.1074/jbc.270.26.15471			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797538	hybrid			2022-12-25	WOS:A1995RG53800008
J	KWAK, EL; LAROCHELLE, DA; BEAUMONT, C; TORTI, SV; TORTI, FM				KWAK, EL; LAROCHELLE, DA; BEAUMONT, C; TORTI, SV; TORTI, FM			ROLE FOR NF-KAPPA-B IN THE REGULATION OF FERRITIN-H BY TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; HEAVY-CHAIN; MESSENGER-RNAS; PROMOTER; BINDING; IRON; EXPRESSION; ACTIVATION; GENE; INTERLEUKIN-1	Ferritin is a ubiquitously distributed iron-binding protein that plays a key role in cellular iron homeostasis. It is composed of two subunits, termed H (heavy or heart) and L (light or liver), In fibroblasts and other cells, the cytokine tumor necrosis factor-alpha (TNF) specifically induces synthesis of the ferritin H subunit. Using nuclear run-off assays, we demonstrate that this TNF-dependent increase in ferritin H is mediated by a selective increase in ferritin H transcription. Transfection of murine fibroblasts with chimeric genes containing the 5'-flanking region of murine ferritin H fused to the human growth hormone reporter gene reveals that the cia-acting element that mediates this response is located similar to 4.8 kilobases distal to the start site of transcription. Deletion analyses delimit the TNF-responsive region to a 40-nucleotide sequence located between nucleotides -4776 and -4736, which we term FER-2. Electrophoretic mobility shift assays and site-specific mutations indicate that this region contains two independent elements: one contains a sequence that binds a member of the NF-kappa B family of transcription factors, and a second contains a novel sequence that partially conforms to the NF-kappa B consensus sequence and may bind a different member of the NF-kappa B/Rel transcription factor family, Thus, effects of an inflammatory cytokine on ferritin are mediated by a family of transcription factors responsive to oxidative stress.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT CANC BIOL,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305; FAC XAVIER BICHAT,INSERM,U409,F-75018 PARIS,FRANCE	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLA G, 1992, J BIOL CHEM, V267, P18148; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; CERMAK J, 1993, CANCER RES, V53, P5308; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JAIN SK, 1985, J BIOL CHEM, V260, P1762; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHASE M, 1986, CELL, V45, P659, DOI 10.1016/0092-8674(86)90780-4; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MUKAIDA N, 1991, ADV EXP MED BIOL, V305, P31; MUROI M, 1993, J BIOL CHEM, V268, P19534; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; ROESER HP, 1980, IRON BIOCH MED, V2, P605; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TSUJI Y, 1992, CYTOKINES HLTH DISEA, P131; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6	39	163	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15285	15293		10.1074/jbc.270.25.15285	http://dx.doi.org/10.1074/jbc.270.25.15285			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797515	hybrid			2022-12-25	WOS:A1995RE66600066
J	KRISTINA, S; ROTH, RA				KRISTINA, S; ROTH, RA			CHARACTERIZATION OF THE ENDOGENOUS INSULIN RECEPTOR-RELATED RECEPTOR IN NEUROBLASTOMAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODIES; LIGAND-BINDING; PROTEIN-KINASE; EXPRESSION; CELLS; SPECIFICITY; ACTIVATION; FAMILY	A gene encoding a putative third member of the insulin receptor family (called the insulin receptor-related receptor or IRR) was isolated in 1989. However, the naturally occurring protein product encoded by this gene has yet to be described, In the present studies, we have generated four monoclonal antibodies to a recombinantly expressed chimera, which contains the extracellular domain of human IRR. These antibodies were found to specifically recognize the chimeric IRR (and not the insulin or insulin-like growth factor I receptors), and two of the antibodies were capable of acting as partial agonists in the cells expressing the chimeric IRR. These antibodies have therefore been utilized to study the expression and properties of the native receptor, In contrast to the two other members of this receptor family, the endogenous IRR protein had only a very limited expression, being detected only in neuroblastomas. In primary neuroblastomas, the levels of the receptor were highest in samples from stage A tumors (those which are generally more highly differentiated and have higher levels of the nerve growth factor receptor), The endogenous IRR could also be detected in a neuroblastoma cell line (called IMR-5 cells), In these cells, IRR could be shown to be partly present as a hybrid with the insulin and insulin-like growth factor-I receptors but not with the receptor for nerve growth factor, The intrinsic tyrosine kinase activity of this endogenous IRR was activated by the agonist monoclonal antibody to IRR but not by nerve growth factor, insulin-like growth factor I, or insulin, Finally, this monoclonal antibody was found to stimulate mitogen-activated protein kinase activity in these cells, In summary, these studies demonstrate for the first time that the IRR protein is normally expressed, that its levels are highest in neuronal tissues, and that it can form hybrid receptors with the two other members of this receptor family but not with the more distantly related nerve growth factor receptor.	STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; HAGINO H, 1994, DIABETES, V43, P274, DOI 10.2337/diabetes.43.2.274; ITOH N, 1993, J BIOL CHEM, V268, P17983; JUI HY, 1994, J BIOL CHEM, V269, P22446; KURACHI H, 1992, BIOCHEM BIOPH RES CO, V187, P934, DOI 10.1016/0006-291X(92)91287-Z; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORGAN DO, 1987, BIOCHEMISTRY-US, V26, P2959, DOI 10.1021/bi00385a001; MORGAN DO, 1985, ENDOCRINOLOGY, V116, P1224, DOI 10.1210/endo-116-3-1224; MORGAN DO, 1986, P NATL ACAD SCI USA, V83, P328, DOI 10.1073/pnas.83.2.328; MOXHAM CP, 1992, J CELL BIOCHEM, V48, P136, DOI 10.1002/jcb.240480205; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; REINHARDT RR, 1994, J NEUROSCI, V14, P4674; REINHARDT RR, 1993, ENDOCRINOLOGY, V133, P3, DOI 10.1210/en.133.1.3; ROTH RA, 1985, HDB RECEPTOR RES INS, P46; SETA KA, 1993, ADV EXP MED BIOL, V343, P113; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SIDDLE K, 1994, HORM RES, V41, P56, DOI 10.1159/000183962; SOOS MA, 1992, J BIOL CHEM, V267, P12955; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001; ZHANG B, 1992, J BIOL CHEM, V267, P18320	27	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1881	1887		10.1074/jbc.270.4.1881	http://dx.doi.org/10.1074/jbc.270.4.1881			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829525	hybrid			2022-12-25	WOS:A1995QD20400060
J	POWERS, T; NOLLER, HF				POWERS, T; NOLLER, HF			A TEMPERATURE-DEPENDENT CONFORMATIONAL REARRANGEMENT IN THE RIBOSOMAL-PROTEIN S4-CENTER-DOT-16-S RIBOSOMAL-RNA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRIMER EXTENSION; BINDING-SITES; RNA; SUBUNITS; DNA; ACID	Ribosomal protein S4 protects a characteristic set of bases in 16 S rRNA from attack by chemical probes. Use of hydroxyl radical as a probe of the RNA backbone shows that ribose residues in these same regions are also protected by S4, confirming the localization of its interactions with 16 S rRNA to the junction of five helical elements in the proximal region of the 5' domain. At 0 degrees C, the nucleotides protected by S4 from base-specific probes are confined almost exclusively to the two compound helices formed by residues 404-499. After subsequent heating of the complex briefly at 30 or 42 degrees C, nucleotides in the three adjacent helices are additionally protected, resulting in a pattern of protection that is identical to that which is observed when 54 is incubated with 16 S rRNA under in vitro reconstitution conditions. Preincubation of the protein or the RNA (or both) separately at elevated temperature does not substitute for heating the S4.RNA complex. The regions in the RNA affected by the heat step are known to interact with proteins S12 and S16, both of which depend upon 54 for their binding to the RNA. Thus, the finding that 54 recruits additional sites of interaction in the RNA following its initial binding suggests a possible mechanism to insure the sequential addition of proteins during ribosomal assembly.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; EHRESMANN C, 1977, FEBS LETT, V81, P188, DOI 10.1016/0014-5793(77)80956-3; GARRETT RA, 1977, CELL BIOL INT REP, V1, P487, DOI 10.1016/0309-1651(77)90086-8; GARRETT RA, 1984, GENE EXPRESSION, P331; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; HELD WA, 1974, J BIOL CHEM, V249, P3103; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; SAPAG A, 1990, BIOCHIM BIOPHYS ACTA, V1050, P34, DOI 10.1016/0167-4781(90)90137-Q; SCHAUP HW, 1971, MOL GEN GENET, V112, P1, DOI 10.1007/BF00266926; SCHULTE C, 1974, BIOCHEMISTRY-US, V13, P1032, DOI 10.1021/bi00702a031; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1986, J MOL BIOL, V192, P101, DOI 10.1016/0022-2836(86)90467-5; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UNGEWICKELL E, 1975, EUR J BIOCHEM, V51, P165, DOI 10.1111/j.1432-1033.1975.tb03917.x; VARTIKAR JV, 1989, J MOL BIOL, V209, P221, DOI 10.1016/0022-2836(89)90274-X; WEITZMANN CJ, 1993, FASEB J, V7, P177, DOI 10.1096/fasebj.7.1.7916699; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135; ZIMMERMANN RA, 1972, P NATL ACAD SCI USA, V69, P1282, DOI 10.1073/pnas.69.5.1282	23	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1238	1242		10.1074/jbc.270.3.1238	http://dx.doi.org/10.1074/jbc.270.3.1238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836385	hybrid			2022-12-25	WOS:A1995QB15600040
J	SHIPTON, CA; PARMRYD, I; SWIEZEWSKA, E; ANDERSSON, B; DALLNER, G				SHIPTON, CA; PARMRYD, I; SWIEZEWSKA, E; ANDERSSON, B; DALLNER, G			ISOPRENYLATION OF PLANT-PROTEINS IN-VIVO - ISOPRENYLATED PROTEINS ARE ABUNDANT IN THE MITOCHONDRIA AND NUCLEI OF SPINACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE-BINDING; GAMMA SUBUNITS CONTAIN; RAT-LIVER; PRENYLATED PROTEINS; ISOPRENOID BIOSYNTHESIS; CIS-PRENYLTRANSFERASE; MEMBRANE ASSOCIATION; CARBOXYL METHYLATION; DOLICHYL PHOSPHATE	Protein isoprenylation in vivo is demonstrated using spinach seedlings labeled with [H-3]mevalonate, This report provides evidence for the occurrence of a large number of isoprenylated proteins in plants. Seedlings, without roots, were labeled quantitatively through the cut stem. Mevinolin treatment of the seedlings resulted in increased incorporation of radiolabel into proteins. Approximately 30 labeled bands could be detected after autoradiography of SDS-polyacrylamide gel electrophoresis-separated polypeptides, ranging in molecular mass from 6 to 200 kDa, Methyl iodide hydrolysis resulted in the release of covalently bound farnesol, geranylgeraniol, phytol, and some unidentified isoprenoid compounds from mevalonate-labeled proteins, It was found that all cellular fractions contained some isoprenylated proteins, although most were located in the mitochondria and nuclei. Subfractionation of the nucleus revealed that the majority of isoprenylated proteins in this compartment were components of the nuclear matrix. The results demonstrate that in vivo labeling of a complex organism can be performed using a plant system in order to study protein isoprenylation and distribution of modified proteins in different cellular compartments.	UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; POLISH ACAD SCI, INST BIOCHEM & BIOPHYS, PL-02532 WARSAW, POLAND; KAROLINSKA INST, NOVUM, CLIN RES CTR, S-14186 HUDDINGE, SWEDEN	Stockholm University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Karolinska Institutet			Andersson, Bertil/C-9328-2009	Parmryd, Ingela/0000-0003-4834-3611; Swiezewska, Ewa/0000-0002-3439-8948				ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANANT JS, 1992, J BIOL CHEM, V267, P687; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; EPSTEIN WW, 1990, P NATL ACAD SCI USA, V87, P7352, DOI 10.1073/pnas.87.19.7352; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; ERICSSON J, 1992, J BIOL CHEM, V267, P19730; ERICSSON J, 1993, J BIOL CHEM, V268, P832; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST JR, 1991, J BIOL CHEM, V266, P9961; GIANNAKOUROS T, 1992, FEBS LETT, V297, P103, DOI 10.1016/0014-5793(92)80337-G; GLASER E, 1995, IN PRESS METHODS CEL, V64; GRAY JC, 1987, ADV BOT RES, V14, P25; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACOBS M, 1988, BIOCHEM BIOPH RES CO, V155, P1478, DOI 10.1016/S0006-291X(88)81308-1; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LI AC, 1988, J LIPID RES, V29, P781; LONG BH, 1979, CELL, V18, P1079, DOI 10.1016/0092-8674(79)90221-6; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MATSUI M, 1989, GENE, V76, P313, DOI 10.1016/0378-1119(89)90171-6; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORRE DJ, 1991, PROTOPLASMA, V160, P49, DOI 10.1007/BF01539956; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OVCHINNIKOV YA, 1985, FEBS LETT, V179, P107, DOI 10.1016/0014-5793(85)80201-5; PALME K, 1992, P NATL ACAD SCI USA, V89, P787, DOI 10.1073/pnas.89.2.787; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SWIEZEWSKA E, 1993, BIOCHEM BIOPH RES CO, V192, P161, DOI 10.1006/bbrc.1993.1395; TERRYN N, 1992, FEBS LETT, V299, P287, DOI 10.1016/0014-5793(92)80133-2; THELIN A, 1991, EUR J BIOCHEM, V195, P755, DOI 10.1111/j.1432-1033.1991.tb15763.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; YANG ZB, 1993, P NATL ACAD SCI USA, V90, P8732, DOI 10.1073/pnas.90.18.8732; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	57	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					566	572		10.1074/jbc.270.2.566	http://dx.doi.org/10.1074/jbc.270.2.566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822281	hybrid			2022-12-25	WOS:A1995QB81600013
J	KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R				KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R			EXPRESSION OF RIL, A NOVEL LIM DOMAIN GENE, IS DOWN-REGULATED IN HRAS-TRANSFORMED CELLS AND RESTORED IN PHENOTYPIC REVERTANTS	ONCOGENE			English	Article						GENETIC SUPPRESSION; CELLULAR TRANSFORMATION; ZINC FINGER PROTEIN; IN SITU HYBRIDIZATION	CYSTEINE-RICH PROTEIN; RAT EMBRYONIC FIBROBLASTS; MESSENGER-RNA; INTESTINAL PROTEIN; TRANSGENIC MICE; LYSYL OXIDASE; DNA-BINDING; SUPPRESSION; ELEGANS; MOTIF	Several candidate genes involved in the maintenance of normal growth control (H-rev) were identified by differential expression cloning on the assumption that they are expressed in phenotypically normal rat cells and repressed in closely related H-ras transformed cells. Previously the genes coding for lysyl oxidase (H-rev142) and for an 18K-protein of unknown function (H-rev107) were recovered as cDNAs by subtraction cloning. Here we describe the identification and expression pattern of ril, a novel member of the heterogeneous group of genes encoding proteins with LIM/double zinc finger domains. The ril gene is expressed in normal fibroblasts and downregulated in H-uas-transformed derivatives. Expression is restored in several independent phenotypic revertants derived from H-ras transformed cells. The predicted protein product of ril harbors a single LIM domain but lacks a homeodomain. The ril gene is highly conserved during evolution and is transcribed in various normal cell lines. Northern blot analysis and in situ hybridization studies showed that ril is expressed in meiotic spermatocytes, in somites of developing mice, and in a side variety of tissues of adult mice.	UNIV ZURICH,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Aguzzi, Adriano/0000-0002-0344-6708; Schafer, Reinhold/0000-0001-7952-2124				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALTZ R, 1992, PLANT CELL, V4, P1465, DOI 10.1105/tpc.4.12.1465; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4371; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HENDERSON C, 1990, J HISTOTECHNOL, V12, P123; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLAUER L, 1993, ONCOGENE, V8, P2531; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHWARTEWALDHOF.I, 1994, ONCOGENE, V9, P899; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TURNER CE, 1994, J CELL SCI, V107, P1583; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	56	74	79	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					61	68						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824279				2022-12-25	WOS:A1995QA98000008
J	SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW				SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW			ADENOVIRUS 5 E1A INDUCED-DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS REQUIRES BINDING TO P300	ONCOGENE			English	Article						E1A MUTATIONS; ENDODERM; RETINOIC ACID; RETINOBLASTOMA PROTEIN	F9 TERATOCARCINOMA CELLS; REGION 1A PROTEINS; MOUSE PGK-1 GENE; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; DNA-SYNTHESIS; TRANSFORMATION; POLYPEPTIDES; EXPRESSION; REPRESSION	We transfected P19 embryonal carcinoma (EC) cells with genes encoding the adenovirus 5 E1A products. Expression of either the 12S or 13S transcripts yielded P19 cells either incapable of proliferating or able to proliferate but having lost the characteristics of the EC cell parent. The proliferating clones of E1A expressing P19 cells were incapable of differentiating in response to retinoic acid or dimethyl sulfoxide, no longer expressed the SSEA-1 surface antigen characteristic of EC cells, and did express cytokeratin 55, a marker of epithelial tissues. We used a number of 12S E1A constructs carrying deletions in the first exon and found that the effects on P19 cell growth and differentiated properties were lost with alterations affecting either the N terminal 25 amino acids or the CR1 region of the E1A protein. Both regions are required to bind the cellular p300 protein that we showed is present in P19 cells. We conclude that binding of E1A to the p300 protein in P19 cells results in the loss of EC cell characteristics.	UNIV OTTAWA, DEPT MED, OTTAWA, ON K1H 8M5, CANADA	University of Ottawa				Slack, Ruth/0000-0002-1552-2835				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOCCO JL, 1993, ONCOGENE, V8, P2977; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1992, CANCER SURV, V12, P161; EAGEN C, 1988, MOL CELL BIOL, V8, P3955; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRIS JF, 1984, J IMMUNOL, V132, P2502; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1988, VIROLOGY, V163, P494; JELMSA TN, 1989, VIROLOGY, V171, P120; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCBURNEY MW, 1994, UNPUB; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLACK RS, 1993, ONCOGENE, V8, P1585; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	43	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824272				2022-12-25	WOS:A1995QA98000003
J	KNUDSEN, BS; FELLER, SM; HANAFUSA, H				KNUDSEN, BS; FELLER, SM; HANAFUSA, H			4 PROLINE-RICH SEQUENCES OF THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR C3G BIND WITH UNIQUE SPECIFICITY TO THE FIRST SRC HOMOLOGY-3 DOMAIN OF CRK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; INSULIN-RECEPTOR SUBSTRATE-1; EPIDERMAL GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; SH3 DOMAINS; V-CRK; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; ONCOGENE PRODUCT; TYROSINE KINASE	The widely expressed cellular Crk protein has the domain structure SH2-SH3-SH3. We have previously demonstrated that the more N-terminal SH3 domain of Crk (CrkSH3(N)) specifically binds several cytoplasmic proteins. A cDNA encoding one of these proteins was isolated and found to have two different splice forms. The sequence is virtually identical to C3G, a guanine-nucleotide exchange factor. The center region of the 145-155-kDa protein contains four similar proline-rich sequences which are capable of binding individually to the SH3(N) domains of c-Crk and v-Crk. Comparison of these sequences in C3G to proline-rich sequences in other Crk-binding proteins suggests that positively charged amino acids following the prolines play an important role in the binding to the CrkSH3(N) domain. The endogenous C3G could be coprecipitated with Crk from cell lysates of cells expressing high levels of c-Crk or v-Crk, suggesting high binding affinity and a possible interaction in vivo. Unlike many other SH3-binding proteins which interact with multiple SH3 domains, C3G from cell lysates binds preferentially to the CrkSH3(N) domain. This unique binding specificity supports the idea that C3G plays an important role in Crk signaling pathways.	ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356, CA09673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHOU M, 1993, THESIS ROCKEFELLER U; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METHODS ENZ; FINAN P, 1994, J BIOL CHEM, V269, P13752; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYANJ, 1993, CURR OPIN STRUC BIOL, V3, P828; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIM WA, 1994, STRUCT BIOL, V1, P221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, J BIOL CHEM, V265, P12000; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; REICHMAN C, 1993, THESIS ROCKEFELLER U; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOBE K, 1993, J BIOL CHEM, V268, P11167; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	194	201	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32781	32787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806500				2022-12-25	WOS:A1994QA63800013
J	MCGEEHAN, GM; BICKETT, DM; GREEN, M; KASSEL, D; WISEMAN, JS; BERMAN, J				MCGEEHAN, GM; BICKETT, DM; GREEN, M; KASSEL, D; WISEMAN, JS; BERMAN, J			CHARACTERIZATION OF THE PEPTIDE SUBSTRATE SPECIFICITIES OF INTERSTITIAL COLLAGENASE AND 92-KDA GELATINASE - IMPLICATIONS FOR SUBSTRATE OPTIMIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; FIBROBLAST COLLAGENASE; ENZYME SPECIFICITY; EXPRESSION; SYNOVIUM; STROMELYSIN; INHIBITOR; PROTEASE; KINETICS; SITE	The peptide substrate specificities of two matrix metalloproteinases (MMPs), interstitial collagenase (MMP-1), and 92-kDa gelatinase (MMP-9), have been examined, Starting with the parent substrate, Dnp-Pro-Leu-Gly similar to Leu-Trp-Ala-D-Arg-NH2, four separate substrate mixtures were synthesized at subsites P-2(Leu) through P-2'(Trp), These mixtures contained either naturally occurring L-amino acids, D-amino acids, or either of two distinct sets of miscellaneous amino acids, Combined, these mixtures gave 88 unique substitutions at each position and, over the four subsites, represented 352 potential substrates, Optimal substrates were identified using a combined high performance liquid chromatography/mass spectrometry analysis as previously reported, The results gave an extended profile of the substrate specificities for both MMP-1 and MMP-9 at subsites P-2(Leu) through P-2'(Trp), Using the data obtained from the mapping, a new peptide substrate, Dnp-Pro-Cha-Abu similar to Smc-His-Ala-D-Arg-NH2 (where Dnp is 2,4-dinitrophenyl, Cha is cyclohexylalanine, Abu is cr aminobutyric acid, and Smc is S-methylcysteine) was designed and characterized, This peptide showed a 36-fold improvement in turnover (k(cat)/K-m) versus the parent substrate by interstitial collagenase, In addition, some collagenase subsite specificities described here were found to be different from those previously reported, Experimental data show that the observed selectivity is dependent on the original peptide template employed, which has broader implications for substrate specificity studies.			MCGEEHAN, GM (corresponding author), GLAXO INC, RES INST, DEPT BIOCHEM, 5 MOORE DR, RES TRIANGLE PK, NC 27709 USA.							ABELES RH, 1960, J BIOL CHEM, V235, P853; ABELES RH, 1960, J BIOL CHEM, V235, P6; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; DICKENS J, 1986, Patent No. 4599361; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4344, DOI 10.1021/bi00067a025; STACK MS, 1989, J BIOL CHEM, V264, P4277; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	22	51	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32814	32820						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806505				2022-12-25	WOS:A1994QA63800018
J	SCHRODER, WP; ARELLANO, JB; BITTNER, T; BARON, M; ECKERT, HJ; RENGER, G				SCHRODER, WP; ARELLANO, JB; BITTNER, T; BARON, M; ECKERT, HJ; RENGER, G			FLASH-INDUCED ABSORPTION-SPECTROSCOPY STUDIES OF COPPER INTERACTION WITH PHOTOSYSTEM-II IN HIGHER-PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; CU(II)-INHIBITORY BINDING-SITE; ABSORBANCE DIFFERENCE SPECTRA; MEMBRANE-FRAGMENTS; SPINACH-CHLOROPLASTS; REDUCTION KINETICS; THYLAKOID MEMBRANES; OXYGEN EVOLUTION; NANOSECOND RANGE; REACTION CENTERS	Measurements of flash-induced absorption changes at 325, 436, and 830 nm and of oxygen evolution were performed in order to analyze in detail the inhibition of photosystem II (PS II) by Cu(II) in PS II membrane fragments from spinach. (a) The kinetics of P680(+) reduction become markedly slower in the presence of 100 mu M CuSO4. (b) The CuSO4-induced kinetics of P680(+) reduction are dominated by a 140-160-mu s decay, (c) The extent of these 140-160-mu s kinetics, normalized to the overall decay, remains virtually unaffected by addition of the exogenous PS II donor, NH2OH. (d) In thoroughly dark-adapted samples the CuSO4-induced 140-160-mu s kinetics are already observed after the first flash and remain unchanged by a train of excitation flashes. (e) The extent of P680(+) and Q(A)(-) formation under repetitive flash excitation is not diminished by addition of 100 mu M CuSO4. (f) The induction of mu s kinetics of P680(+) reduction at the expense of ns kinetics and the inhibition of the saturation rate of oxygen evolution exhibit the same dependence on CuSO4 concentration, (g) CuSO4 also transforms the 10-20-mu s reduction of P680(+) by Tyr(Z) in Tris-washed PS II membrane fragments into 140-160-mu s kinetics without any effect on the extent of flash-induced P680(+) formation. These results unambiguously show that Cu(II) does not affect the charge separation (P680(+)Q(A)(-)), but instead specifically modifies Tyr(Z) and/or its micro environment so that the electron transfer to P680(+) becomes blocked.	CSIC, DEPT PLANT BIOCHEM, ESTAC EXPTL ZAIDIN, E-18008 GRANADA, SPAIN; TECH UNIV BERLIN, MAX VOLMER INST, D-10623 BERLIN, GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Technical University of Berlin	SCHRODER, WP (corresponding author), UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN.		Arellano, Juan B./D-7174-2013; Schröder, Wolfgang/A-8799-2008; Barón, Matilde/G-6940-2015	Arellano, Juan B./0000-0001-8677-8697; Barón, Matilde/0000-0002-8184-6045; Schroder, Wolfgang/0000-0001-9831-1533				ARELLANO JB, 1994, PHYSIOL PLANTARUM, V91, P369, DOI 10.1111/j.1399-3054.1994.tb02962.x; AYALA MB, 1992, PHYSIOL PLANTARUM, V84, P1, DOI 10.1034/j.1399-3054.1992.840101.x; BASZYNSKI T, 1988, J PLANT PHYSIOL, V132, P708, DOI 10.1016/S0176-1617(88)80233-5; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOHNER H, 1980, BIOCHIM BIOPHYS ACTA, V592, P103, DOI 10.1016/0005-2728(80)90117-6; BRETTEL K, 1983, PHOTOBIOCH PHOTOBIOP, V6, P253; CEDENOMALDONADO A, 1972, PLANT PHYSIOL, V50, P698, DOI 10.1104/pp.50.6.698; CHENIAE GM, 1971, PLANT PHYSIOL, V47, P568, DOI 10.1104/pp.47.4.568; CONJEAUD H, 1980, BIOCHIM BIOPHYS ACTA, V590, P353, DOI 10.1016/0005-2728(80)90206-6; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DORING G, 1969, Z NATURFORSCH PT B, VB 24, P1139, DOI 10.1515/znb-1969-0911; DROPPA M, 1984, P NATL ACAD SCI-BIOL, V81, P2369, DOI 10.1073/pnas.81.8.2369; DROPPA M, 1990, CRIT REV PLANT SCI, V9, P111, DOI 10.1080/07352689009382284; ECKERT HJ, 1991, PHOTOSYNTH RES, V27, P97, DOI 10.1007/BF00033249; ECKERT HJ, 1984, FEBS LETT, V167, P316, DOI 10.1016/0014-5793(84)80149-0; ECKERT HJ, 1988, FEBS LETT, V236, P425, DOI 10.1016/0014-5793(88)80070-X; ECKERT HJ, 1992, PHOTOSYNTHETICA, V27, P355; FORD RC, 1985, BIOCHIM BIOPHYS ACTA, V807, P1, DOI 10.1016/0005-2728(85)90047-7; GERKEN S, 1989, BIOCHIM BIOPHYS ACTA, V977, P52, DOI 10.1016/S0005-2728(89)80008-8; GLASER M, 1976, Z NATURFORSCH C, V31, P712, DOI 10.1515/znc-1976-11-1216; Greenfield SS, 1942, AM J BOT, V29, P121, DOI 10.2307/2437439; HAAG E, 1990, EUR J BIOCHEM, V189, P47, DOI 10.1111/j.1432-1033.1990.tb15458.x; HAVEMAN J, 1976, BIOCHIM BIOPHYS ACTA, V440, P346, DOI 10.1016/0005-2728(76)90069-4; HOGANSON CW, 1991, BIOCHIM BIOPHYS ACTA, V1057, P399, DOI 10.1016/S0005-2728(05)80154-9; HSU BD, 1988, PLANT PHYSIOL, V87, P116, DOI 10.1104/pp.87.1.116; LAVERGNE J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P175, DOI 10.1016/S0005-2728(09)91005-2; LIU B, 1993, BIOCHIM BIOPHYS ACTA, V1142, P129, DOI 10.1016/0005-2728(93)90094-V; LJUNGBERG U, 1984, FEBS LETT, V175, P255, DOI 10.1016/0014-5793(84)80746-2; MACDOWALL FDH, 1949, PLANT PHYSIOL, V24, P462, DOI 10.1104/pp.24.3.462; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MOHANTY N, 1989, PLANT PHYSIOL, V90, P175, DOI 10.1104/pp.90.1.175; RENGANATHAN M, 1989, BIOCHIM BIOPHYS ACTA, V974, P247, DOI 10.1016/S0005-2728(89)80240-3; RENGANATHAN M, 1990, PHOTOSYNTH RES, V23, P95, DOI 10.1007/BF00030068; RENGER G, 1976, BIOCHIM BIOPHYS ACTA, V423, P610, DOI 10.1016/0005-2728(76)90214-0; Renger G., 1991, Impact of global climatic changes on photosynthesis and plant productivity. Proceedings of the Indo-US workshop held on 8-12 January 1991 at New Delhi, India., P39; RENGER G, 1992, FEBS LETT, V299, P28, DOI 10.1016/0014-5793(92)80092-U; RENGER G, 1982, FEBS LETT, V137, P217, DOI 10.1016/0014-5793(82)80353-0; RENGER G, 1982, FEBS LETT, V149, P203, DOI 10.1016/0014-5793(82)81101-0; RENGER G, 1993, Z NATURFORSCH C, V48, P234; RENGER G, 1983, OXYGEN EVOLVING SYST, P73; SAMUELSSON G, 1980, PLANT CELL PHYSIOL, V21, P445; Sandmann G., 1983, Inorganic plant nutrition, P563; SCHANSKER G, 1993, PHOTOSYNTH RES, V37, P165, DOI 10.1007/BF02187475; SCHATZ GH, 1985, BIOCHIM BIOPHYS ACTA, V810, P283, DOI 10.1016/0005-2728(85)90212-9; SHIOI Y, 1978, PHYSIOL PLANTARUM, V44, P434, DOI 10.1111/j.1399-3054.1978.tb01651.x; SHIOI Y, 1978, PLANT CELL PHYSIOL, V19, P203; SINGH DP, 1987, PLANT PHYSIOL, V83, P12, DOI 10.1104/pp.83.1.12; STEEMANNNIELSEN E, 1969, PHYSIOL PLANTARUM, V22, P1121; VANBEST JA, 1978, BIOCHIM BIOPHYS ACTA, V503, P178, DOI 10.1016/0005-2728(78)90170-6; VANLEEUWEN PJ, 1993, PHOTOSYNTH RES, V38, P323, DOI 10.1007/BF00046757; VELTHUYS BR, 1988, BIOCHIM BIOPHYS ACTA, V933, P249, DOI 10.1016/0005-2728(88)90032-1; VIERKE G, 1977, Z NATURFORSCH C, V32, P605; VOLKER M, 1987, BIOCHIM BIOPHYS ACTA, V890, P66, DOI 10.1016/0005-2728(87)90069-7; WEISS W, 1986, BIOCHIM BIOPHYS ACTA, V850, P173, DOI 10.1016/0005-2728(86)90172-6; YRUELA I, 1992, PHOTOSYNTH RES, V33, P227, DOI 10.1007/BF00030033; YRUELA I, 1991, J BIOL CHEM, V266, P22847; YRUELA I, 1993, J BIOL CHEM, V268, P1684	57	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32865	32870						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806512				2022-12-25	WOS:A1994QA63800025
J	BAJORATH, J; ARUFFO, A				BAJORATH, J; ARUFFO, A			MOLECULAR-MODEL OF THE EXTRACELLULAR LECTIN-LIKE DOMAIN IN CD69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY ACTIVATION ANTIGEN; T-CELL ACTIVATION; LYMPHOCYTE-ACTIVATION; HOMOLOGOUS PROTEINS; P-SELECTIN; EXPRESSION; RECOGNITION; SEQUENCES; AIM/CD69; CRITERIA	CD69 is described as a T cell activation antigen, but the ligand and physiological function of CD69 are currently unknown. The sequence of the extracellular domain of CD69 shows some similarity with that of calcium-dependent (C-type) lectins, Using comparative computer modeling and inverse folding calculations, we have generated and analyzed a detailed three-dimensional model of the extracellular domain of CD69 based on the crystal structure of the mannose binding protein. The sequence of CD69 appears to be highly compatible with the C-type lectin fold, and assessment of the model using inverse folding calculations suggests its overall correctness. Compared with mannose binding protein and the selectins, CD69 displays significant deletions in loop regions. In addition, residues that form conserved calcium binding sites found in the C-type lectin family are not conserved in CD69. This suggests the presence of structural features in CD69 that depart from some of the conserved motifs seen in two crystal structures of C-type lectins. The CD69 model shows cavity-shaped hydrophobic regions surrounded by charged residues. One of these cavities is proximal to a potential low affinity calcium binding site and may be implicated in specific interactions with ligands.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb			Bajorath, Jürgen/F-7493-2014					BAJORATH J, 1993, PROTEIN SCI, V2, P1798, DOI 10.1002/pro.5560021103; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BAJORATH J, 1992, IMMUNOMETHODS, V1, P137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIEBER T, 1992, J INVEST DERMATOL, V98, P771, DOI 10.1111/1523-1747.ep12499948; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CEBRIAN M, 1988, J EXP MED, V168, P1621, DOI 10.1084/jem.168.5.1621; COSULICH ME, 1987, P NATL ACAD SCI USA, V84, P4205, DOI 10.1073/pnas.84.12.4205; DAMBROSIO D, 1993, EUR J IMMUNOL, V23, P2993, DOI 10.1002/eji.1830231140; DELIA D, 1988, IMMUNOLOGY, V64, P593; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FETROW JS, 1993, BIO-TECHNOL, V11, P479, DOI 10.1038/nbt0493-479; GAVIOLI R, 1992, CELL IMMUNOL, V142, P186, DOI 10.1016/0008-8749(92)90279-X; GEROSA F, 1991, MOL IMMUNOL, V28, P159, DOI 10.1016/0161-5890(91)90100-X; GODZIK A, 1993, J COMPUT AID MOL DES, V7, P397, DOI 10.1007/BF02337559; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GODZIK A, 1992, J MOL BIOL, V227, P227, DOI 10.1016/0022-2836(92)90693-E; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREER J, 1991, METHOD ENZYMOL, V202, P239; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HAMANN J, 1993, J IMMUNOL, V150, P4920; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; NOVOTNY J, 1988, PROTEINS, V4, P19, DOI 10.1002/prot.340040105; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SANTIS AG, 1992, EUR J IMMUNOL, V22, P1253, DOI 10.1002/eji.1830220521; SCHWARTING R, 1989, LEUCOCYTE TYPING, V4, P428; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SIPPL MJ, 1993, J COMPUT AID MOL DES, V7, P473, DOI 10.1007/BF02337562; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TUGORES A, 1992, J IMMUNOL, V148, P2300; WEIS WI, 1994, STRUCTURE, V2, P147, DOI 10.1016/S0969-2126(00)00016-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WODAK SJ, 1993, CURR OPIN STRUC BIOL, V3, P247, DOI 10.1016/S0959-440X(05)80160-5; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737	46	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32457	32463						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798246				2022-12-25	WOS:A1994PX30400067
J	PETERSEN, CCH; BERRIDGE, MJ				PETERSEN, CCH; BERRIDGE, MJ			THE REGULATION OF CAPACITATIVE CALCIUM-ENTRY BY CALCIUM AND PROTEIN-KINASE-C IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PAROTID ACINAR-CELLS; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; LAEVIS OOCYTES; TUMOR PROMOTER; MAST-CELLS; THAPSIGARGIN; INFLUX; ACTIVATION	Agonists linked to the phosphoinositide signaling pathway evoke capacitative calcium entry in Xenopus oocytes. This entry pathway can also be activated by injection of inositol 2,4,5-trisphosphate, application of thapsigargin, or incubation in calcium-free medium. A variety of protocols revealed highly nonlinear behavior of the calcium entry in thapsigargin-treated oocytes suggestive of positive and negative feedback by calcium at the level of its own entry. These feedback mechanisms may account for the highly damped calcium oscillations we observed in thapsigargin-treated oocytes. Low level activation of protein kinase C potentiated calcium influx in thapsigargin-treated oocytes, apparently by blocking the inactivation of the calcium influx. Higher levels of protein kinase C activity inhibited capacitative calcium entry.			PETERSEN, CCH (corresponding author), UNIV CAMBRIDGE,BABRAHAM INST,DEPT ZOOL,MOLEC SIGNALLING LAB,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Petersen, Carl/M-5123-2017	Petersen, Carl/0000-0003-3344-4495	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IINO M, 1990, J GEN PHYSIOL, V101, P67; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MONTERO M, 1993, J BIOL CHEM, V268, P13055; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; PARKER I, 1992, AM J PHYSIOL, V263, pC154, DOI 10.1152/ajpcell.1992.263.1.C154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PETERSEN CCH, 1994, CELL CALCIUM, V16, P391, DOI 10.1016/0143-4160(94)90032-9; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKEMURA H, 1989, BIOCHEM J, V259, P125; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	38	144	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32246	32253						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798225				2022-12-25	WOS:A1994PX30400038
J	AUSTIN, CA; MARSH, KL; WASSERMAN, RA; WILLMORE, E; SAYER, PJ; WANG, JC; FISHER, LM				AUSTIN, CA; MARSH, KL; WASSERMAN, RA; WILLMORE, E; SAYER, PJ; WANG, JC; FISHER, LM			EXPRESSION, DOMAIN-STRUCTURE, AND ENZYMATIC-PROPERTIES OF AN ACTIVE RECOMBINANT HUMAN DNA TOPOISOMERASE II-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NIH-3T3 CELLS; 2 FORMS; YEAST; GENE; PROTEIN; SEQUENCE; PURIFICATION; LOCALIZATION; HOMOLOGY	Human cells express two genetically distinct isoforms of DNA topoisomerase II, alpha and beta, which catalyze ATP-dependent DNA strand passage and are an important antitumor drug target, Here we report for the first time the successful overexpression of human topoisomerase II beta in yeast by cloning a topoisomerase II beta cDNA in a yeast shuttle vector under the control of a galactose inducible promoter, Recombinant human topoisomerase II beta (residues 46-1621 fused to the first 5 residues of yeast topoisomerase II) was purified to homogeneity, yielding an enzymatically active polypeptide in sufficient quantity to allow analysis of its domain structure and comparison with that of recombinant human topoisomerase II alpha. Partial digestion of beta with either trypsin or protease SV8 generated fragments of approximately 130, 90, 62, and 45-50 kDa, arising from cleavage at three limited and discrete regions of the protein (A, B, and C) indicating the presence of at least four structural domains, Recombinant human topoisomerase II alpha and beta induced DNA breakage which was promoted by a variety of agents, Isoform differences in drug-induced DNA breakage were observed, These studies of human topoisomerase II beta in concert with alpha should aid the determination of their individual roles in cancer chemotherapy and should facilitate the design, targeting, and testing of cytotoxic antitumor agents.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT CELLULAR & MOLEC SCI,MOLEC GENET GRP,LONDON SW17 0RE,ENGLAND	Harvard University; St Georges University London	AUSTIN, CA (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Willmore, Elaine/B-4350-2009	Willmore, Elaine/0000-0002-4762-094X; West, Katherine/0000-0002-5994-8969; Fisher, Larry Mark/0000-0002-2172-3369; Austin, Caroline/0000-0002-1921-5947				AUSTIN CA, 1990, BIOCHEM BIOPH RES CO, V170, P763, DOI 10.1016/0006-291X(90)92156-T; AUSTIN CA, 1990, FEBS LETT, V266, P115, DOI 10.1016/0014-5793(90)81520-X; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARON PR, 1993, MOL BIOL DNA TOPOISO, P243; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; NELSON EM, 1984, P NATL ACAD SCI-BIOL, V81, P1361, DOI 10.1073/pnas.81.5.1361; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PETROV P, 1993, EXP CELL RES, V204, P73, DOI 10.1006/excr.1993.1010; PFLUGFELDER MT, 1988, P NATL ACAD SCI USA, V85, P7177; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TAN KB, 1992, CANCER RES, V52, P231; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F; ZWELLING LA, 1981, BIOCHEMISTRY-US, V20, P6553, DOI 10.1021/bi00526a006	40	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15739	15746		10.1074/jbc.270.26.15739	http://dx.doi.org/10.1074/jbc.270.26.15739			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797575	hybrid			2022-12-25	WOS:A1995RG53800048
J	BERG, DT; CALNEK, DS; GRINNELL, BW				BERG, DT; CALNEK, DS; GRINNELL, BW			THE HUMAN APOLIPOPROTEIN-E GENE IS NEGATIVELY REGULATED IN HUMAN LIVER HEPG2 CELLS BY THE TRANSCRIPTION FACTOR BEF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							E MESSENGER-RNA; TRANSGENIC MICE; A-I; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; EXPRESSION; PROTEIN; ELEMENT; LINES	Apolipoprotein E (apoE) is a major constituent of plasma lipoprotein that functions in lipid transport and redistribution (reverse cholesterol transport) and probably plays an important role in inhibiting the development and/or progression of atherosclerosis, While cis-acting regions involved in basal and tissue-specific control of the apoE gene have been identified by promoter mapping studies, much less is known about factors that regulate the gene. In this study, we demonstrate that the region between -94 and -84 upstream of transcriptional start site of the human apoE gene contains a binding site for the transcriptional repressor factor BEF-1, a tyrosine-phosphorylated nuclear protein that was first identified in HeLa cells, Using gel retar dation assays, we show that HeLa cell derived BEF-1 binds the apoE BEF-1 homology, and this binding can be competed with the prototype BEF-1 sequence, but not by a mutated sequence, Furthermore, we demonstrate that the apoE- producing human liver HepG2 cell produces significant levels of BEF-1, which could bind to both the prototype BEF-1 sequence and the apoE homology, and be competed equivalently with cold BEF-1 or apoE homology, To determine if BEF-1 affected the expression of apoE, we performed competition experiments using plasmids containing the intact or mutated BEF-1 homology, The introduction of the intact BEF I site into HepG2 cells resulted in an induction of apoE mRNA, whereas control and mutated BEF-1-containing plasmids had no significant effect, We also found that increasing the level of nuclear BEF-1 by treatment of cells with orthovanadate resulted in a reduction in the level of apoE mRNA Overall, our data suggest that the endogenous apoE gene in the human HepG2 cell hue is repressed by the trans-acting influence of nuclear factor BEF-1.	ELI LILLY & CO,LILLY CORP CTR,LILLY RES LABS,DEPT CARDIOVASC RES,INDIANAPOLIS,IN 46285	Eli Lilly								AZROLAN N, 1990, J LIPID RES, V31, P1141; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS HK, 1985, J BIOL CHEM, V260, P6240; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIO S, 1994, J LIPID RES, V35, P408; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PAIK YK, 1988, J BIOL CHEM, V264, P13340; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; ROSES AD, 1994, NEUROPSYCHOPHARMACOL, V10, P5; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SIMONET WS, 1985, J BIOL CHEM, V266, P8651; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WEISGRABER KH, 1990, ANN NY ACAD SCI, V598, P37, DOI 10.1111/j.1749-6632.1990.tb42274.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15447	15450		10.1074/jbc.270.26.15447	http://dx.doi.org/10.1074/jbc.270.26.15447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797534	hybrid			2022-12-25	WOS:A1995RG53800002
J	MALABA, L; SMELAND, S; SENOO, H; NORUM, KR; BERG, T; BLOMHOFF, R; KINDBERG, GM				MALABA, L; SMELAND, S; SENOO, H; NORUM, KR; BERG, T; BLOMHOFF, R; KINDBERG, GM			RETINOL-BINDING PROTEIN AND ASIALO-OROSOMUCOID ARE TAKEN UP BY DIFFERENT PATHWAYS IN LIVER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-RECEPTOR; STELLATE CELLS; RAT-LIVER; VITAMIN-A; TRANSPORT; ENDOCYTOSIS; CAVEOLAE; SURFACE; MOLECULES; COMPONENT	The intracellular transport and degradation of in vivo endocytosed retinol-binding protein was compared with that of asialo-orosomucoid, a marker for receptor-mediated endocytosis through coated pits, The transport pathways were studied in rat liver cells by means of subcellular fractionation in Nycodenz and sucrose density gradients and by immunoelectron microscopy, Retinol-binding protein and asialo orosomucoid were labeled by covalent attachment of radioiodinated tyramine cellobiose, an adduct which is incapable of crossing cellular membranes and thus provides a marker for the organelles where the protein has been taken up and degraded. The data obtained from subcellular fractionation studies, as well as from immunoelectron microscopy, showed that retinol-binding protein and asialo-orosomucoid were initially localized in different endocytic vesicles, Retinol-binding protein co-localized in density gradients with markers for potocytosis, an alternative endocytic pathway which uses internalization through caveolae instead of clathrin-coated pits. Later, retinol-binding protein and asialo-orosomucoid comigrated in the gradients and they were also observed in the same larger vesicles by immunoelectron microscopy. These data suggest that retinol-binding protein is taken up by Liver cells by potocytosis and that a fraction of the retinol-binding protein is later transferred to larger vesicles located deeper in the cytoplasm where degradation takes place.	UNIV OSLO, SCH MED, INST NUTR RES, N-0316 OSLO, NORWAY	University of Oslo								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P46; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BLOMHOFF R, 1990, METHOD ENZYMOL, V190, P58; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EL-AASER A A, 1969, Histochemical Journal, V1, P417, DOI 10.1007/BF01086983; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; GENZE HJ, 1987, J CELL BIOL, V104, P1715; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KINDBERG GM, 1987, CELLS MEMBRANES DISE, P315; MALABA L, 1993, BIOCHEM J, V291, P187, DOI 10.1042/bj2910187; MCGUIRE BW, 1981, ENDOCRINOLOGY, V108, P658, DOI 10.1210/endo-108-2-658; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; RICKWOOD D, 1983, PROPERTIES IODINATED, P1; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SENOO H, 1990, J LIPID RES, V31, P1229; SENOO H, 1993, P NATL ACAD SCI USA, V90, P3616, DOI 10.1073/pnas.90.8.3616; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; STANG E, 1988, J MICROSC-OXFORD, V149, P77, DOI 10.1111/j.1365-2818.1988.tb04564.x; Tokuyasu K. T., 1984, IMMUNOLABELLING ELEC, P71; TOLLESHAUG H, 1980, H-S Z PHYSIOL CHEM, V361, P1155, DOI 10.1515/bchm2.1980.361.2.1155; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WEBSTER P, 1993, J MICROSC-OXFORD, V169, P85, DOI 10.1111/j.1365-2818.1993.tb03281.x; WIDNELL CC, 1982, CELL, V28, P61, DOI 10.1016/0092-8674(82)90375-0; WISSE E, 1970, J ULTRA MOL STRUCT R, V31, P125, DOI 10.1016/S0022-5320(70)90150-4	43	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15686	15692		10.1074/jbc.270.26.15686	http://dx.doi.org/10.1074/jbc.270.26.15686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797569	hybrid			2022-12-25	WOS:A1995RG53800040
J	TINKER, RL; SANDERS, GM; SEVERINOV, K; KASSAVETIS, GA; GEIDUSCHEK, EP				TINKER, RL; SANDERS, GM; SEVERINOV, K; KASSAVETIS, GA; GEIDUSCHEK, EP			THE COOH-TERMINAL DOMAIN OF THE RNA-POLYMERASE ALPHA-SUBUNIT IN TRANSCRIPTIONAL ENHANCEMENT AND DEACTIVATION AT THE BACTERIOPHAGE-T4 LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL MAP; DNA; ACTIVATION; PROTEIN; BINDING; REGION; COMMUNICATION; INHIBITION; APPARATUS	Many activator proteins generate their positive control of transcription through interactions with the COOH-terminal domain of the Escherichia coli RNA polymerase alpha subunit. We have examined the participation of this alpha-domain in transcriptional enhancement and suppression at bacteriophage T4 late promoters, Enhancement is generated by the T4 gene 45 protein, which is the DNA-tracking processivity factor of viral DNA replication; suppression of unenhanced transcription is generated by the RNA polymerase-binding coactivator T4 gene 33 protein. Enhanced and unenhanced transcription by RNA polymerase reconstituted with intact and truncated alpha subunits and by RNA polymerase containing ADP-ribosylated alpha has been compared; the internal structures of transcription complexes formed with these RNA polymerases have also been analyzed by footprinting and photocross-linking. Comparison of these structural and functional analyses suggests that enhancement of T4 late transcription by gp45 is not compatible with any significant role of the COOH-terminal domain of the RNA polymerase core a subunit in transcriptional initiation. Suppression of unenhanced T4 late transcription by the gene 33 protein also does not require the COOH-terminal domain of alpha.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of California System; University of California San Diego; Rockefeller University	TINKER, RL (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA 92093, USA.		Severinov, Konstantin/C-8545-2016					BARTHOLOMEW B, 1995, IN PRESS METHODS ENZ, V262; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COPPO A, 1975, J MOL BIOL, V96, P601, DOI 10.1016/0022-2836(75)90141-2; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1995, IN PRESS CURR OPIN G; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; EPSTEIN RH, 1964, COLD SPRING HARB SYM, V28, P375; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; KARAM J, 1994, MOL BIOL BACTERIOP T, V4; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; MAILHAMMER R, 1975, P NATL ACAD SCI USA, V72, P4828; Maniatis T., 1982, MOL CLONING; Mathews C.K., 1983, BACTERIOPHAGE T; OUHAMMOUCH M, 1994, J BACTERIOL, V176, P3956, DOI 10.1128/JB.176.13.3956-3965.1994; OUHAMMOUCH M, 1995, P NATL ACAD SCI USA, V92, P1451, DOI 10.1073/pnas.92.5.1451; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; STEVENS A, 1977, BIOCHIM BIOPHYS ACTA, V475, P193, DOI 10.1016/0005-2787(77)90355-0; STITT B, 1994, MOL BIOL BACTERIOP T, V4, P142; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; WILKENS K, 1994, MOL BIOL BACTERIOP T, V4, P132; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	42	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15899	15907		10.1074/jbc.270.26.15899	http://dx.doi.org/10.1074/jbc.270.26.15899			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797594	hybrid			2022-12-25	WOS:A1995RG53800070
J	JANSEN, E; AYOUBI, TAY; MEULEMANS, SMP; VANDEVEN, WJM				JANSEN, E; AYOUBI, TAY; MEULEMANS, SMP; VANDEVEN, WJM			NEUROENDOCRINE-SPECIFIC EXPRESSION OF THE HUMAN PROHORMONE CONVERTASE-1 GENE - HORMONAL REGULATION OF TRANSCRIPTION THROUGH DISTINCT CAMP RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN PROCESSING ENZYME; MESSENGER-RNA; SUBTILISIN FAMILY; PRIMARY SEQUENCE; RAT-BRAIN; PC2; IDENTIFICATION; FURIN; CDNA; PITUITARY	Prohormone convertases are involved in the tissue-specific endoproteolytic processing of prohormones and neuopeptide precursors within the secretory pathway. In the present study, we have isolated genomic clones comprising the 5'-terminal region of the human prohormone convertase 1 (PC1) gene and identified and characterized the PC1 promoter region. We found multiple transcription start sites located within a 15-base pair region, 205 base pairs upstream of the translation start codon. The promoter region is not G+C-rich and does not contain a canonical TATA box nor a CAAT box. Transient expression assays with a set of human PC1 gene fragments containing progressive 5' deletions demonstrate that the proximal promoter region is capable of directing high levels of neuroendocrine-specific expression of reporter gene constructs. In addition, the proximal promoter region confers both basal and hormone-regulated promoter activity. Site-specific mutagenesis experiments demonstrate that two closely spaced cAMP response elements within the proximal promoter region direct cAMP-mediated hormonal regulation of transcription of the PC1 gene.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; FLANDERS INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM	KU Leuven; Flanders Institute for Biotechnology (VIB)								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1992, DNA CELL BIOL, V11, P791, DOI 10.1089/dna.1992.11.791; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; BORELLI E, 1992, CRIT REV ONCOGENESIS, V3, P321; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FTOUHI N, 1994, DNA CELL BIOL, V13, P395, DOI 10.1089/dna.1994.13.395; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; JEANNOTTE L, 1987, MOL CELL BIOL, V7, P4058, DOI 10.1128/MCB.7.11.4058; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MINEO I, 1995, BIOCHEM BIOPH RES CO, V207, P646, DOI 10.1006/bbrc.1995.1236; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OHAGI S, 1992, P NATL ACAD SCI USA, V89, P4977, DOI 10.1073/pnas.89.11.4977; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; PRESTRIDGE DS, 1993, COMPUT APPL BIOSCI, V9, P113; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; SAMBROOOK J, 1989, MOL CLONING LABORATO; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x	46	54	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15391	15397		10.1074/jbc.270.25.15391	http://dx.doi.org/10.1074/jbc.270.25.15391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797529	hybrid			2022-12-25	WOS:A1995RE66600081
J	SORKIN, A; MCKINSEY, T; SHIH, W; KIRCHHAUSEN, T; CARPENTER, G				SORKIN, A; MCKINSEY, T; SHIH, W; KIRCHHAUSEN, T; CARPENTER, G			STOICHIOMETRIC INTERACTION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR WITH THE CLATHRIN-ASSOCIATED PROTEIN COMPLEX AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; COATED VESICLE PROTEINS; AMINO-ACID SEQUENCE; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; ADAPTER PROTEIN; INVITRO BINDING; KINASE-ACTIVITY; PITS; CLONING	Plasma membrane clathrin-associated protein complexes (AP-2) have been shown to co-immunoprecipitate with the epidermal growth factor (EGF) receptor (Sorkin A., and Carpenter, G. (1993) Science 261, 612-615). Hence, we analyzed the stoichiometry of the EGF receptor interaction with AP-2 using a new antibody that efficiently immunoprecipitates native AP-2. EGF receptor AP-2 complexes were isolated from S-35-labeled cells treated with EGF by EGF receptor affinity chroma tography followed by precipitation with the antibody to AP-2. Quantitation of the relative molar concentrations of the proteins found in the complex revealed that 1 mol of AP-2 was associated with approximately 1.1 mol of EGF receptor. No other proteins were present in significant molar concentrations relative to AP-2. indicating that other proteins are not stoichiometrically involved in the interaction of EGF receptors and AP-2 in vitro. Co-immunoprecipitation experiments in cells expressing a mutant EGF receptor demonstrated that the cyto plasmic carboxyl-terminal 214 residues of the EGF receptor are essential for interaction with AP-2.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; CTR BLOOD RES, BOSTON, MA 02115 USA	Vanderbilt University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)				Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA24071] Funding Source: Medline; NIDDK NIH HHS [DK46817] Funding Source: Medline; NIGMS NIH HHS [GM36548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4437; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COHEN S, 1980, J BIOL CHEM, V255, P4834; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HEUSER J, 1985, J ULTRASTRUCT RES, V92, P2457; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LUND KA, 1990, J BIOL CHEM, V265, P15713; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STARBUCK C, 1992, BIOTECHNOL PROGR, V8, P132, DOI 10.1021/bp00014a007; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TUCKER KL, 1990, NUCLEIC ACIDS RES, V18, P5306, DOI 10.1093/nar/18.17.5306; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	50	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					619	625		10.1074/jbc.270.2.619	http://dx.doi.org/10.1074/jbc.270.2.619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822287	hybrid			2022-12-25	WOS:A1995QB81600020
J	YAMASHITA, H; OKADOME, T; FRANZEN, P; TENDIJKE, P; HELDIN, CH; MIYAZONO, K				YAMASHITA, H; OKADOME, T; FRANZEN, P; TENDIJKE, P; HELDIN, CH; MIYAZONO, K			A RAT PITUITARY-TUMOR CELL-LINE (GH(3)) EXPRESSES TYPE-I AND TYPE-II RECEPTORS AND OTHER CELL-SURFACE BINDING PROTEIN(S) FOR TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; ACTIVIN RECEPTOR; CARCINOMA-CELLS; CLONING; INHIBITION; BETAGLYCAN; COMPONENT; COMPLEXES; SIGNALS; LIGAND	A rat pituitary tumor cell line (GH(3)) has been reported to express transforming grow-th factor-beta (TGF-beta) binding components of 70-74 kDa (ligand included), denoted TGF-beta type IV receptor. We investigated whether the type IV receptor corresponds to any of the recently cloned type I receptors for proteins in the TGF-beta superfamily. TGF-beta type I receptor (T beta R-I) complexes of 69-72 kDa formed a heteromeric complex with T beta R-II in GH(3) cells, as detected by immunoprecipitation. In addition, TGF-beta formed complexes of 72-74 kDa, which were different from T beta R-I and the other known type I receptors, and were not dependent on T beta R-II for binding, The GH(3) cells were resistant to the growth inhibitory activity of TGF-beta, but a transcriptional response was activated by TGF-beta in this cell line, presumably through the T beta R-II and T beta R-I complex. These results indicate that GH(3) cells have T beta R-I and T beta R-II and, in addition, other binding protein(s) which form 72-74-kDa complexes with TGF-beta; the function of the latter component(s) remains to be elucidated.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					770	774		10.1074/jbc.270.2.770	http://dx.doi.org/10.1074/jbc.270.2.770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822309	hybrid			2022-12-25	WOS:A1995QB81600043
J	ZHENG, Y; BENDER, A; CERIONE, RA				ZHENG, Y; BENDER, A; CERIONE, RA			INTERACTIONS AMONG PROTEINS INVOLVED IN BUD-SITE SELECTION AND BUD-SITE ASSEMBLY IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; CELL POLARITY; GENETIC-CONTROL; BUDDING YEAST; RAS; MORPHOGENESIS; CDC42; RSR1; PATHWAY; PRODUCT	Bud formation in yeast involves the actions of the Ras-type GTPase Rsr1, which is required for the proper selection of the bud site, and the Rho-type GTPase Cdc42, which is necessary for the assembly of cytoskeletal structures at that site. The Cdc24 protein is required both for proper bud-site selection and bud-site assembly and has been recently shown to display guanine-nucleotide-exchange factor (GEF) activity toward Cdc42. Here, we demonstrate, using recombinant proteins, that Cdc24 can also bind directly to Rsr1. This binding has no effect on the ability of Rsr1 to undergo intrinsic or GEF-stimulated GDP-GTP exchange, However, Cdc24 can inhibit both the intrinsic and GTPase-activating protein-stimulated GTPase activity of Rsr1 and thereby acts as a GTPase-inhibitor protein for Rsr1. Cdc24 thus appears to bind preferentially to the activated form of Rsr1. The SH3 domain-containing bud-site assembly protein Bem1 also binds directly to Cdc24, and we show here that this interaction is inhibited by Ca2+. Neither Bem1 nor Cdc42 affects the GTPase-inhibitor protein activity of Cdc24 toward Rsr1, and neither Bem1 nor Rsr1 affects the GEF activity of Cdc24 toward Cdc42. Taken together, these results suggest that Cdc24 enables the direct convergence of a Ras-like protein (Rsr1) and a Rho-like protein (Cdc42) with the SH3-domain-containing protein (Bem1) and that independent domains of Cdc24 are responsible for these different interactions. These results also suggest that rather than directly controlling the GEF activity of Cdc24, the primary roles of Rsr1 and Bem1 might be to control the positioning of Cdc24 within the cell.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	ZHENG, Y (corresponding author), CORNELL UNIV,DEPT PHARMACOL,SCHURMANN HALL,ITHACA,NY 14850, USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM46271, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458, R01GM046271, R29GM046271] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENTON BK, 1993, EMBO J, V12, P5267, DOI 10.1002/j.1460-2075.1993.tb06222.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; HART MJ, 1994, J BIOL CHEM, V269, P62; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PETERSON J, 1994, IN PRESS J CELL BIOL; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405	31	150	152	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					626	630		10.1074/jbc.270.2.626	http://dx.doi.org/10.1074/jbc.270.2.626			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822288	hybrid			2022-12-25	WOS:A1995QB81600021
J	HEVEKER, N; BONNAFFE, D; ULLMANN, A				HEVEKER, N; BONNAFFE, D; ULLMANN, A			CHEMICAL FATTY ACYLATION CONFERS HEMOLYTIC AND TOXIC ACTIVITIES TO ADENYLATE-CYCLASE PROTOXIN OF BORDETELLA-PERTUSSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALMODULIN; ACTIVATION; PURIFICATION; PENETRATION; PROTEIN; BINDING; CYAC	Adenylate cyclase toxin (ACT), a virulence factor of Bordetella pertussis, acquires hemolytic and toxic activities after post-translational modification of the cyaA gene product, CyaA. The exact nature of this modification is unknown, but homology to the related repeat toxin cu-hemolysin of Escherichia coli suggests that fatty acylation of a lysine residue may be involved, In the present study, we used an in, vitro chemical approach to acylate unmodified, inactive adenylate cyclase protoxin by using a new water soluble compound, acylpyrophosphate. We show that undirected transfer of lauric, myristic, or palmitic acid chains to the CyaA protoxin is able to confer both hemolytic and toxic activities to ACT. The chemically modified protoxin shows a specific requirement for Ca2+ ions for toxic activity, as does the wild type toxin. However, the toxic and hemolytic activities of chemically modified ACT are low in comparison to ACT modified in vivo, suggesting that in vitro fatty acylation of the protoxin involves random modification of nucleophilic residues present in the toxin in contrast to the in vivo modification of specific sites.	INST PASTEUR, DEPT BIOCHIM & GENET MOLEC, UNITE CHIM ORGAN, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HEVEKER, N (corresponding author), INST PASTEUR, UNITE BIOCHIM REGULAT CELLULAIRES, 28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE.		Heveker, Nikolaus/G-5306-2012					BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; HANSKI E, 1985, J BIOL CHEM, V260, P5526; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOSEPH E, 1982, MOL GEN GENET, V185, P262, DOI 10.1007/BF00330796; LADANT D, 1986, J BIOL CHEM, V261, P6264; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; RYU EK, 1979, J LIPID RES, V20, P561; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834	16	5	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32844	32847						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806509				2022-12-25	WOS:A1994QA63800022
J	OUWENS, DM; VANDERZON, GCM; PRONK, GJ; BOS, JL; MOLLER, W; CHEATHAM, B; KAHN, CR; MAASSEN, JA				OUWENS, DM; VANDERZON, GCM; PRONK, GJ; BOS, JL; MOLLER, W; CHEATHAM, B; KAHN, CR; MAASSEN, JA			A MUTANT INSULIN-RECEPTOR INDUCES FORMATION OF A SHC-GROWTH FACTOR-RECEPTOR BOUND PROTEIN-2 (GRB2) COMPLEX AND P21(RAS)-GTP WITHOUT DETECTABLE INTERACTION OF INSULIN-RECEPTOR SUBSTRATE-1 (IRS1) WITH GRB2 - EVIDENCE FOR IRS1-INDEPENDENT P21(RAS)-GTP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN AUTOPHOSPHORYLATION; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL-TRANSDUCTION; TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3'-KINASE; GENE-EXPRESSION; RAS; ACTIVATION; P21RAS; PHOSPHORYLATION	The activation of p21(ras) by receptor tyrosine kinases involves the translocation of the growth factor receptor bound protein 2-mammalian son of sevenless protein (Grb2.SOS) complex to the plasma membrane where p21(ras) is localized, Insulin receptors induce p21(ras)-GTP formation by two possible mechanisms: tyrosine phosphorylation of insulin receptor substrate 1 (IRS1) and its subsequent association with Grb2, or Shc phosphorylation and its subsequent association with Grb2. We investigated the contribution of the major tyrosine autophosphorylation sites Tyr(1158), Tyr(1162), and Tyr(1163) of the insulin receptor to IRS1.Grb2 and Shc.Grb2 association and the formation of p21(ras)-GTP. Chinese hamster ovary-derived cell lines were used overexpressing mutant insulin receptors in which the major tyrosine autophosphorylation sites were stepwise replaced by phenylalanines. In cell lines expressing wild type or mutant Y1158F,Y1162,Y1163 (FYY) receptors, insulin stimulated tyrosine phosphorylation of IRS1 and She and the formation of IRS1.Grb2 and Shc.Grb2 protein complexes, together with an increase in p21(ras)-GTP. Cell lines expressing mutant Y1158,Y1162F,Y1163F (YFF) receptors showed insulin-induced tyrosine phosphorylation of Shc, Shc.Grb2 complex formation, and p21(ras)-GTP formation, whereas tyrosine phosphorylation of IRS1 was strongly decreased and formation of IRS1.Grb2 complexes was undetectable. The activity of FYY and YFF receptors to mediate p21(ras)-GTP formation correlated with their activity to induce She phosphorylation and Shc.Grb2 association. The mutant insulin receptors Y1158F,Y1162F,Y1163 and Y1158F,Y1162F,Y1163F were inactive in inducing any of these responses, We conclude that phosphorylation of Tyr(1158) and Tyr(1162) of the insulin receptor is linked to distinct post-receptor processes and that YFF receptors generate p21(ras)-GTP via the Shc.Grb2 pathway rather than one involving IRS1.Grb2 interaction.	LEIDEN STATE UNIV,DEPT BIOCHEM MED,SYLVIUS LAB,PROT SYNTH & HORMONE REGULAT SECT,2333 AL LEIDEN,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3584 CG UTRECHT,NETHERLANDS; JOSLIN DIABET CTR,BOSTON,MA 02215	Leiden University; Leiden University - Excl LUMC; Utrecht University; Harvard University; Joslin Diabetes Center, Inc.			Ouwens, Margriet/H-2442-2013; Kahn, Ronald/AAY-2435-2021	Ouwens, Margriet/0000-0001-6709-2702; Kahn, Ronald/0000-0002-7583-9228				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KASUGA M, 1981, SCIENCE, V215, P185; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PELICCI G, 1992, CELL, V70, P98; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1993, J BIOL CHEM, V268, P11167; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1994, MOL ENDOCRINOL, V8, P558, DOI 10.1210/me.8.5.558; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHU XY, 1994, J BIOL CHEM, V269, P5518	57	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33116	33122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806540				2022-12-25	WOS:A1994QA63800058
J	PALHA, JA; EPISKOPOU, V; MAEDA, S; SHIMADA, K; GOTTESMAN, ME; SARAIVA, MJM				PALHA, JA; EPISKOPOU, V; MAEDA, S; SHIMADA, K; GOTTESMAN, ME; SARAIVA, MJM			THYROID-HORMONE METABOLISM IN A TRANSTHYRETIN-NULL MOUSE STRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROXINE-BINDING GLOBULIN; MESSENGER-RIBONUCLEIC-ACID; RAT-LIVER; CHOROID-PLEXUS; RING DEIODINATION; PREALBUMIN; TRANSPORT; PROTEINS; SERUM; 5'-DEIODINASE	Transthyretin (TTR) is the principal carrier of thyroid hormones in rodent plasma and the major protein synthesized by the choroid plexus. Mice lacking TTR generated by targeted disruption (Episkopou, V., Maeda, S., Nishiguchi, S., Shimada, K., Gaitanaris, G. A., Gottesman, M. E., and Robertson, E. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2375-2379) had a 50% decrease in total thyroxine (T-4) plasma levels but had normal free hormone levels as compared to wild-type mice. In the mutant serum there was increased T-4 binding to thyroxine-binding globulin. Thyroxine-binding globulin mRNA levels were the same in mutant and wild-type animals. Wild-type serum depleted of TTR also presented increased T-4 binding to thyroxine-binding globulin, suggesting that TTR competes with thyroxine-binding globulin for T-4 binding. Total and free triiodothyronine and thyrotropin-stimulating hormone levels were not affected by the absence of TTR. Liver deiodinase-I activity, mRNA levels, and brain deiodinase II activity were normal in the mutant mice, suggesting that the absence of TTR does not affect tissue thyroid hormone content. The low T-4 levels found in the mutant mice sera cannot be accounted for by increased glucuronidation because the liver activity of UDP-glucuronosyltransferase was not affected in the TTR-deficient mice. We concluded that transthyretin-deficient mice are euthyroid in the absence of the major plasma T-4 carrier. We ascribed this to the normal free hormone levels in the serum of the mutant mice. Our data, therefore, strongly supported the free hormone hypothesis for thyroxine uptake (Mendel, C. M. (1989) Endocr. Rev. 10, 232-274).	COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10032 USA; INST CIENCIAS BIOMED ABEL SALAZAR, P-4000 OPORTO, PORTUGAL; CTR ESTUDOS PARAMILOIDOSE, P-4000 OPORTO, PORTUGAL; ST MARYS HOSP, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; YAMANASHI MED UNIV, DEPT BIOCHEM, YAMANASHI 40938, JAPAN; RES INST MICROBIAL DIS, DEPT MED GENET, DIV MOLEC BIOMED, OSAKA 565, JAPAN	Columbia University; Universidade do Porto; Imperial College London; University of Yamanashi			Palha, Joana Almeida/C-2745-2009; Episkopou, Vasso/E-2952-2010; Saraiva, Maria João/K-3907-2013	Palha, Joana Almeida/0000-0002-8866-368X; Saraiva, Maria João/0000-0002-3360-6899	MRC [MC_U120074332] Funding Source: UKRI; Medical Research Council [MC_U120074332] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1993, J CLIN INVEST, V92, P1517, DOI 10.1172/JCI116730; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BURGER A, 1986, THYROID HORMONE META, P255; DAVIS PJ, 1970, ENDOCRINOLOGY, V87, P978, DOI 10.1210/endo-87-5-978; DESANDRO V, 1992, BIOCHEM PHARMACOL, V43, P1563, DOI 10.1016/0006-2952(92)90215-5; DICKSON PW, 1986, J BIOL CHEM, V261, P3475; DISTEFANO JJ, 1988, AM ZOOL, V28, P373; DIVINO CM, 1990, J BIOL CHEM, V265, P1425; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; GERSHENGORN MC, 1978, ENDOCRINOLOGY, V102, P1122, DOI 10.1210/endo-102-4-1122; GOODMAN DS, 1984, RETINOIDS, V2, P1; GRIMALDI S, 1982, BIOCHEMISTRY-US, V21, P145, DOI 10.1021/bi00530a025; HARMS PJ, 1991, COMP BIOCHEM PHYS B, V99, P239, DOI 10.1016/0305-0491(91)90035-C; HIGUERET P, 1979, J ENDOCRINOL, V80, P223, DOI 10.1677/joe.0.0800223; IMAMURA S, 1991, BIOCHEMISTRY-US, V30, P5406, DOI 10.1021/bi00236a012; KAMBE F, 1988, MOL ENDOCRINOL, V2, P181, DOI 10.1210/mend-2-2-181; KAPLAN MM, 1985, ENDOCRINOLOGY, V117, P1858, DOI 10.1210/endo-117-5-1858; KAPLAN MM, 1983, ENDOCRINOLOGY, V112, P35, DOI 10.1210/endo-112-1-35; KOHRLE J, 1989, ENDOCRINOLOGY, V125, P532, DOI 10.1210/endo-125-1-532; KOHRLE J, 1991, THYROID, P144; MENDEL CM, 1987, ENDOCRINOLOGY, V120, P1742, DOI 10.1210/endo-120-5-1742; MENDEL CM, 1989, J CLIN INVEST, V83, P143, DOI 10.1172/JCI113851; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MENDEL CM, 1992, ENDOCRINOLOGY, V130, P1525, DOI 10.1210/en.130.3.1525; MENJO M, 1993, ENDOCRINOLOGY, V133, P2984, DOI 10.1210/en.133.6.2984; MOL JA, 1985, ENDOCRINOLOGY, V117, P8, DOI 10.1210/endo-117-1-8; NAVAB M, 1977, J BIOL CHEM, V252, P5107; OTTEN MH, 1984, ENDOCRINOLOGY, V115, P887, DOI 10.1210/endo-115-3-887; PARDRIDGE WM, 1987, AM J PHYSIOL, V252, pE157, DOI 10.1152/ajpendo.1987.252.2.E157; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; REFETOFF S, 1989, ENDOCR REV, V10, P275, DOI 10.1210/edrv-10-3-275; ROBBINS J, 1984, THYROID HORMONE META, P3; ROUAZEROMET M, 1992, ACTA ENDOCRINOL-COP, V127, P441, DOI 10.1530/acta.0.1270441; Sambrook J, 1989, MOL CLONING LABORATO; SARAIVA MJM, 1988, ADV NEUROL, V48, P201; SARNE DH, 1988, J CLIN ENDOCR METAB, V67, P1166, DOI 10.1210/jcem-67-6-1166; SAVU L, 1991, BIOCHIM BIOPHYS ACTA, V1097, P19, DOI 10.1016/0925-4439(91)90017-4; SAVU L, 1989, BIOCHEM BIOPH RES CO, V159, P919, DOI 10.1016/0006-291X(89)92196-7; SCHREIBER G, 1990, AM J PHYSIOL, V258, pR338; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; SPANKA M, 1988, BIOL MED, V2, P341; STEIN SA, 1989, NEUROENDOCRINOLOGY, V49, P509, DOI 10.1159/000125160; STEIN SA, 1991, ADV EXP MED BIOL, V299, P47; VISSER TJ, 1993, ENDOCRINOLOGY, V133, P2177, DOI 10.1210/en.133.5.2177; VRANCKX R, 1990, BIOCHEM BIOPH RES CO, V167, P317, DOI 10.1016/0006-291X(90)91767-M; YOUNG RA, 1985, ENDOCRINOLOGY, V116, P1248, DOI 10.1210/endo-116-4-1248	50	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33135	33139						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806543				2022-12-25	WOS:A1994QA63800061
J	REEMS, JA; MCHENRY, CS				REEMS, JA; MCHENRY, CS			ESCHERICHIA-COLI DNA-POLYMERASE-III HOLOENZYME FOOTPRINTS 3 HELICAL TURNS OF ITS PRIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; INITIATION COMPLEX; BETA-SUBUNIT; ACCESSORY PROTEINS; BINDING-PROTEIN; ATP ACTIVATION; SIZE CLASSES; PURIFICATION; TEMPLATE; IDENTIFICATION	Escherichia coli DNA polymerase III holoenzyme in the presence of ATP and E. coli single-stranded DNA-binding protein forms an initiation complex on a primed template capable of rapid and highly processive DNA replication. DNase I digestion of initiation complexes demonstrated that holoenzyme protected 27-30 nucleotides of primer. Like the formation of initiation complexes, this protection required both ATP and E. coli single-stranded DNA-binding protein. Initiation complexes assembled with core DNA polymerase III (alpha, epsilon, and theta subunits), gamma-complex (gamma, delta, delta', chi, and psi) and the beta subunit produced a footprint identical to that formed with intact holoenzyme, indicating that initiation complexes formed with reconstituted enzyme and those formed with holoenzyme were equivalent. The presence of the tau subunit in reconstitituted initiation complexes did not alter the DNase I footprint. Preinitiation complexes (gamma-complex plus beta subunit) assembled onto primer-template in an ATP-dependent reaction protected a larger region of the primer than did holoenzyme. The addition of core DNA polymerase III to preinitiation complexes restored the 30-nucleotide footprint observed with intact holoenzyme. These results suggest that holoenzyme subunits rearrange during initiation complex formation.	UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	REEMS, JA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.				NIGMS NIH HHS [R01 GM 35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWITZ SA, 1971, BIOCHEMISTRY-US, V13, P4825; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; MAKI S, 1988, J BIOL CHEM, V263, P6555; MANIATIS T, 1982, MOL CLONING LABORATO, P142; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1980, J SUPRAMOL STRUCT S, V4, P369; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; MEYER RR, 1980, J BIOL CHEM, V255, P2897; MEYER RR, 1990, MICROBIOL REV, V4, P342; MOLINEUX IJ, 1975, NUCLEIC ACIDS RES, V2, P1821, DOI 10.1093/nar/2.10.1821; MUNN M, 1986, THESIS U CALIFORNIA; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; REEMS JA, 1991, J BIOL CHEM, V266, P4878; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TU SD, 1980, GENE, V10, P177; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P3679, DOI 10.1073/pnas.70.12.3679; WU CA, 1992, J BIOL CHEM, V267, P4030; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUSAF SI, 1984, GENE, V27, P309, DOI 10.1016/0378-1119(84)90075-1	40	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33091	33096						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806536				2022-12-25	WOS:A1994QA63800054
J	ABRUZZO, LV; REITMAN, M				ABRUZZO, LV; REITMAN, M			ENHANCER ACTIVITY OF UPSTREAM HYPERSENSITIVE SITE-2 OF THE CHICKEN BETA-GLOBIN CLUSTER IS MEDIATED BY GATA SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; STAGE SELECTOR ELEMENT; HUMAN ERYTHROID-CELLS; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATION; GENE-TRANSCRIPTION; TRANSGENIC MICE; ACTIVATION REGION; MAMMALIAN-CELLS; BINDING-PROTEIN	Upstream of the chicken beta-globin gene cluster are four DNase I-hypersensitive sites (HS1-4), Hypersensitive sites located upstream of the mammalian beta-globin clusters have enhancer activity and mediate position-independent gene expression, In contrast, a region inside the chicken cluster has enhancer activity and mediates position-independent expression, Here we investigate the function of the chicken upstream sites, which are different from the mammalian ones in sequence, number, and distance from the genes, Each was tested for its effect on reporter gene expression in transfected primary erythroid cells, HS2 and HS3 (4.4 and 6.4 kilobases upstream of rho-globin) showed significant enhancer activity while HS1 and HS4 (1.6 and 11 kilobases upstream of rho-globin) did not, A 237-base pair region of HS2 contained the sequences necessary for enhancer activity. Proteins from erythroid extracts bound HS2 in seven different regions; six of these sites were characterized, GATA-1 bound to four of the sites, Each site contributed to the enhancer activity of HS2, Two Other sequences bound proteins that may be related to Spl and erythroid krup-pel-like factor. Surprisingly, mutations in these elements, which disrupted protein binding, did not affect enhancer activity, Thus, the observed enhancer activity of HS2 is due to the four GATA sites, The existence of multiple GATA sites in both chicken HS2 and the mammalian upstream sites may be due to evolution from a common element with preservation of only very short sequences or to convergent evolution. These observations highlight the crucial role for GATA proteins in globin regulation.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LIEBER MR, 1987, J CELL BIOL, V105, P1055, DOI 10.1083/jcb.105.3.1055; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOON AM, 1991, BLOOD, V77, P2272; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; REITMAN M, 1993, GENOMICS, V18, P616, DOI 10.1016/S0888-7543(05)80364-7; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STALDER J, 1980, CELL, V20, P451, DOI 10.1016/0092-8674(80)90631-5; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	55	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32565	32571						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798259				2022-12-25	WOS:A1994PX30400081
J	SCHOENWAELDER, SM; JACKSON, SP; YUAN, YP; TEASDALE, MS; SALEM, HH; MITCHELL, CA				SCHOENWAELDER, SM; JACKSON, SP; YUAN, YP; TEASDALE, MS; SALEM, HH; MITCHELL, CA			TYROSINE KINASES REGULATE THE CYTOSKELETAL ATTACHMENT OF INTEGRIN ALPHA(IIB)BETA(3) (PLATELET GLYCOPROTEIN IIB/IIIA) AND THE CELLULAR RETRACTION OF FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-STIMULATED PLATELETS; PROTEIN-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEMBRANE SKELETON; IIB-IIIA; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; HERBIMYCIN-A; GPIIB-IIIA; AGGREGATION	Integrins promote cell-substratum and cell-cell adhesion by acting as transmembrane linker molecules between extracellular adhesion proteins and the actin-rich cytoskeleton. The integrin alpha(IIb)beta(3) (platelet glycoprotein IIb/IIIa) is essential for platelet spreading, aggregation, fibrin clot retraction, and for the transduction of extracellular signals. We examined the effect of the specific tyrosine kinase inhibitor herbimycin A on integrin and cytoskeletal-mediated events in thrombin-stimulated platelets. Incubation of washed platelets for 24 h with herbimycin A (5 mu M) abolished the thrombin-stimulated cytoskeletal enzyme activity of pp60(c-src) in parallel with a reduction in the tyrosine phosphorylation of multiple platelet proteins, as assessed with anti-phosphotyrosine immunoblots. However, thrombin-induced activation of protein kinase C and the production of thromboxane A(2) were not altered by herbimycin A. Despite the absence of cytoskeletal pp60(c-src) enzyme activity, platelet shape change, aggregation, and serotonin release were unaltered following platelet stimulation with thrombin (0.05-1.0 unit/ml). Herbimycin A-treated platelets also demonstrated normal platelet aggregation in response to collagen (5 mu g/ml), ionophore A23187 (2 mu M), and ADP/adrenaline (10 pat each). However, the ability of herbimycin A-treated platelets to retract fibrin gels was significantly reduced. This defect in clot retraction was associated with reduced incorporation of integrin alpha(IIb)beta(3) into the cytoskeletal fraction of thrombin-aggregated platelets. Our studies suggest that tyrosine kinases in platelets regulate the cytoskeletal attachment of alpha(IIb)beta(3), as an essential process for the transmission of cellular contractile forces to fibrin polymers.	BOX HILL HOSP, MONASH MED SCH, DEPT MED, BOX HILL, VIC 3128, AUSTRALIA	Box Hill Hospital; Monash University			Schoenwaelder, Simone/E-9506-2011; Jackson, Shaun P/E-9633-2011	Mitchell, Christina A/0000-0001-9372-3192; Jackson, Shaun/0000-0002-4750-1991; Schoenwaelder, Simone/0000-0003-0465-5840				ARDLIE NG, 1974, BRIT J HAEMATOL, V26, P331, DOI 10.1111/j.1365-2141.1974.tb00477.x; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; Baenziger N L, 1974, Methods Enzymol, V31, P149; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FINDIK D, 1990, FEBS LETT, V262, P1, DOI 10.1016/0014-5793(90)80138-9; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1993, BIOCHEM J, V292, P851, DOI 10.1042/bj2920851; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; ODA A, 1992, J BIOL CHEM, V267, P20075; PEERSCHKE EIB, 1989, BLOOD, V74, P682; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P881, DOI 10.1016/0006-2952(92)90119-4; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SMYTH SS, 1993, BLOOD, V81, P2827; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TUSZYNSKI GP, 1987, PLATELET RESPONSES M, V2, P187; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEISS RH, 1992, J BIOL CHEM, V267, P5608; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHANG J, 1992, J BIOL CHEM, V267, P4686	52	56	57	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32479	32487						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798249				2022-12-25	WOS:A1994PX30400070
J	SATO, M; KATAOKA, R; DINGUS, J; WILCOX, M; HILDEBRANDT, JD; LANIER, SM				SATO, M; KATAOKA, R; DINGUS, J; WILCOX, M; HILDEBRANDT, JD; LANIER, SM			FACTORS DETERMINING SPECIFICITY OF SIGNAL-TRANSDUCTION BY G-PROTEIN-COUPLED RECEPTORS - REGULATION OF SIGNAL TRANSFER FROM RECEPTOR TO G-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; HAMSTER OVARY CELLS; ALPHA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; BETA-GAMMA; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; GUANINE-NUCLEOTIDES; AGONIST BINDING; PHOSPHOLIPASE-C	Among subfamilies of G-protein-coupled receptors, agonists initiate several cell signaling events depending on the receptor subtype (R) and the type of G-protein (G) or effector molecule (E) expressed in a particular cell, Determinants of signaling specificity/efficiency may operate at the R-G interface, where events are influenced by cell architecture or accessory proteins found in the receptor's microenvironment, This issue was addressed by characterizing signal transfer from R to G following stable expression of the alpha(2A/D) adrenergic receptor in two different membrane environments (NIH-3T3 fibroblasts and the pheochromocytoma cell line, PC-12), Receptor coupling to endogenous Gr-proteins in both cell types was eliminated by pertussis toxin pretreatment and R-G signal transfer restored by reconstitution of cell membranes with purified brain G-protein, Thus, the receptor has access to the same population of G-proteins in the two different environments, In this signal restoration assay, agonist-induced activation of G was 3-9-fold greater in PC-12 as compared with NIH-3T3 alpha(2)-adrenergic receptor transfectants. The cell-specific differences in signal transfer were observed over a range of receptor densities or G-protein concentration, The augmented signal transfer in PC-12 versus NIH-3T3 transfectants occurred despite a BS-fold lower level of receptors existing in the R-G-coupled state (high affinity, guanyl-5'-yl imidodiphosphate-sensitive agonist binding), suggesting the existence of other membrane factors that influence the nucleotide binding behavior of G-protein in the two cell types, Detergent extraction of PC-12 but not NIH-3T3 membranes yielded a heat-sensitive, macromolecular entity that increased S-35-labeled guanosine 5'-O-(thiotriphosphate) binding to brain G-protein in a concentration-dependent manner. These data indicate that the transfer of signal from R to G is regulated by a cell type-specific, membrane-associated protein that enhances the agonist-induced activation of G.	MED UNIV S CAROLINA, DEPT PHARMACOL, CHARLESTON, SC 29425 USA	Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CANTIELLO HF, 1989, J BIOL CHEM, V264, P16000; CHABRE O, 1994, J BIOL CHEM, V269, P5730; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GRAESER D, 1993, MOL PHARMACOL, V43, P434; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LEE NH, 1993, J BIOL CHEM, V268, P7949; LEIBER D, 1993, J BIOL CHEM, V268, P3833; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MAH SJ, 1992, MOL PHARMACOL, V42, P217; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PILC A, 1986, J PHARMACOL EXP THER, V237, P725; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUPRENANT A, 1992, SCIENCE, V257, P977; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; TIAN WN, 1994, MOL PHARMACOL, V45, P524; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; VAZIRI C, 1992, J BIOL CHEM, V267, P22973	50	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15269	15276		10.1074/jbc.270.25.15269	http://dx.doi.org/10.1074/jbc.270.25.15269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797513	hybrid			2022-12-25	WOS:A1995RE66600064
J	KOZASA, T; GILMAN, AG				KOZASA, T; GILMAN, AG			PURIFICATION OF RECOMBINANT G-PROTEINS FROM SF9 CELLS BY HEXAHISTIDINE TAGGING OF ASSOCIATED SUBUNITS - CHARACTERIZATION OF ALPHA(12), AND INHIBITION OF ADENYLYL-CYCLASE BY ALPHA(Z)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; REGULATORY PROTEINS; GAMMA-SUBUNITS; BINDING; GTP; G-ALPHA-12; ACTIVATION; PRENYLATION; EXPRESSION	A method is described for purification of G protein alpha and beta gamma subunits from Sf9 cells infected with recombinant baculoviruses. The subunit to be purified is coexpressed with an associated subunit bearing a hexahistidine tag. After adsorption of the oligomer to a Ni2+-containing column, the subunit to be purified is eluted specifically by promoting subunit dissociation with AlF4-. The a subunits of G(12), G(q), G(z), and G(i1) and the beta(1) gamma(2) subunit complex were easily and efficiently purified by this method, Results were superior to established procedures in all cases. Purified alpha(12) was characterized for the first time. The protein has a slow rate of guanine nucleotide exchange (k(on,GTP gamma S) = 0.01 min(-1)) and a very slow k(cat) for hydrolysis of GTP (0.1-0.2 min(-1)). GTP gamma S (guanosine 5'-3-O-(thio)triphosphate).alpha(12), does not influence the activity of several adenylyl cyclases or phospholipases. Activated alpha(z) inhibits the activity of type I and type V adenylyl cyclases. It is a somewhat more potent inhibitor of type V adenylyl cyclase than is activated alpha(i1).			KOZASA, T (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.							ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER G, 1994, METHOD ENZYMOL, V237, P212; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; HOCHST H, 1988, J VAC SCI TECHNOL B, V6, P1320, DOI 10.1116/1.584257; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	48	277	281	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1734	1741		10.1074/jbc.270.4.1734	http://dx.doi.org/10.1074/jbc.270.4.1734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829508	hybrid			2022-12-25	WOS:A1995QD20400041
J	LI, YM; MARNERAKIS, M; STIMSON, ER; MAGGIO, JE				LI, YM; MARNERAKIS, M; STIMSON, ER; MAGGIO, JE			MAPPING PEPTIDE-BINDING DOMAINS OF THE SUBSTANCE-P (NK-1) RECEPTOR FROM P388D(1) CELLS WITH PHOTOLABILE AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; TACHYKININ RECEPTORS; AMINO-ACID; PROTEINS; NK1; SPECIFICITY; ANTAGONIST; EPITOPES; GLAND	The tachykinin substance P (SP) is a peptide trans mitter of primary afferents, Its actions on both central and peripheral targets are mediated by a G-protein-coupled receptor of known primary structure. To identify contact sites between the undecapeptide SP and its receptor, we prepared radiolabeled photoreactive analogs of SP (H-RPKPQQFFGLM-NH2) by replacing amino acids in the peptide with p-benzoyl-L-phenylalanine (BPA). SP, EPA(3)-SP, and BPA(8)-SP bind with high affinity (K-d < 3 nM) to SP receptors on the murine cell line P388D(1), triggering intracellular calcium responses. Both binding and calcium responses are blocked by the specific SP receptor antagonist CP-96345. On photolysis, radioiodinated BPA(3)-SP and BPA(8)-SP covalently label a heterogeneously glycosylated protein of about 75 kDa; labeling is abolished by excess unlabeled SP or CP-96345. The labeled receptors were digested with V8 protease and/or trypsin, and the resulting fragments were analyzed by electrophore sis, high pressure liquid chromatography, and chemical or enzymatic modification. BPA(3)-SP and BPA(8)-SP photoincorporate into different regions of the murine SP receptor. The results establish that the third and the eighth positions of SP, respectively, interact with the NH2-terminal extracellular tail (residues 1-21) and second extracellular loop (residues 173-183) of the SP receptor. A model for the agonist peptide binding sites of the SP receptor is proposed based on photoaffinity labeling and mutagenesis studies.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-15904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; BOYD ND, 1991, ANN NY ACAD SCI, V632, P79, DOI 10.1111/j.1749-6632.1991.tb33096.x; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BOYD ND, 1993, J NEUROCHEM, V61, pS63; BOYD ND, 1994, TACHYKININ RECEPTORS, P219; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; DAM TV, 1987, BIOCHEM BIOPH RES CO, V149, P297, DOI 10.1016/0006-291X(87)91638-X; DAWE CJ, 1957, AM J PATHOL, V33, P603; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1994, J BIOL CHEM, V269, P14957; FONG TM, 1993, NATURE, V362, P350; FOURNIER A, 1982, J MED CHEM, V25, P64, DOI 10.1021/jm00343a012; GERARD NP, 1993, REGUL PEPTIDES, V43, P21, DOI 10.1016/0167-0115(93)90404-V; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, MOL PHARMACOL, V45, P500; HUANG RRC, 1994, MOL PHARMACOL, V45, P690; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JENSEN CJ, 1994, MOL PHARMACOL, V45, P294; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; KAUER JC, 1986, J BIOL CHEM, V261, P695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CM, 1983, MOL PHARMACOL, V23, P563; LI YM, 1995, IN PRESS ANESTHESIOL; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; PERNOW B, 1983, PHARMACOL REV, V35, P85; PERSICO FJ, 1988, J IMMUNOL, V141, P3564; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SUNDELIN JB, 1992, EUR J BIOCHEM, V203, P625, DOI 10.1111/j.1432-1033.1992.tb16592.x; TOO HP, 1991, METHODS NEUROSCI, V6, P232; TRUMPPKALLMEYER S, 1994, TACHYKININ RECEPTORS, P237; VIGER A, 1983, J NEUROCHEM, V40, P1030, DOI 10.1111/j.1471-4159.1983.tb08089.x; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	48	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1213	1220		10.1074/jbc.270.3.1213	http://dx.doi.org/10.1074/jbc.270.3.1213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836382	hybrid			2022-12-25	WOS:A1995QB15600037
J	NEGRESCU, EV; DEQUINTANA, KL; SIESS, W				NEGRESCU, EV; DEQUINTANA, KL; SIESS, W			PLATELET SHAPE CHANGE INDUCED BY THROMBIN RECEPTOR ACTIVATION - RAPID STIMULATION OF TYROSINE PHOSPHORYLATION OF NOVEL PROTEIN SUBSTRATES THROUGH AN INTEGRIN-INDEPENDENT AND CA2+-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; MEMBRANE SKELETON; CYCLIC-AMP; KINASE; ASSOCIATION; IDENTIFICATION; MYOSIN; PP60(C-SRC); VASOPRESSIN; AGGREGATION	Activation of human platelets by the peptide YFLLRNP has been shown to induce shape change but not secretion, Ca2+ mobilization, or pleckstrin phosphorylation (Rasmussen, U. B., Gachet, C., Schlesinger, Y., Hanau, D., Ohlmann, P., Van Obberghen-Schilling, E., Pouyssegur, J., Cazenave, J.-P., and Pavirani, A. (1993) J. Biol. Chem. 268, 14322-14328). YFLLRNP was added to washed human platelets that had been pretreated with EGTA at 37 degrees C or preincubated with the fibrinogen receptor antagonist RGDS to preclude the activation of the integrin alpha(IIb)beta(3) (fibrinogen receptor). YFLLRNP induced shape change and stimulated the tyrosine phosphorylation of proteins of 62, 68, and 130 kDa within 7 s. Tyrosine phosphorylation of these proteins reached maximum levels (2-3-fold) 15-30 s after addition of YFLLRNP and decreased subsequently. The chelation of intracellular Ca2+ by BAPTA-AM decreased basal tyrosine protein phosphorylation of P62, P68, and P130 or the shape change induced by YFLLRNP. Preincubation of platelets with the tyrosine kinase inhibitors genistein or tyrphostin A23 completely inhibited platelet shape change and protein tyrosine phosphorylation induced by YFLLRNP. The inactive structural analogs daidzein P130, which exhibited increased tyrosine phosphorylation upon the stimulation with YFLLRNP, were found in the cytoskeleton. P130 was not identical to vinculin or the focal adhesion kinase pp125(FAK). The results indicate that stimulation of G-protein-coupled thrombin receptors rapidly induces protein tyrosine kinase activation through a Ca2+- and integrin-independent mechanism. Protein tyrosine kinase activation and tyrosine phosphorylation of novel protein substrates seem to play an essential role in the induction of platelet shape change.	INST PROPHYLAXE & EPIDEMIOL KREISLAUFKRANKHEITEN,D-80336 MUNICH,GERMANY				Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HALLAM TJ, 1985, BIOCHEM J, V232, P373, DOI 10.1042/bj2320373; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LUBER K, 1994, CELL SIGNAL, V6, P279, DOI 10.1016/0898-6568(94)90032-9; ODA A, 1992, J BIOL CHEM, V267, P20075; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; POLANOWSKAGRABO.R, 1993, BIOCHEM J, V296, P543; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; SIESS W, 1993, CELL SIGNAL, V5, P209, DOI 10.1016/0898-6568(93)90071-S; SIESS W, 1984, J BIOL CHEM, V259, P8286; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIMPSON AWM, 1986, FEBS LETT, V201, P301, DOI 10.1016/0014-5793(86)80628-7; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; VOSTAL JG, 1993, BIOCHEM J, V294, P675, DOI 10.1042/bj2940675; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	28	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1057	1061		10.1074/jbc.270.3.1057	http://dx.doi.org/10.1074/jbc.270.3.1057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836359	hybrid			2022-12-25	WOS:A1995QB15600014
J	PISONI, RL; PARK, GY; VELILLA, VQ; THOENE, JG				PISONI, RL; PARK, GY; VELILLA, VQ; THOENE, JG			DETECTION AND CHARACTERIZATION OF A TRANSPORT-SYSTEM MEDIATING CYSTEAMINE ENTRY INTO HUMAN FIBROBLAST LYSOSOMES - SPECIFICITY FOR AMINOETHYLTHIOL AND AMINOETHYLSULFIDE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER LYSOSOMES; LEUKOCYTE GRANULAR FRACTIONS; AMINO-ACID TRANSPORT; ACETYL COENZYME-A; SIALIC-ACID; NEPHROPATHIC CYSTINOSIS; MEMBRANE-VESICLES; THYROID CELLS; CARRIER; MONOIODOTYROSINE	The uptake of [H-3]cysteamine by Percoll-purified hu man fibroblast lysosomes was investigated to determine whether lysosomes contain a transport system recognizing cysteamine, Lysosomal cysteamine uptake is a Na+-independent process which rapidly attains a steady state within 1 min at pH 7.0 and 37 degrees C. A biphasic Arrhenius plot is observed for cysteamine uptake, giving a Q(10) of 2.2 from 17 to 26 degrees C and a Q(10) of 1.2 from 27 to 35 degrees C. The rate of lysosomal cysteamine uptake is maximal at pH 8.2, half-maximal at pH 6.8, and declines similar to 50-fold from the maximum to show very little transport at pH 5.0. Cysteamine uptake into fibroblast lysosomes displays complete saturability with a K-m of 0.88 mM and V-max of 1410 pmol of beta-N-acetylhexosaminidase/min at pH 7.0 and 37 degrees C. Analog inhibition studies demonstrated that all analogs recognized thus far by the cysteamine carrier are either aminothiols or aminosulfides and contain an amino group and sulfur atom separated by a carbon chain, 2 carbon atoms in length. The K-i constants for these analogs as competitive inhibitors of lysosomal cysteamine uptake are 2-(ethylthio)ethylamine (0.64 mM), 1-amino-2-methyl-2-propanethiol (0.74 mM), 2-dimethylaminoethanethiol (0.87 mM), thiocholine (1.6 mM), and bis(2-aminoethyl)sulfide (4.9 mM), L-Cysteine, D-penicillamine, and analogs lacking either a sulfur atom or amino group are not recognized by the cysteamine carrier including ethanolamine, choline, taurine, beta-mercaptoethanol, ethylenediamine, cadaverine, spermine, spermidine, histamine, dopamine, and 3-hydroxytyramine. In a cystine depletion assay, a 2-h exposure of cystinotic fibroblasts to 1 mM 1-amino-2-methyl-2-propanethiol lowers cell cystine levels to the same low level obtained with cysteamine, Thus, all four aminothiols, known to deplete cystinotic fibroblasts of their accumulated cystine, are recognized as substrates by the lysosomal cysteamine carrier, suggesting the importance of this transporter in the delivery of aminothiols to the lysosomal compartment.			PISONI, RL (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PEDIAT & COMMUNICABLE DIS, ANN ARBOR, MI 48109 USA.		Thoene, Jess/AAF-5305-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025548] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25548] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON HC, 1990, J BIOL CHEM, V265, P10950; BAME KJ, 1985, J BIOL CHEM, V260, P1293; BARRUECO JR, 1991, J BIOL CHEM, V266, P11732; BERNAR J, 1986, J BIOL CHEM, V261, P7107; BIRD SJ, 1990, BIOCHIM BIOPHYS ACTA, V1024, P267, DOI 10.1016/0005-2736(90)90353-P; BLOM HJ, 1990, BIOCHEM J, V268, P621, DOI 10.1042/bj2680621; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Cleland W W, 1979, Methods Enzymol, V63, P103; COLLARINI EJ, 1989, BIOCHIM BIOPHYS ACTA, V987, P139, DOI 10.1016/0005-2736(89)90536-1; DANEHY JP, 1960, J AM CHEM SOC, V82, P2511, DOI 10.1021/ja01495a028; ELDJARN L, 1954, ARCH INT PHYS BIOCH, V62, P476; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1985, BIOCHEM J, V228, P545, DOI 10.1042/bj2280545; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GREENE AA, 1987, BIOCHEM J, V246, P547, DOI 10.1042/bj2460547; IDRISS JM, 1991, J BIOL CHEM, V266, P9438; JOCELYN P, 1972, BIOCH SH GROUP, P122; Jocelyn P.C., 1972, BIOCH SH GROUP, P52; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; JONAS AJ, 1982, P NATL ACAD SCI-BIOL, V79, P4442, DOI 10.1073/pnas.79.14.4442; JONAS AJ, 1990, BIOCHEM J, V272, P323, DOI 10.1042/bj2720323; JONAS AJ, 1989, J BIOL CHEM, V264, P4953; LEMONS RM, 1991, J BIOL CHEM, V266, P14378; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MANCINI GMS, 1991, J CLIN INVEST, V87, P1329, DOI 10.1172/JCI115136; ORLOFF S, 1981, PEDIATR RES, V15, P1063, DOI 10.1203/00006450-198107000-00018; OSHIMA RG, 1974, J BIOL CHEM, V249, P6033; PIHL A, 1958, 4TH INT C BIOCH, V14, P43; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1991, J BIOL CHEM, V266, P979; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; PISONI RL, 1985, J BIOL CHEM, V260, P4791; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROME LH, 1983, J BIOL CHEM, V258, P3006; ROSENBLATT DS, 1985, SCIENCE, V228, P1319, DOI 10.1126/science.4001945; Segel I. H., 1975, ENZYME KINETICS, p[107, 132]; SMITH ML, 1987, J BIOL CHEM, V262, P1244; SMOLIN LA, 1988, PEDIATR RES, V23, P616, DOI 10.1203/00006450-198806000-00018; STEWART BH, 1989, BIOCHIM BIOPHYS ACTA, V987, P145, DOI 10.1016/0005-2736(89)90537-3; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; TIETZE F, 1989, J BIOL CHEM, V264, P4762	47	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1179	1184		10.1074/jbc.270.3.1179	http://dx.doi.org/10.1074/jbc.270.3.1179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836377	hybrid			2022-12-25	WOS:A1995QB15600032
J	SCHEIFFELE, P; PANSEGRAU, W; LANKA, E				SCHEIFFELE, P; PANSEGRAU, W; LANKA, E			INITIATION OF AGROBACTERIUM-TUMEFACIENS T-DNA PROCESSING - PURIFIED PROTEINS VIRD1 AND VIRD2 CATALYZE SITE-SPECIFIC AND STRAND-SPECIFIC CLEAVAGE OF SUPERHELICAL T-BORDER DNA IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; PLASMID RP4; ESCHERICHIA-COLI; ILLEGITIMATE RECOMBINATION; MOLECULAR CHARACTERIZATION; BACTERIAL CONJUGATION; NUCLEOTIDE-SEQUENCE; VIRE2 PROTEIN; GENE-PRODUCT; NICK REGIONS	T-DNA processing during agroinfection of plants is initiated by site- and strand-specific incision at the T-DNA border sequences of the Ti plasmid, Two proteins are required for this reaction: VirD2 (49.6 kDa), catalyzing a site specific cleaving-joining reaction on single-stranded DNA in vitro (Pansegrau, W., Schoumacher, F., Hohn, B., and Lanka, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11538-11542), and VirD1 (16.1 kDa), an accessory protein required for VirD2-mediated specific cleavage of double-stranded DNA, Following efficient overproduction, VirD1 was isolated in active form from inclusion bodies and purified to near homogeneity. The protein was applied together with purified VirD2 protein for specific cleavage of double-stranded T-DNA border sequences in vitro. The reaction proceeds on negative superhelical DNA and requires Mg2+ ions. Relaxed DNA is not cleaved. The 5' terminus of the broken DNA strand is covalently associated with protein, most probably VirD2, and the cleavage site is located at the same position that is found in vivo, indicating that the in vitro reaction mimics the one that takes place in induced agrobacteria. Relaxation of plasmid DNA occurs only upon addition of protein denaturants, suggesting that the DNA in the VirD1/VirD2 complex is topologically constrained by strong protein-DNA interactions. The characteristics of the VirD1/VirD2-mediated cleavage reaction strongly resemble those observed with relaxosomes of IncP plasmids involved in initiation of transfer DNA replication during bacterial conjugation.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,D-14195 BERLIN,GERMANY	Max Planck Society								ALDOORI Z, 1982, GENET RES, V39, P99, DOI 10.1017/S0016672300020772; ALTMOERBE J, 1986, EMBO J, V5, P1129, DOI 10.1002/j.1460-2075.1986.tb04337.x; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; De Vos G, 1989, Mol Plant Microbe Interact, V2, P43, DOI 10.1094/MPMI-2-043; DURRENBERGER F, 1989, P NATL ACAD SCI USA, V86, P9154, DOI 10.1073/pnas.86.23.9154; FILICHKIN SA, 1993, MOL MICROBIOL, V8, P915, DOI 10.1111/j.1365-2958.1993.tb01637.x; GHAI J, 1989, P NATL ACAD SCI USA, V86, P3109, DOI 10.1073/pnas.86.9.3109; GHEYSEN G, 1991, GENE DEV, V5, P287, DOI 10.1101/gad.5.2.287; GIETL C, 1987, P NATL ACAD SCI USA, V84, P9006, DOI 10.1073/pnas.84.24.9006; GRINTER NJ, 1981, PLASMID, V5, P267, DOI 10.1016/0147-619X(81)90004-4; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRAYAMA T, 1988, MOL GEN GENET, V213, P229, DOI 10.1007/BF00339586; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JASPER F, 1994, P NATL ACAD SCI USA, V91, P694, DOI 10.1073/pnas.91.2.694; JAYASWAL RK, 1987, J BACTERIOL, V169, P5035, DOI 10.1128/jb.169.11.5035-5045.1987; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; KADO CI, 1994, MOL MICROBIOL, V12, P17, DOI 10.1111/j.1365-2958.1994.tb00990.x; KADO CI, 1993, MOL MICROBIOL, V9, P803; KOONIN EV, 1993, BIOSYSTEMS, V30, P241, DOI 10.1016/0303-2647(93)90074-M; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; LESSL M, 1992, J BIOL CHEM, V267, P20471; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; MAYERHOFER R, 1991, EMBO J, V10, P697, DOI 10.1002/j.1460-2075.1991.tb07999.x; MCDONNELL MW, 1994, J MEMBRANE BIOL, V110, P119; Miller J. H., 1972, EXPT MOL GENETICS, P433; PANSEGRAU W, 1994, J BIOL CHEM, V269, P2782; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P11538, DOI 10.1073/pnas.90.24.11538; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6565; POHLMAN RF, 1993, NUCLEIC ACIDS RES, V21, P4867, DOI 10.1093/nar/21.21.4867; PORTER SG, 1987, NUCLEIC ACIDS RES, V15, P7503, DOI 10.1093/nar/15.18.7503; REES CED, 1990, MOL MICROBIOL, V4, P1199, DOI 10.1111/j.1365-2958.1990.tb00695.x; ROSENBERG AH, 1993, J BACTERIOL, V175, P716, DOI 10.1128/JB.175.3.716-722.1993; ROSSI L, 1993, MOL GEN GENET, V239, P345, DOI 10.1007/BF00276932; Sambrook J, 1989, MOL CLONING LABORATO; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHIRASU K, 1990, MOL MICROBIOL, V4, P1153, DOI 10.1111/j.1365-2958.1990.tb00690.x; STACHEL SE, 1987, EMBO J, V6, P857, DOI 10.1002/j.1460-2075.1987.tb04831.x; STACHEL SE, 1986, CELL, V46, P325, DOI 10.1016/0092-8674(86)90653-7; THOMPSON DV, 1988, NUCLEIC ACIDS RES, V16, P4621, DOI 10.1093/nar/16.10.4621; TINLAND B, 1992, P NATL ACAD SCI USA, V89, P7442, DOI 10.1073/pnas.89.16.7442; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL AM, 1992, J BACTERIOL, V174, P303, DOI 10.1128/jb.174.1.303-308.1992; VOGEL AM, 1992, J BACTERIOL, V174, P5161, DOI 10.1128/JB.174.15.5161-5164.1992; WARD JE, 1988, J BIOL CHEM, V263, P5804; WATERS VL, 1993, MOL MICROBIOL, V9, P1123, DOI 10.1111/j.1365-2958.1993.tb01242.x; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WEISS AA, 1993, P NATL ACAD SCI USA, V90, P2970, DOI 10.1073/pnas.90.7.2970; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; YANOFSKY MF, 1986, CELL, V47, P471, DOI 10.1016/0092-8674(86)90604-5; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786; ZIEGELIN G, 1989, THESIS FREIE U BERLI	67	62	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1269	1276		10.1074/jbc.270.3.1269	http://dx.doi.org/10.1074/jbc.270.3.1269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836390	hybrid			2022-12-25	WOS:A1995QB15600045
J	ETCHISON, JR; SRIKRISHNA, G; FREEZE, HH				ETCHISON, JR; SRIKRISHNA, G; FREEZE, HH			A NOVEL METHOD TO CO-LOCALIZE GLYCOSAMINOGLYCAN-CORE OLIGOSACCHARIDE GLYCOSYLTRANSFERASES IN RAT-LIVER GOLGI - COLOCALIZATION OF GALACTOSYLTRANSFERASE-I WITH A SIALYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; ASPARAGINE-LINKED OLIGOSACCHARIDES; PROTEIN LINKAGE REGION; BETA-D-XYLOSIDE; SULFATE PROTEOGLYCANS; MOLECULAR DISSECTION; N-ACETYLGLUCOSAMINE; VESICLE MEMBRANES; MUTANT DEFICIENT; BREFELDIN-A	4-Methylumbelliferyl-beta-xyloside (Xyl beta MU) primes glycosaminoglycan synthesis by first serving as an acceptor for the addition of 2 galactoses and 1 glucuronic acid residue to make the typical core structure, GlcUA beta 1, 3Gal beta 1,3Gal beta 1,4Xyl beta MU. To investigate the relative localization of these biosynthetic enzymes, intact and properly oriented rat liver Golgi preparations were incubated with Xyl beta MU and 1 mu M UDP-[H-3]Gal and then chased with 5 mu M of unlabeled UDP-Gal, UDP-GlcUA, UDP-GlcNAc, UDP-GalNAc, and CMP-Neu5Ac. Under these conditions, no intervesicular transport occurs and acceptor labeling depends entirely upon transporter-mediated delivery of the labeled sugar nucleotides into the lumen of a vesicle and co-localization of the appropriate glycosyltransferases. The labeled products were isolated from the incubation medium and from within the Golgi and their structures analyzed by C18, anion-exchange, and amine adsorption high performance liquid chromatography in combination with glycosidase digestions, Surprisingly, the major products within the Golgi mere two sialylated xylosides (Sia alpha 2,3Gal beta 1,4Xyl beta MU and Sia alpha 2,8Sia alpha 2,3Gal beta 1,4Xyl beta MU) rather than the expected group of partially completed GAG core structures, Less than 10% of the products within the Golgi are the expected core structures containing a second Gal residue or, in addition, GlcUA. The amount of the sialylated products is only partially decreased if the chase is omitted or if the chase is done in the absence of added CMP-Sia, suggesting a pool of previously transported CMP-Sia drives synthesis of the major products, Conversely, when detergent permeabilized vesicles are provided with high concentration of the same sugar nucleotides, the ratio of sialylated products is reduced and replaced by an increase in GAG-like products. These results argue that GAG core-specific Gal transferase I and II are not extensively co-localized within the same Golgi compartment. By contrast, glycosaminoglycan core Gal transferase I is substantially co-localized with an alpha-2,3-sialyltransferase and an alpha-2,8-sialyltransferase. Incubating intact Golgi vesicles with exogenous diffusible accepters offers a novel method to assess the functional co-localization of glycosyltransferases of multiple pathways within the Golgi compartments.	LA JOLLA CANC RES FDN,GLYCOBIOL CARBOHYDRATE CHEM PROGRAM,SAN DIEGO,CA 92037					Freeze, Hudson/0000-0001-6316-0501	NCI NIH HHS [R01-CA38701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARINAGA M, 1993, SCIENCE, V260, P487, DOI 10.1126/science.8475382; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; GEUZE HJ, 1991, J ELECTRON MICR TECH, V17, P24, DOI 10.1002/jemt.1060170105; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GRESSNER AM, 1991, CELL MOL BIOL, V37, P549; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAYES BK, 1993, J BIOL CHEM, V268, P16139; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HAYES BK, 1982, ANAL BIOCHEM, V201, P140; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRULL NB, 1992, FEBS LETT, V312, P47, DOI 10.1016/0014-5793(92)81407-D; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; LYON M, 1994, J BIOL CHEM, V269, P11208; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; OSTERMANN J, 1993, CELL, V75, P409; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1985, J BIOL CHEM, V260, P4671; ROTH J, 1991, J ELECTRON MICR TECH, V17, P121, DOI 10.1002/jemt.1060170202; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SILVA LCF, 1992, BIOCHIM BIOPHYS ACTA, V1138, P133, DOI 10.1016/0925-4439(92)90053-P; SOROKA CJ, 1992, J CELL BIOL, V113, P1231; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERTEL BM, 1993, J BIOL CHEM, V268, P11105	44	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					756	764		10.1074/jbc.270.2.756	http://dx.doi.org/10.1074/jbc.270.2.756			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822307	hybrid			2022-12-25	WOS:A1995QB81600041
J	WILLIAMS, AJ; KAGUNI, LS				WILLIAMS, AJ; KAGUNI, LS			STIMULATION OF DROSOPHILA MITOCHONDRIAL-DNA POLYMERASE BY SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID SYNTHESIS; RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI SSB; UNWINDING PROTEIN; III HOLOENZYME; XENOPUS-LAEVIS; SYNTHESIS INVITRO; REPLICATION; PROCESSIVITY; PURIFICATION	Mitochondrial DNA polymerase from Drosophila embryos has been characterized with regard to its mechanism of DNA synthesis in the presence of single-stranded DNA-binding protein from Escherichia coli. The rate of DNA synthesis by DNA polymerase gamma was increased nearly 40-fold upon addition of single-stranded DNA-binding protein. Processivity of mitochondrial DNA polymerase was increased similar to 2-fold, while its intrinsic rate of nucleotide polymerization was unaffected. Primer extension analysis showed that the rate of initiation of DNA strand synthesis by DNA polymerase gamma was increased 25-fold in the presence of single-stranded DNA-binding protein. Our results indicate that the stimulation of Drosophila DNA polymerase gamma by single-stranded DNA-binding protein results primarily from an increased rate of primer recognition and binding. Concurrent achievement of maximal activity and processivity by mitochondrial DNA polymerase in the presence of binding protein suggests that DNA polymerase gamma, like other replicative DNA polymerases, associates with accessory factors in vivo to catalyze efficient and processive DNA synthesis.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; FAY PJ, 1982, J BIOL CHEM, V257, P5692; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; GODDARD JM, 1980, NUCLEIC ACIDS RES, V8, P741; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KAGUNI LS, 1988, CANCER CELL, V6, P425; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; KUNKEL TA, 1979, P NATL ACAD SCI USA, V76, P6331, DOI 10.1073/pnas.76.12.6331; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEDWITH BJ, 1986, J BIOL CHEM, V261, P6571; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MERRILL BM, 1984, J BIOL CHEM, V259, P850; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MOLINEUX IJ, 1974, J BIOL CHEM, V249, P6090; MYERS TW, 1988, J BIOL CHEM, V263, P17006; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SHERMAN LA, 1976, J MOL BIOL, V103, P61, DOI 10.1016/0022-2836(76)90052-8; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, J BIOL CHEM, V262, P16212; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1981, J BIOL CHEM, V256, P2772; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0	43	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					860	865		10.1074/jbc.270.2.860	http://dx.doi.org/10.1074/jbc.270.2.860			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822323	hybrid			2022-12-25	WOS:A1995QB81600057
J	LEE, HC; TOUNG, YPS; TU, YSL; TU, CPD				LEE, HC; TOUNG, YPS; TU, YSL; TU, CPD			A MOLECULAR-GENETIC APPROACH FOR THE IDENTIFICATION OF ESSENTIAL RESIDUES IN HUMAN GLUTATHIONE-S-TRANSFERASE FUNCTION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITE; CATALYTIC ACTIVITY; INTRONLESS GENE; SUBUNIT CDNA; PLASMID DNA; HUMAN-LIVER; RAT; PI	The common substrate for glutathione S-transferases (GSTs), 1-chloro-2,4-dinitrobenzene (CDNB), is an inhibitor of Escherichia coli growth. This growth inhibition by CDNB is enhanced when E. coli expresses a functional GST. Cells under growth inhibition have reduced intracellular GSH levels and form filaments when they resume growth. Based on this differential growth inhibition by CDNB we have developed a simple procedure to select for null-mutants of a human GST in E. coli. Null mutations in the human GST gene from hydroxylamine mutagenesis or oligonucleotide directed mutagenesis can be selected for on agar plates containing CDNB after transformation. The molecular nature of each mutation can be identified by DNA sequence analysis of the mutant GST gene. We have identified three essential amino acid residues in an alpha class human GST at Glu(31), Glu(96), and Gly(97). Single substitution at each of these residues, E31K, E96K, G97D, resulted in mutant GST proteins with loss of CDNB conjugation activity and failure in binding to the S-hexyl GSH affinity matrix. In contrast, a mutant GST (Y8F) resulting from substitution of the conserved tyrosine near the N terminus has much reduced CDNB conjugation activity but was still capable of binding to the S-hexyl GSH-agarose. Additional mutant GSTs with substitutions at position 96 (E96F, E96Y) and 97 (G97P, G97T, G97S) resulted in changes in both K-m and k(cat) to different extents. The in vitro CDNB conjugation activity of the purified mutant enzymes correlate negatively with the plating efficiencies of strains encoding them in the presence of CDNB. Based on the x-ray structure model of human GST 1-1, two of these residues are involved in salt bridges (Arg(19)-Glu(31), Arg(68)-Glu(96))) and the third Gly(97) is in the middle of the helix alpha 4. Our results provide evidence in vivo that Tyr(8), Gly(97), and the two salt bridges are important for GST structure-function. This molecular genetic approach for the identification of essential amino acids in GSTs should be applicable to any GSTs with CDNB conjugation activity. It should also complement the x-ray crystallographic approach in understanding the structure and function of GSTs.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005661] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 05661] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P10, DOI 10.1016/0304-4165(75)90206-8; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; AWASTHI YC, 1981, BLOOD, V58, P733; BATIST G, 1986, J BIOL CHEM, V261, P5544; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG LH, 1990, BIOCHEMISTRY-US, V29, P744, DOI 10.1021/bi00455a022; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOW NWI, 1988, J BIOL CHEM, V263, P12797; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; ELMORE MJ, 1990, MOL MICROBIOL, V4, P405, DOI 10.1111/j.1365-2958.1990.tb00607.x; FU HH, 1994, ACTA CRYSTALLOGR D, V2, P219; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HASHIMOTO T, 1976, J BACTERIOL, V127, P1561, DOI 10.1128/JB.127.3.1561-1563.1976; HAYES JD, 1990, GLUTATHIONE S TRANSF; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; HOESCH RM, 1989, J BIOL CHEM, V264, P17712; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; Leung DW, 1989, TECHNIQUE, V1, P11; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MANOHARAN TH, 1992, J MOL BIOL, V226, P319, DOI 10.1016/0022-2836(92)90949-K; MCLAGGAN D, 1994, J BIOL CHEM, V269, P1911; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; NOVOGRODSKY A, 1979, P NATL ACAD SCI USA, V76, P4932, DOI 10.1073/pnas.76.10.4932; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PENNINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAMM VL, 1984, J BIOL CHEM, V259, P714; SIMULA TP, 1993, CARCINOGENESIS, V14, P1371, DOI 10.1093/carcin/14.7.1371; SIMULA TP, 1993, CARCINOGENESIS, V14, P2303, DOI 10.1093/carcin/14.11.2303; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; TESSMAN I, 1968, VIROLOGY, V35, P330, DOI 10.1016/0042-6822(68)90275-4; Tew Kenneth D., 1993, STRUCTURE FUNCTION G, V1st; THIER R, 1993, P NATL ACAD SCI USA, V90, P8576, DOI 10.1073/pnas.90.18.8576; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; WANG AL, 1985, CANCER TREAT REP, V69, P677; WANG RW, 1992, J BIOL CHEM, V267, P19866; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T	65	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					99	109		10.1074/jbc.270.1.99	http://dx.doi.org/10.1074/jbc.270.1.99			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814427	hybrid			2022-12-25	WOS:A1995QA28700021
J	THOMAS, WG; THEKKUMKARA, TJ; MOTEL, TJ; BAKER, KM				THOMAS, WG; THEKKUMKARA, TJ; MOTEL, TJ; BAKER, KM			STABLE EXPRESSION OF A TRUNCATED AT(1A) RECEPTOR IN CHO-KI CELLS - THE CARBOXYL-TERMINAL REGION DIRECTS AGONIST-INDUCED INTERNALIZATION BUT NOT RECEPTOR SIGNALING OR DESENSITIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; SMOOTH-MUSCLE CELLS; CLONING; IDENTIFICATION; ENDOCYTOSIS; SEQUESTRATION; ACTIVATION; PATHWAYS; DOMAINS; LIGAND	Phosphorylation of serine and threonine residues in the carboxyl-terminal region of many G-protein-coupled receptors directs the rapid uncoupling from signal transduction pathways, In Chinese hamster ovary cells, we have stably expressed a truncated mutant of the angiotensin II (AT(1A)) receptor devoid of the carboxyl-terminal 45 amino acids, encompassing 13 serine/threonine residues. One clone, designated TL(314) to indicate truncation after leucine 314, expressed a single class of angiotensin II receptors with a dissociation constant of 1.08 nM and a receptor density of 560 fmol/mg of protein (similar to 75,000 receptors/cell). A nonhydrolyzable analog of GTP accelerated the angiotensin II-induced dissociation of [I-125] angiotensin II from TL(314) plasma membranes 3.6-fold, indicating G-protein coupling. In TL(314) cells, angiotensin II stimulated the release of intracellular calcium and the induction of mitogen-activated protein kinase activity, the levels of which were comparable with the full-length AT(1A) receptor. The AII-stimulated calcium response was rapidly desensitized in both full-length and truncated AT(1A) receptors. Interestingly, angiotensin II-induced endocytosis of the truncated receptor was almost completely inhibited, suggesting that a recognition motif within the carboxyl-terminal 45 amino acids of the AT(1A) receptor promotes sequestration. Thus, truncation of the AT(1A) receptor after leucine 314 inhibits agonist-induced internalization without affecting the capacity of the expressed protein to adopt the correct conformation necessary for high affinity binding of angiotensin II, coupling to G-proteins, and activation of signal transduction pathways, The rapid desensitization and refractoriness of the angiotensin II-induced calcium transient in the TL(314) cell line, in which putative carboxyl-terminal phosphorylation sites are absent, suggests that the mechanism of AT(1A) receptor desensitization differs from that of other prototypical G-protein coupled receptors.	WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA				Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; Thekkumkara, Thomas/0000-0001-8865-1446	NHLBI NIH HHS [HL44883, HL44379] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044379, R01HL044883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATT KJ, 1993, RENIN ANGIOTENSIN SY, V1; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CYR CR, 1993, J BIOL CHEM, V268, P26071; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; ELTON TS, 1992, BIOCHEM BIOPH RES CO, V184, P1067, DOI 10.1016/0006-291X(92)90700-U; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; GRIENDLING KK, 1993, SEMIN NEPHROL, V13, P558; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MORI S, 1991, J BIOL CHEM, V266, P21158; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; PEPPERELL JR, 1993, ENDOCRINOLOGY, V133, P1678, DOI 10.1210/en.133.4.1678; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBERTSON JI, 1993, RENIN ANGIOTENSIN SY, V1; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SCHELLING JR, 1992, J CLIN INVEST, V90, P2472, DOI 10.1172/JCI116139; SCHELLING JR, 1994, AM J PHYSIOL, V266, pC669, DOI 10.1152/ajpcell.1994.266.3.C669; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; THEKKUMKARA TJ, 1993, FASEB J, V7, pA491; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244	43	130	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					207	213		10.1074/jbc.270.1.207	http://dx.doi.org/10.1074/jbc.270.1.207			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814375	hybrid			2022-12-25	WOS:A1995QA28700035
J	POLUHA, W; POLUHA, DK; ROSS, AH				POLUHA, W; POLUHA, DK; ROSS, AH			TRKA NEUROGENIC RECEPTOR REGULATES DIFFERENTIATION OF NEUROBLASTOMA-CELLS	ONCOGENE			English	Note						APHIDICOLIN; TERMINAL DIFFERENTIATION; TYROSINE KINASE; NERVE GROWTH FACTOR; NGF RECEPTOR; C-MYC	NERVE GROWTH-FACTOR; DEVELOPING SENSORY NEURONS; PROTOONCOGENE; EXPRESSION; BLASTOMA; LINES; PROTEIN; ENCODES; TUMORS	We examined events associated with neuronal differentiation of neuroblastoma cell line SH-SY5Y, Treatment with nerve growth factor (NGF) and aphidicolin, an inhibitor of DNA polymerases alpha and delta, induces terminal differentiation of SH-SY5Y cells, Following 3-4 days of treatment with NGF+aphidicolin, the cells irreversibly ceased proliferation and differentiated. There was a succession of events preceding differentiation, Downregulation of c-myc was an early event occurring after less than 1 day of treatment with NGF+aphidicolin. Upregulation of the trkA and low-affinity NGF receptors (LNGFR) occurred after 3 days of NGF+aphidicolin treatment and required treatment with both NGF and aphidicolin, To test the role of TrkA in neuroblastic differentiation, we transfected SH-SY5Y cells with a TrkA-expression plasmid, In response to NGF in the absence of aphidicolin, the TrkA-transformant line ceased proliferation and irreversibly differentiated. SH-SY5Y cells bearing a control plasmid displayed only modest, reversible differentiation and did not cease cell proliferation in response to NGF, Hence, expression of NGF receptors is upregulated during differentiation of SH-SY5Y cells, and overexpression of TrkA enhances NGF-induced differentiation.	WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research					NICHD NIH HHS [HD-07312] Funding Source: Medline; NINDS NIH HHS [NS-21716, NS-28760] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716, R01NS028760] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; DONOVAN MJ, 1993, AM J PATHOL, V143, P1560; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JENSEN LM, 1987, DEV BIOL, V120, P56, DOI 10.1016/0012-1606(87)90103-5; JENSEN LM, 1992, J BIOL CHEM, V267, P19325; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KOGNER P, 1993, CANCER RES, V53, P2044; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; ROSS AH, 1985, ARCH BIOCHEM BIOPHYS, V242, P540, DOI 10.1016/0003-9861(85)90241-3; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; WYATT S, 1993, DEVELOPMENT, V119, P635; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	26	60	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					185	189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824271				2022-12-25	WOS:A1995QA98000021
J	SAKAI, R; IWAMATSU, A; HIRANO, N; OGAWA, S; TANAKA, T; NISHIDA, J; YAZAKI, Y; HIRAI, H				SAKAI, R; IWAMATSU, A; HIRANO, N; OGAWA, S; TANAKA, T; NISHIDA, J; YAZAKI, Y; HIRAI, H			CHARACTERIZATION, PARTIAL-PURIFICATION, AND PEPTIDE SEQUENCING OF P130, THE MAIN PHOSPHOPROTEIN ASSOCIATED WITH V-CRK ONCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SRC HOMOLOGY REGION-2; SH3 DOMAINS; SARCOMA-VIRUS; TRANSFORMING ACTIVITY; CYTOPLASMIC PROTEIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; ONCOGENE PRODUCT; PHOSPHOLIPASE-C	The transforming gene v-crk found in CT10 and ASV-1 avian sarcoma viruses induces marked phosphorylation of several proteins in cells expressing p47(v-crk) (v-Crk), In this work, the main tyrosine-phosphorylated proteins in ASV-1-infected chicken cells and v-crk transfected rat cells were characterized biochemically, Both these proteins have a molecular mass of about 130 kDa and are tightly associated with v-Crk in vivo, Two-dimensional gel electrophoresis revealed that they are both essentially single proteins (p130) with modifications that result in a broad spot in an acidic region, The broad band of semi-purified p130 became sharp at an elevated position in the gel upon treatment with orthovanadate in vivo or with c-Src kinase produced using a baculovirus vector in vitro, whereas it shifted at a lower position upon treatment with alkaline phosphatase in vitro, These results suggest multiple phosphorylation states of p130, which result in a broad band of p130. Two procedures of immunoaffinity purification were used to purify p130 from SY1 cells transfected with v-crk. Approximately 30 pmol of purified p130 was obtained in an immobilized form on a filter starting from 3 x 10(10) cells, Peptide mapping of p130 digested in situ by peptidase revealed that the purity and quantity of the final material were enough for peptide sequencing, Several stretches of partial amino acid sequences were determined, and they indicated that p130 is a novel protein.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOLEC BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KIRIN BREWERY CO LTD, CENT LAB KEY TECHNOL, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	University of Tokyo; Jichi Medical University; Kirin Brewery Company Limited			Tanaka, Tomoyuki U/A-4775-2008	Sakai, Ryuichi/0000-0001-6833-1103				AOYAMA H, 1988, J PROTEIN CHEM, V7, P191; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DECUE JE, 1987, P NATL ACAD SCI USA, V84, P9064; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POTTS WM, 1987, VIROLOGY, V160, P494, DOI 10.1016/0042-6822(87)90024-9; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIE H, 1989, ONCOGENE, V4, P1281; WIRTH PJ, 1987, CANCER RES, V47, P2839; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32740	32746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806494				2022-12-25	WOS:A1994QA63800007
J	SUNDARAMOORTHY, M; KISHI, K; GOLD, MH; POULOS, TL				SUNDARAMOORTHY, M; KISHI, K; GOLD, MH; POULOS, TL			THE CRYSTAL-STRUCTURE OF MANGANESE PEROXIDASE FROM PHANEROCHAETE-CHRYSOSPORIUM AT 2.06-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN-DEGRADING BASIDIOMYCETE; CYTOCHROME-C PEROXIDASE; EXTRACELLULAR HEME ENZYME; SPECTRAL CHARACTERIZATION; CRYSTALLOGRAPHIC REFINEMENT; OXIDIZED STATES; OXIDATION; BIODEGRADATION; COMPOUND; MODEL	The crystal structure of manganese peroxidase (MnP) from the lignin degrading basidiomycetous fungus Phanerochaete chrysosporium has been solved using molecular replacement techniques and refined to R = 0.20 at 2.06 Angstrom. The overall structure is similar to that of two other fungal peroxidases, lignin peroxidase from P. chrysosporium and Arthromyces ramosus peroxidase. Like the other fungal peroxidases, MnP has two structural calcium ions. MnP also has two N-acetylglucosamine residues N-linked to Asn(131) that are readily visible in the electron density map. The active site, consisting of a proximal His ligand H-bonded to an Asp residue and a distal side peroxide binding pocket consisting of a catalytic His and Arg, is the same as in the aforementioned fungal peroxidases as well as yeast cytochrome c peroxidase. MnP differs in having five rather than four disulfide bonds. The additional disulfide bond, Cys(341)-Cys(348), is located near the C terminus of the polypeptide chain. Importantly, a new cation binding site, which we propose is the manganese-binding site of MnP, was located in the crystal structure. The ligands constituting the Mn2+-binding site include Asp(179), Glu(35), Glu(39), a heme propionate, and two water molecules. Electron transfer from Mn2+ to the heme edge or iron center is envisioned to occur through a sigma-bonded pathway along a heme propionate.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291	University of California System; University of California Irvine; University of California System; University of California Irvine								ALIC M, 1987, APPL ENVIRON MICROB, V53, P1464, DOI 10.1128/AEM.53.7.1464-1469.1987; ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; BANCI L, 1993, BIOCHEMISTRY-US, V32, P5825, DOI 10.1021/bi00073a015; BANCI L, 1991, P NATL ACAD SCI USA, V88, P6956, DOI 10.1073/pnas.88.16.6956; BROWN JA, 1990, J BACTERIOL, V172, P3125, DOI 10.1128/jb.172.6.3125-3130.1990; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, SYSTEM XRAY REFINEME; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; DEMMER H, 1980, COORDINATION COMPOUN, V56, P1; DEROPP JS, 1991, J BIOL CHEM, V266, P15001; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1989, ACS SYM SER, V389, P127; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOLD MH, 1993, PLANT PEROXIDASES BI, P87; Greppin H., 1993, PLANT PEROXIDASES BI, P35; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HIGUCHI T, 1990, WOOD SCI TECHNOL, V24, P23, DOI 10.1007/BF00225306; JOHNSON F, 1993, PLANT PEROXIDASES BI, P31; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LI HY, 1994, STRUCTURE, V2, P461, DOI 10.1016/S0969-2126(00)00046-0; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MAYFIELD MB, 1994, APPL ENVIRON MICROB, V60, P4303, DOI 10.1128/AEM.60.12.4303-4309.1994; MINO Y, 1988, J BIOL CHEM, V263, P7029; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; POULOS TL, 1994, PEROXIDASES STRUCTUR, V30, P25; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SCHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SUNDARAMOORTHY M, 1994, J MOL BIOL, V238, P845, DOI 10.1006/jmbi.1994.1338; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; [No title captured]	54	341	360	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32759	32767						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806497				2022-12-25	WOS:A1994QA63800010
J	BLAIKIE, P; IMMANUEL, D; WU, J; LI, NX; YAJNIK, V; MARGOLIS, B				BLAIKIE, P; IMMANUEL, D; WU, J; LI, NX; YAJNIK, V; MARGOLIS, B			A REGION IN SHC DISTINCT FROM THE SH2 DOMAIN CAN BIND TYROSINE-PHOSPHORYLATED GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGF RECEPTOR; EXPRESSION CLONING; KINASES; PROTEINS; RAS; ASSOCIATION; GRB2; SITE; SRC; GAP	Shc is a ubiquitously expressed Src homology 2 (SH2) domain protein that can transform fibroblasts and differentiate PC12 cells in a Ras dependent fashion, Shc binds a variety of tyrosine-phosphorylated growth factor receptors presumably via its carboxyl-terminal SH2 domain, We cloned a fragment of She when screening a bacterial expression library with tyrosine-phosphorylated epidermal growth factor (EGF) receptor. Surprisingly, this fragment encodes the amino terminus of She, a region that has no significant similarity to an SH2 domain, When expressed as a glutathione S-transferase fusion protein, this amino-terminal domain binds to autophosphorylated EGF receptor, as web as HER2/neu and TrkA receptors, This fragment acts like an SH2 domain in that it does not bind non-phosphorylated EGF receptor or EGF receptor with all tyrosine phosphorylation sites mutated or deleted, Our data define a novel domain in She that has the potential to interact with growth factor receptors and other tyrosine-phosphorylated proteins.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LI N, 1994, IN PRESS ONCOGENE; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2	28	310	324	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32031	32034						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798194				2022-12-25	WOS:A1994PX30400003
J	GU, LY; HUANG, SM; SANDER, M				GU, LY; HUANG, SM; SANDER, M			SINGLE AMINO-ACID CHANGES ALTER THE REPAIR SPECIFICITY OF DROSOPHILA RRP1 - ISOLATION OF MUTANTS DEFICIENT IN REPAIR OF OXIDATIVE DNA-DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; COLI EXONUCLEASE-III; ENZYME APEX NUCLEASE; ESCHERICHIA-COLI; 3'-5' EXONUCLEASE; POLYMERASE-I; CDNA; MUTAGENESIS; EXPRESSION; HOMOLOGY	Drosophila Rrp1 has several tightly associated enzymatic activities, including double-strand DNA 3'-exo-nuclease, apurinic/apyrimidinic endonuclease, 3'-phosphatase, and 3'-phosphodiesterase. The carboxyl-terminal third of Rrp1, homologous to Escherichia coli exonuclease III, is sufficient to repair oxidative and alkylation-induced DNA damage in vivo. Using a screen for partial complementation of repair-deficient E., coli, we isolated three mutants of the nuclease domain of Rrp1: T462A, K463Q, and L484P, that protect against methyl methanesulfonate (MMS)-induced but not t-BuO(2)H-induced DNA damage, Thr-462 and Lys-463 are highly conserved residues found in a cluster of 5 conserved amino acids (LQETK), while Leu-484 is poorly conserved. Gln-460 Glu-461, Thr-462, and Lys-463 and Leu-484 were altered by site-directed mutagenesis using a plasmid including the entire Rrp1 gene and mutant proteins were purified, Mutants of the three residues Glu-461, Thr-462, and Lys-463 demonstrate 8-200-fold lower phosphodiesterase specific activity than wild-type Rrp1., E46lA has a 30-fold reduction in AP endonuclease and is MMS-sensitive, but all other mutants have near-normal AP endonuclease and are MMS-resistant, Glu-461 appears to be essential for the nuclease function of Rrp1. Lys-463 and, to a lesser extent, Thr-462 influence the substrate specificity of the Rrp1 nuclease.	NIEHS, MOLEC GENET LAB, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								[Anonymous], 1985, DNA REPAIR; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; BOYD JB, 1987, J CELL SCI, P39; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; GU LY, 1993, NUCLEIC ACIDS RES, V21, P4788, DOI 10.1093/nar/21.20.4788; HENRICH B, 1986, GENE, V42, P345, DOI 10.1016/0378-1119(86)90239-8; IZUMI T, 1992, J BACTERIOL, V174, P7711, DOI 10.1128/JB.174.23.7711-7716.1992; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1993, J MOL BIOL, V229, P239, DOI 10.1006/jmbi.1993.1021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; NUGENT M, 1993, BIOCHEMISTRY-US, V32, P11445, DOI 10.1021/bi00093a023; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1993, J BIOL CHEM, V268, P2075; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Von Sontag C., 1987, CHEM BASIS RAD BIOL, P221; WILSON TM, 1994, NUCLEIC ACIDS RES, V22, P530, DOI 10.1093/nar/22.3.530; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32685	32692						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798276				2022-12-25	WOS:A1994PX30400099
J	MONNET, V; NARDI, M; CHOPIN, A; CHOPIN, MC; GRIPON, JC				MONNET, V; NARDI, M; CHOPIN, A; CHOPIN, MC; GRIPON, JC			BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF PEPF, AN OLIGOPEPTIDASE FROM LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-CREMORIS H61; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; PZ-PEPTIDASE; NATURAL PEPTIDES; SIGNAL PEPTIDE; RAT TESTES; DCP GENE; PURIFICATION	Lactococcus lactis possesses a complex proteolytic system which is essential for its growth in milk. me characterized one of the peptidases of this system, oligopeptidase PepF, together with its structural gene. PepF hydrolyzed peptides containing between 7 and 17 amino acids with a rather wide specificity. It was purified to homogeneity. The N-terminal sequences of PepF and of peptides resulting from tryptic digestion of PepF were determined and used to design degenerate oligonucleotides which served to amplify a DNA fragment internal to pepF. This fragment was used as a probe to screen a lactococcal genomic library in Escherichia coli and to clone the entire gene pepF. The gene coded for a 70 kDa protein and was located on a 55-kilobase lactose-protease plasmid. A motif His-Glu-X-X-His, characteristic of metallopeptidases was evidenced. Two regions of PepF were found similar, first to a stretch of 43 amino acids around the zinc-binding site of several other peptidases, second to a stretch of 33 amino acids well conserved among creatine and arginine kinases. Preliminary results suggest the presence of a second copy of pepF.	INRA,GENET MICROBIENNE LAB,F-78352 JOUY EN JOSAS,FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay	MONNET, V (corresponding author), INRA,RECH LAITIERES STN,ENZYMOL GRP,F-78352 JOUY EN JOSAS,FRANCE.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARRETT AJ, 1990, BIOL CHEM H-S, V371, P311; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CONLIN CA, 1992, J BACTERIOL, V174, P5881, DOI 10.1128/jb.174.18.5881-5887.1992; CONLIN CA, 1992, J BACTERIOL, V174, P1631, DOI 10.1128/jb.174.5.1631-1640.1992; DANIELSEN EM, 1980, BIOCHEM J, V191, P645, DOI 10.1042/bj1910645; DESMAZEAUD MJ, 1976, ANN BIOL ANIM BIOCH, V16, P851, DOI 10.1051/rnd:19760608; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSSANTOS ALL, 1987, FEMS MICROBIOL LETT, V42, P209, DOI 10.1111/j.1574-6968.1987.tb02074.x; DUMAS C, 1993, J BIOL CHEM, V268, P21599; GIBSON TJ, 1984, THESIS U CAMBRIDGE E; HAMILTON S, 1992, J BACTERIOL, V174, P1626, DOI 10.1128/jb.174.5.1626-1630.1992; HENRICH B, 1993, J BACTERIOL, V175, P7290, DOI 10.1128/JB.175.22.7290-7300.1993; HUANG DC, 1991, FEMS MICROBIOL LETT, V77, P101, DOI [10.1016/S0378-1097(99)00297-9, 10.1111/j.1574-6968.1991.tb04329.x]; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KIRSCHNER RJ, 1981, METHOD ENZYMOL, V80, P702; KIWAKI M, 1989, MOL MICROBIOL, V3, P359, DOI 10.1111/j.1365-2958.1989.tb00181.x; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENHOUTS KJ, 1994, PLASMIDS PRACTICAL A, P65; LEENHOUTS KJ, 1995, APPL ENVIRON MICROB, V57, P2562; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAYO B, 1993, APPL ENVIRON MICROB, V59, P2049, DOI 10.1128/AEM.59.7.2049-2055.1993; MIERAU I, 1993, J BACTERIOL, V175, P2087, DOI 10.1128/JB.175.7.2087-2096.1993; MILLS OE, 1978, NEW ZEAL J DAIRY SCI, V13, P209; MONNET V, IN PRESS METHODS ENZ; MORALES TI, 1977, J BIOL CHEM, V252, P4855; MORIYAMA A, 1988, BIOCHIM BIOPHYS ACTA, V956, P151, DOI 10.1016/0167-4838(88)90261-0; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; NOVAK P, 1986, J BIOL CHEM, V261, P420; NOVAK P, 1988, J BACTERIOL, V170, P5067, DOI 10.1128/jb.170.11.5067-5075.1988; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; RABIER D, 1973, BIOCHIMIE, V55, P389, DOI 10.1016/S0300-9084(73)80204-4; RAUCH PJG, 1990, NUCLEIC ACIDS RES, V18, P4253, DOI 10.1093/nar/18.14.4253; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIMON D, 1985, FEMS MICROBIOL LETT, V26, P239, DOI 10.1111/j.1574-6968.1985.tb01598.x; TAN PST, 1991, APPL ENVIRON MICROB, V57, P3593, DOI 10.1128/AEM.57.12.3593-3599.1991; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; VANDEGUCHTE M, 1991, MOL GEN GENET, V227, P65, DOI 10.1007/BF00260708; VIMR ER, 1983, J BACTERIOL, V153, P1259, DOI 10.1128/JB.153.3.1259-1265.1983; YAN TR, 1987, EUR J BIOCHEM, V163, P259, DOI 10.1111/j.1432-1033.1987.tb10796.x; YAN TR, 1987, APPL ENVIRON MICROB, V53, P2296, DOI 10.1128/AEM.53.10.2296-2302.1987	58	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32070	32076						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798200				2022-12-25	WOS:A1994PX30400012
J	TOKER, A; MEYER, M; REDDY, KK; FALCK, JR; ANEJA, R; ANEJA, S; PARRA, A; BURNS, DJ; BALLAS, LM; CANTLEY, LC				TOKER, A; MEYER, M; REDDY, KK; FALCK, JR; ANEJA, R; ANEJA, S; PARRA, A; BURNS, DJ; BALLAS, LM; CANTLEY, LC			ACTIVATION OF PROTEIN-KINASE-C FAMILY MEMBERS BY THE NOVEL POLYPHOSPHOINOSITIDES PTDINS-3,4-P-2 AND PTDINS-3,4,5-P-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-SUBSPECIES BLOCKS; NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; PHOSPHOINOSITIDE 3-KINASE; ACTIN POLYMERIZATION; MITOGENIC SIGNAL; HUMAN-PLATELETS	The effect of phosphoinositides on the activity of protein kinase C (PKC) isotypes was investigated. PKC alpha, beta I, beta II, gamma, delta, epsilon, eta, and zeta were expressed in baculovirus-infected insect cells and purified by column chromatography. The calcium-activated PKC isotypes alpha, beta I, beta II, and gamma were not significantly activated by any of the phosphoinositides investigated (phosphatidylinositol-4-phosphate (PtdIns-4-P), PtdIns-3-P, PtdIns-4,5-P-2, PtdIns-3,4-P-2, and PtdIns-3,4,5-P-3) when added in the presence of concentrations of phosphatidylserine that give maximal stimulation. The calcium-insensitive PKC isotypes delta, epsilon, and eta also showed little response to PtdIns3-P, PtdIns-4-P, or PtdIns-4,5-P-2 when these lipids were added in the presence of phosphatidylserine. In contrast, PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 caused a 5-15-fold stimulation of these enzymes compared with phosphatidylserine alone. 50 % maximal stimulation of PKC epsilon by PtdIns-3,4,5-P-3 occurred when this lipid was present at about 1% of the carrier PtdIns-4,5-P-2 (about 100 nM). These lipids had little effect on baculovirus-expressed PKC zeta, which was constitutively active. A short chain version of PtdIns-3,4,5-P-3, dioctanoyl-PtdIns-3,4,5-P-3, activated PKC delta, epsilon, and eta in the absence of other lipids, whereas a short chain version of PtdIns-4,5-P-2, dihexanoyl-PtdIns-4,5-P-2, did not. Since PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 are nominally absent in unstimulated cells and appear within seconds to minutes of stimulation by various cell activators, these Lipids could act as second messengers to activate PHC delta, epsilon, or eta in vivo.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; SPHINX PHARMACEUT, DURHAM, NC 27717 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; CORNELL UNIV, DIV FUNCT LIPIDS, LANGMUIR LAB, ITHACA, NY 14850 USA	Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cornell University	TOKER, A (corresponding author), BETH ISRAEL HOSP, DEPT MED,DIV SIGNAL TRANSDUCT,WARREN ALPERT BLDG, RM 146, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM049594, R44GM049594, R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37361, GM41890, GM49594, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ANEJA R, 1970, BIOCHIM BIOPHYS ACTA, V218, P102, DOI 10.1016/0005-2760(70)90097-4; ANEJA R, 1974, Biochemical Society Transactions, V2, P38; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLAS LM, 1993, FASEB J S, P35; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CACACE AM, 1993, ONCOGENE, V8, P2095; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHOUINARD PM, 1986, J ORG CHEM, V51, P75, DOI 10.1021/jo00351a015; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DREEF CE, 1988, TETRAHEDRON LETT, V29, P6513, DOI 10.1016/S0040-4039(00)82387-4; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FALCK JR, 1993, BIOORG MED CHEM LETT, V3, P717, DOI 10.1016/S0960-894X(01)81261-0; FALCK JR, 1991, ACS SYM SER, V463, P145; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIGGINS JA, 1978, BIOCHEM J, V174, P563, DOI 10.1042/bj1740563; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KOCHS G, 1993, BIOCHEM J, V291, P627, DOI 10.1042/bj2910627; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LIMATOLA C, 1993, 34TH INT C BIOCH LIP; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; NAHAS N, 1989, FEBS LETT, V246, P30, DOI 10.1016/0014-5793(89)80247-9; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1991, METHOD ENZYMOL, V200, P228; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; RANKL NB, 1994, IN PRESS PROTEIN EXP; RAY TK, 1969, J BIOL CHEM, V244, P5528; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RICE JW, 1993, BIOTECHNIQUES, V15, P1052; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WENNSTROM S, 1994, ONCOGENE, V9, P651; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686	83	563	572	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32358	32367						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798235				2022-12-25	WOS:A1994PX30400053
J	ARAVINDA, S; GOPALAKRISHNAN, B; DEY, CS; TOTEY, SM; PAWSHE, CH; SALUNKE, D; KAUR, K; SHAHA, C				ARAVINDA, S; GOPALAKRISHNAN, B; DEY, CS; TOTEY, SM; PAWSHE, CH; SALUNKE, D; KAUR, K; SHAHA, C			A TESTICULAR PROTEIN IMPORTANT FOR FERTILITY HAS GLUTATHIONE-S-TRANSFERASE ACTIVITY AND IS LOCALIZED EXTRACELLULARLY IN THE SEMINIFEROUS TUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SPERM; MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; HUMAN TESTIS; RAT TESTES; EXPRESSION; ANTIGENS; BINDING; MOUSE; CELLS	A 24-kDa protein isolated by preparative gel electrophoresis from rat testes was reported by us as an active immunogen in rats. Anti-24-kDa antibodies inhibited murine sperm-oocyte binding in vitro. Here, we show similarity at the NH2 terminus shared by this protein purified on Sephadex G-75 followed by anion exchange high performance liquid chromatography with glutathione S-transferase (GST)-mu subunits. This protein purified by glutathione affinity chromatography also demonstrated similarity to GST-mu NH2 terminus in a 30-amino-acid overlap. Both proteins showed activity toward the GST substrate 1-chloro-2,4-dinitrobenzene (K-m of 33 mu M and 50 mu M) which was inhibited by 17 beta-estradiol 3-sulfate. Antisera against both proteins recognized liver GST-mu on Western blots and sperm acrosome of multiple species immunocytochemically. Both antisera significantly inhibited in vitro fertilization of goat oocytes by sperm preincubated with them while anti-liver GST sera did not. GST activity was localized on rat sperm, seminiferous tubular fluid, and Sertoli cells. Seminiferous tubular fluid 24-kDa protein shared similarity to the NH2 terminus of GST-mu subunits in a 20-amino-acid overlap. Time dependent accumulation of GST was detected in the spent culture medium of seminiferous tubules from rats of different ages suggesting secretion.	NATL INST IMMUNOL, NEW DELHI 110067, INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583				ADACHI Y, 1991, Hokkaido Journal of Medical Science, V66, P818; AWONIYI CA, 1990, ENDOCRINOLOGY, V127, P177, DOI 10.1210/endo-127-1-177; Bardin C.W., 1988, P933; BOGGARDS JJP, 1992, BIOCHEM J, V286, P383; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; GONDOS B, 1993, SERTOLI CELL, P116; HERR JC, 1990, BIOL REPROD, V42, P181, DOI 10.1095/biolreprod42.1.181; HINTON BT, 1993, SERTOLI CELL, P250; ISHIKAWA T, 1988, EUR J BIOCHEM, V176, P551, DOI 10.1111/j.1432-1033.1988.tb14313.x; JOHNSON JA, 1992, BIOCHEM J, V252, P279; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KLYS HS, 1992, BRIT J CANCER, V66, P589, DOI 10.1038/bjc.1992.319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE MG, 1993, J NEUROCHEM, V61, P533; Listowsky Irving, 1993, P397; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MATHER JP, 1984, METHODS SERUM FREE C, P29; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MUKHTAR H, 1978, BIOCHEM BIOPH RES CO, V83, P1093, DOI 10.1016/0006-291X(78)91507-3; NAZ RK, 1993, IMMUNOLOGY REPRODUCT, P37; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAWSHE CH, 1994, THERIOGENOLOGY, V42, P117, DOI 10.1016/0093-691X(94)90668-9; RAM PA, 1989, GAMETE RES, V22, P321, DOI 10.1002/mrd.1120220309; Ritzen EM, 1981, TESTIS COMPREHENSIVE, P171; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; SHAHA C, 1991, MOL REPROD DEV, V29, P302, DOI 10.1002/mrd.1080290314; SHAHA C, 1994, MOL REPROD DEV, V38, P393, DOI 10.1002/mrd.1080380407; SHAHA C, 1990, INT J ANDROL, V13, P17, DOI 10.1111/j.1365-2605.1990.tb00956.x; SHAHA C, 1988, INT J ANDROL, V11, P479, DOI 10.1111/j.1365-2605.1988.tb01022.x; SHAHA C, 1993, HYBRIDOMA, V12, P709, DOI 10.1089/hyb.1993.12.709; SHAHA C, 1990, CONRAD W S, P75; SHAHA C, 1989, HYBRIDOMA, V8, P647, DOI 10.1089/hyb.1989.8.647; SHUR BD, 1979, DEV BIOL, V71, P243, DOI 10.1016/0012-1606(79)90167-2; SNEDECOR GW, 1967, STATISTICAL METHODS, P329; SURI A, 1993, SCI BAS FER, P427; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG PS, 1990, BIOL REPROD, V42, P351, DOI 10.1095/biolreprod42.2.351; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P998; VITALE R, 1973, ANAT REC, V176, P333, DOI 10.1002/ar.1091760309; WARHOLM M, 1985, METHOD ENZYMOL, V113, P499; WHEAT TE, 1985, MOL IMMUNOL, V22, P643, DOI 10.1016/0161-5890(85)90093-8; WHEAT TE, 1985, ANN NY ACAD SCI, V438, P156; YOGANATHAN T, 1989, BIOCHEM INT, V19, P667; ZWAIN IH, 1992, ENDOCRINOLOGY, V131, P1511, DOI 10.1210/en.131.3.1511	48	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15675	15685		10.1074/jbc.270.26.15675	http://dx.doi.org/10.1074/jbc.270.26.15675			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797568	hybrid			2022-12-25	WOS:A1995RG53800039
J	CHEN, CY; SCHWARTZ, RJ				CHEN, CY; SCHWARTZ, RJ			IDENTIFICATION OF NOVEL DNA-BINDING TARGETS AND REGULATORY DOMAINS OF A MURINE TINMAN HOMEODOMAIN FACTOR, NKX-2.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; DROSOPHILA; PROTEIN; HEART; SEQUENCE; COMPLEX; CELLS; MYOD	A murine cardiac-specific homeodomain gene named csx (Komuro, I., and Izumo, S, (1993) Proc. Natl. Acad, Sci, U, S, A. 90, 8145-8149) and nkx-2.5 (Lints, T, J,, Parsons, L, M,, Hartley, L,, Lyons, I,, and Harvey, R. P, (1993) Development 119, 419-431) was identified as a potential vertebrate homologue of Drosophila tinman, a mesoderm determination factor required for insect heart formation (Bodmer, R, (1993) Development 118, 719-729), Bacterial expression of the nkx-2.5 homeodomain allowed us to identify downstream DNA targets from a library of randomly generated oligonucleotides. High affinity nkx-2.5 DNA binding sites, 5'-TNNAGTG-3', represented novel binding sequences, whereas intermediate and weaker affinity sites, 5'-C(APT)TTAATTN-3', contained the typical 5'-TAAT-3' core required by most homeodomain factors for DNA binding, We also ob served that nkx-2.5 served as a modest transcription activator in transfection assays done in 10T1/2 fibroblasts with multimerized binding sites linked to a luciferase reporter gene, Functional dissection of nkx-2.5 revealed a COOH-terminal inhibitory domain composed mainly of clusters of alanines and prolines, which appeared to mask a potent activation domain composed of hydrophobic and highly charged amino acids.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NHLBI NIH HHS [P01 HL49953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHANG KS, 1985, NUCLEIC ACIDS RES, V13, P1223, DOI 10.1093/nar/13.4.1223; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GAUZZI S, 1990, EMBO J, V9, P3631; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARVEY RP, 1994, J CELL BIOCHEM, V18, P477; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LEE TC, 1994, ONCOGENE, V9, P1047; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOSS JB, 1994, J BIOL CHEM, V269, P12731; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; OTTING G, 1991, EMBO J, V9, P3085; SASSOON D, 1989, NATURE, V34, P303; SATORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	33	183	185	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15628	15633		10.1074/jbc.270.26.15628	http://dx.doi.org/10.1074/jbc.270.26.15628			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797561	hybrid			2022-12-25	WOS:A1995RG53800031
J	PEDERSEN, PL; HULLIHEN, J; BIANCHET, M; AMZEL, LM; LEBOWITZ, MS				PEDERSEN, PL; HULLIHEN, J; BIANCHET, M; AMZEL, LM; LEBOWITZ, MS			RAT-LIVER ATP SYNTHASE - RELATIONSHIP OF THE UNIQUE SUBSTRUCTURE OF THE F1 MOIETY TO ITS NUCLEOTIDE-BINDING PROPERTIES, ENZYMATIC STATES, AND CRYSTALLINE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ISOLATED BETA-SUBUNIT; ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; CATALYTIC SITES; F1 MOIETY; OXIDATIVE-PHOSPHORYLATION; QUATERNARY STRUCTURE; PROTEIN INHIBITOR; MECHANISM	The F-1 moiety of rat liver ATP synthase has a molecular mass of 370,000, exhibits the unique substructure alpha(3) beta(3) gamma delta epsilon, and fully restores ATP synthesis to F-1-depleted membranes, Here we provide new information about rat liver F-1 as it relates to the relationship of its unique substructure to its nucleotide binding properties, enzymatic states, and crystalline form. Seven types of experiments were performed in a comprehensive study. First, the capacity of F-1 to bind [H-3]ADP, the substrate for ATP synthesis and [P-32]AMP-PNP (5'-adenylyl-beta,gamma-imidodiphosphate), a nonhydrolyzable ATP analog, was quantified, Second, double label experiments were performed to establish whether ADP and AMP-PNP bind to the same or different sites. Third, total nucleotide binding was assessed by the luciferin-luciferase assay. Fourth, F-1 was subfractionated into an alpha gamma and a beta delta epsilon fraction, both of which were subjected to nucleotide binding assays, Fifth, the nucleotide binding capacity of F-1 was quantified after undergoing ATP hydrolysis. Sixth, the intensity of the fluorescence probe pyrene maleimide bound at cu subunits was monitored before and after F-1 experienced ATP hydrolysis, Finally, the catalytic activity and nucleotide content of F-1, obtained from crystals being used in x-ray crystallographic studies was determined. The picture of rat liver F-1 that emerges is one of an enzyme molecule that 1) loads nucleotide readily at five sites; 2) requires for catalysis both the alpha gamma and the beta delta epsilon fractions; 3) directs the reversible binding of ATP and ADP to different regions of the enzyme's substructure; 4) induces inhibition of ATP hydrolysis only after ADP fills at least five sites; and 5) exists in several distinct forms, one an active, symmetrical form, obtained in the presence of ATP and high P-i and on which an x-ray map at 3.6 Angstrom has been reported (Bianchet, M., Ysern, X., Hullihen, J., Pedersen, P. L., and Amzel, L. M., (1991) J. Biol. Chem. 266, 21197-21201). These results are discussed within the context of a multistate model for rat liver F-1 and also discussed relative to those reported for bovine heart F-1, which has been crystallized with inhibitors in an asymmetrical form and has a propensity for binding nucleotides more tightly.	JOHNS HOPKINS UNIV, SCH MED, MOLEC & CELLULAR BIOENERGET LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & PHYS CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	PEDERSEN, PL (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.		Bianchet, Mario a/K-2131-2015	Bianchet, Mario a/0000-0001-9032-7549; Amzel, L. Mario/0000-0002-0129-9572	NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025432] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline; NIGMS NIH HHS [GM 25432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AGGELER R, 1992, J BIOL CHEM, V267, P21355; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; ALSHAWI MK, 1990, J BIOL CHEM, V265, P5595; AMZEL LM, 1992, J BIOENERG BIOMEMBR, V24, P429, DOI 10.1007/BF00762358; AMZEL LM, 1978, J BIOL CHEM, V253, P2067; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOULAY F, 1985, BIOCHEMISTRY-US, V24, P7372, DOI 10.1021/bi00346a052; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CATTERALL WA, 1972, J BIOL CHEM, V247, P7969; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; COX GB, 1978, J BACTERIOL, V133, P287, DOI 10.1128/JB.133.1.287-292.1978; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; CROSS RL, 1982, J BIOL CHEM, V257, P2874; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KIRONDE FAS, 1987, J BIOL CHEM, V262, P3488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P20308; MILGROM YM, 1991, EUR J BIOCHEM, V200, P789, DOI 10.1111/j.1432-1033.1991.tb16246.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NALIN CM, 1985, BIOCHEMISTRY-US, V24, P2318, DOI 10.1021/bi00330a029; PEDERSEN PL, 1978, J BIOL CHEM, V253, P2176; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; PEDERSEN PL, 1987, BIOCHEMISTRY-US, V26, P8631, DOI 10.1021/bi00400a021; PEDERSEN PL, 1976, J BIOL CHEM, V251, P934; PEDERSEN PL, 1975, J SUPRAMOL STR CELL, V3, P222, DOI 10.1002/jss.400030304; PEDERSEN PL, 1974, MEMBRANE PROTEINS TR, P43; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1981, J BIOL CHEM, V256, P4763; TURINA P, 1994, J BIOL CHEM, V269, P13465; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILLIAMS DE, 1964, ANN NY ACAD SCI, V121, P373, DOI 10.1111/j.1749-6632.1964.tb14210.x; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; WILLIAMS N, 1984, BIOCHEMISTRY-US, V23, P780, DOI 10.1021/bi00299a030; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WISE JG, 1981, J BIOL CHEM, V256, P383	56	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1775	1784		10.1074/jbc.270.4.1775	http://dx.doi.org/10.1074/jbc.270.4.1775			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829514	hybrid			2022-12-25	WOS:A1995QD20400047
J	LIN, ZL; SCHWARZ, FP; EISENSTEIN, E				LIN, ZL; SCHWARZ, FP; EISENSTEIN, E			THE HYDROPHOBIC NATURE OF GROEL-SUBSTRATE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROCESSES INVOLVING PROTEINS; CARBONIC-ANHYDRASE-B; SUBTILISIN BPN'; ESCHERICHIA-COLI; INTERMEDIATE; COOPERATIVITY; POLYPEPTIDE; STABILITY	The molecular chaperone GroEL from Escherichia coli is a member of the highly conserved Hsp60 family of proteins that facilitates protein folding. A central question regarding the mechanism of GroEL-assisted refolding of proteins concerns its broad substrate specificity. The nature of GroEL-polypeptide chain interaction was investigated by isothermal titration calorimetry using proteins that maintain a non native conformation in neutral buffer solutions. A single molecule of an unfolded variant of subtilisin BPN' binds non-cooperatively to GroEL with micromolar affinity and a positive enthalpy change. Additional calorimetric titrations of this chain with GroEL show that the positive enthalpy change decreases with increasing temperature between 6 and 25 degrees C, yielding a Delta C-p of -0.85 kcal mol(-1) degree(-1). alpha-Casein similarly binds to GroEL with micromolar affinity and a positive enthalpy change in the range of 15-23 degrees C, yielding a Delta C-p of -0.44 kcal mol(-1) degree(-1). The negative heat capacity change provides strong evidence for the role of hydrophobic interactions as the driving force for the association of these substrates with the GroEL chaperonin.	CTR ADV RES BIOTECHNOL, ROCKVILLE, MD 20850 USA; UNIV MARYLAND, INST BIOTECHNOL, ROCKVILLE, MD 20850 USA; NATL INST STAND & TECHNOL, ROCKVILLE, MD 20850 USA; UNIV MARYLAND, DEPT CHEM & BIOCHEM, BALTIMORE, MD 21228 USA	University System of Maryland; University of Maryland Baltimore; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore			Lin, Zhanglin/A-7232-2011		NIGMS NIH HHS [GM49316] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRYAN P, 1992, BIOCHEMISTRY-US, V31, P4937, DOI 10.1021/bi00136a003; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; DILL KA, 1993, P NATL ACAD SCI USA, V90, P1942, DOI 10.1073/pnas.90.5.1942; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KLOTZ IM, 1973, ANN NY ACAD SCI, V226, P18, DOI 10.1111/j.1749-6632.1973.tb20465.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LORIMER GH, 1992, CURR OPIN STRUC BIOL, V2, P26; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SWAISGOO.HE, 1968, ARCH BIOCHEM BIOPHYS, V125, P344, DOI 10.1016/0003-9861(68)90670-X; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WONG KP, 1973, J BIOL CHEM, V248, P8518; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	40	133	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1011	1014		10.1074/jbc.270.3.1011	http://dx.doi.org/10.1074/jbc.270.3.1011			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836352	hybrid			2022-12-25	WOS:A1995QB15600007
J	RAMAN, N; DIRUSSO, CC				RAMAN, N; DIRUSSO, CC			ANALYSIS OF ACYL-COENZYME A BINDING TO THE TRANSCRIPTION FACTOR FADR AND IDENTIFICATION OF AMINO-ACID-RESIDUES IN THE CARBOXYL-TERMINUS REQUIRED FOR LIGAND BINGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LAC REPRESSOR; GENE FADR; CLONING; METABOLISM; PROTEIN; DEGRADATION; REGULATOR; STRAINS	The Escherichia coli FadR protein regulates the transcription of many unlinked genes and operons encoding proteins required for fatty acid synthesis and degradation. Previously, we demonstrated that the ability of purified FadR to bind DNA in vitro is inhibited by long chain acyl coenzyme A esters (DiRusso, D. D., Heimert, T. L., and Metzger, A, K. (1992) J. Biol. Chem. 267, 8685-8691). In the present work, we show that FadR binds acyl-CoA directly. Ligand binding resulted in a shift in the apparent pI of FadR from 6.9 to 6.2 and in a marked decrease in intrinsic fluorescence. The K-m for FadR binding of oleoyl coenzyme A was determined to be 12.1 nM using the fluorescence quenching assay, The binding site for acyl-CoA was identified by selection of noninducible mutations in the FadR gene. One altered protein carrying the change Ser(219) to Asn (S219N) was purified and shown to have a reduced affinity for oleoyl coenzyme A as evidenced by a K-m of 257 nM. S219N retained the ability to bind DNA and to repress or activate transcription. Alanine substitution of amino acid residues 215 through 230 identified Gly(216) and Trp(223) as also required specifically for induction. This region of FadR shares amino acid identities and similarities with the coenzyme A-binding site of Clostridium thermoaceticum CO dehydrogenase/acetyl-coenzyme A synthase. Due to the alteration in binding affinity of the purified S219N protein, the non-inducible phenotype of several proteins carrying alanine substitutions and similarities to CO dehydrogenase/acetyl-coenzyme A synthase we propose this region of FadR forms part of the acyl-CoA-binding domain.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center			DiRusso, Concetta C/M-1884-2014	DiRusso, Concetta/0000-0001-7388-9152	NIGMS NIH HHS [GM38104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038104] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; BLACK PN, 1992, J BIOL CHEM, V267, P25513; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHANG WI, 1993, J BIOL CHEM, V268, P17613; Cleland W W, 1979, Methods Enzymol, V63, P103; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HUGHES KT, 1988, J BACTERIOL, V170, P1666, DOI 10.1128/jb.170.4.1666-1671.1988; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MORTON TA, 1991, J BIOL CHEM, V266, P23824; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SHANMUGASUNDARA.T, 1988, BIOCHEMISTRY-US, V28, P7112; SIMONS RW, 1980, J BACTERIOL, V143, P726, DOI 10.1128/JB.143.2.726-730.1980; SUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WARD LD, 1985, METHOD ENZYMOL, V117, P400; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	61	63	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1092	1097		10.1074/jbc.270.3.1092	http://dx.doi.org/10.1074/jbc.270.3.1092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836365	hybrid			2022-12-25	WOS:A1995QB15600020
J	SIRES, UI; DUBLET, B; AUBERTFOUCHER, E; VANDERREST, M; WELGUS, HG				SIRES, UI; DUBLET, B; AUBERTFOUCHER, E; VANDERREST, M; WELGUS, HG			DEGRADATION OF THE COL1 DOMAIN OF TYPE-XIV COLLAGEN BY 92-KDA GELATINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; FIBRIL-ASSOCIATED COLLAGENS; BASEMENT-MEMBRANE COLLAGEN; AMINO-ACID SEQUENCE; FETAL BOVINE SKIN; IV COLLAGENASE; IX COLLAGEN; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; II COLLAGEN	Type XIV collagen is a newly described member of the fibril-associated collagens with interrupted triple helices (FACITs). Expression of this collagen has been localized to various embryonic tissues, suggesting that it has a functional role in development. All FACITs thus far described (types IX, XII, XIV, and XVI) contain a highly homologous carboxyl-terminal triple helical domain designated COL1. We have studied the capacity of various matrix metalloproteinases (interstitial collagenase, stromelysin, matrilysin, and 92-kDa gelatinase) to degrade the COL1 domain of collagen XIV. We found that only 92-kDa gelatinase cleaves COL1. Furthermore, digestion of whole native collagen XIV by the 92-kDa gelatinase indicates that this enzyme specifically region of the molecule. COL1 is cleaved by 92-kDa gelatinase at 30 degrees C, a full 5-6 degrees C below the melting temperature (T-m) of this domain; native collagen XIV is also degraded at 30 degrees C. In comparison to interstitial collagenase degradation of its physiologic native type I collagen substrate, the 92-kDa enzyme cleaved COL1 (XIV) with comparable catalytic efficacy. Interestingly, following thermal denaturation of the COL1 fragment, its susceptibility to 92-kDa gelatinase increases, but only to a degree that leaves it several orders of magnitude less sensitive to degradation than denatured collagens I and III. These data indicate that native COL1 and collagen XIV are readily and specifically cleaved by 92-kDa gelatinase. They also suggest a role for 92-kDa gelatinase activity in the structural tissue remodeling of the developing embryo.	ST LOUIS CHILDRENS HOSP, DEPT PEDIAT, ST LOUIS, MO 63110 USA; INST BIOL & CHEM PROT, CNRS, UPR 412, LYON, FRANCE	St. Louis Children's Hospital; Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS)	SIRES, UI (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV DERMATOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284, R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47328] Funding Source: Medline; NIAMS NIH HHS [T32-AR07284, AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P397, DOI 10.1111/j.1432-1033.1984.tb08115.x; CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340; CHU ML, 1988, J BIOL CHEM, V263, P18601; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DUBLET B, 1990, ANN NY ACAD SCI, V580, P436, DOI 10.1111/j.1749-6632.1990.tb17953.x; DUBLET B, 1991, J BIOL CHEM, V266, P6853; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; FONT B, 1993, J BIOL CHEM, V268, P25015; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; HASTY KA, 1990, J BIOL CHEM, V265, P11421; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; REPONEN P, 1992, J BIOL CHEM, V267, P7856; ROSWIT WT, 1988, ARCH BIOCHEM BIOPHYS, V262, P67, DOI 10.1016/0003-9861(88)90169-5; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SELTZER JL, 1985, J CHROMATOGR, V326, P147, DOI 10.1016/S0021-9673(01)87440-9; SENGEL P, 1983, BIOCH PHYSL SKIN, P102; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SIRES UI, 1993, J BIOL CHEM, V268, P2069; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; TRELSTAD RL, 1976, ANAL BIOCHEM, V71, P114, DOI 10.1016/0003-2697(76)90016-6; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VANDERREST M, 1991, BIOCHEM SOC T, V19, P820, DOI 10.1042/bst0190820; VANDERREST M, 1990, STRUCTURE FUNCTION C, P195; WATT SL, 1992, J BIOL CHEM, V267, P20093; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	58	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1062	1067		10.1074/jbc.270.3.1062	http://dx.doi.org/10.1074/jbc.270.3.1062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836360	hybrid			2022-12-25	WOS:A1995QB15600015
J	CZUPRYN, MJ; MCCOY, JM; SCOBLE, HA				CZUPRYN, MJ; MCCOY, JM; SCOBLE, HA			STRUCTURE-FUNCTION-RELATIONSHIPS IN HUMAN INTERLEUKIN-11 - IDENTIFICATION OF REGIONS INVOLVED IN ACTIVITY BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR-BINDING SITE; HUMAN GROWTH-HORMONE; IL-6 SIGNAL TRANSDUCER; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; EXTRACELLULAR DOMAIN; SECONDARY STRUCTURE; AMINO-ACIDS	Chemical modification approaches combined with site-directed and deletion mutagenesis have been used to identify functionally critical regions/residues of recombinant human IL-11 (rhIL-11), Incubation of rhIL-11 with iodoacetic acid results in specific alkylation of a single methionine residue, Met(58), and a 25-fold reduction of in vitro biological activity on mouse plasmacytoma cells. A similar decrease in activity is observed when Met(58) is substituted with Ala, Leu, Gin, Glu, or Lys by site-directed mutagenesis. Treatment of rhIL-11 with succinic anhydride leads to modification of the aminoterminal amino group and partial labeling of 2 lysines, Lys(4l) and Lys(98), and to a 3-fold decrease in activity. The activity losses can be attributed to modification of the lysine residues, since the succinyl derivative of the amino terminus is fully active. In addition, carboxyl-terminal deletion mutagenesis studies have demonstrated that removal of the last 4 residues reduces rhIL-11 activity 25-fold, whereas removal of 8 or more amino acids results in an inactive molecule. Based on secondary structure predictions and the location of exon/intron boundaries in the IL-11 genomic structure, we propose a four-helix bundle topology as a structural model for rhIL-11. This model has been tested by limited proteolysis using three side chain-specific endoproteinases. A limited number of protease-sensitive cleavage sites are present in rhIL-11, and all but two are located in the postulated helix interconnecting loops or at helix termini, alpha-Helices, which in the proposed structure form a compact core of the molecule, are inaccessible to digestion under limiting conditions. According to the model, Met(58), Lys(41) and Lys(98) are located on the surface of the molecule, in agreement with their preferential accessibility to chemical modification. By analogy with human growth hormone, we postulate that Met(58) and the carboxyl terminus of rhIL-11 are involved in the primary receptor binding site (site I), whereas Lys(41) and Lys(98) may be a part of binding site II.			CZUPRYN, MJ (corresponding author), GENET INST INC, 1 BURTT RD, ANDOVER, MA 01810 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KAUSHANSKY K, 1993, BLOOD, V82, P3229; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LE HV, 1991, BIOCHEMISTRY-US, V30, P9576, DOI 10.1021/bi00104a003; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; MAIER R, 1993, J BIOL CHEM, V268, P21527; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MCKINLEY D, 1992, GENOMICS, V13, P814, DOI 10.1016/0888-7543(92)90158-O; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL SR, 1992, INT J CELL CLONING, V10, P135, DOI 10.1002/stem.5530100303; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; RAMANATHAN L, 1993, BIOCHEMISTRY-US, V32, P3549, DOI 10.1021/bi00065a005; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; WALTER MR, 1992, J BIOL CHEM, V267, P20371; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WARD LD, 1993, PROTEIN SCI, V2, P1472, DOI 10.1002/pro.5560020911; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG YC, 1992, BIOFACTORS, V4, P15; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555	45	46	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					978	985		10.1074/jbc.270.2.978	http://dx.doi.org/10.1074/jbc.270.2.978			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822338	hybrid			2022-12-25	WOS:A1995QB81600074
J	KUBLAOUI, B; LEE, J; PILCH, PF				KUBLAOUI, B; LEE, J; PILCH, PF			DYNAMICS OF SIGNALING DURING INSULIN-STIMULATED ENDOCYTOSIS OF ITS RECEPTOR IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; ISOLATED RAT ADIPOCYTES; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; ADIPOSE CELL; INTERNALIZATION; PHOSPHORYLATION; ACTIVATION; IRS-1	Insulin causes rapid insulin receptor autophosphorylation, receptor endocytosis, and phosphorylation of its principle substrate (IRS-I). Using rat adipocytes, we studied the dynamics of receptor autophosphorylation, the kinase activity, and the IRS-1 phosphorylation state relative to the subcellular localization of these proteins. After 2 min of insulin exposure, the specific phosphotyrosine content of the insulin receptor in the internal membranes (IM) peaks at a level 5-6-fold higher than the plasma membrane (PM) receptor and then declines after 5-8 min to a level similar to the PM receptor. The exogenous kinase activity of these receptors exactly mirrored their phosphotyrosine content. The distribution of IRS-1 is 80% cytosolic, 20% IM-associated, and essentially undetectable in the PM, The phosphorylation state of IRS-1 in the IM parallels that of the insulin receptor, but cytosolic IRS-1 phosphorylation remains constant. Insulin-dependent GLUT4 translocation to the PM occurs after the peak of IRS-1 phosphorylation. The data are consistent with the hypothesis that insulin action may be mediated by receptor internalization and interaction with its substrate(s) associated with internal membranes. A small fraction of phosphorylated insulin receptors is sufficient for signal transduction, The dephosphorylation of the insulin receptor and IRS-1 in the IM appears to be a concerted process, possibly mediated by the same enzyme.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University			Lee, Jongsoon/AAG-1674-2020	Lee, Jongsoon/0000-0002-0891-5059; Pilch, Paul/0000-0003-1997-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK036424] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30425, DK-36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; DELVECCHIO RL, 1989, BIOCHIM BIOPHYS ACTA, V986, P41, DOI 10.1016/0005-2736(89)90270-8; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FEHLMANN M, 1982, P NATL ACAD SCI-BIOL, V79, P5921, DOI 10.1073/pnas.79.19.5921; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MARSHALL S, 1979, J BIOL CHEM, V254, P153; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OHARE T, 1989, J BIOL CHEM, V264, P602; OKADA T, 1994, J BIOL CHEM, V269, P3568; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONNE O, 1984, BIOCHIM BIOPHYS ACTA, V804, P404, DOI 10.1016/0167-4889(84)90067-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG CC, 1983, J BIOL CHEM, V258, P5129; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILEY HS, 1989, J BIOL CHEM, V264, P18912	48	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					59	65		10.1074/jbc.270.1.59	http://dx.doi.org/10.1074/jbc.270.1.59			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814420	hybrid			2022-12-25	WOS:A1995QA28700015
J	PERRINO, BA; NG, LY; SODERLING, TR				PERRINO, BA; NG, LY; SODERLING, TR			CALCIUM REGULATION OF CALCINEURIN PHOSPHATASE-ACTIVITY BY ITS B-SUBUNIT AND CALMODULIN - ROLE OF THE AUTOINHIBITORY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BINDING PROTEIN; ALPHA-SUBUNIT; DEPHOSPHORYLATION; IDENTIFICATION; PURIFICATION; DETERMINANTS; MUTAGENESIS; PROMOTER; SEQUENCE	Calcineurin (CaN) contains an autoinhibitory element (residues 457-482) 43 residues COOH-terminal of the calmodulin binding domain (Hashimoto, Y., Perrino, B. A., and Soderling, T. R. (1990) J. Biol. Chem. 265, 1924-1927) that regulates the Ca2+-dependent activation of its phosphatase activity, Substitution of Arg(476) and Arg(477) or Asp(467) to Ala in the autoinhibitory peptide 457-482 significantly decreased its inhibitory potency. CaN A subunits with these residues mutated to Ala were coexpressed with the Ca2+-binding B subunit using the baculovirus/Sf9 cell system. Kinetic analysis showed that although the purified mutants had no activity in the absence of calcium, they were less dependent than the wild-type enzyme on calcium and calmodulin for activity. To determine if additional autoinhibitory motifs were present in the COOH terminus of calcineurin, the A subunit was truncated at residues 457 or 420 and co expressed with B subunit. The V-max values of both truncation mutants with or without Ca2+ were increased relative to wild-type calcineurin. The increased Ca2+-independent activity of CaN420 relative to CaN457 indicates the presence of additional autoinhibitory element(s) within residues 420-457. CaN420 had similar high V-max values with or without Ca2+, but the K-m value for peptide substrate was increased 5-fold to 125 mu M in the absence of Ca2+. The K-m values of all the expressed calcineurin species were increased in the absence of Ca2+. The CaN A or CaN A(420) subunits alone have low V-max and high K-m (115 mu M) values even in the presence of Ca2+. These results indicate that 1) there are several autoinhibitory motifs between the CaM-binding domain and the COOH terminus that are relieved by Ca2+ binding to CaM and the B subunit, 2) Ca2+ binding to the B subunit also regulates enzyme activity by lowering the K-m of the catalytic subunit for substrate, 3) binding of the B sub-unit is required for high V-max values even after removal of the autoinhibitory domain. These results are consistent with synergistic activation of calcineurin by Ca2+ acting through both CaM and the B subunit.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017808, T32DK007680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK17808, DK07680] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FONG YL, 1990, J BIOL CHEM, V265, P11091; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V257, P418; HIGUCHI S, 1991, J BIOL CHEM, V256, P18104; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID RL, 1988, METHOD ENZYMOL, V159, P627; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8923; KING MM, 1987, J BIOL CHEM, V262, P10658; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MAHAJAN PB, 1993, J BIOL CHEM, V268, P16693; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; PERRINO BA, 1990, FASEB J, V4, pA2237; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SCHWANINGER M, 1993, J BIOL CHEM, V268, P111; SMITH MK, 1992, J BIOL CHEM, V267, P1761; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; STEWART AA, 1983, EUR J BIOCHEM, V132, P289, DOI 10.1111/j.1432-1033.1983.tb07361.x; UEKI K, 1993, J BIOL CHEM, V268, P6554; WOLFF DJ, 1985, J BIOL CHEM, V260, P4195	33	142	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					340	346		10.1074/jbc.270.1.340	http://dx.doi.org/10.1074/jbc.270.1.340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814394	hybrid			2022-12-25	WOS:A1995QA28700054
J	CARDINAUX, JR; CHAPEL, S; WAHLI, W				CARDINAUX, JR; CHAPEL, S; WAHLI, W			COMPLEX ORGANIZATION OF CTF/NF-I, C/EBP, AND HNF3 BINDING SITES WITHIN THE PROMOTER OF THE LIVER-SPECIFIC VITELLOGENIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-DEPENDENT INTERACTION; ESTROGEN-RESPONSIVE ELEMENT; TUMOR VIRUS PROMOTER; XENOPUS-LAEVIS; TRANSCRIPTION FACTORS; INVITRO TRANSCRIPTION; NUCLEAR FACTOR; YOLK PROTEINS; DNA-BINDING; RAT-LIVER	Vitellogenin genes are expressed specifically in the liver of female oviparous vertebrates under the strict control of estrogen. To explain this tissue-specific expression, we performed a detailed analysis of the Xenopus laevis vitellogenin gene B1 promoter by DNase I footprinting and gel mobility-shift assays. We characterized five binding sites for the ubiquitous factor CTF/NF-I. Two of these sites are close to the TATA-box, whereas the others are located on both sides of the estrogen responsive unit formed by two imperfect estrogen response elements. Moreover two liver-enriched factors, C/EBP and HNF3, were found to interact with multiple closely spaced proximal promoter elements in the first 100 base pairs upstream of the TATA-box. To confirm the physiological significance of this in vitro analysis, in vivo DNase I footprinting experiments were carried out using the ligation-mediated polymerase chain reaction technique. The various cis-elements characterized in vitro as binding sites for known transcription factors and more particularly for liver enriched transcription factors are efficiently recognized in vivo as well, suggesting that they play an important role in the control of the liver-specific vitellogenin gene B1 expression.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND	University of Lausanne			Wahli, Walter/I-3194-2019; Cardinaux, Jean-René/G-5391-2012; Wahli, Walter/B-1398-2009	Cardinaux, Jean-René/0000-0001-6423-0014; Wahli, Walter/0000-0002-5966-9089				ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BAKKER O, 1988, MOL CELL BIOL, V8, P4557, DOI 10.1128/MCB.8.10.4557; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DOBBELING U, 1988, EMBO J, V7, P2495, DOI 10.1002/j.1460-2075.1988.tb03096.x; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; DREWES T, 1991, NUCLEIC ACIDS RES, V19, P6383, DOI 10.1093/nar/19.23.6383; GERBERHUBER S, 1987, NUCLEIC ACIDS RES, V15, P4737, DOI 10.1093/nar/15.12.4737; GERMOND JE, 1983, NUCLEIC ACIDS RES, V11, P2979, DOI 10.1093/nar/11.10.2979; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GREELEY MS, 1986, COMP BIOCHEM PHYS B, V84, P1, DOI 10.1016/0305-0491(86)90262-2; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KALING M, 1991, MOL CELL BIOL, V11, P93, DOI 10.1128/MCB.11.1.93; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUGLER W, 1990, NUCLEIC ACIDS RES, V18, P6943, DOI 10.1093/nar/18.23.6943; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MARILLEY D, 1994, MOL CELL ENDOCRINOL, V101, P227, DOI 10.1016/0303-7207(94)90239-9; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PHILIPSEN JNJ, 1988, NUCLEIC ACIDS RES, V16, P9663, DOI 10.1093/nar/16.20.9663; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SALUZ HP, 1988, P NATL ACAD SCI USA, V85, P6697, DOI 10.1073/pnas.85.18.6697; SALUZ HP, 1987, LABORATORY GUIDE GEN; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; SEILERTUYNS A, 1986, NUCLEIC ACIDS RES, V14, P8755, DOI 10.1093/nar/14.22.8755; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WAHLI W, 1979, CELL, V16, P535, DOI 10.1016/0092-8674(79)90028-X; WAHLI W, 1981, SCIENCE, V212, P298, DOI 10.1126/science.7209528; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WAHLI W, 1989, J STEROID BIOCHEM, V34, P17, DOI 10.1016/0022-4731(89)90062-9; WAHLI W, 1982, P NATL ACAD SCI-BIOL, V79, P6832, DOI 10.1073/pnas.79.22.6832; WAHLI W, 1980, CELL, V20, P107, DOI 10.1016/0092-8674(80)90239-1; WALKER P, 1983, EMBO J, V2, P2271, DOI 10.1002/j.1460-2075.1983.tb01734.x; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; XU QL, 1992, MECH DEVELOP, V38, P69, DOI 10.1016/0925-4773(92)90039-M; YOUNG D, 1983, MOL CELL BIOL, V3, P720, DOI 10.1128/MCB.3.4.720	67	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32947	32956						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806524				2022-12-25	WOS:A1994QA63800037
J	DOURSZIMMERMANN, MT; ZIMMERMANN, DR				DOURSZIMMERMANN, MT; ZIMMERMANN, DR			A NOVEL GLYCOSAMINOGLYCAN ATTACHMENT DOMAIN IDENTIFIED IN 2 ALTERNATIVE SPLICE VARIANTS OF HUMAN VERSICAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR-BETA-1; LARGE AGGREGATING PROTEOGLYCAN; CORE PROTEIN; PG-M; GENE-EXPRESSION; CARTILAGE; AGGRECAN; CLONING; MATRIX	We have cloned an alternatively spliced glycosaminoglycan attachment domain (GAG-alpha) of human versican from cDNA libraries derived from U251MG glioma cells, Inserted carboxyl-terminal of the hyaluronan-binding region, this domain adds another 987 amino acids to the original versican (V1) core protein giving rise to the large V0 isoform with 3396 amino acids and 17-23 putative glycosaminoglycan attachment sites, The GAG-alpha domain is encoded by exon 7 of the human versican gene (Naso ct al., J, Biol, Chem,, 32999-33008), Sequence comparisons revealed a slight similarity to the alternative splice domain of PG-M, further supporting the notion that PG-M is the chicken homologue of versican, On immunoblots of a proteoglycan preparation from U251MG culture medium, anti-GAG-alpha antibodies reacted exclusively with the larger of two versican core proteins recognized by antibodies against the original GAG-beta domain, Using reverse transcription-polymerase chain reaction, we detected both the V0 and V1 isoforms in the cerebral cortex, aorta, intervertebral disc, liver, myometrium, and prostate, whereas keratinocytes exclusively expressed versican V1, In brain tissue, we identified a short versican variant (V2) including only the GAG-alpha domain, By expressing particular splice forms of versican, cells may control the hydration properties of their pericellular hyaluronan coat and thus could modulate interactions with the extracellular matrix or neighboring cells.	UNIV ZURICH,INST CLIN PATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich								BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FULOP C, 1993, J BIOL CHEM, V268, P17377; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; Heinegard Dick, 1993, P189; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; NASO MF, 1994, J BIOL CHEM, V269, P32999; PERIDES G, 1992, J BIOL CHEM, V267, P23883; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P389; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	32	191	201	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32992	32998						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806529				2022-12-25	WOS:A1994QA63800043
J	DARMON, AJ; EHRMAN, N; CAPUTO, A; FUJINAGA, J; BLEACKLEY, RC				DARMON, AJ; EHRMAN, N; CAPUTO, A; FUJINAGA, J; BLEACKLEY, RC			THE CYTOTOXIC T-CELL PROTEINASE GRANZYME-B DOES NOT ACTIVATE INTERLEUKIN-1-BETA-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TOXIC LYMPHOCYTES-T; SERINE PROTEASES; MOLECULAR-CLONING; CONVERTING ENZYME; APOPTOSIS; CYTOLYSIS; SUBSTRATE; GRANULES; GENES; ACID	Murine granzyme B (cytotoxic cell proteinase-1 (CCP1)) is a member of a family of seven serine proteases found in cytoplasmic granules of cytotoxic T lymphocytes (CTLs). Evidence has suggested that it is involved in target cell DNA fragmentation during CTL-mediated cytotoxicity, although intracellular substrates for granzyme B have not yet been identified. The substrate specificity of granzyme B, requiring an aspartic acid residue at site P1, is unique among eukaryotic serine proteases and is shared with only one other known eukaryotic protease, interleukin-1 beta-converting enzyme (ICE). ICE is responsible for processing pro-interleukin-1 beta to produce biologically active interleukin-1 beta and is itself synthesized as an inactive precursor. Recent evidence has suggested a role for ICE in programmed cell death, which led to a model for CTL-mediated cytotoxicity. In this proposal granzyme B activates ICE in the target cell by proteolytically processing the ICE precursor, resulting in active ICE heterodimer that induces apoptosis in the target cell. We have isolated the cDNA encoding murine ICE and generated in vitro translated ICE precursor. Using lysates from COS cells expressing granzyme B we show that ICE precursor is not a substrate for granzyme B and propose an alternate mechanism for CTL-mediated cytotoxicity.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,AB,CANADA	University of Alberta								BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAY R, 1991, Methods in Molecular and Cellular Biology, V2, P254; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NETT MA, 1992, J IMMUNOL, V149, P3254; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	27	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32043	32046						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798197				2022-12-25	WOS:A1994PX30400006
J	DING, Y; CASEY, JR; KOPITO, RR				DING, Y; CASEY, JR; KOPITO, RR			THE MAJOR KIDNEY AE1 ISOFORM DOES NOT BIND ANKYRIN (ANK1) IN-VITRO - AN ESSENTIAL ROLE FOR THE 79 NH2-TERMINAL AMINO-ACID-RESIDUES OF BAND-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE ANION-EXCHANGER; CYTOPLASMIC DOMAIN; INTERCALATED CELLS; COLLECTING DUCT; RAT-KIDNEY; MEMBRANE-CYTOSKELETON; TRANSPORT PROTEIN; EPITHELIAL-CELLS; SPECTRIN; LOCALIZATION	The AE1 (band 3) protein mediates the exchange of anions across the erythrocyte plasma membrane and, via association with the adapter molecule, ankyrin (Ank1), forms the major link between the membrane and the underlying spectrin cytoskeleton. The major kidney isoform of AE1 (kAE1), a protein that is otherwise identical to erythroid AE1 but lacks the NH2-terminal 79 amino acids, is localized to the basolateral plasma membrane of acid-secreting (alpha-type) intercalated cells of distal nephron. It has been proposed that this polarized distribution of kAE1 is due, at least in part, to its association with the ankyrin-spectrin cytoskeleton. In this study, we have used cell-free binding assays to investigate the interaction of anion exchangers with an Ank1 fragment, R13-H, that contains the AE1 binding site. Microsomes from cells expressing full-length erythroid AE1 bound I-125-labeled R13-H, revealing the presence of both high (K-d = 12.5 nM) and low (K-d = 166 nM) affinity sites. This binding was specific, as evidenced by the failure to observe high affinity binding of I-125-R13-H to microsomes from cells transfected with vector alone or with AE1m, a mutant lacking the similar to 400 amino acid NH2-terminal cytoplasmic ankyrin binding domain, Using this assay, we could detect no high affinity association between kAE1 and I-125-R13-H. We conclude that the NH2-terminal 79 amino acids play an essential role in high affinity and specific binding of AE1 to Ank1.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056	NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BECKER PS, 1985, CLIN HAEMATOL, V14, P15; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CASEY JR, 1991, J BIOL CHEM, V266, P15726; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DRENCKHAHN D, 1993, RENAL PHYSIOL BIOCH, V16, P6; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; DRENCKHAHN D, 1987, AM J PHYSIOL, V252, pC570, DOI 10.1152/ajpcell.1987.252.5.C570; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1985, ANNU REV PHYSIOL, V47, P519; KOPITO RR, 1987, P NATL ACAD SCI USA, V84, P7149, DOI 10.1073/pnas.84.20.7149; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1988, CELL PHYSL BLOOD, P151; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LOW PS, 1989, ANION TRANSPORT PROT, P103; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MORGANS CW, 1993, J CELL SCI, V105, P1137; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OGEL ZB, 1992, PROTEIN ENG, V5, P467, DOI 10.1093/protein/5.5.467; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	49	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32201	32208						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798219				2022-12-25	WOS:A1994PX30400031
J	JANMEY, PA; HVIDT, S; KAS, J; LERCHE, D; MAGGS, A; SACKMANN, E; SCHLIWA, M; STOSSEL, TP				JANMEY, PA; HVIDT, S; KAS, J; LERCHE, D; MAGGS, A; SACKMANN, E; SCHLIWA, M; STOSSEL, TP			THE MECHANICAL-PROPERTIES OF ACTIN GELS - ELASTIC-MODULUS AND FILAMENT MOTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUASIELASTIC LIGHT-SCATTERING; F-ACTIN; BINDING PROTEIN; NUCLEOTIDE EXCHANGE; POLYMERIZED ACTIN; ALPHA-ACTININ; NETWORKS; LENGTH; MACROPHAGES; MOBILITY	To address large discrepancies reported in the literature, the viscoelastic properties of gels formed by purified actin filaments have been measured by five different techniques and five different instruments using actin preparations purified separately in four different laboratories, These measurements consistently showed that the elastic shear modulus of 2 mg/ml F-actin is on the order of several hundred pascals, and depends very strongly on the length of the filaments and on the history of the sample prior to measurement. Shortening of actin filaments with gelsolin and mechanical perturbations reduce the shear modulus to low values identical to some reported in the literature, indicating that such perturbations account for low shear moduli and poor responsiveness to filament modifying treatments reported previously, The structures of individual actin filaments within gels very similar or identical to those studied rheometrically were also examined by dynamic light scattering and fluorescence microscopy. Dynamic light scattering data were analyzed by a new method to confirm that actin filaments have no stable associations with each other and fluctuate in solution at a rate governed by the filament bending modulus or persistence length, determined to be approximately 10 mu m. Fluorescence microscopy confirmed that applying even small shear stresses to F-actin can orient and rupture the filaments, and that in a minimally perturbed viscoelastic gel, long actin filaments are free to diffuse within a limit of constraints formed by their neighbors, These findings confirm that relatively isotropic F-actin networks are sufficiently strong to stabilize cells.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOMED & BIOL SCI, BOSTON, MA 02115 USA; ROSKILDE UNIV CTR, DEPT CHEM, DK-4000 ROSKILDE, DENMARK; HUMBOLDT UNIV BERLIN, FAK MED CHARITE, INST MED PHYS & BIOPHYS, O-1040 BERLIN, GERMANY; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEORET GRP, PARIS 06, FRANCE; TECH UNIV MUNICH, DEPT PHYS, D-85748 GARCHING, GERMANY; UNIV MUNICH, INST ZELLBIOL, D-80336 MUNICH 2, GERMANY	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Roskilde University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Technical University of Munich; University of Munich	JANMEY, PA (corresponding author), BRIGHAM & WOMENS HOSP, DIV EXPTL MED, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.			Kas, Josef A./0000-0003-3158-2480; Hvidt, Soren/0000-0002-7315-3089	NHLBI NIH HHS [HL07680, HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almdal K., 1993, POLYM GELS NETW, V1, P5, DOI [10.1016/0966-7822(93)90020-I, DOI 10.1016/0966-7822(93)90020-I]; BALE MD, 1988, THROMB RES, V52, P565, DOI 10.1016/0049-3848(88)90129-6; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; Brown W., 1993, DYNAMIC LIGHT SCATTE, P272; BURLACU S, 1992, AM J PHYSIOL, pC569; BUXBAUM RE, 1987, SCIENCE, V235, P1511, DOI 10.1126/science.2881354; CASELLA JF, 1993, CYTOSKELETON CELL FU, P44; COPPIN CM, 1992, BIOPHYS J, V63, P794, DOI 10.1016/S0006-3495(92)81647-8; CORTESE JD, 1988, J CELL BIOL, V107, P1477, DOI 10.1083/jcb.107.4.1477; DEGENNES PG, 1976, MACROMOLECULES, V9, P587, DOI 10.1021/ma60052a011; Doi M., 1986, THEORY POLYM DYNAMIC, V1st ed.; ELSON EL, 1988, ANNU REV BIOPHYS BIO, V17, P397; EVANS E, 1993, J CELL BIOL, V122, P1295, DOI 10.1083/jcb.122.6.1295; FARGE E, 1993, MACROMOLECULES, V26, P5041, DOI 10.1021/ma00071a009; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FERRY JD, 1983, ANN NY ACAD SCI, V408, P1, DOI 10.1111/j.1749-6632.1983.tb23229.x; FUJIME S, 1971, J MOL BIOL, V62, P251, DOI 10.1016/0022-2836(71)90144-6; FURUKAWA R, 1993, BIOCHEMISTRY-US, V32, P12346, DOI 10.1021/bi00097a010; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HASKELL J, 1994, BIOPHYS J, V66, pA196; HVIDT S, 1990, PHYSICAL NETWORKS PO, P195; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1985, BIOCHIM BIOPHYS ACTA, V841, P151, DOI 10.1016/0304-4165(85)90016-9; JANMEY PA, 1990, NATURE, V345, P89, DOI 10.1038/345089a0; JANMEY PA, 1986, J BIOL CHEM, V261, P8357; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; Janmey PA, 1991, CURR OPIN CELL BIOL, V3, P4, DOI 10.1016/0955-0674(91)90159-V; KAS J, 1994, NATURE, V368, P226, DOI 10.1038/368226a0; KAS J, 1993, EUROPHYS LETT, V21, P865, DOI 10.1209/0295-5075/21/8/012; KERST A, 1990, P NATL ACAD SCI USA, V87, P4241, DOI 10.1073/pnas.87.11.4241; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LARCHE D, 1993, J PHYS III, V3, P1283; LUBYPHELPS K, 1993, CURR OPIN CELL BIOL, V6, P3; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MIYAMOTO S, 1993, BIOPHYS J, V64, P1139, DOI 10.1016/S0006-3495(93)81480-2; MULLER O, 1991, MACROMOLECULES, V24, P3111; NEWMAN J, 1993, BIOPHYS J, V64, P1559, DOI 10.1016/S0006-3495(93)81525-X; NIEDERMAN R, 1983, J CELL BIOL, V96, P1400, DOI 10.1083/jcb.96.5.1400; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; OTT A, 1993, PHYS REV E, V48, pR1642, DOI 10.1103/PhysRevE.48.R1642; PACAUD M, 1987, EUR J BIOCHEM, V165, P139, DOI 10.1111/j.1432-1033.1987.tb11204.x; PACAUD M, 1987, J CELL SCI, V88, P81; PIEKENBROCK T, 1992, BIOPOLYMERS, V32, P1471, DOI 10.1002/bip.360321107; PIEKENBROCK T, 1991, AIP CONF PROC, V226, P282; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; Ruddies R., 1993, Biochemical Society Transactions, V21, p37S; SACKMANN E, 1994, MACROMOL CHEM PHYSIC, V195, P7, DOI 10.1002/macp.1994.021950103; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; SATO M, 1985, J BIOL CHEM, V260, P8585; SCHMIDT CF, 1989, MACROMOLECULES, V22, P3638, DOI 10.1021/ma00199a023; SIMON SI, 1990, J BIOMECH ENG-T ASME, V112, P303, DOI 10.1115/1.2891188; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUZUKI A, 1991, BIOPHYS J, V59, P25, DOI 10.1016/S0006-3495(91)82194-4; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WEGNER A, 1988, J BIOL CHEM, V263, P13739; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; ZANER KS, 1986, J BIOL CHEM, V261, P7615; ZANER KS, 1988, J BIOL CHEM, V263, P4532; ZIEMANN F, 1994, BIOPHYS J, V66, P2210, DOI 10.1016/S0006-3495(94)81017-3	68	223	225	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32503	32513						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798252				2022-12-25	WOS:A1994PX30400073
J	KOJIMA, R; FUJIMORI, T; KIYOTA, N; TORIYA, Y; FUKUDA, T; OHASHI, T; SATO, T; YOSHIZAWA, Y; TAKEYAMA, K; MANO, H; MASUSHIGE, S; KATO, S				KOJIMA, R; FUJIMORI, T; KIYOTA, N; TORIYA, Y; FUKUDA, T; OHASHI, T; SATO, T; YOSHIZAWA, Y; TAKEYAMA, K; MANO, H; MASUSHIGE, S; KATO, S			IN-VIVO ISOMERIZATION OF RETINOIC ACIDS - RAPID ISOMER EXCHANGE AND GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; BINDING-PROTEIN; THYROID-HORMONE; X-RECEPTORS; ALL-TRANS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; MESSENGER-RNA; VITAMIN-D; II GENE	The in vivo isomerization of all-trans- and 9-cis-retinoic acids (RAs) was evaluated by high performance Liquid chromatography after oral administration to rats. Ah-trans (2 ng/ml)- and 13-cis (1.8 ng/ml)-RAs, but not 9-cis-RA, were detected in the serum of normal rats. When an excess of either ah-trans-HA or 9-cis-RA (100 mu g/rat) was intragastrically administered to the retinoid-depleted rats, a rapid isomer exchange between 9-cis- and all-trans-RAs along with appearance of the administered RA occurred shortly after the dose (30 min). RA rapidly isomerized when an excess of either all-trans- or 9-cis-RA (1 mg/rat) was administered to normal rats. To examine whether the isomerized RAs elicit biological actions in vivo, the induction of target genes-[cellular retinol-binding protein type II (CRBP II) for 9-cis-RA and all-trans-retinoic acid receptor beta (RAR beta) for 9-cis- and all-trans-RAs] was determined. The degree of induction of the two genes did not differ 4 h after administration of either 9-cis-RA or all-trans-Rk However, unlike all-trans-RA, the RAR-specific synthetic retinoids did not induce the CRBP II gene. These results suggested that the apparent actions of 9-cis- and all-trans-RAs on gene expression in vivo may be mediated to some extent by the converted stereoisomer.	TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN	Tokyo University of Agriculture								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLUM ME, 1985, J BIOL CHEM, V260, P590; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3828; HASHIMOTO Y, 1991, CELL STRUCT FUNCT, V16, P113, DOI 10.1247/csf.16.113; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KTO S, 1994, J NUTR SCI VITAMINOL, V39, P545; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIVREA MA, 1993, RETINOIDS; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MANO H, 1994, J BIOL CHEM, V269, P1591; MATSUURA T, 1993, ARCH BIOCHEM BIOPHYS, V301, P221, DOI 10.1006/abbi.1993.1137; NINOMIYA Y, 1992, BIOCHEM BIOPH RES CO, V187, P1374, DOI 10.1016/0006-291X(92)90454-S; OLSON JA, 1992, J NUTR, V122, P615, DOI 10.1093/jn/122.suppl_3.615; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; TANG GW, 1990, J LIPID RES, V31, P175; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WOLF G, 1992, NUTR REV, V50, P197, DOI 10.1111/j.1753-4887.1992.tb01325.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	53	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32700	32707						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798278				2022-12-25	WOS:A1994PX30400101
J	LUO, GX; HOROWITZ, PM				LUO, GX; HOROWITZ, PM			THE STABILITY OF THE MOLECULAR CHAPERONIN CPN60 IS AFFECTED BY SITE-DIRECTED REPLACEMENT OF CYSTEINE-518	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GROEL; RHODANESE; PROTEINS; ATP; PURIFICATION; CARBOXYLASE; POLYMERASE; DNA	Cysteine 518 of the molecular chaperonin cpn60 (groEL) has been replaced with serine (C518S) by site directed mutagenesis. The resulting mutant chaperonin protein is still functional and it can: (a) arrest the spontaneous folding of rhodanese in the absence of GroES and ATP, (b) assist refolding of the enzyme rhodanese in the presence of GroES and ATP/Mg2+, and (c) permit the urea-induced release and refolding of rhodanese from its complex with cpn60, ATP/Mg2+, alone, could discharge active rhodanese from cpn60 complexes formed with either wild type or C518S, In contrast with wild type cpn60, C518S has: (a) reduced stability of its quaternary structure, (b) reduced ability to reassemble tetradecamers after dissociation by urea; (c) reduced ATPase activity; and (d) more easily exposed hydrophobic surfaces, The data suggest that replacement of Cys-518 with Ser in cpn60 destabilizes its oligomeric structure, but there is no significant effect on cpn60 function or the stability of the monomers formed in urea.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROVITZ A, 1994, J MOL BIOL, V238, P133, DOI 10.1006/jmbi.1994.1275; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32151	32154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798211				2022-12-25	WOS:A1994PX30400023
J	MCCANCE, SG; MENHART, N; CASTELLINO, FJ				MCCANCE, SG; MENHART, N; CASTELLINO, FJ			AMINO-ACID-RESIDUES OF THE KRINGLE-4 AND KRINGLE-5 DOMAINS OF HUMAN PLASMINOGEN THAT STABILIZE THEIR INTERACTIONS WITH OMEGA-AMINO ACID LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; RECOMBINANT KRINGLE-1; H-1-NMR SPECTROSCOPY; ACTIVATOR; FIBRIN; PURIFICATION; FRAGMENTS; REGIONS; COMPLEX	Regions of the human plasminogen (Pg) cDNA containing its kringle 4 (K4) and K5 domains have been expressed in Escherichia coli, and binding constants of omega-amino acid ligands for recombinant (r)-[R4(Pg)] and r-[K5(Pg)] have been obtained. In each case, the results showed that of a series of aliphatic alpha,omega-amino acid analogues, g-aminohexanoic acid showed maximal affinity for these modules, and all ligands interacted more strongly with r-[K4(Pg)] than with r-[K5(Pg)]. Site-directed mutagenesis investigations demonstrated that the major amino acid side chain contributors to ligand binding were similar for each of these kringles. Ligand binding was stabilized by charged groups at Asp(56) of r-[K4(Pg)] and Asp(57) of r-[K5(Pg)] as well as by Arg(69) Of both r-[K4(Pg)] and r-[K5(Pg)]. Some hydrophobic amino acids that contributed significantly to the binding strength of the ligands were identified. These were provided by homologous residues in each of the domains, viz. Trp(60) and Trp(70) of r-[K4(Pg)] and Trp(62) and Tyr(72) of r-[K5(Pg)]. Tyr(74) of r-[K5(Pg)] also substantially contributed to its ligand binding energy,	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R37HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BYEON IJL, 1989, BIOCHEMISTRY-US, V28, P9350, DOI 10.1021/bi00450a016; BYEON IJL, 1991, EUR J BIOCHEM, V197, P155, DOI 10.1111/j.1432-1033.1991.tb15894.x; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DEMARCO A, 1987, EUR BIOPHYS J BIOPHY, V14, P359, DOI 10.1007/BF00262321; DEMARCO A, 1989, BIOCHIM BIOPHYS ACTA, V994, P121, DOI 10.1016/0167-4838(89)90151-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DESERRANO VS, 1994, BIOCHEMISTRY-US, V33, P3509, DOI 10.1021/bi00178a007; DESERRANO VS, 1993, BIOCHEMISTRY-US, V32, P3540, DOI 10.1021/bi00065a004; DESERRANO VS, 1992, ARCH BIOCHEM BIOPHYS, V292, P206, DOI 10.1016/0003-9861(92)90069-9; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P11698, DOI 10.1021/bi00162a005; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; HOCHSCHWENDER SM, 1981, J BIOL CHEM, V256, P1172; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; NIELSEN PR, 1993, BIOCHEMISTRY-US, V32, P13019, DOI 10.1021/bi00211a010; NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6; PETROS AM, 1989, BIOCHEMISTRY-US, V28, P1368, DOI 10.1021/bi00429a064; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; THEWES T, 1990, J BIOL CHEM, V265, P3906; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TREXLER M, 1982, J BIOL CHEM, V257, P7401; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; URANO T, 1987, J BIOL CHEM, V262, P15959; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030	33	50	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32405	32410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798240				2022-12-25	WOS:A1994PX30400059
J	TAM, LY; LOO, TW; CLARKE, DM; REITHMEIER, RAF				TAM, LY; LOO, TW; CLARKE, DM; REITHMEIER, RAF			IDENTIFICATION OF AN INTERNAL TOPOGENIC SIGNAL SEQUENCE IN HUMAN BAND-3, THE ERYTHROCYTE ANION-EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE-PROTEIN TOPOLOGY; ENDOPLASMIC-RETICULUM; TRANSPORT PROTEIN; MICROSOMAL-MEMBRANES; RECOGNITION PARTICLE; ALKALINE-PHOSPHATASE; GLUCOSE TRANSPORTER; XENOPUS-LAEVIS; BETA-LACTAMASE	The insertion of Band 3, the human erythrocyte anion exchanger, into microsomal membranes was studied in an in vitro reticulocyte lysate translation system. Band 3 consists of a 43-kDa amino-terminal cytosolic domain and a carboxyl-terminal 52-kDa membrane domain containing up to 14 transmembrane segments with a single N-glycosylation site at Asn-642. Insertion of truncated Band 3 molecules into microsomal membranes was assayed by glycosylation, resistance to alkaline extraction, and tryptic removal of the cytosolic domain. Truncations containing either the first four or the last eight putative transmembrane segments were stably integrated into microsomes showing that an intact membrane domain was not required for membrane integration. Furthermore, the extracytosolic domain following the seventh transmembrane segment was properly translocated across the microsomal membrane and glycosylated whether the seventh transmembrane segment was the first, last, or the only transmembrane segment in the construct. The ability of the entire membrane domain, the truncated domain beginning with the seventh transmembrane segment, or the seventh transmembrane segment to insert into microsomes was dependent on the presence of the signal recognition particle receptor. The seventh transmembrane segment in Band 3 therefore has the topogenic properties of an internal signal sequence.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA	University of Toronto	TAM, LY (corresponding author), UNIV TORONTO, DEPT MED, MRC, MEMBRANE BIOL GRP, TORONTO M5S 1A8, ON, CANADA.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRAELL WA, 1982, CELL, V28, P23, DOI 10.1016/0092-8674(82)90371-3; BRAELL WA, 1981, J BIOL CHEM, V256, P1337; BROCK CJ, 1983, BIOCHEM J, V213, P577, DOI 10.1042/bj2130577; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CASEY JR, 1993, BIOCHEMISTRY-US, V32, P1172, DOI 10.1021/bi00055a023; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1982, NATURE, V318, P338; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GOMEZ S, 1993, J BIOL CHEM, V268, P19593; GROVES JD, 1992, J BIOL CHEM, V267, P22163; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JAROLIM P, 1994, J CLIN INVEST, V93, P121, DOI 10.1172/JCI116935; JAY DG, 1986, BIOCHEMISTRY-US, V25, P554, DOI 10.1021/bi00351a006; JENNINGS ML, 1992, KIDNEY PHYSL PATHOPH; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIEBERMAN DM, 1988, J BIOL CHEM, V263, P10022; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1986, NATURE, V322, P549, DOI 10.1038/322549a0; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARBAN E, 1981, J CELL BIOL, V91, P637; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	66	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32542	32550						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798256				2022-12-25	WOS:A1994PX30400078
J	AUTHIER, F; MORT, JS; BELL, AW; POSNER, BI; BERGERON, JJM				AUTHIER, F; MORT, JS; BELL, AW; POSNER, BI; BERGERON, JJM			PROTEOLYSIS OF GLUCAGON WITHIN HEPATIC ENDOSOMES BY MEMBRANE-ASSOCIATED CATHEPSIN-B AND CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ISOLATED CANINE HEPATOCYTES; RAT PROCATHEPSIN-B; MACROPHAGE ENDOSOMES; LYSOSOMAL-ENZYMES; MICROSOMAL-MEMBRANES; LIVER ENDOSOMES; RECEPTOR KINASE; HEPG2 CELLS; INSULIN	The acidic glucagon-degrading activity of hepatic endosomes has been attributed to membrane-bound forms of cathepsins B and D. Endosomal lysates processed full-length nonradiolabeled glucagon to 32 different peptides that were identified by amino acid analysis and full-length sequencing, These indicated C-terminal carboxypeptidase, endopeptidase as well as N-terminal tripeptidyl-aminopeptidase activities in endosomes. Glucagon proteolysis was inhibited 95% by E-64 and pepstatin A, inhibitors of cathepsins B and D, respectively. This was confirmed by the pH 6-dependent chemical cross-linking of [I-125]iodoglucagon to a polypeptide of 30 kDa, which was immunodepleted by polyclonal anti cathepsin B antibody, and the removal of greater than 80% of glucagon-degrading activity by polyclonal antibodies to cathepsins B and D, By similar criteria, insulin-degrading enzyme was ruled out as a candidate enzyme for endosomal proteolysis of glucagon. Lysosomal contamination was unlikely since all forms of cathepsin B in endosomes, i.e. the major 45-kDa inactive precursor as well as the lesser amounts of the 32- and 28-kDa active forms, were tightly bound to endosomal membranes. Furthermore the mature 29-kDa single-chain and 22-kDa heavy-chain forms of cathepsin L were undetectable in endosomes, although high levels of the 37-kDa preform were observed. Membrane association of the cathepsins B and D was not to the mannose g-phosphate receptor since association was unaffected by mannose B-phosphate and/or EDTA, thereby indicating a distinct endosomal receptor. Hence, a pool of active cathepsins B and D as well as a poorly defined tripeptidyl aminopeptidase is maintained in endosomes by selective membrane retention. These hydrolases degrade glucagon internalized into Liver parenchyma early in endocytosis.	MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,SHELDON BIOTECHNOL CTR,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL,PQ H3G 1A6,CANADA	McGill University; McGill University; McGill University; McGill University	AUTHIER, F (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U30,F-75015 PARIS,FRANCE.		Bergeron, John/AAW-1893-2021; Posner, Barry/B-6733-2008					AFTING EG, 1981, BIOCHEM J, V197, P519, DOI 10.1042/bj1970519; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; AUTHIER F, 1990, BIOCHEM J, V272, P703, DOI 10.1042/bj2720703; AUTHIER F, 1991, BIOCHEM J, V280, P211, DOI 10.1042/bj2800211; AUTHIER F, 1992, ENDOCRINOLOGY, V131, P447, DOI 10.1210/en.131.1.447; AUTHIER F, 1994, CELLULAR PROTEOLYTIC, V15, P89; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BLACHE P, 1990, J BIOL CHEM, V265, P21514; Blum J S, 1993, Subcell Biochem, V19, P69; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUCKWORTH WC, 1974, DIABETES, V23, P536, DOI 10.2337/diab.23.6.536; FIANI ML, 1993, ARCH BIOCHEM BIOPHYS, V307, P225, DOI 10.1006/abbi.1993.1583; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAGOPIAN WA, 1987, J CLIN INVEST, V79, P409, DOI 10.1172/JCI112827; HAGOPIAN WA, 1984, J BIOL CHEM, V259, P8986; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; JASPAN LJ, 1981, AM J PHYSIOL, V240, P233; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUO WL, 1994, J BIOL CHEM, V269, P22599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATRISIAN LM, 1984, J BIOL CHEM, V259, P3047; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; OU WJ, 1992, J BIOL CHEM, V267, P23789; PLANCK SR, 1984, J BIOL CHEM, V259, P3053; POLGAR L, 1987, J BIOL CHEM, V262, P14448; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; RODMAN JS, 1990, J LEUKOCYTE BIOL, V48, P116, DOI 10.1002/jlb.48.2.116; ROSE K, 1988, BIOCHEM J, V256, P847, DOI 10.1042/bj2560847; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SHEETZ MJ, 1988, J BIOL CHEM, V263, P8509; SHEETZ MJ, 1988, J BIOL CHEM, V263, P19210; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILEY HS, 1985, J BIOL CHEM, V260, P5290	59	76	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15798	15807		10.1074/jbc.270.26.15798	http://dx.doi.org/10.1074/jbc.270.26.15798			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797582	hybrid			2022-12-25	WOS:A1995RG53800055
J	LAKIN, ND; MORRIS, PJ; THEIL, T; SATO, TN; MOROY, T; WILSON, MC; LATCHMAN, DS				LAKIN, ND; MORRIS, PJ; THEIL, T; SATO, TN; MOROY, T; WILSON, MC; LATCHMAN, DS			REGULATION OF NEURITE OUTGROWTH AND SNAP-25 GENE-EXPRESSION BY THE BRN-3A TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN PROTEIN; ANTISENSE OLIGONUCLEOTIDES; NEURONAL CELLS; RNASE-H; I-POU; DIFFERENTIATION; HOMEODOMAIN; REDISTRIBUTION; SECRETION; DISTINCT	SNAP-25 is a presynaptic nerve terminal protein which is also essential for the process of neurite outgrowth in vivo and in vitro. However the processes regulating its expression have not been characterized previously. We show that the gene encoding this protein, SNAP, is strongly activated by the Brn-3a POU (Pit-Oct-Unc) family transcription factor. Expression of both Brn-3a and SNAP-25 increases when ND7 neuronal cells are induced to extend neurite processes by serum removal. Inhibition of Brn-3a expression in these cells inhibits SNAP-25 expression and abolishes the neurite outgrowth that normally occurs in response to serum removal. These results identify Brn-3a as the first transcription factor having a role in process outgrowth in neuronal cells acting, at least in part, via the activation of SNAP-25 gene expression.	UNIV COLL & MIDDLESEX SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	University of London; University College London; Philipps University Marburg; Scripps Research Institute			Moroy, Tarik/D-9923-2011	Theil, Thomas/0000-0001-6590-8309	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048989] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 48989] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAMILLI P, 1993, NATURE, V364, P387; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DHILLON VB, 1993, ANN RHEUM DIS, V52, P436, DOI 10.1136/ard.52.6.436; FALKNER FG, 1986, NUCLEIC ACIDS RES, V13, P7847; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HESS EJ, 1992, J NEUROSCI, V12, P2865; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WHEATLEY SC, 1992, NEUROSCIENCE, V51, P575, DOI 10.1016/0306-4522(92)90297-F; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; [No title captured]	38	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15858	15863		10.1074/jbc.270.26.15858	http://dx.doi.org/10.1074/jbc.270.26.15858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797590	hybrid			2022-12-25	WOS:A1995RG53800064
J	LI, QT; KARAM, SM; GORDON, JI				LI, QT; KARAM, SM; GORDON, JI			SIMIAN-VIRUS-40 T-ANTIGEN-INDUCED AMPLIFICATION OF PRE-PARIETAL CELLS IN TRANSGENIC MICE - EFFECTS ON OTHER GASTRIC EPITHELIAL CELL LINEAGES AND EVIDENCE FOR A P53-INDEPENDENT APOPTOTIC MECHANISM THAT OPERATES IN A COMMITTED PROGENITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-BINDING PROTEIN; GROWTH-FACTOR-ALPHA; MOUSE STOMACH; DUODENAL MUCOSA; BETA-SUBUNIT; CORPUS; DYNAMICS; GENE; TRANSFORMATION; EXPRESSION	Gastric units in the glandular epithelium of the mouse stomach contain several types of continuously renewing epithelial cells. Acid-producing parietal cells are derived from a multipotent stem cell that also gives rise to mucus producing pits cells and pepsinogen- and intrinsic factor-producing zymogenic cells. We used nucleotides -1035 to +24 of the mouse H+/K+-ATPase beta subunit gene (H+/K+-ATPase beta subunit (-1035) (to) (+24)) to examine the consequences of expressing simian virus 40 T antigen (SV 40 TAg) in the normally rare, nonproliferating, short-lived pre-parietal cell progenitor. Light and electron microscopic morphologic studies plus multilabel immunohistochemical analyses of postnatal day (P) 14-80-day transgenic mice revealed that SV 40 TAg produces a 50-70-fold amplification of pre-parietal cells which become the predominant cell type in gastric units. Differentiation to mature parietal cells is blocked, resulting in hypochlorhydria and an associated systemic iron deficiency. SV 40 TAg-induced pre-parietal proliferation is accompanied by apoptosis. Examination of adult transgenic mice homozygous for p53 wild type or p53 null alleles established that the apoptosis occurs through a p53-independent pathway. H+/K+-ATPase beta subunit(-1035) (to) (+24)/SV40 Tag is not expressed during differentiation of the zymogenic lineage. Nonetheless, P28-P80 transgenic mice exhibit an apparent block in the conversion of pre-zymogenic to zymogenic cells. This neck to neck cells and neck to pre-zymogenic cells is not affected. Comparison of normal and transgenic mice that are p53(+/+) or p53(-/-) confirmed that the loss of mature zymogenic cells is not dependent upon p53. Although H+/K+-ATPase beta subunit-(-1035) (to) (+24) is not active in pit cell progenitors or their differentiated descendants, there is a 2-3-fold increase in mature pit cells in transgenic animals. Our findings (i) demonstrate an approach for amplifying and characterizing pre-parietal or other progenitor cell populations in gastric units, (ii) reveal an SV 40 Tag-inducible, p53-independent apoptotic mechanism that operates in a committed epithelial progenitor cell, and (ii) provide a transgenic mouse model for defining factors that may mediate progression through specific points in the differentiation programs of the parietal and zymogenic cell lineages or that may influence decisions about allocation to the pit cell lineage.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; KUWAIT UNIV,FAC MED,DEPT ANAT,SAFAT 13110,KUWAIT	Washington University (WUSTL); Kuwait University					NIDDK NIH HHS [DK33487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CANFIELD VA, 1991, P NATL ACAD SCI USA, V88, P8247, DOI 10.1073/pnas.88.18.8247; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEW CS, 1994, ANNU REV PHYSIOL, V56, P445; COHN SM, 1984, J BIOL CHEM, V259, P2456; CONRAD ME, 1991, GASTROENTEROLOGY, V100, P129, DOI 10.1016/0016-5085(91)90592-9; CONRAD ME, 1987, J LAB CLIN MED, V110, P418; CONRAD ME, 1992, BLOOD, V79, P244, DOI 10.1182/blood.V79.1.244.bloodjournal791244; CONRAD ME, 1990, J BIOL CHEM, V265, P5273; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1995, AM J PHYSIOL-GASTR L, V268, pG553, DOI 10.1152/ajpgi.1995.268.4.G553; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUGLIETTA A, 1994, DIGEST DIS SCI, V49, P177; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HOGAN B, 1986, MANIPULATING MOUSE E; KAKEI N, 1983, BIOCHEM BIOPH RES CO, V197, P310; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1994, AM J PHYSIOL, V266, pG745, DOI 10.1152/ajpgi.1994.266.4.G745; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LEE EY, 1989, GASTROENTEROLOGY, V97, P1171, DOI 10.1016/0016-5085(89)91687-9; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; Luna L.G., 1968, MANUAL HISTOLOGIC ST, P184; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORLEY GP, 1992, J BIOL CHEM, V267, P1165; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; RHODES JA, 1986, P NATL ACAD SCI USA, V83, P3844, DOI 10.1073/pnas.83.11.3844; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; Sambrook J., 1989, MOL CLONING LAB MANU; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHARP R, 1995, DEVELOPMENT, V121, P149; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU W, 1994, P NATL ACAD SCI USA, V91, P3602	51	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15777	15788		10.1074/jbc.270.26.15777	http://dx.doi.org/10.1074/jbc.270.26.15777			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797580	hybrid			2022-12-25	WOS:A1995RG53800053
J	REHLI, M; KRAUSE, SW; KREUTZ, M; ANDREESEN, R				REHLI, M; KRAUSE, SW; KREUTZ, M; ANDREESEN, R			CARBOXYPEPTIDASE-M IS IDENTICAL TO THE MAX.1 ANTIGEN AND ITS EXPRESSION IS ASSOCIATED WITH MONOCYTE TO MACROPHAGE DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND CARBOXYPEPTIDASE; CELL-LINE HL-60; MATURATION; INDUCTION; PROTEINS; ENZYME; 1,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; HETEROGENEITY; SARCOIDOSIS	The two monoclonal antibodies MAX.1 and MAX.11 recognize cell surface antigens that are almost undetectable on monocytes but highly expressed on differentiated macrophages. Biochemical characterization revealed that both antibodies detect the same 58-64-kDa glycoprotein anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. We purified the MAX.1/11 antigen by immunoaffinity chromatography using monoclonal antibody MAX.11. The NH2-terminal amino acid sequence was determined and turned out to be identical to the NH2-terminal sequence of the membrane-bound carboxypeptidase M. By precipitation with antibodies MAX.1 and MAX.11, membrane preparations of macrophages and placental microvilli were almost completely depleted of enzyme activity, indicating that the two antibodies indeed recognize carboxypeptidase M. Immunoreactivity of both antibodies correlates with the reported tissue distribution of enzyme activity. Expression of carboxypeptidase M on mRNA level and enzymatic activity markedly increase during in vitro differentiation of monocytes, according to the described increase in MAX.1 and MAX.11 antigen expression. Moreover, in vitro differentiated macrophages show the highest specific activity yet described in any tissue. In addition, carboxypeptidase M expression could be detected in HL-60, U937, and THP-1 myeloid cell lines. Vitamin D-3-induced monocytic differentiation resulted in an increased carboxypeptidase M expression in all three cell lines. Further studies are needed to elucidate the functional role of carboxypeptidase M during monocytic differentiation and activation.	UNIV REGENSBURG, DEPT HEMATOL & ONCOL, D-93042 REGENSBURG, GERMANY	University of Regensburg			Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Krause, Stefan/0000-0002-5259-4651				ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; ANDREESEN R, 1986, BLOOD, V67, P1257; ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2; ANDREESEN R, 1988, CELL TISSUE RES, V253, P271; ANDREESEN R, 1994, ERNST SCHERING RES F, V11, P9; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; CHODIMELLA V, 1991, AM REV RESPIR DIS, V144, P869, DOI 10.1164/ajrccm/144.4.869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; DESMAZES N, 1992, AM J RESP CELL MOL, V7, P477, DOI 10.1165/ajrcmb/7.5.477; DRAGOVIC T, 1993, AM REV RESPIR DIS, V147, P1491, DOI 10.1164/ajrccm/147.6_Pt_1.1491; GORDON S, 1992, CURR OPIN IMMUNOL, V4, P25, DOI 10.1016/0952-7915(92)90119-Y; KRAUSE SW, 1992, ANN HEMATOL, V64, P190, DOI 10.1007/BF01696222; KREUTZ M, 1990, BLOOD, V76, P2449; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN J, 1989, CLIN LAB MED, V9, P745, DOI 10.1016/S0272-2712(18)30602-4; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MUSSON RA, 1983, AM J PATHOL, V111, P331; NAGAE A, 1993, AM J RESP CELL MOL, V9, P221, DOI 10.1165/ajrcmb/9.2.221; NAGAE A, 1992, J NEUROCHEM, V59, P2201; OLSSON I, 1983, CANCER RES, V43, P5862; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUTHERFORD MS, 1993, J LEUKOCYTE BIOL, V53, P602, DOI 10.1002/jlb.53.5.602; SHAPIRO AL, 1967, BIOCHEM BIOPH RES CO, V126, P155; SKIDGEL RA, 1989, J BIOL CHEM, V264, P2236; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; SKIDGEL RA, 1991, METHODS NEUROSCIENCE, V6, P373; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAN FL, 1989, J BIOL CHEM, V264, P13165; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERSCHOOT CE, 1989, LEUCOCYTE TYPING, V4, P887; VANFURTH R, 1982, IMMUNOBIOLOGY, V161, P178, DOI 10.1016/S0171-2985(82)80072-7; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	41	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15644	15649		10.1074/jbc.270.26.15644	http://dx.doi.org/10.1074/jbc.270.26.15644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797563	hybrid			2022-12-25	WOS:A1995RG53800034
J	KIM, J; KLOOSTER, S; SHAPIRO, DJ				KIM, J; KLOOSTER, S; SHAPIRO, DJ			INTRINSICALLY BENT DNA IN A EUKARYOTIC TRANSCRIPTION FACTOR RECOGNITION SEQUENCE POTENTIATES TRANSCRIPTION ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; RNA-POLYMERASE; ESCHERICHIA-COLI; RESPONSE ELEMENT; KINETOPLAST DNA; PROTEIN; PROMOTER; INVITRO; BINDING; GENE	Many eukaryotic transcription factors induce DNA bending on binding to their recognition sequences. DNA bending could play a structural role by altering contacts between the protein and DNA. Alternatively, DNA bending could play a more direct role in transcription activation. To distinguish between these possibilities, we inserted two to eight copies of the intrinsic bending sequence, AAAAAACGTG, into a minimal promoter containing only a TATA box. The intrinsic DNA bending sequence was a potent activator of transcription in both in vivo transfection experiments and in a cell-free transcription system. A protein binds to the intrinsic bending sequence with high specificity in gel mobility shift assays and was required for its transcription in cell-free extracts, The intercalator, distamycin, which eliminates the ability of the sequence to bend, specifically reduced its transcription by about 60%. Mutations in the sequence which abolished DNA bending reduced transcription by approximately 70% in vivo. Competition gel mobility shift assays showed that the transcription factor bound equally well to mutants in which DNA bending was abolished and to the intrinsic bending sequence. These data indicate that DNA bending can play a direct role in the activation of eukaryotic transcription.	UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DOBBELING U, 1988, EMBO J, V7, P2495, DOI 10.1002/j.1460-2075.1988.tb03096.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KING IN, 1993, J BIOL CHEM, V268, P495; KING IN, J BIOL CHEM, V268, P495; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PEREZMARTIN J, 1993, SCIENCE, V260, P805, DOI 10.1126/science.8387228; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SABBAH M, 1992, BIOCHEM BIOPH RES CO, V185, P944, DOI 10.1016/0006-291X(92)91718-6; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; SHAPIRO DJ, 1988, DNA CELL BIOL, V7, P44; SHATZKYSCHWARTZ M, 1992, BIOCHEMISTRY-US, V31, P2339, DOI 10.1021/bi00123a019; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; WESCHLER DS, 1992, P NATL ACAD SCI USA, V89, P7635; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WONG YC, 1985, CHROMOSOMA, V92, P124, DOI 10.1007/BF00328464; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	60	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1282	1288		10.1074/jbc.270.3.1282	http://dx.doi.org/10.1074/jbc.270.3.1282			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836392	hybrid			2022-12-25	WOS:A1995QB15600047
J	MATTINGLY, JR; IRIARTE, A; MARTINEZCARRION, M				MATTINGLY, JR; IRIARTE, A; MARTINEZCARRION, M			HOMOLOGOUS PROTEINS WITH DIFFERENT AFFINITIES FOR GROEL - THE REFOLDING OF THE ASPARTATE-AMINOTRANSFERASE ISOZYMES AT VARYING TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MITOCHONDRIAL MALATE-DEHYDROGENASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; DIHYDROFOLATE-REDUCTASE; POLYPEPTIDE; COMPLEX; PRECURSOR; INVITRO; CELL	The homologous cytosolic and mitochondrial isozymes of aspartate aminotransferase (c- and mAspAT, respectively) seem to follow very different folding pathways after synthesis in rabbit reticulocyte lysate, suggesting that the nascent proteins interact differently with molecular chaperones (Mattingly, J. R., Jr., Iriarte, A., and Martinez-Carrion, M. (1993) J. Biol. Chem. 268, 26320-26327). In an attempt to discern the structural basis for this phenomenon, we have begun to study the effect of temperature on the refolding of the guanidine hydrochloride-denatured, purified proteins and their interaction with the groEL/groES molecular chaperone system for Escherichia coli. In the absence of chaperones, temperature has a critical effect on the refolding of the two isozymes, with mAspAT being more susceptible than cAspAT to diminishing refolding yields at increasing temperatures. No refolding is observed for mAspAT at physiological temperatures. The molecular chaperons groEL and groES can extend the temperature range over which the AspAT isozymes successfully refold; however, cAspAT can still refold at higher temperatures than mAspAT. In the absence of groES and MgATP, the two isozymes interact differently with groEL. groEL arrests the refolding of mAspAT throughout the temperature range of 0-45 degrees C. Adding only MgATP releases very little mAspAT from groEL; both groES and MgATP are required for significant refolding of mAspAT in the presence of groEL. On the other hand, the extent to which groEL inhibits the refolding of cAspAT depends upon the temperature of the refolding reaction, only slowing the reaction at 0 degrees C but arresting it completely at 30 degrees C. MgATP alone is sufficient to effect the release of cAspAT from groEL at any temperature examined; inclusion of groES along with MgATP has no effect on the refolding yield bu does increase the refolding rate at temperatures greater than 15 degrees C. These results demonstrate that groEL can have significantly different affinities for proteins highly homologous final tertiary and quarternary structures and suggest that dissimilarities in the primary sequence of the protein substrates may control the structure of the folding intermediates captured by groEL and/or the composition of the surfaces through which the folding proteins interact with groEL.	UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA	University of Missouri System; University of Missouri Kansas City					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROV N, 1993, PROTEIN SCI, V2, P1989, DOI 10.1002/pro.5560021121; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HARTMANN C, 1991, NATURE, V352, P762, DOI 10.1038/352762b0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HUYNH QK, 1980, J BIOCHEM, V88, P231; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P107; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KUBO T, 1993, J BIOL CHEM, V268, P19346; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MENDOZA JA, 1992, J PROTEIN CHEM, V11, P589, DOI 10.1007/BF01024958; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; REYES AM, 1993, J BIOL CHEM, V268, P22281; RICHARME G, 1994, J BIOL CHEM, V269, P7095; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522; YANG YR, 1993, P NATL ACAD SCI USA, V90, P11980, DOI 10.1073/pnas.90.24.11980; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	59	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1138	1148		10.1074/jbc.270.3.1138	http://dx.doi.org/10.1074/jbc.270.3.1138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836372	hybrid			2022-12-25	WOS:A1995QB15600027
J	PAP, EHW; VANDENBERG, PAW; BORST, JW; VISSER, AJWG				PAP, EHW; VANDENBERG, PAW; BORST, JW; VISSER, AJWG			THE INTERACTION BETWEEN PROTEIN-KINASE-C AND LIPID COFACTORS STUDIED BY SIMULTANEOUS OBSERVATION OF LIPID AND PROTEIN FLUORESCENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; MIXED MICELLES; RAT-BRAIN; PHOSPHOLIPID-VESICLES; SIGNAL TRANSDUCTION; HYDROPHOBIC REGION; LATERAL DIFFUSION; ENERGY-TRANSFER; ACTIVATION; DIACYLGLYCEROL	The interaction of protein kinase C (PKC) with lipids was probed by a dual approach. Pyrene-labeled lipid analogues of diacylglycerol, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylinositol 4-phosphate (PIP), and phosphatidylcholine (PC) were used both as accepters of tryptophan excitation energy of PKC and as membrane probes for intra- and intermolecular lipid chain collisions by measuring the ratio of excimer-to-monomer fluorescence intensity (EM). Both in micelles of polyoxyethylene 9-lauryl ether and in dioleoyl-PC vesicles, interaction of PKC with monopyrenyl PS (pyr-PS) in the absence of calcium resulted in a relatively slow decrease of the EM value. This effect on the lipid dynamics was accompanied by quenching of the tryptophan fluorescence of PKC. Addition of calcium resulted in a rapid further decrease of the EM ratio of pyr-PS and in additional quenching of the tryptophan fluorescence. When 4 mol % of pyr-PS was replaced by 0.5 mol % of dipyrenyl-labeled diacylglycerol a decrease of the intramolecular excimer formation rate and tryptophan fluorescence could only be detected in the presence of calcium and PS. Strong binding was also observed with dipyrenyl-labeled PIP (dipyr-PIP), but not with the other dipyrenyl-labeled lipids: PI, PS, or PC. In addition, the EM ratios of dipyr-PIP were not affected by phorbol 12-myristate 13-acetate, indicating that phorbol 12-myristate 13-acetate and dipyr-PIP can bind simultaneously to PKC.	AGR UNIV WAGENINGEN, DEPT BIOCHEM, 6703 HA WAGENINGEN, NETHERLANDS	Wageningen University & Research			Borst, Jan Willem/B-1259-2011					BANNO Y, 1992, J BIOL CHEM, V267, P6488; BASTIAENS PIH, 1993, BIOPHYS CHEM, V48, P183, DOI 10.1016/0301-4622(93)85009-7; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BONI LT, 1985, J BIOL CHEM, V260, P819; BROCKERHOFF H, 1986, FEBS LETT, V201, P1, DOI 10.1016/0014-5793(86)80559-2; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; COMFURIUS P, 1990, J LIPID RES, V31, P1719; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FORSTER T, 1955, Z ELEKTROCHEM, V59, P976; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GALLA HJ, 1974, BIOCHIM BIOPHYS ACTA, V339, P103, DOI 10.1016/0005-2736(74)90336-8; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LEE MH, 1989, J BIOL CHEM, V264, P14797; LESTER DS, 1990, BIOCHIM BIOPHYS ACTA, V1039, P33, DOI 10.1016/0167-4838(90)90223-3; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MYHER JJ, 1984, CAN J BIOCHEM CELL B, V62, P352, DOI 10.1139/o84-049; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PAP EHW, 1993, BIOCHEMISTRY-US, V32, P13310, DOI 10.1021/bi00211a044; PATEL KM, 1979, J LIPID RES, V20, P674; RANDO RR, 1984, BIOCHEM BIOPH RES CO, V122, P818, DOI 10.1016/S0006-291X(84)80107-2; SASSAROLI M, 1990, BIOPHYS J, V57, P281, DOI 10.1016/S0006-3495(90)82530-3; SEELIG J, 1990, CELL BIOL INT REP, V14, P353, DOI 10.1016/0309-1651(90)91204-H; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHAH J, 1992, BIOCHIM BIOPHYS ACTA, V1119, P19, DOI 10.1016/0167-4838(92)90228-6; SNOEK GT, 1988, BIOCHEM J, V255, P629; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TRUDELL JR, 1989, BIOCHEM BIOPH RES CO, V162, P45, DOI 10.1016/0006-291X(89)91959-1; VANDERKOOI JM, 1974, BIOCHEMISTRY-US, V13, P4000, DOI 10.1021/bi00716a028; WALLACH DFH, 1974, EVOLVING STRATEGIES, P74; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	56	13	13	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1254	1260		10.1074/jbc.270.3.1254	http://dx.doi.org/10.1074/jbc.270.3.1254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836388	hybrid			2022-12-25	WOS:A1995QB15600043
J	RICCI, G; LOBELLO, M; CACCURI, AM; PASTORE, A; NUCCETELLI, M; PARKER, MW; FEDERICI, G				RICCI, G; LOBELLO, M; CACCURI, AM; PASTORE, A; NUCCETELLI, M; PARKER, MW; FEDERICI, G			SITE-DIRECTED MUTAGENESIS OF HUMAN GLUTATHIONE TRANSFERASE P1-1 - MUTATION OF CYS-47 INDUCES A POSITIVE COOPERATIVITY IN GLUTATHIONE TRANSFERASE P1-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI-BI MECHANISM; S-TRANSFERASE; 3-DIMENSIONAL STRUCTURE; HUMAN-PLACENTA; ASPARTATE-TRANSCARBAMYLASE; BINDING-PROPERTIES; ACTIVE-SITE; PI; RESOLUTION; RESIDUES	Glutathione transferase P1-1 (EC 2.5.1.18) is a dimeric enzyme composed of identical subunits each containing one binding site for GSH and a second for the co-substrate e.g. 1-chloro-2,4-dinitrobenzene. Steady-state kinetics are strictly hyperbolic toward both these substrates, Replacement of Cys-47 with alanine or serine decreases the affinity for GSH and triggers a positive kinetic cooperativity with respect to this substrate. Hill coefficients were 1.31 and 1.43 for the C47A and C47S mutants, C47A/C101A and C47S/C101S double mutants display lower affinity for GSH and higher sill coefficients (1.57 and 1.56, respectively) when compared with C47A and C47S single mutants, Conversely, replacement of Cys-101 with alanine or serine does not yield any cooperativity and any marked change of kinetic parameters, Fluorometric experiments gave sigmoidal isothermic GSH binding curves for all the Cys-47 mutants, with Hill coefficients similar to that obtained by the kinetic approach, These data, together with the activation experiments performed in the presence of S-hexylglutathione, suggest that the substitution of Cys-47 yields a dimeric low-affinity enzyme which can be converted to a higher affinity state upon binding of GSH on one sub unit. These findings indicate a structural communication between subunits which may be revealed by the lack of a peculiar electrostatic bond between the thiolate form of Cys-47 and the protonated amino group of Lys-54.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	St. Vincent's Institute of Medical Research	RICCI, G (corresponding author), UNIV ROMA TOR VERGATA,DEPT BIOL,VIALE RIC SCI,I-00133 ROME,ITALY.		CACCURI, ANNA MARIA/AFU-2643-2022; Pastore, Anna/J-8409-2014; Parker, Michael W/F-9069-2013	Pastore, Anna/0000-0002-0990-9419; Parker, Michael W/0000-0002-3101-1138; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; CACCURI AM, 1991, ITAL J BIOCHEM, V40, P304; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; DELBOCCIO G, 1991, J BIOL CHEM, V266, P13777; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; HABIG WH, 1981, METHOD ENZYMOL, V77, P898; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1989, J BIOL CHEM, V264, P5462; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; Segel IH, 1975, ENZYME KINETICS, P460; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; VANDERJAGT DL, 1981, FEBS LETT, V136, P319, DOI 10.1016/0014-5793(81)80644-8	37	89	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1243	1248		10.1074/jbc.270.3.1243	http://dx.doi.org/10.1074/jbc.270.3.1243			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836386	hybrid			2022-12-25	WOS:A1995QB15600041
J	ALTIERI, DC; DUPERRAY, A; PLESCIA, J; THORNTON, GB; LANGUINO, LR				ALTIERI, DC; DUPERRAY, A; PLESCIA, J; THORNTON, GB; LANGUINO, LR			STRUCTURAL RECOGNITION OF A NOVEL FIBRINOGEN GAMMA-CHAIN SEQUENCE(117-133) BY INTERCELLULAR-ADHESION MOLECULE-1 MEDIATES LEUKOCYTE-ENDOTHELIUM INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; ALPHA-CHAIN; ACTIVATION; LIGAND; DOMAIN	In addition to its role in hemostasis, fibrinogen is obligatorily required to mount competent inflammatory responses in vivo. A molecular prerequisite of fibrinogen-dependent inflammation may reside in its ability to associate with intercellular adhesion molecule-1 (ICAM-1), and enhance monocyte adhesion to endothelium by bridging the two cell types. Structure-function characterization of the novel ICAM-1 recognition of fibrinogen was carried out by synthetic peptidyl mimicry of the fibrinogen gamma chain, A novel peptide sequence, N(117)NQKIVNLKEKVAQLEA(133), designated gamma 3, dose-dependently inhibited (IC50 similar to 20-40 mu g/ml) binding of I-125 fibrinogen to endothelial cells or ICAM-1-expressing B lymphoblastoid Daudi cells. In contrast, none of the previously identified vascular cell fibrinogen interacting sequences was effective. Increasing concentrations of gamma 3 completely inhibited fibrinogen-mediated adhesion of peripheral blood mononuclear cells or vitamin D-3-differentiated monocytic HL-60 cells to endothelium, but did not affect leukocyte-endothelium interaction in the absence of fibrinogen, I-125-Labeled gamma 3 bound specifically and saturably to genetically engineered ICAM-1 transfectants, but not to control non-transfected cells, and associated with ICAM-1 on cytokine-activated endothelium with a K-d of 34 mu M. Consistent with functional recognition of ICAM-1, immobilized gamma 3 supported adhesion of JY lymphoblasts in a dose-dependent reaction inhibited by monoclonal antibodies to ICAM-1. We conclude that a novel fibrinogen gamma 3 sequence N(117)NQKIVNLKEKVAQLEA(133) binds to ICAM-1 and modulates ICAM-1-dependent adhesion. These findings define the structural basis of fibrinogen:ICAM-1 recognition and provide a potential selective target for inhibiting fibrinogen-dependent inflammatory responses.	RW JOHNSON PHARMACEUT RES INST,SAN DIEGO,CA 92121	Johnson & Johnson; Johnson & Johnson USA	ALTIERI, DC (corresponding author), YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT PATHOL,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.		Duperray, Alain/E-8428-2012	Duperray, Alain/0000-0002-2719-252X; Languino, Lucia/0000-0001-9011-7031; Thornton, George/0000-0002-8744-4987	NHLBI NIH HHS [HL-54131, R01 HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R01HL043773, R37HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1993, BLOOD, V81, P569; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; COLLINS SJ, 1987, BLOOD, V70, P1233; COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LI R, 1993, J BIOL CHEM, V268, P17513; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MCRITCHIE DI, 1991, J LAB CLIN MED, V118, P48; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; WU XB, 1994, J CLIN INVEST, V94, P928, DOI 10.1172/JCI117459	21	93	96	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					696	699		10.1074/jbc.270.2.696	http://dx.doi.org/10.1074/jbc.270.2.696			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822297	hybrid			2022-12-25	WOS:A1995QB81600031
J	GUREVICH, VV; DION, SB; ONORATO, JJ; PTASIENSKI, J; KIM, CM; STERNEMARR, R; HOSEY, MM; BENOVIC, JL				GUREVICH, VV; DION, SB; ONORATO, JJ; PTASIENSKI, J; KIM, CM; STERNEMARR, R; HOSEY, MM; BENOVIC, JL			ARRESTIN INTERACTIONS WITH G-PROTEIN-COUPLED RECEPTORS - DIRECT BINDING-STUDIES OF WILD-TYPE AND MUTANT ARRESTINS WITH RHODOPSIN, BETA(2)-ADRENERGIC, AND M2-MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT PHOSPHORYLATION; ROD OUTER SEGMENTS; 48-KDA PROTEIN; PHOTORECEPTOR-MEMBRANES; PHOTOEXCITED RHODOPSIN; BETA-2-ADRENERGIC RECEPTOR; SYNTHETIC PEPTIDES; KINASE ACTIVATION; VISUAL ARRESTIN	Arrestins play an important role in quenching signal transduction initiated by G protein-coupled receptors. To explore the specificity of arrestin-receptor interaction, we have characterized the ability of various wildtype arrestins to bind to rhodopsin, the beta(2)-adrenergic receptor (beta(2)AR), and the m2 muscarinic cholinergic receptor (m2 mAChR), Visual arrestin was found to be the most selective arrestin since it discriminated best between the three different receptors tested (highest binding to rhodopsin) as web as between the phosphorylation and activation state of the receptor (>10-fold higher binding to the phosphorylated Light-activated form of rhodopsin compared to any other form of rhodopsin). While beta-arrestin and arrestin 3 were also found to preferentially bind to the phosphorylated activated form of a given receptor, they only modestly discriminated among the three receptors tested. To explore the structural characteristics important in arrestin function, we constructed a series of truncated and chimeric arrestins. Analysis of the binding characteristics of the various mutant arrestins suggests a common molecular mechanism involved in determining receptor binding selectivity. Structural elements that contribute to arrestin binding include: 1) a C-terminal acidic region that serves a regulatory role in controlling arrestin binding selectivity toward the phosphorylated and activated form of a receptor, without directly participating in receptor interaction; 2) a basic N-terminal domain that directly participates in receptor interaction and appears to serve a regulatory role via intramolecular interaction with the C-terminal acidic region; and 3) two centrally localized domains that are directly involved in determining receptor binding specificity and selectivity. A comparative structure-function model of all arrestins and a kinetic model of beta-arrestin and arrestin 3 interaction with receptors are proposed.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611; UNIV WISCONSIN,DEPT MED,MADISON,WI 53792	Jefferson University; Northwestern University; University of Wisconsin System; University of Wisconsin Madison			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NIGMS NIH HHS [GM47417, GM44944, GM47120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R29GM047120, R01GM047417, R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; HAGA K, 1994, J BIOL CHEM, V269, P12594; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KIM CM, 1993, RECEPTOR, V3, P39; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEFKOWITZ RJ, 1982, FED PROC, V41, P2664; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH WC, 1994, J BIOL CHEM, V269, P15407; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMAKI K, 1990, J BIOL CHEM, V265, P20757	49	316	326	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					720	731		10.1074/jbc.270.2.720	http://dx.doi.org/10.1074/jbc.270.2.720			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822302	hybrid			2022-12-25	WOS:A1995QB81600036
J	KOVOOR, A; HENRY, DJ; CHAVKIN, C				KOVOOR, A; HENRY, DJ; CHAVKIN, C			AGONIST-INDUCED DESENSITIZATION OF THE MU-OPIOID RECEPTOR-COUPLED POTASSIUM CHANNEL (GIRK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC K+ CHANNELS; LOCUS-CERULEUS NEURONS; GTP-BINDING PROTEINS; EGG CELL-MEMBRANE; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; RAT-BRAIN; ACTIVATION; CLONING; SUBUNITS	In Xenopus oocytes expressing the rat mu receptor and the G protein-gated, inwardly rectifying K+ channel (known as KGA or GIRK1), application of [D-Ala(2),MePhe(4),Glyol(5)]enkephalin) , a mu opioid agonist, evoked a dose-dependent increase in KC conductance, With sustained agonist exposure, the amplitude of the response decayed with a t(1/2) of 8 +/- 2 min. In oocytes coexpressing the mu and 5HT1A receptors with GIRK1, stimulation of either receptor resulted in heterologous desensitization of the subsequent response to the other, Injection of guanosine 5'-O-(thiotriphosphate) (1 mM) increased the basal GIRK1 activity and the total response to the application of agonist, but did not affect the rate of desensitization. Basal channel activity in the absence of agonist also desensitized at the same rate when the oocytes were exposed to high K+ (96 mM) solution, The above results indicate that the desensitization of the response occurred at a site downstream of the receptor, possibly at the channel, The rate of desensitization was not significantly altered by any of the following treatments: removal of external Ca2+, preloading the oocytes with 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-tetra-(acetoxymethyl)-ester (0.5-1 mM), elevation of cAMP levels, treatment with phorbol esters (1 mu M), staurosporine (0.5 mu M), okadaic acid (1 mu M), Or cytochalasin B (0.5 mu M). These results suggest that desensitization may not involve a calcium or phosphorylation-dependent mechanism.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; CALTECH, COMPUTAT NEUROSCI PROGRAM, PASADENA, CA 91125 USA	University of Washington; University of Washington Seattle; California Institute of Technology			Chavkin, Charles/G-2797-2010		NIDA NIH HHS [DA 05160, DA 04123] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BRANN MR, 1993, PROG BRAIN RES, V98, P121; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CARMELIET E, 1986, J PHYSIOL-LONDON, V371, P239, DOI 10.1113/jphysiol.1986.sp015971; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DASCAL N, 1992, METHODS MOL BIOL, V13; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; HARRIS GC, 1991, J NEUROSCI, V11, P2574; HILLE B, 1988, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OHMORI H, 1980, J MEMBRANE BIOL, V53, P143, DOI 10.1007/BF01870582; PASTERNAK GW, 1988, OPIATE RECEPTORS; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	34	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					589	595		10.1074/jbc.270.2.589	http://dx.doi.org/10.1074/jbc.270.2.589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822283	hybrid			2022-12-25	WOS:A1995QB81600016
J	ABRAHAM, DG; PATEL, PP; COOPER, AJL				ABRAHAM, DG; PATEL, PP; COOPER, AJL			ISOLATION FROM RAT-KIDNEY OF A CYTOSOLIC HIGH-MOLECULAR-WEIGHT CYSTEINE-S-CONJUGATE BETA-LYASE WITH ACTIVITY TOWARD LEUKOTRIENE E(4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE TRANSAMINASE-K; SERINE O-SULFATE; ASPARTATE-AMINOTRANSFERASE; POLYACRYLAMIDE GELS; PURIFICATION; METABOLISM; ACID; PROTEINS; LIVER; NEPHROTOXICITY	A cytosolic high M(r) cysteine-S-conjugate beta-lyase (apparent M(r) of similar to 330,000) has been partially purified from rat kidneys. The high M(r) lyase is also present in the mitochondria, The purified enzyme contains at least two proteins with apparent M(r) values of similar to 50,000 and similar to 70,000. Activity is stimulated by dithiothreitol, alpha-keto acids, and pyridoxal 5'-phosphate; aminooxyacetate is an inhibitor. The enzyme catalyzes a competing (half) transamination reaction between pyridoxal 5'-phosphate cofactor and cysteine-S-conjugate substrate; added alpha-keto acids promote conversion of active site pyridoxamine 5'-phosphate to pyridoxal 5'-phosphate. The enzyme also catalyzes a full (but weak) transamination between L-phenylalanine and alpha-keto-gamma-methiolbutyrate. The purified enzyme is not recognized by polyclonal rabbit antibodies to cytosolic rat kidney glutamine transaminase K (another cysteine-S-conjugate beta-lyase of rat kidney) and has no obvious similarities to other pyridoxal 5'-phosphate-containing enzymes. In addition to catalyzing elimination reactions with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,1,2,2-tetrafluoroethyl)-L-cysteine, the enzyme reacts with leukotriene E(4) and 5'-S-cysteinyldopamine. Finally, the cytosolic and mitochondrial enzymes are activated by alpha-ketoglutarate. Thus, the possibility must be considered that, in kidneys of animals exposed to various cysteine conjugates, the high M(r) lyase contributes to the generation of pyruvate, ammonia, and reactive fragments in vivo. Many cysteine conjugates are nephrotoxic, and the high M(r) lyase(s) may be involved.	CORNELL UNIV, MED CTR, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, DEPT NEUROL & NEUROSCI, NEW YORK, NY 10021 USA	Cornell University; Cornell University			Cooper, Arthur J.L./H-5171-2016		NIDDK NIH HHS [DK 16739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016739] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM DG, 1991, ANAL BIOCHEM, V197, P421, DOI 10.1016/0003-2697(91)90414-O; ALLEN DE, 1990, AM J PHYSIOL, V258, pR1034; BADR KF, 1987, AM J PHYSIOL, V253, pF239, DOI 10.1152/ajprenal.1987.253.2.F239; BERNSTROM K, 1989, ARCH BIOCHEM BIOPHYS, V275, P531, DOI 10.1016/0003-9861(89)90399-8; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; Blanchard M, 1944, J BIOL CHEM, V155, P421; BRAUNSTEIN AE, 1984, ADV ENZYMOL RAMB, V56, P1; BUXTON PH, 1967, J NEUROL NEUROSUR PS, V30, P511, DOI 10.1136/jnnp.30.6.511; CAVALLIN.D, 1973, EUR J BIOCHEM, V39, P301, DOI 10.1111/j.1432-1033.1973.tb03127.x; CHAYKIN S, 1969, ANAL BIOCHEM, V31, P375, DOI 10.1016/0003-2697(69)90278-4; CHEN Q, 1990, J BIOL CHEM, V265, P21603; Cooper A J, 1994, Adv Pharmacol, V27, P71, DOI 10.1016/S1054-3589(08)61030-3; COOPER AJL, 1989, ANAL BIOCHEM, V183, P210, DOI 10.1016/0003-2697(89)90469-7; COOPER AJL, 1990, ANN NY ACAD SCI, V585, P118, DOI 10.1111/j.1749-6632.1990.tb28048.x; COOPER AJL, 1981, COMP BIOCHEM PHYS B, V69, P137, DOI 10.1016/0305-0491(81)90223-6; COOPER AJL, 1978, ANAL BIOCHEM, V89, P451, DOI 10.1016/0003-2697(78)90374-3; COOPER AJL, 1993, J NEUROCHEM, V61, P1731, DOI 10.1111/j.1471-4159.1993.tb09810.x; COOPER AJL, 1974, J BIOL CHEM, V249, P2554; DEKANT W, 1988, CHEM RES TOXICOL, V1, P175, DOI 10.1021/tx00003a008; DULEY JA, 1976, EUR J BIOCHEM, V63, P163, DOI 10.1111/j.1432-1033.1976.tb10219.x; Elfarra Adnan A., 1993, P387; FAULER J, 1991, PROSTAGLANDINS, V42, P239, DOI 10.1016/0090-6980(91)90113-T; FILCDERICCO S, 1990, CANCER RES, V50, P4839; GULBINS E, 1991, EUR J CLIN INVEST, V21, P184, DOI 10.1111/j.1365-2362.1991.tb01808.x; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; JONES TW, 1988, MOL PHARMACOL, V34, P621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE M, 1989, TOXICOL APPL PHARM, V98, P185, DOI 10.1016/0041-008X(89)90224-X; MACFARLANE M, 1993, TOXICOLOGY, V77, P133, DOI 10.1016/0300-483X(93)90144-H; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MEISTER A, 1952, J BIOL CHEM, V197, P309; MILES EW, 1986, VITAMIN B6 PYRIDOXAL, P253; MOORE KP, 1992, KIDNEY INT, V41, P1543, DOI 10.1038/ki.1992.224; MORINO Y, 1974, J BIOL CHEM, V249, P6684; REICHERT D, 1976, ARCH TOXICOL, V37, P23, DOI 10.1007/BF00353352; RELYEA NM, 1974, J BIOL CHEM, V249, P1519; ROSENGREN E, 1985, J NEURAL TRANSM, V63, P247, DOI 10.1007/BF01252029; ROSENTHAL A, 1983, CAN J PHYSIOL PHARM, V61, P325, DOI 10.1139/y83-049; SALA A, 1990, J BIOL CHEM, V265, P21771; SIMON D, 1973, BIOCHIM BIOPHYS ACTA, V321, P361, DOI 10.1016/0005-2744(73)90091-0; SIMONSON MS, 1986, KIDNEY INT, V30, P524, DOI 10.1038/ki.1986.217; SKOVBY F, 1984, J BIOL CHEM, V259, P583; SLIVKA A, 1985, J BIOL CHEM, V260, P5466; SMITH P, 1967, J CHROMATOGR, V30, P273, DOI 10.1016/S0021-9673(00)84158-8; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1985, J BIOL CHEM, V260, P7945; STEVENS JL, 1990, DRUG METAB REV, V22, P617, DOI 10.3109/03602539008991457; Stevens JL, 1989, GLUTATHIONE CHEM B B, P45; STEWART HB, 1953, BIOCHEM J, V55, pR26; TONG J, 1993, CLIN BIOCHEM, V26, P199, DOI 10.1016/0009-9120(93)90026-3; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; WARD L D, 1991, Peptide Research, V4, P187; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAUCHI A, 1993, PROTEIN EXPRES PURIF, V4, P552, DOI 10.1006/prep.1993.1073	57	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					180	188		10.1074/jbc.270.1.180	http://dx.doi.org/10.1074/jbc.270.1.180			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814371	hybrid			2022-12-25	WOS:A1995QA28700031
J	MACAULAY, C; MEIER, E; FORBES, DJ				MACAULAY, C; MEIER, E; FORBES, DJ			DIFFERENTIAL MITOTIC PHOSPHORYLATION OF PROTEINS OF THE NUCLEAR-PORE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; LINKED N-ACETYLGLUCOSAMINE; DNA TOPOISOMERASE-II; RNA POLYMERASE-II; CASEIN KINASE-II; LAMIN-B RECEPTOR; CELL-FREE SYSTEM; ASSEMBLY INVITRO; XENOPUS OOCYTES; EGG EXTRACTS	During each cell cycle, the nucleus of higher eukaryotes undergoes a dramatic assembly and disassembly, These events can be faithfully reproduced in vitro using cell-free extracts derived from Xenopus eggs, Such extracts contain three major N-acetylglucosaminylated proteins, p200, p97, and p60, Ah three become assembled into reconstituted nuclear pores, Here we show that p200, p97, and p60 exist in eggs in soluble high molecular mass complexes of 1000, 450, and 600 kDA, respectively, The bulk of p60 is stably associated with proteins of 58 and 54 kDa, while p200 is associated with a fraction of p60 in a separate complex lacking p58 and p54. Upon examining the behavior of these proteins in the cell cycle, we find that p200 and p97 are highly phosphorylated at mitosis, both in vivo and in vitro, Moreover, in extracts that cycle between interphase and mitosis, p200 and p97 are specifically phosphorylated at mitosis. Corresponding with their mitotic phosphorylation, both p200 and p97 are specific substrates for purified mitotic Cdc2 kinase, whereas nucleoporin p60 is not, Analysis indicates that the size of the complexes containing the pore N-acetylglucosamine glycoproteins does not change during mitosis, suggesting that such complexes represent stable multicomponent modules into which the nucleus disassembles at mitosis.			MACAULAY, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.			Macaulay, Colin/0000-0003-0118-7674	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033279] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33279, R01 GM033279] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AIZAWA H, 1991, BIOCHEM BIOPH RES CO, V179, P1620, DOI 10.1016/0006-291X(91)91760-A; APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; BEMENT WM, 1990, J ELECTRON MICR TECH, V16, P202, DOI 10.1002/jemt.1060160303; BLOEMENDAL H, 1989, BIOCHIM BIOPHYS ACTA, V1007, P245, DOI 10.1016/0167-4781(89)90144-9; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CAPONY JP, 1986, DEV BIOL, V117, P1, DOI 10.1016/0012-1606(86)90342-8; CARDENAS ME, 1993, J CELL SCI, V104, P533; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CORDES V, 1991, EUR J CELL BIOL, V55, P31; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DA J, 1991, J CELL BIOL, V115, P1203; DABAUVALLE MC, 1990, CHROMOSOMA, V100, P56, DOI 10.1007/BF00337603; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDMAN AE, 1992, J CELL BIOL, V119, P725, DOI 10.1083/jcb.119.4.725; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HAREL A, 1989, J CELL SCI, V94, P463; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1986, J BIOL CHEM, V261, P8049; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KITA K, 1993, J BIOCHEM-TOKYO, V113, P377, DOI 10.1093/oxfordjournals.jbchem.a124054; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MALLER JL, 1985, DEV BIOL, V109, P150, DOI 10.1016/0012-1606(85)90355-0; MAUL GG, 1977, J CELL BIOL, V74, P492, DOI 10.1083/jcb.74.2.492; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MEIKRANTZ W, 1991, J CELL SCI, V98, P303; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MILLER MW, 1994, J BIOL CHEM, V269, P9289; Moir RD, 1993, CURR OPIN CELL BIOL, V5, P408, DOI 10.1016/0955-0674(93)90004-A; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; RIH HP, 1991, EMBO J, V10, P633; ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINERT G, 1974, J ULTRA MOL STRUCT R, V49, P188, DOI 10.1016/S0022-5320(74)80031-6; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VIGERS GPA, 1992, J CELL SCI, V102, P273; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; YEO JP, 1994, NATURE, V367, P288, DOI 10.1038/367288a0	90	164	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					254	262		10.1074/jbc.270.1.254	http://dx.doi.org/10.1074/jbc.270.1.254			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814383	hybrid			2022-12-25	WOS:A1995QA28700041
J	FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF				FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF			OVEREXPRESSION OF MOS ONCOGENE PRODUCT IN SWISS 3T3 CELLS INDUCES APOPTOSIS PREFERENTIALLY DURING S-PHASE	ONCOGENE			English	Article						APOPTOSIS; MOS ONCOGENE; CELL CYCLE; S-PHASE	MURINE SARCOMA-VIRUS; MEIOTIC MATURATION; XENOPUS-OOCYTES; MAP KINASE; PROTO-ONCOGENE; EARLY EVENT; DEATH; ENDONUCLEASE; INVITRO; FIBROBLASTS	When Swiss 3T3 cells are acutely infected with Moloney murine sarcoma virus containing the v-mos oncogene, 90% of the cells round up and detach from the monolayer (floating cells) and express high levels of v-Mos. The majority of the floating cells are generated between 30 and 70 h post infection when the cellular level of Mos reaches similar to 0.1% of the total protein. Seventy percent of the floating cells exclude trypan blue but are growth arrested with 2C or 4C DNA content, whereas the remaining floating cells with <2C DNA content, are dead or dying, and show characteristic apoptotic phenotypes. The apoptotic cells are most likely generated from cells in S-phase since these cells are absent from the viable floating cell population and the percentage of cells with <2C DNA approximated the expected S-phase fraction of logarithmically growing cells. In addition, 5'-bromo-2'-deoxyuridine-labeling studies showed that similar to 50% of the floating cells with typical apoptotic phenotypes were metabolically-labeled with the drug. These analyses show that cell populations in different stages of the cell cycle are differently affected by high levels of v-Mos expression and cells in S-phase appear to be uniquely sensitive and undergo apoptosis.	NCI, FREDERICK CANC RES & DEV CTR, ABL, BASIC RES PROGRAM, FREDERICK, MD 21702 USA; NCI, DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM, MATH BIOL LAB,MEMBRANE BIOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS SI, 1989, J IMMUNOL, V142, P1789; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KUNG AL, 1990, CANCER RES, V50, P7307; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOCK RB, 1990, CANCER RES, V50, P3761; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; UCKER DS, 1991, NEW BIOL, V3, P103; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					1	8						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824263				2022-12-25	WOS:A1995QA98000001
J	KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD				KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD			TRANSFORMING GROWTH-FACTOR-BETA-1 INHIBITS CYCLIN D1 EXPRESSION IN INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article						TGF-BETA; CYCLIN; CELL CYCLE; EPITHELIAL CELL; CYCLIN-DEPENDENT KINASE; GENE EXPRESSION	SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT KINASE CDK4; RAT SMALL-INTESTINE; FACTOR-BETA; TGF-BETA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; GENE-EXPRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS	Transforming growth factor-beta 1 (TGF-beta 1) inhibits most epithelial cell types by blocking cell cycle progression during the G(1) phase. D cyclins are normally expressed during G(1) and are regulators of G(1) progression. One of the crucial functions of D cyclins is their ability to bind to a cyclin-dependent kinase (Cdk4). In mink lung epithelial cells, TGF-beta 1 inhibits Cdk4 expression. We have measured cell cycle progression and D cyclins and Cdk4 expression in non-transformed rat intestinal epithelial cell lines (IEC-6 and RIE-1) after TGF-beta 1 treatment. In exponentially growing cultures, TGF-beta 1 blocked DNA synthesis and suppressed cyclin D1 mRNA and protein expression, whereas the levels of cyclins D2, D3 and Cdk4 remained relatively unchanged. TGF-beta 1 was also added to Go-synchronized IEC-6 cells after serum stimulation. TGF-beta 1 prevention of G(1) progression was associated with an inhibition of cyclin D1 protein expression. Cyclin D3 levels were not affected by TGF-beta 1 during G(1) traverse. Our results suggest that cyclin D/Cdk4 is a crucial target of TGF-beta 1 and that regulation of this kinase is mediated through cyclin D1 in intestinal epithelial cells.	UNIV TEXAS, MED BRANCH, DEPT SURG, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Babyatsky M. W., 1991, TXB GASTROENTEROLOGY, P475; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLAY J, 1986, J CELL PHYSIOL, V129, P343, DOI 10.1002/jcp.1041290312; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRESLIN JS, 1993, AM J RESP CELL MOL, V9, P533, DOI 10.1165/ajrcmb/9.5.533; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMUS J, 1992, ONCOGENE, V7, P521; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GINTY DD, 1989, AM J PHYSIOL, V256, pG342, DOI 10.1152/ajpgi.1989.256.2.G342; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1993, SURGERY, V114, P147; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAEMMLI UK, 1983, NATURE, V303, P497; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1992, CANCER SURV, V12, P81; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGEE DW, 1991, CYTOKINE, V3, P543, DOI 10.1016/1043-4666(91)90480-2; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOLL T, 1993, PHILOS T ROY SOC B, V340, P351, DOI 10.1098/rstb.1993.0078; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; THOMPSON EA, 1980, J NATL CANCER I, V65, P477; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	142	146	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					177	184						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824270				2022-12-25	WOS:A1995QA98000020
J	HEIDARAN, MA; MAHADEVAN, D; LAROCHELLE, WJ				HEIDARAN, MA; MAHADEVAN, D; LAROCHELLE, WJ			BETA-PDGFR-IGG CHIMERA DEMONSTRATES THAT HUMAN BETA-PDGFR IG-LIKE DOMAIN-1 TO DOMAIN-3 ARE SUFFICIENT FOR HIGH-AFFINITY PDGF-BB BINDING	FASEB JOURNAL			English	Article						FUSION PROTEINS; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; SURAMIN	GROWTH-FACTOR RECEPTORS; SIMIAN SARCOMA-VIRUS; MONOCLONAL-ANTIBODY; HUMAN-ALPHA; EXTRACELLULAR DOMAIN; FUSION PROTEINS; LIGAND-BINDING; V-SIS; EXPRESSION; INHIBITION	To localize human beta PDGFR binding determinants, we constructed a fusion protein comprising beta PDGFR Ig-like domains 1 to 3 and an IgG(1) Fc domain (beta PDGFR-HFc). beta PDGFR-HFc was expressed as a 200 kDa dimeric molecule and contained Fc epitopes as demonstrated by anti-mouse Fc antibody recognition. Scatchard analysis revealed that PDGF BB possessed a dissociation constant of 1.5 nM for beta PDGFR-HFc. Thus, beta PDGFR Ig-like domains 1 to 3 are sufficient for high affinity PDGF BB binding. We exploited this fusion protein technology to identify and characterize beta PDGFR antagonists using a sensitive beta PDGFR immunosorbent assay. In this assay, beta PDGFR-HFc half-maximally bound to PDGF BB with an affinity of around 150 pM. Suramin, as well as bacterially expressed and refolded human alpha PDGFR domains 1-3, inhibited beta PDGFR-HFc binding to PDGF BB half-maximally at 25 mu M and 10 nM respectively. Therefore, alpha PDGFR D1-3, like beta PDGFR D1-3, are sufficient for high affinity PDGF BB binding. Furthermore, the beta PDGFR-HFc immunosorbent assay will be useful to identify beta PDGFR antagonists as well as to study alpha and beta PDGFR substitution mutants which further map receptor binding determinants.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COGNE M, 1992, BLOOD, V79, P2181; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1992, CANCER RES, V52, P4550; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HERREN B, 1993, J BIOL CHEM, V268, P15088; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LIU YC, 1993, BIOCHEM BIOPH RES CO, V197, P1094, DOI 10.1006/bbrc.1993.2590; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; NISTER M, 1991, J BIOL CHEM, V266, P16755; RAMAKRISHNAN V, 1993, GROWTH FACTORS, V8, P253, DOI 10.3109/08977199308991571; ROONEY BC, 1994, FEBS LETT, V339, P181, DOI 10.1016/0014-5793(94)80411-7; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SMITS A, 1992, AM J PATHOL, V140, P639; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	45	22	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					140	145		10.1096/fasebj.9.1.7821753	http://dx.doi.org/10.1096/fasebj.9.1.7821753			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821753				2022-12-25	WOS:A1995QD20200022
J	OHNISHI, Y; NISHIYAMA, M; HORINOUCHI, S; BEPPU, T				OHNISHI, Y; NISHIYAMA, M; HORINOUCHI, S; BEPPU, T			INVOLVEMENT OF THE COOH-TERMINAL PRO-SEQUENCE OF SERRATIA-MARCESCENS SERINE-PROTEASE IN THE FOLDING OF THE MATURE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; DENATURED SUBTILISIN; PRECURSOR; EXCRETION; CHAPERONE; PROTEINS; CLONING; GENE	The serine protease (SSP) from a Gram-negative organism, Serratia marcescens, is excreted even from Escherichia coli, The protease is synthesized as a 1045-amino-acid precursor (preproSSP) composed of three functional portions, a typical NH2-terminal signal peptide of 27 amino acids, the mature protease part of 618 amino acids, and a large COOH-terminal part of 400 amino acids. After the mature part (Ala(28) to Asp(645)) has been liberated into the medium, most of the COOH-terminal part (Phe(717) to Phe(1045)) remains stably in the outer membrane, When a mutated gene encoding the preproSSP with deletion of the junction region (Ser(646) to Gly(716)) between the mature protease and the processed COOH-terminal protein was expressed in E. coli, the SSP protein was not detected in any fractions of the cells nor in the medium, whereas a processed COOH-terminal protein was found in the outer membrane, However, when the outer membrane fraction prepared from the transformant exhibiting the junction region (Ser(646) to Gly(716)) probably on the cell surface was co cultured with the transformant, SSP was found in the medium. Furthermore, a significant portion of the SSP protein denatured with guanidine hydrochloride was correctly refolded in vitro into the active protease, only in the presence of the outer membrane preparation from the transformant exhibiting the junction region, These results suggest that the junction region is exposed outside the cells, and it plays a role for guiding the folding of SSP in the correct conformation.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo				Ohnishi, Yasuo/0000-0001-7633-9236				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CORNELIS P, 1982, MOL GEN GENET, V186, P507, DOI 10.1007/BF00337957; FABRE E, 1992, J BIOL CHEM, V267, P15049; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; HAGIHARA B, 1958, J BIOCHEM-TOKYO, V45, P185, DOI 10.1093/oxfordjournals.jbchem.a126856; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUBARA M, 1994, FEBS LETT, V342, P193, DOI 10.1016/0014-5793(94)80499-0; Miller J.H., 1972, EXPT MOL GENETICS; MIURA T, 1969, BIOCHIM BIOPHYS ACTA, V193, P268; MIYAZAKI H, 1989, J BACTERIOL, V171, P6566, DOI 10.1128/jb.171.12.6566-6572.1989; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SHIKATA S, 1992, J BIOCHEM-TOKYO, V111, P627, DOI 10.1093/oxfordjournals.jbchem.a123809; SHIKATA S, 1993, J BIOCHEM, V114, P723, DOI 10.1093/oxfordjournals.jbchem.a124244; SHIMADA K, 1994, J BIOCHEM-TOKYO, V116, P327, DOI 10.1093/oxfordjournals.jbchem.a124527; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	21	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32800	32806						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806503				2022-12-25	WOS:A1994QA63800016
J	NOLAND, TD; FRIDAY, BB; MAULIT, MT; GERTON, GL				NOLAND, TD; FRIDAY, BB; MAULIT, MT; GERTON, GL			THE SPERM ACROSOMAL MATRIX CONTAINS A NOVEL MEMBER OF THE PENTAXIN FAMILY OF CALCIUM-DEPENDENT BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG SPERM; OLIGOSACCHARIDE SIDE-CHAINS; C-REACTIVE PROTEIN; INITIAL CHARACTERIZATION; EPIDIDYMAL SPERMATOZOA; 2-DIMENSIONAL ANALYSIS; POLYACRYLAMIDE GELS; SECRETORY GRANULES; TISSUE PROTEINS; CELL FRACTIONS	The sperm acrosome is a regulated secretory granule that undergoes exocytosis during fertilization, To elucidate the structural organization of the contents within the acrosome, guinea pig sperm acrosomal apical segments were isolated and mapped by two-dimensional polyacrylamide gel electrophoresis (PAGE), Although complex, the two-dimensional PAGE map was dominated by two M(r) 50,000 polypeptides (p50 and proacrosin), a M(r) 67,000 polypeptide (p67), and a M(r) 32,000 polypeptide (sp32), Proacrosin (pi >8.0), p67, and sp32 were extracted from apical segments by 1 M NaCl. Protein p50, a relatively acidic polypeptide, was not extracted in 1 M NaCl and/or 1% Triton X-100 at 4 degrees C, but was solubilized with 6 M urea, Protein p50 was purified from the urea extract by elution from DEAE-Sephacel with 100 mM guanidine HCl and appeared homogeneous by SDS-PAGE, Antibodies to p50 were monospecific as judged by Western blot analysis, Indirect immunofluorescence indicated that p50 was restricted to the acrosomal apical segment, Incubation of apical segments at pH 7.5 in the presence of 1 mM EDTA at 37 degrees C resulted in the release of p50 into the 200,000 x g supernatant fluid, a process that was reversed by a subsequent incubation with 1.5 mM CaCl2 but not with MgCl2. The Ca2+-dependent reassociation of p50 with the acrosomal apical segments was reversed by the addition of 2.0 mM EGTA, indicating that p50 binding is dependent on free Ca2+ concentrations. When acrosomal matrices were purified following Triton X-100 extraction, p50 was the major component, with p67, proacrosin, and sp32 as less prominent constituents. Molecular cloning demonstrated that p50 is a unique, testis-specific member of the pentaxin family of calcium-dependent binding proteins.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT DEV & CELL BIOL,PHILADELPHIA,PA 19104; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	University of Pennsylvania; University of Pennsylvania; Vanderbilt University			Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274, R01HD022899] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22899, HD06274] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADEKUNLE AO, 1987, BIOL REPROD, V37, P201, DOI 10.1095/biolreprod37.1.201; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAKWE OO, 1991, MOL REPROD DEV, V29, P294, DOI 10.1002/mrd.1080290313; ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BABA T, 1994, J BIOL CHEM, V269, P10133; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; CHIDGEY MAJ, 1993, BIOESSAYS, V15, P317, DOI 10.1002/bies.950150505; COURTENS JL, 1978, J ULTRA MOL STRUCT R, V65, P182, DOI 10.1016/S0022-5320(78)90055-2; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEVRIES JWA, 1985, EUR J CELL BIOL, V37, P81; DICARLANTONIO G, 1988, GAMETE RES, V21, P425, DOI 10.1002/mrd.1120210410; EDDY EM, 1993, PHYSL REPROD, P29; FAWCETT DW, 1963, Z ZELLFORSCH MIK ANA, V60, P276, DOI 10.1007/BF00350481; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; FAWCETT DW, 1975, FUNCTIONAL ANATOMY S, P199; FLAHERTY SP, 1988, ANAT REC, V220, P267, DOI 10.1002/ar.1092200307; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; FULLER SA, 1991, CURRENT PROTOCOLS MO; GREEN DPL, 1978, J CELL SCI, V32, P153; GREEN DPL, 1978, J CELL SCI, V32, P177; HARDY DM, 1987, BIOL REPROD, V37, P189, DOI 10.1095/biolreprod37.1.189; HARDY DM, 1991, BIOCHEM J, V275, P759, DOI 10.1042/bj2750759; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HUANG TTF, 1985, BIOL REPROD, V32, P451, DOI 10.1095/biolreprod32.2.451; JONES R, 1990, DEVELOPMENT, V109, P41; KASHIWABARA S, 1990, J BIOCHEM-TOKYO, V108, P785, DOI 10.1093/oxfordjournals.jbchem.a123281; KOLBBACHOFEN V, 1991, IMMUNOBIOLOGY, V183, P133, DOI 10.1016/S0171-2985(11)80193-2; KOPF GS, 1991, ELEMENTS MAMMALIAN F, V1, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GW, 1993, J IMMUNOL, V150, P1804; NOLAND TD, 1990, BIOL REPROD, V42, P252, DOI 10.1095/biolreprod42.2.252; NOLAND TD, 1989, J BIOL CHEM, V264, P13586; NOLAND TD, 1987, BIOL REPROD, V37, P171, DOI 10.1095/biolreprod37.1.171; NUZZO NA, 1990, MOL REPROD DEV, V25, P52, DOI 10.1002/mrd.1080250110; OLSON GE, 1987, GAMETE RES, V17, P77, DOI 10.1002/mrd.1120170109; OLSON GE, 1985, BIOL REPROD, V33, P761, DOI 10.1095/biolreprod33.3.761; REID MS, 1994, J BIOL CHEM, V269, P32615; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGER TA, 1991, CURRENT PROTOCOLS MO; STOJANOFF A, 1987, GAMETE RES, V17, P321, DOI 10.1002/mrd.1120170405; TALBOT P, 1985, J HISTOCHEM CYTOCHEM, V33, P1169, DOI 10.1177/33.11.4056380; TALBOT P, 1974, J REPROD FERTIL, V39, P429, DOI 10.1530/jrf.0.0390429; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; Tooze S A, 1992, Semin Cell Biol, V3, P357, DOI 10.1016/1043-4682(92)90021-M; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESTBROOKCASE VA, 1994, BIOL REPROD, V51, P1, DOI 10.1095/biolreprod51.1.1; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	60	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32607	32614						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798265				2022-12-25	WOS:A1994PX30400087
J	KANG, CH; FROMM, HJ				KANG, CH; FROMM, HJ			IDENTIFICATION OF AN ESSENTIAL 2ND METAL-ION IN THE REACTION-MECHANISM OF ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE; COMPLEXES; PURIFICATION; PURA; ACID	This study reports that two Mg2+ ions are required for Escherichia coli adenylosuccinate synthetase activity, The first metal ion is presumably coordinated with beta-and gamma-phosphoryl groups of GTP to provide an electron sink, and the second one seems to interact with aspartate in the enzyme active site, Regarding the latter metal ion, kinetic studies show that aspartate and the second Mg2+ ion bind to the enzyme active site randomly with a k(cat) value of 1.47 s(-1) and with K-m values for cat aspartate and Mg2+ of 225 and 114 mu M, respectively, The dissociation constants for aspartate and Mg2+ of the enzyme . GTP . IMP (aspartate or Mg2+) complex are 79.2 and 40.0 mu M, respectively. However, variable amounts of aspartate or Mg2+ did not show any significant changes in the K-m values for GTP and IMP, Kinetic studies using Mn2+ and Ca2+ ions indicate that the k(cat) values (0.930 and 0.235 s(-1), respectively) were slightly decreased compared with the value obtained using Mg2+; however, the K-m values for aspartate and GTP in the presence of Mn2+ and Ca2+ were significantly decreased compared with those obtained using Mg2+ ion (4.5 and 4.6 times for Mn2+ ion and 5.6 and 5.8 times for Ca2+ ion, respectively), On the other hand, the K-m values for IMP were not significantly changed (1.9 and 1.8 times for Mn2+ and Ca2+ ions, respectively), Taken together, these kinetic results imply that aspartate may interact with Mg2+ to form a Mg aspartate complex in the enzyme active site, An inhibition study of the enzyme with ZnCl2 (its K-i Value is 29 nM) also suggested that Zn2+ competes with aspartate as well as Mg2+, implying that Zn2+ might form a complex with aspartate in the active site, On the basis of these results, it is suggested that Mg . aspartate complex formation in the active site of adenylosuccinate synthetase may be important in activation of the protonated amino group of aspartate, enhancement of the enzyme's binding affinity, and its specificity for aspartate.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS 10548] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BUCHANAN JM, 1959, ADV ENZYMOL REL S BI, V21, P199; CHEN M, 1994, J BIOL CHEM, V269, P5554; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; COOPER BF, 1982, FED PROC, V41, P742; EVANS CA, 1979, MET IONS BIOL SYST, V9, P41; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GLASS E., 1956, Zeitschrift fur Botanik, V44, P1; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HAUGLAND PR, 1992, HDB FLUORESCENT PROB, P145; Hsie AW, 1979, TRACE METALS HLTH DI, P55; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MARKHAM GD, 1977, ARCH BIOCHEM BIOPHYS, V184, P24, DOI 10.1016/0003-9861(77)90322-8; MARKHAM GD, 1977, THESIS U PENNSYLVANI; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; Pettit L.D., 1979, MET IONS BIOL SYST, V9, P174; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; SARIBAS AS, 1994, J BIOL CHEM, V269, P6313; SCHMIDBAUR H, 1986, ANGEW CHEM INT EDIT, V25, P1013, DOI 10.1002/anie.198610131; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; TU AT, 1971, MET IONS BIOL SYST, V1, P1; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; WAGNER FW, 1988, METHOD ENZYMOL, V158, P21, DOI 10.1016/0076-6879(88)58045-X; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	41	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15539	15544		10.1074/jbc.270.26.15539	http://dx.doi.org/10.1074/jbc.270.26.15539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797548	hybrid			2022-12-25	WOS:A1995RG53800018
J	BRADY, JP; KANTOROW, M; SAX, CM; DONOVAN, DM; PIATIGORSKY, J				BRADY, JP; KANTOROW, M; SAX, CM; DONOVAN, DM; PIATIGORSKY, J			MURINE TRANSCRIPTION FACTOR ALPHA-A-CRYSTALLIN BINDING-PROTEIN-I - COMPLETE SEQUENCE, GENE STRUCTURE, EXPRESSION, AND FUNCTIONAL INHIBITION VIA ANTISENSE RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA-B; ZINC-FINGER PROTEIN; MESSENGER-RNA; EUKARYOTIC CELLS; RAT TESTIS; MOUSE; ENHANCER; PROMOTER; DNA	alpha A-crystallin binding protein I (alpha A-CRYBP1) is a ubiquitously expressed DNA binding protein that was previously identified by its ability to interact with a functionally important sequence in the mouse alpha A-crystallin gene promoter, Here, we have cloned a single copy gene with 10 exons spanning greater than 70 kb of genomic DNA that encodes alpha A-CRYBP1. The mouse alpha A-CRYBP1 gene specifies a 2,688-amino acid protein with 72% amino acid identity to its human homologue, PRDII-BF1. Both the human and the mouse proteins contain two sets of consensus C2H2 zinc fingers at each end as well a central nonconsensus zinc finger. The alpha A-CRYBP1 gene produces a 9.5-kb transcript in II different tissues as well as a testis-specific, 7.7 kb transcript, alpha A-CRYBP1 cDNA clones were isolated from adult mouse brain and testis as well as from cell lines derived from mouse lens (alpha TN4-1) and muscle (C2C12). A single clone isolated from the muscle C2C12 library contains an additional exon near the 5'-end that would prevent production of a functional protein if the normal translation start site were utilized; however, there is another potential initiation codon located downstream that is in frame with the rest of the coding region, In addition, we identified multiple cDNAs from the testis in which the final intron is still present. Finally, we used an antisense expression construct derived from an alpha A-CRYBP1 cDNA clone to provide the first functional evidence that alpha A-CRYBP1 regulates gene expression, When introduced into the alpha TN4-1 mouse lens cell line, the antisense construct significantly inhibited expression from a heterologous promoter that utilized the alpha A-CRYBP1 binding site as an enhancer.	NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEN LT, 1994, MOL CELL BIOL, V14, P2140; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DONOVAN DM, 1992, J MOL EVOL, V35, P337, DOI 10.1007/BF00161171; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOO NC, 1991, ENDOCRINOLOGY, V128, P2118, DOI 10.1210/endo-128-4-2118; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KANTOROW M, 1993, GENE, V131, P159, DOI 10.1016/0378-1119(93)90289-F; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MITCHELMORE C, 1991, NUCLEIC ACIDS RES, V19, P141, DOI 10.1093/nar/19.1.141; MUCHARDT C, 1992, J VIROL, V66, P244, DOI 10.1128/JVI.66.1.244-250.1992; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI USA, V82, P7815; PIATIGORSKY J, 1989, FASEB J, V3, P1933, DOI 10.1096/fasebj.3.8.2656357; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RON D, 1991, MOL CELL BIOL, V11, P2887, DOI 10.1128/MCB.11.5.2887; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SAX CM, 1990, MOL CELL BIOL, V10, P6813, DOI 10.1128/MCB.10.12.6813; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREZISE AEO, 1993, HUM MOL GENET, V2, P801, DOI 10.1093/hmg/2.6.801; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; WALDMAN AS, 1992, CRIT REV ONCOL HEMAT, V12, P49, DOI 10.1016/1040-8428(92)90064-W; WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791	45	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1221	1229		10.1074/jbc.270.3.1221	http://dx.doi.org/10.1074/jbc.270.3.1221			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836383	hybrid			2022-12-25	WOS:A1995QB15600038
J	MATUSLEIBOVITCH, N; NUSSENZVEIG, DR; GERSHENGORN, MC; ORON, Y				MATUSLEIBOVITCH, N; NUSSENZVEIG, DR; GERSHENGORN, MC; ORON, Y			TRUNCATION OF THE THYROTROPIN-RELEASING-HORMONE RECEPTOR CARBOXYL TAIL CAUSES CONSTITUTIVE ACTIVITY AND LEADS TO IMPAIRED RESPONSIVENESS IN XENOPUS OOCYTES AND ATT20 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PITUITARY-CELLS; BETA-2-ADRENERGIC RECEPTOR; INOSITOL TRISPHOSPHATE; MUSCARINIC RESPONSES; MUTATION; CALCIUM; INTERNALIZATION; DESENSITIZATION; SEQUESTRATION; ACTIVATION	We studied the activity of a truncated thyrotropin-releasing hormone receptor (TRH-R), which lacks the last 59 amino acids of the carboxyl tail, where Cys-335 was mutated to a stop codon (C335Stop) (Nussenzveig, D. R., Heinflink, M., and Gershengorn, M. C. (1993) J. Biol. Chem. 268, 2389-2392). In Xenopus laevis oocytes expressing C335Stop TRH-Rs, TRH binding was higher, whereas chloride current, Ca-45(2+) efflux, and [Ca2+](i) responses evoked by TRH were 23, 39, and 21%, respectively, of those in oocytes expressing wild type mouse pituitary TRH-Rs (WT TRH-Rs). In oocytes expressing C335Stop TRH-Rs, basal Ca-45(2+) efflux and [Ca2+](i) were twice those in oocytes expressing WT TRH-Rs; chelation of Ca2+ caused a rapid increase in holding current, which is consistent with basal activation; and coexpression with other receptors caused inhibition of the responses to the other cognate agonists. In AtT20 pituitary cells stably expressing C335Stop TRH-Rs, thyrotropin-releasing hormone (TRH)-independent inositol phosphate formation was 1.32 +/- 0.11-fold higher, basal [Ca2+](i) was 1.8 +/- 0.2-fold higher, and the [Ca2+](i) response to TRH was much lower than in cells expressing WT TRH-Rs. We conclude that a TRH-R mutant truncated at Cys-335 exhibits constitutive activity that results in desensitization of the response to TRH.	TEL AVIV UNIV, SACKLER FAC MED, DEPT PHYSIOL & PHARMACOL, IL-69978 RAMAT AVIV, ISRAEL; CUNY, NEW YORK HOSP, COLL MED, DEPT MED, DIV MOLEC MED, NEW YORK, NY 10021 USA	Tel Aviv University; Sackler Faculty of Medicine; NewYork-Presbyterian Hospital					NIDDK NIH HHS [DK43036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BUCK F, 1991, BIOCHEM BIOPH RES CO, V178, P1421, DOI 10.1016/0006-291X(91)91052-E; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DASCAL N, 1984, J PHYSIOL-LONDON, V352, P551, DOI 10.1113/jphysiol.1984.sp015310; GERSHENGORN MC, 1994, J BIOL CHEM, V269, P6779; GOLDBERG G, 1992, PFLUG ARCH EUR J PHY, V420, P313, DOI 10.1007/BF00374464; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERTEL C, 1990, J BIOL CHEM, V265, P17988; IMAI A, 1986, P NATL ACAD SCI USA, V83, P8540, DOI 10.1073/pnas.83.22.8540; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LIPINSKY D, 1993, PFLUG ARCH EUR J PHY, V425, P140, DOI 10.1007/BF00374514; LUPUMEIRI M, 1990, PFLUG ARCH EUR J PHY, V417, P391, DOI 10.1007/BF00370658; LUPUMEIRI M, 1990, FEBS LETT, V262, P165, DOI 10.1016/0014-5793(90)80180-Q; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; MATUSLEIBOVITCH N, 1992, BIOCHEM J, V285, P753, DOI 10.1042/bj2850753; MATUSLEIBOVITCH N, 1994, BIOCHEM J, V303, P129, DOI 10.1042/bj3030129; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ORON Y, 1987, MOL ENDOCRINOL, V1, P918, DOI 10.1210/mend-1-12-918; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; REN Q, 1993, J BIOL CHEM, V268, P16483; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SHAPIRA H, 1990, BIOPHYS J, V57, P1281, DOI 10.1016/S0006-3495(90)82646-1; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SINGER D, 1990, PFLUG ARCH EUR J PHY, V416, P7, DOI 10.1007/BF00370215; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRAUB RE, 1989, MOL ENDOCRINOL, V3, P907, DOI 10.1210/mend-3-6-907; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002	33	42	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1041	1047		10.1074/jbc.270.3.1041	http://dx.doi.org/10.1074/jbc.270.3.1041			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836357	hybrid			2022-12-25	WOS:A1995QB15600012
J	KERN, G; KERN, D; SCHMID, FX; FISCHER, G				KERN, G; KERN, D; SCHMID, FX; FISCHER, G			A KINETIC-ANALYSIS OF THE FOLDING OF HUMAN CARBONIC-ANHYDRASE-II AND ITS CATALYSIS BY CYCLOPHILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERIZATION; PROLYL ISOMERASE; PROLINE ISOMERIZATION; ENZYMATIC CATALYSIS; HOMOLOG NINAA; PROTEIN; ACID; RIBONUCLEASE-T1; MUTAGENESIS; COLLAGEN	The kinetics of unfolding and refolding of human carbonic anhydrase II (HCAII) and its catalysis by the peptidyl-prolyl-cis/trans-isomerase cyclophilin were investigated, HCAII contains 15 trans- and 2 cis-prolyl peptide bonds, and, when long-term denatured, virtually all unfolded molecules contain non-native prolyl isomers, In unfolding these molecules (U-s) are produced slowly in a biphasic process reflecting the isomerization of several trans-prolines and of one cis-proline. In refolding, the rapid formation of an intermediate of the molten globule type is followed by several slow prolyl isomerizations, which determine the rate of reactivation, By a short 10-s incubation in 5.0 M guanidinium chloride at 2 degrees C, unfolded HCAII species with all prolines still in the native conformation (U-f) could be produced, Surprisingly, only a fraction of U-f refolds rapidly, but the other molecules refold slowly. Evidently, some prolyl peptide bonds isomerize early in refolding, at the stage of the molten globule and as a consequence, molecules with incorrect prolyl isomers are formed in competition with the productive folding of U-f. This fraction of slow-folding molecules is strongly increased when cyclophilin is present, because it accelerates the formation of non-native prolyl isomers as long as the molecules remain in the molten globule state, Later cyclophilin catalyzes the isomerization of these prolyl peptide bonds toward the native state, which are stabilized in their conformation by further folding to the native state. This catalysis is very efficient, because only prolines that are accessible in the molten globule are involved in this sequence of isomerization and reisomerization.	UNIV BAYREUTH,BIOCHEM LAB,D-95440 BAYREUTH,GERMANY	University of Bayreuth	KERN, G (corresponding author), MAX PLANCK ARBEITSGRP ENZYMOL PEPTIDBINDUNG,WEINBERGWEG 16A,D-06120 HALLE,GERMANY.							BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; CASSIM JY, 1969, BIOCHEMISTRY-US, V8, P1947, DOI 10.1021/bi00833a026; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; IKAI A, 1979, ARCH BIOCHEM BIOPHYS, V190, P39; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KELLEY RF, 1984, BIOCHEMISTRY-US, V23, P5095, DOI 10.1021/bi00317a003; KERN G, 1994, FEBS LETT, V348, P145, DOI 10.1016/0014-5793(94)00591-5; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MARTENSSON LG, 1993, BIOCHEMISTRY-US, V32, P224, DOI 10.1021/bi00052a029; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MCCOY LF, 1980, BIOCHEMISTRY-US, V19, P4738, DOI 10.1021/bi00562a003; MCCOY LF, 1981, BIOCHEMISTRY-US, V20, P3062, DOI 10.1021/bi00514a012; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; ONDEK B, 1992, J BIOL CHEM, V267, P16460; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; VEERARAGHAVAN S, 1994, BIOCHEMISTRY-US, V33, P687, DOI 10.1021/bi00169a009	33	62	64	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					740	745		10.1074/jbc.270.2.740	http://dx.doi.org/10.1074/jbc.270.2.740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822304	hybrid			2022-12-25	WOS:A1995QB81600038
J	MURPHY, C; BECKERS, J; RUTHER, U				MURPHY, C; BECKERS, J; RUTHER, U			REGULATION OF THE HUMAN C-REACTIVE PROTEIN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; INTERLEUKIN-6; INFLAMMATION; INDUCTION; PROMOTER; RNA	Human C-reactive protein (hCRP) is a major acute-phase reactant in man. The regulation of the hCRP gene in transgenic mice is similar to that in humans. To map DNA regions required for the correct regulation of the hCRP gene, several constructs have been generated, and their expression in transgenic mice has been analyzed. Constructs lacking DNA regions surrounding the poly(A) site of the gene are not expressed either before or after induction in transgenic mice. Minimal regions 540 base pairs upstream and 1.2 kilobases downstream of the hCRP gene are sufficient for liver-specific expression. Extended 5'- and 3'-flanking regions are required to silence the expression prior to induction. Our findings demonstrate that regulatory sequences shown to confer inducible expression of the hCRP gene in hepatoma cell lines are insufficient in transgenic mice.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	European Molecular Biology Laboratory (EMBL); Hannover Medical School			Murphy, Carol/ABE-4282-2021; Beckers, Johannes/K-7237-2012	Murphy, Carol/0000-0003-1353-8558; Beckers, Johannes/0000-0001-7874-3822				ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1989, IN VITRO CELL DEV, V25, P113; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P5893; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GREAVES DR, 1990, CELL, V56, P979; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGAN B, 1986, MANIPULATING MOUSE E; LI SP, 1990, J BIOL CHEM, V265, P4136; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; RUTHER U, 1993, ONCOGENE, V8, P87; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; TONIATTI C, 1990, MOL BIOL MED, V7, P199; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WILLIAMS M, 1991, GENE DEV, V5, P2352	22	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					704	708		10.1074/jbc.270.2.704	http://dx.doi.org/10.1074/jbc.270.2.704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822299	hybrid			2022-12-25	WOS:A1995QB81600033
J	PLASCHKESCHLUTTER, A; BEHRENS, J; GHERARDI, E; BIRCHMEIER, W				PLASCHKESCHLUTTER, A; BEHRENS, J; GHERARDI, E; BIRCHMEIER, W			CHARACTERIZATION OF THE SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR GENE PROMOTER - POSITIVE AND NEGATIVE REGULATORY ELEMENTS DIRECT GENE-EXPRESSION TO MESENCHYMAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HUMAN FIBROBLASTS; MESSENGER-RNA; HEPATOCYTE; RECEPTOR; IDENTIFICATION; REGION; LIVER; DIFFERENTIATION; SECRETION	Scatter factor/hepatocyte growth factor (SF/HGF) and its receptor c-Met represent a paracrine signaling system involved in mesenchymal-epithelial interactions during development and during tumor progression. We have examined the promoters of the mouse and human SF/HGF genes by deletion mapping followed by CAT assays as well as by gel retardation and footprinting analysis. The promoter sequences are highly conserved (89.5% identity) up to position -453 from the major transcription start site but diverged considerably further upstream. Both promoters are active in mesenchymal but not epithelial cells thus reflecting the expression pattern of the SF/HGF gene in cells in vitro and in vivo. We have here identified two regulatory sequences in the SF/HGF promoter: a negative element at positions -239 to -258 and a positive element near the major transcription start site; specific deletions destroyed the activities of these elements. We were not able to localize elements on the SF/HGF promoter region that mediate the previously described effects of transforming growth factor beta, 12-O-tetradecanoylphorbol-13-acetate, and coculture of epithelial cells on SF/HGF gene expression. This study represents a first step toward understanding the intricately regulated and cell type-specific expression of the paracrine acting SF/HGF.	UNIV CAMBRIDGE, SCH MED, IMPERIAL CANC RES FUND, CELL INTERACT LAB, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	PLASCHKESCHLUTTER, A (corresponding author), MAX DELBRUCK CTR MOLEC MED, ROBERT ROSSLE STR 10, D-13125 BERLIN, GERMANY.		Gherardi, Ermanno/AAB-9608-2022	GHERARDI, ERMANNO/0000-0002-0016-2945				ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEN YY, 1994, ONCOGENE, V9, P2269; ERLICH AH, 1989, PCR TECHNOLOGY PRINC, P61; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GOHDA E, 1992, CELL BIOL INT REP, V16, P917, DOI 10.1016/S0309-1651(06)80171-2; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HU Z, 1991, AM J PATHOL, V142, P1823; KAMALATI T, 1992, J CELL SCI, V101, P323; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; LIU YH, 1994, J BIOL CHEM, V269, P4152; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P9011; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; RAMADORI G, 1992, BIOCHEM BIOPH RES CO, V183, P739, DOI 10.1016/0006-291X(92)90545-V; ROSEN EM, 1990, BIOCHEM BIOPH RES CO, V168, P1082, DOI 10.1016/0006-291X(90)91140-N; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Sambrook J, 1989, MOL CLONING LABORATO; Saxen L., 1987, ORGANOGENESIS KIDNEY; SESLAR SP, 1993, CANCER RES, V53, P1233; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314	45	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					830	836		10.1074/jbc.270.2.830	http://dx.doi.org/10.1074/jbc.270.2.830			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822318	hybrid			2022-12-25	WOS:A1995QB81600052
J	VIADIU, H; OSUNA, J; FINK, AL; SOBERON, X				VIADIU, H; OSUNA, J; FINK, AL; SOBERON, X			A NEW TEM BETA-LACTAMASE DOUBLE MUTANT WITH BROADENED SPECIFICITY REVEALS SUBSTRATE-DEPENDENT FUNCTIONAL INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-LICHENIFORMIS 749/C; STAPHYLOCOCCUS-AUREUS PC1; CLASS-A; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; RESOLUTION; HYDROLYSIS; CEPHALOSPORINS; SITE; INTERMEDIATE	Using a random combinatorial mutagenesis of TEM beta-lactamase, directed against residues potentially involved in substrate discrimination, followed by selection on third generation cephalosporins, we obtained the double mutant E104M/G238S. Additionally, by using cloning strategies and site-directed mutagenesis we constructed the individual single mutants and also the single modification E104K and the double mutant E104K/G238S, which broaden the specificity of clinically isolated TEM beta-lactamase variants. The kinetic characterization of the purified double mutant E104M/G238S and its single counterparts E104M and G238S was carried out. The single mutant E104M exhibited increased k(cat) values against all substrates tested. K-m values remained similar to the values shown by the wild-type enzyme. The mutation at E104M was responsible for the increased hydrolysis rate against cefuroxime shown by the double mutant E104M/G238S. The effect of mutation G238S varied more pronouncedly, depending on the substrate. In general, a lower K-m was observed, but also a decreased k(cat). The double mutant E104M/G238S exhibited a higher hydrolytic rate against cefotaxime compared with the corresponding single mutations. We observed nearly a 1000-fold greater k(cat)/K-m for the double mutant than for the wild type. This improvement in catalysis was the consequence of increased k(cat) and decreased K-m values. Computed contact interactions from modeling substrate complexes show reliable results only for benzylpenicillin. The modeling results with this substrate confirmed the observed enzyme activities for the different single and double mutants. Analysis of the apparent coupling energies, as calculated from the kinetic parameters of the single and double mutants, showed that the quantitative effect of a second mutation on a single mutant was either absent, additive, partially additive, or synergistic with respect to the first mutation, depending on the substrate analyzed.	UNIV NACL AUTONOMA MEXICO, INST BIOTECNOL, CUERNAVACA 62271, MORELOS, MEXICO; UNIV CALIF SANTA CRUZ, DEPT CHEM & BIOCHEM, SANTA CRUZ, CA 95064 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California Santa Cruz			Soberon, Xavier/A-8826-2008; Viadiu, Hector/E-7785-2013	Osuna, Joel/0000-0002-8904-0724				AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; COUTURE F, 1992, MOL MICROBIOL, V6, P1693, DOI 10.1111/j.1365-2958.1992.tb00894.x; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JUTEAU JM, 1992, PROTEIN ENG, V5, P693, DOI 10.1093/protein/5.7.693; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KNOX JR, 1993, PROTEIN ENG, V6, P11, DOI 10.1093/protein/6.1.11; LEE KY, 1991, PROTEINS, V11, P45, DOI 10.1002/prot.340110106; MERINO E, 1992, BIOTECHNIQUES, V12, P508; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; SOUGAKOFF W, 1988, FEMS MICROBIOL LETT, V56, P343, DOI 10.1111/j.1574-6968.1988.tb03204.x; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; VANHUIJSDUIJNEN RAMH, 1992, NUCLEIC ACIDS RES, V20, P919, DOI 10.1093/nar/20.4.919; WALEY SG, 1974, BIOCHEM J, V139, P789, DOI 10.1042/bj1390789	22	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					781	787		10.1074/jbc.270.2.781	http://dx.doi.org/10.1074/jbc.270.2.781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822311	hybrid			2022-12-25	WOS:A1995QB81600045
J	CHAMBLISS, KL; CAUDLE, DL; HINSON, DD; MOOMAW, CR; SLAUGHTER, CA; JAKOBS, C; GIBSON, KM				CHAMBLISS, KL; CAUDLE, DL; HINSON, DD; MOOMAW, CR; SLAUGHTER, CA; JAKOBS, C; GIBSON, KM			MOLECULAR-CLONING OF THE MATURE NAD(+)-DEPENDENT SUCCINIC SEMIALDEHYDE DEHYDROGENASE FROM RAT AND HUMAN - CDNA ISOLATION, EVOLUTIONARY HOMOLOGY, AND TISSUE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; BRAIN; LIVER; IDENTIFICATION; ENZYME; GENE	Three rat brain cDNA clones similar to 3500, 1465, and 1135 base pairs in length encoding succinic semialdehyde dehydrogenase (SSADH; EC 1.2.1.24) were isolated from two cDNA libraries using a polymerase chain reaction derived probe. Restriction mapping and DNA sequencing revealed that the 3.5-kilobase clone contained an 84-base pair (28 amino acid) insert in the coding region. Composite clones encoding mature SSADH predicted proteins with 488 amino acids (M(r) = 52,188) when including the insert and 460 amino acids (M(r) = 48,854) without the insert. The cDNA clones were confirmed by expression of enzyme activity in bacteria and protein sequence data obtained from sequencing purified rat brain SSADH. Two human liver SSADH cDNA clones of 1091 and 899 base pairs were also isolated. Human and rat SSADH share 83 and 91% identity in nucleotide and protein sequence, respectively Northern blot analysis revealed two differentially expressed SSADH transcripts of approximately 2.0 and 6.0 kilobases in both rat and human tissues. Human genomic Southern blots indicate that the two SSADH transcripts are encoded by a greater than 20-kilobase single copy gene. Mammalian SSADH contains significant homology to bacterial NADP(+)-succinic semialdehyde dehydrogenase (EC 1.2.1.16) and conserved regions of general aldehyde dehydrogenases (EC 1.2.1.3), suggesting it is a member of the aldehyde dehydrogenase superfamily of proteins.	BAYLOR UNIV,MED CTR,CTR METAB DIS,DALLAS,TX 75226; BAYLOR UNIV,MED CTR,DALLAS,TX 75226; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; FREE UNIV AMSTERDAM,DEPT PEDIAT,1081 HV AMSTERDAM,NETHERLANDS	Baylor University; Baylor University Medical Center; Baylor University; Baylor University Medical Center; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam								ABRIOLA DP, 1987, BIOCHEMISTRY-US, V26, P5679, DOI 10.1021/bi00392a015; ANDRE B, 1990, NUCLEIC ACIDS RES, V18, P3049, DOI 10.1093/nar/18.10.3049; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CHAMBLISS KL, 1992, INT J BIOCHEM, V24, P1493, DOI 10.1016/0020-711X(92)90077-E; CHAMBLISS KL, 1993, J INHERIT METAB DIS, V16, P523, DOI 10.1007/BF00711671; CHAMBLISS KL, 1994, PEDIATR RES, V35, pA151; Erdo S.L., 1992, GABA OUTSIDE CNS, P97; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; HAU LC, 1985, P NATL ACAD SCI USA, V82, P3771; HEMPEL JD, 1981, J BIOL CHEM, V256, P889; HUANG WM, 1990, P NATL ACAD SCI USA, V87, P8491, DOI 10.1073/pnas.87.21.8491; KURYS G, 1993, EUR J BIOCHEM, V218, P311, DOI 10.1111/j.1432-1033.1993.tb18379.x; KWON OS, 1992, J BIOL CHEM, V267, P7215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANTHEY CL, 1990, CANCER RES, V50, P4991; MEDINAKAUWE LK, 1994, J NEUROCHEM, V62, P1267; NIEGEMANN E, 1993, ARCH MICROBIOL, V160, P454, DOI 10.1007/BF00245306; Pearl PL, 2006, FUTUR NEUROL, V1, P631, DOI 10.2217/14796708.1.5.631; RYZLAK MT, 1988, ARCH BIOCHEM BIOPHYS, V266, P386, DOI 10.1016/0003-9861(88)90270-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNEAD OC, 1978, NEUROLOGY, V28, P636, DOI 10.1212/WNL.28.7.636; STEFFEN D, 1979, P NATL ACAD SCI USA, V76, P4554, DOI 10.1073/pnas.76.9.4554; [No title captured]	23	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					461	467		10.1074/jbc.270.1.461	http://dx.doi.org/10.1074/jbc.270.1.461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814412	hybrid			2022-12-25	WOS:A1995QA28700073
J	HUANG, ZM; CHEN, Y; NISSENSON, RA				HUANG, ZM; CHEN, Y; NISSENSON, RA			THE CYTOPLASMIC TAIL OF THE G-PROTEIN-COUPLED RECEPTOR FOR PARATHYROID-HORMONE AND PARATHYROID HORMONE-RELATED PROTEIN CONTAINS POSITIVE AND NEGATIVE SIGNALS FOR ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ADENYLATE CYCLASE SYSTEM; OPOSSUM KIDNEY-CELLS; MEDIATED ENDOCYTOSIS; CARBOXYL-TERMINUS; PLASMA-MEMBRANE; DOWN-REGULATION; KINASE-ACTIVITY; BONE-CELLS; INTERNALIZATION	The present studies were done to evaluate the role of the cytoplasmic tail of the G-protein-coupled receptor for parathyroid hormone (PTH) and PTH related protein (PTHrP) in the endocytosis of agonist-occupied receptors. PTH/PTHrP receptor mutants progressively truncated from the C terminus were expressed in COS-7 cells, and their ability to internalize I-125-PTHrP(1-34) amide was determined. Most of the C terminal tail (91 of 127 residues) could be deleted without affecting internalization. However, further truncation removing residues 475-494 resulted in a 50-60% decrease in ligand internalization. A mutant with an internal deletion of these 20 amino acids showed a similar reduction in internalization, confirming the presence of a positive endocytic signal. No additional positive signals were found in the membrane-proximal region of the tail. How ever, alanine mutagenesis of the membrane-proximal residues 459-461 (EVQ --> AAA) resulted in a mutant PTH/PTHrP receptor displaying a 40% increase in ligand endocytosis, indicating that EVQ functions as a negative signal. Treatment of COS-7 cells with hypertonic sucrose (to disrupt clathrin lattices) markedly suppressed (by > 80%) PTH/PTHrP receptor internalization. These results demonstrate the presence of both positive and negative endocytic signals in the membrane-proximal cytoplasmic tail of the PTH/PTHrP receptor and suggest that these signals regulate the ability of the receptor to accumulate in clathrin-coated pits.	VET ADM MED CTR,ENDOCRINE RES UNIT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK35323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BROWN RC, 1991, AM J PHYSIOL, V260, pE544, DOI 10.1152/ajpendo.1991.260.4.E544; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; LAMEH J, 1993, J BIOL CHEM, V267, P13406; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAHONEY CA, 1983, J CLIN INVEST, V72, P411, DOI 10.1172/JCI110989; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MORO O, 1994, J BIOL CHEM, V269, P6651; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NISSENSON RA, 1985, CANCER RES, V45, P5358; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PERNALETE N, 1990, ENDOCRINOLOGY, V126, P407, DOI 10.1210/endo-126-1-407; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROHER J, 1993, MOL BIOL CELL, V4, P511; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TEITELBAUM AP, 1984, ENDOCRINOLOGY, V114, P980, DOI 10.1210/endo-114-3-980; TEITELBAUM AP, 1986, ENDOCRINOLOGY, V118, P595, DOI 10.1210/endo-118-2-595; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	39	120	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					151	156		10.1074/jbc.270.1.151	http://dx.doi.org/10.1074/jbc.270.1.151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814366	hybrid			2022-12-25	WOS:A1995QA28700027
J	SUCHANEK, B; SEEBURG, PH; SPRENGEL, R				SUCHANEK, B; SEEBURG, PH; SPRENGEL, R			GENE STRUCTURE OF THE MURINE N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT NR2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CENTRAL-NERVOUS-SYSTEM; EXCITATORY AMINO-ACIDS; NMDA RECEPTOR; BINDING-PROTEIN; CHANNEL; FAMILY; EXPRESSION; GENOME; MEMBER	The murine N-methyl D-aspartate receptor subunit NR2C (epsilon-3) is encoded by a unique gene composed of 12 translated and three 5'-untranslated exons that spread over similar to 20 kilobases of genomic sequence. The GC-rich promoter that lacks TATA- and CAAT-positioning elements has two transcriptional start sites separated by 18 base pairs. One of these sites is located in a conserved initiator motif and, together with the first four exons, specifies the 5'-untranslated sequence of 772 nucleo tides. In this sequence, two alternative splice variants were detected that show identical expression patterns in adult mouse brain. Comparison of intron positions in genes encoding different members of the glutamate receptor family confirms a close evolutionary relationship of the NR2C and NMDAR1 subunit genes.	UNIV HEIDELBERG,CTR BIOL MOLEC,NEUROENDOCRINOL MOLEC LAB,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; GREGOR P, 1992, MOL BRAIN RES, V16, P179, DOI 10.1016/0169-328X(92)90223-X; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Sambrook J, 1989, MOL CLONING LABORATO; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SPRENGEL R, 1993, FEBS LETT, V325, P90, DOI 10.1016/0014-5793(93)81420-5; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAKANO H, 1993, BIOCHEM BIOPH RES CO, V197, P922, DOI 10.1006/bbrc.1993.2567; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005	28	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					41	44		10.1074/jbc.270.1.41	http://dx.doi.org/10.1074/jbc.270.1.41			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814402	hybrid			2022-12-25	WOS:A1995QA28700011
J	SEETHARAM, L; GOTOH, N; MARU, Y; NEUFELD, G; YAMAGUCHI, S; SHIBUYA, M				SEETHARAM, L; GOTOH, N; MARU, Y; NEUFELD, G; YAMAGUCHI, S; SHIBUYA, M			A UNIQUE SIGNAL-TRANSDUCTION FROM FLT TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR VEGF	ONCOGENE			English	Article						ENDOTHELIAL GROWTH FACTOR; VEGF; ANGIOGENESIS; FIT TYROSINE KINASE; SIGNAL TRANSDUCTION	TRK PROTOONCOGENE PRODUCT; PERMEABILITY FACTOR; CELL GROWTH; BINDING-SITES; DEVELOPMENTAL EXPRESSION; SENSITIVE METHOD; AMINO-ACID; PROTEIN; ANGIOGENESIS; MITOGEN	Flt-1 (fms-like tyrosine kinase-1), a receptor-type tyrosine kinase of sharing similar features with two other flt-family encoded proteins KDR/Flk-1 and Flt-4, has been recently identified as a receptor for Vascular Endothelial Growth Factor (VEGF) known to induce the proliferation of vascular endothelial cells. In this study, we demonstrate that Flt-1 encodes for a 180 kDa glycoprotein, binds VEGF with high affinity, undergoes autophosphorylation but does not generate any mitogenic response in transfected NIH3T3 fibroblasts. Interestingly, the immediate early gene c-myc was not induced, whereas the c-fos was induced very weakly in Flt-1 expressing NIH3T3 cells. A comparative analysis of the Flt-1 signal cascade in the environment of endothelial cells with that of Flt-1 expressing NIH3T3 cells showed that VEGF induced phosphorylation of PLC gamma and GAP complex on tyrosine in both type of cells. However, a strong activation of MAP kinases was observed only in endothelial cells. Further, different from many other receptor tyrosine kinases, tyrosine phosphorylation of She protein, an important adaptor for signal transduction from many receptor kinases, was very weak in both Flt-1-NIH3T3 cells and endothelial cells. These results suggest that Flt-1 kinase utilizes a unique signal transduction system in endothelial cells, and the activation of the Flt-1 kinase is insufficient to trigger a mitogenic response in NIH3T3 fibroblasts.	UNIV TOKYO, INST MED SCI, DEPT GENET, TOKYO 108, JAPAN; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	University of Tokyo; Technion Israel Institute of Technology			GOTOH, Noriko/D-8430-2015; Neufeld, Gera/F-1524-2019					APRELIKOVA O, 1992, CANCER RES, V52, P746; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIER G, 1992, DEVELOPMENT, V114, P521; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COFFIN JD, 1988, DEVELOPMENT, V102, P735; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH Y, 1990, EUR J BIOCHEM, V193, P611; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KLAGSBRUN M, 1987, ANGIOGENIS MECHANISM; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9627; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULER R, 1986, ONCOGENES GROWTH CON; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1986, P NATL ACAD SCI USA, V83, P3855, DOI 10.1073/pnas.83.11.3855; RISAU W, 1988, DEVELOPMENT, V102, P471; ROSNET O, 1993, ONCOGENE, V8, P173; Sambrook J, 1989, MOL CLONING LABORATO; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHESSINGER J, 1992, NEURON, V9, P383; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WRANA JL, 1994, ANTURE, V370, P341; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAMANE A, 1994, ONCOGENE, V9, P2683; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	79	417	439	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					135	147						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824266				2022-12-25	WOS:A1995QA98000016
J	TSUCHIYA, Y; TAKAHASHI, T; SAKURAI, Y; IWAMATSU, A; TAKAHASHI, K				TSUCHIYA, Y; TAKAHASHI, T; SAKURAI, Y; IWAMATSU, A; TAKAHASHI, K			PURIFICATION AND CHARACTERIZATION OF A NOVEL MEMBRANE-BOUND ARGININE-SPECIFIC SERINE PROTEINASE FROM PORCINE INTESTINAL-MUCOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOMELANOCORTIN-CONVERTING ENZYME; SUBSTRATE-SPECIFICITY; YEAST KEX2; RAT-LIVER; PROCESSING ENDOPROTEASES; MICROSOMAL ENDOPEPTIDASE; FUNCTIONAL EXPRESSION; STRUCTURAL HOMOLOGY; PEPTIDE PRECURSORS; CONSENSUS SEQUENCE	A novel membrane-bound serine proteinase has been purified from the microsomal membranes of porcine intestinal mucosa. It was solubilized from the microsomal membrane fraction with 1% sodium deoxycholate, then purified by a series of column chromatographic steps on DE52, butyl-Toyopearl, Bio-Gel P-150, Mono Q, and benzamidine-Sepharose in the presence of 0.02% Lubrol PX. Its molecular mass was estimated to be 50 kDa both by SDS-polyacrylamide gel electrophoresis under nonreducing conditions and by gel filtration, and to be 32 kDa by SDS-polyacrylamide gel electrophoresis under reducing conditions, suggesting that the enzyme may exist as a homodimer in which two subunits are linked by disulfide bond(s). It had a pH optimum at around 9 and did not require Ca2+ for activity. It cleaved several peptide 4-methylcoumaryl-7-amide substrates almost exclusively after arginine residues, the best substrate among those tested being t-butyloxycarbonyl-Gln-Ala-Arg-4-methylcoumaryl-7-amide. Various neuropeptides were also cleaved by this enzyme after arginine, mainly between paired basic amino acid residues, Arg-Arg or Arg-Lys. Activity toward protein substrates was scarcely detected. Further, its partial amino acid sequences were highly homologous, but not identical, with those of trypsin-type serine proteinases. These results indicate that the present enzyme is a novel arginine-specific trypsinlike endopeptidase, possibly involved as a processing proteinase in the production of certain gastrointestinal neuropeptides or peptide hormones from their precursors, or their specific degradation.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Kirin Brewery Company Limited								AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DEGAN SJF, 1983, BIOCHEMISTRY-US, V22, P2087; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; FURIE B, 1982, J BIOL CHEM, V257, P3875; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KESSLER M, 1978, BIOCHIM BIOPHYS ACTA, V506, P136, DOI 10.1016/0005-2736(78)90440-6; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LOH YP, 1985, J BIOL CHEM, V260, P7194; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARX J, 1991, SCIENCE, V252, P779, DOI 10.1126/science.1674172; MASSON D, 1986, EMBO J, V5, P1595, DOI 10.1002/j.1460-2075.1986.tb04401.x; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SILBERRING J, 1992, J BIOL CHEM, V267, P21324; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGAWA K, 1981, J BIOCHEM-TOKYO, V90, P1243, DOI 10.1093/oxfordjournals.jbchem.a133588; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI K, 1991, BIOCHEM BIOPH RES CO, V175, P1152, DOI 10.1016/0006-291X(91)91686-7; TAMANOUE Y, 1993, J BIOCHEM-TOKYO, V113, P229, DOI 10.1093/oxfordjournals.jbchem.a124031; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WALSH KA, 1964, P NATL ACAD SCI USA, V52, P834; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YANAGIDA M, 1991, BIOMED RES-TOKYO, V12, P113, DOI 10.2220/biomedres.12.113	50	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32985	32991						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806528				2022-12-25	WOS:A1994QA63800042
J	BRAKEBUSCH, C; VARFOLOMEEV, EE; BATKIN, M; WALLACH, D				BRAKEBUSCH, C; VARFOLOMEEV, EE; BATKIN, M; WALLACH, D			STRUCTURAL REQUIREMENTS FOR INDUCIBLE SHEDDING OF THE P55 TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR TNF RECEPTOR; FACTOR-BINDING PROTEIN; MOLECULAR-CLONING; CELL-SURFACE; SOLUBLE FORM; MONOCLONAL-ANTIBODIES; PHORBOL ESTER; GENE-PRODUCT; EXPRESSION	Induced shedding of the p55 tumor necrosis factor receptor (p55-R) was previously shown 60 be independent of the amino acid sequence properties of the intracellular domain of this receptor. We now find it also independent of the sequence properties of the transmembrane domain and of the cysteine-rich region that constitutes most of the extracellular domain of the receptor. The shedding is shown to depend solely on the sequence properties of a small region within the spacer that Links the cysteine-rich region in the extracellular domain to the transmembrane domain. Detailed tests of effects of mutations in the spacer on the shedding indicate that the process is independent of the amino acid side-chain identity in this region except for a limited dependence on the identity of 1 residue (Val-173), located downstream to the putative major cleavage site of the receptor. It is strongly affected, however, by some mutations that seem to change the conformation of the spacer region. These findings suggest that a short amino acid sequence in the p55-R is essential and sufficient for its shedding and that the shedding is mediated either by a protease with limited sequence specificity or by several different proteases that recognize different amino acid sequences, yet it strictly depends on some conformational features of the cleavage region in the receptor.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Brakebusch, Cord/0000-0002-9342-1634				ADERKA D, 1991, CANCER RES, V51, P5602; ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ADERKA D, 1993, TUMOR NECROSIS FACTO, V4, P191; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; AVIVI A, 1991, ONCOGENE, V6, P673; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1993, TUMOR NECROSIS FACTO, V4, P40; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENDLY BM, 1990, CANCER RES, V50, P1550; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; ISRAEL S, 1986, IMMUNOL LETT, V12, P217, DOI 10.1016/0165-2478(86)90007-6; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LITTLEFIELD JW, 1964, NATURE, V203, P1142, DOI 10.1038/2031142a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOSSALAYI MD, 1991, B I PASTEUR, V89, P139; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SELDEN RF, 1994, CURRENT PROTOCOLS MO, V1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUNADA H, 1985, ANAL BIOCHEM, V149, P438, DOI 10.1016/0003-2697(85)90595-0; TAGA T, 1989, CELL, V58, P578; ULRICH A, 1984, NATURE, V309, P418; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; WALLACH D, 1991, TUMOR NECROSIS FACTO, V3, P47; WARE CF, 1991, J IMMUNOL, V147, P4229; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	55	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32488	32496						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798250				2022-12-25	WOS:A1994PX30400071
J	CARRIER, F; SMITH, ML; BAE, I; KILPATRICK, KE; LANSING, TJ; CHEN, CY; ENGELSTEIN, M; FRIEND, SH; HENNER, WD; GILMER, TM; KASTAN, MB; FORNACE, AJ				CARRIER, F; SMITH, ML; BAE, I; KILPATRICK, KE; LANSING, TJ; CHEN, CY; ENGELSTEIN, M; FRIEND, SH; HENNER, WD; GILMER, TM; KASTAN, MB; FORNACE, AJ			CHARACTERIZATION OF HUMAN GADD45, A P53-REGULATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; KINASE-C; P53; ACTIVATION; CELLS; RNA; RADIATION; INDUCTION; ARREST	GADD45 (growth arrest and DNA damage) is a DNA-damage-inducible gene regulated in part by the tumor suppressor p53. A role in negative growth control has recently been suggested based on significant (more than 75%) reduction of colony formation following over expression of Gadd45. To better understand the role of Gadd45, we have developed specific rabbit and murine antibodies raised against the human recombinant protein. Using these antibodies, we have found that in ML-1 cells Gadd45 is predominantly a nuclear protein. MyD118, a protein induced by terminal differentiation sharing 57% homology with Gadd45, does not cross-react with any of the antibodies produced. As expected, the induction of Gadd45 protein by ionizing radiation (IR) was also found to be dependent on a mild type p53 phenotype. Interestingly, WI-L2-NS, a human lymphoid cell line, showed very high basal levels of Gadd45 mRNA and protein in addition to a high constitutive level of a mutated p53 protein. In this cell Line, the high levels of GADD45 did not inhibit cellular growth in spite of the fact that no mutations were found in GADD45 sequence. These results indicate that some cell line(s) can tolerate high levels of Gadd45 and abrogate its growth suppression function.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; OREGON HLTH SCI UNIV,SCH MED,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201; MASSACHUSETTS GEN HOSP E,BOSTON,MA 02129	GlaxoSmithKline; GlaxoSmithKline; Oregon Health & Science University	CARRIER, F (corresponding author), NCI,DCT,DTP,MOLEC PHARMACOL LAB,BETHESDA,MD 20892, USA.		Carrier, France/C-3063-2008	Carrier, France/0000-0002-5517-5284				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY JA, 1968, CANCER-AM CANCER SOC, V22, P517, DOI 10.1002/1097-0142(196809)22:3<517::AID-CNCR2820220305>3.0.CO;2-A; LORD KA, 1990, ONCOGENE, V5, P387; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	23	111	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32672	32677						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798274				2022-12-25	WOS:A1994PX30400097
J	CHEN, DW; SWENSON, RP				CHEN, DW; SWENSON, RP			CLONING, SEQUENCE-ANALYSIS, AND EXPRESSION OF THE GENES ENCODING THE 2 SUBUNITS OF THE METHYLOTROPHIC BACTERIUM W3A1 ELECTRON-TRANSFER FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS ORS571; AMINO-ACID-SEQUENCE; FAD-BINDING SITE; TRIMETHYLAMINE DEHYDROGENASE; METHYLOPHILUS-METHYLOTROPHUS; PARACOCCUS-DENITRIFICANS; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; MOLECULAR-CLONING; ESCHERICHIA-COLI	The genes encoding the two different subunits of the electron transfer flavoprotein (ETF) from the methylotrophic bacterium W3A1 have been identified, cloned, and sequenced. A 0.8-kilobase pair DNA fragment was generated for use as a molecular probe by the amplification of genomic sequences using the polymerase chain reaction and a primer pair with degenerate sequences derived from the NH2-terminal amino acid sequences determined for the ETF subunits purified hom W3A1, The screening of a partial genomic minilibrary containing size-selected BamHI-SalI fragments using this probe identified a 2.2-kilobase pair insert containing the complete coding sequences for both W3A1 ETF subunits, The genes are arranged in tandem in the genomic DNA with only 2 bases between the TAG translation termination codon of the small subunit and the ATG translation initiation codon of the large subunit, The deduced amino acid sequences of each of the W3A1 ETF subunits exhibit only similar to 30% identity with the corresponding subunits of the ETF from human, rat, and Paracoccus denitrificans, which as a group are greater than 50% identical, Thus, the ETF from W3A1 may exhibit some unique structural features that, like other differences in some of its physical and functional properties, may distinguish this ETF from others in this family. A highly homologous region near the COOH terminus of the large subunit in all the ETF proteins was found to contain a sequence that matches in several ways the ADP-binding motif of flavoproteins and other dinucleotide-binding proteins, suggesting that the large subunit forms a portion of the FAD (or AMP) binding site in these proteins. Under control of the tac promoter, the cloned ETF subunit genes were co-expressed in Escherichia coli producing the heterodimeric holoprotein with physical, spectral, and electron-accepting properties essentially identical to the ETF isolated from W3A1, The recombinant ETF serves as the electron acceptor for W3A1 trimethylamine dehydrogenase in vitro, accumulating as the air-stable anionic semiquinone in the presence of excess trimethylamine, Fully reduced ETF could not be obtained even after prolonged enzymatic reduction.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	Ohio State University					NIGMS NIH HHS [GM36490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMAN E, 1983, GENE, V25, P167; ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; BACHMANN BJ, 1983, MICROBIOL REV, V47, P180, DOI 10.1128/MMBR.47.2.180-230.1983; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CROSS AR, 1980, BIOCHEM J, V192, P429, DOI 10.1042/bj1920429; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; EARL CD, 1987, J BACTERIOL, V169, P1127, DOI 10.1128/jb.169.3.1127-1136.1987; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FRERMAN FE, 1987, T BIOCH SOC, V16, P416; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORELICK RJ, 1986, BIOCHEMISTRY-US, V25, P7092, DOI 10.1021/bi00370a050; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMS LR, 1990, BIOCHEM BIOPH RES CO, V168, P809, DOI 10.1016/0006-291X(90)92393-E; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1990, METHOD ENZYMOL, V188, P309; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; JOH T, 1987, J BIOL CHEM, V262, P15127; JORNVALL H, 1977, EUR J BIOCHEM, V72, P443, DOI 10.1111/j.1432-1033.1977.tb11268.x; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM LW, 1986, J BIOL CHEM, V261, P5140; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P250; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; RYAN T, 1983, J BIOL CHEM, V258, P4690; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIMO SS, 1969, J BACTERIOL, V98, P368, DOI 10.1128/JB.98.2.368-374.1969; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; SCHLEIF RF, 1981, PRACTICAL METHODS MO, P98; SCHULZ GE, 1982, J MOL BIOL, V160, P287, DOI 10.1016/0022-2836(82)90177-2; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SHINZAWA K, 1988, BIOCHEM BIOPH RES CO, V155, P300, DOI 10.1016/S0006-291X(88)81084-2; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; SWENSON RP, 1991, FLAVINS AND FLAVOPROTEINS 1990, P415; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; VOGT VM, 1970, J BIOL CHEM, V245, P4760; WALLER JP, 1963, J MOL BIOL, V7, P483, DOI 10.1016/S0022-2836(63)80096-0; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	57	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32120	32130						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798207				2022-12-25	WOS:A1994PX30400019
J	CHEN, WN; LIM, L				CHEN, WN; LIM, L			THE CAENORHABDITIS-ELEGANS SMALL GTP-BINDING PROTEIN RHOA IS ENRICHED IN THE NERVE RING AND SENSORY NEURONS DURING LARVAL DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; SACCHAROMYCES-CEREVISIAE; ADP-RIBOSYLTRANSFERASE; REGULATORY PROTEIN; RAS SUPERFAMILY; GENE FAMILY; EXPRESSION; CLONING; ENCODES; SEQUENCE	p21 Res has been implicated in vulval differentiation in Caenorhabditis elegans. We now describe the characteristics during nematode development of the related p21 RhoA which has been ascribed a morphological role in mammals. The CeRhoA cDNA isolated in this study encodes a sequence of 192 amino acids residues with 87.6% identity to human RhoA Genomic Southern analysis indicates the presence of a single Rho gene in C. elegans. Its 2-kilobase mRNA is expressed at the highest levels during embryogenesis and decreases gradually thereafter. However, the level of the 24-kDa protein detected by the anti-CeRhoA antibody is high at the larval stages but low in embryos. The glutathione S-transferase/CeRhoA fusion protein expressed in Escherichia coli displays conserved biochemical activities. Unlike its counterpart in mammalian cells which is predominantly cytosolic, most of CeRhoA is associated with the membrane and the cytoskeleton throughout development. Indirect immunofluorescence analysis indicates an ubiquitous expression of CeRhoA throughout development with a particular enrichment at larval stages in the pharyngeal nerve ring and at the tip of the head containing chemosensory and mechanosensory neurons. This suggests a stage specific role for p21 RhoA in mediating the signaling pathway underlying the sensory circuitry in C. elegans post-embryonic development.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	CHEN, WN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, GLAXO IMCB GRP, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.			, Yang/0000-0002-6620-8897				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHEN WN, 1994, J BIOL CHEM, V269, P820; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HAFEN E, 1993, DEVELOPMENT, P41; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; ISOMURA M, 1991, ONCOGENE, V6, P119; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; LAND M, 1994, J BIOL CHEM, V269, P9234; LU XY, 1990, J BIOL CHEM, V265, P3293; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PERONA R, 1993, ONCOGENE, V8, P1285; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1993, ONCOGENE, V8, P655; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMAS JH, 1994, SCIENCE, V264, P1698, DOI 10.1126/science.7911601; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILLIAMSON KC, 1990, J BIOL CHEM, V265, P20807; WOLINSKY E, 1990, BEHAV GENET, V20, P169, DOI 10.1007/BF01067789; Wood WB, 1988, NEMATODE CAENORHABDI; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	56	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32394	32404						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798239				2022-12-25	WOS:A1994PX30400058
J	ENDO, K; ICHIKAWA, F; UCHIYAMA, Y; KATSUMATA, K; OHKAWA, H; KUMAKI, K; OGATA, E; IKEDA, K				ENDO, K; ICHIKAWA, F; UCHIYAMA, Y; KATSUMATA, K; OHKAWA, H; KUMAKI, K; OGATA, E; IKEDA, K			EVIDENCE FOR THE UPTAKE OF A VITAMIN-D ANALOG (OCT) BY A HUMAN CARCINOMA AND ITS EFFECT OF SUPPRESSING THE TRANSCRIPTION OF PARATHYROID HORMONE-RELATED PEPTIDE GENE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D ENDOCRINE SYSTEM; INFECTED T-CELLS; HUMORAL HYPERCALCEMIA; PROTEIN; EXPRESSION; IDENTIFICATION; MALIGNANCY; RECEPTOR; CANCER; GROWTH	The present study was undertaken to clarify the pharmacokinetics of 22-oxa-1,25-dihydroxyvitamin D-3 (22-oxa-1,25-(OH)(2)D-3, OCT), a vitamin D-3 analogue with little calcemic activity, and its effect on the transcription of parathyroid hormone-related peptide (PTHRP) gene in nude mice bearing a human carcinoma (FA-6) associated with humoral hypercalcemia. FA-6 tumor expressed vitamin D receptor (VDR) mRNA, and its nuclear extract contained a specific and saturable 1,25-(OH)(2)D-3 binding activity. Although [H-3]OCT administered intravenously into FA-6 tumor-bearing nude mice was cleared from the circulation more rapidly than [H-3]1,25-(OH)(2)D-3, the uptake of [H-3]OCT into the tumor tissue, relative to the radioactivity in the circulation, was greater than that of [H-3]1,25-(OH)(2)D-3. Intravenous or oral administration of OCT reduced the steady-state levels of PTHRP mRNA in FA-6 tumor, and nuclear run off assays demonstrated that the effect of OCT on PTHRP gene expression occurred at a transcriptional level. RNase mapping analysis revealed that both upstream and downstream promoters of the human PTHRP gene were down-regulated by OCT. Finally, OCT exerted a preventive as well as therapeutic effect on cancer-associated hypercalcemia with a marked prolongation of the survival time in tumor-bearing animals. These results suggest that OCT is effectively taken up by a VDR-positive human carcinoma in vivo and has a therapeutic potential for cancer-associated hypercalcemia through suppression of PTHRP gene transcription.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,DIV ENDOCRINOL,BUNKYO KU,TOKYO 112,JAPAN; CHUGAI PHARMACEUT CO LTD,BONE DIS LAB,SHIZUOKA 412,JAPAN; CANC INST HOSP,JAPANESE FDN CANC RES,TOKYO 115,JAPAN	University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Japanese Foundation for Cancer Research								ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1993, CANCER RES, V53, P2534; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BIKLE DD, 1992, ENDOCR REV, V13, P765, DOI 10.1210/er.13.4.765; BILEZIKIAN JP, 1992, NEW ENGL J MED, V326, P1196; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROWN AJ, 1993, ENDOCRINOLOGY, V133, P1158, DOI 10.1210/en.133.3.1158; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; IKEDA K, 1993, J BIOL CHEM, V268, P1174; IKEDA K, 1989, J BIOL CHEM, V264, P15743; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1990, J BIOL CHEM, V265, P5398; INOUE D, 1993, J BIOL CHEM, V268, P16730; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOBAYASHI T, 1994, J BIOCHEM-TOKYO, V115, P373, DOI 10.1093/oxfordjournals.jbchem.a124346; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1927, DOI 10.1210/endo-128-4-1927; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; MANGIN M, 1988, MOL ENDOCRINOL, V2, P1049, DOI 10.1210/mend-2-11-1049; MANGIN M, 1988, P NATL ACAD SCI USA, V85, P597, DOI 10.1073/pnas.85.2.597; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MURAYAMA E, 1986, CHEM PHARM BULL, V34, P4410; NAGATA N, 1989, ENDOCRINOL JAPON, V36, P75; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; PIERCE EA, 1987, J BIOL CHEM, V262, P17092; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; STREWLER GJ, 1990, ANNU REV MED, V41, P35; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VASAVADA RC, 1993, MOL ENDOCRINOL, V7, P273, DOI 10.1210/me.7.2.273; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WATANABE H, 1992, STEROIDS, V57, P444, DOI 10.1016/0039-128X(92)90098-T; WECKSLER WR, 1979, ANAL BIOCHEM, V92, P314, DOI 10.1016/0003-2697(79)90664-X	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32693	32699						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798277				2022-12-25	WOS:A1994PX30400100
J	HERRICK, KR; SALAZAR, D; GOODMAN, SI; FINOCCHIARO, G; BEDZYK, LA; FRERMAN, FE				HERRICK, KR; SALAZAR, D; GOODMAN, SI; FINOCCHIARO, G; BEDZYK, LA; FRERMAN, FE			EXPRESSION AND CHARACTERIZATION OF HUMAN AND CHIMERIC HUMAN PARACOCCUS-DENITRIFICANS ELECTRON-TRANSFER FLAVOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA DEHYDROGENASE; COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; ACIDEMIA TYPE-II; UBIQUINONE OXIDOREDUCTASE; PIG-LIVER; NUCLEOTIDE-SEQUENCE; CIRCULAR-DICHROISM; MOLECULAR-CLONING; ALPHA-SUBUNIT	Electron transfer flavoprotein (ETF) is a heterodimer that contains a single equivalent of FAD and accepts electrons from nine flavoprotein dehydrogenases in the mitochondrial matrix, Human ETF was expressed in Escherichia coli using the expression vector previously employed to express Paracoccus denitrificans ETF (Bedzyk, L. A., Escudero, K. A., Gill, R. E., Griffin, K. J., and Frerman, F. E. (1993) J. Biol. Chem. 268, 20211-20217). cDNAs encoding the beta and alpha subunits of the human protein were inserted into the vector, mimicking the arrangement of the P. denitrificans genes in which coding sequences are joined by overlapping termination and initiation codons, A human ETF containing 30% P. denitrificans sequence at the amino terminus of the beta subunit was also expressed and purified, This chimeric ETF has 64% sequence identity with the human sequence in the substituted region, Kinetic constants of medium chain and short chain acyl-CoA dehydrogenases for the chimeric ETFs were slightly changed from those of human ETF; but, there are marked differences in the kinetic constants of sarcosine dehydrogenase and electron transfer flavoprotein-ubiquinone oxidoreductase with the two ETFs, Absorption spectra of the three redox states of human, chimeric, and P. denitrificans ETF flavins are identical, However, the flavin circular dichroism spectra of the three ETFs are characteristic for each species, The spectrum of the chimeric ETF has both human and P. denitrificans ETF features, The amplitude of the 436 nm band is identical to that of the of the human ETF flavin, but the amplitude of the 375 nm band is identical to that of the P. denitrificans ETF flavin, Thus, flavin in the chimeric ETF appears to be exposed to dipoles in the protein framework provided by human and bacterial sequences, These spectral data indicate that the flavin is located in the vicinity of the amino-terminal region of the beta subunit, The kinetic data suggest that the amino-terminal region of the beta subunit comprises part of the docking site for some primary dehydrogenases and electron transfer flavoprotein-ubiquinone oxidoreductase.	UNIV COLORADO, SCH MED, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, PROGRAM CELLULAR & DEV BIOL, DENVER, CO 80262 USA; IST NAZL NEUROL CE BESTA, BIOCHIM & GENET LAB, I-20133 MILAN, ITALY	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Finocchiaro, Gaetano/0000-0003-3583-4040	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD004024, T32HD007385] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08315, T32 HD07385, HD04024] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUER HE, 1980, J BIOL CHEM, V255, P8157; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; BEINERT H, 1962, J BIOL CHEM, V237, P2988; EDMONDSO.DE, 1971, BIOCHEMISTRY-US, V10, P113; EDMONDSON DE, 1971, BIOCHEMISTRY-US, V10, P133; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; FRENEAUX E, 1992, J CLIN INVEST, V90, P1679, DOI 10.1172/JCI116040; FRERMAN FE, 1990, PROG CLIN BIOL RES, V321, P79; FRERMAN FE, 1988, BIOCHEM SOC T, V16, P416, DOI 10.1042/bst0160416; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; GORLICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830; GORLICK RJ, 1986, BIOCHEMISTRY-US, V25, P7092; HALL C, 1982, J BIOL CHEM; HAUGE JG, 1956, J AM CHEM SOC, V78, P5266, DOI 10.1021/ja01601a032; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSU MC, 1971, J AM CHEM SOC, V93, P3515; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; IZAI K, 1992, J BIOL CHEM, V267, P1027; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MCKEAN MC, 1979, J BIOL CHEM, V254, P2730; MCKEAN MC, 1983, J BIOL CHEM, V258, P1866; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; SCOLANAG.G, 1972, Z NATURFORSCH PT B, VB 27, P1044; SONG PS, 1972, Z NATURFORSCH PT B, VB 27, P1011, DOI 10.1515/znb-1972-0901; STEENKAMP DJ, 1988, BIOCHEM J, V255, P869, DOI 10.1042/bj2550869; STEENKAMP DJ, 1987, BIOCHEM J, V243, P519, DOI 10.1042/bj2430519; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; WATMOUGH NJ, 1991, BIOCHEMISTRY-US, V30, P1317, DOI 10.1021/bi00219a023; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102	36	24	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32239	32245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798224				2022-12-25	WOS:A1994PX30400037
J	RAO, GN; BAAS, AS; GLASGOW, WC; ELING, TE; RUNGE, MS; ALEXANDER, RW				RAO, GN; BAAS, AS; GLASGOW, WC; ELING, TE; RUNGE, MS; ALEXANDER, RW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES BY ARACHIDONIC-ACID AND ITS METABOLITES IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MAP KINASE; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; MESANGIAL CELLS; ANGIOTENSIN-II; MESSENGER-RNA; LINOLEIC-ACID; DNA-SYNTHESIS; 3T3 CELLS	Previous studies from this laboratory and others suggest that arachidonic acid and its metabolites play important roles in a variety of biological processes such as signal transduction, contraction, chemotaxis, and cell growth and differentiation. Here we studied the effect of arachidonic acid on mitogen-activated protein (MAP) kinases in vascular smooth muscle cells (VSMC). Arachidonic acid activated MAP kinases in VSMC in a time-and dose-dependent manner. Nordihydroguaiaretic acid (NDGA), a potent inhibitor of the Lipoxygenase system, significantly blocked the arachidonic acid-induced activation of MAP kinases, whereas indomethacin, an inhibitor of cyclooxygenase, had no effect. In VSMC, arachidonic acid was converted to 15-hydroxyeicosatetraenoic acid (15-HETE); NDGA inhibited the formation of this HETE. Exogenous addition of 15-HETE to VSMC caused stimulation of MAP kinases. Depletion of protein kinase C attenuated both the arachidonic acid- and 15-HETE-induced activation of MAP kinases in VSMC. Together these results suggest that 1) arachidonic acid activates MAP kinases in VSMC; 2) 15-HETE, a 15-lipoxygenase product of arachidonic acid, at least in part, mediates the arachidonic acid effect on MAP kinases; and 3) protein kinase C appears to be important in arachidonic acid activation of MAP kinases, Therefore, MAP kinases may play an important role in arachidonic acid signaling of VSMC growth and function.	EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322; NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709	Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CL, 1985, CIRC RES, V56, P97, DOI 10.1161/01.RES.56.1.97; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DELL KR, 1989, BIOCHEM J, V258, P171, DOI 10.1042/bj2580171; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOW CE, 1984, J LIPID RES, V25, P1090; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; PALMBERG L, 1987, J CELL SCI, V88, P151; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PORTER NA, 1975, J ORG CHEM, V40, P3614, DOI 10.1021/jo00912a037; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1994, J BIOL CHEM, V269, P7180; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SIEGEL MI, 1982, BIOCHEM BIOPH RES CO, V104, P874, DOI 10.1016/0006-291X(82)91330-4; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	62	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32586	32591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798262				2022-12-25	WOS:A1994PX30400084
J	SCHMID, RM; LIPTAY, S; BETTS, JC; NABEL, GJ				SCHMID, RM; LIPTAY, S; BETTS, JC; NABEL, GJ			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF NF-KAPPA-B - DETERMINANTS OF DNA-BINDING SPECIFICITY AND PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; REL ONCOGENE; SUBUNIT; P50; INHIBITION; CLONING; ONCOPROTEIN; ENCODES; MOTIFS; GENE	The NF-kappa B transcription factors display a high degree of sequence conservation in a domain initially described in the rel oncogene. Two family members, NF-kappa B1 and NF-kappa B2, have distinct DNA binding properties and functionally distinct effects on different enhancers. NF-kappa B1, for example, binds to the kappa B Site from the human immunodeficiency virus (HIV) with similar to 15-fold higher affinity than NF-kappa B2. In this study, we have defined regions within the Rel domain which determine DNA binding specificity and interaction with other proteins. We find that the COOH-terminal putative Rel dimerization domain of NF-kappa B1 is required for preferential binding to the HIV KB site. In contrast, preferential stimulation of the HIV enhancer by NF-kappa B2 with RelA(p65) is determined by both the NH2- and COOH-terminal Rel domains of NF-kappa B2. These two regions of NF-kappa B2 also mediate preferential synergy with Bcl3. These data suggest that a specific subdomain of the Rel conserved region has evolved to control the fine specificity of DNA binding, and two distinct subregions within the Rel domain determine the specificity of interaction with other transcription factors. These specific Rel-conserved domains therefore determine the specificity of NF-kappa B interactions and contribute to selective gene activation.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852	29	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32162	32167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798213				2022-12-25	WOS:A1994PX30400025
J	TAKAHARA, K; LYONS, GE; GREENSPAN, DS				TAKAHARA, K; LYONS, GE; GREENSPAN, DS			BONE MORPHOGENETIC PROTEIN-1 AND A MAMMALIAN TOLLOID HOMOLOG (MTLD) ARE ENCODED BY ALTERNATIVELY SPLICED TRANSCRIPTS WHICH ARE DIFFERENTIALLY EXPRESSED IN SOME TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; CELLS; GENE; PROTEASE; PATTERN; PRODUCT; DOMAIN; EMBRYO; BMP-1	Bone morphogenetic protein-1 (BMP-1) is a metalloprotease purified from extracts capable of inducing ectopic bone formation. In humans, it has a domain structure similar to that of the Drosophila dorsal-ventral patterning gene-product tolloid (Tld), but is considerably shorter. Here we show that, in humans and mice, alternatively spliced transcripts encode BMP-1 and a longer protein, designated mammalian tolloid (mTld), with a domain structure identical to that of Drosophila Tld. A third alternatively spliced product, in which a novel domain is inserted near the BMP-1 C terminus, is also reported. Low levels of transcripts for mTld were found in all adult human tissues surveyed, while BMP-1 transcripts were detectable in all adult tissues except brain. This differential expression was mirrored in embryonic mouse tissues where in situ hybridization found high levels of mTld transcripts, but was unable to detect BMP-1 transcripts, in the floor plate of the neural tube of the developing central nervous system. The third alternatively spliced form was not detected in adult human tissues. In situ hybridizations found punctate signals for all three forms localized to trophoblast giant cells in 17.5-day mouse placenta, with highest levels of expression, especially for BMP-1, near the maternal interface.	UNIV WISCONSIN, SCH MED, DEPT PATHOL & LAB MED, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT ANAT, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, CELL & MOLEC BIOL PROGRAM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Greenspan, Daniel/0000-0001-8096-7446	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029471] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-29471] Funding Source: Medline; NIGMS NIH HHS [GM-46846] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; LEE ST, 1988, J BIOL CHEM, V263, P13414; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; PLACZEK M, 1991, DEVELOPMENT, P105; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SOARES MJ, 1993, TROPHOBLAST CELLS PA, P46; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1990, J CELL SCI, P149	26	140	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32572	32578						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798260				2022-12-25	WOS:A1994PX30400082
J	SUKEGAWA, J; BLOBEL, G				SUKEGAWA, J; BLOBEL, G			A PUTATIVE MAMMALIAN RNA HELICASE WITH AN ARGININE-SERINE-RICH DOMAIN COLOCALIZES WITH A SPLICING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; PROTEIN; DNA; IDENTIFICATION; COMPONENTS; ENCODES; CLONING; YEAST	We have cloned a rat cDNA whose deduced primary structure yields a protein of 117.4 kDa. Because this protein contains RNA helicase consensus motifs, among them a ''DEAD'' box, we have termed it HEL117 (for helicase of 117.4 kDa). Besides the helicase consensus motifs, HEL117 contains an arginine-serine (RS)-rich domain, which occurs in some proteins involved in RNA splicing. Moreover, the COOH-terminal region of 78 residues of HEL117 is 38.5% identical and 59% similar to the COOH-terminal region of a yeast PRP5 protein that is involved in RNA splicing. Rabbit antibodies generated against a synthetic peptide of HEL117 identified a single polypeptide not only in rat cells but also in cells of other mammals as well as chicken. The antibodies revealed a finely punctate and speckled intranuclear staining in immunofluorescence microscopy. A monoclonal antibody against a human splicing factor containing an RS domain (SC35) showed, in double immunofluorescence microscopy, largely overlapping staining consistent with HEL117 being involved in RNA splicing.			SUKEGAWA, J (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; LEE CG, 1993, J BIOL CHEM, V268, P13472; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; 1991, PROGRAM MANUAL GCG P	28	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15702	15706		10.1074/jbc.270.26.15702	http://dx.doi.org/10.1074/jbc.270.26.15702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797571	hybrid			2022-12-25	WOS:A1995RG53800042
J	CREIGHTON, AM; HULFORD, A; MANT, A; ROBINSON, D; ROBINSON, C				CREIGHTON, AM; HULFORD, A; MANT, A; ROBINSON, D; ROBINSON, C			A MONOMERIC, TIGHTLY FOLDED STROMAL INTERMEDIATE ON THE DELTA-PH-DEPENDENT THYLAKOIDAL PROTEIN-TRANSPORT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; TRANSIT PEPTIDE; PRECURSOR PROTEIN; ENERGY-REQUIREMENTS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PROTON GRADIENT; PHOTOSYSTEM-II; 23-KDA PROTEIN; IMPORT	Two distinct mechanisms have been previously identified for the transport of proteins across the chloroplast thylakoid membrane, one of which is unusual in that neither soluble factors nor ATP are required; the system requires only the transthylakoidal Delta pH. We have examined this mechanism by studying the properties of one of its substrates: the extrinsic 23-kDa protein (23K) of photosystem II, Previous work has shown that this protein can be transported into isolated thylakoids as the full-length precursor protein; we show that the stromal import intermediate form of this protein is similarly translocation-competent. Gel filtration tests indicate that the stromal intermediate is probably monomeric, Protease sensitivity tests on both the initial in vitro translation product and the stromal import intermediate show that the presequence is highly susceptible to digestion whereas the mature protein is resistant to high concentrations of trypsin, The mature protein be comes very sensitive to digestion if unfolded in urea, or after heating, and we therefore propose that the natural substrate for this translocation system consists of a relatively unfolded presequence together with a tightly folded passenger protein, The ability of thylakoids to import pre 23K is destroyed by prior treatment of the thylakoids with low concentrations of trypsin, demonstrating the involvement of surface-exposed proteins in the import process, However, we can find no evidence for the binding of pre-23K or i23K to the thylakoid surface, and we therefore propose that the initial interaction of these substrates with the thylakoidal translocase is weak, reversible, and probably Delta pH-independent. In the second phase of the translocation mechanism, the Delta pH drives either the translocation and unfolding of proteins, or the translocation of a fully folded protein.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick				Mant, Alexandra/0000-0001-7169-209X				AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; BROCK IW, 1993, PLANT MOL BIOL, V23, P717, DOI 10.1007/BF00021527; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HENRY R, 1994, J BIOL CHEM, V269, P10189; HULFORD A, 1994, J BIOL CHEM, V269, P3251; JAMES HE, 1991, PLANT MOL BIOL, V17, P179, DOI 10.1007/BF00036827; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KLOSGEN RB, 1992, PLANT MOL BIOL, V18, P1031, DOI 10.1007/BF00019226; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KONISHI T, 1993, PLANT CELL PHYSIOL, V34, P315; KUWABARA T, 1987, P NATL ACAD SCI USA, V84, P8230, DOI 10.1073/pnas.84.23.8230; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LUIRINK J, 1994, MOL MICROBIOL, V11, P9, DOI 10.1111/j.1365-2958.1994.tb00284.x; MEYER DI, 1988, TRENDS BIOCHEM SCI, V13, P471, DOI 10.1016/0968-0004(88)90233-2; Mills J. D., 1986, Photosynthesis: energy transduction: a practical approach, P143; MOULD RM, 1991, J BIOL CHEM, V266, P17286; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NIELSEN VS, 1994, J BIOL CHEM, V269, P3762; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P1165	40	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1663	1669		10.1074/jbc.270.4.1663	http://dx.doi.org/10.1074/jbc.270.4.1663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829500	hybrid			2022-12-25	WOS:A1995QD20400030
J	COFFEY, RL; PURICH, DL				COFFEY, RL; PURICH, DL			NONCOOPERATIVE BINDING OF THE MAP-2 MICROTUBULE-BINDING REGION TO MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 2ND REPEATED SEQUENCE; TAU-PROTEIN; CYTOPLASMIC MICROTUBULES; INVITRO; SITE; PHOSPHORYLATION; NEUROFILAMENTS; DYNAMICS; TUBULIN	Microtubule-associated protein (MAP)-2 is a multi-domain cytoskeletal protein that copurifies with brain microtubules (MTs) through repeated cycles of warm polymerization and cold disassembly. Recent equilibrium binding studies of high molecular weight MAP-2ab to taxol-stabilized MTs suggest that the interactions are highly cooperative, as indicated by sigmoidal binding curves, non-linear Scatchard plots, and an apparent all-or-none response in MAP binding in titration experiments (Wallis, K. T., Azhar, S., Rho, M. B., Lewis, S. A., Cowan, N. J., and Murphy, D. B. (1993) J. Biol. Chem. 268, 15158-15167). To learn more about the mechanism of MAP-2 binding to MTs, we investigated the binding properties of bacterially expressed MT-binding region (MTBR) of bovine brain MAP-2. Scatchard plots of the binding data showed no evidence of cooperativity, as reflected by the linear plots of ($) over bar upsilon/[MTBR](free) versus ($) over bar upsilon. The stoichiometry was 1-1.1 mol of MTBR/mol of tubulin dimer, and the dissociation constant for the MTBR was 1.1 mu M. Bovine brain tau protein competitively inhibited MAP-2 binding, as evidenced by an increased K-d value for MTBR binding to MTs. Although the second repeat peptide m(2) (VTSKCGSLKNIRHRPGGG) is thought to play a dominant role in MAP-2 binding to MTs, a MTBR mutant (with m(2) replaced by the third octadecapeptide repeat m(3)) displays an K-d of 2.8 +/- 0.1 mu M and a stoichiometry of 0.9 +/- 0.05 mol of MTBR/mol of tubulin dimer. Another mutant with additional copies of the second repeat, designated by us as MTBR[m(12)m(2)m(32)], displayed noncooperative binding with a K-d of 0.53 +/- 0.05 mu M and a stoichiometry of 2.2 +/- 0.2 mol of mutant MTBR/tubulin dimer. Equilibrium sedimentation experiments demonstrated that the wild-type MTBR is monomeric, whereas MTBR[m(12)m(2)m(32)] self-associates to a stable dimer over the concentration range used in our MT binding studies. This finding indicates that only one of the two MT-binding sites on the dimer is probably linked to a microtubule at any given time.	UNIV FLORIDA,HLTH SCI CTR,COLL MED,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIGMS NIH HHS [GM-44823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAMODT EJ, 1984, BIOCHEMISTRY-US, V23, P6023, DOI 10.1021/bi00320a019; AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; ELLISMAN MH, 1980, J CELL BIOL, V87, P464, DOI 10.1083/jcb.87.2.464; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FLYNN G, 1987, BIOCHEM BIOPH RES CO, V148, P1453, DOI 10.1016/S0006-291X(87)80295-4; FLYNN G, 1987, J BIOL CHEM, V262, P15443; FLYNN GC, 1988, THESIS U CALIF, P102; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; HAIMO LT, 1979, P NATL ACAD SCI USA, V76, P5759, DOI 10.1073/pnas.76.11.5759; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MACPHERSON MJ, 1991, DIRECTED MUTAGENESIS; MATUS A, 1990, J PHYSIOL-PARIS, V84, P131; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCATCHARD G, 1946, J AM CHEM SOC, V68, P2315, DOI 10.1021/ja01215a054; SCHERSON T, 1984, J CELL BIOL, V99, P425, DOI 10.1083/jcb.99.2.425; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VALLEE RB, 1977, J BIOL CHEM, V252, P377; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WICHE G, 1989, BIOCHEM J, V259, P1; WUERKER R B, 1969, Tissue and Cell, V1, P387, DOI 10.1016/S0040-8166(69)80012-1; YAMAUCHI PS, 1993, J NEUROCHEM, V60, P817, DOI 10.1111/j.1471-4159.1993.tb03225.x	36	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1035	1040		10.1074/jbc.270.3.1035	http://dx.doi.org/10.1074/jbc.270.3.1035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836356	hybrid			2022-12-25	WOS:A1995QB15600011
J	ROLLAND, V; DUGAIL, I; LELIEPVRE, X; LAVAU, M				ROLLAND, V; DUGAIL, I; LELIEPVRE, X; LAVAU, M			EVIDENCE OF INCREASED GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE AND FATTY-ACID SYNTHETASE PROMOTER ACTIVITIES IN TRANSIENTLY TRANSFECTED ADIPOCYTES FROM GENETICALLY-OBESE RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; GENE; EXPRESSION; INSULIN; PROTEIN; IDENTIFICATION; SYNTHASE; ENHANCER; CELLS; DNA	Previous studies have shown that the adipose tissue of young genetically obese Zucker rats was characterized by a coordinate overtranscription of lipogenic genes, suggesting that the fa mutation triggers transcription factor(s) acting in common on the promoters of these genes. To test this hypothesis, we developed a system of transient transfection of rat adipocytes with constructs containing glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and fatty acid synthetase (FAS) promoters fused to gene reporter CAT. Those transfected cells expressed high levels of promoter-driven chloramphenicol acetyltransferase (CAT) activity through correctly initiated transcription as shown by primer extension analysis. Using this system we found a direct effect of insulin on GAPDH and FAS gene expression in rat adipocytes, In transfected adipocytes from obese compared to lean rats, activity of GAPDH and FAS promoters fused to CAT, was 2.6- and 8-fold increased, respectively In contrast when reporter gene activity was driven by either phosphoenolpyruvate carboxykinase or beta-actin promoter, no difference could be observed between lean and obese, pointing out the promoter specificity of genotype effect, 5' deletion analysis of GAPDH promoter allowed us to narrow down the fa responsive region to nucleotide -488-329. As assessed by gel retardation and DNase I footprinting analysis, adipocyte nuclear protein interactions to this 159-bp fragment were found to be identical and to footprint the same 20-bp sequence. This study pointed out that overexpression of GAPDH and FAS genes in adipose tissue of genetically obese rats relies on promoter activation, through a 159-bp cis-acting region within the GAPDH promoter. The effects of the fa mutation on trans-acting factors binding to this region remain to be identified.			ROLLAND, V (corresponding author), INST BIOMED CORDELIERS,INSERM,U177,UNITE RECH PHYSIOPATHOL NUTR,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Dugail, Isabelle/L-1567-2017	Dugail, Isabelle/0000-0003-3631-2252				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUGAIL I, 1988, BIOCHEM J, V254, P483, DOI 10.1042/bj2540483; DUGAIL I, 1992, BIOCHEM J, V281, P607, DOI 10.1042/bj2810607; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GUICHARD C, 1992, J LIPID RES, V33, P679; HAINAULT I, 1991, J CLIN INVEST, V87, P1127, DOI 10.1172/JCI115077; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KRIEF S, 1991, P EXP BIOL MED SOC, P528; MAXAM A, 1980, METHOD ENZYMOL, V152, P721; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; ZUCKER LM, 1961, J HERED, V62, P275	22	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1102	1106		10.1074/jbc.270.3.1102	http://dx.doi.org/10.1074/jbc.270.3.1102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836367	hybrid			2022-12-25	WOS:A1995QB15600022
J	LOPEZ, MJ; UPCHURCH, BH; RINDI, G; LEITER, AB				LOPEZ, MJ; UPCHURCH, BH; RINDI, G; LEITER, AB			STUDIES IN TRANSGENIC MICE REVEAL POTENTIAL RELATIONSHIPS BETWEEN SECRETIN-PRODUCING CELLS AND OTHER ENDOCRINE CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-POLYPEPTIDE; GASTROINTESTINAL-TRACT; INTESTINAL EPITHELIUM; T-ANTIGEN; GENE; EXPRESSION; DIFFERENTIATION; ENTEROENDOCRINE; GLUCAGON; SOMATOSTATIN	We have produced transgenic mice expressing fusion genes consisting of 1.6 kilobase pairs of the secretin gene 5' flanking region to direct the expression of human growth hormone (hGH) or simian virus 40 large T antigen to secretin-producing cells, Analysis of different mouse tissues for hGH transcripts revealed expression in each of the major secretin-producing tissues, namely the intestine and endocrine pancreas. Multiple label immunohistochemistry demonstrated that the transgene was correctly directed to secretin cells in the intestinal tract, including a previously unrecognized population of secretin cells in the colon of adult and developing mice, In the small intestine, subpopulations of hGH-containing cells frequently coexpressed substance P, serotonin, and cholecystokinin whereas in the colon cells expressing hGH frequently coexpressed glucagon, peptide YY, or neurotensin, Transgenic mice expressing large T antigen in secretin cells developed poorly differentiated neuroendocrine tumors of the small intestine, well differentiated colonic tumors containing glucagon-expressing cells, and insulin-producing tumors in pancreas, These studies indicate that the major cis-regulatory sequences necessary for secretin expression in enteroendocrine cells and fetal islets are localized with 1.6 kilobase pairs of the transcriptional start site, Coexpression of reporter transgenes with several gastrointestinal hormones suggests a potential relationships between secretin cells and other enteroendocrine cell types, as well as pancreatic beta cells.	TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111	Tufts Medical Center; Tufts University				RINDI, Guido/0000-0003-2996-4404	NIDDK NIH HHS [DK34928, DK43673, DK07471] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043673, P30DK034928, T32DK007471] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILA MC, 1991, P NATL ACAD SCI USA, V88, P11485, DOI 10.1073/pnas.88.24.11485; BISHOP AE, 1988, PATHOL RES PRACT, V183, P119, DOI 10.1016/S0344-0338(88)80040-2; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CETIN Y, 1990, HISTOCHEMISTRY, V93, P601, DOI 10.1007/BF00272202; CHANG TM, 1985, PEPTIDES, V6, P193, DOI 10.1016/0196-9781(85)90039-7; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLER PJ, 1989, J IMMUNOL, V143, P1015; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HOGAN B, 1986, MANIPULATING MOUSE E; INOKUCHI H, 1985, GASTROENTEROLOGY, V89, P1014, DOI 10.1016/0016-5085(85)90202-1; KOPIN AS, 1990, P NATL ACAD SCI USA, V87, P2299, DOI 10.1073/pnas.87.6.2299; KOPIN AS, 1991, P NATL ACAD SCI USA, V88, P5335, DOI 10.1073/pnas.88.12.5335; LARSSON LI, 1977, CELL TISSUE RES, V181, P361, DOI 10.1007/BF00223111; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEITER AB, 1993, GUT PEPTIDES, P147; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MUTT V, 1979, LIFE SCI, V25, P1703, DOI 10.1016/0024-3205(79)90472-7; RINDI G, 1990, AM J PATHOL, V136, P1349; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; STRAUS E, 1978, GASTROENTEROLOGY, V75, P401; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TSUBOUCHI S, 1979, AM J ANAT, V156, P431, DOI 10.1002/aja.1001560403; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531	30	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					885	891		10.1074/jbc.270.2.885	http://dx.doi.org/10.1074/jbc.270.2.885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822327	hybrid			2022-12-25	WOS:A1995QB81600061
J	MITCHELL, J; GUTIERREZ, J; NORTHUP, JK				MITCHELL, J; GUTIERREZ, J; NORTHUP, JK			PURIFICATION, CHARACTERIZATION, AND PARTIAL AMINO-ACID-SEQUENCE OF A G-PROTEIN-ACTIVATED PHOSPHOLIPASE-C FROM SQUID PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; GUANINE-NUCLEOTIDE BINDING; VISUAL EXCITATION; ALPHA-SUBUNITS; IMMUNOLOGICAL IDENTIFICATION; INVERTEBRATE PHOTORECEPTORS; BOVINE BRAIN; DROSOPHILA; LIGHT; MEMBRANES	Invertebrate visual transduction is thought to be initiated by photoactivation of rhodopsin and its subsequent interaction with a guanyl nucleotide-binding protein (G protein), The identities of the G protein and its target effector have remained elusive, although evidence suggests the involvement of a phospholipase C (PLC). We have identified a phosphatidylinositol-specific PLC from the cytosol of squid retina, The enzyme was purified to near-homogeneity by a combination of carboxymethyl-Sepharose and heparin-Sepharose chromatography. The purified PLC, identified as an approximately 140-kDa protein by sodium dodecyl sulfate-polyacrylamide gels, hydrolyzed phosphatidylinositol 4,5-bisphosphate (PIP2) at a rate of 10-15 mu mol/min/mg of protein with 1 mu M Ca2+. The partial amino acid sequence of the protein showed homology with a PLC cloned from a Drosophila head library (PLC21) and lesser homology with Drosophila norpA protein and mammalian PLC beta isozymes. Reconstitution of purified squid PLC with an AIF(-)-activated 44-kDa G protein a subunit extracted from squid photoreceptor membranes resulted in a significant increase in PIP2 hydrolysis over a range of Ca2+ concentrations while reconstitution with mammalian G(t) alpha or G(i)1 alpha was without effect, These results suggest that cephalopod phototransduction is mediated by G alpha-44 activation of a 140-kDa cytosolic PLC.	NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	MITCHELL, J (corresponding author), UNIV TORONTO, DEPT PHARMACOL, MED SCI BLDG, TORONTO, ON M5S 1A8, CANADA.							BACIGALUPO J, 1983, NATURE, V304, P268, DOI 10.1038/304268a0; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOLSOVER SR, 1982, J PHYSIOL-LONDON, V332, P325, DOI 10.1113/jphysiol.1982.sp014416; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Charbonneau H, 1989, PRACTICAL GUIDE PROT; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FEIN A, 1981, SCIENCE, V212, P555, DOI 10.1126/science.6782676; FEIN A, 1979, SCIENCE, V204, P77, DOI 10.1126/science.34877; FEIN A, 1986, SCIENCE, V232, P1543, DOI 10.1126/science.3487116; FUNG BKK, 1983, J BIOL CHEM, V258, P495; INOUE H, 1988, J BIOCHEM-TOKYO, V103, P91, DOI 10.1093/oxfordjournals.jbchem.a122246; INOUE H, 1985, BIOCHEM BIOPH RES CO, V132, P513, DOI 10.1016/0006-291X(85)91163-5; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; KIRKWOOD A, 1989, P NATL ACAD SCI USA, V86, P3872, DOI 10.1073/pnas.86.10.3872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PARK DG, 1993, J BIOL CHEM, V268, P3710; Paulsen R., 1986, Progress in Zoology, V33, P299; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; ROBINSON PR, 1990, BIOCHEM J, V272, P79, DOI 10.1042/bj2720079; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; TSUDA M, 1986, FEBS LETT, V198, P5, DOI 10.1016/0014-5793(86)81173-5; TSUDA M, 1987, RETINAL PROTEINS, P393; VANDENBERG CA, 1984, BIOCHEMISTRY-US, V23, P2339, DOI 10.1021/bi00306a003; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WONG F, 1978, NATURE, V276, P76, DOI 10.1038/276076a0; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171	43	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					854	859		10.1074/jbc.270.2.854	http://dx.doi.org/10.1074/jbc.270.2.854			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822322	hybrid			2022-12-25	WOS:A1995QB81600056
J	SARUTA, F; KURAMOCHI, T; NAKAMURA, K; TAKAMIYA, S; YU, Y; AOKI, T; SEKIMIZU, K; KOJIMA, S; KITA, K				SARUTA, F; KURAMOCHI, T; NAKAMURA, K; TAKAMIYA, S; YU, Y; AOKI, T; SEKIMIZU, K; KOJIMA, S; KITA, K			STAGE-SPECIFIC ISOFORMS OF COMPLEX-II (SUCCINATE-UBIQUINONE OXIDOREDUCTASE) IN MITOCHONDRIA FROM THE PARASITIC NEMATODE, ASCARIS-SUUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER COMPLEXES; FUMARATE REDUCTASE-ACTIVITY; SULFUR PROTEIN SUBUNIT; CYTOCHROME-C OXIDASE; ESCHERICHIA-COLI; MUSCLE MITOCHONDRIA; NUCLEOTIDE-SEQUENCE; RESPIRATORY-CHAIN; PURIFICATION; FLAVOPROTEIN	Complex II from mitochondria of the adult parasitic nematode, Ascaris suum, exhibits high fumarate reductase activity and plays a key role in the anaerobic electron transport observed in these organelles. In contrast, mitochondria isolated from free living second stage larvae (L2) of A. suum show much lower fumarate reductase activity than those from adults, whereas succinate dehydrogenase activities of mitochondria in both stages are comparable. In the present study, biochemical. and antigenic properties of the partially purified enzymes from both larval and adult mitochondria were compared. Larval complex II eluted hom the DEAE-Cellulofine column chromatography at a lower salt concentration than adult enzyme, whereas the apparent molecular size of both enzyme complexes estimated by gel permeation column chromatography was the same, The fumarate reductase activity of larval complex II was less than 3% of that of adult enzyme, and the K-m values for substrates were significantly different between the two complexes. The flavoprotein subunit of larval complex II could be distinguished from that of adult complex II by two-dimensional gel electrophoresis and peptide mapping. The antibody against the smallest subunit (small subunit of cytochrome b(558)) of the adult enzyme did not cross-react with that of the larval enzyme. These results suggest that larval complex II differs hom adult enzyme and is more similar to aerobic mammalian enzymes with low fumarate reductase activity, This is the first direct indication of the two different stage-specific forms of mitochondrial complex II.	UNIV TOKYO,INST MED SCI,DEPT PARASITOL,MINATO KU,TOKYO 108,JAPAN; JUNTENDO UNIV,SCH MED,DEPT PARASITOL,TOKYO 113,JAPAN; KYUSHU UNIV,FAC PHARMACEUT SCI,FUKUOKA 812,JAPAN	University of Tokyo; Juntendo University; Kyushu University				Kita, Kiyoshi/0000-0002-0426-4308				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BISSON R, 1986, J BIOL CHEM, V261, P4373; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; ERABI T, 1975, J BIOCHEM-TOKYO, V78, P795, DOI 10.1093/oxfordjournals.jbchem.a130968; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HIRAWAKE H, 1994, J BIOCHEM-TOKYO, V116, P221, DOI 10.1093/oxfordjournals.jbchem.a124497; KADENBACH B, 1982, FEBS LETT, V138, P236, DOI 10.1016/0014-5793(82)80450-X; KITA K, 1988, BIOCHIM BIOPHYS ACTA, V935, P130, DOI 10.1016/0005-2728(88)90210-1; KITA K, 1992, PARASITOL TODAY, V8, P155, DOI 10.1016/0169-4758(92)90009-Q; KITA K, 1988, COMP BIOCHEM PHYS B, V89, P31, DOI 10.1016/0305-0491(88)90256-8; KITA K, 1989, J BIOL CHEM, V264, P2672; KITA K, 1985, BIOCHEM INT, V10, P319; KOHLER P, 1991, PHYSL STRATEGIES GAS, P15; KOMUNIECKI R, 1988, COMP BIOCH PARASITIC, P1; KURAMOCHI T, 1994, IN PRESS MOL BIOCH P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA YC, 1993, J BIOL CHEM, V268, P20360; MORRIS AAM, 1994, BBA-BIOENERGETICS, V1185, P125, DOI 10.1016/0005-2728(94)90203-8; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENNOYER JD, 1988, BIOCHIM BIOPHYS ACTA, V935, P195, DOI 10.1016/0005-2728(88)90216-2; ROBINSON JJ, 1982, CAN J BIOCHEM CELL B, V60, P811, DOI 10.1139/o82-101; TAKAMIYA S, 1990, BIOCHEM INT, V21, P1073; TAKAMIYA S, 1986, BIOCHIM BIOPHYS ACTA, V848, P99, DOI 10.1016/0005-2728(86)90165-9; TAKAMIYA S, 1993, BIOCHIM BIOPHYS ACTA, V1141, P65, DOI 10.1016/0005-2728(93)90190-Q; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YU L, 1987, J BIOL CHEM, V262, P1137	29	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					928	932		10.1074/jbc.270.2.928	http://dx.doi.org/10.1074/jbc.270.2.928			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822332	hybrid			2022-12-25	WOS:A1995QB81600067
J	XU, YZ; HUANG, P; PLUNKETT, W				XU, YZ; HUANG, P; PLUNKETT, W			FUNCTIONAL COMPARTMENTATION OF DCTP POOLS - PREFERENTIAL UTILIZATION OF SALVAGED DEOXYCYTIDINE FOR DNA-REPAIR IN HUMAN LYMPHOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN RIBONUCLEOTIDE REDUCTASE; DEOXYNUCLEOSIDE TRIPHOSPHATE POOLS; HUMAN-LEUKEMIA-CELLS; S-PHASE; THYMIDYLATE SYNTHASE; REPLICATION OCCURS; HUMAN-LYMPHOCYTES; THYMIDINE KINASE; L1210 CELLS; CYCLE	The utilization of dCTP derived from de nora synthesis through ribonucleotide reductase in exponentially growing CCRF-CEM cells was compared with the metabolic fate of dCTP produced by the salvage pathway, Exogenous dCyd was not effectively incorporated into replicating DNA; instead, dCTP derived from 1 ribonucleotide reductase (labeled by [5-H-3]Cyd) was the main precursor for that purpose, apparently because of functional compartmentation of the dCTP pool in these cells, Studies of the metabolic route of incorporation of exogenous [5-H-3]dCyd into DNA of growing CCRF-CEM cells demonstrated that it was mainly incorporated through the DNA repair pathway. Incorporation of [5-H-3]dCyd into DNA of synchronized cell populations was maximal in G(1) cells, whereas [H-3]dThd incorporation occurred predominantly in S phase cells, When cellular DNA was density labeled by incubation with BrdUrd, repaired DNA, which was less dense than replicated DNA, was preferentially labeled by [5-H-3]dCyd. In contrast, replicated DNA was labeled by both [H-3]dThd and [5-H-3]Cyd, The DNA-damaging agents methylmethanesulfonate, ultraviolet irradiation, and gamma-irradiation inhibited [H-3]dThd incorporation, whereas they stimulated the accumulation of [5-H-3]dCyd in DNA. Based on these results, we propose that the dCTP pool is functionally compartmentalized in growing CCRF-CEM cells, dCTP derived from the salvage pathway is utilized predominantly for DNA repair, whereas the de nova pathway supplies dCTP far DNA replication.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT CLIN INVEST, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER; NCI NIH HHS [CA28596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; ASHMAN CR, 1981, SOMAT CELL GENET, V7, P751, DOI 10.1007/BF01538762; BALL CR, 1972, CHEM-BIOL INTERACT, V4, P297, DOI 10.1016/0009-2797(72)90024-5; BALZARINI J, 1984, BIOCHEM J, V217, P245, DOI 10.1042/bj2170245; COHEN A, 1983, J BIOL CHEM, V258, P2334; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; ELLIOTT GC, 1986, MUTAT RES, V166, P295, DOI 10.1016/0167-8817(86)90029-5; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FRIEDBERG EC, 1985, DNA REPAIR, P459; GREER WL, 1986, EXP CELL RES, V166, P399, DOI 10.1016/0014-4827(86)90486-6; GREGOIRE V, 1994, CANCER RES, V54, P468; HAMMOND RA, 1989, EXP CELL RES, V183, P284, DOI 10.1016/0014-4827(89)90389-3; HARVEY G, 1988, J CELL PHYSIOL, V134, P25, DOI 10.1002/jcp.1041340104; HEINEMANN V, 1989, BIOCHEM PHARMACOL, V38, P4115, DOI 10.1016/0006-2952(89)90693-X; HEINEMANN V, 1992, CANCER RES, V52, P533; HOLMBERG M, 1988, MUTAT RES, V202, P111, DOI 10.1016/0027-5107(88)90171-6; HOPKINS RL, 1980, P NATL ACAD SCI-BIOL, V77, P1801, DOI 10.1073/pnas.77.4.1801; HORZAK P, 1993, CELL, V73, P361; HUANG P, 1992, ANAL BIOCHEM, V207, P163, DOI 10.1016/0003-2697(92)90518-C; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1990, J BIOL CHEM, V265, P16617; JACKSON DA, 1994, J CELL SCI, V107, P1753; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; JACKSON RC, 1992, THEORETICAL F CANCER, P299; KARLE JM, 1983, CANCER LETT, V19, P147, DOI 10.1016/0304-3835(83)90148-9; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; LILIEMARK JO, 1986, CANCER RES, V46, P1079; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; MCKENNA PG, 1986, SOMAT CELL MOLEC GEN, V12, P325, DOI 10.1007/BF01570726; MEUTH M, 1974, CELL, V2, P109, DOI 10.1016/0092-8674(74)90099-3; MILLS AD, 1989, J CELL SCI, V94, P471; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; MOYER JD, 1985, CRC CR REV BIOCH MOL, V19, P45, DOI 10.3109/10409238509086787; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NGUYEN BT, 1986, BIOCHEM J, V234, P263, DOI 10.1042/bj2340263; NICANDER B, 1983, P NATL ACAD SCI-BIOL, V80, P1347, DOI 10.1073/pnas.80.5.1347; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; PLAGEMANN PGW, 1978, CANCER RES, V38, P978; PLUNKETT W, 1993, SEMIN ONCOL, V20, P50; Reddy G P, 1993, Crit Rev Eukaryot Gene Expr, V3, P255; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RUSSEV G, 1992, EUR J BIOCHEM, V204, P267, DOI 10.1111/j.1432-1033.1992.tb16633.x; SASVARISZEKELY M, 1989, BIOCHEM BIOPH RES CO, V163, P1158, DOI 10.1016/0006-291X(89)92342-5; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SHEWACH DS, 1992, BIOCHEM PHARMACOL, V43, P1579, DOI 10.1016/0006-2952(92)90217-7; SHEWACH DS, 1994, CANCER RES, V54, P3218; SIKORSKA M, 1990, BIOCHEM CELL BIOL, V68, P880, DOI 10.1139/o90-130; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; SNYDER RD, 1984, MUTAT RES, V131, P163, DOI 10.1016/0167-8817(84)90057-9; SPASOKUKOTSKAJA T, 1992, FEBS LETT, V297, P151, DOI 10.1016/0014-5793(92)80348-K; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SPYROU G, 1989, J BIOL CHEM, V264, P960; STARNES MC, 1987, J BIOL CHEM, V262, P988; SWENSON PA, 1966, J MOL BIOL, V15, P201, DOI 10.1016/S0022-2836(66)80221-8; TALJANIDISZ J, 1986, BIOCHIM BIOPHYS ACTA, V885, P266, DOI 10.1016/0167-4889(86)90241-7; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; XU YZ, 1993, J BIOL CHEM, V268, P22363; XU YZ, 1992, BIOCHEM PHARMACOL, V44, P1819; YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146	68	37	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					631	637		10.1074/jbc.270.2.631	http://dx.doi.org/10.1074/jbc.270.2.631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822289	hybrid			2022-12-25	WOS:A1995QB81600022
J	DIBELLA, EE; MAURER, MC; SCHERAGA, HA				DIBELLA, EE; MAURER, MC; SCHERAGA, HA			EXPRESSION AND FOLDING OF RECOMBINANT BOVINE PRETHROMBIN-2 AND ITS ACTIVATION TO THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-ALPHA-CHAIN; FIBRINOGEN-LIKE PEPTIDES; PRO-ARG CHLOROMETHYLKETONE; PANCREATIC RIBONUCLEASE-A; BLOOD-COAGULATION; CATALYZED ACTIVATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TRP INSERTION; RESIDUES 7-16	Bovine prethrombin-2 has been produced in Escherichia coli using a T7 expression system. The expressed prethrombin-2 formed intracellular inclusion bodies which were solubilized by reversible sulfonation of the cysteines in the presence of 7 M guanidine hydrochloride. Sulfonated prethrombin-2 was refolded in the presence of 4 M guanidine hydrochloride, using oxidized and reduced glutathione as the redox couple. The folded protein was purified by heparin affinity chromatography and activated to thrombin with Echis carinatus snake venom. The resulting thrombin was also purified by heparin affinity chromatography. Kinetic constants were determined for the hydrolysis of H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline by recombinant thrombin (k(cat) = 123 +/- 10 s(-1) and K-m = 2.91 +/- 0.3 mu M). These values are in good agreement with those determined for wild-type thrombin (k(cat) = 97 +/- 8 s(-1) and K-m = 2.71 +/- 0.25 mu M). From the thrombin-mediated release of fibrinopeptide A from fibrinogen, k(cat)/K-m was found to be the same for recombinant (17.3 +/- 1.2 mu M(-1) s(-1)) and wild-type (16.7 +/- 2.0 mu M(-1) s(-1)) thrombin. These results, taken together with circular dichroism spectra and the elution position of prethrombin-2 from a heparin affinity resin, indicate that prethrombin-2 was folded into a conformation similar to that of the wild-type protein. In addition, since E. coli produces deglycosylated enzymes, these findings suggest that the carbohydrate on the B chain of wild-type thrombin does not affect the amidolytic and fibrinolytic activities of thrombin. Finally, this expression system can be used to prepare mutants of prethrombin-2 for future structure function studies involving thrombin and its substrates; some preliminary results of this type are presented here.	CORNELL UNIV, BAKER LAB CHEM, ITHACA, NY 14853 USA	Cornell University					NHLBI NIH HHS [HL-30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER M, 1988, BIOCHEMISTRY-US, V27, P2471, DOI 10.1021/bi00407a033; ARCONE R, 1994, J CELL BIOCHEM, P150; BAUER RS, 1980, J BIOL CHEM, V255, P5900; Bevington PR, 1969, DATA REDUCTION ERROR, P92; BLOMBACK B, 1969, SCAND J CLIN LAB INV, VS 24, P59; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CHOI E H, 1989, Korean Biochemical Journal, V22, P154; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DAVIE EW, 1986, J PROTEIN CHEM, V5, P247, DOI 10.1007/BF01025423; DENTON JB, 1982, BIOCHEMISTRY-US, V21, P5155, DOI 10.1021/bi00264a008; DUDA CT, 1982, J BIOL CHEM, V257, P9866; ESMON CT, 1974, J BIOL CHEM, V249, P8045; ESMON NL, 1982, J BIOL CHEM, V257, P859; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GAN ZR, 1991, BIOCHEMISTRY-US, V30, P11694, DOI 10.1021/bi00114a013; GOEDDEL DV, 1990, METHOD ENZYMOL, V185, P3; HAGEMAN TC, 1975, ARCH BIOCHEM BIOPHYS, V171, P327, DOI 10.1016/0003-9861(75)90039-9; Hartley BS, 1971, ENZYMES, V3, P323; HOYER LW, 1981, J LAB CLIN MED, V97, P50; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; LAITY JH, 1993, P NATL ACAD SCI USA, V90, P615, DOI 10.1073/pnas.90.2.615; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEWIS SD, 1984, THROMB RES, V35, P111, DOI 10.1016/0049-3848(84)90206-8; LIGHT A, 1979, J BIOL CHEM, V254, P9162; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MARTINELLI RA, 1979, ANAL BIOCHEM, V96, P246, DOI 10.1016/0003-2697(79)90579-7; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; NI F, 1992, THROMBIN STRUCTURE F, P63; ODORZYNSKI TW, 1979, J BIOL CHEM, V254, P4291; PEI G, 1991, J BIOL CHEM, V266, P9598; SCHERAGA HA, 1986, ANN NY ACAD SCI, V485, P124, DOI 10.1111/j.1749-6632.1986.tb34574.x; SCHERAGA HA, 1957, ADV PROTEIN CHEM, V12, P1, DOI 10.1016/S0065-3233(08)60115-1; SINHA NK, 1975, J BIOL CHEM, V250, P8624; So I. S., 1992, KOREAN BIOCH J, V25, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x; WINZOR DJ, 1964, ARCH BIOCHEM BIOPHYS, V104, P202, DOI 10.1016/S0003-9861(64)80004-7; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; WU QY, 1994, J BIOL CHEM, V269, P3725	56	35	43	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					163	169		10.1074/jbc.270.1.163	http://dx.doi.org/10.1074/jbc.270.1.163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814368	hybrid			2022-12-25	WOS:A1995QA28700029
J	SMULSON, ME; KANG, VH; NTAMBI, JM; ROSENTHAL, DS; DING, RC; SIMBULAN, CMG				SMULSON, ME; KANG, VH; NTAMBI, JM; ROSENTHAL, DS; DING, RC; SIMBULAN, CMG			REQUIREMENT FOR THE EXPRESSION OF POLY(ADP-RIBOSE) POLYMERASE DURING THE EARLY STAGES OF DIFFERENTIATION OF 3T3-L1 PREADIPOCYTES, AS STUDIED BY ANTISENSE RNA INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; DNA STRAND BREAKS; GENE-EXPRESSION; CELL-CYCLE; CHICK LIMB; ADIPOCYTE DIFFERENTIATION; TOPOISOMERASE-I; CHROMATIN; PROTEIN; COMPLEX	Poly(ADP-ribose) polymerase (PADPRP) is biologically significant in the rejoining of DNA strand breaks. Post confluent cultures of 3T3-L1 preadipocytes showed marked increases in PADPRP protein and activity when the cells were induced to differentiate into adipocytes. When this increase in PADPRP expression was prevented in stably transfected 3T3-L1 cells by induction of PADPRP antisense RNA synthesis, the cells did not differentiate nor undergo the two or three rounds of DNA replication that are required for initiation of the differentiation process. 3T3-L1 cells expressing PADPRP antisense RNA under differentiation conditions were easily detached from plates and in some cases eventually died. When newly expressed PADPRP protein and DNA synthesis was assessed in cells at zero time or at 24 h after induction of differentiation by incorporation of bromodeoxyuridine or [H-3]thymidine into DNA, significant incorporation was shown to occur in control cells after 24 h, but not in antisense cells. Furthermore, during the first 24 h, the co-immunoprecipitation of PADPRP and DNA polymerase cu was observed in control cells, whereas no such complex formation was noted in the induced antisense cells, nor in uninduced control cells.			SMULSON, ME (corresponding author), GEORGETOWN UNIV, SCH MED,DEPT BIOCHEM & MOLEC BIOL,BASIC SCI BLDG, RM 351, 3900 RESERVOIR RD, WASHINGTON, DC 20007 USA.		Rosenthal, Dean S/J-2360-2014; Simbulan-Rosenthal, Cynthia M./W-8429-2019	Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NCI NIH HHS [CA25344] Funding Source: Medline; NIDDK NIH HHS [DK-42825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTHAUS FR, 1985, ADP RIBOSYLATION PRO; BAKSI K, 1987, EXP CELL RES, V172, P110, DOI 10.1016/0014-4827(87)90098-X; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERGER NA, 1987, J CLIN INVEST, V79, P1558, DOI 10.1172/JCI112989; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BHATIA K, 1990, CARCINOGENESIS, V11, P123, DOI 10.1093/carcin/11.1.123; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BLAHO JA, 1992, J VIROL, V66, P6398, DOI 10.1128/JVI.66.11.6398-6407.1992; BRAC T, 1985, P446; BUTT TR, 1978, NUCLEIC ACIDS RES, V5, P2775, DOI 10.1093/nar/5.8.2775; BUTT TR, 1980, BIOCHEMISTRY-US, V19, P5243, DOI 10.1021/bi00564a014; BUTT TR, 1979, P NATL ACAD SCI USA, V76, P1628, DOI 10.1073/pnas.76.4.1628; CAPLAN AI, 1979, DEV BIOL, V72, P102, DOI 10.1016/0012-1606(79)90101-5; CAPLAN AI, 1975, P NATL ACAD SCI USA, V72, P1852, DOI 10.1073/pnas.72.5.1852; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; CHERNEY BW, 1985, DEV BIOL, V112, P115, DOI 10.1016/0012-1606(85)90125-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1983, EMBO J, V2, P543, DOI 10.1002/j.1460-2075.1983.tb01460.x; DING RC, 1992, J BIOL CHEM, V267, P12804; FANGTSYR L, 1992, GENE DEV, V6, P533; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; FARZANEH F, 1987, NUCLEIC ACIDS RES, V15, P3493, DOI 10.1093/nar/15.8.3493; FERRO AM, 1984, J BIOL CHEM, V259, P547; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HOTLUND J, 1983, EUR J BIOCHEM, V130, P309; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JANSSEN OE, 1989, EUR J BIOCHEM, V180, P595, DOI 10.1111/j.1432-1033.1989.tb14686.x; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1031, DOI 10.1021/bi00546a031; KASID UN, 1989, J BIOL CHEM, V264, P18687; KAUFMANN S, 1994, CANCER RES, V54, P3976; KIDWELL WR, 1976, BIOCHEMISTRY-US, V15, P1213, DOI 10.1021/bi00651a006; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEWIS JE, 1982, FEBS LETT, V146, P37, DOI 10.1016/0014-5793(82)80700-X; LI CJ, 1993, J CELL BIOCHEM, V53, P405, DOI 10.1002/jcb.240530418; LONN U, 1988, EUR J BIOCHEM, V178, P47, DOI 10.1111/j.1432-1033.1988.tb14427.x; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MATHIS G, 1986, J BIOL CHEM, V261, P5758; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; MORIOKA K, 1979, GANN, V70, P37; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; PEKALA PH, 1981, J BIOL CHEM, V256, P4871; PEKALA PH, 1983, MOL CELL BIOCHEM, V53-4, P221; RASTL E, 1978, J BIOL CHEM, V253, P4333; Reddy G P, 1993, Crit Rev Eukaryot Gene Expr, V3, P255; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703; ROBERTS JH, 1974, P NATL ACAD SCI USA, V71, P3212, DOI 10.1073/pnas.71.8.3212; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SMULSON ME, 1977, CANCER RES, V37, P3006; SUROWY CS, 1985, BIOCHIM BIOPHYS ACTA, V832, P33, DOI 10.1016/0167-4838(85)90171-2; SUZUKI H, 1989, ADP RIBOSE TRANFER R, P511; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VILLARREAL LP, 1991, MICROBIOL REV, V55, P512, DOI 10.1128/MMBR.55.3.512-542.1991; WENZ HM, 1992, P NATL ACAD SCI USA, V89, P1065, DOI 10.1073/pnas.89.3.1065; WONG M, 1983, P NATL ACAD SCI-BIOL, V80, P205, DOI 10.1073/pnas.80.1.205; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522	68	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					119	127		10.1074/jbc.270.1.119	http://dx.doi.org/10.1074/jbc.270.1.119			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814362	hybrid			2022-12-25	WOS:A1995QA28700023
J	YOSHIOKA, H; GREENWEL, P; INOGUCHI, K; TRUTER, S; INAGAKI, Y; NINOMIYA, Y; RAMIREZ, F				YOSHIOKA, H; GREENWEL, P; INOGUCHI, K; TRUTER, S; INAGAKI, Y; NINOMIYA, Y; RAMIREZ, F			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE PROMOTER OF THE HUMAN ALPHA-1(XI) COLLAGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHABDOMYOSARCOMA CELL-LINE; ARGININE-RICH PROTEIN; V COLLAGEN; NH2-TERMINAL DOMAIN; PRO-ALPHA-1(XI) COLLAGEN; I COLLAGEN; CHAIN; XI; EXPRESSION; CARTILAGE	In order to eventually elucidate the mechanisms regulating alpha 1(XI) collagen expression in cartilaginous and non-cartilaginous tissues, we performed an initial analysis of the structural-functional features of the promoter of the human gene (COL11A1). After cloning and sequencing the 5' portion of COL11A1, primer extension and nuclease protection assays identified several minor transcriptional start sites clustered around a major one located 318 base pairs from the ATG codon. Consistent with this finding, analysis of the upstream sequence revealed the absence of a TATA motif and the presence of several GC boxes. Transient transfection experiments delineated the smallest promoter sequence directing relatively high expression of a reporter gene in a cell type-specific manner. Nine nuclear protein-bound areas were located within this promoter sequence of the COL11A1 gene. Sequence homologies suggested that the majority of the footprints correspond to potential binding sites for ubiquitous nuclear proteins, such as AP2 and Sp1. Additional experimental evidence indicated that one of the protected areas may bind a transcriptional complex that is identical or closely related to the one that regulates tissue specificity in the coordinately expressed alpha 2(V) collagen gene.	MT SINAI MED CTR, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; OKAYAMA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, OKAYAMA 700, JAPAN	Icahn School of Medicine at Mount Sinai; Okayama University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI E, 1989, MATRIX, V9, P232, DOI 10.1016/S0934-8832(89)80055-1; ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ALITALO K, 1980, EUR J BIOCHEM, V109, P247, DOI 10.1111/j.1432-1033.1980.tb04790.x; ALITALO K, 1982, J BIOL CHEM, V257, P9016; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOAST S, 1990, J BIOL CHEM, V265, P13351; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LACKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MARTIN JD, 1985, J VIROL, V53, P306, DOI 10.1128/JVI.53.1.306-311.1985; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS GF, 1986, P NATL ACAD SCI USA, V83, P1; NAH HD, 1992, J BIOL CHEM, V267, P22581; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TRUTER S, 1993, CONNECT TISSUE RES, V29, P51, DOI 10.3109/03008209309061966; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	37	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					418	424		10.1074/jbc.270.1.418	http://dx.doi.org/10.1074/jbc.270.1.418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814404	hybrid			2022-12-25	WOS:A1995QA28700066
J	MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D				MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D			NDF HEREGULIN ACTIVATES MAP KINASE AND P70/P85 S6 KINASE DURING PROLIFERATION OR DIFFERENTIATION OF MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article						TYPE I RECEPTOR TYROSINE KINASES; HC11 CELLS; BREAST TUMOR CELLS; ERBB-2; PROTEIN KINASE C	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; HUMAN-BREAST-CANCER; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ERBB-2 RECEPTOR; NEU ONCOGENE; TYROSINE PHOSPHORYLATION; C-ERBB-2 PROTOONCOGENE; EXTRACELLULAR DOMAIN	Neu differentiation factors (NDF) are a novel family of polypeptide factors which activate sub-class I tyrosine kinase receptors. In all mammary epithelial cells analysed in this study, NDF activates the same signalling pathways while it induces different, cell-specific biological effects. In AU565 cells which are growth inhibited, as well as in T47D or HC11 cells which proliferate in response to NDF, the MAP kinase isoforms p44(ERK1) and p42(ERK2) and the p70/p85 S6 kinase are activated. NDF stimulates tyrosine phosphorylation and the in vitro kinase activity of ErbB-2. When PKC is activated by TPA, NDF is no longer able to activate ErbB-2 in T47D cells, leading to a blockage of cell proliferation. Activation of ErbB-2 by point mutation, or by monoclonal antibodies, also stimulates both the MAPK and the p70/p85 S6 kinase pathways. The same monoclonal antibodies can induce AU565 cell differentiation. In summary, during growth or differentiation of mammary epithelial cells, NDF stimulates several independent signalling pathways which can also be triggered by ErbB-2 stimulation alone. PKC activation blocks the biological effect induced by NDF through negative modulation of ErbB-2.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; CIBA GEIGY LTD,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis			taverna, daniela/J-8358-2016	taverna, daniela/0000-0002-6365-527X				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; BACUS SS, 1993, CANCER RES, V53, P5251; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CAO HN, 1991, ONCOGENE, V6, P705; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	59	123	124	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					167	175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824269				2022-12-25	WOS:A1995QA98000019
J	ECKMANN, L; HUANG, GTJ; SMITH, JR; MORZYCKAWROBLEWSKA, E; KAGNOFF, MF				ECKMANN, L; HUANG, GTJ; SMITH, JR; MORZYCKAWROBLEWSKA, E; KAGNOFF, MF			INCREASED TRANSCRIPTION AND COORDINATE STABILIZATION OF MESSENGER-RNAS FOR SECRETED IMMUNOGLOBULIN ALPHA-HEAVY-CHAIN AND KAPPA-LIGHT-CHAIN FOLLOWING STIMULATION OF IMMUNOGLOBULIN-A EXPRESSING B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; MURINE LYMPHOCYTES-B; HALF-LIFE; ESCHERICHIA-COLI; GENE-EXPRESSION; IGA PRODUCTION; DIFFERENTIATION; GROWTH; LIPOPOLYSACCHARIDE; INTERLEUKIN-5	Immunoglobulin A (IgA) plays a key role in host protection at mucosal surfaces, yet little is known regarding the molecular mechanisms that govern the expression of this isotype, The studies herein investigated mechanisms that control IgA secretion in response to stimulation with interleukin-4 and interleukin-5, cytokines which are known to regulate IgA responses, and to bacterial lipopolysaccharide, Two mechanisms were shown to govern agonist induced IgA expression in a murine IgA expressing B cell line, In the initial period after stimulation, increased mRNA levels for the secreted form of alpha heavy chain (alpha(S)), and kappa light chain were paralleled by a transient increase in transcription rates of the corresponding genes, However, with prolonged agonist stimulation, gene transcription rates decreased to near control levels, and increased mRNA levels were associated with a coordinate increase in alpha(S) and kappa mRNA stability. In striking contrast, these agonists did not affect levels or stability of mRNA for the membrane form of alpha heavy chain (alpha(M)). alpha(S) mRNAs contained multiple poly(A) addition sites located 13-32 nucleotides downstream of a single AAUAAA sequence, Nonetheless, the differential usage of these sites as a mechanism for controlling alpha(S) mRNA stability could be excluded, since the relative abundance of these different alpha(S) mRNAs did not differ significantly after agonist stimulation, These data, taken together, suggest that sequences within 107 nucleotides of the 3' end of alpha(S) mRNA, which are absent in alpha(M) mRNA, are required for the regulation of alpha(S) mRNA stability, possibly by acting as targets for regulated trans-acting cellular factors.			ECKMANN, L (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED 0623D,MUCOSAL IMMUNOL LAB,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07202, DK35108] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD LW, 1988, J IMMUNOL, V140, P4355; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133; BERBERICH I, 1990, EUR J IMMUNOL, V20, P445, DOI 10.1002/eji.1830200233; CHEN SS, 1990, CELL IMMUNOL, V128, P353, DOI 10.1016/0008-8749(90)90032-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; DUNNICK W, 1989, MOL CELL BIOL, V95, P1850; ECKMANN L, 1992, IMMUNOLOGY, V76, P235; FLASPOHLER JA, 1990, J IMMUNOL, V144, P2802; GALLI G, 1987, GENE DEV, V1, P471, DOI 10.1101/gad.1.5.471; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GENOVESE C, 1990, MOL IMMUNOL, V27, P733, DOI 10.1016/0161-5890(90)90082-B; GREENBERG JR, 1972, NATURE, V240, P102, DOI 10.1038/240102a0; GRUMMT I, 1980, MOL GEN GENET, V177, P223, DOI 10.1007/BF00267433; HARRIMAN GR, 1988, J IMMUNOL, V140, P3033; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HEATH CV, 1990, J BIOL CHEM, V265, P9098; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; JACK HM, 1988, EMBO J, V7, P1041, DOI 10.1002/j.1460-2075.1988.tb02911.x; KIM PH, 1990, J IMMUNOL, V145, P3773; KING LB, 1990, MOL CELL BIOL, V10, P4211, DOI 10.1128/MCB.10.8.4211; LEBMAN DA, 1992, J IMMUNOL, V148, P3282; LEBMAN DA, 1993, INT IMMUNOL, V6, P113; LEDUC I, 1992, CLIN EXP IMMUNOL, V90, P141; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; Mason PJ, 1985, NUCLEIC ACID HYBRIDI, P113; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MURRAY PD, 1987, J IMMUNOL, V139, P2669; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHOCKETT P, 1991, J IMMUNOL, V147, P4374; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; TUCKER PW, 1981, P NATL ACAD SCI-BIOL, V78, P7684, DOI 10.1073/pnas.78.12.7684; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEBB CF, 1991, MOL CELL BIOL, V11, P5197, DOI 10.1128/MCB.11.10.5197; WORD CJ, 1983, EMBO J, V2, P887, DOI 10.1002/j.1460-2075.1983.tb01518.x; YUAN D, 1989, MOL IMMUNOL, V26, P1059, DOI 10.1016/0161-5890(89)90070-9; YUAN D, 1984, J EXP MED, V160, P564, DOI 10.1084/jem.160.2.564; YUAN D, 1992, J IMMUNOL, V148, P3652; YUAN D, 1982, J EXP MED, V156, P962, DOI 10.1084/jem.156.4.962; ZAK R, 1979, PHYSIOL REV, V59, P407, DOI 10.1152/physrev.1979.59.2.407	58	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33102	33108						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806538				2022-12-25	WOS:A1994QA63800056
J	PEREZSTABLE, C				PEREZSTABLE, C			DISTINCT NEGATIVE REGULATORY MECHANISMS INVOLVED IN THE REPRESSION OF HUMAN EMBRYONIC EPSILON-GLOBIN AND FETAL G-GAMMA-GLOBIN GENES IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAGE SELECTOR ELEMENT; LOCUS ACTIVATION REGION; ERYTHROID-SPECIFIC EXPRESSION; BETA-GLOBIN; DEVELOPMENTAL REGULATION; HYPERSENSITIVE SITE; CHROMATIN STRUCTURE; PROMOTER; MOUSE; TRANSCRIPTION	A current model for human beta-globin gene switching proposes that the stage-specific activation of embryonic and fetal globin genes requires the interaction of the beta-globin locus control region with proximal promoter elements. Subsequent repression in fetal and adult stages likely involves negative regulatory promoter elements and factors. To begin addressing these negative regulatory mechanisms, the regulation of human fetal G gamma-globin promoter fused to the SV40 T antigen gene was analyzed in transgenic mice. The results showed correct developmental expression in erythroid tissue, but lower levels of expression were also detected in non erythroid tissue. Thus, the 5'-flanking G gamma-globin promoter sequence contains stage-specific erythroid elements but is lacking nonerythroid-specific negative elements. In contrast, the human embryonic epsilon-globin gene was only expressed in nonerythroid tissue of transgenic embryos, suggesting the presence of an erythroid specific negative element(s). With the locus control region, complete repression of epsilon-globin RNA in fetal liver was observed in epsilon-globin genes without the previously characterized silencer, suggesting the presence of additional negative elements. Overall, this transgenic study suggests that distinct negative regulatory mechanisms function in the repression of embryonic and fetal globin genes.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	Columbia University								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARALLE FE, 1980, CELL, V21, P621, DOI 10.1016/0092-8674(80)90425-0; BARKER JE, 1969, DEV BIOL, V18, P14; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FARACE MG, 1984, J BIOL CHEM, V259, P7123; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; HANSEN JN, 1982, J BIOL CHEM, V257, P1048; HILL A, 1984, J BIOL CHEM, V259, P3739; HOGAN B, 1986, MANIPULATING MOUSE E; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MAGRAM J, 1989, MOL CELL BIOL, V9, P4581, DOI 10.1128/MCB.9.10.4581; MAGRAM J, 1985, NATURE, V315, P338, DOI 10.1038/315338a0; MOTAMED K, 1993, GENE AMST, V123, P253; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1993, J BIOL CHEM, V268, P3066; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1987, HEMOGLOBIN SWITCHING, P66; STAMATOYANNOPOU.G, 1993, MOL CELL BIOL, V13, P7636; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; TRUDEL M, 1987, REGULATION GLOBIN GE, P305; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VYAS P, 1992, BLOOD, V80, P1832; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; YU CY, 1991, J BIOL CHEM, V266, P8907	52	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33109	33115						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806539				2022-12-25	WOS:A1994QA63800057
J	CHAN, HC; KAETZEL, MA; GOTTER, AL; DEDMAN, JR; NELSON, DJ				CHAN, HC; KAETZEL, MA; GOTTER, AL; DEDMAN, JR; NELSON, DJ			ANNEXIN-IV INHIBITS CALMODULIN-DEPENDENT PROTEIN-KINASE II-ACTIVATED CHLORIDE CONDUCTANCE - A NOVEL MECHANISM FOR ION-CHANNEL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; CYSTIC-FIBROSIS; BINDING PROTEIN; LINE T84; CALCIUM; ANTIBODY; PURIFICATION; CURRENTS	Ca2+-activated Cl- current (I-Cl,I-Ca) in colonic T84 cells is inhibited by the specific peptide inhibitor of Ca2+/calmodulin-dependent Kinase II (CaM KII). Annexin IV, a Ca2+-dependent phospholipid binding protein also inhibits Ca2+-dependent anion current activation (Kaetzel, M, A, Chan, H.-C., Dubinsky, W. P., Dedman, J. R, and Nelson, D, J, (1994) J. Biol. Chem. 269, 5297-5302). Intracellular injection of antibodies against annexin IV enhances current activation; this activation is inhibited by the peptide inhibitor of CaM KII, Intracellular application of autonomously active CaM KII in the presence of ATP induced a Cl- current similar to that activated by the Ca2+ ionophore A23187, Current activation by the exogenous kinase was completely inhibited in the presence of purified annexin IV. In vitro, annexin IV does not inhibit CaM KII activity nor does it act as a substrate for CaM KII. Thus, it appears that annexin IV inhibits phosphorylation-dependent anion conductance activation by preventing CaM KII-ion channel interaction rather than by direct interaction with the enzyme itself. These findings suggest a novel mechanism by which Ca2+-dependent membrane binding proteins, cytoplasmic kinases, and ion channels interact to regulate membrane conductance, The characterization of unique channel regulatory pathways in Cl- transporting epithelia may identify potential avenues of alternate therapy to compensate for the loss of functional Cl- channels in the disease of cystic fibrosis.	UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; CHINESE UNIV HONG KONG,DEPT PHYSIOL,SHA TIN,HONG KONG; UNIV CINCINNATI,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,CINCINNATI,OH 45267	University of Chicago; University of Chicago; Chinese University of Hong Kong; University System of Ohio; University of Cincinnati			Chan, Hsiao Chang/E-1507-2016		NIDDK NIH HHS [DK41740, DK44840] Funding Source: Medline; NIGMS NIH HHS [GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740, P01DK044840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; DEDMAN JR, 1978, J BIOL CHEM, V253, P7515; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; KAETZEL MA, 1989, BIOCHEM BIOPH RES CO, V160, P1233, DOI 10.1016/S0006-291X(89)80135-4; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; MILLS JW, 1994, J EXP ZOOL, V268, P111, DOI 10.1002/jez.1402680207; Moss S. E, 1992, ANNEXINS; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SEATON BA, 1990, J BIOL CHEM, V265, P4567; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	23	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32464	32468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798247				2022-12-25	WOS:A1994PX30400068
J	HRESKO, RC; MURATA, H; MARSHALL, BA; MUECKLER, M				HRESKO, RC; MURATA, H; MARSHALL, BA; MUECKLER, M			DISCRETE STRUCTURAL DOMAINS DETERMINE DIFFERENTIAL ENDOPLASMIC-RETICULUM TO GOLGI TRANSIT TIMES FOR GLUCOSE-TRANSPORTER ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-TARGET SIZE; XENOPUS-OOCYTES; HUMAN-ERYTHROCYTES; INTRACELLULAR SEQUESTRATION; MEMBRANE-GLYCOPROTEINS; FUNCTIONAL EXPRESSION; CELL-SURFACE; PROTEIN; INSULIN; GLUT1	The rate of movement of the glucose transporter isoforms Glut1 and Glut4 from the endoplasmic reticulum (ER) to the Golgi apparatus was investigated by pulse labeling and monitoring endoglycosidase H resistance in mRNA-injected Xenopus oocytes and in 3T3-L1 adipocytes, a cell line that naturally expresses both transporter isoforms. Despite their high degree of sequence identity, Glut1 and Glut4 exhibited dramatically different transit times. The t(1/2) values for ER to Golgi transit for Glut1 and Glut4 were < 1 and 24 h, respectively, in oocytes and similar to 5 and 20 min, respectively, in 3T3-L1 adipocytes. Pulse-chase in conjunction with sucrose density gradient analysis revealed that the rate-limiting step in the ER to Golgi processing of Glut4 was exit from the ER and not retention in an early Golgi compartment. We analyzed the biosynthesis of Glut1/Glut4 chimeric transporters in Xenopus oocytes in order to determine whether specific domains in Glut1 and Glut4 were responsible for their distinct transit times. The first exofacial glycosylated loop and the cytoplasmic carboxyl-terminal domain of Glut4 were crucial for its delayed exit from the ER. The first transmembrane, the first exofacial, and the cytoplasmic COOH-terminal domains of Glut1 were largely responsible for Glut1's rapid processing in the ER Some of the chimeric transporters were not fully processed. Approximately 50% of chimeric molecules containing the cytoplasmic COOH-terminal domain of Glut1 and either the first transmembrane or first exofacial domain of Glut4 were retained in early Golgi compartments and prevented from complete maturation, Normal processing of these chimeras was achieved by replacing the cytoplasmic COOH-terminal domain of Glut1 with that of Glut4. These data suggest that amino acid residues within the glycosylated exofacial loop and the cytoplasmic COOH terminus participate in a rate-limiting step in the folding of both Glut1 and Glut4 or could act as transient ER retention signals. Additionally, these results show that even chimeric molecules constructed from two highly homologous proteins can exhibit aberrant folding and post-translational processing.			HRESKO, RC (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CUPPOLETTI J, 1981, J BIOL CHEM, V256, P1305; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DAVIES A, 1990, BIOCHEM J, V266, P799; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGUCHI R, 1990, RECOMBINANT PCR; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JARVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V855, P312, DOI 10.1016/0005-2736(86)90179-3; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JUNG CY, 1980, J BIOL CHEM, V255, P361; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KELLER K, 1989, J BIOL CHEM, V264, P18884; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW SH, 1994, J BIOL CHEM, V269, P1985; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SOGIN DC, 1978, J SUPRAMOL STR CELL, V8, P447, DOI 10.1002/jss.400080407; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725	48	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32110	32119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798206				2022-12-25	WOS:A1994PX30400018
J	LO, TWC; WESTWOOD, ME; MCLELLAN, AC; SELWOOD, T; THORNALLEY, PJ				LO, TWC; WESTWOOD, ME; MCLELLAN, AC; SELWOOD, T; THORNALLEY, PJ			BINDING AND MODIFICATION OF PROTEINS BY METHYLGLYOXAL UNDER PHYSIOLOGICAL CONDITIONS - A KINETIC AND MECHANISTIC STUDY WITH N-ALPHA-ACETYLARGININE, N-ALPHA-ACETYLCYSTEINE, AND N-ALPHA-ACETYLLYSINE, AND BOVINE SERUM-ALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYOXALASE SYSTEM; DIABETES-MELLITUS; ALDOSE REDUCTASE; AMINO-ACIDS; PHENYLGLYOXAL; COMPLICATIONS; 1,2-DIAMINO-4,5-DIMETHOXYBENZENE; REAGENTS; ASSAY	The physiological alpha-oxoaldehyde methylglyoxal binds and modifies arginine, lysine, and cysteine residues in proteins. The kinetics and mechanism of these reactions were investigated with N alpha-acetylamino acids and bovine serum albumin at pH 7.4 and 37 degrees C. The reaction of methylglyoxal with N alpha-acetylarginine involved the initial reversible formation of glycosylamine and 4,5-dihydroxy-5-methylimidazolidine derivatives, with further slow irreversible conversion to an imidazolone, N alpha-acetyl-N delta-(5-methyl-4-imidazolon-2-yl) ornithine. The imidazolone was fluorescent with an excitation lambda(max), value of 320 nn and an emission lambda(max) value of 398 nm. Methylglyoxal reacted reversibly with N alpha-acetyllysine to form glycosylamine and bisglycosylamine derivatives. Further reaction of these glycosylamines occurred to form brown, fluorescent oligomers that were not characterized, Methylglyoxal reacted rapidly and reversibly with N alpha-acetylcysteine to farm the hemithioacetal adduct. The reaction of methylglyoxal with bovine serum albumin (BSA) at pH 7.4 and 37 degrees C involved the reversible and irreversible formation of methylglyoxal-BSA adducts. Irreversible modification of BSA occurred mainly on arginine residues to form imidazolone, The formation of methylglyoxal-modified proteins involves glycoxidation leading to advanced glycation end product-like fluorescence. It is expected to be increased in diabetes mellitus and may be linked to the development of diabetic complications.	UNIV ESSEX,DEPT CHEM & BIOL CHEM,COLCHESTER CO4 3SQ,ESSEX,ENGLAND	University of Essex			Lo, Theodore/AAE-5275-2020	Thornalley, Paul/0000-0001-7659-443X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; CLELLAND JD, 1990, J LABELLED COMPDS RA, V28, P1454; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; KATO H, 1986, J NUTR SCI VITAMINOL, V32, P55, DOI 10.3177/jnsv.32.55; KWON CH, 1991, J MED CHEM, V34, P1845, DOI 10.1021/jm00110a013; LEE T-H, 1989, Korean Journal of Biochemistry, V21, P75; LEONCINI G, 1980, FEBS LETT, V117, P17, DOI 10.1016/0014-5793(80)80903-3; LEONCINI G, 1981, EXPERIENTIA, V37, P443, DOI 10.1007/BF01986121; Lo TWC, 1993, AMINO ACIDS, V5, P172; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V2, P1; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MIGLIETTA A, 1985, CELL BIOCHEM FUNCT, V3, P9, DOI 10.1002/cbf.290030104; MIGLIETTA A, 1986, RES COMMUN PATHOL PH, V51, P249; MIRA ML, 1991, BIOCHIM BIOPHYS ACTA, V1060, P257, DOI 10.1016/S0005-2728(05)80315-9; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; RAE C, 1990, EUR J BIOCHEM, V193, P83, DOI 10.1111/j.1432-1033.1990.tb19307.x; Selwood Trevor, 1993, Biochemical Society Transactions, V21, p170S; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P395, DOI 10.1093/oxfordjournals.jbchem.a131471; TAKAHASHI K, 1977, J BIOCHEM-TOKYO, V81, P403, DOI 10.1093/oxfordjournals.jbchem.a131472; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293	32	589	625	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32299	32305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798230				2022-12-25	WOS:A1994PX30400045
J	MARSTON, SB; FRASER, IDC; HUBER, PAJ				MARSTON, SB; FRASER, IDC; HUBER, PAJ			SMOOTH-MUSCLE CALDESMON CONTROLS THE STRONG BINDING INTERACTION BETWEEN ACTIN-TROPOMYOSIN AND MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; THIN-FILAMENTS; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; COOPERATIVE BINDING; CALMODULIN-BINDING; REGULATED ACTIN; SKELETAL; COMPLEX; DISSOCIATION	We have demonstrated that caldesmon does not alter the affinity of weak binding actomyosin complexes when it inhibits actin-tropomyosin activation at physiological ratios (1 per 14 actins), and we proposed that it acts upon the strong binding complexes in the same way that troponin-tropomyosin does. We therefore compared the effect of caldesmon, caldesmon fragments, and troponin upon the interaction of the strongly bound complexes S-1 ADP, S-1 adenylyl imidodiphosphate (AMP-PNP), and N-ethylmaleimide-treated myosin subfragment-1 (NEM-S1) with actin-tropomyosin. In 0.17 M ionic strength buffer [C-14]iodoacetamide-labeled S1-ADP bound to actin-smooth muscle tropomyosin with no evidence of cooperativity; K-d = 0.8 +/- 0.3 mu M (n = 5). Inhibitory concentrations of sheep aorta caldesmon or rabbit skeletal muscle troponin made the binding highly cooperative. At low levels of saturation the apparent K-d was 10-40 mu M with 10 mu M caldesmon and 8-20 mu M with 6 mu M troponin; at > 50% saturation the binding was indistinguishable from actin-tropomyosin alone. A similar result was obtained for the binding of [C-14]iodoacetamide-labeled S-1.AMP.PNP to actin-smooth muscle tropomyosin at 0.03 M ionic strength (K-d = 0.47 +/- 0.05 mu M). Binding was slightly cooperative and became highly cooperative in the presence of inhibitory concentrations of troponin, caldesmon, and the human caldesmon fragments H7 (amino acids 622-767) and H9 (amino acids 726-793). We conclude that caldesmon and troponin both act as allosteric effecters of the ''on''/''off'' equilibrium of actin-tropomyosin. 0.1 NEM-S-1/actin potentiated actin-smooth muscle tropomyosin activation of myosin MgATPase 7-fold at 0.03 M ionic strength. Caldesmon inhibited the ATPase in the presence and absence of 0.5 mu M NEM-S-1. NEM-S-1 reactivated actin-tropomyosin, which had been inhibited by troponin, caldesmon, H7, or H9. This is compatible with opposing effects of NEM-S-1 and caldesmon or troponin upon the actin-tropomyosin on/off equilibrium.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907; Marston, Steven/0000-0001-6054-6070; Huber, Pia AJ/0000-0001-9823-7863				BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUBER PAJ, 1993, J MUSCLE RES CELL M, V14, P385, DOI 10.1007/BF00121289; HUBER PAJ, 1994, BIOPHYS J, V66, P197; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; ISCHII Y, 1987, BIOCHEMISTRY-US, V26, P4922; LEHMAN W, 1993, BIOCHIM BIOPHYS ACTA, V1203, P53, DOI 10.1016/0167-4838(93)90035-P; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON SB, 1982, BIOCHEM J, V203, P453, DOI 10.1042/bj2030453; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1976, J MOL BIOL, V104, P263, DOI 10.1016/0022-2836(76)90012-7; MARSTON SB, 1980, BIOCHEM J, V185, P355, DOI 10.1042/bj1850355; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1982, J MOL BIOL, V157, P275, DOI 10.1016/0022-2836(82)90234-0; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAGGART MJ, 1988, FEBS LETT, V242, P171, DOI 10.1016/0014-5793(88)81009-3; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022	55	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32104	32109						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798205				2022-12-25	WOS:A1994PX30400017
J	FURMAN, E; GLITZ, DG				FURMAN, E; GLITZ, DG			PURIFICATION OF THE SPLICEOSOME A-COMPLEX AND ITS VISUALIZATION BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; SPLICING COMPLEXES; U2 SNRNP; 2'-OME RNA; AFFINITY-CHROMATOGRAPHY; ASSEMBLY PATHWAY; PARTICLES; U5; OLIGONUCLEOTIDES	Pre-mRNA splicing occurs on splceosomes, a family of ribonucleoprotein particles. Spliceosome assembly on exogenous adenovirus pre-mRNA was blocked at the A-complex (or pre-spliceosome) stage, either by destruction of the small nuclear ribonucleoproteins (snRNPs) that comprise the U4/U5/U6 tri-snRNP complex, or by interference in tri-snRNP assembly and interactions. The A-complex was isolated by size exclusion chromatography; homogeneity was shown by electrophoresis in nondenaturing polyacrylamide gels, gradient sedimentation, and electron microscopy. Northern hybridization showed UI and U2 snRNAs to be present in the preparation, but not U4, U5, or U6. Antibodies specific for a component of the U1 snRNP or for a component that is common to all snRNPs (except U6) each precipitated an A-complex containing pre-mRNA, U1 and U2 snRNPs. Electron micrographs showed 230 x 270-Angstrom particles whose two components appear similar to individual U1 and U2 snRNPs. Electron micrographs of an A-complex-5'-biotinyl oligonucleotide streptavidin-gold composite allowed identification of the U2 snRNP within the structure and the localization of the 5'-segment of U2 snRNA at a unique site in the A-complex. This region of U2 RNA is adjacent to the developing catalytic center of the spliceosome.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 51195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051195, R55GM051195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; Baserga S., 1993, RNA WORLD, P359; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; CIRSPINO J, 1994, SCIENCE, V265, P1866; CLARK MW, 1988, EMBO J, V7, P3829, DOI 10.1002/j.1460-2075.1988.tb03268.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GRABOWSKI PJ, 1990, METHOD ENZYMOL, V184, P319; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KASTNER B, 1992, J CELL BIOL, V116, P839, DOI 10.1083/jcb.116.4.839; KASTNER B, 1989, EMBO J, V8, P277, DOI 10.1002/j.1460-2075.1989.tb03374.x; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LASATER LS, 1988, BIOCHEMISTRY-US, V27, P4687, DOI 10.1021/bi00413a016; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MATTER L, 1982, ARTHRITIS RHEUM, V25, P1278, DOI 10.1002/art.1780251102; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MONTESANORODITIS L, 1994, J BIOL CHEM, V269, P6458; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1994, CURR OPIN CELL BIOL, V6, P360, DOI 10.1016/0955-0674(94)90027-2; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; OLSON HM, 1988, J BIOL CHEM, V263, P15196; OLSON HM, 1991, J BIOL CHEM, V266, P1896; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; SIBBALD MJ, 1993, J STRUCT BIOL, V110, P111, DOI 10.1006/jsbi.1993.1011; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	59	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15515	15522		10.1074/jbc.270.26.15515	http://dx.doi.org/10.1074/jbc.270.26.15515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797545	hybrid			2022-12-25	WOS:A1995RG53800015
J	BUISSON, B; LAFLAMME, L; BOTTARI, SP; DEGASPARO, M; GALLOPAYET, N; PAYET, MD				BUISSON, B; LAFLAMME, L; BOTTARI, SP; DEGASPARO, M; GALLOPAYET, N; PAYET, MD			A G-PROTEIN IS INVOLVED IN THE ANGIOTENSIN AT(2) RECEPTOR INHIBITION OF THE T-TYPE CALCIUM CURRENT IN NON-DIFFERENTIATED NG108-15 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; BINDING-SITES; II RECEPTORS; TUMOR-CELLS; SUBTYPES; MECHANISMS; PATHWAYS; CHANNELS	In non-differentiated NG108-15 cells, both angiotensin II (Ang II) (100 nM) and CGP 42112 (100 nM) decreased the T-type calcium current amplitude by 24 +/- 2% and 21 +/- 3%, respectively. cGMP is not a mediator of the Ang II effect, since loading of cells with 50 mu M cGMP did not prevent the inhibitory effects of Ang II. The effects of Ang II involves a non-identified GTPase activity since incubation with GDP beta S (3 mM) completely reversed the inhibitory effect of Ang II while GTP gamma S mimicked its effect. However, Ang II binding was not affected by GTP gamma S, and the effect of Ang II was not modified in pertussis toxin-treated cells, The inhibitory effect of Ang II on the T-type Ca2+ current involves a phosphotyrosine phosphatase activity since sodium orthovanadate prevented the effects of Ang II, although microcystin-LR, a selective Ser/Thr phosphatase 1 and 2A inhibitor, did not modify the effect of Ang II. These results provide the first evidence of a modulation of membrane conductance by Ang II through the AT(2) receptor and demonstrate the involvement of a phosphotyrosine phosphatase and a G protein in the AT(2) transduction mechanism in NG108-15 cells. Moreover, our data suggest that phosphotyrosine phosphatase activation is proximal to receptor occupation, since sodium orthovanadate inhibits both GTPase activity and T-type current blockage induced by Ang II or CGP 42112, while GTP gamma S inhibition of the T-type calcium current is not impaired.	UNIV SHERBROOKE,FAC MED,DEPT PHYSIOL & BIOPHYS,SHERBROOKE,PQ J1H 5N4,CANADA; UNIV SHERBROOKE,FAC MED,SERV ENDOCRINOL,SHERBROOKE,PQ J1H 5N4,CANADA; CIBA GEIGY AG,DEPT CARDIOVASC RES,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	University of Sherbrooke; University of Sherbrooke; Novartis			Bottari, Serge/ABF-3990-2021	Bottari, Serge P./0000-0002-4172-2400				BARNES JM, 1993, EUR J PHARMACOL, V230, P251, DOI 10.1016/0014-2999(93)90558-Y; BOTTARI SP, 1991, EUR J PHARM-MOLEC PH, V207, P157, DOI 10.1016/0922-4106(91)90091-U; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; BRECHLER V, 1992, REGUL PEPTIDES, V44, P207; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; CARRITHER MD, 1992, SOC NEUR ABSTR, V18; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FLORIO T, 1992, J BIOL CHEM, V267, P24169; GEHLERT DR, 1991, NEUROSCIENCE, V44, P501, DOI 10.1016/0306-4522(91)90073-W; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GORDON JA, 1991, METHOD ENZYMOL, V201, pB477; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; HEEMSKERK FMJ, 1993, NEUROREPORT, V4, P103, DOI 10.1097/00001756-199301000-00027; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; JOHNSON MC, 1991, ENDOCRINOLOGY, V129, P1266, DOI 10.1210/endo-129-3-1266; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KATER SB, 1991, J NEUROSCI, V11, P891; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; OBERMULLER N, 1991, NEUROSCI LETT, V132, P11, DOI 10.1016/0304-3940(91)90420-X; ODA H, 1991, P SOC EXP BIOL MED, V196, P175; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SHAPIRO MS, 1994, NEURON, V12, P1319, DOI 10.1016/0896-6273(94)90447-2; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPETH R C, 1989, Peptide Research, V2, P232; SPETH RC, 1993, REGUL PEPTIDES, V44, P189, DOI 10.1016/0167-0115(93)90242-Z; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SUMNERS C, 1991, AM J PHYSIOL, V260, pC79, DOI 10.1152/ajpcell.1991.260.1.C79; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409	44	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1670	1674		10.1074/jbc.270.4.1670	http://dx.doi.org/10.1074/jbc.270.4.1670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829501	hybrid			2022-12-25	WOS:A1995QD20400031
J	BELL, AC; KOUDELKA, GB				BELL, AC; KOUDELKA, GB			HOW 434-REPRESSOR DISCRIMINATES BETWEEN O(R)1 AND O(R)3 - THE INFLUENCE OF CONTACTED AND NONCONTACTED BASE-PAIRS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-434 REPRESSOR; LAC REPRESSOR; DNA; OPERATOR; BINDING; RECOGNITION; RESOLUTION; SPECIFICITY; PHAGE-434; AFFINITY	The sequence of the bacteriophage 434 O(R)1 (ACAAAACTTTCTTGT) differs from its O(R)3 (ACAGTTTTTCTTGT) at positions 4-6. X-ray analysis shows that the side chain of Gln(33) of the 434 repressor makes van der Waals' and H-bond contacts with the T at position 4' in complex with O(R)1, but no specific contact is observed at this position in 434 repressor-O(R)3 complexes, No contacts are made by repressor to the bases at positions 5 or 6 in either binding site, The significance of the sequence differences between O(R)1 and O(R)3 in determining the operator affinity for repressor were examined by con structing synthetic variants of these operators, Measurements of the affinity of these operators for repressor as a function of ionic strength revealed that although base pairs 5 and 6 are not contacted by 434 repressor, they can nonetheless influence operator affinity for repressor by modulating the degree to which ionic interactions contribute to the overall binding energy. Both the magnitude and direction of their effect depends on the status of repressor's contacts to the bases at position 4. The role of contact made by Gln(33) to position 4 was examined by mutating this amino acid to Ala and by examining the affinity of wild type repressor for an operator bearing a 5-methylcytosine at position 4' in an O(R)1-4G mutant. These experiments showed that repressor's preferences at operator positions 5 and 6 are linked to its position 4 preference via a van der Waals' contact between amino acid 33 and a methyl group on the base at operator position 4'. Together, the results of the experiments shown here reveal that bases that do not contact the protein alter its preferences for bases at the contacted operator position 4.	SUNY BUFFALO,DEPT SCI BIOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042138, R29GM042138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BELL AC, 1993, J MOL BIOL, V234, P542, DOI 10.1006/jmbi.1993.1610; BUSHMAN FD, 1993, J MOL BIOL, V230, P28, DOI 10.1006/jmbi.1993.1123; BUSHMAN FD, 1986, P NATL ACAD SCI USA, V83, P9353, DOI 10.1073/pnas.83.24.9353; BUSHMAN FD, 1985, NATURE, V316, P651, DOI 10.1038/316651a0; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1993, J BIOL CHEM, V268, P23812; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Ptashne M., 1986, A GENETIC SWITCH; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RODGERS DW, 1993, STRUCTURE, V1, P227, DOI 10.1016/0969-2126(93)90012-6; Sambrook J, 1989, MOL CLONING LABORATO; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1986, THESIS HARVARD U; WHARTON RP, 1985, CELL, V38, P361	29	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1205	1212		10.1074/jbc.270.3.1205	http://dx.doi.org/10.1074/jbc.270.3.1205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836381	hybrid			2022-12-25	WOS:A1995QB15600036
J	JIANG, Y; GRALLA, JD				JIANG, Y; GRALLA, JD			NUCLEOTIDE REQUIREMENTS FOR ACTIVATED RNA-POLYMERASE-II OPEN COMPLEX-FORMATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-DOMAIN KINASE; TRANSCRIPTION INITIATION; ATP REQUIREMENT; PROMOTER DNA; LAC PROMOTER; FACTOR-DELTA; RAT-LIVER; MECHANISM; INVITRO; METHYLATION	The role of nucleotides in activated RNA polymerase II transcription was studied, Permanganate footprinting confirmed that there is a strict nucleotide requirement for forming open promoter complexes that cannot be overcome by the addition of a dinucleotide primer corresponding to the start site sequence. However, higher concentrations of other nucleoside triphosphates can substitute for ATP in catalyzing open complex formation. Opening catalyzed by these nucleotides is inhibited by the ATP analogue adenosine 5'-O-(thiotriphosphate), suggesting that they may function through cross-binding to the ATP site. The K-M for ATP for opening and the involvement of other nucleotides in opening differs from the characteristics reported for TFIIH helicase and C-terminal domain kinase activities. This raises the possibility that opening does not involve these activities. The results alleviate very significantly the considerable current uncertainty concerning the role of ATP in the mammalian mRNA transcription initiation pathway.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1994, J BIOL CHEM, V269, P5505; JIANG Y, 1993, J BIOL CHEM, V268, P6535; JIANG Y, 1994, IN PRESS NUCLEIC ACI; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAWADOGO M, 1984, J BIOL CHEM, V250, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	34	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1277	1281		10.1074/jbc.270.3.1277	http://dx.doi.org/10.1074/jbc.270.3.1277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836391	hybrid			2022-12-25	WOS:A1995QB15600046
J	SHASTRI, N; NGUYEN, V; GONZALEZ, F				SHASTRI, N; NGUYEN, V; GONZALEZ, F			MAJOR HISTOCOMPATIBILITY CLASS-I MOLECULES CAN PRESENT CRYPTIC TRANSLATION PRODUCTS TO T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGENIC PEPTIDES; MESSENGER-RNAS; EXPRESSION; GENE; PROTEIN; CLONING; LYMPHOCYTES; DEGRADATION; GENERATION; INITIATION	Self or foreign cellular proteins provide peptides for presentation by major histocompatibility complex (MHC) class I molecules on the surface of antigen presenting cells (APC). Surprisingly, several studies have shown that T-cells can recognize APC transfected with antigen genes that were not present in the appropriate translational context. To understand the basis of this phenomenon, APC were transfected with DNA constructs encoding the OVA257-264 (SL8) peptide, but with varying translation initiation codons. We report that, in addition to ATG, 6 other codons (ATT, ACG, CTG, GCG, TGG, GAT) also allowed presentation to SL8.K-b-specific T-cells, Significantly, this set includes 3 of 4 known non-ATG translation initiation codons strongly suggesting that cryptic translation accounts for this phenomenon, Although expression of the SL8.K-b complex was readily detected by T-cell activation, the amount of processed peptides was below detection limit (<30 copies/cell) in cell extracts. Thus, the fortuitous presence of these cryptic translation initiation sites in transcribed genes can explain how peptide.MHC complexes were obtained in sufficient amounts for T-cell activation, The translation initiation codons identified here could also be useful for identifying potential open reading frames that possess biological and/or immunological activities.			SHASTRI, N (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,LSA 421,BERKELEY,CA 94720, USA.							BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BOON T, 1989, COLD SH Q B, V54, P587; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FETTEN JV, 1991, J IMMUNOL, V147, P2697; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIPFORD GB, 1993, J IMMUNOL, V150, P1212; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; SHASTRI N, 1993, J IMMUNOL, V150, P2724; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; VANBLEEK GM, 1990, NATURE, V348, P213; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	29	41	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1088	1091		10.1074/jbc.270.3.1088	http://dx.doi.org/10.1074/jbc.270.3.1088			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836364	hybrid			2022-12-25	WOS:A1995QB15600019
J	ANDERSEN, JP				ANDERSEN, JP			FUNCTIONAL CONSEQUENCES OF ALTERATIONS TO AMINO-ACIDS AT THE M5S5 BOUNDARY OF THE CA2+-ATPASE OF SARCOPLASMIC-RETICULUM - MUTATION TYR763-]GLY UNCOUPLES ATP HYDROLYSIS FROM CA2+ TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; FROG SKELETAL-MUSCLE; RECONSTITUTED PROTEOLIPOSOMES; CA-2+-ATPASE; OCCLUSION; DOMAIN; STATE; CELLS; CRATP; PUMP	The roles of the hydrophobic side chains of residues Phe(760), Ile(761), Tyr(763), Leu(764), and Ile(765) located at the M5S5 boundary of the Ca2+-ATPase of sarcoplasmic reticulum were analyzed by site-directed mutagenesis. Substitution of Tyr(763) with glycine resulted in a new phenotypic variant of the Ca2+-ATPase that catalyzed a high rate of Ca2+-activated ATP hydrolysis without net accumulation of Ca2+ in the microsomal vesicles. The ATPase activity of the Tyr(763), Gly mutant displayed characteristics similar to the ATPase activity of the mild-type enzyme measured in the presence of calcium ionophore, and the mutant was able to form the ADP-insensitive phosphoenzyme intermediate. Mutants Phe(760) --> Gly, Ile(761) --> Gly, Leu(764) --> Gly, and Ile(765) --> Gly were able to accumulate Ca2+. In mutants Leu(764) --> Gly and Ile(765) --> Gly, the turnover rate was low due to inhibition of dephosphorylation of the ADP-insensitive phosphoenzyme intermediate. On the other hand, mutant Leu(764) --> Lys dephosphorylated rapidly. Mutants Phe(760) --> Gly and Leu(764) --> Lys displayed apparent Ca2+ affinities that were reduced two and three orders of magnitude, respectively, relative to that of the wild-type.			ANDERSEN, JP (corresponding author), AARHUS UNIV,INST PHYSIOL,DANISH BIOMEMBRANE RES CTR,OLE WORMS ALLE 160,UNIV PK,DK-8000 AARHUS C,DENMARK.			Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1992, ACTA PHYSIOL SCAND, V146, P151; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY D, 1990, J BIOL CHEM, V265, P19524; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; NORREGAARD A, 1993, FEBS LETT, V336, P248, DOI 10.1016/0014-5793(93)80813-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sillen L, 1964, STABILITY CONSTANTS; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, FEBS LETT, V306, P213, DOI 10.1016/0014-5793(92)81003-5; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WOLOSKER H, 1992, J BIOL CHEM, V267, P5785; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9	41	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					908	914		10.1074/jbc.270.2.908	http://dx.doi.org/10.1074/jbc.270.2.908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822330	hybrid			2022-12-25	WOS:A1995QB81600064
J	KRUPENKO, SA; WAGNER, C; COOK, RJ				KRUPENKO, SA; WAGNER, C; COOK, RJ			CYSTEINE-707 IS INVOLVED IN THE DEHYDROGENASE ACTIVE-SITE OF RAT 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FOLATE-BINDING-PROTEIN; ALDEHYDE DEHYDROGENASE; DIRECTED MUTAGENESIS; CYTOSOL-I; LIVER; NITROCELLULOSE; PURIFICATION; FLUORESCENCE; EXPRESSION; STABILITY	The enzyme, 10-formyltetrahydrofolate dehydrogenase (10-FTHFDH) (EC 1.5.1.6) catalyzes both the NADP(+)-dependent oxidation of 10-formyltetrahydrofolate to tetrahydrofolate and CO2 and the NADP(+) independent hydrolysis of 10-formyltetrahydrofolate to tetrahydrofolate and formate, The COOH-terminal domain of the 10-FTHFDH (residues 417-902) shows a 46% identity with a series of NAD(+)-dependent aldehyde dehydrogenases (EC 1.2.1.3), All known members of the aldehyde dehydrogenase family and 10-FTHFDH have a strictly conserved cysteine (Cys-707 for 10-FTHFDH), which has been predicted to be at the active site of these enzymes, Rat liver 10-FTHFDH was expressed in a baculovirus system, and site directed mutagenesis has been used to study the role of cysteine 707 in the activity of 10-FTHFDH. 10-FTHFDH with alanine substituted for cysteine at position 707 had no dehydrogenase activity, while hydrolase activity and binding of NADP(+) were unchanged. Light scattering analysis revealed that wild type and mutant 10-FTHFDH exist as tetramers, We conclude that cysteine 707 is directly involved in the active site of 10-FTHFDH responsible for dehydrogenase activity, and there is a separate site for the hydrolase activity.	DEPT VET AFFAIRS MED CTR,RES SERV,NASHVILLE,TN 37212	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	KRUPENKO, SA (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,612 LH,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046788, R01DK015289, R37DK015289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15289, DK46788] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BLATTER EE, 1992, BIOCHEM J, V282, P353, DOI 10.1042/bj2820353; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASE GL, 1988, J BIOL CHEM, V263, P1024; CHOW SF, 1985, J BIOL CHEM, V260, P5516; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; COOK RJ, 1991, J BIOL CHEM, V266, P4965; COOK RJ, 1986, METHOD ENZYMOL, V122, P251; COOK RJ, 1982, BIOCHEMISTRY-US, V21, P4427, DOI 10.1021/bi00261a036; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GARVEY EP, 1990, PROTEIN ENG, P37; Goldenberg David P., 1992, P353; HANIOKA N, 1992, J STEROID BIOCHEM, V43, P1037, DOI 10.1016/0960-0760(92)90331-C; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; ROUT UK, 1994, BIOCHEMISTRY-US, V33, P8955, DOI 10.1021/bi00196a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; WEINER H, 1991, ENZYMOLOGY MOL BIOL, V3, P13; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; YARMUSH DM, 1988, MOL IMMUNOL, V25, P17, DOI 10.1016/0161-5890(88)90086-7	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					519	522		10.1074/jbc.270.2.519	http://dx.doi.org/10.1074/jbc.270.2.519			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822273	hybrid			2022-12-25	WOS:A1995QB81600005
J	OBRYAN, JP; FRIDELL, YW; KOSKI, R; VARNUM, B; LIU, ET				OBRYAN, JP; FRIDELL, YW; KOSKI, R; VARNUM, B; LIU, ET			THE TRANSFORMING RECEPTOR TYROSINE KINASE, AXL, IS POSTTRANSLATIONALLY REGULATED BY PROTEOLYTIC CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CARCINOMA-CELLS; EGF RECEPTOR; C-ERBB; EXPRESSION; PROTEIN; GENE; ACTIVATION; ONCOGENE; LIGAND	Several receptor tyrosine kinases generate soluble ligand binding domains either by differential splicing resulting in a truncated RNA transcript, or by proteolytic cleavage, Although the exact role in vivo of these soluble extracellular domains is unclear, proteolysis may function to down-regulate the receptor, and soluble extracellular domains (ECD) may compete with the intact receptor binding to ligand, Ax1 is a member of a new class of receptor tyrosine kinases characterized by an ECD resembling cell adhesion molecules and unique sequences in the kinase domain, In addition, Ax1 is transforming in both fibroblast and hematopoietic cells, and appears to be involved in mesenchymal development, We now find that Ax1 is post-translationally processed by cleavage in a 14 amino acid region immediately NH2-terminal to the transmembrane domain resulting in a soluble ECD and a membrane bound kinase domain, The sequence of this putative cleavage site shares no homology with recognition sites of known proteases, Characterization of this proteolytic processing shows that it does not require protein synthesis or transport but is augmented by phorbol ester treatment, Since the cleavage of Ax1 enhances turnover of the kinase on the cell surface, we suggest that proteolytic processing down-regulates Ax1 kinase activity.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CURRICULUM GENET,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599; AMGEN CORP,THOUSAND OAKS,CA 91320	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Amgen			Liu, Edison/C-4141-2008	O'Bryan, John/0000-0001-5386-1080	NATIONAL CANCER INSTITUTE [R01CA049240] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BURNETTE WN, 1988, BIO-TECHNOL, V6, P699, DOI 10.1038/nbt0688-699; DAI W, 1994, ONCOGENE, V9, P975; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FAUST M, 1992, ONCOGENE, V7, P1287; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FUJIMOTO J, 1994, ONCOGENE, V9, P693; HALEY JD, 1989, ONCOGENE, V4, P273; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LIN YZJ, 1991, ONCOGENE, V6, P639; MARK MR, 1994, J BIOL CHEM, V269, P10720; MCCLOSKEY RP, 1994, IN PRESS CELL GROWTH; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NEUBAUER A, 1994, IN PRESS BLOOD; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OBRYAN JP, 1992, THESIS U N CAROLINA; OHASHI K, 1994, ONCOGENE, V9, P699; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUPA SM, 1993, ONCOGENE, V8, P2917; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	36	131	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					551	557		10.1074/jbc.270.2.551	http://dx.doi.org/10.1074/jbc.270.2.551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822279	hybrid			2022-12-25	WOS:A1995QB81600011
J	NOGALES, D; LIGHTNER, DA				NOGALES, D; LIGHTNER, DA			ON THE STRUCTURE OF BILIRUBIN IN SOLUTION - C-13(H-1) HETERONUCLEAR OVERHAUSER EFFECT NMR ANALYSES IN AQUEOUS BUFFER AND ORGANIC-SOLVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; INDUCED CIRCULAR-DICHROISM; CONFORMATION; DERIVATIVES; RESOLUTION; SULFOXIDES; C-13	Select hydrogen-carbon distances have been determined from C-13(H-1) heteronuclear Overhauser effects observed in a 99% carbon-13 enriched (CO2H)-C-13 bilirubin analog, [8(3),12(3)-C-13(2)]-mesobilirubin XIII alpha. Analysis of the data confirms that the propionic acid carbonyl lies within hydrogen bonding distance to the dipyrrinone lactam and pyrrole N-H groups in chloroform and indicates, surprisingly, that those distances are only slightly longer in dimethyl sulfoxide solvent or when the carboxyl group is ionized in pH 7.4 aqueous buffered solutions of the pigment. The data supports the presence and persistence of folded, intramolecularly hydrogen-bonded bilirubin conformations in solution.	UNIV NEVADA,DEPT CHEM,RENO,NV 89557; UNIV NEVADA,DEPT BIOCHEM,RENO,NV 89557; UNIV NEVADA,CELL & MOLEC BIOL PROGRAM,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017779] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-17779] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOIADJIEV SE, 1992, J AM CHEM SOC, V114, P10123, DOI 10.1021/ja00052a006; BONNETT R, 1978, PROC R SOC SER B-BIO, V202, P249, DOI 10.1098/rspb.1978.0066; BRODERSEN R, 1986, BILE PIGMENTS JAUNDI, P158; CATIVIELA C, 1985, MAGN RESON CHEM, V23, P1072, DOI 10.1002/mrc.1260231209; CISTOLA DP, 1982, J LIPID RES, V23, P795; Falk H., 1989, CHEM LINEAR OLIGOPYR; Fischer H, 1941, H-S Z PHYSIOL CHEM, V268, P197, DOI 10.1515/bchm2.1941.268.5-6.197; GAWRONSKI JK, 1990, TETRAHEDRON, V46, P8053, DOI 10.1016/S0040-4020(01)81462-9; GOLLAN JL, 1988, SEMIN LIVER DIS, V8, P8; HORE PJ, 1983, J MAGN RESON, V54, P539, DOI 10.1016/0022-2364(83)90335-9; HSIEH YZ, 1988, J AM CHEM SOC, V110, P62, DOI 10.1021/ja00209a009; JAMES TL, 1991, ANNU REV PHYS CHEM, V42, P501, DOI 10.1146/annurev.physchem.42.1.501; KAPLAN D, 1981, J CHEM SOC PERK T 2, P1374, DOI 10.1039/p29810001374; KAPLAN D, 1983, ISRAEL J CHEM, V23, P177; KAPLAN D, 1982, BIOCHEM J, V201, P605, DOI 10.1042/bj2010605; KHALED M A, 1983, Journal of the American Chemical Society, V105, P3363, DOI 10.1021/ja00348a083; LEBAS G, 1980, ACTA CRYSTALLOGR B, V36, P3007, DOI 10.1107/S0567740880010692; LIU H, 1993, J AM CHEM SOC, V115, P1590, DOI 10.1021/ja00057a062; MAISELS MJ, 1990, CLIN PERINATOLOGY NE, V17; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1985, PEDIATRICS, V75, P443; MCDONAGH AF, 1991, FALK SYMP, V57, P47; MUKUNDAN S, 1991, J AM CHEM SOC, V113, P3021, DOI 10.1021/ja00008a034; NEUHAUS D, 1988, NUCLEAR OVERHAUSER E; NOGALES DF, 1994, J LABELLED COMPD RAD, V34, P453, DOI 10.1002/jlcr.2580340508; Ostrow JD., 1986, BILE PIGMENTS JAUNDI; PESON RV, 1994, J AM CHEM SOC, V116, P42; PU YM, 1991, TETRAHEDRON, V47, P6163, DOI 10.1016/S0040-4020(01)86549-2; PUZICHA G, 1991, J AM CHEM SOC, V113, P3583, DOI 10.1021/ja00009a055; SEBA HB, 1990, J CHEM SOC CHEM COMM, P996, DOI 10.1039/c39900000996; SHOUT DP, 1993, SPECTROSC LETT, V26, P461; TIRIBELLI C, 1993, HEPATOLOGY, V17, P715, DOI 10.1002/hep.1840170428; TRULL FR, 1987, J HETEROCYCLIC CHEM, V24, P1573, DOI 10.1002/jhet.5570240614; TRULL FR, 1983, ISRAEL J CHEM, V23, P211; TRULL FR, 1992, TETRAHEDRON, V48, P8189, DOI 10.1016/S0040-4020(01)80488-9; YU C, 1984, J AM CHEM SOC, V106, P6533, DOI 10.1021/ja00334a013	36	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					73	77		10.1074/jbc.270.1.73	http://dx.doi.org/10.1074/jbc.270.1.73			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814422	hybrid			2022-12-25	WOS:A1995QA28700017
J	FUKUDA, M; GOTOH, Y; KOSAKO, H; HATTORI, S; NISHIDA, E				FUKUDA, M; GOTOH, Y; KOSAKO, H; HATTORI, S; NISHIDA, E			ANALYSIS OF THE RAS P21-MITOGEN ACTIVATED PROTEIN-KINASE SIGNALING IN-VITRO AND IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ONCOGENIC P21(RAS); ACTS DOWNSTREAM; RAF-1; CELLS; GROWTH; TRANSDUCTION; MATURATION	Ras p21 in the GTP-bound form was shown to act as an upstream activator for mitogen activated protein (MAP) kinase kinase (MAPKK) and MAP kinase, and Raf-1 was reported to act as a MAPKK kinase. Further, physical association between Ras and Raf-1 was demonstrated. Here we have shown that incubation of Xenopus immature oocyte extracts with Ras enhances the ability of endogenous Raf-1 to activate MAPKK. Moreover, a dominant negative form of Raf-1 blocked the Ras-induced activation of MAPKK and MAP kinase in the extracts, but not the cyclin A dependent activation of MAP kinase. When the extracts were depleted of 45-kDa MAPKK with polyclonal anti-MAPKK antibody, no activation of MAP kinase occurred even after incubation with Ras. These results suggest that Ras can activate the MAPKK kinase activity of Raf-1 in the extracts and that MAPKK is indispensable for the Ras-induced MAP kinase activation. It is well known that Ras can induce oocyte maturation when injected into immature Xenopus oocytes. Go-injection of Ras with an anti-MAPKK antibody that inhibits the MAPKK activity prevented the Ras-induced germinal vesicle breakdown, suggesting that MAPKK mediates, at least, one of cellular functions of Ras.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA,TOKYO 187,JAPAN	Kyoto University; University of Tokyo; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/I-7915-2014; Fukuda, Makoto/C-9745-2009	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HATTORI S, 1985, MOL CELL BIOL, V5, P1449, DOI 10.1128/MCB.5.6.1449; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORN LJ, 1987, SCIENCE, V236, P1502; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAPP UR, 1991, ONCOGENE, V6, P495; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33097	33101						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806537				2022-12-25	WOS:A1994QA63800055
J	TOHYAMA, Y; YANAGI, S; SADA, K; YAMAMURA, H				TOHYAMA, Y; YANAGI, S; SADA, K; YAMAMURA, H			TRANSLOCATION OF P72(SYK) TO THE CYTOSKELETON IN THROMBIN-STIMULATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SKELETON; ACTIN POLYMERIZATION; TYROSINE PHOSPHORYLATION; BLOOD-PLATELETS; PROTEIN; ASSOCIATION; IDENTIFICATION; AGGREGATION; PP60(C-SRC); PP60C-SRC	Thrombin stimulation induces a dramatic increase in the activity of p72(syk) in platelets. We have found that activated p72(syk), which is phosphorylated on tyrosine residue(s), translocates from the Triton X-100-soluble fraction to the Triton X-100-insoluble, cytoskeleton-rich fraction after thrombin stimulation. In addition, the redistribution of p72(syk) from the 100,000 x g Triton X-soluble fraction and the membrane skeleton was found to correlate with an increased level of p72(syk) in the cytoskeleton. Furthermore, the early phase of p72(syk) translocation (within 60 s) was significantly inhibited with cytochalasin D, whereas the late phase of p72(syk) translocation (after 90 s) was completely inhibited with RGDS tetrapeptide treatment. These results suggest that translocation of the activated p72(syk) to the cytoskeleton correlates with different phases of the platelet activation process through actin polymerization and glyco protein IIb/IIIa-fibrinogen-mediated aggregation of platelets and, hence, may have a regulatory role in tyrosine phosphorylation of platelets.	FUKUI MED SCH,DEPT BIOCHEM,MATSUOKA,FUKUI 91011,JAPAN; KOBE UNIV,BIOSIGNAL RES CTR,NADA KU,KOBE 657,JAPAN	University of Fukui; Kobe University			Sada, Kiyonao/H-7373-2015	Sada, Kiyonao/0000-0001-6124-3100				BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HORVATH AR, 1992, EMBO J, V11, P821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1992, J BIOL CHEM, V267, P20075; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; ZHANG J, 1992, J BIOL CHEM, V267, P4686	22	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32796	32799						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806502				2022-12-25	WOS:A1994QA63800015
J	PILZ, RB; BERJIS, M; IDRISS, SD; SCHEELE, JS; SUHASINI, M; GAO, L; SCHEFFLER, IE; BOSS, GR				PILZ, RB; BERJIS, M; IDRISS, SD; SCHEELE, JS; SUHASINI, M; GAO, L; SCHEFFLER, IE; BOSS, GR			ISOLATION AND CHARACTERIZATION OF HL-60 CELLS RESISTANT TO NITROPRUSSIDE-INDUCED DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; DEPENDENT PROTEIN-KINASE; PROMYELOCYTIC LEUKEMIA-CELLS; NITRIC-OXIDE; MOLECULAR-CLONING; RAT LUNG; HUMAN-PLATELETS; C-MYC; TISSUE PREPARATIONS; LINE HL-60	Sodium nitroprusside and sodium nitrite, which generate nitric oxide and increase the intracellular cGMP concentration, and 8-bromo-cGMP, a membrane-permeable cGMP analog, induce myelomonocytic differentiation of HL-60 cells (Boss, G. R. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7174-7178). We have selected HL-60 cells resistant to nitroprusside-induced differentiation as assessed by acquisition of the OKM-1 antigen, reduction of nitro blue tetrazolium, and morphologic maturation. The variant cells were also resistant to differentiation induced by sodium nitrite and two cGMP analogs but still differentiated in response to other inducing agents such as dimethyl sulfoxide and cAMP analogs and showed the same changes in c-myc and c-fos expression in response to the latter drugs as occurred in parental cells. We studied the early steps of the NO/cGMP signal transduction pathway in the variant cells and found that basal and nitroprusside-stimulated guanylate cyclase activity was similar in parental and variant cell extracts and that nitroprusside increased the intracellular cGMP concentration to the same extent in parental and variant cells. As part of these studies we found that HL-60 cells expressed only alpha(2) and beta(2) guanylate cyclase mRNA; the abundance of these two mRNA species was similar in parental and variant cells. Neither nitroprusside nor 8-bromo-cGMP changed the intracellular calcium concentration in parental or variant cells. The data suggest that the defect in the variant cells is after guanylate cyclase activation in the NO/cGMP transduction pathway and that the cGMP and cAMP transduction pathways operate independently in inducing differentiation of HL-60 cells.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	PILZ, RB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093, USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018835, R01GM049360] Funding Source: NIH RePORTER; NCI NIH HHS [KO8 CA01548] Funding Source: Medline; NIGMS NIH HHS [R01 GM18835, R01 GM49360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; ASANO T, 1977, BIOCHEM BIOPH RES CO, V78, P910, DOI 10.1016/0006-291X(77)90509-5; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; CHHAJLANI V, 1989, BIOCHEM INT, V19, P1039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DOUGLAS SD, 1990, HEMATOLOGY, P859; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HIGUCHI M, 1991, MOL IMMUNOL, V28, P1039; IDRISS SD, 1992, BIOCHEM BIOPH RES CO, V183, P312, DOI 10.1016/0006-291X(92)91645-7; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; LANDER HM, 1993, J IMMUNOL, V150, P1509; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUELLER R, 1985, Nature (London), V314, P546; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; OKAZAKI T, 1986, CANCER RES, V46, P6059; PILZ RB, 1984, J BIOL CHEM, V259, P2927; PILZ RB, 1990, J BIOL CHEM, V265, P8880; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SPRENGER H, 1991, IMMUNOBIOLOGY, V183, P94, DOI 10.1016/S0171-2985(11)80189-0; TSUDA T, 1987, J BIOCHEM-TOKYO, V102, P1579, DOI 10.1093/oxfordjournals.jbchem.a122207; UJIIE K, 1993, J CLIN INVEST, V91, P730, DOI 10.1172/JCI116255; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; YEN A, 1987, CANCER RES, V47, P129; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; ZWILLER J, 1981, BIOCHIM BIOPHYS ACTA, V658, P64, DOI 10.1016/0005-2744(81)90250-3	52	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32155	32161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798212				2022-12-25	WOS:A1994PX30400024
J	SEKIYA, F; USUI, H; INOUE, K; FUKUDOME, K; MORITA, T				SEKIYA, F; USUI, H; INOUE, K; FUKUDOME, K; MORITA, T			ACTIVATION OF PROTHROMBIN BY A NOVEL MEMBRANE-ASSOCIATED PROTEASE - AN ALTERNATIVE PATHWAY FOR THROMBIN GENERATION INDEPENDENT OF THE COAGULATION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; FACTOR-X; ENZYMATIC-PROPERTIES; RECEPTOR ACTIVATION; NEURITE OUTGROWTH; FACTOR-VIIA; CELLS; COMPLEX; IDENTIFICATION; ANTITHROMBIN	We herein report that a novel membrane-associated protease capable of activating prothrombin is present in several mammalian cells, This protease can directly convert prothrombin to active thrombin and induces blood clotting both in vivo and in. vitro but is apparently different from coagulation factor Xa, which has been thought to be the only physiological activator of prothrombin, This protease activity was initially found and was very high in 8C feline kidney fibroblast cells, and we characterized its enzymological features using this cell Line, Activity was detected in neither the cytosolic fraction nor the culture medium but found in the membranes and identified on the surface of intact cells, The activation of prothrombin required Ca2+ ions, and the apparent K-m value for prothrombin was 0.2 mu M. The activity was irreversibly inhibited by exposure to EDTA, but various inhibitors for serine proteases including antithrombin III were without effect, Based on these results, we propose that this novel enzyme, membrane-associated prothrombin activator, catalyzes an alternative pathway for generation of thrombin, which is independent of the blood coagulation cascade, and that the thrombin generated is involved in certain pathological states and/or in activation of cells that are spatially separated from the bloodstream.	MEIJI COLL PHARM, DEPT BIOCHEM, TANASHI, TOKYO 188, JAPAN; SHIONOGI & CO LTD, SHIONOGI INST MED SCI, OSAKA 566, JAPAN	Meiji Pharmaceutical University; Shionogi & Company Limited								ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1990, J IMMUNOL, V145, P246; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; EDWARDS RL, 1993, THROMB HAEMOSTASIS, V69, P205; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GORDON SG, 1981, J CLIN INVEST, V67, P1665, DOI 10.1172/JCI110203; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JENKINS AL, 1993, J BIOL CHEM, V268, P21433; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KISIEL W, 1987, J BIOL CHEM, V262, P12607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MANN KG, 1990, BLOOD, V76, P1; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MORITA T, 1986, J BIOL CHEM, V261, P4008; MORITA T, 1974, J BIOCHEM, V76, P1031; ROSING J, 1992, TOXICON, V30, P1515, DOI 10.1016/0041-0101(92)90023-X; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUZUKI K, 1984, J BIOCHEM-TOKYO, V96, P455, DOI 10.1093/oxfordjournals.jbchem.a134857; TAPPARELLI C, 1993, TRENDS PHARMACOL SCI, V14, P366, DOI 10.1016/0165-6147(93)90095-2; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32441	32445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798243				2022-12-25	WOS:A1994PX30400064
J	SHUMAN, S				SHUMAN, S			NOVEL-APPROACH TO MOLECULAR-CLONING AND POLYNUCLEOTIDE SYNTHESIS USING VACCINIA DNA TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; BINDING	Construction of chimaeric DNA molecules in vitro relies traditionally on two enzymatic steps catalyzed by separate protein components. Site-specific restriction endonucleases are used to generate linear DNAs with defined termini that can then be joined covalently at their ends via the action of DNA ligase. A novel approach to the synthesis of recombinant DNAs exploits the ability of a single enzyme, vaccinia DNA topoisomerase, to both cleave and rejoin DNA strands with extreme specificity at each step. Placement of the CCCTT cleavage motif for vaccinia topoisomerase near the end of a duplex DNA permits efficient generation of a stable, highly recombinogenic protein-DNA adduct that can religate only to acceptor DNAs that contain complementary single-strand extensions. Linear DNAs containing CCCTT cleavage sites at both ends (bivalent substrates) can be activated by topoisomerase and inserted into a plasmid vector in a simple and rapid in vitro procedure that is especially well suited to the molecular cloning of polymerase chain reaction-amplified DNAs. Activation of polyvalent (e.g. branched) DNA substrates by topoisomerase offers a potentially powerful method for the synthesis of two- and three dimensional polynucleotide networks.			SHUMAN, S (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.							CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043	13	122	177	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32678	32684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798275				2022-12-25	WOS:A1994PX30400098
J	TSUGA, H; KAMEYAMA, K; HAGA, T; KUROSE, H; NAGAO, T				TSUGA, H; KAMEYAMA, K; HAGA, T; KUROSE, H; NAGAO, T			SEQUESTRATION OF MUSCARINIC ACETYLCHOLINE-RECEPTOR M2 SUBTYPES - FACILITATION BY G-PROTEIN-COUPLED RECEPTOR KINASE (GRK2) AND ATTENUATION BY A DOMINANT-NEGATIVE MUTANT OF GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; NEURO-BLASTOMA CELLS; 3RD CYTOPLASMIC LOOP; CHOLINERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; GAMMA-SUBUNITS; DEPENDENT PHOSPHORYLATION; CHICK HEART; DESENSITIZATION; AGONIST	Sequestration of m2 receptors (muscarinic acetylcholine receptor m2 subtypes), which was assessed as loss of N-[H-3]methylscopolamine ([H-3]NMS) binding activity from the cell surface, was examined in COS7 and BHK-21 cells that had been transfected with expression vectors encoding the m2 receptor and, independently, vectors encoding a G protein-coupled receptor kinase (GRK2) (beta-adrenergic receptor kinase 1) or a GRK2 dominant-negative mutant (DN-GRK2). The sequestration of m2 receptors became apparent when the cells were treated with 10(-5) M or higher concentrations of carbamylcholine. In this case, approximately 40% or 20-25% of the [H-3]NMS binding sites on COS 7 or BHK-21 cells, respectively, were sequestered with a half-life of 15-25 min. In cells in which GRK2 was also expressed, the sequestration became apparent in the presence of 10(-7) M carbamylcholine. Approximately 40% of the [H-3]NMS binding sites on both COS 7 and BHK-21 cells were sequestered in the presence of 10(-6) nr or higher concentrations of carbamylcholine. When DN-GRK2 was expressed in COS 7 cells, the proportion of [H-3]NMS binding sites sequestered in the presence of 10(-5) M or higher concentrations of carbamylcholine was reduced to 20-30%. These results indicate that the phosphorylation of m2 receptors by GRK2 facilitates their sequestration. These results are in contrast with the absence of a correlation between sequestration and the phosphorylation of beta-adrenergic receptors by the GRK2 and suggests that the consequences of phosphorylation by GRK2 are different for different receptors.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHARMACOL & TOXICOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	TSUGA, H (corresponding author), UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIGENBAUM P, 1985, J PHARMACOL EXP THER, V233, P134; FISHER SK, 1988, MOL PHARMACOL, V33, P414; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GALPER JB, 1982, J BIOL CHEM, V257, P344; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; IKEGAYA T, 1993, J NEUROCHEM, V60, P1143, DOI 10.1111/j.1471-4159.1993.tb03265.x; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1994, J BIOL CHEM, V269, P10093; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MALOTEAUX JM, 1983, FEBS LETT, V156, P103, DOI 10.1016/0014-5793(83)80257-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4	41	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32522	32527						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798253				2022-12-25	WOS:A1994PX30400075
J	LI, SW; OKAMOTO, T; CHUN, MY; SARGIACOMO, M; CASANOVA, JE; HANSEN, SH; NISHIMOTO, I; LISANTI, MP				LI, SW; OKAMOTO, T; CHUN, MY; SARGIACOMO, M; CASANOVA, JE; HANSEN, SH; NISHIMOTO, I; LISANTI, MP			EVIDENCE FOR A REGULATED INTERACTION BETWEEN HETEROTRIMERIC G-PROTEINS AND CAVEOLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; TRANS-GOLGI-NETWORK; ALPHA-SUBUNIT; GTP-BINDING; GUANINE-NUCLEOTIDES; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; RECEPTOR; INSULIN	Caveolae are flash-shaped plasma membrane specializations, A 22-kDa protein, caveolin, is a principal component of caveolar membranes in vivo, As recent evidence suggests that caveolae may participate in G protein-coupled signaling events, we have investigated the potential interaction of caveolin with heterotrimeric G proteins, Using cell fractionation techniques, we found that mutational or pharmacologic activation of G(s alpha) prevents its co-fractionation with caveolin, In a second independent approach, we directly examined the interaction of G proteins with caveolin, For this purpose, we recombinantly expressed caveolin as a glutathione S-transferase fusion protein, Using an in vitro binding assay, we found that caveolin interacts with G protein alpha subunits (G(s), G(o), and G(i)). Mutational or pharmacologic activation (with guanosine 5'-O-(thiotriphosphate)) of G(alpha) subunits prevents this interaction, indicating that the inactive GDP-bound form of G(alpha) subunits preferentially interacts with caveolin, This G protein binding activity is located within a 41-amino acid region of caveolin's cytoplasmic N-terminal. domain (residues 61-101), Further functional analysis shows that a polypeptide derived from this region of caveolin (residues 82-101) effectively suppresses the basal activity of purified G proteins, apparently by inhibiting GDP/GTP exchange, This caveolin sequence is homologous to a region of the Rab GDP dissociation inhibitor, a known inhibitor of GDP/GTP exchange for Rab proteins, These data suggest that caveolin could function to negatively regulate the activation state of heterotrimeric G proteins.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MASSACHUSETTS GEN HOSP EAST, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP EAST, DEPT PEDIAT GASTROENTEROL, DIV MUCOSAL IMMUNOL, BOSTON, MA 02129 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Lisanti, Michael/B-6131-2018; li, wj/HGD-7322-2022; Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Li, Shengwen Calvin/0000-0002-9699-9204; Sargiacomo, Massimo/0000-0003-4040-706X; Hansen, Steen/0000-0002-9408-4676	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIAID NIH HHS [AI-32991] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032991, R01AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASALOVICH AM, 1987, DOKL AKAD NAUK SSSR+, V297, P470; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1993, FEBS LETT, V334, P143, DOI 10.1016/0014-5793(93)81700-A; OKAMOTO T, 1994, J BIOL CHEM, V269, P13756; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Raposo G, 1994, Trends Cell Biol, V4, P418, DOI 10.1016/0962-8924(94)90096-5; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	560	573	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15693	15701		10.1074/jbc.270.26.15693	http://dx.doi.org/10.1074/jbc.270.26.15693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797570	hybrid			2022-12-25	WOS:A1995RG53800041
J	YEH, CH; SHATKIN, AJ				YEH, CH; SHATKIN, AJ			A CIS-ACTING ELEMENT IN ROUS-SARCOMA VIRUS LONG TERMINAL REPEAT REQUIRED FOR PROMOTER REPRESSION BY HELA NUCLEAR-PROTEIN P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; C-FOS GENE; MAMMALIAN-CELLS; XENOPUS EMBRYOS; TRANSCRIPTION; IDENTIFICATION; EXPRESSION; ENHANCER; CARG	HeLa cell basic nuclear protein (p21), which represses Rous sarcoma virus long terminal repeat (RSV LTR) promoter activity, diminished v-src expression and the appearance at permissive temperature of the transformed phenotype in tsRSVLA23 Rat-1, a cell line transformed with a temperature-sensitive mutant of RSV. Nuclear run on analyses using COS-l cells cotransfected with p21 cDNA and chloramphenicol acetyltransferase reporter indicated that p21 inhibits transcription initiation by targeting a region in the RSV LTR promoter between positions -108 and -85 upstream of the cap site. Insertion of this 24-base pair sequence in place of one of the 72-base pair enhancers in the SV40 early promoter rendered it sensitive to pal repression. Electrophoretic mobility shift assays using a synthetic oligomer corresponding to the 24-base pair LTR promoter element revealed that p21 altered the pattern of protein . DNA complex formation apparently without binding DNA directly. Complex formation assayed by UV cross-linking and DNA affinity chromatography indicated further that a cellular factor which can interact with this element was decreased in cells transfected with p21 expression plasmid. The results indicate that p21 repression of RSV LTR is mediated by a cis-acting element and may occur by alteration of protein complexes formed on this promoter element.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854									ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; BOULDEN A, 1990, VIROLOGY, V174, P204, DOI 10.1016/0042-6822(90)90069-4; CARROLL RC, 1978, P NATL ACAD SCI USA, V75, P5015, DOI 10.1073/pnas.75.10.5015; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1985, MOL CELL BIOL, V5, P438, DOI 10.1128/MCB.5.3.438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMARTIN GM, 1983, MOL CELL BIOL, V3, P1834, DOI 10.1128/MCB.3.10.1834; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HABEL DE, 1993, J VIROL, V67, P1545, DOI 10.1128/JVI.67.3.1545-1554.1993; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAIMINS LA, 1984, NUCLEIC ACIDS RES, V12, P6427, DOI 10.1093/nar/12.16.6427; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NORTON PA, 1987, J VIROL, V61, P1171, DOI 10.1128/JVI.61.4.1171-1179.1987; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YEH CH, 1994, GENE, V143, P285; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002; ZACHOW KR, 1992, J VIROL, V66, P1959, DOI 10.1128/JVI.66.4.1959-1970.1992	38	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15815	15820		10.1074/jbc.270.26.15815	http://dx.doi.org/10.1074/jbc.270.26.15815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797584	hybrid			2022-12-25	WOS:A1995RG53800057
J	ZHAO, XM; KOBAYASHI, T; MALAK, H; GRYCZYNSKI, I; LAKOWICZ, J; WADE, R; COLLINS, JH				ZHAO, XM; KOBAYASHI, T; MALAK, H; GRYCZYNSKI, I; LAKOWICZ, J; WADE, R; COLLINS, JH			CALCIUM-INDUCED TROPONIN FLEXIBILITY REVEALED BY DISTANCE DISTRIBUTION MEASUREMENTS BETWEEN ENGINEERED SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; FREQUENCY-DOMAIN FLUOROMETRY; AMINO-ACID SEQUENCE; PROTEOLYTIC FRAGMENTS; BIOLOGICAL-ACTIVITY; BINDING-SITES; ESCHERICHIA-COLI; ENERGY-TRANSFER; THIN-FILAMENTS; CA2+ BINDING	The contraction of vertebrate striated muscle is regulated by Ca2+ binding to troponin C (TnC). This causes conformational changes which alter the interaction of TnC with the inhibitory protein TnI and the tropomyosin-binding protein TnT. We have used the frequency domain method of fluorescence resonance energy transfer to measure TnT-TnC and TnT-TnI distances and distance distributions, in the presence of Ca2+, Mg2+, or EGTA, in TnC . TnI . TnT complexes. We reconstituted functional, ternary troponin complexes using the following recombinant subunits n- hose sequences were based on those of rabbit skeletal muscle: wild-type TnC; TnT(25), a mutant C-terminal 25-kDa fragment of TnT containing a single Trp(212) which was used as the sole donor for fluorescence energy transfer measurements; Trp-less TnI: mutants which contained either no Cys or a single Cys at position 9, 96, or 117. Energy acceptor groups were introduced into TnC or TnI by labeling with dansyl aziridine or N-(iodoacetyl)-N'-( 1-sulfo-5-naphthyl)ethylenediamine. Our results indicate that the troponin complex is relatively rigid in relaxed muscle, but becomes much more flexible when Ca2+ binds to regulatory sites in TnC. This increased flexibility may be propagated to the whole thin filament, releasing the inhibition of actomyosin ATPase activity and allowing the muscle to contract. This is the first report of distance distribution measurements between troponin subunits.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,INST BIOTECHNOL,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NCRR NIH HHS [RR-08119] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Cherry R J, 1978, Methods Enzymol, V54, P47; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; COLLINS JH, 1973, FEBS LETT, V26, P268; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FUJIMORI K, 1990, NATURE, V344, P182; FUJITA S, 1992, J BIOCHEM-TOKYO, V112, P306, DOI 10.1093/oxfordjournals.jbchem.a123896; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HUDSON EN, 1972, BIOCHEMISTRY-US, V12, P4154; ISHIWATA S, 1972, J MOL BIOL, V68, P511, DOI 10.1016/0022-2836(72)90103-9; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1978, J BIOL CHEM, V253, P6451; KLUWE L, 1993, FEBS LETT, V232, P83; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LAKOWICZ JR, 1987, CHEM PHYS LETT, V138, P587, DOI 10.1016/0009-2614(87)80130-6; LAKOWICZ JR, 1990, BIOPHYS CHEM, V36, P99, DOI 10.1016/0301-4622(90)85014-W; LAKOWICZ JR, 1994, PHOTOCHEM PHOTOBIOL, V59, P16, DOI 10.1111/j.1751-1097.1994.tb04996.x; LAKOWICZ JR, 1988, BIOCHEMISTRY-US, V27, P9149, DOI 10.1021/bi00426a012; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; OHTSUKI I, 1984, J BIOCHEM, V95, P1337, DOI 10.1093/oxfordjournals.jbchem.a134740; OOSAWA F, 1972, COLD SPRING HARB SYM, V37, P177; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RAGGI A, 1989, BIOCHIM BIOPHYS ACTA, V997, P135, DOI 10.1016/0167-4838(89)90145-3; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SILVA ACR, 1993, EUR J BIOCHEM, V213, P599; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; WANG CK, 1986, J MOL BIOL, V190, P509; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; ZOT AS, 1987, J BIOL CHEM, V262, P15418; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	58	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15507	15514		10.1074/jbc.270.26.15507	http://dx.doi.org/10.1074/jbc.270.26.15507			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797544	hybrid			2022-12-25	WOS:A1995RG53800014
J	FAINZILBER, M; LODDER, JC; KITS, KS; KOFMAN, O; VINNITSKY, I; VANRIETSCHOTEN, J; ZLOTKIN, E; GORDON, D				FAINZILBER, M; LODDER, JC; KITS, KS; KOFMAN, O; VINNITSKY, I; VANRIETSCHOTEN, J; ZLOTKIN, E; GORDON, D			A NEW CONOTOXIN AFFECTING SODIUM CURRENT INACTIVATION INTERACTS WITH THE DELTA-CONOTOXIN RECEPTOR-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN; SCORPION TOXIN; CHANNELS; ACID; LOCALIZATION; VENOM; SNAIL; BRAIN	We describe a new peptide conotoxin affecting sodium current inactivation, that competes on binding with S-conotoxin TxVIA (delta TxVIA). The amino acid sequence of the new toxin, designated conotoxin NgVIA (NgVIA), is SKCFSOGTFCGIKOGLCCSVRCFSLFCISFE (where O is trans-4-hydroxyproline). The primary structure of NgVIA has an identical cysteine framework and similar hydrophobicity as delta TxVIA but differs in its net charge. NgVIA competes with delta TxVIA on binding to rat brain synaptosomes and molluscan central nervous system and strongly inhibits sodium current inactivation in snail neurons, as does delta TxVIA. In contrast to delta TxVIA, NgVIA is a potent paralytic toxin in vertebrate systems, its binding appears to be voltage-dependent, and it synergically increases veratridine-induced sodium influx to rat brain synaptosomes. delta TxVIA acts as a partial antagonist to NgVIA in rat brain in vivo. NgVIA appears to act via a receptor site distinct from that of delta TxVIA but similar to that of Conus striatus toxin. This new toxin provides a lead for structure function relationship studies in the delta-conotoxins and will enable analysis of the functional significance of this complex of receptor sites in gating mechanisms of sodium channels.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,BEER SHEVA MENTAL HLTH CTR,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,DEPT BEHAV SCI,IL-84105 BEER SHEVA,ISRAEL; UNIV AIX MARSEILLE 2,FAC MED,DEPT BIOCHEM,F-13916 MARSEILLE 20,FRANCE	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; UDICE-French Research Universities; Aix-Marseille Universite	FAINZILBER, M (corresponding author), VRIJE UNIV AMSTERDAM,FAC BIOL,GRAD SCH NEUROSCI AMSTERDAM,NEUROSCI RES INST,DE BOELELAAN 1087,1081 HV AMSTERDAM,NETHERLANDS.			Fainzilber, Mike/0000-0001-8173-8557				ADAMS ME, 1994, TRENDS NEUROSCI, V17, P151, DOI 10.1016/0166-2236(94)90092-2; BETNER I, 1986, CHROMATOGRAPHIA, V22, P381, DOI 10.1007/BF02268795; BRUSSAARD AB, 1991, J PHYSIOL-LONDON, V441, P385, DOI 10.1113/jphysiol.1991.sp018757; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; DREIJER AMC, 1995, IN PRESS NEUROSCIENC; FAINZILBER M, 1992, TOXICON, V30, P465, DOI 10.1016/0041-0101(92)90543-E; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; GONOI T, 1986, MOL PHARMACOL, V29, P347; GONOI T, 1987, MOL PHARMACOL, V32, P691; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; HILLYARD DR, 1989, BIOCHEMISTRY-US, V28, P358, DOI 10.1021/bi00427a049; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KOFMAN O, 1993, PSYCHOPHARMACOLOGY, V110, P229, DOI 10.1007/BF02246978; LORET EP, 1994, J BIOL CHEM, V269, P16785; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAY R, 1978, J BIOL CHEM, V25, P7307; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SKALICKY JJ, 1993, PROTEIN SCI, V2, P1591, DOI 10.1002/pro.5560021005; STEPHAN MM, 1994, J MEMBRANE BIOL, V137, P1; TAMKUN MM, 1981, MOL PHARMACOL, V19, P78; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161	32	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1123	1129		10.1074/jbc.270.3.1123	http://dx.doi.org/10.1074/jbc.270.3.1123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836370	hybrid			2022-12-25	WOS:A1995QB15600025
J	CAO, J; SATO, H; TAKINO, T; SEIKI, M				CAO, J; SATO, H; TAKINO, T; SEIKI, M			THE C-TERMINAL REGION OF MEMBRANE TYPE MATRIX METALLOPROTEINASE IS A FUNCTIONAL TRANSMEMBRANE DOMAIN REQUIRED FOR PRO-GELATINASE-C ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; IV COLLAGENASE; CELL-SURFACE; INTERSTITIAL COLLAGENASE; SACCHAROMYCES-CEREVISIAE; PLASMINOGEN-ACTIVATOR; HUMAN INTERLEUKIN-2; EXPRESSION; PRECURSOR; INVASION	We identified a new matrix metalloproteinase (membrane type matrix metalloproteinase (MT-MMP)) that has a potential transmembrane (TM) domain at the C terminus and reported its expression on the surface of invasive tumor cells. The expression of MT-MMP induced specific activation of 72-kDa pro-gelatinase A (Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65). Thus, MT-MMP on the cell surface is thought to play an important role in various physiological and pathological processes accompanying tissue remodeling. In this study, we demonstrated that the potential TM domain deduced from the amino acid sequence functions as a membrane linker when it is fused to a secretory protein, tissue inhibitor of matrix metalloproteinases-1. The progelatinase A activation function of MT-MMP was abolished by truncation of the TM domain and recovered by fusing the MT-MMP mutant with the TRI domain of interleukin 2 receptor alpha-chain. The truncated MT-MMP was released from the cells into the medium and detected as processed or modified forms. In spite of the deletion of the TM domain some portions of the mutant MT-MMP were still retained on the surface of cells. Thus, MT-MMP has an additional device to keep it on the cell surface. The TM domain however, plays an essential role in the pro-gelatinase A activation function of MT-MMP, probably regulating its fine orientation or the localization that is necessary to interact with substrate.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT ORAL SURG,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University			SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015; TAKINO, Takahisa/D-8460-2015					AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CLEMENTS JM, 1991, GENE, V106, P267, DOI 10.1016/0378-1119(91)90209-T; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EMONARD HP, 1992, CANCER RES, V52, P5845; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GERMAIN D, 1993, FEBS LETT, V323, P129, DOI 10.1016/0014-5793(93)81463-A; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAKAJIMA M, 1989, CANCER RES, V49, P1698; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STETLERSTEVENSO.WG, 1993, ANNU REV CELL BIOL, V9, P541; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TAKINO T, 1994, IN PRESS GENE AMST; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WATERHOUSE P, 1990, J BIOL CHEM, V265, P5585; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	40	251	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					801	805		10.1074/jbc.270.2.801	http://dx.doi.org/10.1074/jbc.270.2.801			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822314	hybrid			2022-12-25	WOS:A1995QB81600048
J	MEDH, JD; FRY, GL; BOWEN, SL; PLADET, MW; STRICKLAND, DK; CHAPPELL, DA				MEDH, JD; FRY, GL; BOWEN, SL; PLADET, MW; STRICKLAND, DK; CHAPPELL, DA			THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN MODULATES LIPOPROTEIN CATABOLISM BY BINDING TO LDL RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; ACTIVATOR INHIBITOR TYPE-1; LOW-DENSITY LIPOPROTEINS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; HEYMANN NEPHRITIS; IN-VITRO; CELL-SURFACE; MONOCLONAL-ANTIBODIES; APOLIPOPROTEIN-E	The 39-kDa receptor-associated protein (RAP) is cosynthesized and co-purifies with the low density lipoprotein receptor-related protein (LRP)/alpha(2)-macroglobulin receptor and is thought to modulate Ligand binding to LRP, In addition to binding LRP, RAP binds two other members of the low density lipoprotein (LDL) receptor family, gp330 and very low density lipoprotein (VLDL) receptors, Here, we show that RAP binds to LDL receptors as well, In normal human foreskin fibroblasts, RAP inhibited LDL receptor-mediated binding and catabolism of LDL and VLDL with S-f 20-60 or 100-400, RAP inhibited I-125 labeled LDL and S-f 100-400 lipoprotein binding at 4 degrees C with K-1 values of 60 and 45 nM, respectively, The effective concentrations for 50% inhibition (EC(50)) of cellular degradation of 2.0 nM I-125-labeled LDL, 4.7 nM I-125-labeled S-f 20-60, and 3.6 nM I-125-labeled S-f 100-400 particles were 40, 70, and 51 nM, respectively, Treatment of cells with lovastatin to induce LDL receptors increased cellular binding, internalization, and degradation of RAP by 2.3-, 1.7-, and 2.6-fold, respectively, In solid-phase assays, RAP bound to partially purified LDL receptors in a dose-dependent manner, The dissociation constant (K-D) of RAP binding to LDL receptors in the solid-phase assay was 250 nM, which is higher than that for LRP, gp330, or VLDL receptors in similar assays by a factor of 14 to 350. Also, RAP inhibited I-125-labeled LDL and S-f 100-400 VLDL binding to LDL receptors in solid-phase assays with K-I values of 140 and 130 nM, respectively, Because LDL bind via apolipoprotein (ape) B100 whereas VLDL bind via apoE, our results show that RAP inhibits LDL receptor interactions with both apoB100 and apoE, These studies establish that RAP is capable of binding to LDL receptors and modulating cellular catabolism of LDL and VLDL by this pathway.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	University of Iowa; American Red Cross					NHLBI NIH HHS [HL49264, HL50787] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ESSER V, 1988, J BIOL CHEM, V263, P13282; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	48	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					536	540		10.1074/jbc.270.2.536	http://dx.doi.org/10.1074/jbc.270.2.536			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822276	hybrid			2022-12-25	WOS:A1995QB81600008
J	DONALD, R; BALLARD, DW; HAWIGER, J				DONALD, R; BALLARD, DW; HAWIGER, J			PROTEOLYTIC PROCESSING OF NF-KAPPA-B I-KAPPA-B IN HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; PRECURSOR P105; P50 PRECURSOR; REL ONCOGENE; C-REL; ALPHA; GENE; ACTIVATION; PROTEINS	Proteolytic processing of select constituents of the nuclear factor kappa B (NF-kappa B)/inhibitor kappa B alpha (I kappa B) transcription factor system plays an important role in regulating the biological responses of monocytes to pro-inflammatory mediators. Nuclear translocation of NF-KB is preceded by the proteolytic degradation of I kappa B alpha, an ankyrin motif-rich inhibitor that traps NF-kappa B in the cytoplasm. In addition, formation of cytoplasmic NF-kappa B/I kappa B alpha complexes in quiescent cells requires constitutive proteolytic processing of p105, another ankyrin motif-rich inhibitory protein from which the p50 subunit of NF-kappa B is generated, We have demonstrated that, following stimulation of human monocytic cells with lipopolysaccharide or tumor necrosis factor-alpha, this critical p105 processing event is up-regulated in concert with the inactivation of I kappa B alpha. Moreover, the degradative loss of both p105 and I kappa B alpha is prevented in cells depleted of intracellular ATP. In activated monocytes, however, I kappa B alpha degradation occurs more rapidly than p105 processing to p50, Together these findings provide direct biochemical evidence that p105 and I kappa B alpha are differentially sensitive targets for inducible proteolysis via ATP-dependent degradative pathways.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37212; VANDERBILT UNIV,MED CTR,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University					NHLBI NIH HHS [HL 45994, HL 30647] Funding Source: Medline; NIAID NIH HHS [1 RO1 AI33839] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030647, R37HL030647, R01HL045994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREEN PL, 1992, J VIROL, V66, P4325, DOI 10.1128/JVI.66.7.4325-4330.1992; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOLMSEN H, 1974, BIOCHEM J, V144, P385, DOI 10.1042/bj1440385; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; ZIEGLERHEITBROC.HW, 1994, J BIOL CHEM, V269, P17001	30	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					9	12		10.1074/jbc.270.1.9	http://dx.doi.org/10.1074/jbc.270.1.9			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814425	hybrid			2022-12-25	WOS:A1995QA28700003
J	ZHANG, GF; PATTON, WA; LEE, FJS; LIYANAGE, M; HAN, JS; RHEE, SG; MOSS, J; VAUGHAN, M				ZHANG, GF; PATTON, WA; LEE, FJS; LIYANAGE, M; HAN, JS; RHEE, SG; MOSS, J; VAUGHAN, M			DIFFERENT ARF DOMAINS ARE REQUIRED FOR THE ACTIVATION OF CHOLERA-TOXIN AND PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; GOLGI MEMBRANES; DROSOPHILA; TRANSPORT; COP	ADP-ribosylation factors (ARE's), initially described as activators of cholera toxin ADP-ribosyltransferase activity, regulate intracellular vesicular membrane trafficking and stimulate a phospholipase D (PLD) isoform, ARF-like (ARL) proteins are structurally related to ARFs but do not activate cholera toxin and have relatively little effect on PLD. A new human ARL gene termed hARL1, which shares 57% amino acid identity with hARF1, was identified using a polymerase chain reaction based cloning method. To determine whether different structural elements are responsible for the activation of the A subunit of cholera toxin and PLD, chimeric proteins were constructed by switching the amino-terminal 73 amino acids of ARF1 and ARL1. The recombinant rL73/F protein, in which the amino-terminal 73 amino acids of ARL1 replaced those of ARF1, activated the A subunit of cholera toxin, whereas the rF73/L protein, in which the NH2-terminal 73 amino acids of ARF1 replaced those of ARL1, was inactive. The two chimeric proteins had quite opposite effects on PLD activity, rF73/L activated PLD as effectively as rARF1, whereas rL73/F protein activated PLD only slightly. It appears that the amino terminal region of ARF1 is not critical for its action as a GTP-dependent activator of cholera toxin, whereas it is necessary for activation of the putative effector enzyme, PLD.	NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	ZHANG, GF (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,RM 5N307,BLDG 10,BETHESDA,MD 20892, USA.		; Han, Joong-Soo/P-2072-2015	LEE, FANG-JEN/0000-0002-2167-2426; Han, Joong-Soo/0000-0002-0875-6158				BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FIELD M, 1979, AM J CLIN NUTR, V32, P189, DOI 10.1093/ajcn/32.1.189; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KELLY MT, 1986, PEDIATR INFECT DIS J, V5, pS101; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MASSENBURG D, 1994, IN PRESS P NATL ACAD; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1993, CELL SIGNAL, V5, P367, DOI 10.1016/0898-6568(93)90076-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; WELSH CF, 1994, J BIOL CHEM, V269, P15583	25	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					21	24		10.1074/jbc.270.1.21	http://dx.doi.org/10.1074/jbc.270.1.21			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814376	hybrid			2022-12-25	WOS:A1995QA28700006
J	DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS				DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS			BHRF1, A VIRAL HOMOLOG OF THE BCL-2 ONCOGENE, DISTURBS EPITHELIAL-CELL DIFFERENTIATION	ONCOGENE			English	Article						BHRF1; BCL-2; EBV; APOPTOSIS; EPITHELIAL	EPSTEIN-BARR-VIRUS; ORAL HAIRY LEUKOPLAKIA; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; B-CELLS; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; INFECTED-CELLS; REPLICATION; PROTEIN	Epstein-Barr virus (EBV) is associated with tumours of both lymphoid and epithelial origin. Whilst a role for EBV latent genes in the development of these malignancies is accepted, it is also possible that viral proteins involved in EBV replication may influence the oncogenic process. BHRF1 is an immediate early protein which has homology with the Bcl-2 oncogene and can protect B cells from apoptosis. In vivo this protein is most abundantly expressed in the upper layers of oral 'hairy' leukoplakia (HL), a benign hyperparakeratotic tongue lesion which represents a focus EBV replication. We have transfected BHRF1 into the human squamous cell carcinoma line SCC12F which retains several features of normal keratinocytes behaviour in vitro. BHRF1 expression in these epithelial cells is associated with a delay in the commitment of cells to terminal differentiation, increased resistance to the DNA damaging drug, cis-platin and enhanced survival under conditions of serum deprivation. As the differentiation of epithelial cells is an apoptotic process, this data strongly suggests that BHRF1 expression delays the terminal differentiation of epithelial cells through the prevention of apoptosis. This effect of BHRF1, which may normally function to promote productive EBV infection, could contribute to the development of EBV-associated tumours.	UNIV BIRMINGHAM, SCH MED, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham			ELIOPOULOS, ARISTIDES/R-9449-2018; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COCHET C, 1993, VIROLOGY, V197, P358, DOI 10.1006/viro.1993.1597; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIGILEITNER O, 1986, DIFFERENTIATION, V31, P191, DOI 10.1111/j.1432-0436.1986.tb00400.x; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HICKISH T, 1994, CANCER RES, V54, P2808; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; LEE MA, 1992, J VIROL, V66, P1899, DOI 10.1128/JVI.66.4.1899-1906.1992; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; MILLER G, 1990, VIROLOGY, P1921; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIEDOBITEK G, 1991, J GEN VIROL, V72, P3035, DOI 10.1099/0022-1317-72-12-3035; OITVAI ZN, 1993, CELL, V74, P609; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, BLOOD, V78, P1162; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SANDVEJ K, 1992, HISTOPATHOLOGY, V20, P387, DOI 10.1111/j.1365-2559.1992.tb01008.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; THOMAS JA, 1991, AM J PATHOL, V139, P1369; THOMAS JA, 1991, ADV CANCER RES, V57, P329; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	47	53	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					69	77						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824280				2022-12-25	WOS:A1995QA98000009
J	KIM, KS; LEWIS, IC; SYKES, BD				KIM, KS; LEWIS, IC; SYKES, BD			SOLUTION STRUCTURE OF GRO/MELANOMA GROWTH-STIMULATORY ACTIVITY DETERMINED BY H-1-NMR SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; HUMAN INTERLEUKIN-8 RECEPTOR; MOLECULAR CHARACTERIZATION; BETA-THROMBOGLOBULIN; SECONDARY STRUCTURE; PROTEIN STRUCTURES; DISTANCE GEOMETRY; ACTIVITY MGSA	The three dimensional solution structure of the growth-related protein-alpha/melanoma growth stimulatory activity (GRO/MGSA) has been solved by two-dimensional H-1 nuclear magnetic resonance spectroscopy. The GRO/MGSA monomer consists of an NH2-terminal loop, a three-stranded antiparallel beta-sheet, and a COOH-terminal alpha-helix. Dimerization, which is apparent under the experimental conditions used (2 mM, pH 5.10, 30 degrees C), results in a six stranded antiparallel beta-sheet and a pair of helices with 2-fold symmetry. While the basic fold is similar to that seen for interleukin-8 (IL-8) (Clore, G. M., Appella, E., Yamada, M., Matsushima, K., and Gronenborn, A. M. (1990) Biochemistry, 29, 1689-1696), there are differences in the ELR motif (residues 6-8), the turn involving residues 31-36, which is linked to the NH2-terminal region through the 9-35 disulfide bond. The most significant differences are in the NH2-terminal loop (residues 12-23). In IL-8, all the corresponding regions have been shown to be required for receptor binding (Clark-Lewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M. (1994) J. Biol. Chem. 269, 16075-16081). The structural differences thus have been identified between GRO/MGSA and IL-8 could contribute to their different receptor binding specificities.	UNIV ALBERTA, PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, PENCE, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOLEC BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of Alberta; University of Alberta; University of British Columbia; University of British Columbia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM50969-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BAX A, 1989, METHOD ENZYMOL, V176, P151; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1989, J BIOL CHEM, V264, P18907; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; FAIRBROTHER WJ, 1993, FEBS LETT, V330, P302, DOI 10.1016/0014-5793(93)80893-Y; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, J BIOL CHEM, V268, P541; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; PROOST P, 1993, BIOCHEMISTRY-US, V32, P10170, DOI 10.1021/bi00089a037; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WALZ A, 1989, BIOCHEM BIOPH RES CO, V159, P969, DOI 10.1016/0006-291X(89)92203-1; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; WUTHRICH K, 1986, NMR PROTEIN NUCLEIC; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402; [No title captured]	46	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32909	32915						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806518				2022-12-25	WOS:A1994QA63800031
J	REED, VS; YANG, DCH				REED, VS; YANG, DCH			CHARACTERIZATION OF A NOVEL N-TERMINAL PEPTIDE IN HUMAN ASPARTYL-TRANSFER-RNA SYNTHETASE - ROLES IN THE TRANSFER OF AMINOACYL-TRANSFER-RNA FROM AMINOACYL-TRANSFER-RNA SYNTHETASE TO THE ELONGATION-FACTOR 1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; STRUCTURAL ORGANIZATION; MULTISYNTHETASE COMPLEX; AMPHIPHILIC HELIX; ESCHERICHIA-COLI; DOMAIN; MODEL; FORMS	The kinetics of the N-terminal 32 residue deleted human aspartyl-tRNA synthetase (hDRS Delta 32) was analyzed, The kinetics of aspartyl-adenylate formation and Asp-tRNA synthesis by hDRS Delta 32 were indistinguishable from those of hDRS, However, the dissociation of Asp-tRNA from hDRS Delta 32 was much faster than that of hDRS, Unlike hDRS Delta 32-catalyzed aspartylation of tRNA was not affected by the elongation factor 1 alpha. Two N-terminal peptides of hDRS, hDRS(T5-E26) and hDRS(D12-R27), were synthesized, Both peptides bind to tRNA-Sepharose, Both peptides, hDRS(T5-E26) and hDRS(D12-R27), are monomeric and oligomerize at high peptide concentration or in 50% propylene glycol, The peptide hDRS(T5-E26) showed little alpha-helical content as analyzed by CD spectroscopy, while hDRS(D12-R27) showed appreciable alpha-helical contents in nonpolar solvents. These results suggest that the N terminus in hDRS may mediate the slow release of Asp-tRNA and facilitate the interaction of the hDRS Asp-tRNA complex with the elongation factor 1 alpha. The demonstration of alpha-helix formation of the hDRS N-terminal peptide is consistent with the hypothetical amphiphilic helix of the N terminal extension in hDRS. A model for the transfer of Asp-tRNA from hDRS to elongation factor 1 alpha is presented,	GEORGETOWN UNIV, DEPT CHEM, WASHINGTON, DC 20057 USA	Georgetown University			Yang, David/A-7294-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-25848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CIRAKOGLU B, 1985, FEBS LETT, V183, P185; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FETT R, 1991, J BIOL CHEM, V266, P1448; GHOSH HP, 1967, J MOL BIOL, V25, P275, DOI 10.1016/0022-2836(67)90142-8; GODAR DE, 1988, BIOCHEMISTRY-US, V27, P6921, DOI 10.1021/bi00418a038; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; KELLERMANN O, 1982, J BIOL CHEM, V257, P1041; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; REED VS, 1994, J BIOL CHEM, V269, P32932; REMY P, 1972, FEBS LETT, V27, P134, DOI 10.1016/0014-5793(72)80426-5; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SIDDIQUI FA, 1985, BIOCHIM BIOPHYS ACTA, V828, P177, DOI 10.1016/0167-4838(85)90055-X; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; Xie J., UNPUB; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325	23	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32937	32941						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806522				2022-12-25	WOS:A1994QA63800035
J	YAMAGATA, H; MASUZAWA, T; NAGAOKA, Y; OHNISHI, T; IWASAKI, T				YAMAGATA, H; MASUZAWA, T; NAGAOKA, Y; OHNISHI, T; IWASAKI, T			CUCUMISIN, A SERINE-PROTEASE FROM MELON FRUITS, SHARES STRUCTURAL HOMOLOGY WITH SUBTILISIN AND IS GENERATED FROM A LARGE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; DENATURED SUBTILISIN; PRO-SEQUENCE; GENE; EXPRESSION; PROTEINS; CLONING; SECRETION; PEPTIDE	Cucumisin is a thermostable alkaline serine protease that is found in the juice of melon fruits (Cucumis melo L.). We have determined the complete nucleotide sequence of a cucumisin cDNA (2,552 nucleotides) and deduced the corresponding amino acid sequence, The open reading frame of the cDNA consists of 731 codons and encodes a large precursor (molecular weight, 78,815) relative to the observed size of mature native cucumisin (67 kDa), Sequence comparisons reveal that cucumisin has several features in common with the microbial proteases of the subtilisin family, The highly conserved sequences to the proximal regions of the catalytic triad amino acids Asp, His, and Ser, together with the substrate binding site in subtilisin, can be found within the deduced amino acid sequence of the protease domain of the cucumisin precursor, Cucumisin is the first known plant protease with such characteristics. Examination of the primary structure of cucumisin revealed that it is synthesized as a precursor, consisting of four functional domains: a possible signal peptide (22 amino acid residues), an NH2-terminal pro-sequence (88 residues), a 54-kDa protease domain (505 residues), which is the active enzyme domain of the 67-kDa native cucumisin, and a 14-kDa COOH-terminal polypeptide (116 residues), which arises by limited autolysis of the 67-kDa native cucumisin, This structure of cucumisin suggests that it is probably synthesized as an inactive precursor.			YAMAGATA, H (corresponding author), KOBE UNIV,FAC AGR,BIOCHEM LAB,NADA KU,ROKKODAI CHO 1,KOBE,HYOGO 657,JAPAN.							BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CHRISPEELS MJ, 1991, PLANT MOL BIOL, V2, P575; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; Glazer A., 1971, ENZYMES, P501; GRIERSON D, 1984, PLANT MOL BIOL, P22; GUNKEL FA, 1989, EUR J BIOCHEM, V179, P185, DOI 10.1111/j.1432-1033.1989.tb14539.x; HOLWERDA BC, 1992, PLANT CELL, V4, P307, DOI 10.1105/tpc.4.3.307; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACOBS M, 1985, NUCLEIC ACIDS RES, V13, P8913, DOI 10.1093/nar/13.24.8913; KANEDA M, 1986, J BIOCHEM-TOKYO, V99, P569, DOI 10.1093/oxfordjournals.jbchem.a135513; KANEDA M, 1975, J BIOCHEM, V78, P1287, DOI 10.1093/oxfordjournals.jbchem.a131026; KANEDA M, 1977, PHYTOCHEMISTRY, V16, P345, DOI 10.1016/0031-9422(77)80061-7; KANEDA M, 1984, J BIOCHEM-TOKYO, V95, P825, DOI 10.1093/oxfordjournals.jbchem.a134674; KANEDA M, 1986, AGR BIOL CHEM TOKYO, V50, P2413, DOI 10.1080/00021369.1986.10867760; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P417, DOI 10.1093/nar/12.1Part1.417; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOEHLE CM, 1987, MOL CELL BIOL, V7, P4390, DOI 10.1128/MCB.7.12.4390; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROGERS SO, 1986, PLANT MOL BIOL, V5, P69; Ryan CA, 1981, BIOCH PLANTS, P321; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; TERADA I, 1990, J BIOL CHEM, V265, P6576; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; VERNET T, 1990, J BIOL CHEM, V265, P16661; VONHEIJNE G, 1991, PLANT MOL BIOL, V2, P583; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WU XC, 1990, J BIOL CHEM, V265, P6845; YAMAGATA H, 1989, AGR BIOL CHEM TOKYO, V53, P1009, DOI 10.1080/00021369.1989.10869404; YAMAGATA H, 1982, PLANT PHYSIOL, V70, P1094, DOI 10.1104/pp.70.4.1094; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	44	127	134	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32725	32731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806492				2022-12-25	WOS:A1994QA63800005
J	NAYERNIA, K; NIETER, S; KREMLING, H; OBERWINKLER, H; ENGEL, W				NAYERNIA, K; NIETER, S; KREMLING, H; OBERWINKLER, H; ENGEL, W			FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF THE TRANSCRIPTIONAL REGULATORY REGION OF THE PROACROSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; TRANSGENIC MICE; SPERMATOGENIC CELLS; FUSION GENES; ACROSIN; PROMOTER; DNA; PGK-2; LOCUS	Proacrosin, the zymogen form of the serine protease acrosin, is located within the acrosomal vesicle of mammalian spermatozoa and has been suggested to be involved in the fertilization process, In mouse and rat, expression of the proacrosin gene starts in pachytene spermatocytes and continues through the early stages of spermiogenesis, We have shown recently that 2.3 kilobase pairs of the 5'-flanking region of the rat proacrosin gene is sufficient to direct chloramphenicol acetyltransferase gene expression in a germ cell-specific and developmental stage-specific manner in the mouse, Additional transgenic lines have been generated which include two deletions in the 5'-flanking region and a tyrosinase minigene as marker for gene expression, Transgenic mice bearing these two truncated fragments showed different patterns of reporter gene expression, Transgenic lines (BM, B3, B2) harboring the 397-base pair (bp) fragment (from 45 to 442 bp upstream of ATG) showed no chloramphenicol acetyltransferase (CAT) activity in either testis or other tissues, but analysis via reverse transcription polymerase chain reaction confirmed low levels of reporter gene transcription in testis, Transgenic line TC bearing a longer fragment of 877 bp (from 45 to 922 bp upstream of ATG) showed a reporter gene expression and chloramphenicol acetyl-transferase enzyme activity which was identical to that found in mice harboring the 2.3-kilobase pair 5'-flanking region, The analysis of the CAT gene expression during testicular development showed diploid transcription and haploid translation, It can be concluded that all sequences required for a basic level of testis-specific transcription of transgene are present within the 397-bp fragment, and other DNA sequences located outside of the 397-bp fragment but present within the 877-bp fragment can function as enhancer elements. Two fragments within the 877-bp region were identified by gel retardation assays as binding exclusively to nuclear factor(s) from testis protein extracts. In both fragments we identified sequence elements which are present in the promoter region of the germ cell-specific genes for histone H2B and protamine 1, respectively.	UNIV GOTTINGEN,INST HUMAN GENET,D-37073 GOTTINGEN,GERMANY	University of Gottingen								BEERMANN F, 1991, NUCLEIC ACIDS RES, V19, P958, DOI 10.1093/nar/19.4.958; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CUNLIFFE V, 1990, GENOMICS, V8, P331, DOI 10.1016/0888-7543(90)90290-B; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EWULONU UK, 1993, DEVELOPMENT, V117, P89; FLORKE S, 1983, DIFFERENTIATION, V24, P250, DOI 10.1111/j.1432-0436.1983.tb01328.x; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANDEL MA, 1987, SPERMATOGENESIS GENE, P1; HANNAUER A, 1983, NUCLEIC ACIDS RES, V11, P3505; HOGAN B, 1986, MANIPULATING MOUSE E, P151; KALLAJOKI M, 1986, BIOL REPROD, V35, P157, DOI 10.1095/biolreprod35.1.157; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KLEMM U, 1991, HUM GENET, V87, P635; KREMER EJ, 1992, GENE, V110, P167, DOI 10.1016/0378-1119(92)90644-5; KREMLING H, 1991, GENOMICS, V11, P828, DOI 10.1016/0888-7543(91)90005-Y; Kremling H, 1991, DNA Seq, V2, P57, DOI 10.3109/10425179109008440; LATCHMAN DS, 1992, EUKARYOTIC TRANSCRIP, P16; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NAYERNIA K, 1992, MOL REPROD DEV, V31, P241, DOI 10.1002/mrd.1080310403; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SALEHIASHTIANI K, 1993, P NATL ACAD SCI USA, V90, P8886, DOI 10.1073/pnas.90.19.8886; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; TAMURA T, 1989, TECHNIQUE, V1, P33; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6761; WATANABE K, 1991, J BIOCHEM-TOKYO, V109, P828, DOI 10.1093/oxfordjournals.jbchem.a123466; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; ZINN SA, 1991, J BIOL CHEM, V266, P23850; [No title captured]	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32181	32186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798216				2022-12-25	WOS:A1994PX30400028
J	YAMAGUCHI, M; HAYASHI, Y; NISHIMOTO, Y; HIROSE, F; MATSUKAGE, A				YAMAGUCHI, M; HAYASHI, Y; NISHIMOTO, Y; HIROSE, F; MATSUKAGE, A			A NUCLEOTIDE-SEQUENCE ESSENTIAL FOR THE FUNCTION OF DRE, A COMMON PROMOTER ELEMENT FOR DROSOPHILA DNA REPLICATION-RELATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; GROWTH-REGULATION; BUDDING YEAST; EXPRESSION; MELANOGASTER; PROTEIN; TRANSCRIPTION; CYCLE; BINDING	Promoter regions of the Drosophila proliferating cell nuclear antigen (PCNA) gene and the DNA polymerase alpha 180-kDa catalytic subunit gene contain a common 8 base pair (bp) promoter element, 5'-TATCGATA (DRE, Drosophila DNA replication-related element), We have generated various base substitutions and internal deletions in and around DRE (nucleotide positions -93 to -100 with respect to the transcription initiation site) of the PCNA gene in vitro and subsequently examined their effects on the binding to DREF (DRE-binding factor) and PCNA gene promoter activity in cultured Drosophila Kc cells as well as in living flies, Gel mobility shift assays using nuclear extracts of Kc cells with and without competitor DNA fragments carrying the mutations indicated that the 10-bp sequence from positions -91 to -100 is essential for complex formation with DREF, Transient expression assays of chloramphenicol acetyltransferase (CAT) in Kc cells transfected with PCNA promoter-CAT fusion genes carrying the mutations revealed that the g-bp sequence from -93 to -100 is essential for activation of the promoter in Kc cells, Examination of lacZ expression hom PCNA promoter-lacZ fusion genes carrying the mutations, introduced into flies by germ-line transformation, revealed that the 8-bp sequence is also important for DRE function during development, However, we obtained two exceptional mutations in the 8-bp sequence that did not or only marginally affected the PCNA gene promoter activity in transgenic flies, Both of these mutations effectively reduced the promoter activity in CAT transient expression assay in He cells and the binding to DREF in vitro, Therefore, the 8-bp sequence requirement for DRE function appears to be less stringent in Living flies than in the cultured cell or in vitro cases.			YAMAGUCHI, M (corresponding author), AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							BASERGA R, 1991, J CELL SCI, V98, P433; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; FRIDELL YWC, 1992, MOL CELL BIOL, V12, P4571, DOI 10.1128/MCB.12.10.4571; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1994, JPN J CANCER RES, V85, P1; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEVINS JR, 1992, SCIENCE, V258, P424; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yamaguchi Masamitsu, 1995, Gene Expression, V4, P183; [No title captured]	27	55	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15808	15814		10.1074/jbc.270.26.15808	http://dx.doi.org/10.1074/jbc.270.26.15808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797583	hybrid			2022-12-25	WOS:A1995RG53800056
J	KETCHNER, SL; DRAPIER, D; OLIVE, J; GAUDRIAULT, S; GIRARDBASCOU, J; WOLLMAN, FA				KETCHNER, SL; DRAPIER, D; OLIVE, J; GAUDRIAULT, S; GIRARDBASCOU, J; WOLLMAN, FA			CHLOROPLASTS CAN ACCOMMODATE INCLUSION-BODIES - EVIDENCE FROM A MUTANT OF CHLAMYDOMONAS-REINHARDTII DEFECTIVE IN THE ASSEMBLY OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; II PROTEIN COMPLEX; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BODY FORMATION; NUCLEAR GENES; LARGE SUBUNIT; DNA-SEQUENCE; EXPRESSION; PHOTOPHOSPHORYLATION	We identified two neighboring missense mutations in the chloroplast atpA gene which are responsible for the defect of ATP synthase assembly in the FUD16 mutant from Chlamydomonas reinhardtii. The two corresponding amino acid substitutions, Ile(184) --> Asn and Asn(186) --> Tyr, occurred at strictly conserved sites among the alpha and beta subunits of (C)F-1 complexes from bacteria, mitochondria, and chloroplasts. The altered region in the alpha polypeptide chain is located 7 amino acids downstream of the P-loop, which forms most of the conserved nucleotide binding site. Although the resulting chloroplast mutant fails to accumulate most of the ATP synthase subunits, it displays an increased intracellular content in both the cy and beta subunits. We demonstrate that the two subunits do not bind to the thylakoid membranes but associate and overaccumulate in the chloroplast stroma as inclusion bodies. Increased rates of synthesis of the two subunits in the mutant point to an early interaction between the two subunits during their biogenesis.	INST BIOL PHYSICOCHIM, SERV PHOTOSYNTH, CNRS, URA 1187, F-75005 PARIS, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, MICROSCOPIE ELECTR LAB, CNRS, PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			, Gaudriault/AAK-9152-2021	, Gaudriault/0000-0003-2789-4959				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; ASCHENBRENNER M, 1993, FEBS LETT, V323, P27, DOI 10.1016/0014-5793(93)81441-2; ATTEIA A, 1994, CR ACAD SCI III-VIE, V317, P11; BEECHEY RB, 1975, BIOCHEM J, V148, P533, DOI 10.1042/bj1480533; BINDER M, 1991, EUR J CELL BIOL, V54, P305; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; DRON M, 1983, PLASMID, V9, P321, DOI 10.1016/0147-619X(83)90009-4; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; KIM JM, 1991, J BIOL CHEM, V266, P14931; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; LEMAIRE C, 1989, J BIOL CHEM, V264, P10228; LEU S, 1992, PLANT MOL BIOL, V18, P613, DOI 10.1007/BF00040681; LEVINE RP, 1960, ANNU REV MICROBIOL, V14, P197, DOI 10.1146/annurev.mi.14.100160.001213; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NICOLAS L, 1993, FEMS MICROBIOL LETT, V106, P275, DOI 10.1111/j.1574-6968.1993.tb05976.x; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1987, FEMS MICROBIOL LETT, V46, P13, DOI 10.1111/j.1574-6968.1987.tb02449.x; Sambrook J, 1989, MOL CLONING LABORATO; SMART EJ, 1993, J BIOENERG BIOMEMBR, V25, P275, DOI 10.1007/BF00762588; STOLLAR NE, 1994, PLANT PHYSIOL, V105, P1167, DOI 10.1104/pp.105.4.1167; TAYLOR G, 1986, BIO-TECHNOL, V4, P553, DOI 10.1038/nbt0686-553; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VALLON O, 1985, FEBS LETT, V183, P245, DOI 10.1016/0014-5793(85)80786-9; VANLOON APGM, 1983, GENE, V26, P261, DOI 10.1016/0378-1119(83)90196-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065	47	14	14	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15299	15306		10.1074/jbc.270.25.15299	http://dx.doi.org/10.1074/jbc.270.25.15299			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797517	hybrid			2022-12-25	WOS:A1995RE66600068
J	SMITH, VM; LEE, PP; SZYCHOWSKI, S; WINOTO, A				SMITH, VM; LEE, PP; SZYCHOWSKI, S; WINOTO, A			GATA-3 DOMINANT-NEGATIVE MUTANT - FUNCTIONAL REDUNDANCY OF THE T-CELL RECEPTOR-ALPHA AND RECEPTOR-BETA ENHANCERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR PROTEINS INTERACT; DNA-BINDING PROTEIN; TRANSCRIPTIONAL ENHANCER; REGULATORY ELEMENTS; GENE-EXPRESSION; CHAIN GENE; MULTIGENE FAMILY; LOCUS; IDENTIFICATION; LINEAGE	The GATA family of transcription factors regulates a wide variety of genes, including those involved in differentiation of erythrocytes and T lymphocytes. We report here the creation of a dominant negative mutant of GATA-3, KRR, which effectively blocks wild-type GATA-1, GATA-2, and GATA-3 transactivation when coexpressed in transient assays. KRR was generated by site-directed mutagenesis while investigating a putative activation domain of GATA-3, located between its two zinc fingers. The GATA-3 KRR mutation does not affect expression, nuclear translocation, or the ability to bind to a consensus GATA sequence. KRR can suppress the activity of the minimal T cell receptor (TCR) alpha and beta enhancers by 12- and 3.4-fold, respectively. However, KRR did not have a significant effect on the activity of larger TCR-alpha and -beta enhancer fragments. Thus, functional redundancy in the TCR-alpha and -beta enhancers can compensate for the loss of GATA-3 activity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031558] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI31558] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BORIES JC, 1990, J EXP MED, V171, P75, DOI 10.1084/jem.171.1.75; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GILL LL, 1991, EUR J IMMUNOL, V21, P807, DOI 10.1002/eji.1830210339; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P2204, DOI 10.1073/pnas.88.6.2204; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LANDRY DB, 1993, J EXP MED, V178, P941, DOI 10.1084/jem.178.3.941; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MCDOUGALL S, 1988, SCIENCE, V241, P205, DOI 10.1126/science.2968651; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; ORKIN SH, 1992, BLOOD, V80, P575; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SPENCER DM, 1991, P NATL ACAD SCI USA, V88, P800, DOI 10.1073/pnas.88.3.800; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	38	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1515	1520		10.1074/jbc.270.4.1515	http://dx.doi.org/10.1074/jbc.270.4.1515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829479	hybrid			2022-12-25	WOS:A1995QD20400008
J	GOUX, WJ; STRONG, AAD; SCHNEIDER, BL; LEE, WNP; REITZER, LJ				GOUX, WJ; STRONG, AAD; SCHNEIDER, BL; LEE, WNP; REITZER, LJ			UTILIZATION OF ASPARTATE AS A NITROGEN-SOURCE IN ESCHERICHIA-COLI - ANALYSIS OF NITROGEN FLOW AND CHARACTERIZATION OF THE PRODUCTS OF ASPARTATE CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; SACCHAROMYCES-CEREVISIAE; GLUTAMINE-SYNTHETASE; KLEBSIELLA-AEROGENES; AMINO-ACIDS; L-ARGININE; TCA CYCLE; PATHWAY; MUTANTS; ASSIMILATION	N-15 NMR, reverse phase high performance liquid chromatography and gas chromatography/mass spectrometry have been used to follow nitrogen metabolism in Escherichia coli labeled on medium containing L-[N-15]aspartate, The flow of N-15 through various nitro gen-containing metabolites was followed over the course of the labeling period. For wild-type E. coli labeled on L-[N-15]aspartate as sole source of nitrogen, significant N-15 labeling was detected only in the intracellular L-glutamate, L-alanine, L-aspartate, and putrescine pools. Intracellular concentrations of L-aspartate and L-glutamate differed significantly in extracts of an arginine auxotroph (argG(-)), which is deficient in a potential aspartate-assimilating reaction. When the L-[N-15]aspartate containing labeling medium was supplemented with unlabeled arginine, extracts of wild-type E. coli were shown to contain significant amounts of unlabeled ammonia and putrescine. There was substantial dilution of N-15 in the glutamate pool. The observation that glutamate, aspartate, and alanine are N-15-labeled, but ammonia is not, suggests that these amino acids are not the immediate source of ammonia. Our results suggest that arginine may be an intermediate for the degradation of some of the aspartate and that arginine may be an intermediate for ammonia production during nitrogen-limited growth. Our results also strongly suggest the presence of a previously uncharacterized pathway of arginine degradation.	UNIV TEXAS,DEPT MOLEC & CELL BIOL,RICHARDSON,TX 75083; UNIV CALIF LOS ANGELES,HARBOR MED CTR,TORRANCE,CA 90509	University of Texas System; University of Texas Dallas; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	GOUX, WJ (corresponding author), UNIV TEXAS,DEPT CHEM,POB 830688,RICHARDSON,TX 75083, USA.		Reitzer, Larry/A-2510-2016	Reitzer, Larry/0000-0002-4406-6090	NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038877] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [2 S07 RR07133-23] Funding Source: Medline; NIGMS NIH HHS [R29 GM 38877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAMATSU N, 1978, J BACTERIOL, V133, P409, DOI 10.1128/JB.133.1.409-410.1978; ALBRECHT AM, 1964, J BIOL CHEM, V239, P1872; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BAX A, 1982, 2 DIMENSIONAL NUCLEA, P50; BRENCHLEY JE, 1973, J BIOL CHEM, V248, P6122; BRENCHLEY JE, 1974, J BACTERIOL, V117, P544, DOI 10.1128/JB.117.2.544-550.1974; BROACH J, 1976, J BACTERIOL, V128, P86, DOI 10.1128/JB.128.1.86-98.1976; CSONKA LN, 1977, J BIOL CHEM, V252, P3392; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; CUNNINGHAMRUNDL.S, 1975, J BACTERIOL, V124, P791; HAAS D, 1984, MOL GEN GENET, V193, P437, DOI 10.1007/BF00382081; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HARAN N, 1983, J BIOL CHEM, V258, P2929; JANN A, 1986, P NATL ACAD SCI USA, V83, P4937, DOI 10.1073/pnas.83.13.4937; LAPIDOT A, 1977, P NATL ACAD SCI USA, V74, P1988, DOI 10.1073/pnas.74.5.1988; LEE WNP, 1992, BIOL MASS SPECTROM, V20, P451; LEGERTON TL, 1981, P NATL ACAD SCI-BIOL, V78, P1495, DOI 10.1073/pnas.78.3.1495; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MARCUS M, 1969, BIOCHIM BIOPHYS ACTA, V177, P314, DOI 10.1016/0304-4165(69)90141-X; MERCENIER A, 1980, J GEN MICROBIOL, V116, P381; MERCENIER A, 1980, J BACTERIOL, V144, P159, DOI 10.1128/JB.144.1.159-163.1980; Morris DR, 1970, J BACTERIOL, V101, P731, DOI 10.1128/JB.101.3.731-737.1970; MORRIS DR, 1969, J BIOL CHEM, V244, P6094; PAHEL G, 1978, J BACTERIOL, V133, P139, DOI 10.1128/JB.133.1.139-148.1978; Reitzer L.J., 1987, E COLI SALMONELLA CE, P302; REITZER LJ, 1982, J BACTERIOL, V151, P1299, DOI 10.1128/JB.151.3.1299-1313.1982; RICHARZ R, 1978, BIOPOLYMERS, V17, P2133, DOI 10.1002/bip.1978.360170908; ROBERTS MF, 1990, J BIOL CHEM, V265, P18207; ROBERTS RB, 1955, CARNEGIE I WASHINGTO, V607, P279; ROTHSTEIN DM, 1980, P NATL ACAD SCI-BIOL, V77, P7372, DOI 10.1073/pnas.77.12.7372; SHAIBE E, 1985, J BACTERIOL, V163, P933, DOI 10.1128/JB.163.3.933-937.1985; STALON V, 1985, EVOLUTION PROKARYOTE, P277; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SUMEGI B, 1993, BIOCHEMISTRY-US, V32, P12725, DOI 10.1021/bi00210a022; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TYLER B, 1978, ANNU REV BIOCHEM, V47, P1127, DOI 10.1146/annurev.bi.47.070178.005403; WILKINSON JM, 1978, J CHROMATOGR SCI, V16, P547, DOI 10.1093/chromsci/16.11.547; Wohlhueter R, 1973, ENZYMES GLUTAMINE ME, P45	39	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					638	646						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822290				2022-12-25	WOS:A1995QB81600023
J	NADA, MA; RHEAD, WJ; SPRECHER, H; SCHULZ, H; ROE, CR				NADA, MA; RHEAD, WJ; SPRECHER, H; SCHULZ, H; ROE, CR			EVIDENCE FOR INTERMEDIATE CHANNELING IN MITOCHONDRIAL BETA-OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; ACYL-COA DEHYDROGENASE; CULTURED FIBROBLASTS; SHORT-CHAIN; PURIFICATION; DEFICIENCY; DISORDERS; QUANTITATION	The accumulation of beta-oxidation intermediates was studied by incubating normal and beta-oxidation enzyme-deficient human fibroblasts with [H-2(4)]linoleate and L-carnitine and analyzing the resultant acylcarnitines by tandem mass spectrometry. Labeled decenoyl-, octanoyl-, hexanoyl-, and butyrylcarnitines were the only intermediates observed with normal cells. Intermediates of longer chain length, corresponding to substrates for the beta-oxidation enzymes associated with the inner mitochondrial membrane, were not observed unless a cell line was deficient in one of these enzymes, such as very-long chain acyl-CoA dehydrogenase, long-chain 3-hydroxyacyl-CoA dehydrogenase, or electron transfer flavoprotein dehydrogenase. Matrix enzyme deficiencies, such as medium- and short-chain acyl-CoA dehydrogenases, were characterized by elevated concentrations of intermediates corresponding to their respective substrates (octanoyl- and decenoylcarnitines in medium-chain acyl-CoA dehydrogenase deficiency and butyrylcarnitine in short-chain acyl-CoA dehydrogenase deficiency). These observations agree with the notion of intermediate channeling due to the organization of beta-oxidation enzymes in complexes. The only exception is the incomplete channeling from thiolase to acyl-CoA dehydrogenase in the matrix. This situation may be a consequence of only one 3-ketoacyl-CoA thiolase being unable to interact with the several acyl-CoA dehydrogenases in the matrix.	UNIV IOWA, DEPT PEDIAT, IOWA CITY, IA 52242 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; CUNY CITY COLL, DEPT CHEM, NEW YORK, NY 10031 USA	University of Iowa; Ohio State University; City University of New York (CUNY) System; City College of New York (CUNY)	NADA, MA (corresponding author), DUKE UNIV, MED CTR, DEPT PEDIAT, DIV BIOCHEM GENET, POB 14991, RES TRIANGLE PK, NC 27709 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033289] Funding Source: NIH RePORTER; NCRR NIH HHS [M-01-RR-30] Funding Source: Medline; NICHD NIH HHS [HD24908] Funding Source: Medline; NIDDK NIH HHS [DK33289] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; BOHMER T, 1968, BIOCHIM BIOPHYS ACTA, V152, P559, DOI 10.1016/0005-2760(68)90096-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COATES PM, 1988, J CLIN INVEST, V81, P171, DOI 10.1172/JCI113290; DING JH, 1992, PROG CLIN BIOL RES, V375, P479; DOMMES V, 1984, J BIOL CHEM, V259, P1789; FONG JC, 1978, J BIOL CHEM, V252, P6917; HE XY, 1992, ARCH BIOCHEM BIOPHYS, V298, P527, DOI 10.1016/0003-9861(92)90445-3; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IZAI K, 1992, J BIOL CHEM, V267, P1027; KELLEY RI, 1992, BIOCHEM BIOPH RES CO, V182, P1002, DOI 10.1016/0006-291X(92)91831-A; KERNER J, 1990, BIOCHEMISTRY-US, V29, P4326, DOI 10.1021/bi00470a010; KLER RS, 1991, J BIOL CHEM, V266, P22932; KOLVRAA S, 1982, CLIN CHIM ACTA, V126, P53, DOI 10.1016/0009-8981(82)90361-8; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; MILLINGTON DS, 1991, INT J MASS SPECTROM, V111, P211, DOI 10.1016/0168-1176(91)85056-R; MILLINGTON DS, 1989, SYNTHESIS APPLICATIO, P189; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; OSBOND JM, 1961, J CHEM SOC, P2779, DOI 10.1039/jr9610002779; POLLTHE BT, 1988, J INHERIT METAB DIS, V11, P183, DOI 10.1007/BF01804230; RAKOFF H, 1992, LIPIDS, V27, P567, DOI 10.1007/BF02536142; RHEAD WJ, 1987, PEDIATR RES, V21, P371, DOI 10.1203/00006450-198704000-00010; SAUDUBRAY JM, 1982, PEDIATR RES, V16, P877, DOI 10.1203/00006450-198210000-00015; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SPRECHER H, 1982, METHOD ENZYMOL, V86, P357; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; THORPE C, 1990, PROG CLIN BIOL RES, V321, P91; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; YAMAGUCHI S, 1993, PEDIATR RES, V34, P111, DOI 10.1203/00006450-199307000-00025	31	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					530	535		10.1074/jbc.270.2.530	http://dx.doi.org/10.1074/jbc.270.2.530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822275	hybrid			2022-12-25	WOS:A1995QB81600007
J	NIRUNSUKSIRI, W; PRESLAND, RB; BRUMBAUGH, SG; DALE, BA; FLECKMAN, P				NIRUNSUKSIRI, W; PRESLAND, RB; BRUMBAUGH, SG; DALE, BA; FLECKMAN, P			DECREASED PROFILAGGRIN EXPRESSION IN ICHTHYOSIS-VULGARIS IS A RESULT OF SELECTIVELY IMPAIRED POSTTRANSCRIPTIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3' UNTRANSLATED REGION; MESSENGER-RNA DEGRADATION; CELL-CYCLE REGULATION; DNA GLYCOSYLASE GENE; NONCODING SEQUENCES; EPIDERMAL KERATINS; HUMAN SKIN; FILAGGRIN; IDENTIFICATION	Ichthyosis vulgaris is an autosomal dominant disorder of keratinization characterized by mild hyperkeratosis and reduced or absent keratohyalin granules in the epidermis, Profilaggrin, a major component of keratohyalin grannies, is reduced or absent from the skin of individuals with ichthyosis vulgaris. In this report, we have further characterized the molecular basis of low profilaggrin expression, which occurs in this disease. fn situ hybridization revealed little profilaggrin mRNA in ichthyosis vulgaris-affected epidermis, In keratinocytes cultured from the epidermis of affected individuals, the abundance of profilaggrin was reduced to less than 10% of normal controls, while the mRNA level was decreased to 30-60% of controls, Expression of K1 and loricrin, other markers of epidermal differentiation, were not affected, Nuclear run-on assays indicated that the decrease in mRNA levels was not caused by aberrant transcription. Nucleotide sequencing of 5'-upstream, 3'-noncoding and flanking regions of the profilaggrin gene from ichthyosis vulgaris-affected individuals revealed only minor changes, probably due to genetic polymorphisms. Our results indicate that defective profilaggrin expression in ichthyosis vulgaris is a result of selectively impaired posttranscriptional control.	UNIV WASHINGTON,DEPT MED,DIV DERMATOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ORAL BIOL & PERIODONT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Presland, Richard/0000-0003-1440-7402	NIADDK NIH HHS [P01 AM 21557] Funding Source: Medline; NIDCR NIH HHS [R37 DE 04660] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P01AM021557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004660] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANTONLAM.I, 1972, HUMANGENETIK, V15, P261, DOI 10.1007/BF00702363; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DALE BA, 1993, MOL BIOL SKIN, V1, P79; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FISHER C, 1987, J INVEST DERMATOL, V88, P661, DOI 10.1111/1523-1747.ep12470281; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; FLECKMAN P, 1987, J INVEST DERMATOL, V88, P640, DOI 10.1111/1523-1747.ep12470251; FLECKMAN P, 1985, J INVEST DERMATOL, V85, P507, DOI 10.1111/1523-1747.ep12277306; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; GAY DA, 1987, CELL, V50, P671, DOI 10.1016/0092-8674(87)90325-4; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; GREENBERG ME, 1990, CURRENT PROTOCOLS MO; HAYDOCK PV, 1993, J INVEST DERMATOL, V101, P118, DOI 10.1111/1523-1747.ep12363609; Hennings H, 1980, Curr Probl Dermatol, V10, P3; HOHL D, 1993, AM J DERMATOPATH, V15, P20, DOI 10.1097/00000372-199302000-00004; HOHL D, 1991, J BIOL CHEM, V266, P6626; IWAI Y, 1993, J IMMUNOL, V150, P4386; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; KRAMER J, 1993, J CLIN INVEST, V91, P1258, DOI 10.1172/JCI116290; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MERRETT JD, 1967, AM J HUM GENET, V19, P575; MEYERSIEGLER K, 1992, CARCINOGENESIS, V13, P2127, DOI 10.1093/carcin/13.11.2127; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MILSTONE LM, 1982, J INVEST DERMATOL, V79, P253, DOI 10.1111/1523-1747.ep12500073; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; PERFETTI V, 1991, LEUKEMIA, V5, P1110; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; PRESLAND RB, 1994, IN PRESS J INVEST DE; RASMUSSEN HH, 1993, J INVEST DERMATOL, V101, P560, DOI 10.1111/1523-1747.ep12365986; REPASKE DR, 1992, PROG BRAIN RES, V93, P295; RESING KA, 1993, J BIOL CHEM, V268, P25139; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WELLS RS, 1966, BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5493.947; WELLS RS, 1966, J INVEST DERMATOL, V46, P530, DOI 10.1038/jid.1966.80; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WU CH, 1991, J BIOL CHEM, V266, P2983; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	59	44	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					871	876		10.1074/jbc.270.2.871	http://dx.doi.org/10.1074/jbc.270.2.871			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822325	hybrid			2022-12-25	WOS:A1995QB81600059
J	KAHN, RA; CLARK, J; RULKA, C; STEARNS, T; ZHANG, CJ; RANDAZZO, PA; TERUI, T; CAVENAGH, M				KAHN, RA; CLARK, J; RULKA, C; STEARNS, T; ZHANG, CJ; RANDAZZO, PA; TERUI, T; CAVENAGH, M			MUTATIONAL ANALYSIS OF SACCHAROMYCES-CEREVISIAE ARF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; STIMULATORY REGULATORY COMPONENT; GTP-BINDING-PROTEIN; ADENYLATE-CYCLASE; CHOLERA-TOXIN; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; ALPHA-SUBUNIT; YEAST; COFACTOR	Wild type and eight point mutants of Saccharomyces cerevisiae ARF1 were expressed in yeast and bacteria to determine the roles of specific residues in in vivo and in vitro activities. Mutations at either Gly(2) or Asp(26) resulted in recessive loss of function. It was concluded that N-myristoylation is required for Arf action in cells but not for either nucleotide exchange or cofactor activities in vitro. Asp(26) (homologous to Gly(12) of p21(ras)) was essential for the binding of the activating nucleotide, guanosine 5'-3-O-(thio)triphosphate. This is in marked contrast to results obtained after mutagenesis of the homologous residue in p21(ras) or G(s) alpha, and suggests a fundamental difference in the guanine nucleotide binding site of Arf with respect to these other GTP binding proteins. Two dominant alleles were also identified, one activating dominant ([Q71L]Arf1) and the other ([N126I]) a negative dominant. A conditional allele, [W66R]Arf1, was characterized and shown to have approximate to 300-fold lower specific activity in an in vitro Arf assay. Two high-copy suppressors of this conditional phenotype were cloned and sequenced. One of these suppressors, SFS4, was found to be identical to PBS2/HOG4, recently shown to encode a microtubule associated protein kinase kinase in yeast.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA; STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601; Stearns, Tim/0000-0002-0671-6582				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GANSTER RW, 1993, MOL CELL BIOL, V13, P3650, DOI 10.1128/MCB.13.6.3650; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HANEY SA, 1994, J BIOL CHEM, V269, P16541; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1993, HDB EXPT PHARM GTPAS, P529; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDAZZO PA, 1994, IN PRESS METHODS ENZ; ROSENWALD AG, 1994, CHALL MOD MED, V6, P143; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TEAL SB, 1994, J BIOL CHEM, V269, P3135; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	48	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					143	150		10.1074/jbc.270.1.143	http://dx.doi.org/10.1074/jbc.270.1.143			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814365	hybrid			2022-12-25	WOS:A1995QA28700026
J	LI, J; PERRELLA, MA; TSAI, JC; YET, SF; HSIEH, CM; YOSHIZUMI, M; PATTERSON, C; ENDEGE, WO; ZHOU, F; LEE, ME				LI, J; PERRELLA, MA; TSAI, JC; YET, SF; HSIEH, CM; YOSHIZUMI, M; PATTERSON, C; ENDEGE, WO; ZHOU, F; LEE, ME			INDUCTION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE-EXPRESSION BY INTERLEUKIN-1-BETA IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANGIOGENESIS; ATHEROSCLEROSIS; RECEPTOR; INVIVO; INHIBITION; ARTERIES; PROTEIN; MITOGEN	Vascular endothelial growth factor (VEGF) is a potent and specific mitogen for vascular endothelial cells and promotes neovascularization in vivo. To determine whether interleukin-1 beta (IL-1 beta), which is present in atherosclerotic lesions, induces VEGF gene expression in vascular smooth muscle cells, we performed RNA blot analysis on rat aortic smooth muscle cells (RASMC) with a rat VEGF cDNA probe. IL-1 beta increased VEGF mRNA levels in RASMC in a time- and dose-dependent manner. As little as 0.1 ng/ml IL-1 beta increased VEGF mRNA levels by S-fold and 10 ng/ml IL-1 beta increased VEGF mRNA by 4-fold. We also measured the half-life of VEGF mRNA and performed nuclear run on experiments before and after addition of IL-1 beta to see if IL-1 beta increased VEGF mRNA levels by stabilizing the mRNA or by increasing its rate of transcription. The normal, 2-h half-life of VEGF mRNA in RASMC was lengthened to 3.2 h (60%) by IL-1 beta, and IL-1 beta increased the rate of VEGF gene transcription by 2.1-fold. In immunoblot experiments with an antibody specific for VEGF, we found that IL-1 beta increased VEGF protein levels in RASMC by 3.3-fold. Together these data indicate that IL-1 beta induces VEGF gene expression in smooth muscle cells. This IL-1 beta-induced expression of VEGF may accelerate the progression of atherosclerotic lesions by promoting the development of new blood vessels.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010					Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061; BO WJ, 1992, ATHEROSCLEROSIS, V94, P71, DOI 10.1016/0021-9150(92)90189-N; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EISENSTEIN R, 1991, PHARMACOL THERAPEUT, V49, P1, DOI 10.1016/0163-7258(91)90019-I; FAN TPD, 1993, BRIT J PHARMACOL, V110, P43, DOI 10.1111/j.1476-5381.1993.tb13769.x; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRYER JA, 1987, J VASC SURG, V6, P341, DOI 10.1067/mva.1987.avs0060341; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; KAHLON R, 1992, CAN J CARDIOL, V8, P60; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI XM, 1994, J BIOL CHEM, V269, P19653; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLAUER B, 1993, CELL, V72, P895; MOYER CF, 1991, AM J PATHOL, V138, P951; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SAEGUSA Y, 1990, J CELL PHYSIOL, V142, P488, DOI 10.1002/jcp.1041420307; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sueishi K, 1993, Curr Top Pathol, V87, P47; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2483	37	311	328	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					308	312		10.1074/jbc.270.1.308	http://dx.doi.org/10.1074/jbc.270.1.308			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814392	hybrid			2022-12-25	WOS:A1995QA28700049
J	ZWEIER, JL; WANG, PH; KUPPUSAMY, P				ZWEIER, JL; WANG, PH; KUPPUSAMY, P			DIRECT MEASUREMENT OF NITRIC-OXIDE GENERATION IN THE ISCHEMIC HEART USING ELECTRON-PARAMAGNETIC-RESONANCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; MYOCARDIAL REPERFUSION INJURY; RELAXING FACTOR; L-ARGININE; ENDOTHELIAL DYSFUNCTION; SUPEROXIDE-DISMUTASE; MECHANISM; RAT; ACETYLCHOLINE; REJECTION	Nitric oxide, NO., exerts numerous important regulatory functions in biological tissues and has been hypothesized to have a role in the pathogenesis of cellular injury in a number of diseases, It has been suggested that alterations in NO. generation are a critical cause of injury in the ischemic heart, However, the precise alterations in NO. generation which occur are not known, and there is considerable controversy regarding whether myocardial ischemia results in increased or decreased NO. formation, Therefore, electron paramagnetic resonance studies were performed to directly measure NO. in isolated rat hearts subjected to global ischemia, using the direct NO. trap Fe2+-N-methyl-D-glucamine dithiocarbamate, which specifically binds NO. giving rise to a characteristic triplet EPR spectrum with g = 2.04 and a(N) = 13.2 G, While only a small triplet signal was observed in normally perfused hearts, a 10-fold increase in this triplet EPR spectrum was observed after 30 min of ischemia indicating a marked increase in NO. formation and trapping, Measurements were performed as a function of the duration of ischemia, and it was determined that with increased duration of ischemia NO. formation and trapping was also increased, NO. generation was inhibited by the nitric oxide synthase blocker, N-nitro-L-arginine methyl ester (L-NAME), suggesting that NO. was generated via nitric oxide synthase, Blockade of NO. generation with L-NAME resulted in more than a 2-fold increase in the recovery of contractile function in hearts reperfused after 30 min of global ischemia, Thus, ischemia causes a marked duration-dependent increase of NO. in the heart which may in turn mediate postischemic injury.	JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	ZWEIER, JL (corresponding author), JOHNS HOPKINS MED INST, JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD USA.				NHLBI NIH HHS [HL-17655, HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017655, R29HL038324, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREENBERG SS, 1990, CIRC RES, V67, P1446, DOI 10.1161/01.RES.67.6.1446; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANGREHR JM, 1993, TRANSPLANTATION, V55, P1205, DOI 10.1097/00007890-199306000-00001; LANGREHR JM, 1992, SURGERY, V112, P395; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; SHLAFER M, 1982, J THORAC CARDIOV SUR, V83, P830; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	30	217	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					304	307		10.1074/jbc.270.1.304	http://dx.doi.org/10.1074/jbc.270.1.304			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814391	hybrid			2022-12-25	WOS:A1995QA28700048
J	MORRICAL, SW; HEMPSTEAD, K; MORRICAL, MD				MORRICAL, SW; HEMPSTEAD, K; MORRICAL, MD			THE GENE 59 PROTEIN OF BACTERIOPHAGE-T4 MODULATES THE INTRINSIC AND SINGLE-STRANDED DNA-STIMULATED ATPASE ACTIVITIES OF GENE-41 PROTEIN, THE T4-REPLICATIVE DNA HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA PRIMERS; PURIFICATION; EXPRESSION; CLONING; INVITRO	The T4 gene 59 protein (gp59) serves as an accessory protein to the essential T4-encoded DNA helicase, the gene 41 protein (gp41). gp59 stimulates gp41-dependent DNA synthesis reactions by promoting the assembly of gp41 onto single-stranded DNA (ssDNA), where the enzyme is activated to perform its DNA helicase functions. To better understand the mechanism of helicase-ssDNA assembly, we have studied the effects of gp59 on the intrinsic and ssDNA-stimulated ATPase activities of gp41. Our results indicate that gp59 exerts a direct effect upon the conformation and ATPase activity of gp41, by increasing the affinity of gp41 for ATP. In addition, we find that gp59 is nearly essential for promoting the assembly of gp41 onto ssDNA molecules that are covered with saturating amounts of the T4 encoded helix-destabilizing protein, gene 32 protein (gp32). Results of protein affinity chromatography experiments suggest that gp59 contains distinct binding sites for gp41 and gp32 and may therefore act as a molecular adapter between the helicase and helix-destabilizing proteins. Together, the data indicate that specific gp59-gp41 and gp59-gp32 protein-protein interactions both play important roles in the assembly of the helicase onto single-stranded DNA.	UNIV VERMONT, COLL MED, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, VERMONT CANC CTR, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont	MORRICAL, SW (corresponding author), UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048847, R56GM048847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BITTNER M, 1979, J BIOL CHEM, V254, P9565; CHA TA, 1988, CANCER CELL, V6, P1; DONG F, 1993, BIOPHYS J, V64, pA238; EASTERBY JS, 1973, BIOCHIM BIOPHYS ACTA, V293, P552, DOI 10.1016/0005-2744(73)90362-8; Fersht AR., 1977, ENZYME STRUCTURE MEC; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, UCLA S MOL CELLULAR, V47, P173; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1979, COLD SPRING HARB SYM, V43, P469, DOI 10.1101/SQB.1979.043.01.053; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; SILVER LL, 1982, J BIOL CHEM, V257, P1696; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	34	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33069	33081						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806535				2022-12-25	WOS:A1994QA63800052
J	SMITH, JW; HU, D; SATTERTHWAIT, A; PINZSWEENEY, S; BARBAS, CF				SMITH, JW; HU, D; SATTERTHWAIT, A; PINZSWEENEY, S; BARBAS, CF			BUILDING SYNTHETIC ANTIBODIES AS ADHESIVE LIGANDS FOR INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SURFACE-PLASMON RESONANCE; PHASE PEPTIDE-SYNTHESIS; PLATELET-AGGREGATION; CELL-ADHESION; BINDING-SITE; MONOCLONAL-ANTIBODY; GPIIB-IIIA; RECEPTOR; FIBRINOGEN	An antibody engineering strategy was employed to build high affinity ligands and antagonists of integrins alpha(v) beta(3) and alpha(IIb)beta(3). Previously, we inserted the integrin recognition motif, RGD, into the antigen binding site of a human antibody and selected the optimal flanking sequences from a phage-display library (Barbas, C. F., Languino, L. R., and Smith, J. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10003-10007). The resulting antibody, Fab-9, blocked the function of integrin gp, but also bound to the ligand binding site of platelet integrin alpha(IIb)beta(3). In this report, the antibody engineering effort has been extended by 1) redesigning Fab-9 to achieve specificity for platelet integrin alpha(IIb)beta(3), 2) building non-RGD-containing antibodies that bind the ligand binding site of both beta(3)-integrins, and 3) testing the hypothesis that peptides derived from complementarity determining regions (CDR) can be used to emulate the activity of the parent synthetic antibody. These goals were accomplished by subjecting the original antibody, Fab-9, to a ''motif optimization'' (MTF). A phage library was constructed in which the residues flanking the RGD motif in Fab-9 were maintained, but the RGDX sequence was randomized. This library was panned on purified alpha(IIb)beta(3) to identify high affinity binders. Four function-blocking antibodies lacking RGD, but with specificity for alpha(IIb)beta(3), were characterized. The antibody with the highest preference for alpha(IIb)beta(3), MTF-10, had an adhesion sequence of KGDN. This sequence is similar in primary structure to the active sequence within the disintegrin barbourin, which also antagonizes alpha(IIb)beta(3) (Scarborough, R. M., Rose, J. W., Hsu, M. A., Phillips, D. R., Fried, V. A., Campbell, A. M., Nannizzi, L., and Charo, I. F. (1991) J. Biol. Chem. 266, 9359-9362). MTF-10 had a 70-fold higher affinity for alpha(IIb)beta(3) than alpha(v) beta(3). Through our selection strategy, we also identified several antibodies that lack RGD but still blocked ligand binding to both integrins with high affinity. Therefore, the RGD sequence is not necessary for a high affinity interaction with the ligand binding site of beta(3)-integrins. Further investigation showed that the activity of inhibitory antibodies could be emulated by synthetic peptides derived from the protein sequences of the antibody's HCDR3. CDR-derived peptides blocked ligand binding to integrins and maintained essentially the same specificity as the parent antibody.	SCRIPPS RES INST, DEPT MOLEC BIOL MB11, LA JOLLA, CA 92037 USA	Scripps Research Institute	SMITH, JW (corresponding author), Scripps Clinic, DEPT VASC VB1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA56483] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; Barbas Carlos F. Iii, 1993, Current Opinion in Biotechnology, V4, P526, DOI 10.1016/0958-1669(93)90072-5; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMURA Y, 1992, BLOOD, V80, P1247; ISOAI A, 1992, CANCER LETT, V65, P259, DOI 10.1016/0304-3835(92)90241-M; KARPATKIN S, 1981, ANN INTERN MED, V95, P636, DOI 10.7326/0003-4819-95-5-636; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4374, DOI 10.1073/pnas.90.10.4374; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MENTER DG, 1987, CANCER RES, V47, P6751; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; STEWART JM, 1984, SOLID PHASE PEPTIDE, P116; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, BLOOD, V79, P2302; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	44	48	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32788	32795						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806501				2022-12-25	WOS:A1994QA63800014
J	CHACKO, GW; DUCHEMIN, AM; COGGESHALL, KM; OSBORNE, JM; BRANDT, JT; ANDERSON, CL				CHACKO, GW; DUCHEMIN, AM; COGGESHALL, KM; OSBORNE, JM; BRANDT, JT; ANDERSON, CL			CLUSTERING OF THE PLATELET FC-GAMMA RECEPTOR INDUCES NONCOVALENT ASSOCIATION WITH THE TYROSINE KINASE P72(SYK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-G; MULTIPLE ISOFORMS; PROTEIN; IGG; EXPRESSION; RII; PHOSPHORYLATION	The Fc receptor for IgG in platelets was identified as the integral membrane isoform encoded by the Fc gamma RIIA gene. Functional analysis of this molecule determined that activated Fc gamma RIIA is tyrosine phosphorylated and that activation induced the physical association with the protein tyrosine kinase p72(syk). Other tyrosine-phosphorylated molecules also co-immunoadsorbed with the activated receptor. Tyrosine kinase activity co-immuno-adsorbing with the platelet Fc gamma R was enhanced upon activation and specifically induced the phosphorylation, on tyrosine residues, of a physically associated 72-kDa protein. These data support a model of Fc gamma receptor-mediated platelet activation where signal is transduced through inducible association of the tyrosine kinase p72(syk) with the low affinity Fc gamma receptor. Thrombin, a potent platelet agonist, has been shown to up-regulate the activity of the tyrosine kinase p72(syk) in platelets, Consequently, our findings identify a second pathway by which p72(syk) in activated in platelets.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chacko, George/I-4945-2014	Chacko, George/0000-0002-2127-1892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046652] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL46652] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1987, J IMMUNOL, V138, P2254; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANDERSON GP, 1990, BLOOD, V76, P1165; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; BUDDE P, 1994, LEUKOCYTE TYPING, V5; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GHAZIZADEH S, 1994, J IMMUNOL, V152, P30; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; GRIFFITH L, 1991, BLOOD, V78, P1753; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAO KJ, 1989, TRANSFUSION, V29, P774, DOI 10.1046/j.1537-2995.1989.29990070180.x; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLER MA, 1993, PCR METH APPL, V3, P32; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1990, CELL IMMUNOL, V128, P462, DOI 10.1016/0008-8749(90)90041-O; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; RAPPAPORT EF, 1993, EXP HEMATOL, V21, P689; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; ROSENFELD SI, 1989, PLATELET IMMUNOBIOLO, P337; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SEKI T, 1989, IMMUNOGENETICS, V30, P5, DOI 10.1007/BF02421463; SHEN ZH, 1994, J IMMUNOL, V152, P3017; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPF TF, 1983, J IMMUNOL, V131, P3064	50	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32435	32440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798242				2022-12-25	WOS:A1994PX30400063
J	LI, SW; FERBER, A; MIURA, M; BASERGA, R				LI, SW; FERBER, A; MIURA, M; BASERGA, R			MITOGENICITY AND TRANSFORMING ACTIVITY OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR WITH MUTATIONS IN THE TYROSINE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; RAT GLIOBLASTOMA; PHOSPHORYLATION; PROTEINS; CELLS; AUTOPHOSPHORYLATION; PROLIFERATION; EXPRESSION; ANTIGEN; IGF-1	We have investigated the effect of mutations in tyrosines 1131, 1135, and 1136 of the human insulin-like growth factor-I receptor (IGF-IR) on the growth and transformation of mammalian cells. We have used for this purpose R(-) cells, which are 3T3-like fibroblasts derived from mouse embryos with a targeted disruption of the IGF-IR genes. These cells have no IGF-IR, do not grow in serum-free medium supplemented with the growth factors that sustain the growth of 3T3 cells, and cannot be transformed by simian virus 40 large tumor antigen or other oncogenes. The R(-) cells were transfected with plasmids expressing: 1) a wild type human IGF-IR cDNA; 2) a receptor with a triple mutation in the above mentioned tyrosines; and 3) receptors with single tyrosine mutations. Cells expressing the wild type or the single tyrosine mutants Y1 (Y1131F) and Y2 (Y1135F) grew in serum-free medium supplemented solely with IGF-I. Cells expressing the triple tyrosine mutant YF or the single mutant Y3 (Y1136F) failed to grow in response to IGF-I only. Ah mutants, though, failed to form colonies in soft agar, indicating that a fully functional IGF-IR is more critical for anchorage-independent growth than for monolayer growth. The triple mutant expression plasmid also functioned as a dominant negative, inhibiting the growth of wild type cells transformed by the simian virus tumor antigen.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, INSULIN LIKE GROWTH; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BASERGA R, 1985, BIOL CELL REPRODUCTI; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; GOLDRING MB, 1991, EUKARYOTIC GENE EXPR, V1, P301; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MIURA M, 1994, CANCER RES, V54, P2472; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; REISS K, 1992, ONCOGENE, V7, P2243; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; SAOSAOKA T, 1994, J BIOL CHEM, V269, P13689; SASOAKA T, 1994, J BIOL CHEM, V269, P10734; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SMITH HS, 1971, VIROLOGY, V44, P359, DOI 10.1016/0042-6822(71)90267-4; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	43	97	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32558	32564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798258				2022-12-25	WOS:A1994PX30400080
J	CHERNIACK, AD; KLARLUND, JK; CONWAY, BR; CZECH, MP				CHERNIACK, AD; KLARLUND, JK; CONWAY, BR; CZECH, MP			DISASSEMBLY OF SON-OF-SEVENLESS PROTEINS FROM GRB2 DURING P21(RAS) DESENSITIZATION BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL-GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; RECEPTOR TYROSINE KINASES; GENE-EXPRESSION; P21RAS ACTIVATION; MAP KINASES; RAS; PHOSPHORYLATION; STIMULATION	Insulin receptor signaling acutely stimulates GTP loading of p21(ras), apparently by mobilizing complexes of Grb2 and the guanine nucleotide exchangers Son-of-sevenless (Sos) 1 and 2 to associate with tyrosine-phosphorylated proteins in the plasma membrane. Here we show that in P-32-labeled 3T3-L1 adipocytes the elevated cellular concentrations of [P-32]GTP-bound p21(ras) in response to insulin return to near basal levels after 20-30 min of hormone stimulation, while insulin receptors remain activated. Lysates of such desensitized cells were quantitatively immunoprecipitated with an antiserum recognizing both Sos1 and Sos2 proteins or a specific anti-Sos2 antiserum. Immunoblot analysis of these precipitates revealed that insulin causes a marked hyperphosphorylation of Sos1 and a 50% decrease in Grb2 associated with Sos proteins under these conditions. Similarly, anti-Grb2 immunoprecipitates of such lysates revealed the presence of decreased Sos1 protein due to insulin action. The disassembly of Grb2 from Sos proteins slightly precedes the time course of p21(ras) deactivation in response to insulin, These data are consistent with the hypothesis that the dissociation of Grb2 from Sos proteins caused by insulin in 3T3-L1 cells mediates p21(ras) deactivation and desensitization.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CHERNIACK, AD (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLANCY BM, 1991, J BIOL CHEM, V265, P12434; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KNUTSON VP, 1992, J BIOL CHEM, V267, P931; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIHLING L, 1993, CELL, V72, P269; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAFUKU M, 1992, J BIOL CHEM, V267, P19448; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PELLICI G, 1992, CELL, V70, P93; PERALDI P, 1993, EUR J BIOCHEM, V218, P815, DOI 10.1111/j.1432-1033.1993.tb18436.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P2; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	49	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1485	1488		10.1074/jbc.270.4.1485	http://dx.doi.org/10.1074/jbc.270.4.1485			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829473				2022-12-25	WOS:A1995QD20400002
J	KUNJI, ERS; HAGTING, A; DEVRIES, CJ; JUILLARD, V; HAANDRIKMAN, AJ; POOLMAN, B; KONINGS, WN				KUNJI, ERS; HAGTING, A; DEVRIES, CJ; JUILLARD, V; HAANDRIKMAN, AJ; POOLMAN, B; KONINGS, WN			TRANSPORT OF BETA-CASEIN-DERIVED PEPTIDES BY THE OLIGOPEPTIDE TRANSPORT-SYSTEM IS A CRUCIAL STEP IN THE PROTEOLYTIC PATHWAY OF LACTOCOCCUS-LACTIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSP CREMORIS WG2; STREPTOCOCCUS-LACTIS; MECHANISM; GROWTH	In the proteolytic pathway of Lactococcus lactis, milk proteins (caseins) are hydrolyzed extracellularly to oligopeptides by the proteinase (PrtP). The fate of these peptides, i.e. extracellular hydrolysis followed by amino acid uptake or transport followed by intracellular hydrolysis, has been addressed. Mutants have been constructed that lack a functional di-tripeptide transport system (DtpT) and/or oligopeptide transport system (Opp) but do express the P-1-type proteinase (specific for hydrolysis of beta- and to a lesser extent kappa-casein). The wild type strain and the DtpT(-) mutant accumulate all beta-casein-derived amino acids in the presence of beta-casein as protein substrate and glucose as a source of metabolic energy. The amino acids are not accumulated significantly inside the cells by the Opp(-) and DtpT(-) Opp(-) mutants. When cells are incubated with a mixture of amino acids mimicking the composition of beta-casein, the amino acids are taken up to the same extent in all four strains. Analysis of the extracellular peptide fraction, formed by the action of PrtP on beta-casein, indicates that distinct peptides disappear only when the cells express an active Opp system. These and other experiments indicate that (i) oligopeptide transport is essential for the accumulation of all beta-casein-derived amino acids, (ii) the activity of the Opp system is sufficiently high to support high growth rates on beta-casein provided leucine and histidine are present as free amino acids, and (iii) extracellular peptidase activity is not present in L. lactis.	UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS; UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT GENET,9751 NN HAREN,NETHERLANDS	University of Groningen; University of Groningen			Konings, Wilhelmus N./C-7063-2013; Kunji, Edmund/AAH-2362-2020	Kunji, Edmund/0000-0002-0610-4500				ANDERSON DG, 1983, APPL ENVIRON MICROB, V46, P549, DOI 10.1128/AEM.46.3.549-552.1983; BAANKREIS R, 1992, THESIS U WAGENINGEN; EXTERKATE FA, 1990, APPL MICROBIOL BIOT, V33, P401, DOI 10.1007/BF00176654; GASSON MJ, 1980, FEMS MICROBIOL LETT, V7, P51, DOI 10.1111/j.1574-6941.1980.tb01575.x; GASSON MJ, 1983, J BACTERIOL, V154, P1; HAGTING A, 1994, J BIOL CHEM, V269, P11391; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; HUGENHOLTZ J, 1985, FEMS MICROBIOL ECOL, V31, P57, DOI 10.1111/j.1574-6968.1985.tb01131.x; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KOK J, 1993, GENETICS BIOTECHNOLO, P169; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; LAAN H, 1989, APPL ENVIRON MICROB, V55, P3101, DOI 10.1128/AEM.55.12.3101-3106.1989; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; LEENHOUTS KJ, 1991, APPL ENVIRON MICROB, V57, P2568, DOI 10.1128/AEM.57.9.2568-2575.1991; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PAYNE JW, 1994, ADV MICROB PHYSIOL, V36, P1, DOI 10.1016/S0065-2911(08)60176-9; POOLMAN B, 1987, J BACTERIOL, V169, P2755, DOI 10.1128/jb.169.6.2755-2761.1987; POOLMAN B, 1987, J BACTERIOL, V169, P5597, DOI 10.1128/jb.169.12.5597-5604.1987; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; PRITCHARD GG, 1993, FEMS MICROBIOL REV, V12, P179, DOI [10.1016/0168-6445(93)90063-F, 10.1111/j.1574-6976.1993.tb00018.x]; SMID EJ, 1989, J BACTERIOL, V171, P6135, DOI 10.1128/jb.171.11.6135-6140.1989; SMID EJ, 1989, J BACTERIOL, V171, P292, DOI 10.1128/jb.171.1.292-298.1989; SMID EJ, 1991, APPL ENVIRON MICROB, V57, P2447, DOI 10.1128/AEM.57.9.2447-2452.1991; TAN PST, 1990, APPL ENVIRON MICROB, V56, P526, DOI 10.1128/AEM.56.2.526-532.1990; TAN PST, 1992, APPL ENVIRON MICROB, V58, P285, DOI 10.1128/AEM.58.1.285-290.1992; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993	26	91	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1569	1574		10.1074/jbc.270.4.1569	http://dx.doi.org/10.1074/jbc.270.4.1569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829486	hybrid, Green Submitted			2022-12-25	WOS:A1995QD20400016
J	ROULEAU, J; MACLEOD, AR; SZYF, M				ROULEAU, J; MACLEOD, AR; SZYF, M			REGULATION OF THE DNA METHYLTRANSFERASE BY THE RAS-AP-1 SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO METHYLATION; C-JUN; GLUCOCORTICOID RECEPTOR; CARCINOMA-CELLS; GENE-EXPRESSION; COLON CANCER; CPG ISLANDS; HA-RAS; LEVEL; CDNA	Using deletion analysis and site-specific mutagenesis to map the 5' regulatory region of the DNA methyltransferase (MeTase) gene, we show that a 106-bp sequence (at -1744 to -1650) bearing three AP-1 sites is responsible for induction of DNA MeTase promoter activity. Using transient cotransfection chloramphenicol acetyltransferase assays in P19 cells, we show that the DNA MeTase promoter is induced by c-Jun or Ha-Ras but not by a dominant negative mutant of Jun, partial derivative 9. The activation of the DNA MeTase promoter by Jun is inhibited in a ligand dependent manner by the glucocorticoid receptor, Stable expression of Ha-Ras in P19 cells results in induction of transcription of the DNA MeTase mRNA as determined by nuclear run on assays and the steady state levels of DNA MeTase mRNA as determined by an RNase protection assay. These experiments establish a potential molecular link between nodal cellular signaling pathways and the control of expression of the DNA MeTase gene. This provides us with a possible molecular explanation for the hyperactivation of DNA MeTase in many cancer cells and suggests that DNA MeTase is one possible downstream effector of Ras.	MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; AUSBEL FM, 1988, CURRENT PROTOCOLS MO; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MIGEON BR, 1991, SOMAT CELL MOLEC GEN, V17, P159, DOI 10.1007/BF01232973; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SZYF M, 1992, J BIOL CHEM, V267, P12831; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1989, P NATL ACAD SCI USA, V86, P6853, DOI 10.1073/pnas.86.18.6853; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WELLER MD, 1987, J BIOL CHEM, V262, P15202; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	45	124	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1595	1601		10.1074/jbc.270.4.1595	http://dx.doi.org/10.1074/jbc.270.4.1595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829490	hybrid			2022-12-25	WOS:A1995QD20400020
J	WANG, GL; SEMENZA, GL				WANG, GL; SEMENZA, GL			PURIFICATION AND CHARACTERIZATION OF HYPOXIA-INDUCIBLE FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; DNA-BINDING ACTIVITY; FACTOR-I; TRANSCRIPTIONAL RESPONSE; POLYACRYLAMIDE GELS; ENHANCER ELEMENT; HEPATOMA-CELLS; PHORBOL ESTER; EXPRESSION; PROTEIN	Hypoxia-inducible factor 1 (HIP-1) is a DNA-binding protein that activates erythropoietin (Epo) gene transcription in Hep3B cells subjected to hypoxia or cobalt chloride treatment. HIF-1 DNA binding activity is also induced by hypoxia or cobalt in non-Epo-producing cells, suggesting a general role for HIF-1 in hypoxia signal transduction and transcriptional regulation. Here we report the biochemical purification of HIF-1 from Epo-producing Hep3B cells and non-Epo-producing HeLa S3 cells. HIF-1 protein was purified 11,250-fold by DEAE ion-exchange and DNA affinity chromatography. Analysis of HIF-1 isolated from a preparative gel shift assay revealed four polypeptides. Peptide mapping of these HIF-1 components demonstrated that 91-, 93-, and 94-kDa polypeptides had similar tryptic maps, whereas the 120-kDa polypeptide had a distinct profile. Glycerol gradient sedimentation analysis suggested that HIF-1 exists predominantly in a heterodimeric form and to a lesser extent as a heterotetramer. Partially purified HIF-1 bound specifically to the wild-type HIF-1 binding site from the EPO enhancer but not to a mutant sequence that lacks hypoxia-inducible enhancer activity. UV cross-linking analysis with purified HIF-1 indicated that both subunits of HIF-1 contact DNA directly. We conclude that in both cobalt chloride treated HeLa cells and hypoxic Hep3B cells HIF-1 is composed of two different subunits: 120-kDa HIF-1 alpha and 91-94-kDa HIF-1 beta.	JOHNS HOPKINS UNIV, SCH MED, CTR GENET MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, CTR GENET MED, DEPT MED, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University					NIDDK NIH HHS [DK 39869] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BEST S, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P205; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JELKMANN W, 1991, BIOCHEM BIOPH RES CO, V179, P1441, DOI 10.1016/0006-291X(91)91734-T; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KRANTZ SB, 1991, BLOOD, V77, P419; KURTZ A, 1992, AM J PHYSIOL, V262, pC1204, DOI 10.1152/ajpcell.1992.262.5.C1204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316	36	1615	1717	5	139	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1230	1237		10.1074/jbc.270.3.1230	http://dx.doi.org/10.1074/jbc.270.3.1230			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836384	hybrid			2022-12-25	WOS:A1995QB15600039
J	BEGUM, N				BEGUM, N			STIMULATION OF PROTEIN PHOSPHATASE-1 ACTIVITY BY INSULIN IN RAT ADIPOCYTES - EVALUATION OF THE ROLE OF MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; GLYCOGEN-SYNTHESIS; SIGNALING PATHWAY; GLUCOSE-TRANSPORT; PHOSPHORYLATION; SUBUNIT; CELLS; CAMP; IDENTIFICATION	In this study, we examined the distribution of protein serine/threonine phosphatase-1 (PP-1) and analyzed the effect of insulin on PP-1 and its mechanism of activation in freshly isolated rat adipocytes. The adipocyte particulate fraction (PF) constituted approximate to 80% of cellular PP-1 activity, while PP-2A was entirely cytosolic. Insulin rapidly stimulated PF PP-1 in a time- and dose-dependent manner (maximum stimulation at 5 min with 4 nM insulin). Immunoprecipitation of PF with an antibody against the site-1 sequence of rabbit skeletal muscle glycogen-associated PP-1 (PP-1G) subunit indicated that approximate to 40% of adipocyte PP-1 activity was due to PP-1G form of the enzyme, Insulin stimulated PP-1G (120% over basal levels) without affecting the other forms of PP-1 in the PF. Insulin activation of PP-1 was accompanied by > 2-fold increase in the phosphorylation state of the 160-kDa regulatory subunit of PP-1. Stimulation of p21(Ras)/mitogen-activated protein kinase pathway (MAP) with GTP analogues also resulted in stimulation of PP-1 similar to insulin, The insulin effect on MAP kinase and PP-1 activation was blocked by a GTP antagonist, guanyl-5'-yl thiophosphate. The inhibitors of MAP kinase activation (viz. cAMP agonists, SpcAMP and ML-9) also blocked PP-1 stimulation by insulin. The time course of MAP kinase activation preceded the phosphorylation of PP-1 regulatory subunit and PP-1 activation, We conclude that insulin rapidly activates a membrane-associated PP-1 in adipocytes, which may be similar to rabbit skeletal muscle PP-1G, and the activation is mediated by p21(Ras)/MAP kinase pathway.	SUNY STONY BROOK, SCH MED, STONY BROOK, NY 11790 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	BEGUM, N (corresponding author), WINTHROP UNIV HOSP, DIABET RES LAB, 259 1ST ST, MINEOLA, NY 11501 USA.							ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; AVRUCH J, 1976, J BIOL CHEM, V251, P1511; BEGUM N, 1994, AM J PHYSIOL, V267, pE14, DOI 10.1152/ajpendo.1994.267.1.E14; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1989, J BIOL CHEM, V264, P21435; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRUPPUSO PA, 1987, BIOCHEM BIOPH RES CO, V148, P1174, DOI 10.1016/S0006-291X(87)80256-5; HIRAGA A, 1987, EUR J BIOCHEM, V163, P253, DOI 10.1111/j.1432-1033.1987.tb10795.x; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INOUE G, 1993, J BIOL CHEM, V268, P5272; KLARLUND JK, 1993, J BIOL CHEM, V268, P7646; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; OKADA T, 1994, J BIOL CHEM, V269, P3563; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEALS JR, 1979, J BIOL CHEM, V254, P6991; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; TANG PM, 1991, J BIOL CHEM, V266, P15782; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	41	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					709	714		10.1074/jbc.270.2.709	http://dx.doi.org/10.1074/jbc.270.2.709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822300	hybrid			2022-12-25	WOS:A1995QB81600034
J	CHENG, D; CHANG, CCY; QU, XM; CHANG, TY				CHENG, D; CHANG, CCY; QU, XM; CHANG, TY			ACTIVATION OF ACYL-COENZYME A-CHOLESTEROL ACYLTRANSFERASE BY CHOLESTEROL OR BY OXYSTEROL IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; METABOLISM; COA; ATHEROSCLEROSIS; RECONSTITUTION; FIBROBLASTS	Acyl-coenzyme A:cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the conjugation of long chain fatty acid and cholesterol to form cholesteryl esters. It is an integral membrane protein located in the endoplasmic reticulum. Experiments performed in intact mammalian cells have shown that the rate of cholesteryl ester synthesis in intact cells, as well as the ACAT activity from cell extracts, are greatly activated by the addition of low density lipoprotein (LDL) or oxygenated sterols such as 25-hydroxycholesterol to the growth medium, However, the molecular mechanism(s) by which sterol(s) stimulate the ACAT activity remains to be elucidated. Recently, our laboratory reported the expression cloning of human ACAT cDNA (Chang, C. C. Y., Huh, H. Y., Cadigan, K. M., and Chang, T. Y. 1993) J. Biol. Chem. 268, 20747-20755). In the current study, we report the expression of human ACAT cDNA in insect Sf9 cells, Uninfected Sf9 cells do not express detectable ACAT-like activity. Infecting these cells with recombinant virus containing ACAT cDNA caused these cells to express high levels of ACAT protein and high levels of ACAT activity when assayed in vitro. The catalytic properties of ACAT expressed in these cells were found to be similar to those found in human tissue culture cells, The combination of high level of ACAT protein expression and the low level of cellular cholesterol content in the infected cells have provided us a novel opportunity to establish a simple cell-free system, whereby stimulation of ACAT by sterols can be readily demonstrated, Using this system, we have shown that cholesterol itself can serve as an ACAT activator in vitro, in addition to its role as an ACAT substrate. The current work provides the experimental basis to hypothesize that, inside mammalian cells, cholesterol itself may serve as a physiological regulator of ACAT.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College				Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036709, R01HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; BILLHEIMER JT, 1990, Patent No. 372445; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1975, J BIOL CHEM, V250, P4925; CADIGAN KM, 1988, J LIPID RES, V29, P1683; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1700, DOI 10.1021/bi00355a039; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1994, TRENDS CARDIOVAS MED, V4, P223, DOI 10.1016/1050-1738(94)90038-8; CHANG TY, 1983, ENZYMES, V16, P523; COLEMAN RA, 1983, ENZYMES, V16, P605; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; ERICKSON SK, 1994, J LIPID RES, V35, P763; ERICKSON SK, 1980, J LIPID RES, V21, P930; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; HARTE RA, 1993, BIOCHEM SOC T, V21, P3255; HEYMANN E, 1980, ENZYMATIC BASIS DETO, V2, P291; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; KRAUSE BR, 1989, 10TH INT S DRUGS AFF; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LAUTENSCHLAEGER H H, 1986, Drugs of the Future, V11, P26; LICHTENSTEIN AH, 1980, J BIOL CHEM, V255, P9098; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OZOLS J, 1989, J BIOL CHEM, V264, P12533; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUDEL LL, 1973, J LIPID RES, V14, P364; Sambrook J, 1989, MOL CLONING LABORATO; SINENSKY M, 1981, ARCH BIOCHEM BIOPHYS, V209, P321, DOI 10.1016/0003-9861(81)90287-3; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SUCKLING KE, 1985, J LIPID RES, V26, P647; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TABAS I, 1988, J BIOL CHEM, V263, P1266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENTIMIGLIA JB, 1986, ANAL BIOCHEM, V157, P323, DOI 10.1016/0003-2697(86)90633-0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	53	143	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					685	695		10.1074/jbc.270.2.685	http://dx.doi.org/10.1074/jbc.270.2.685			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822296	hybrid			2022-12-25	WOS:A1995QB81600030
J	KEREN, N; GONG, HS; OHAD, I				KEREN, N; GONG, HS; OHAD, I			OSCILLATIONS OF REACTION-CENTER-II D1-PROTEIN-DEGRADATION IN-VIVO INDUCED BY REPETITIVE LIGHT-FLASHES - CORRELATION BETWEEN THE LEVEL OF RCII-Q(B)(-), AND PROTEIN-DEGRADATION IN LOW-LIGHT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; II REACTION CENTER; PHOTOSYSTEM-II; THERMO-LUMINESCENCE; D1 PROTEIN; CHLAMYDOMONAS-REINHARDTII; PHOTOINHIBITION INVIVO; SCENEDESMUS-OBLIQUUS; THYLAKOID MEMBRANES; ELECTRON-TRANSFER	The D1 protein subunit of the photochemical reaction center II (RCII) turns over rapidly in oxygenic photosynthetic organisms exposed to the light. At high photon nux densities (PFD), photoinactivation of RCII precedes the degradation of the D1 protein. We Pound that the apparent quantum yield for the DI protein degradation in Chlamydomonas cells is severalfold higher at low PFDs (10-100 mu mol m(-2) s(-1)) as compared to that observed at PFDs which induce photoinactivation of RCII (1.53 x 10(3) mu mol m(-2) s(-1)). Relative high levels of reduced RCII secondary plastoquinone acceptor, Q(B)(-), are induced in cells exposed to low PFDs as determined by thermoluminescence measurements. The probability of generating elevated levels of Q(B)(-) which may recombine with the S-2,S-3 oxidized states of the oxygen evolving complex decreases with increase in the light intensities at which consecutive double reduction of Q(B) and exchange with the plastoquinone pool prevail. We have used light flashes to test if a correlation exists between the degradation of D1 protein and the relative level of Q(B)(-). D1 protein degradation could be induced in dark-incubated cells exposed to a series of 1.4 x 10(3) single light flashes given at intervals compatible with generation of elevated levels of Q(B)(-) and its decay by charge recombination. Oscillations of the Q(B)(-) level in cells exposed to 960-1440 series of 1 to several flashes correlated with oscillations of the D1 protein degradation in Chlamydomonas cells and in the Scenedesmus wild type but not in the LF-1 mutant lacking photosystem II donor side activity. In this mutant the ''S state cycle'' and Q(B)(-) oscillations are abolished. We propose that the process of recombination of long lived RCII-Q(B)(-) with the S-2,S-3 states may involve damaging events related to the D1 protein degradation induced by light flashes or continuous low light in vivo.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV OSLO,DEPT BIOL,N-0316 OSLO 3,NORWAY	Hebrew University of Jerusalem; University of Oslo				Keren, Nir/0000-0002-7356-8831				ADIR N, 1988, J BIOL CHEM, V263, P283; ANDERSSON B, 1992, 2 PHOTOSYSTEMS OXYGE, P122; ARNTZ B, 1986, FEBS LETT, V194, P43, DOI 10.1016/0014-5793(86)80048-5; ARO EM, 1990, BIOCHIM BIOPHYS ACTA, V1019, P269, DOI 10.1016/0005-2728(90)90204-H; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; DEMETER S, 1989, PHYSIOL PLANTARUM, V75, P121, DOI 10.1111/j.1399-3054.1989.tb02073.x; DINER BA, 1988, J BIOL CHEM, V263, P8972; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; ECKERT HJ, 1991, PHOTOSYNTH RES, V27, P97, DOI 10.1007/BF00033249; ETIENNE AL, 1993, PHOTOSYNTH RES, V38, P387, DOI 10.1007/BF00046765; GEIGER R, 1987, Z NATURFORSCH C, V42, P491; GONG H, 1991, J BIOL CHEM, V266, P21293; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; HIDEG E, 1994, BBA-BIOENERGETICS, V1186, P143, DOI 10.1016/0005-2728(94)90173-2; HUNDAL T, 1990, FEBS LETT, V267, P203, DOI 10.1016/0014-5793(90)80925-9; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KOIVUNIEMI A, 1993, FEBS LETT, V327, P343, DOI 10.1016/0014-5793(93)81017-T; KRIEGER A, 1992, BIOCHIM BIOPHYS ACTA, V1102, P167, DOI 10.1016/0167-4838(92)90507-A; KRIEGER A, 1993, PHOTOSYNTH RES, V37, P117, DOI 10.1007/BF02187470; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANON H, 1982, MOL BIOL BIOCH BIOPH, V35, P152; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MEUNIER PC, 1993, PHOTOSYNTH RES, V36, P111, DOI 10.1007/BF00016276; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; OHAD I, 1990, J BIOL CHEM, V265, P1972; OHAD I, 1988, BIOCHIM BIOPHYS ACTA, V933, P288, DOI 10.1016/0005-2728(88)90036-9; OHAD I, 1994, PHOTOINHIBITION PHOT, P165; OHAD N, 1990, Z NATURFORSCH C, V45, P402; ONO T, 1989, BIOCHIM BIOPHYS ACTA, V973, P443, DOI 10.1016/S0005-2728(89)80386-X; PEREWOSKA I, 1994, PLANT PHYSIOL, V104, P235, DOI 10.1104/pp.104.1.235; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; RADMER RJ, 1977, ENCYCLOPEDIA PLANT P, V5, P125; RAVEN AJ, 1982, PLANT CELL ENVIRON, V5, P117; ROVA M, 1994, PHOTOSYNTH RES, V39, P75, DOI 10.1007/BF00027145; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; SCHNETTGER B, 1994, PLANT CELL ENVIRON, V17, P85; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SEIBERT M, 1989, BIOCHIM BIOPHYS ACTA, V974, P185, DOI 10.1016/S0005-2728(89)80371-8; SUNDBY C, 1993, J BIOL CHEM, V268, P25476; VANGORKOM HJ, 1985, PHOTOSYNTH RES, V6, P97, DOI 10.1007/BF00032785; VANGORKOM HJ, 1986, PHOTOSYNTH RES, V9, P55, DOI 10.1007/BF00029731; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VASS I, 1981, BIOCHIM BIOPHYS ACTA, V634, P140, DOI 10.1016/0005-2728(81)90134-1; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VOLK M, 1993, FEBS LETT, V336, P357, DOI 10.1016/0014-5793(93)80837-K; ZER H, 1994, J BIOL CHEM, V269, P17670	54	92	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					806	814		10.1074/jbc.270.2.806	http://dx.doi.org/10.1074/jbc.270.2.806			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822315	hybrid			2022-12-25	WOS:A1995QB81600049
J	MACDOUGALD, OA; CORNELIUS, P; LIU, R; LANE, MD				MACDOUGALD, OA; CORNELIUS, P; LIU, R; LANE, MD			INSULIN REGULATES TRANSCRIPTION OF THE CCAAT/ENHANCER BINDING-PROTEIN (C/EBP) ALPHA-GENE, BETA-GENE, AND DELTA-GENE IN FULLY-DIFFERENTIATE 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ALPHA-1-ACID GLYCOPROTEIN GENE; ADIPOSE CELL LINE; GLUCOSE TRANSPORTER; MESSENGER-RNA; ACTIVATOR PROTEIN; OKADAIC ACID; DNA-BINDING; EXPRESSION; PREADIPOCYTES	The effect of insulin on expression of CCAAT/enhancer binding protein (C/EBP) alpha, beta, and delta was investigated in fully-differentiated 3T3-L1 adipocytes. Treatment of adipocytes with insulin stimulated rapid dephosphorylation of C/EBP alpha, and repressed the expression of C/EBP alpha within 2-4 h, with > 90% suppression occurring at 24 h, While insulin induced expression of C/EBP beta and C/EBP delta within 1 h and caused a > 20-fold increase by 4 h, expression returned to nearly pretreat ment levels by 24 h, The insulin concentration dependence of these effects was consistent with involvement of the insulin receptor, Gel shift analysis revealed that 6 h of insulin treatment decreased the binding of nuclear C/EBP alpha while increasing binding of nuclear C/EBP beta and C/EBP delta. The reciprocal effects of insulin on the steady-state levels of C/EBP transcription factors can be accounted for kinetically and quantitatively by changes in their mRNA levels, which can be accounted for by effects on gene transcription. The effects of insulin on adipocyte gene transcription (e.g. GLUT4) may be mediated, at least in part, by down-regulation of C/EBP alpha and/or its dephosphorylation.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				MacDougald, Ormond/0000-0001-6907-7960				ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JEANRENAUD B, 1960, J BIOL CHEM, V235, P2217; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0	58	141	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					647	654		10.1074/jbc.270.2.647	http://dx.doi.org/10.1074/jbc.270.2.647			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822291	hybrid			2022-12-25	WOS:A1995QB81600024
J	WEI, SH; EPISKOPOU, V; PIANTEDOSI, R; MAEDA, S; SHIMADA, K; GOTTESMAN, ME; BLANER, WS				WEI, SH; EPISKOPOU, V; PIANTEDOSI, R; MAEDA, S; SHIMADA, K; GOTTESMAN, ME; BLANER, WS			STUDIES ON THE METABOLISM OF RETINOL AND RETINOL-BINDING PROTEIN IN TRANSTHYRETIN-DEFICIENT MICE PRODUCED BY HOMOLOGOUS RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; PLASMA RETINOL; ACID-BINDING; RAT-TISSUES; LIQUID-CHROMATOGRAPHY; TRANSPORT PROTEIN; NUCLEAR RECEPTOR; CHOROID-PLEXUS; MESSENGER-RNA; HUMAN-SERUM	Tissue needs for retinoids are believed to be satisfied through the delivery in the circulation of retinol by its specific plasma transport protein, retinol-binding protein (REP), which circulates as a 1-to-1 protein complex with transthyretin (TTR). The binding of REP to TTR is thought to prevent filtration of retinol-RBP in the kidney and to play a role in secretion of REP from hepatocytes. Recently a strain of mice (TTR(-)) that totally lacks immunoreactive TTR was produced by targeted mutagenesis. We have explored the effects of TTR deficiency on retinol and REP metabolism in this mutant strain. In pooled plasma from the TTR(-) mice retinol levels averaged 6% of those of wild type animals. Similarly, plasma REP in the TTR(-) mice was found to be 5% of wild type levels. Hepatic retinol and retinyl ester levels were similar for mutant and wild type mice, suggesting that the mutation affects neither the uptake nor storage of dietary retinol. Levels of retinol and retinyl esters in testis, kidney, spleen, and eye cups from TTR(-) mice were normal. Plasma all-trans-retinoic acid levels for the TTR(-) mice were 2.3-fold higher than those of wild type (425 versus 190 ng/dl). Kidney REP levels were similar for the mutant and wild type mice and we were unable to detect intact REP in urine from TTR(-) mice. Hepatic REP levels in the TTR(-) mice were 60% higher than those of wild type mice (39.8 versus 25.0 pp of RBP/g of tissue). These data may suggest that there is a partial blockage in REP secretion from TTR(-) hepatocytes that leads to lessened plasma levels of retinol-RBP.	COLUMBIA UNIV,COLL PHYS & SURG,INST HUMAN NUTR,NEW YORK,NY 10032; ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; YAMANASHI MED UNIV,DEPT BIOCHEM,TAMAHO,YAMANASHI 40938,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MED GENET,DIV MOLEC BIOMED,SUITA,OSAKA 565,JAPAN; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032	Columbia University; Imperial College London; University of Yamanashi; Osaka University; Columbia University			Episkopou, Vasso/E-2952-2010		MRC [MC_U120074332] Funding Source: UKRI; Medical Research Council [MC_U120074332] Funding Source: Medline; NIDDK NIH HHS [DK47389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047389] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BHAT PV, 1991, CAN J PHYSIOL PHARM, V69, P826, DOI 10.1139/y91-124; BHAT PV, 1988, BIOCHEM CELL BIOL, V66, P735, DOI 10.1139/o88-084; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; Blaner William S., 1994, P229; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1987, J BIOL CHEM, V262, P53; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1985, J NUTR, V115, P856, DOI 10.1093/jn/115.7.856; BLANER WS, 1986, J LIPID RES, V27, P1084; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; CHANOINE JP, 1992, ENDOCRINOLOGY, V130, P933, DOI 10.1210/en.130.2.933; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLUM ME, 1985, J BIOL CHEM, V260, P590; DE LUCA LM, 1991, FASEB J, V5, P2924; DELEENHEER AP, 1982, J LIPID RES, V23, P1362; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; ECKHOFF C, 1990, J LIPID RES, V31, P1445; EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOODMAN DS, 1965, J LIPID RES, V6, P390; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GOODMAN DS, 1983, BIOCHIM BIOPHYS ACTA, V750, P223, DOI 10.1016/0005-2760(83)90022-X; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOODMAN DS, 1984, RETINOIDS, V2, P1; HERBERT J, 1986, NEUROLOGY, V36, P900, DOI 10.1212/WNL.36.7.900; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KANDA Y, 1974, J BIOL CHEM, V249, P6796; KATO M, 1985, J BIOL CHEM, V260, P4832; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS KC, 1990, J LIPID RES, V31, P1535; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MELHUS H, 1991, EXP CELL RES, V197, P119, DOI 10.1016/0014-4827(91)90488-G; MOORE T, 1957, VITAMIN A, P295; MORALES C, 1987, ENDOCRINOLOGY, V121, P432, DOI 10.1210/endo-121-1-432; NAPOLI JL, 1985, J LIPID RES, V26, P387; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; PANGARO LN, 1990, PRINCIPLES PRACTICE, P271; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAJAN N, 1990, J LIPID RES, V31, P821; RAZ A, 1970, J BIOL CHEM, V245, P1903; Sambrook J, 1989, MOL CLONING LABORATO; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; Snedecor G.W., 1980, STAT METHODS, V7; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; SOPRANO DR, 1988, J BIOL CHEM, V263, P2934; SUHARA A, 1990, J LIPID RES, V31, P1669; Underwood BA, 1984, RETINOIDS, P281; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; WAKASUGI S, 1986, J BIOCHEM-TOKYO, V100, P49, DOI 10.1093/oxfordjournals.jbchem.a121705; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	56	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					866	870		10.1074/jbc.270.2.866	http://dx.doi.org/10.1074/jbc.270.2.866			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822324	hybrid			2022-12-25	WOS:A1995QB81600058
J	HU, B; COULSON, L; MOYER, B; PRICE, PA				HU, B; COULSON, L; MOYER, B; PRICE, PA			ISOLATION AND MOLECULAR-CLONING OF A NOVEL BONE PHOSPHOPROTEIN RELATED IN SEQUENCE TO THE CYSTATIN FAMILY OF THIOL PROTEASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GLA PROTEIN; CYSTEINE PROTEINASES; PROTEOGLYCAN-II; BOVINE BONE; CDNA; RAT; SIALOPROTEIN; PEPTIDES; ACID; ALPHA-2-HS-GLYCOPROTEIN	We describe here the isolation of a novel non-collagenous protein from the acid demineralization extract of bovine cortical bone. This 24-kDa protein is multiply phosphorylated at serine residues in Ser-X-Glu/Ser(P) sequences, a recognition motif for phosphorylation by the secretory pathway protein kinase, and we have termed this protein secreted phosphoprotein 24 (spp24). The cDNA structure of spp24 was determined by sequencing cDNA fragments obtained by reverse transcription-polymerase chain reaction, 3'-rapid amplification of cDNA ends, and screening a lambda gt11 cDNA library. This cDNA sequence predicts a 200-residue initial translation product which consists of a 20-residue signal sequence and the 180-residue mature spp24. Northern blot analysis using the spp24 cDNA showed that spp24 mRNA is in liver and bone but not in heart, lung, kidney, or spleen. A search of existing protein sequences revealed that the N-terminal 107 residues of mature spp24 are related in sequence to the cystatin family of thiol protease inhibitors, which suggests that spp24 could function to modulate the thiol protease activities that are known to be involved in bone turnover. Several of the proteins in the cystatin family that are most closely related to spp24 are not only thiol protease inhibitors but are also precursors to peptides with potent biological activity, peptides such as bradykinin and the neutrophil antibiotic peptides. It is therefore possible that the intact form of spp24 found in bone could also be a precursor to a biologically active peptide, a peptide which could coordinate an aspect of bone turnover.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR25921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P2919, DOI 10.1073/pnas.85.9.2919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; ELZANOWSKI A, 1988, FEBS LETT, V227, P167, DOI 10.1016/0014-5793(88)80890-1; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GOTO T, 1993, HISTOCHEMISTRY, V99, P411, DOI 10.1007/BF00717054; HALE JE, 1991, J BIOL CHEM, V266, P21145; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEE CC, 1987, P NATL ACAD SCI USA, V84, P4403, DOI 10.1073/pnas.84.13.4403; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MEGGIO F, 1988, EUR J BIOCHEM, V177, P281, DOI 10.1111/j.1432-1033.1988.tb14374.x; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; OHNISHI T, 1993, J BONE MINER RES, V8, P367; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P3374, DOI 10.1073/pnas.73.10.3374; PRICE PA, 1994, PROTEIN SCI, V3, P822; PRICE PA, 1985, J BIOL CHEM, V260, P4971; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SORENSEN ES, 1994, BIOCHEM BIOPH RES CO, V198, P200, DOI 10.1006/bbrc.1994.1028; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275; ZANETTI M, 1993, J BIOL CHEM, V268, P522	37	47	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					431	436		10.1074/jbc.270.1.431	http://dx.doi.org/10.1074/jbc.270.1.431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814406	hybrid			2022-12-25	WOS:A1995QA28700068
J	SEARLES, RP; MIDSON, CN; NIPPER, VJ; MACHIDA, CA				SEARLES, RP; MIDSON, CN; NIPPER, VJ; MACHIDA, CA			TRANSCRIPTION OF THE RAT BETA(1)-ADRENERGIC RECEPTOR GENE - CHARACTERIZATION OF THE TRANSCRIPT AND IDENTIFICATION OF IMPORTANT SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-1-ADRENERGIC RECEPTOR; BETA-ADRENERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTORS; MOLECULAR-CLONING; PROMOTER REGION; MESSENGER-RNA; REPORTER GENE; EXPRESSION; INVITRO	We have characterized the 5' and 3' ends of the rat beta(1)-adrenergic receptor transcript using RNase protection assays and have used transient transfection analysis to identify regions of the beta(1)-adrenergic gene 5'-flanking sequences which are important for expression, The transcript has multiple start sites, occurring primarily in two clusters at bases -250 and -280, relative to the first base of the initiation codon, Two potential polyadenylation signals at +2450 and +2732 are both functional, although the site at +2732 is preferred both in C6 glioma cells and in heart tissue. Characterization of the gene by transient transfection analysis has identified a region between bases -389 and -325 which is necessary for expression. The specific deletion of a potentially functional inverted CCAAT sequence within this region does not significantly alter activity, In addition to the region from -389 and -325, deletion of the bases between -1 and -159 and between -186 and -211 significantly alters expression. Both of these regions are downstream from the beta(1)-adrenergic receptor gene start sites and may function either through regulation of transcription or through alteration of the transcript structure.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University	SEARLES, RP (corresponding author), OREGON REG PRIMATE RES CTR,DIV NEUROSCI,505 NW 185TH AVE,BEAVERTON,OR 97006, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042358, F32HL008189, R01HL042358] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0163] Funding Source: Medline; NHLBI NIH HHS [HL42358, HL08189] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRODDE OE, 1991, PHARMACOL REV, V43, P203; COHEN JA, 1993, DNA CELL BIOL, V12, P537, DOI 10.1089/dna.1993.12.537; COLLINS S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P171, DOI 10.1016/0167-4781(93)90287-N; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FENG P, 1990, J BIOL CHEM, V265, P2022; FRIELLE T, 1988, TRENDS NEUROSCI, V11, P321, DOI 10.1016/0166-2236(88)90095-1; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GAO B, 1994, J BIOL CHEM, V269, P15762; GILMAN M, 1993, CURRENT PROTOCOLS MO; GRANNEMAN JG, 1992, MOL PHARMACOL, V40, P895; HANDY DE, 1992, J BIOL CHEM, V267, P24017; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V171, P46; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MAHAN LC, 1987, ANNU REV PHARMACOL, V27, P215; MANN KP, 1993, MOL CELL BIOL, V9, P2411; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NICHOLAS AP, 1993, NEUROSCIENCE, V56, P1023, DOI 10.1016/0306-4522(93)90148-9; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SEARLES RP, 1994, DNA SEQUENCE, V4, P231, DOI 10.3109/10425179409020846; STEGGLES AW, 1989, BIOTECHNIQUES, V7, P241	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					157	162		10.1074/jbc.270.1.157	http://dx.doi.org/10.1074/jbc.270.1.157			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814367	hybrid			2022-12-25	WOS:A1995QA28700028
J	STEWART, AE; ARFIN, SM; BRADSHAW, RA				STEWART, AE; ARFIN, SM; BRADSHAW, RA			THE SEQUENCE OF PORCINE PROTEIN NH2-TERMINAL ASPARAGINE AMIDOHYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POST-TRANSLATIONAL MODIFICATION; ESCHERICHIA-COLI; BINDING-SITES; GENE; PURIFICATION; SPECIFICITY; RESIDUE; LIGASE; CELLS	Co- and post translational amino-terminal processing of proteins is one mechanism by which intracellular proteins can be either protected from or targeted to degradation by the N-end Rule pathway (Bachmair, A., Finley, D., and Varshavsky, A. (1986) Science 234, 179-186). A novel enzyme, protein NH2-terminal asparagine amidohydrolase, which can function in this pathway by potentially directing critical regulatory proteins possessing an amino-terminal asparagine residue formed from the removal of N-acetylmethionine, has recently been purified and characterized (Stewart, A. E., Arfin, S. M., and Bradshaw, R. A. (1994) J. Biol. Chem. 269, 23509-23517). Here, we report the isolation and characterization of a cDNA for porcine protein NH2-terminal asparagine amidohydrolase, which indicates that it is a new type of enzyme, not homologous to any previously identified protein, This provides strong evidence for the importance of regulated protein degradation in cellular functioning.	UNIV CALIF IRVINE,SCH MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIDDK NIH HHS [DK-32456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; AUSEBEL FM, 1987, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BONTHRON DT, 1990, GENE, V91, P101, DOI 10.1016/0378-1119(90)90168-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; Sambrook J, 1989, MOL CLONING LABORATO; SOFFER RL, 1973, MOL CELL BIOCHEM, V2, P3, DOI 10.1007/BF01738673; SPRING KJ, 1986, J BACTERIOL, V166, P135, DOI 10.1128/jb.166.1.135-142.1986; STEWART AE, 1994, J BIOL CHEM, V269, P23509; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1010, DOI 10.1021/bi00218a018	24	18	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					25	28		10.1074/jbc.270.1.25	http://dx.doi.org/10.1074/jbc.270.1.25			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814382	hybrid			2022-12-25	WOS:A1995QA28700007
J	TAO, Y; CHEN, KY				TAO, Y; CHEN, KY			PURIFICATION OF DEOXYHYPUSINE SYNTHASE FROM NEUROSPORA-CRASSA TO HOMOGENEITY BY SUBSTRATE ELUTION AFFINITY-CHROMATOGRAPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL FORMATION; SPERMIDINE DEHYDROGENASE; POLYACRYLAMIDE GELS; PROTEIN; POLYAMINES; HYPUSINE; BINDING	Deoxyhypusine synthase is an NAD(+)-dependent enzyme that catalyzes the formation of deoxyhypusine residue on the eIF-5A precursor by using spermidine as the substrate. Deoxyhypusine synthase bound tightly to 1,12-diaminododecane-agarose and could be eluted selectively by spermidine. This finding enabled us to develop a simple two column procedure to purify deoxyhypusine synthase from Neurospora crassa to apparent homogeneity. The purified enzyme had a specific activity of 130,000 units/mg of protein, representing a 64,000-fold purification from cell extracts. Size exclusion chromatography indicated that the native enzyme had a molecular mass of 180 kDa. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the pure enzyme showed a single band at the 40-kDa position, suggesting that Neurospora deoxyhypusine synthase is a homotetramer. Deoxyhypusine synthase appeared to be hydrophobic and required non-ionic detergent such as Tween 20 to stabilize the activity. Treatment of the enzyme with sulfhydryl reagents resulted in a complete loss of activity. Inclusion of NAD(+) reduced the inactivation rate by manyfold, indicating the presence of -SH groups at or near the active site. Partial amino acid sequences of four peptide fragments that cover about one quarter of the enzyme were obtained for cDNA and genomic cloning work.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,GRAD PROGRAM BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick				Chen, Kuang Yu/0000-0002-5629-7785	NATIONAL CANCER INSTITUTE [R01CA049695] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; COHEN SS, 1971, INTRO POLYAMINES, P1; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DOU QP, 1990, BIOCHIM BIOPHYS ACTA, V1036, P128, DOI 10.1016/0304-4165(90)90024-Q; HISANO T, 1992, BIOSCI BIOTECH BIOCH, V56, P1916, DOI 10.1271/bbb.56.1916; JAKUS J, 1993, J BIOL CHEM, V268, P13151; OKADA M, 1979, J BIOCHEM, V85, P1225; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1984, J BIOL CHEM, V259, P4563; SCARBOROUGH GA, 1975, J BIOL CHEM, V250, P1106; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAO Y, 1994, BIOCHEM J, V302, P517, DOI 10.1042/bj3020517; TAO Y, 1994, ANAL BIOCHEM, V221, P103, DOI 10.1006/abio.1994.1385; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704	18	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					383	386		10.1074/jbc.270.1.383	http://dx.doi.org/10.1074/jbc.270.1.383			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814398	hybrid			2022-12-25	WOS:A1995QA28700060
J	BARRY, J; ALBERTS, B				BARRY, J; ALBERTS, B			A ROLE FOR 2 DNA HELICASES IN THE REPLICATION OF T4-BACTERIOPHAGE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ACCESSORY PROTEINS; RNA-POLYMERASE; DDA PROTEIN; HOLOENZYME; APPARATUS; PURIFICATION; TEMPLATE; INVITRO; PASS; FORK	The T4 bacteriophage gene 41 protein is the highly processive DNA helicase of the T4 primosome, a central part of the protein machinery that moves the T4 DNA replication fork. The T4 gene 59 protein accelerates the loading of 41 protein onto DNA covered with 32 protein (the T4 single strand binding protein), and it makes the 41 protein DNA helicase activity rapidly available to catalyze replication fork movement through a DNA double helix (Barry, J., and Alberts, B. M. (1994) J. Biol. Chem. 269, 33049-33062). With the aid of the 59 protein, we show that the T4 primosome (the T4 gene 41 and 61 proteins) can move rapidly through a promoter-bound RNA polymerase molecule that would otherwise stop replication fork movement. A second, very different DNA helicase, the T4 dda protein, provides an alternative pathway for replication past this DNA-bound RNA polymerase (Bedinger, P., Hochstrasser, M., Jongeneel, C. V., and Alberts, B. M. (1983) Cell 34, 115-123). Combined with other data, these in vitro experiments allow us to propose a model that explains why either the 59 protein or the dda protein, but not both, are required to begin efficient DNA replication inside the T4 bacteriophage-infected cell.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM24020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2933; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LIU CC, 1981, J BIOL CHEM, V256, P2813; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1975, P NATL ACAD SCI USA, V72, P4800, DOI 10.1073/pnas.72.12.4800; MOSIG G, 1983, BACTERIOPHAGE T4, P120; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; Nossal Nancy G., 1994, P43; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SINHA NK, 1980, J BIOL CHEM, V255, P4290; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; YONESAKI T, 1990, J BIOL CHEM, V269, P1284; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	29	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33063	33068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806534				2022-12-25	WOS:A1994QA63800051
J	TAMAOKA, A; ODAKA, A; ISHIBASHI, Y; USAMI, M; SAHARA, N; SUZUKI, N; NUKINA, N; MIZUSAWA, H; SHOJI, S; KANAZAWA, I; MORI, H				TAMAOKA, A; ODAKA, A; ISHIBASHI, Y; USAMI, M; SAHARA, N; SUZUKI, N; NUKINA, N; MIZUSAWA, H; SHOJI, S; KANAZAWA, I; MORI, H			APP717 MISSENSE MUTATION AFFECTS THE RATIO OF AMYLOID-BETA PROTEIN SPECIES (A-BETA-1-42/43 AND A-BETA-1-40) IN FAMILIAL ALZHEIMERS-DISEASE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PRECURSOR PROTEIN; PEPTIDE; GENE; CODON-717; DEPOSITS; VAL->ILE; PLAQUE	We have biochemically purified A beta from brains of two unrelated familial Alzheimer's disease (FAD) pedigrees with the APP717 mutation (Val --> Ile) and from two sporadic Alzheimer's disease (AD) brains and characterized them by means of mass spectrometry and enzyme-linked immunosorbent assay, We observed two types of amyloid beta protein (A beta), the short-tail form (A beta 1-40) and the long tail form (A beta 1-42/43), in sporadic AD and FAD brains, and found that the ratio of the long-tail form of A beta (A beta 1-42/43) to total A beta was increased in FAD brains. These in vivo results were confirmed in vitro using cultured cells transfected with three kinds of APP cDNAs bearing the APP717 mutations (Val --> Ile, Gly, or Phe). Taken together with the hypothesis that A beta 1-42/43 functions as a ''seed'' that increases the kinetics of amyloid fibril formation (Jarrett, J. T., and Lansbury, P. T., Jr. (1993) Cell 73, 1055-1058), we conclude that the APP717 missense mutation does not create new A beta species but promotes the increased accumulation of A beta 1-42/43 in the brain, which results in the enhancement of amyloid fibril formation from soluble A beta. These findings provide a causal relationship between this FAD genotype and the pathological phenotype of A beta deposition and senile plaque formation.	TOKYO INST PSYCHIAT,DEPT MOLEC BIOL,SETAGAYA KU,TOKYO 156,JAPAN; UNIV TSUKUBA,INST CLIN MED,DEPT NEUROL,TSUKUBA,IBARAKI 305,JAPAN; TAKEDA CHEM IND LTD,DIV DISCOVERY RES,TSUKUBA,IBARAKI 30042,JAPAN; UNIV TOKYO,SCH MED,INST BRAIN RES,DEPT NEUROL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Institute of Psychiatry; University of Tsukuba; Takeda Chemical Industries; University of Tokyo			Nukina, Nobuyuki/GPP-6265-2022					CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; FRUCHT SJ, 1992, J NEUROPATH EXP NEUR, V51, P369; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; LADROR US, 1994, J BIOL CHEM, V269, P18422; LIEPNIEKS JJ, 1993, BIOCHEM BIOPH RES CO, V197, P386, DOI 10.1006/bbrc.1993.2491; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MIZUSAWA H, 1992, 33RD P ANN M JAP SOC, P140; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI H, 1992, J BIOL CHEM, V267, P17082; MULLAN M, 1993, NEUROBIOL AGING, V14, P407, DOI 10.1016/0197-4580(93)90099-W; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SHOJI M, 1992, SCIENCE, V58, P126; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; YOSHIZAWA T, 1993, J NEUROL SCI, V117, P12, DOI 10.1016/0022-510X(93)90147-Q	23	154	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32721	32724						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806491				2022-12-25	WOS:A1994QA63800004
J	THOMPSON, J; ZIMMERMANN, W; NOLLAU, P; NEUMAIER, M; WEBERARDEN, J; SCHREWE, H; CRAIG, I; WILLCOCKS, T				THOMPSON, J; ZIMMERMANN, W; NOLLAU, P; NEUMAIER, M; WEBERARDEN, J; SCHREWE, H; CRAIG, I; WILLCOCKS, T			CGM2, A MEMBER OF THE CARCINOEMBRYONIC ANTIGEN GENE FAMILY IS DOWN-REGULATED IN COLORECTAL CARCINOMAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-REACTING ANTIGEN; IMMUNOGLOBULIN SUPERGENE FAMILY; BILIARY GLYCOPROTEIN GENE; CELL-ADHESION MOLECULE; GLYCOSYL-PHOSPHATIDYLINOSITOL; MONOCLONAL-ANTIBODIES; GENOMIC ORGANIZATION; SEQUENCE-ANALYSIS; CEA; EXPRESSION	We have determined the precise chromosomal location, the exon structure, and the expression pattern of CGM2, a member of the carcinoembryonic antigen (CEA) gene family. CGM2 cDNA was amplified by reverse transcription-polymerase chain reaction (RT/PCR) from the colon adenocarcinoma cell line, LS174T. A defective exon is missing from this cDNA clone, leading to a novel domain organization for the human CEA family with two immunoglobulin-like domains. The derived C-terminal domain predicts that the CGM2 protein is membrane-bound through a glycosyl phosphatidylinositol anchor. RT/PCR analyses identified CGM2 transcripts in mucinous ovarian and colonic adenocarcinomas as well as in adjacent colonic tissue, but not in other tumors including leukocytes from six chronic myeloid leukemia patients. Thus, unlike several other family members, CGM2 is not expressed in granulocytes but reveals a more CEA-like expression pattern. Northern blot analyses identified a 2.5-kilobase CGM2 mRNA that is strongly downregulated in colonic adenocarcinomas compared with adjacent colonic mucosa, suggesting a possible tumor suppressor function. In addition, a 3.2-kilobase transcript was observed in a number of colon tumors that is not detectable in normal colonic tissue. This mRNA species could represent a tumor-specific CGM2 splice variant.	UNIV HAMBURG,HOSP EPPENDORF,DEPT CLIN CHEM,D-20251 HAMBURG,GERMANY; UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; NATL UNIV IRELAND UNIV COLL DUBLIN,CTR BIOTECHNOL,DUBLIN 4,IRELAND	University of Hamburg; University of Oxford; University College Dublin	THOMPSON, J (corresponding author), UNIV FREIBURG,INST IMMUNBIOL,STEFAN MEIER STR 8,D-79104 FREIBURG,GERMANY.		Zimmermann, Wolfgang/L-9277-2013; Craig, Ian/AAF-9167-2019	Craig, Ian/0000-0002-4063-1005				AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BENCHIMOL S, 1987, CELL, V57, P327; BERLING B, 1990, CANCER RES, V50, P6534; BOUCHER D, 1989, CANCER RES, V49, P847; BRANDRIFF BF, 1992, GENOMICS, V12, P773, DOI 10.1016/0888-7543(92)90308-F; CHI KF, 1991, TUMOR BIOL, V12, P298, DOI 10.1159/000217718; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIEL S, 1993, INT J CANCER, V55, P303, DOI 10.1002/ijc.2910550222; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HASHINO J, 1994, BIOCHEM BIOPH RES CO, V200, P1748, DOI 10.1006/bbrc.1994.1655; HEFTA LJF, 1990, CANCER RES, V50, P2397; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIXSON DC, 1989, CANCER RES, V49, P6788; KODELJA V, 1989, J BIOL CHEM, V264, P6906; KOLBINGER F, 1989, BIOCHEM BIOPH RES CO, V161, P1126, DOI 10.1016/0006-291X(89)91359-4; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUROKI M, 1991, J BIOL CHEM, V266, P11810; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; MAHRENHOLZ AM, 1993, J BIOL CHEM, V268, P13015; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NAP M, 1988, TUMOR BIOL, V9, P145, DOI 10.1159/000217555; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; STOFFEL A, 1993, J IMMUNOL, V150, P4978; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; TEGLUND S, 1994, GENOMICS, V23, P669, DOI 10.1006/geno.1994.1556; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON J, 1993, INT J CANCER, V55, P311, DOI 10.1002/ijc.2910550223; THOMPSON J, 1990, BIOCHEM BIOPH RES CO, V167, P848, DOI 10.1016/0006-291X(90)92103-7; THOMPSON J, 1989, CARCINOEMBRYONIC ANT, P65; THOMPSON JA, 1987, P NATL ACAD SCI USA, V84, P2965, DOI 10.1073/pnas.84.9.2965; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; TORIBARA NW, 1989, CANCER RES, V49, P3321; TYNAN K, 1992, NUCLEIC ACIDS RES, V20, P1629, DOI 10.1093/nar/20.7.1629; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLCOCKS TC, 1990, GENOMICS, V8, P492, DOI 10.1016/0888-7543(90)90036-T; WILLCOCKS TC, 1989, ANN HUM GENET, V53, P141, DOI 10.1111/j.1469-1809.1989.tb01778.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZIMMERMANN W, 1987, P NATL ACAD SCI USA, V84, P2960, DOI 10.1073/pnas.84.9.2960	53	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32924	32931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806520				2022-12-25	WOS:A1994QA63800033
J	THONBERG, H; ZHANG, SJ; TVRDIK, P; JACOBSSON, A; NEDERGAARD, J				THONBERG, H; ZHANG, SJ; TVRDIK, P; JACOBSSON, A; NEDERGAARD, J			NOREPINEPHRINE UTILIZES ALPHA(1)-ADRRENOCEPTORS AND BETA-ADRENOCEPTORS SYNERGISTICALLY TO MAXIMALLY INDUCE C-FOS EXPRESSION IN BROWN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN THERMOGENIN; ADIPOSE-TISSUE; GENE-EXPRESSION; FAT-CELLS; GROWTH-HORMONE; ADRENERGIC CONTROL; KINASE-C; PROTOONCOGENES FOS; 3T3-L1 FIBROBLASTS; PRIMARY CULTURE	In order to examine how norepinephrine stimulates proliferation and differentiation in brown fat cells, we have investigated the ability of brown fat cells to respond to norepinephrine stimulation with an increase in the expression of the proto-oncogene c-fos. Stimulation of brown fat precursor cells (isolated from young mice and grown for 4 days in culture) with norepinephrine led to a marked but transient (maximal approximate to 30 min) induction of c-fos expression. The magnitude of this induction was similar in pre- and postconfluent cells, The norepinephrine effect could be blocked by both alpha(1)- and beta-adrenergic antagonists. Forskolin had a small inductive ability, as had the selective alpha(1)-agonist cirazoline, but with both together a high induction was obtained, The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) could in itself induce c-fos expression, but pretreatment with TPA did not abolish the ability of norepinephrine to induce c-fos expression, indicating that TPA sensitive protein kinase C was not a primary mediator in this pathway. Also the Ca2+ ionophore A23187 had in itself an inductive ability, but A23187 in combination with forskolin led to a large increase in c-fos expression, indicating synergistic interaction between a cAMP pathway and a [Ca2+](i) pathway. This interaction was not proximal, i.e. alpha(1) stimulation or increase in [Ca2+](i) by A23187 did not augment forskolin induced cAMP levels, and beta stimulation or forskolin did not affect [Ca2+](i) levels; and it did not require protein synthesis. It was concluded that norepinephrine, in agreement with its fundamental role in the control of brown fat cell growth and development, was able to induce c-fos expression, that this induction was not exclusively linked to promotion of either proliferation or differentiation, and that the induction was mediated via a distal synergism between beta/cAMP and alpha(1)/[Ca2+](i) pathways, thus conferring to the alpha(1)-adrenoreceptors on the cell a potentially significant role in the control of cell growth and development.			THONBERG, H (corresponding author), UNIV STOCKHOLM, WENNER GREN INST, ARRHENIUS LABS F3, S-10691 STOCKHOLM, SWEDEN.		Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Tvrdik, Petr/AAK-4398-2021	Tvrdik, Petr/0000-0002-8750-9672; Nedergaard, Jan/0000-0003-2070-1587				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASHCOM G, 1992, ENDOCRINOLOGY, V131, P1915, DOI 10.1210/en.131.4.1915; BARCELLINICOUGET S, 1994, BIOCHEM BIOPH RES CO, V199, P136, DOI 10.1006/bbrc.1994.1205; BARCELLINICOUGET S, 1993, ENDOCRINOLOGY, V132, P53, DOI 10.1210/en.132.1.53; BARGE RM, 1988, AM J PHYSIOL, V254, pE323, DOI 10.1152/ajpendo.1988.254.3.E323; BORNER C, 1992, J BIOL CHEM, V267, P12892; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; BRASELMANN S, 1992, J CELL SCI, P97; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CHAMPIGNY O, 1992, MOL CELL ENDOCRINOL, V86, P73, DOI 10.1016/0303-7207(92)90177-8; CONNOLLY E, 1984, EUR J BIOCHEM, V141, P187, DOI 10.1111/j.1432-1033.1984.tb08173.x; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CUNNINGHAM SA, 1987, BIOCHEM J, V245, P485, DOI 10.1042/bj2450485; CURRAN T, 1993, ADV SEC MESS PHOSPH, V28, P271; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DICKER A, 1992, AM J PHYSIOL, V263, pE654, DOI 10.1152/ajpendo.1992.263.4.E654; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOSTER DO, 1985, INT J OBESITY, V9, P25; GABELLINI N, 1991, EXP CELL RES, V194, P210, DOI 10.1016/0014-4827(91)90356-Y; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; GRANNEMAN JG, 1988, J PHARMACOL EXP THER, V245, P1075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HEICK HMC, 1973, CAN J PHYSIOL PHARM, V51, P751, DOI 10.1139/y73-114; HERRON D, 1989, AM J PHYSIOL, V257, pC920, DOI 10.1152/ajpcell.1989.257.5.C920; HERRON D, 1990, FEBS LETT, V268, P296, DOI 10.1016/0014-5793(90)81031-I; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1018, P243, DOI 10.1016/0005-2728(90)90258-6; JACOBSSON A, 1986, BIOSCIENCE REP, V6, P621, DOI 10.1007/BF01114756; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; LEE SC, 1993, AM J PHYSIOL, V264, pC217, DOI 10.1152/ajpcell.1993.264.1.C217; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; MOHELL N, 1984, MOL PHARMACOL, V25, P64; MOHELL N, 1983, EUR J PHARMACOL, V93, P183, DOI 10.1016/0014-2999(83)90136-X; MOHELL N, 1983, EUR J PHARMACOL, V92, P15, DOI 10.1016/0014-2999(83)90103-6; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORY G, 1984, FEBS LETT, V166, P393, DOI 10.1016/0014-5793(84)80120-9; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; NANBERG E, 1984, BIOCHIM BIOPHYS ACTA, V804, P291, DOI 10.1016/0167-4889(84)90132-0; NANBERG E, 1986, FEBS LETT, V195, P319, DOI 10.1016/0014-5793(86)80185-5; NANBERG E, 1987, BIOCHIM BIOPHYS ACTA, V930, P438, DOI 10.1016/0167-4889(87)90017-6; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; NEDERGAARD J, 1994, OBESITY EUROPE 1993, P69; PAVELKA S, 1993, BIOCHEM J, V292, P303, DOI 10.1042/bj2920303; PICO C, 1994, BIOCHEM J, V302, P81, DOI 10.1042/bj3020081; PUIGSERVER P, 1992, BIOCHEM J, V284, P393, DOI 10.1042/bj2840393; RAASMAJA A, 1990, ACTA PHYSIOL SCAND, V139, P7; RAASMAJA A, 1989, ENDOCRINOLOGY, V125, P2502, DOI 10.1210/endo-125-5-2502; RAASMAJA A, 1988, BIOCHEM J, V249, P831, DOI 10.1042/bj2490831; RAASMAJA A, 1984, BIOSCIENCE REP, V4, P851, DOI 10.1007/BF01138167; RAASMAJA A, 1984, EUR J PHARMACOL, V106, P489, DOI 10.1016/0014-2999(84)90052-9; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REHNMARK S, 1993, FEBS LETT, V318, P235, DOI 10.1016/0014-5793(93)80519-Z; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHIMMEL RJ, 1983, AM J PHYSIOL, V244, pC362, DOI 10.1152/ajpcell.1983.244.5.C362; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1993, ADV NEUROL, V59, P285; SPIEGELMAN BM, 1988, J CELL BIOL, V107, P829, DOI 10.1083/jcb.107.3.829; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUMANTRAN VN, 1992, ENDOCRINOLOGY, V130, P2016, DOI 10.1210/en.130.4.2016; UEHARA T, 1991, BIOCHIM BIOPHYS ACTA, V1088, P41, DOI 10.1016/0167-4781(91)90151-B; VALVERDE AM, 1991, EXP CELL RES, V194, P232, DOI 10.1016/0014-4827(91)90359-3; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WILCKE M, 1989, BIOCHEM BIOPH RES CO, V163, P292, DOI 10.1016/0006-291X(89)92134-7; YAMASHITA H, 1994, ADV PHARM SCI TEMPER, P241	74	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33179	33186						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806548				2022-12-25	WOS:A1994QA63800068
J	BERG, JP; REE, AH; SANDVIK, JA; TASKEN, K; LANDMARK, BF; TORJESEN, PA; HAUG, E				BERG, JP; REE, AH; SANDVIK, JA; TASKEN, K; LANDMARK, BF; TORJESEN, PA; HAUG, E			1,25-DIHYDROXYVITAMIN D-3 ALTERS THE EFFECT OF CAMP IN THYROID-CELLS BY INCREASING THE REGULATORY SUBUNIT TYPE II-BETA OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; MOLECULAR-CLONING; CYCLIC-AMP; CDNA STRUCTURE; HORMONAL-REGULATION; RIBONUCLEIC-ACID; IODIDE UPTAKE; HUMAN TESTIS; RI-BETA; RAT	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) attenuates the stimulatory effects of cAMP on proliferation and iodide uptake in rat thyroid FRTL-5 cells. This study examines the effects of 1,25-(OH)(2)D-3 on the cAMP-dependent protein kinase (PKA). Cytosol proteins separated by anion exchange chromatography showed increased [H-3]cAMP binding activity as well as increased kinase activity in the fractions containing PKA type II in 1,25(OH)(2)D-3 (10 nM)-treated cells compared to the control cells, Western blot analysis of 1,25-(OH)(2)D-3-treated cells revealed a 4-fold increase in the cytosolic amount of the PKA regulatory subunit RII beta, whereas no changes were detected in the regulatory subunits RI alpha and RII alpha or the catalytic (C) subunit. Northern blot analyses showed a similar increase in RII beta mRNA in cells treated for 12 h with 1,25-(OH)(2)D-3 (10 nM), and RII beta mRNA increased further to 10-fold above control cell level after 96 h of incubation. Iodide uptake was synergistically stimulated with both PKAI- and PKAII-directed pairs of cAMP analogs, The PKAI synergism was, however, inhibited by 1,25-(OH)(2)D-3 treatment of the cells, whereas the PKAII synergism was unaffected. In conclusion, 1,25-(OH)(2)D-3 attenuates both PKAI formation and PKAI-stimulated iodide uptake in rat thyroid FRTL-5 cells by increasing the level of RII beta without altering the other PKA subunit levels.	NORWEGIAN RADIUM HOSP, INST CANC RES, DEPT TISSUE CULTURE, N-0310 OSLO, NORWAY; UNIV OSLO, INST MED BIOCHEM, N-0317 OSLO, NORWAY	University of Oslo; University of Oslo	BERG, JP (corresponding author), AKER HOSP, HORMONE LAB, TRONDHEIMSVEIEN 235, N-0514 OSLO, NORWAY.		Landmark, Brynjar/AAK-2165-2020; Berg, Jens P/G-1455-2012	Berg, Jens P/0000-0003-0157-5888; Ree, Anne H./0000-0002-8264-3223				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BERG JP, 1994, J STEROID BIOCHEM, V50, P145, DOI 10.1016/0960-0760(94)90021-3; BERG JP, 1991, ACTA ENDOCRINOL-COP, V125, P574, DOI 10.1530/acta.0.1250574; BERG JP, 1994, ENDOCRINOLOGY, V135, P595, DOI 10.1210/en.135.2.595; BERG JP, 1993, THYROID, V3, P245, DOI 10.1089/thy.1993.3.245; BERG JP, 1991, MOL CELL ENDOCRINOL, V76, P201, DOI 10.1016/0303-7207(91)90274-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COBB CE, 1988, METHOD ENZYMOL, V159, P202; COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; EGAN JJ, 1988, ANAL BIOCHEM, V175, P552, DOI 10.1016/0003-2697(88)90583-0; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG-ALLARDT C, 1991, MOL CELL ENDOCRINOL, V81, P25, DOI 10.1016/0303-7207(91)90201-3; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OGREID D, 1989, EUR J BIOCHEM, V167, P27; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P1293; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5186; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SOLBERG R, 1991, BIOCHEM BIOPH RES CO, V176, P166, DOI 10.1016/0006-291X(91)90904-L; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TASKEN K, 1994, MOL CELL ENDOCRINOL, P185; TORTORA G, 1993, CELL GROWTH DIFFER, V4, P359; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANSANDE J, 1989, EUR J BIOCHEM, V183, P699, DOI 10.1111/j.1432-1033.1989.tb21101.x; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WALTER U, 1983, METHOD ENZYMOL, V99, P154; WALTERS MR, 1992, ENDOCR REV, V13, P4719; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P2123	48	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32233	32238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798223				2022-12-25	WOS:A1994PX30400036
J	KIMURA, M; HAMA, Y; SUMI, T; ASAKAWA, M; RAO, BNN; HORNE, AP; LI, SC; LI, YT; NAKAGAWA, H				KIMURA, M; HAMA, Y; SUMI, T; ASAKAWA, M; RAO, BNN; HORNE, AP; LI, SC; LI, YT; NAKAGAWA, H			CHARACTERIZATION OF A DEAMINATED NEURAMINIC ACID-CONTAINING GLYCOPROTEIN FROM THE SKIN MUCUS OF THE LOACH MISGURNUS-ANGUILLICAUDATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCAN CHAINS; RAINBOW-TROUT EGGS; RICH GLYCOPROTEIN; JELLY COAT; VITELLINE ENVELOPE; KDN; POLYSIALOGLYCOPROTEIN; CHROMATOGRAPHY; DETERMINANTS	Using NMR spectroscopy and mass spectrometry, the major sialic acid of the skin mucus of the leach, Misgurnus anguillicaudatus was found to be 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN). We have subsequently devised a method to isolate a KDN-containing glycoprotein preparation from leach skin mucus. The method involves the sonication of the skin mucus with 0.05 M Tris-HCl, pH 8.0, to solubilize the glycoprotein, followed by DE52-cellulose chromatography of the extract, Nuclease P-1 treatment, and Sepharose CL-4B gel filtration. The purified glycoprotein preparation was found to contain 38.5% KDN, 0.4% NeuAc, 24.6% GalNAc, 3.3% Gal, and 28.2% amino acids (w/w). The amino acid composition of this glycoprotein preparation revealed that it is unusually rich in Thr, and 6 amino acids, Thr, Ser, Glu (or Gin), Pro, Gly and Ala, account for 83% of the total amino acids. This glycoprotein is extremely poor in Cys, Met, Tyr, Phe, Arg, and Trp. Treatment of this glycoprotein with alkali resulted in the destruction of 83% of Thr suggesting that most of the sugar chains in this glycoprotein are linked through Thr. Alkaline borohydride treatment of 100 mg of the glycoprotein preparation, followed by Sephadex G-25 (superfine) gel filtration, yielded two major oligosaccharide alditols, I (15.4 mg) and II (15.6 mg). Using Liquid secondary ion mass spectrometry and methylation analysis, I was identified to be KDN alpha 2-->6GalNAc-ol and II, KDN alpha 2-->6(KDN alpha 2-->3)-GalNAc-ol. KDN alpha 2-->GalNAc is structurally similar to NeuAc alpha 2-->6GalNAc found in ovine submaxillary glycoprotein while II represents a novel structure which contains two sialic acids linked to a GalNAc through both alpha 2-->3 and alpha 2-->6 linkages. This structure has never been found in mucin type glycoproteins including mammalian epithelial mucin glycoproteins. This is the first report of the presence of a mucin type glycoprotein which contains ISDN instead of NeuAc or NeuGc in fish skin mucus.	TULANE UNIV, SCH MED, DEPT BIOCHEM, NEW ORLEANS, LA 70112 USA; SAGA UNIV, FAC AGR, DEPT APPL BIOL SCI, SAGA 840, JAPAN; KUMAMOTO UNIV, FAC EDUC, FOOD SCI LAB, KUMAMOTO 860, JAPAN; GLYCOMED INC, ALAMEDA, CA 94501 USA	Tulane University; Saga University; Kumamoto University					NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUDDECKE E, 1972, GLYCOPROTEINS      A, P535; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; FAILLARD H, 1972, GLYCOPROTEINS THEIR, P1246; GOTTSCHALK A, 1972, GLYCOPROTEINS THEIR, P810; HARRIS G, 1954, CHEM IND-LONDON, P249; Haverkamp J., 1982, SIALIC ACIDS CHEM ME, P127; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; LI YT, 1990, J BIOL CHEM, V265, P21629; NADANO D, 1986, J BIOL CHEM, V261, P1550; PICKERING AD, 1974, J FISH BIOL, V6, P111, DOI 10.1111/j.1095-8649.1974.tb04531.x; RAUVALA H, 1977, CARBOHYD RES, V56, P1, DOI 10.1016/S0008-6215(00)84231-7; ROSE MC, 1989, METHOD ENZYMOL, V179, P3; SARTIN JL, 1980, J BIOL CHEM, V255, P8633; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; WHITEAR M, 1984, BIOL INTEGUMENT, V2, P8; WOLD JK, 1977, COMP BIOCHEM PHYS B, V56, P215, DOI 10.1016/0305-0491(77)90002-5; YU RK, 1970, J LIPID RES, V11, P506	28	56	58	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32138	32143						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798209				2022-12-25	WOS:A1994PX30400021
J	SANADA, K; KOKAME, K; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y; FUKADA, Y				SANADA, K; KOKAME, K; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y; FUKADA, Y			ROLE OF HETEROGENEOUS N-TERMINAL ACYLATION OF RECOVERIN IN RHODOPSIN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING PROTEIN; ROD OUTER SEGMENTS; CGMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; LIGHT ADAPTATION; AMINO TERMINUS; ALPHA-SUBUNIT; RETINAL RODS; S-MODULIN; KINASE	Recoverin, a new member of the EF-hand superfamily, plays a critical role in the light/dark adaptation of retinal rods by regulating rhodopsin phosphorylation in a Ca2+-dependent manner. Recoverin is composed of four isoforms, each of which is modified at its N terminus by myristate (C14:0) or its structurally related fatty acid (C12:0, C14:2, or C14:1). Although the N-fatty acylation is implicated in protein-membrane and protein-protein interactions, the functional difference among the recoverin isoforms and the significance of the heterogeneous acylation have not been defined. Here we separated the heterogeneous recoverin into three fractions, C14:0-recoverin, C14:1-recoverin, and a mixture of C14:2- and C12:0- (C14:2/C12:0-) recoverin to evaluate the individual properties. Recoverin in every fraction bound Ca2+ as assessed by fluorescence spectroscopy and inhibited the light-dependent rhodopsin phosphorylation in the same range of free Ca2+ concentration (0.3-0.8 mu M). However, the magnitude of the inhibition at higher Ca2+ concentration was different among the isoforms and ranked in the same order of the hydrophobicity of the N fatty acyl groups: C14:0 > C14:1 > C14:2/C12:0. These results indicate that the diverged hydrophobicity of the recoverin N terminus plays an important role in the interaction with the membranes and/or its target protein but not with Ca2+.	UNIV TOKYO, GRAD SCH ARTS & SCI, DEPT LIFE SCI, MEGURO KU, TOKYO 153, JAPAN; OSAKA SANGYO UNIV, FAC ENGN, DEPT INFORMAT SYST ENGN, OSAKA 574, JAPAN; OSAKA UNIV, INST PROT RES, OSAKA 565, JAPAN	University of Tokyo; Osaka University			吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299; Sanada, Kamon/0000-0002-0280-8957				AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V86, P5262; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; POLANS AS, 1993, METH NEUROSCI, V15, P248; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	35	31	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15459	15462		10.1074/jbc.270.26.15459	http://dx.doi.org/10.1074/jbc.270.26.15459			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797536	hybrid			2022-12-25	WOS:A1995RG53800005
J	YUN, HY; EIPPER, BA				YUN, HY; EIPPER, BA			ADDITION OF AN ENDOPLASMIC-RETICULUM RETENTION RETRIEVAL SIGNAL DOES NOT BLOCK MATURATION OF ENZYMATICALLY ACTIVE PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE PROCESSING ENZYME; SECRETORY GRANULES; PROTEIN RETENTION; ATT-20 CELLS; EXPRESSION; INTERMEDIATE; ACTIVATION; CLEAVAGE; CONTAIN; DOMAIN	Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the COOH-terminal alpha-amidation of neural and endocrine peptides via a two-step reaction carried out in sequence by the monooxygenase and lyase domains contained in this bifunctional protein. Peptide alpha-amidation is thought to take place primarily in the secretory granules in which mature bioactive peptides are stored, and it is not known where in the secretory compartment newly synthesized PAM protein becomes enzymatically active. To address this question, PAM-3, a soluble bifunctional protein, was modified by addition of the KDEL endoplasmic reticulum (ER) retention/retrieval signal to its COOH terminus. PAM 3 KDEL protein stably expressed in hEK-293 cells or in AtT-20 cells was efficiently retained in the ER based on immunocytochemistry, pulse-chase experiments, and maintained endoglycosidase H sensitivity. The effect of the KDEL sequence was specific since PAM-3 with an inactive ER retention/retrieval signal (PAM-3-KDEV) moved through the secretory pathway Like wild type PAM-3. In AtT-20 cells, PAM-3-KDEL was not subjected to the COOH-terminal endoproteolytic cleavage that generates a 75 kDa PAM protein from PAM-3 and PAM-3 KDEV. PAM-3-KDEL protein exhibited both monooxygenase and lyase activities with specific activities similar to those of the wild type PAM-3 and PAM-3-KDEV proteins. Thus, although PAM catalyzes a reaction that occurs primarily in the secretory granules, newly synthesized PAM protein becomes enzymatically competent in the ER.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R01DK032949, R37DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ANDRES DA, 1991, J BIOL CHEM, V266, P14277; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; DENECKE J, 1992, EMBO J, V11, P2345, DOI 10.1002/j.1460-2075.1992.tb05294.x; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; FISHER JM, 1988, J BIOL CHEM, V263, P16515; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VINDROLA O, 1993, MOL ENDOCRINOL, V6, P1441; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; YUN HY, 1994, J BIOL CHEM, V269, P10946; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P777; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633; ZHOU A, 1994, J BIOL CHEM, V269, P17440	39	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15412	15416		10.1074/jbc.270.25.15412	http://dx.doi.org/10.1074/jbc.270.25.15412			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797530	hybrid			2022-12-25	WOS:A1995RE66600084
J	MILBURN, JL; HIROSE, H; LEE, YH; NAGASAWA, Y; OGAWA, A; OHNEDA, M; BELTRANDELRIO, H; NEWGARD, CB; JOHNSON, JH; UNGER, RH				MILBURN, JL; HIROSE, H; LEE, YH; NAGASAWA, Y; OGAWA, A; OHNEDA, M; BELTRANDELRIO, H; NEWGARD, CB; JOHNSON, JH; UNGER, RH			PANCREATIC BETA-CELLS IN OBESITY - EVIDENCE FOR INDUCTION OF FUNCTIONAL, MORPHOLOGIC, AND METABOLIC ABNORMALITIES BY INCREASED LONG-CHAIN FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; GLUCOSE TRANSPORTERS; ISLETS; OXIDATION	To elucidate the mechanism of the basal hyperinsulinemia of obesity, we perfused pancreata from obese Zucker and lean Wistar rats with substimulatory concentrations of glucose, Insulin secretion at 4.2 and 5.6 mM glucose was similar to 10 times that of controls, whereas beta-cell volume fraction was increased only 4-fold and DNA per islet 3,5-fold. We therefore compared glucose usage at 1.4, 2.8, and 5.6 mM, Usage was 8-11.4 times greater in Zucker islets at 1.4 and 2.8 mM and 4 times greater at 5.6 mM; glucose oxidation at 2.8 and 5.6 mM glucose was >12 times lean controls, To determine if the high free fatty acid (FFA) levels of obesity induce these abnormalities, normal Wistar islets were cultured with 0, 1, or 2 mM long chain FFA for 7 days. Compared to islets cultured without EFA insulin secretion by FFA-cultured islets (2 mM) perifused with 1.4, 3, or 5.6 mM glucose was increased more than P-fold, bromodeoxyuridine incorporation was increased 3-fold, and glucose usage at 2.8 and 5.6 mM glucose was increased approximately 2-fold (1 mM FFA) and 3-fold (2 mM FFA), We conclude that hypersecretion of insulin by islets of obese Zucker fatty rats is associated with, and probably caused by, enhanced low K-m glucose metabolism and beta-cell hyperplasia, abnormalities that can be induced in normal islets by increased FFA.	UNIV TEXAS, SW MED CTR, CTR DIABET RES, GIFFORD LABS, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; DEPT VET AFFAIRS MED CTR, DALLAS, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK02700, 1-P01-DK42582] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582, R01DK002700, R37DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1981, ISLETS LANGERHANS BI, P117; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BERNE C, 1975, BIOCHEM J, V152, P661, DOI 10.1042/bj1520661; BERNSTEIN IA, 1957, METHOD ENZYMOL, V4, P561, DOI 10.1016/0076-6879(57)04071-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPBELL PJ, 1994, AM J PHYSIOL, V266, pE600, DOI 10.1152/ajpendo.1994.266.4.E600; CHAN CB, 1993, CAN J PHYSIOL PHARM, V71, P34, DOI 10.1139/y93-005; CRESPIN SR, 1969, J CLIN INVEST, V48, P1934, DOI 10.1172/JCI106160; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; GORDON ES, 1960, AM J CLIN NUTR, V8, P740, DOI 10.1093/ajcn/8.5.740; Grodsky G M, 1975, Methods Enzymol, V39, P364; HISATOMI A, 1985, J CLIN INVEST, V75, P420, DOI 10.1172/JCI111716; HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KARAM JH, 1963, DIABETES, V12, P197, DOI 10.2337/diab.12.3.197; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MADISON LL, 1968, METABOLISM, V17, P301, DOI 10.1016/0026-0495(68)90097-8; MATCHINSKY FM, 1980, DIABETES 1979, P154; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NAHER SP, 1980, DIABETOLOGIA, V19, P439; NILSSON NO, 1980, FEBS LETT, V111, P125, DOI 10.1016/0014-5793(80)80776-9; OGAWA A, 1992, J CLIN INVEST, V90, P497, DOI 10.1172/JCI115886; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; PORTE D, 1973, J CLIN INVEST, V52, P210, DOI 10.1172/JCI107168; RANDLE PJ, 1963, LANCET, V1, P785; RASSCHAERT J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P353, DOI 10.1016/0005-2728(90)90040-B; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; VOSSMCCOWAN ME, 1994, J BIOL CHEM, V269, P15814; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P101; YALOW RS, 1960, DIABETES, V9, P254, DOI 10.2337/diab.9.4.254; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1276, DOI 10.1210/endo-100-5-1276; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	39	267	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1295	1299		10.1074/jbc.270.3.1295	http://dx.doi.org/10.1074/jbc.270.3.1295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836394	hybrid			2022-12-25	WOS:A1995QB15600049
J	FUTEY, LM; MEDLEY, QG; COTE, GP; EGELHOFF, TT				FUTEY, LM; MEDLEY, QG; COTE, GP; EGELHOFF, TT			STRUCTURAL-ANALYSIS OF MYOSIN HEAVY-CHAIN KINASE-A FROM DICTYOSTELIUM - EVIDENCE FOR A HIGHLY DIVERGENT PROTEIN-KINASE DOMAIN, AN AMINO-TERMINAL COILED-COIL DOMAIN, AND A DOMAIN HOMOLOGOUS TO THE BETA-SUBUNIT OF HETEROTRIMERIC G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT-ELICITED INCREASES; CYCLIC-GMP; CONSERVED FEATURES; PHOSPHORYLATION; FAMILY; DISCOIDEUM; GENE; IDENTIFICATION; CYTOSKELETON; PURIFICATION	We report here the cloning and characterization of the gene encoding the 130-kDa myosin heavy chain kinase (MHCK A) from the amoeba Dictyostelium. Previous studies have shown that purified MHCK A phosphorylates threonines in the carboxyl-terminal tail portion of the Dictyostelium myosin II heavy chain and that phosphorylation of these sites is critical in regulating the assembly and disassembly of myosin II filaments in vitro and in vivo. Biochemical analysis of MHCK A, together with analysis of the primary sequence, suggests that the amino-terminal similar to 500 amino acids form an alpha-helical colied-coli domain and that residues from position similar to 860 to the carboxyl terminus (residue 1146) form a domain with significant similarity to the beta-subunit of heterotrimeric G proteins, No part of the MHCK A sequence displays significant similarity to the catalytic domain of conventional eukaryotic protein kinases, However, both native and recombinant MHCK A displayed autophosphorylation activity following renaturation from SDS gels, and MHCK A expressed in Escherichia coli phosphorylated purified Dictyostelium myosin, confirming that MHCK A is a bona fide protein kinase. Cross-linking studies demonstrated that native MHCK A is a multimer, consistent with the presence of an amino-terminal colied-coli domain, Southern blot analysis indicates that MHCK A is encoded by a single gene that has no detectable introns.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA	Case Western Reserve University; Queens University - Canada					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BERLOT CH, 1987, J BIOL CHEM, V262, P3918; CARBONI JM, 1985, J CELL BIOL, V100, P1884, DOI 10.1083/jcb.100.6.1884; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COTE GP, 1987, J BIOL CHEM, V262, P1065; COTE GP, 1987, J BIOL CHEM, V262, P13033; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KLUMPP DJ, 1988, J BACTERIOL, V170, P2763, DOI 10.1128/jb.170.6.2763-2769.1988; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIU G, 1988, J CELL SCI, V90, P123; LIU G, 1993, J CELL SCI, V106, P591; LIU G, 1991, J CELL SCI, V98, P483; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MARUTA H, 1983, EMBO J, V2, P535, DOI 10.1002/j.1460-2075.1983.tb01459.x; MEDLEY Q G, 1991, Journal of Cell Biology, V115, p29A; Medley Q.G., 1990, Protein Expression and Purification, V1, P155, DOI 10.1016/1046-5928(90)90010-V; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sambrook J, 1989, MOL CLONING LABORATO; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; TAN JL, 1991, J BIOL CHEM, V266, P16044; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5	47	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					523	529		10.1074/jbc.270.2.523	http://dx.doi.org/10.1074/jbc.270.2.523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822274	hybrid			2022-12-25	WOS:A1995QB81600006
J	PETRUSKA, J; GOODMAN, MF				PETRUSKA, J; GOODMAN, MF			ENTHALPY-ENTROPY COMPENSATION IN DNA MELTING THERMODYNAMICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE FIDELITY; PROTEINS; WATER; SEQUENCE; BINDING; ACIDS	We investigate enthalpy-entropy compensation for melting of nearest-neighbor doublets in DNA. Eased on data for 10 normal doublets and for doublets containing a mispaired or analog base, the correlation of Delta S degrees with Delta H degrees follows a rectangular hyperbola. Doublet melting temperature relates linearly to Delta H degrees by T-m = T-o + Delta H degrees/a, where T-o approximate to 273 K and a approximate to 80 cal/mol-K. Thus T-m is proportional to Delta H degrees + aT(o) rather than to Delta H degrees alone as previously thought by assuming Delta S degrees to be constant. The term aT(o) approximate to 21.8 kcal/mol may reflect a constant enthalpy change in solvent accompanying the DNA enthalpy change for doublet melting and is roughly equivalent to breaking four H-bonds between water molecules for each melted doublet. The solvent entropy change (aT(o)/T-m) declines with increasing T-m, while the DNA entropy change (Delta H degrees/T-m) rises, so the combined DNA + solvent entropy change stays constant at 80 cal/K/mol of doublet. If such constancy in DNA + solvent entropy changes also holds for enzyme clefts as ''solvent,'' then free energy differences for competing correct and incorrect base pairs in polymerase clefts may be as large as enthalpy differences and possibly sufficient to account for DNA polymerase accuracy. The hyperbolic relationship between Delta S degrees and Delta H degrees observed in 1 M salt can be used to evaluate Delta H degrees and Delta S degrees from T-m at lower, physiologically relevant, salt concentrations.			PETRUSKA, J (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.				NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM21422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; BLAKE RD, 1990, BIOPOLYMERS, V29, P393, DOI 10.1002/bip.360290211; BLAKE RD, 1987, BIOPOLYMERS, V26, P1063, DOI 10.1002/bip.360260706; BRESLAUER KJ, 1987, P NATL ACAD SCI USA, V84, P8922, DOI 10.1073/pnas.84.24.8922; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; DELCOURT SG, 1991, J BIOL CHEM, V266, P15160; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GAFFNEY BL, 1989, BIOCHEMISTRY-US, V28, P5881, DOI 10.1021/bi00440a026; GALAS DJ, 1978, J MOL BIOL, V88, P653; GOODMAN MF, 1988, MUTAT RES, V200, P11, DOI 10.1016/0027-5107(88)90067-X; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARKY LA, 1987, BIOPOLYMERS, V26, P1621, DOI 10.1002/bip.360260912; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MARTIN FH, 1971, J MOL BIOL, V57, P201, DOI 10.1016/0022-2836(71)90341-X; Pauling L., 1960, NATURE CHEM BOND, V3rd; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; PORSCHKE D, 1971, BIOPOLYMERS, V10, P1989, DOI 10.1002/bip.360101016; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; SARAI A, 1988, BIOCHEMISTRY-US, V27, P8498, DOI 10.1021/bi00422a030; Segel I.H., 1975, ENZYME KINETICS	24	82	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					746	750		10.1074/jbc.270.2.746	http://dx.doi.org/10.1074/jbc.270.2.746			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822305	hybrid			2022-12-25	WOS:A1995QB81600039
J	MA, YS; KOBRINSKY, E; MARKS, AR				MA, YS; KOBRINSKY, E; MARKS, AR			CLONING AND EXPRESSION OF A NOVEL TRUNCATED CALCIUM-CHANNEL FROM NONEXCITABLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; ALPHA-1 SUBUNIT; INDUCED-DIFFERENTIATION; SMOOTH-MUSCLE; CA2+ CHANNELS; ACINAR-CELLS; RECEPTOR; IDENTIFICATION	Calcium entry, via a dihydropyridine-sensitive pathway, is required for differentiation in murine erythroleukemia cells (MELC). Calcium channel currents have been identified physiologically in some non-excitable cells, but little is known regarding the structure of these channels. We show that a truncated form of the alpha(1) subunit of the cardiac voltage-gated calcium channel (dihydropyridine receptor, DHPR) is expressed in MELC. This MELC calcium channel lacks the first four transmembrane segments of the DHPR (IS1 to IS4). A MELC calcium channel/cardiac DHPR chimera, co-expressed with the alpha(2) and beta subunits of the DHPR, forms a functional calcium channel in Xenopus oocytes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,PROGRAM MOLEC MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,PROGRAM MOLEC MED,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NINDS NIH HHS [R01-NS29814] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029814] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; FRIEND C, 1977, HARVEY LECT, P253; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLO B, 1993, BLOOD, V81, P783; HALLAM TJ, 1989, TRENDS PHARMACOL SCI, V10, P8, DOI 10.1016/0165-6147(89)90092-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HENSOLD JO, 1991, BLOOD, V77, P1362; Hille B., 1992, IONIC CHANNELS EXCIT; HOCKBERGER PE, 1987, CELL MOL NEUROBIOL, V7, P229, DOI 10.1007/BF00711301; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; Maniatis T., 1982, MOL CLONING; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MASON WT, 1986, NEUROENDOCRINOLOGY, V43, P205, DOI 10.1159/000124529; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MELLONI E, 1988, P NATL ACAD SCI USA, V85, P3835, DOI 10.1073/pnas.85.11.3835; MERRITT JE, 1987, J BIOL CHEM, V262, P4958; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PECHT I, 1987, EMBO J, V6, P1935, DOI 10.1002/j.1460-2075.1987.tb02454.x; PENNER R, 1988, J EXP BIOL, V139, P329; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PURI TS, 1994, BIOPHYS J, V66, pA319; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RINK TJ, 1988, NATURE, V334, P649, DOI 10.1038/334649a0; Sambrook J, 1989, MOL CLONING LABORATO; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	41	28	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					483	493		10.1074/jbc.270.1.483	http://dx.doi.org/10.1074/jbc.270.1.483			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814415	hybrid			2022-12-25	WOS:A1995QA28700076
J	SANTOS, MA; GARCIARAMIREZ, JJ; REVUELTA, JL				SANTOS, MA; GARCIARAMIREZ, JJ; REVUELTA, JL			RIBOFLAVIN BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE - CLONING, CHARACTERIZATION, AND EXPRESSION OF THE RIB5 GENE ENCODING RIBOFLAVIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; YEAST; SEQUENCE; TRANSFORMATION; TRANSCRIPTION; PURIFICATION; MUTAGENESIS; PROTEIN; POLYMERASE	Saccharomyces cerevisiae has a monofunctional riboflavin synthase that catalyzes the formation of riboflavin from 6,7-dimethyl-8-ribityllumazine. We have isolated the gene encoding this enzyme from a yeast genomic library by functional complementation of a mutant, rib5-10, lacking riboflavin synthase activity. Deletion of the chromosomal copy of RIB5 led to riboflavin auxotrophy and loss of enzyme activity. Intragenic complementation between point and deletion mutant alleles suggested that the encoded protein (Rib5p) assembles into a multimeric complex and predicted the existence of a discrete functional domain located at the N terminus. Nucleotide sequencing revealed a 714-base pair open reading frame encoding a 25-kDa protein, Rib5p was purified to apparent homogeneity by a simple procedure. The specific activity of the enzyme was enriched 8500-fold. The N-terminal sequence of the purified enzyme was identical to the sequence predicted from the nucleotide sequence of the RIB5 gene. Initial structural characterization of riboflavin synthase by gel filtration chromatography and both nondenaturing pore limit and SDS-polyacrylamide gel electrophoresis showed that the enzyme forms a trimer of identical 25-kDa subunits. The derived amino acid sequence of RIB5 shows extensive homology to the sequences of the alpha subunits of riboflavin synthase from Bacillus subtilis and other prokaryotes. In addition, the sequence also shows internal homology between the N-terminal and the C-terminal halves of the protein. Taken together, these results suggest that the Rib5p subunit contains two structurally related (substrate binding) but catalytically different (acceptor and donator) domains.	UNIV SALAMANCA, DEPT GENET & MICROBIOL, E-37007 SALAMANCA, SPAIN	University of Salamanca			Revuelta, Jose L/C-2324-2012; Revuelta, Jose Luis/ABG-1502-2020; Santos, Maria Angeles/H-2239-2015; Garcia-Ramirez, Jose J/L-2153-2014	Revuelta, Jose L/0000-0001-7838-5308; Revuelta, Jose Luis/0000-0001-7838-5308; Santos, Maria Angeles/0000-0002-1257-7611; Garcia-Ramirez, Jose J/0000-0002-8348-3727				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CIGAN AM, 1987, GENE, V59, P1; DEMAIN AL, 1972, ANNU REV MICROBIOL, V26, P369, DOI 10.1146/annurev.mi.26.100172.002101; DOIGNON F, 1993, YEAST, V9, P189, DOI 10.1002/yea.320090210; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADENSTEIN R, 1986, J MOL BIOL, V187, P87, DOI 10.1016/0022-2836(86)90408-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MCNEIL JB, 1986, J MOL BIOL, V187, P363, DOI 10.1016/0022-2836(86)90439-0; OKANE DJ, 1991, P NATL ACAD SCI USA, V88, P110; OLTMANNS O, 1972, J BACTERIOL, V110, P818, DOI 10.1128/JB.110.3.818-822.1972; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; OTTO MK, 1981, EUR J BIOCHEM, V115, P511; PLAUT GWE, 1970, BIOCHEMISTRY-US, V9, P771, DOI 10.1021/bi00806a010; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; PLAUT GWE, 1971, COMPREHENSIVE BIOCH, V21, P11; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MD, 1988, CURR GENET, V14, P419; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; Sherman F., 1986, METHODS YEAST GENETI; SILVERMAN SJ, 1982, MOL CELL BIOL, V2, P1212, DOI 10.1128/MCB.2.10.1212; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; WICKERHAM LJ, 1951, TECH B US DEP AGRIC, V1029, P1; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	50	28	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					437	444		10.1074/jbc.270.1.437	http://dx.doi.org/10.1074/jbc.270.1.437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814407	hybrid			2022-12-25	WOS:A1995QA28700069
J	WANG, YL; MACDONALD, JIS; KENT, C				WANG, YL; MACDONALD, JIS; KENT, C			IDENTIFICATION OF THE NUCLEAR-LOCALIZATION SIGNAL OF RAT-LIVER CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHOLIPASE-C TREATMENT; MEMBRANE-ASSOCIATED CTP; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; LARGE-T; CELLS; PROTEIN; EXPRESSION	CTP:phosphocholine cytidylyltransferase (CT) is a major regulatory enzyme in phosphatidylcholine synthesis in mammalian cells, CT is found in both soluble and particulate forms, both of which are nuclear. We report here the identification of a al-residue sequence at the amino terminus of CT, (8)KVNSRKRRKEVPGPNGATEED(28), which was sufficient to direct beta-galactosidase into the cell nucleus. Further deletions from either end of this sequence greatly reduced the nuclear localization of beta-galactosidase. Deletions of amino acids within the nuclear localization signal or of the entire signal disrupted CT nuclear localization, but CT was not completely excluded from the nucleus. Clones of stable transfectants of the nuclear localization signal-deficient CT expressed in Chinese hamster ovary (CHO) 58 cells, which is temperature-sensitive for growth and CT activity, were isolated and characterized. The deletion mutants were active under the same conditions as the wildtype enzyme. Despite the difference in subcellular location from wild-type CT, the nuclear localization mutants were fully able to complement the CT-deficient cell line CHO 58 for both growth and choline incorporation into phosphatidylcholine at the nonpermissive temperature. The mobility of the mutant enzymes on SDS gels was altered relative to the mobility of wild-type CT; however, the extent of phosphorylation of the mutant enzymes was decreased only slightly. Thus, the distribution of CT in both cytoplasm and nucleus, rather than exclusively nucleus, has little effect on the ability of CT to function in growing CHO cells.	UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNELL R, 1989, J BIOL CHEM, V264, P9077; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELDMAN DA, 1993, J BIOL CHEM, V268, P3127; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HIGGINS JA, 1987, J LIPID RES, V28, P268; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MORAND JN, 1989, J BIOL CHEM, V264, P13785; PELECH SL, 1983, J BIOL CHEM, V258, P6782; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RUTHERFORD MS, 1992, GENOMICS, V18, P698; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; TERCE F, 1992, BIOCHEM J, V282, P333, DOI 10.1042/bj2820333; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	37	84	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					354	360		10.1074/jbc.270.1.354	http://dx.doi.org/10.1074/jbc.270.1.354			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814396	hybrid			2022-12-25	WOS:A1995QA28700056
J	ZHANG, Y; FILLINGAME, RH				ZHANG, Y; FILLINGAME, RH			CHANGING THE ION-BINDING SPECIFICITY OF THE ESCHERICHIA-COLI H+-TRANSPORTING ATP SYNTHASE BY DIRECTED MUTAGENESIS OF SUBUNIT-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONIGENIUM-MODESTUM; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; NA+/H+ ANTIPORTER; F1F0 ATPASE; UNC OPERON; F0; DICYCLOHEXYLCARBODIIMIDE; TRANSLOCATION; EXPRESSION	Most F1F0 type ATP synthases, including that in Escherichia coli, use H+ as the coupling ion for ATP synthesis. However, the structurally related F1F0 ATP synthase in Propionigenium modestum uses Na+ in stead. The binding site for Na+ resides in the F-0 sector of the P. modestum enzyme. We postulated that Na+ might interact with subunit c of F-0. Subunit c of P. modestum and E. coli are reasonably homologous (19% identity) but show striking variations around the H+-translocating, dicyclohexylcarbodiimide-reactive carboxyl (Asp(61) in E. coli). Several hydrophobic residues around Asp(61) were replaced with polar residues according to the P. modestum sequence in the hope that the polar replacements might provide liganding groups for Na+. One mutant from 31 different mutation combinations did generate an active enzyme that binds Li+, the combination being V60A, D61E, A62S, and I63T. Li+ binding was detected by Li+ inhibition of ATP-driven H+ transport, Li+ inhibition of F1F0-ATPase activity, and Li+ inhibition of F-0-mediated H+ transport. The Li+ effects were observed with membrane vesicles prepared from a Delta nhaA, Delta nhaB mutant background which lacks Na+/H+ antiporters, and with purified, reconstituted preparations of F-0 prepared from this background strain. Li+ inhibition was observed at pH 8.5 but not at pH 7.0. H+ thus appears to compete with Li+ for the binding site. Li+ binding was abolished by replacement of Glu(61) by Asp or Ser(62) by Ala. The side chains at Ala(60) and Thr(63) may act in a supporting structural role by providing a more flexible conformation for the Li+ binding cavity. Thr(63) does not appear to provide a liganding group since H+ transport in two other mutants, with Gly or Ala in place of Thr(63), was also inhibited by Li+. We suggest that a X-Glu-Ser-Y or X-Glu-Thr-Y sequence may provide a general structural motif for monovalent cation binding, and that the flexibility provided by residues X and Y will prove crucial to this structure.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023105, R37GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADGER J, 1994, BIOPHYS J, V66, P286, DOI 10.1016/S0006-3495(94)80795-7; BRUSILOW WSA, 1983, J BACTERIOL, V155, P1265, DOI 10.1128/JB.155.3.1265-1270.1983; DOWNIE JA, 1979, J BACTERIOL, V137, P711, DOI 10.1128/JB.137.2.711-718.1979; ESSER U, 1990, NUCLEIC ACIDS RES, V18, P5887, DOI 10.1093/nar/18.19.5887; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FIMMEL AL, 1983, BIOCHEM J, V213, P481; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1991, J BACTERIOL, V173, P2639, DOI 10.1128/jb.173.8.2639-2643.1991; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1990, THESIS U WISCONSIN M; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HILLE B, 1990, IONIC CHANNELS EXCIT, P261; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; KAIM G, 1993, EUR J BIOCHEM, V218, P937, DOI 10.1111/j.1432-1033.1993.tb18450.x; KAIM G, 1992, EUR J BIOCHEM, V207, P463, DOI 10.1111/j.1432-1033.1992.tb17072.x; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KLUGE C, 1992, BIOCHEMISTRY-US, V31, P12665, DOI 10.1021/bi00165a017; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; KLUGE C, 1993, J BIOL CHEM, V268, P14557; KLUGE C, 1994, FEBS LETT, V340, P245, DOI 10.1016/0014-5793(94)80147-9; LAUBINGER W, 1987, EUR J BIOCHEM, V168, P475, DOI 10.1111/j.1432-1033.1987.tb13441.x; LAUBINGER W, 1990, BIOCHEMISTRY-US, V29, P5458, DOI 10.1021/bi00475a008; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LUDWIG W, 1990, EUR J BIOCHEM, V193, P395, DOI 10.1111/j.1432-1033.1990.tb19352.x; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; PINNER E, 1993, J BIOL CHEM, V268, P1729; SCHNEIDER E, 1984, P NATL ACAD SCI USA, V51, P7279; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SONE N, 1977, J BIOCHEM-TOKYO, V82, P1751, DOI 10.1093/oxfordjournals.jbchem.a131873; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WEBER E, 1981, TOP CURR CHEM, V98, P1; ZHANG Y, 1994, J BIOL CHEM, V269, P5473; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	42	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					87	93		10.1074/jbc.270.1.87	http://dx.doi.org/10.1074/jbc.270.1.87			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814424	hybrid			2022-12-25	WOS:A1995QA28700019
J	PADLAN, EA; ABERGEL, C; TIPPER, JP				PADLAN, EA; ABERGEL, C; TIPPER, JP			IDENTIFICATION OF SPECIFICITY-DETERMINING RESIDUES IN ANTIBODIES	FASEB JOURNAL			English	Article						COMPLEMENTARITY-DETERMINING REGIONS; HUMANIZATION	3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; ANTIGEN COMPLEX; BINDING-SITE; LIGHT-CHAINS; COMPLEMENTARITY; PROTEIN; MOUSE; NEURAMINIDASE; RESOLUTION	The successful identification of the residues that contact ligand has important implications, especially in view of the increasing use of antibodies in various medical and industrial applications. Analysis of the crystallographically derived, three-dimensional Structures of five antibody-antigen complexes and of the available amino acid sequence data on antibody variable regions reveals that the residues that contact antigen are in the main also the most variable. It is proposed that a good first guess of the identity of the specificity-determining residues can be made from an examination of the variability values at sequence positions. New boundaries for the complementarity-determining regions are proposed.			PADLAN, EA (corresponding author), NIDDKD,MOLEC BIOL LAB,BLDG 5,ROOM 303,BETHESDA,MD 20892, USA.			Abergel, Chantal/0000-0003-1875-4049				ABERGEL C, 1994, RES IMMUNOL, V145, P49, DOI 10.1016/S0923-2494(94)80043-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E A, 1978, Adv Protein Chem, V32, P1, DOI 10.1016/S0065-3233(08)60574-4; KABAT EA, 1977, J BIOL CHEM, V252, P6609; KABAT EA, 1991, PHS NIH913242 PUBL; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1977, P NATL ACAD SCI USA, V74, P2551, DOI 10.1073/pnas.74.6.2551; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PADLAN EA, 1992, IMMUNOMETHODS, V1; PADLAN EA, 1994, IN PRESS ANTIBODY AN; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PRASAD L, 1988, J BIOL CHEM, V263, P2571; SCHLOM J, 1991, BIOL THERAPY CANCER, P464; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; [No title captured]	31	112	350	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					133	139		10.1096/fasebj.9.1.7821752	http://dx.doi.org/10.1096/fasebj.9.1.7821752			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821752				2022-12-25	WOS:A1995QD20200021
J	ROBERTS, VA; GETZOFF, ED				ROBERTS, VA; GETZOFF, ED			METALLOANTIBODY DESIGN	FASEB JOURNAL			English	Article						METALLOPROTEIN; PROTEIN DESIGN; PROTEIN ENGINEERING; ZINC	METAL-BINDING SITES; 3-DIMENSIONAL STRUCTURE; CATALYTIC ANTIBODIES; PROTEINS; SEQUENCE; ANTIGEN; FAB	Metal-binding sites were designed within the antigen-binding pocket of the catalytic antibody 43C9 based on a 3-dimensional antibody model and crystallographic structures of Zn-binding metalloenzymes. These tetrahedral Zn-binding sites were designed to mimic both secondary and tertiary structural characteristics of catalytic metal sites in enzymes. Each site was planned to have two His ligands across from each other on adjacent antiparallel beta-strands. Sites were selected to sequester the metal ion from bulk solvent and place an open metal coordination position next to the antigen or potential substrates. Three distinct metal-site designs, with ligands in the variable light domain, in the variable heavy domain, and in both domains, were later implemented experimentally and shown spectroscopically to bind metal ions as predicted. These results demonstrate the success of our design approach, the versatility of the antibody structure for metalloprotein design, and the validity of the 3-dimensional model. The ability to predictably design multiple metal sites in the ordered antigen-recognition region at the bottom of the pocket allows tuning of metal ion placement and enhances the likelihood of interaction with putative substrates.			ROBERTS, VA (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, MB4, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM 48495, GM 48877] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048877, P01GM048495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROWNER MF, 1994, NAT STRUCT BIOL, V1, P327, DOI 10.1038/nsb0594-327; CHEN C, 1992, J EXP MED, V176, P855, DOI 10.1084/jem.176.3.855; FRIEDMAN AR, 1994, PROTEINS, V20, P15, DOI 10.1002/prot.340200104; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; IRVING H, 1953, J CHEM SOC, P3192, DOI 10.1039/jr9530003192; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JANDA KD, 1991, J AM CHEM SOC, V113, P291, DOI 10.1021/ja00001a042; KAAT EA, 1991, SEQUENCES PROTEINS I; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KIEFER LL, 1993, BIOCHEMISTRY-US, V32, P9896, DOI 10.1021/bi00089a004; KIEFER LL, 1993, J AM CHEM SOC, V115, P12581, DOI 10.1021/ja00079a046; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MUHEIM A, 1993, J AM CHEM SOC, V115, P5312, DOI 10.1021/ja00065a060; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; Stewart J D, 1993, Int Rev Immunol, V10, P229, DOI 10.3109/08830189309061698; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1994, DOI 10.1021/bi00174a004; STEWART JD, 1994, J AM CHEM SOC, V116, P415, DOI 10.1021/ja00080a065; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; TAINER JA, 1991, CURR OPIN BIOTECH, V2, P582, DOI 10.1016/0958-1669(91)90084-I; WADE WS, 1993, J AM CHEM SOC, V115, P4449, DOI 10.1021/ja00064a005; WADE WS, 1993, J AM CHEM SOC, V115, P4906, DOI 10.1021/ja00064a068; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	35	14	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1995	9	1					94	100		10.1096/fasebj.9.1.7821766	http://dx.doi.org/10.1096/fasebj.9.1.7821766			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821766				2022-12-25	WOS:A1995QD20200015
J	HAYNES, PA; MEDH, JD; WEIGEL, PH				HAYNES, PA; MEDH, JD; WEIGEL, PH			INHIBITION OF TYROSINE PHOSPHORYLATION IN THE RAT HEPATIC LECTIN-1 SUBUNIT OF THE RAT ASIALOGLYCOPROTEIN RECEPTOR PREVENTS ATP-DEPENDENT RECEPTOR INACTIVATION IN PERMEABILIZED HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSYL RECEPTORS; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; PHORBOL ESTERS; MONENSIN; VANADATE; SUBPOPULATION; CHLOROQUINE; SURFACE; DEPLETION	We previously reconstituted the ATP dependent inactivation of asialoglycoprotein receptors (ASGPRs) in digitonin-permeabilized hepatocytes (Medh, J. D., and Weigel, P. H. (1991) J. Biol. Chem. 266, 8771-8778). Here we report that rat hepatic lectin 1 (RHL1) is the only ASGPR subunit that becomes radiolabeled when permeabilized washed hepatocytes are incubated at 4 degrees C in the presence of [gamma-P-32]ATP; RHL2 and RHL3 are not radiolabeled. Phosphorylation of RHL1 was rapid (t1/2 approximate to 4 min) and complete within 30 min. Inclusion of 20 mM EDTA inhibited phosphorylation of RHL1 completely. Phosphoamino acid analysis identified Tyr(P) as the predominant (>90%) radiolabeled phosphoamino acid. Addition of vanadate enhanced phosphorylation of Tyr in RHL1 4-fold. Phosphorylation of RHL1 occurred to the same extent in hepatocytes permeabilized with either 0.006% (w/v) or 0.055% digitonin and in the presence or the absence of ligand (50 mu g/ml asialo-orosomucoid; ASOR) and/or 10 mM CaCl2. Sequential purification of active ASGPRs (using ASOR-Sepharose) and inactive ASGPRs from the ASOR-Sepharose flow-through (using anti-ASGPR antibody-Sepharose) demonstrated that radiolabeled RHL1 was present almost exclusively in active ASGPR oligomers. When permeabilized hepatocytes radiolabeled with [gamma-P-32]ATP at 4 degrees C were warmed to 37 degrees C, a temperature at which ATP-dependent ASGPR inactivation occurs, RHL1 was dephosphorylated rapidly (t1/2 approximate to 4 min) and completely within similar to 30 min. Western blot analysis using a monoclonal anti-Tyr(P) antibody showed that the steady-state level of endogenous Tyr(P) in RHL1 doubled as a result of ATP treatment at 4 degrees C and then decreased to undetectable levels upon warming to 37 degrees C. The protein-tyrosine kinase inhibitor tyrphostin 51 inhibited phosphorylation of RHL1 at 4 degrees C and also prevented ATP-dependent ASGPR inactivation at 37 degrees C. We conclude that phosphorylation of Tyr in RHL1 of active ASGPRs is a prerequisite for ATP-dependent ASGPR inactivation.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NIGMS NIH HHS [GM 49695, GM 30218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695, R01GM030218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG T, 1983, EXP CELL RES, V148, P319, DOI 10.1016/0014-4827(83)90156-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CLARKE BL, 1985, J BIOL CHEM, V260, P128; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EARP HS, 1983, FEBS LETT, V161, P180; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FIETE D, 1983, J BIOL CHEM, V258, P817; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRUPPUSO PA, 1991, BIOCHEM J, V274, P361, DOI 10.1042/bj2740361; HAYNES PA, 1994, J BIOL CHEM, V269, P33146; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCABEE DD, 1989, BIOCHEM BIOPH RES CO, V161, P261, DOI 10.1016/0006-291X(89)91589-1; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MEDH JD, 1991, J BIOL CHEM, V266, P8771; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; RAY DA, 1985, ANAL BIOCHEM, V145, P37, DOI 10.1016/0003-2697(85)90323-9; SCARMATO P, 1986, BIOL CELL, V56, P255, DOI 10.1111/j.1768-322X.1986.tb00457.x; Schwartz A L, 1991, Targeted Diagn Ther, V4, P3; SCHWARTZ AL, 1984, BIOCHEM J, V223, P481, DOI 10.1042/bj2230481; STEER CJ, 1986, PROG LIVER DIS, V8, P99; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TOLLESHAUG H, 1979, BIOCHEM PHARMACOL, V28, P2919, DOI 10.1016/0006-2952(79)90586-0; TOLLESHAUG H, 1985, BIOCHEM PHARMACOL, V34, P1639, DOI 10.1016/0006-2952(85)90628-8; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1993, ENDOCYTIC COMPONENTS, P125; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	45	16	16	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					33152	33158						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806545				2022-12-25	WOS:A1994QA63800064
J	POTGENS, AJG; LUBSEN, NH; VANALTENA, MC; VERMEULEN, R; BAKKER, A; SCHOENMAKERS, JGG; RUITER, DJ; DEWAAL, RMW				POTGENS, AJG; LUBSEN, NH; VANALTENA, MC; VERMEULEN, R; BAKKER, A; SCHOENMAKERS, JGG; RUITER, DJ; DEWAAL, RMW			COVALENT DIMERIZATION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR IS ESSENTIAL FOR ITS BIOLOGICAL-ACTIVITY - EVIDENCE FROM CYS TO SER MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TUMOR-GROWTH; FACTOR VEGF; EXPRESSION; CELLS; ANGIOGENESIS; IDENTIFICATION; INHIBITION; RESOLUTION; RECEPTORS	Vascular permeability factor, or vascular endothelial growth factor (VPF/VEGF) is an important factor in the regulation of vascular growth and vascular permeability. VPF is a secreted, dimeric protein and has 8 cysteine residues conserved with platelet-derived growth factor (PDGF). To study the role of some of these cysteine residues in maintaining the structure and function of VPF, we replaced the codons for the second, third, fourth, and fifth cysteine by serine codons, and expressed the mutant proteins in a mammalian expression system. Cysteine residues 2 and 4 in VPF were found to be directly involved in anti parallel interchain disulfide bonds, as in PDGF. VPF mutants lacking one of these cysteines were severely impaired in their S-linked dimerization, while upon coexpression of both mutants the ability to form dimers was restored. The VPF mutants lacking cysteine residue 2 or 4 also competed poorly for receptor binding of labeled VPF and had low biological activity, but these defects were also complemented by coexpressing the two mutants, indicating that for efficient receptor binding and activation VPF needs to be a covalent dimer, unlike PDGP-BB. Furthermore, cysteine residue 5 was found to be essential for VPF dimerization and activity, while the mutant lacking cysteine residue 3 was only mildly affected in its ability to dimerize and had partial biological activity.	UNIV NIJMEGEN HOSP,INST PATHOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,DEPT BIOL MOLEC,NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Ruiter, D.J./L-4617-2015; Bakker, Arnold B./F-8494-2010; Waal, R.M.W./L-4739-2015; Lubsen, Nicolette H./B-8426-2011	Bakker, Arnold B./0000-0003-1489-1847; 				ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; POTGENS AJG, 1994, THROMB HAEMOSTASIS, V71, P208; Sambrook J, 1989, MOL CLONING LABORATO; SARVER N, 1981, MOL CELL BIOL, V1, P486, DOI 10.1128/MCB.1.6.486; SAUER MK, 1988, MOL CELL BIOL, V3, P1011; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHEN H, 1993, BLOOD, V81, P2767; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; UDAKA K, 1970, P SOC EXP BIOL MED, V133, P1384; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; VASSBOTN FS, 1993, MOL CELL BIOL, V13, P4066, DOI 10.1128/MCB.13.7.4066; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; YEO TK, 1991, BIOCHEM BIOPH RES CO, V179, P1568, DOI 10.1016/0006-291X(91)91752-X	37	86	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32879	32885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806514				2022-12-25	WOS:A1994QA63800027
J	GOFFIN, V; STRUMAN, I; MAINFROID, V; KINET, S; MARTIAL, JA				GOFFIN, V; STRUMAN, I; MAINFROID, V; KINET, S; MARTIAL, JA			EVIDENCE FOR A 2ND RECEPTOR-BINDING SITE ON HUMAN PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ALANINE-SCANNING MUTAGENESIS; EXTRACELLULAR DOMAIN; BIOLOGICAL PROPERTIES; LACTOGENIC HORMONES; BOVINE PROLACTIN; RATIONAL DESIGN; PROTEIN; FAMILY; ERYTHROPOIETIN	The existence of a second receptor binding site on human prolactin (hPRL) was investigated by site-directed mutagenesis. First, 12 residues of helices 1 and 3 were mutated to alanine. Since none of the resulting mutants exhibit reduced bioactivity in the Nb2 cell proliferation bioassay, the mutated residues do not appear to be functionally necessary. Next, small residues surrounding the helix 1-helix 3 interface were replaced with Arg and/or Trp, the aim being to sterically hinder the second binding site. Several of these mutants exhibit only weak agonistic properties, supporting our hypothesis that the channel between helices 1 and 3 is involved in a second receptor binding site. We then analyzed the antagonistic and self-antagonistic properties of native hPRL and of several hPRLs analogs altered at binding site 1 or 2. Even at high concentrations (similar to 10 mu M), no self-inhibition was observed with native hPRL; site 2 hPRL mutants self-antagonized while site 1 mutants did not. From these data, we propose a model of hPRL-PRL receptor interaction which slightly differs from that proposed earlier for the homologous human growth hormone (hGH) (Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., and Goeddel, D. V., and Well, J. A. (1992) Science 256, 1677-1680). Like hGH, hPRL would bind sequentially to two receptor molecules, first through site 1, then through site 2, but we would expect the two sites of hPRL to display, unlike the two binding sites of hGH, about the same binding affinity, thus preventing self-antagonism at high concentrations.	UNIV LIEGE,MOLEC BIOL & GENET ENGN LAB,B-4000 SART,BELGIUM	University of Liege			GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086; kinet, sandrina/0000-0003-0699-108X; struman, ingrid/0000-0003-2550-3707				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clarke W.C., 1980, Hormonal Proteins and Peptides, V8, P105; COOKE NE, 1981, J BIOL CHEM, V256, P4007; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EIGENBROT C, 1992, Current Opinion in Biotechnology, V3, P333, DOI 10.1016/0958-1669(92)90160-K; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FONTANA A, 1991, CURR OPIN BIOTECH, V2, P551, DOI 10.1016/0958-1669(91)90080-O; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; GOUT PW, 1980, CANCER RES, V40, P2433; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YOUNG P R, 1992, Current Opinion in Biotechnology, V3, P408, DOI 10.1016/0958-1669(92)90170-N	43	65	71	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32598	32606						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798264				2022-12-25	WOS:A1994PX30400086
J	NISHIDA, M; KONG, KH; INOUE, H; TAKAHASHI, K				NISHIDA, M; KONG, KH; INOUE, H; TAKAHASHI, K			MOLECULAR-CLONING AND SITE-DIRECTED MUTAGENESIS OF GLUTATHIONE-S-TRANSFERASE FROM ESCHERICHIA-COLI - THE CONSERVED TYROSYL RESIDUE NEAR THE N-TERMINUS IS NOT ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; 3-DIMENSIONAL STRUCTURE; CDNA CLONE; COMPLEX; PURIFICATION; EXPRESSION; RESOLUTION; GENE; P1-1; TYROSINE-7	Glutathione S-transferase (GST) was purified from Escherichia coli K-12, and its N-terminal sequence was determined to be MKLFYKPGAXSLAS. The gene encoding this sequence was cloned and mapped at 1731-1732 kilobases on the E. coli gene map. It encoded a polypeptide of 201 amino acid residues with a calculated molecular weight of 22,860. The overexpressed product of the gene was confirmed to have GST activity toward 1-chloro-2,4-dinitrobenzene and ethacrynic acid and GSH-dependent peroxidase activity toward cumene hydroperoxide. The relative molecular mass of the gene product was determined to be 40,000 by gel chromatography and 25,000 by SDS-polyacrylamide gel electrophoresis, indicating a homodimeric structure. The deduced amino acid sequence was 54% identical with that of Proteus mirabilis GST. Although the homologies between the GSTs hom E. coli and mammals were low, many of the residues assigned to be important for the enzymatic function or structure in mammalian cytosolic GSTs were found to be conserved in E. coli GST. Therefore, E. coli GST is considered to have diverged from the same ancestor with other cytosolic GSTs. A specific tyrosyl residue in the vicinity of the N terminus is conserved in all of the known cytosolic GSTs and has been shown to function as a catalytic residue in alpha, mu, and pi class GSTs from mammals. Although Tyr(5) in E. coli GST appeared to be the counterpart of the catalytic residue, its replacement with phenylalanine did not significantly affect the enzymatic activity. Therefore, this apparently conserved tyrosyl residue is not essential for catalytic activity in E. coli GST.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AOYAGI T, 1992, J ANTIBIOT, V45, P1385, DOI 10.7164/antibiotics.45.1385; ARCA P, 1990, FEBS LETT, V263, P77, DOI 10.1016/0014-5793(90)80709-R; BOARD PG, 1987, P NATL ACAD SCI USA, V84, P2377, DOI 10.1073/pnas.84.8.2377; DIILIO C, 1991, BIOCHIM BIOPHYS ACTA, V1077, P141; DING GJF, 1985, J BIOL CHEM, V260, P3268; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; Habig W H, 1981, Methods Enzymol, V77, P398; IIZUKA M, 1989, J BACTERIOL, V171, P6039, DOI 10.1128/jb.171.11.6039-6042.1989; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KANO T, 1987, CANCER RES, V47, P5626; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1992, J BIOCHEM-TOKYO, V112, P725, DOI 10.1093/oxfordjournals.jbchem.a123965; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; KONG KH, 1993, PROTEIN ENG, V6, P1015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE SD, 1990, J BACTERIOL, V172, P164, DOI 10.1128/JB.172.1.164-171.1990; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MASAI E, 1993, FEBS LETT, V323, P135, DOI 10.1016/0014-5793(93)81465-C; MEYER DJ, 1991, BIOCHEM J, V274, P8430; MIGNOGNA G, 1993, EUR J BIOCHEM, V211, P421, DOI 10.1111/j.1432-1033.1993.tb17566.x; OGURA K, 1991, BIOCHEM BIOPH RES CO, V181, P1294, DOI 10.1016/0006-291X(91)92079-Y; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PICCOLOMINI R, 1989, J GEN MICROBIOL, V135, P3119; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN D, 1993, COMP BIOCHEM PHYS B, V104, P1, DOI 10.1016/0305-0491(93)90330-8; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STAYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; WANG RW, 1993, J BIOL CHEM, V268, P23981; WANG RW, 1992, J BIOL CHEM, V267, P19866; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	46	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32536	32541						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798255				2022-12-25	WOS:A1994PX30400077
J	SASAOKA, T; LANGLOIS, WJ; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM				SASAOKA, T; LANGLOIS, WJ; LEITNER, JW; DRAZNIN, B; OLEFSKY, JM			THE SIGNALING PATHWAY COUPLING EPIDERMAL GROWTH-FACTOR RECEPTORS TO ACTIVATION OF P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE-ACTIVITY; GUANINE-NUCLEOTIDES; PROTO-ONCOGENE; RAS; GRB2; TRANSDUCTION; INSULIN; P21RAS; SH2	Epidermal growth factor (EGF) treatment causes autophosphorylation of the epidermal growth factor receptor (EGFR) leading to increased guanine nucleotide exchange factor (GEF; Sos) activity and enhanced formation of p21(ras)-GTP. The connection of the EGFR to p21(ras) activation can occur through binding of Grb2 Sos complexes to the EGFR or through the adaptor protein Shc via EGFR.Shc.Grb2.Sos multimeric complexes. Therefore, we investigated the importance of She in coupling the EGFR to activation of ras GEF (Sos). EGF treatment led to rapid tyrosine phosphorylation of She. Although phosphorylated EGFR can bind to both She and Grb2, the predominant linkage was observed between EGFR and She. Similarly, more Grb2 was associated with She than with EGFR after EGF stimulation. Immunoprecipitation of She from EGF-stimulated cells removed almost all EGFR-associated Grb2. Furthermore, immunodepletion of She proteins from membrane fractions of EGF-stimulated cells removed 93% of the ras GEF activity, whereas, precipitation of EGFR had only a small effect on ras GEF activity. These data indicate that coupling to She provides the major pathway linking activated EGFRs to Grb2.Sos and stimulation of the p21(ras) pathway,	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	28	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32621	32625						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798267				2022-12-25	WOS:A1994PX30400089
J	PEMBERTON, PA; WONG, DT; GIBSON, HL; KIEFER, MC; FITZPATRICK, PA; SAGER, R; BARR, PJ				PEMBERTON, PA; WONG, DT; GIBSON, HL; KIEFER, MC; FITZPATRICK, PA; SAGER, R; BARR, PJ			THE TUMOR-SUPPRESSOR MASPIN DOES NOT UNDERGO THE STRESSED TO RELAXED TRANSITION OR INHIBIT TRYPSIN-LIKE SERINE PROTEASES - EVIDENCE THAT MASPIN IS NOT A PROTEASE INHIBITORY SERPIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CONFORMATIONAL CHANGE; ALPHA-1-ANTITRYPSIN; YEAST	The role of tumor suppressor proteins in the development of malignancy has made the understanding of their molecular mechanisms of action of great importance. Maspin is a tumor suppressor produced by a number of cell types of epithelial origin, Exogenous recombinant maspin has been shown to block the growth, motility, and invasiveness of breast tumor cell lines in vitro and in vivo. Although belonging to the the serine proteinase inhibitor (serpin) superfamily of proteins, the molecular mechanism of maspin is currently unknown, Here we show that the reactive site loop of maspin exists in an exposed conformation that does not require activation by cofactors. The reactive site loop of maspin, however, does not act as an inhibitor of proteinases such as chymotrypsin, elastase, plasmin, thrombin, and trypsin but rather as a substrate. Maspin is also unable to inhibit tissue and urokinase type plasminogen activators. Stability studies show that maspin cannot undergo the stressed-relaxed transition typical of proteinase-inhibitory serpins, and the protein is capable of spontaneous polymerization induced by changes in pH. It is likely, therefore, that maspin is structurally more closely related to ovalbumin and angiotensinogen, and its tumor suppressor activity is independent of a latent or intrinsic trypsin-like serine proteinase-inhibitory activity.	DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute	PEMBERTON, PA (corresponding author), LXR BIOTECHNOL,1401 MARINA WAY S,RICHMOND,CA 94804, USA.							BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; EVANS DLI, 1991, THESIS U CAMBRIDGE; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; GANESH S, 1994, CANCER RES, V54, P4065; GEORGE PM, 1989, BLOOD, V73, P490; GOLDENBERG DP, 1990, PROTEIN STRUCTURE PR, P225; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HOPKINS PCR, 1994, SCIENCE, V265, P1893; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P2720; MIKUS P, 1993, EUR J BIOCHEM, V278, P1071; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; SAGER R, 1995, IN PRESS COLD SPRING; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; WEI A, 1994, STRUCT BIOL, V1, P251; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	124	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15832	15837		10.1074/jbc.270.26.15832	http://dx.doi.org/10.1074/jbc.270.26.15832			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797587	hybrid			2022-12-25	WOS:A1995RG53800060
J	COLLINS, BS; PIPAS, JM				COLLINS, BS; PIPAS, JM			T ANTIGENS ENCODED BY REPLICATION-DEFECTIVE SIMIAN-VIRUS-40 MUTANT-DL1135 AND MUTANT-5080	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-TUMOR-ANTIGEN; SV40 LARGE-T; POLYMERASE-ALPHA-PRIMASE; DNA-REPLICATION; INSECT CELLS; PROTEIN PHOSPHATASE-2A; HYDROPHOBIC REGION; CELLULAR PROTEIN; VIRAL ORIGIN; BINDING	We present a preliminary biochemical characterization of two simian virus 40 mutants that affect different T antigen replication functions, SV40 T antigen mutants dl1135 (Delta 17-27 amino acids) and 5080 (P-L) have been studied extensively with regard to their ability to transform cells in culture and induce tumors in transgenic mice. Both mutants are defective for viral DNA replication in vivo. In order to assess in more detail the molecular basis for the in vivo replication defects of 5080 and dl1135, we expressed the mutant proteins using the baculovirus system and purified them by immunoaffinity chromatography. With each of the purified proteins, we examined some of the biochemical activities of T antigen required for replication, viz, ATPase, binding to the origin of replication (ori) and assembly on ori, DNA helicase and unwinding, and replication in in vitro assays, Consistent with previous studies, we found that the 5080 protein is defective for multiple biochemical activities including ATPase, helicase, ori-specific unwinding, and ATP-induced hexamerization. However, this mutant retains some sequence-specific DNA binding activity. In contrast, the dl1135 protein exhibited significant levels of activity in all assays, including the ability to drive SV40 DNA replication in vitro. Thus, dl1135 is one of several mutants with an altered aminoterminal domain which can replicate DNA in vitro, but not in vivo. Thus, while the 5080 mutation affects a T antigen enzymatic function directly required far viral DNA synthesis, dl1135 may alter an activity required to prepare the cell for viral replication.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA 09077] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COSMAN DJ, 1981, VIROLOGY, V112, P605, DOI 10.1016/0042-6822(81)90306-8; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DIXON RAF, 1985, J VIROL, V53, P1001, DOI 10.1128/JVI.53.3.1001-1004.1985; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; GANNON J V, 1990, New Biologist, V2, P84; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOSS A, 1990, J VIROL, V64, P4799; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MAULBECKER C, 1992, J VIROL, V66, P2195, DOI 10.1128/JVI.66.4.2195-2207.1992; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MOAREFI IF, 1993, J VIROL, V67, P4992, DOI 10.1128/JVI.67.8.4992-5002.1993; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; SPENCE SL, 1994, VIROLOGY, V204, P200, DOI 10.1006/viro.1994.1524; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; VANDYKE TA, 1994, CANCER BIOL, V5, P47; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; YANIUK P, 1991, MOL CELL BIOL, V11, P2116	62	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15377	15384		10.1074/jbc.270.25.15377	http://dx.doi.org/10.1074/jbc.270.25.15377			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7797527	hybrid			2022-12-25	WOS:A1995RE66600079
J	LIU, SJ; BAKER, JC; ROCHE, TE				LIU, SJ; BAKER, JC; ROCHE, TE			BINDING OF THE PYRUVATE-DEHYDROGENASE KINASE TO RECOMBINANT CONSTRUCTS CONTAINING THE INNER LIPOYL DOMAIN OF THE DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-X; BOVINE KIDNEY; TRANSACETYLASE COMPONENT; NUCLEOTIDE-SEQUENCE; COMPLEX; PURIFICATION; CORE; CLEAVAGE; SURFACE; REGION	The dihydrolipoyl acetyltransferase (E2) component of the mammalian pyruvate dehydrogenase complex forms a 60-subunit core in which E2's inner domain forms a dodecahedron shaped structure surrounded by its globular outer domains that are connected to each other and the inner domain by 2-3-kDa mobile hinge regions. Two of the outer domains are similar to 10 kDa lipoyl domains, an NH2-terminal one, E2(L1), and, after the first hinge region a second one, E2(L2). The pyruvate dehydrogenase kinase binds tightly to the lipoyl domain region of the oligomeric E2 core and phosphorylates and inactivates the pyruvate dehydrogenase (E1) component. We wished to determine whether lipoyl domain constructs prepared by recombinant techniques from a cDNA for human E2 could bind the bovine E1 kinase and, that being the case, to pursue which lipoyl domain the kinase binds. We also wished to gain insights into how a molecule of kinase tightly bound to the E2 core can rapidly phosphorylate 20-30 molecules of the pyruvate dehydrogenase (E1) component which are also bound to an outer domain of the E2 core. We prepared recombinant constructs consisting of the entire lipoyl domain region or the individual lipoyl domains with or without the intervening hinge region. Constructs were made and used both as free lipoyl domains and fused to glutathione S-transferase (GST). Using GSH-Sepharose to selectively bind GST constructs, tightly bound kinase was shown to rapidly transfer in a highly preferential way from intact E2 core to GST constructs containing the E2(L2) domain rather than to ones containing only the E2(L1) domain. GST E2(L2)-kinase complexes could be eluted from GSH-Sepharose with glutathione. Delipoylation of E2(L2) by treatment with lipoamidase eliminated kinase binding supporting a direct role of the lipoyl prosthetic group in this association. Transfer to and selective binding of the kinase by E2(L2) but not E2(L1) was also demonstrated with free constructs using a sucrose gradient procedure to separate the large E2 core from the various lipoyl domain constructs. E2(L2) but not E2(L1) increased the activity of resolved kinase by up to 43%. We conclude that the kinase selectively binds to the inner lipoyl domain of E2 subunits and that this association involves its lipoyl prosthetic group. We further suggest that transfer of tightly bound kinase between E2(L2) domains occurs by a direct interchange mechanism without formation of free kinase (model presented), Such interdomain movement would explain how a kinase molecule can rapidly phosphorylate a large complement of pyruvate dehydrogenase tetramers which are bound throughout the surface of the E2 oligomer.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University					NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2958, DOI 10.1021/bi00281a027; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2966, DOI 10.1021/bi00281a028; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; JAKOBY WB, 1985, METHOD ENZYMOL, V113, P495; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; ONO K, 1993, J BIOL CHEM, V268, P26135; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; REED LJ, 1990, J BIOL CHEM, V265, P8971; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P168, DOI 10.1111/j.1749-6632.1989.tb14994.x; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; STEPP LR, 1983, J BIOL CHEM, V258, P9454; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SUZUKI K, 1963, J BIOL CHEM, V238, P4021; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5	30	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					793	800		10.1074/jbc.270.2.793	http://dx.doi.org/10.1074/jbc.270.2.793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822313	hybrid			2022-12-25	WOS:A1995QB81600047
J	SABERS, CJ; MARTIN, MM; BRUNN, GJ; WILLIAMS, JM; DUMONT, FJ; WIEDERRECHT, G; ABRAHAM, RT				SABERS, CJ; MARTIN, MM; BRUNN, GJ; WILLIAMS, JM; DUMONT, FJ; WIEDERRECHT, G; ABRAHAM, RT			ISOLATION OF A PROTEIN TARGET OF THE FKBP12-RAPAMYCIN COMPLEX IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC-BINDING-PROTEIN; P70 S6 KINASE; CYCLOSPORINE-A; IMMUNOSUPPRESSANT RAPAMYCIN; SEQUENCE-ANALYSIS; LYMPHOCYTES-T; ACTIVATION; CALCINEURIN; FK-506; YEAST	The immunosuppressive drug, rapamycin, interferes with an undefined signaling pathway required for the progression of G(1)-phase T-cells into S phase. Genetic analyses in yeast indicate that binding of rapamycin to its intracellular receptor, FKBP12, generates a toxic complex that inhibits cell growth in G(1) phase. These analyses implicated two related proteins, TOR1 and TOR2, as targets of the FKBP12-rapamycin complex in yeast. In this study, we have used a glutathione S-transferase (GST)-FKBP12-rapamycin affinity matrix to isolate putative mammalian targets of rapamycin (mTOR) from tissue extracts. In the presence of rapamycin, immobilized GST-FKBP12 specifically precipitates similar high molecular mass proteins from both rat brain and murine T-lymphoma cell extracts, Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines. The latter results suggest that mTOR is a relevant target of rapamycin in these cells. Finally, we report the isolation of a full-length mTOR cDNA that encodes a direct ligand for the FKBP12-rapamycin complex. The deduced amino acid sequence of mTOR displays 42 and 45% identity to those of yeast TOR1 and TOR2, respectively, These results strongly suggest that the FKBP12-rapamycin complex interacts with homologous ligands in yeast and mammalian cells and that the loss of mTOR function is directly related to the inhibitory effect of rapamycin on G(1)- to S-phase progression in T-lymphocytes and other sensitive cell types.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065	Mayo Clinic; Mayo Clinic; Merck & Company					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMEYER A, 1993, CYTOKINE, V5, P133, DOI 10.1016/1043-4666(93)90052-7; ALTMEYER A, 1991, CELL IMMUNOL, V138, P94, DOI 10.1016/0008-8749(91)90135-X; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DUMONT FJ, 1994, J IMMUNOL, V152, P992; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; KOZAK M, 1986, NUCLEIC ACIDS RES, V15, P8125; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MORICE WG, 1993, J BIOL CHEM, V268, P3734; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103	29	661	689	3	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					815	822		10.1074/jbc.270.2.815	http://dx.doi.org/10.1074/jbc.270.2.815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822316	hybrid			2022-12-25	WOS:A1995QB81600050
J	SINGHAL, RK; PRASAD, R; WILSON, SH				SINGHAL, RK; PRASAD, R; WILSON, SH			DNA-POLYMERASE-BETA CONDUCTS THE GAP-FILLING STEP IN URACIL-INITIATED BASE EXCISION-REPAIR IN A BOVINE TESTIS NUCLEAR EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MONKEY CELLS; IDENTIFICATION; ALPHA; ENDONUCLEASES; GLYCOSYLASES; PURIFICATION; RESIDUES; ENZYME; DOMAIN	The GU mismatch in genomic DNA mainly arises from deamination of cytosine residues and is repaired by the base excision repair pathway, We found that a bovine testis crude nuclear extract conducts uracil-initiated base excision repair in vitro. A 51-base pair synthetic DNA substrate containing a single G:U mismatch was used, and incorporation of dCMP during repair was exclusively to replace uracil. A neutralizing polyclonal antibody against DNA polymerase beta (beta-pol) inhibited the repair reaction, ddCTP also inhibited the repair reaction, whereas aphidicolin had no significant effect, suggesting that activity of beta-pol was required, Next, the base excision repair system was reconstituted using partially purified components. Several of the enzymatic activities required were resolved, such that DNA Ligase and the uracil-DNA glycosylase/apurinic/apyrimidinic endonuclease activities were separated from the DNA polymerase requirement. We found that purified beta-pol could restore full DNA repair activity to the DNA polymerase-depleted fraction, whereas purified DNA polymerases alpha, delta, and epsilon could not, These results with purified proteins corroborated results obtained with the crude extract and indicate that beta-pol is responsible for the single-nucleotide gap filling reaction involved in this in vitro base excision repair system.	UNIV TEXAS, MED BRANCH, SEALY CTR MOLEC SCI, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FREIDBERG EC, 1985, DNA REPAIR; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HARLOW E, 1988, ANTIBODIES LABORATOR; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KARAWYA E, 1984, P NATL ACAD SCI-BIOL, V81, P7777, DOI 10.1073/pnas.81.24.7777; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PERRINO FW, 1990, MUTAT RES, V236, P289, DOI 10.1016/0921-8777(90)90012-T; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; REGAN JD, 1974, CANCER RES, V34, P3318; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; TANABE K, 1983, NUCLEIC ACIDS RES, V11, P8253, DOI 10.1093/nar/11.23.8253; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WANG LM, 1992, CANCER RES, V52, P4824; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	34	292	300	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					949	957		10.1074/jbc.270.2.949	http://dx.doi.org/10.1074/jbc.270.2.949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822335	hybrid			2022-12-25	WOS:A1995QB81600070
J	GU, W; MORALES, C; HECHT, NB				GU, W; MORALES, C; HECHT, NB			IN MALE-MOUSE GERM-CELLS, COPPER-ZINC SUPEROXIDE-DISMUTASE UTILIZES ALTERNATIVE PROMOTERS THAT PRODUCE MULTIPLE TRANSCRIPTS WITH DIFFERENT TRANSLATION POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CDNA CLONE; MOLECULAR-BIOLOGY; GENE-EXPRESSION; TRANSGENIC MICE; DOWNS-SYNDROME; CYTOCHROME-C; RAT TESTIS; SPERMATOGENESIS; PROTEIN	Copper zinc superoxide dismutase (SOD-1) is an enzyme that is widely expressed in eukaryotic cells and performs a vital role in protecting cells against free radical damage. In mouse testis, three different sizes of SOD-l mRNAs of about 0.73, 0.80, and 0.93 kilobases (kb) are detected. The 0.73-kb mRNA is found in early stages of male germ cells and in all somatic tissues. The mRNAs of 0.80 and 0.93 kb are exclusively detected in post-meiotic germ cells. RNase H digestions and Northern blot analyses reveal that the three SOD-l mRNAs are derived from two transcripts, a ubiquitously expressed transcript and a post-meiotic transcript, which differ by 114-120 nucleotides. RNase protection assays demonstrate that the additional nucleotides present in the post-meiotic mRNA are solely in the 5'-untranslated region. Using a probe derived from the 5'-untranslated region of the 0.93-kb SOD-l mRNA, we have established that it originates from an alternative upstream promoter contiguous with the somatic SOD-l promoter. Polysomal gradient analysis of the three mouse testis SOD-1 mRNAs reveals that the 0.93-kb SOD-l mRNA is primarily non-polysomal, while the 0.80 and 0.73 kb SOD-l mRNAs are mostly polysome associated. A faster migrating form of the 0.93-kb SOD-l mRNA is present on polysomes as a result of partial deadenylation. In a cell-free translation system, the 0.73-kb SOD-1 mRNA translates about 2-fold more efficiently than the 0.93 kb SOD-l mRNA These data demonstrate that male germ cells transcribe two size classes of SOD-1 mRNAs with different translation potential by utilizing two different promoters, post meiotic SOD-1 mRNAs undergo adenylation changes, and one of the post-meiotic SOD-l mRNAs is transcribed during mid-spermiogenesis and translated days later in a partially deadenylated form.	TUFTS UNIV, DEPT BIOL, MEDFORD, MA 02155 USA; MCGILL UNIV, DEPT ANAT, MONTREAL, PQ H3A 2B2, CANADA	Tufts University; McGill University					NICHD NIH HHS [HD 28832] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCIVAR AA, 1989, DEV BIOL, V135, P263, DOI 10.1016/0012-1606(89)90178-4; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BARRA D, 1984, J BIOL CHEM, V259, P2595; BENEDETTO MT, 1991, GENE, V99, P191, DOI 10.1016/0378-1119(91)90126-V; BEWLEY GC, 1988, NUCLEIC ACIDS RES, V16, P2728, DOI 10.1093/nar/16.6.2728; CEHALLOSPICOT I, 1992, EXPER SUPPL BASEL, V62, P89; CHURCH GM, 1984, P NATL ACAD SCI USA, V74, P5463; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; GRISWOLD MD, 1988, OXFORD REV REPROD B, V10, P124; GU W, 1994, IN PRESS MOL REPROD; HAKE LE, 1990, DEVELOPMENT, V110, P249; HAKE LE, 1993, J BIOL CHEM, V268, P4788; Hecht N. B., 1990, Biology of mammalian germ cell mutagenesis.., P67; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; HEIDARAN MA, 1987, GENE, V54, P281, DOI 10.1016/0378-1119(87)90498-7; HSU JL, 1992, BIOCHEM BIOPH RES CO, V186, P936, DOI 10.1016/0006-291X(92)90836-A; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JOW WW, 1993, J ANDROL, V14, P439; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KIM YH, 1993, GENE, V133, P267; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LIEMANHURWITZ J, 1982, P NATL ACAD SCI-BIOL, V79, P2808, DOI 10.1073/pnas.79.9.2808; Maniatis T., 1982, MOL CLONING; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MORALES CR, 1994, BIOL REPROD, V50, P309, DOI 10.1095/biolreprod50.2.309; NANBU R, 1991, BIOCHIM BIOPHYS ACTA, V1088, P71, DOI 10.1016/0167-4781(91)90154-E; NONOGAKI T, 1992, HUM REPROD, V7, P81, DOI 10.1093/oxfordjournals.humrep.a137565; RAO SM, 1993, J BIOL CHEM, V268, P22164; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHERMAN L, 1984, NUCLEIC ACIDS RES, V12, P9349, DOI 10.1093/nar/12.24.9349; SINET PM, 1982, ANN NY ACAD SCI, V396, P83, DOI 10.1111/j.1749-6632.1982.tb26845.x; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; YIU G, 1994, IN PRESS NUCLEIC ACI	49	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					236	243		10.1074/jbc.270.1.236	http://dx.doi.org/10.1074/jbc.270.1.236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814380	hybrid			2022-12-25	WOS:A1995QA28700039
J	SHARMA, E; LOMBROSO, PJ				SHARMA, E; LOMBROSO, PJ			A NEURONAL PROTEIN-TYROSINE-PHOSPHATASE INDUCED BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; TRK PROTOONCOGENE; RECEPTOR; PHOSPHORYLATION; PURIFICATION; DIFFERENTIATION; EXPRESSION; CLONING; KINASE; PRODUCT	A new protein tyrosine phosphatase (PC12-PTP1) was identified in nerve growth factor (NGF) treated PC12 cells, The mRNA level of PC12-PTP1 is increased 9-fold over the initial 8 h of NGF treatment and then decreases dramatically after 24 h of treatment, In rat brain, three transcripts corresponding to 1.5, 2.6, and 3.0 kilobases (kb) in size are detected by Northern blot analysis. Although the 1.5- and 2.6-kb transcripts are present in brain and other tissues, the 3-kb transcript is exclusively expressed in brain and the expression of this transcript alone increases following NGF treatment, PC12-PTP1 is a non-receptor protein tyrosine phosphatase (PTP) with a 50% sequence homology in the phosphatase domain with several other non-receptor PTPs. PC12-PTP1 fusion protein exhibits tyrosine phosphatase activity, and in vitro translation of the PC12-PTP1 transcript produces a major protein of 39 kDa. The data presented suggest that NGF regulates the expression of PC12-PTP1 during periods of neuronal growth and differentiation.	YALE UNIV,SCH MED,CTR CHILD STUDY,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH049351] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00856, MH18268, MH49351] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ALTIN JG, 1989, J NEUROCHEM, V54, P1666; APARICIO LF, 1992, CELL GROWTH DIFFER, V3, P363; BARKER PA, 1992, MOL CELL BIOCHEM, V110, P1, DOI 10.1007/BF02385000; CARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DITCHLER MA, 1977, NATURE, V268, P501; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1975, NATURE, V258, P341; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; JONES SW, 1989, J BIOL CHEM, V264, P7747; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P444; MEI L, 1991, J BIOL CHEM, V266, P16063; NAEGELE JR, 1995, IN PRESS CRIT REV NE; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; PAN MG, 1993, J BIOL CHEM, V268, P19284; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; RICHTERLANDSBER.C, 1985, J NEUROSCI, V5, P468; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAO H, 1990, J BIOL CHEM, V265, P15471; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; YAN H, 1993, J BIOL CHEM, V268, P24880; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	36	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					49	53		10.1074/jbc.270.1.49	http://dx.doi.org/10.1074/jbc.270.1.49			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814416	hybrid			2022-12-25	WOS:A1995QA28700013
J	KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A				KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A			DIFFERENTIATION OF P19 EC CELLS LEADS TO DIFFERENTIAL MODULATION OF CYCLIN-DEPENDENT KINASE-ACTIVITIES AND TO CHANGES IN THE CELL-CYCLE PROFILE	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASES; PIG CELLS; DIFFERENTIATION; CELL CYCLE CONTROL; RETINOBLASTOMA GENE PRODUCT	EMBRYONAL CARCINOMA-CELLS; SUSCEPTIBILITY GENE-PRODUCT; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-REPLICATION; EXPRESSION; FAMILY; E2F; PHASE	The retinoblastoma gene product (pRb) is essential for normal embryonic development, Phosphorylation of pRb by cyclin dependent kinases (cdk's) is believed to be crucial for the regulation of its function, In this report we have studied the regulation of pRb and cdk's during in vitro differentiation of P19 embryonal carcinoma (EC) cells, as a model for early developmental processes, During EC cell differentiation, the synthesis of pRb is strongly induced, In addition, the phosphorylation state of induced pRb is modulated, yielding mainly underphosphorylated pRb, Concomitantly, the pRb kinases cdk2 and cdk4 are differentially regulated: cdk2 kinase activity is impaired, whereas cdk4 kinase activity is stimulated, due to an induction of cyclins D1 and D2. Furthermore, the DNA binding activity of E2F transcription factors is strongly impaired during differentiation and the number of cells in G1 is increased. Thus, P19 EC cell differentiation is accompanied by changes in cdk-activities, pRb regulation and E2F DNA-binding, resulting in the generation of cell types with an altered cell cycle profile.	UNIV UTRECHT HOSP,DEPT PULM DIS,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center	KRANENBURG, O (corresponding author), LEIDEN UNIV,DEPT MOLEC CARCINOGENESIS,SYLVIUS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				AJCHENBAUM F, 1993, J BIOL CHEM, V25, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATA JY, 1993, GENE DEV, V7, P331; KITAGAWA M, 1992, ONCOGENE, V7, P1067; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALERMO L, 1993, ONCOGENES, V8, P1049; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	51	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					87	95						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824282				2022-12-25	WOS:A1995QA98000011
J	BAENZIGER, NL; DALEMAR, LR; MACK, P; HADDOCK, RC				BAENZIGER, NL; DALEMAR, LR; MACK, P; HADDOCK, RC			HISTAMINE DEGRADATIVE UPTAKE BY CULTURED HUMAN PULMONARY VASCULAR ENDOTHELIAL-CELLS UTILIZES AN INFLAMMATORY CELL DIAMINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS SYNDROME; INDUCED LUNG INJURY; FIBROBLAST GROWTH-FACTOR; PROSTAGLANDIN BLOCKADE; PROSTACYCLIN SYNTHESIS; VASOACTIVE SUBSTANCES; COMPLEMENT ACTIVATION; SKIN FIBROBLASTS; LOCALIZATION; NEUTROPHIL	Neutrophil-endothelial interactions, altered clearance properties of the lung toward vasoactive mediators, and damaging effects of histamine that target the lung represent prominent elements of the inflammatory response at the systemic level, The pulmonary vasculature is unusual in that, unlike other tissues and vascular beds, it normally does not metabolize circulating histamine in vivo, although histamine-metabolizing enzyme activities have been detected in disrupted lung tissue, We have therefore explored the capability of human pulmonary artery endothelial cells in culture to express the receptor mediated histamine degradative uptake system we previously defined in systemic endothelial cells (Haddock, R. C., Mack, P., Leal, S., and Baenziger, N. L, (1990) J. Biol. Chem. 265, 14395-14401), Pulmonary endothelial cells display all components of this system: histamine methyltransferase generating the proximal cell-associated metabolite tele-methylhistamine and receptors binding diamine oxidase which generates the distal product methylimidazoleacetic acid that is accumulated by the cells, A diamine oxidase released from human neutrophil granules by activation with Ca2+ ionophore binds pulmonary and systemic endothelial cell and fibroblast diamine oxidase receptors and, thereby, participates in histamine degradative uptake, This enzyme utilizes cell-associated tele-methylhistamine as a substrate, preferentially generating methylimidazoleacetic acid in addition to reactive oxygen species, Thus the enzymatic and interactive cellular machinery for histamine clearance is inherently present as a functional unit in two major human pulmonary cell types, It interacts with products of inflammatory host defense cells, and pulmonary endothelial-neutrophil interactions via this pathway may influence the progression of inflammation.			BAENZIGER, NL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,BOX 8108,4566 SCOTT AVE,ST LOUIS,MO 63110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007296] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033699] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33699] Funding Source: Medline; NIADDK NIH HHS [2T32 AMO7296] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER N L, 1990, Journal of Cell Biology, V111, p184A; BAENZIGER NL, 1981, CELL, V24, P915, DOI 10.1016/0092-8674(81)90117-3; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BAENZIGER NL, 1994, J BIOL CHEM, V269, P14892; BENNETT A, 1965, BRIT J PHARM CHEMOTH, V24, P147, DOI 10.1111/j.1476-5381.1965.tb02089.x; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263; BOILEAU JC, 1970, CAN J PHYSIOL PHARM, V48, P681, DOI 10.1139/y70-100; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; BYRNE K, 1990, CRIT CARE MED, V18, P303, DOI 10.1097/00003246-199003000-00012; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; DANIELE B, 1990, GASTROENTEROLOGY, V99, P1675, DOI 10.1016/0016-5085(90)90474-F; DEMLING RH, 1990, CIRC SHOCK, V30, P297; EISEMAN B, 1964, J THORAC CARDIOV SUR, V48, P798, DOI 10.1016/S0022-5223(19)33363-X; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P543, DOI 10.1111/j.1476-5381.1973.tb17265.x; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GILLIS CN, 1976, BIOCHEM PHARMACOL, V25, P2547, DOI 10.1016/0006-2952(76)90508-6; GILLIS CN, 1982, ANN NY ACAD SCI, V384, P458, DOI 10.1111/j.1749-6632.1982.tb21392.x; GILLIS CN, 1982, ANNU REV PHYSIOL, V44, P269, DOI 10.1146/annurev.ph.44.030182.001413; GILLIS CN, 1986, AM REV RESPIR DIS, V134, P739; GLORIANO VV, 1969, P SOC EXP BIOL MED, V130, P387; HADDOCK RC, 1987, J BIOL CHEM, V262, P10220; HADDOCK RC, 1990, J BIOL CHEM, V265, P14395; HADDOCK RC, 1985, FED PROC, V44, P1843; HENSON PM, 1984, FED PROC, V43, P2799; HENSON PM, 1982, ANN NY ACAD SCI, V384, P287, DOI 10.1111/j.1749-6632.1982.tb21379.x; HERNANDEZ A, 1991, PHARMACOL RES, V24, P385, DOI 10.1016/1043-6618(91)90043-W; HOUGH LB, 1979, J PHARMACOL EXP THER, V208, P422; HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268; JOHNSON AR, 1985, FED PROC, V44, P19; JOHNSON AR, 1980, J CLIN INVEST, V65, P841, DOI 10.1172/JCI109736; JUNOD AF, 1982, ANN NY ACAD SCI, V384, P66, DOI 10.1111/j.1749-6632.1982.tb21363.x; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LEEPERWOODFORD SK, 1993, AM J RESP CELL MOL, V8, P169, DOI 10.1165/ajrcmb/8.2.169; LILJA B, 1961, J ALLERGY, V31, P492; LINDENSCHMIDT RC, 1986, AM REV RESPIR DIS, V133, P274; LONGENECKER JP, 1983, J CELL PHYSIOL, V114, P7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MCKENNA PJ, 1992, AM J PHYSIOL, V263, pH1492, DOI 10.1152/ajpheart.1992.263.5.H1492; OKUYAMA T, 1961, ARCH BIOCHEM BIOPHYS, V95, P242, DOI 10.1016/0003-9861(61)90141-2; RIGGS D, 1988, J APPL PHYSIOL, V64, P2508, DOI 10.1152/jappl.1988.64.6.2508; RINGEL EW, 1984, IMMUNOLOGY, V52, P649; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; RYAN US, 1976, TISSUE CELL, V8, P125, DOI 10.1016/0040-8166(76)90025-2; SELIG WM, 1986, J APPL PHYSIOL, V61, P233, DOI 10.1152/jappl.1986.61.1.233; SIELAFF TD, 1987, SURGERY, V102, P350; SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76, DOI 10.1139/y93-012; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STALCUP SA, 1982, ANN NY ACAD SCI, V384, P435, DOI 10.1111/j.1749-6632.1982.tb21391.x; TAKEDA T, 1992, J CELL SCI, V101, P745; THOMAS DP, 1967, NATURE, V216, P335, DOI 10.1038/216335a0; TILL GO, 1991, FREE RADICAL BIO MED, V10, P379, DOI 10.1016/0891-5849(91)90046-6; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALDMEIER PC, 1977, J NEUROCHEM, V29, P785, DOI 10.1111/j.1471-4159.1977.tb10719.x; WARD PA, 1990, J TRAUMA, V30, pS75; WIENERKRONISH JP, 1990, BRIT J ANAESTH, V65, P107, DOI 10.1093/bja/65.1.107; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZEIGER RS, 1976, J EXP MED, V144, P1049, DOI 10.1084/jem.144.4.1049; ZEIGER RS, 1976, J ALLERGY CLIN IMMUN, V58, P172, DOI 10.1016/0091-6749(76)90152-4; Zeller EA, 1938, HELV CHIM ACTA, V21, P880, DOI 10.1002/hlca.193802101115; ZIMMERMAN GA, 1984, AM REV RESPIR DIS, V129, P798, DOI 10.1164/arrd.1984.129.5.798	61	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32858	32864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806511				2022-12-25	WOS:A1994QA63800024
J	KATZAV, S; SUTHERLAND, M; PACKHAM, G; YI, TL; WEISS, A				KATZAV, S; SUTHERLAND, M; PACKHAM, G; YI, TL; WEISS, A			THE PROTEIN-TYROSINE KINASE ZAP-70 CAN ASSOCIATE WITH THE SH2 DOMAIN OF PROTO-VAV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CELL ANTIGEN RECEPTOR; AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; ZETA-CHAIN; TRANSCRIPTION FACTOR; PROTOONCOGENE PRODUCT	Stimulation of the T cell antigen receptor (TCR) leads to tyrosine phosphorylation of a number of cellular proteins, including the vav proto-oncogene product. We now report the detection of several phosphotyrosine proteins (80, 74, and 70 kDa) from TCR-stimulated T cells that bind to the Src homology 2 (SH2) domain of proto-Vav (Vav-SH2) and co-immunoprecipitate with the proto-Vav product. Their binding to Vav-SH2 differs from that observed with SH2 domains from other proteins. None of the Vav-SH2-associated phosphoproteins bind to either of the Src homology 3 (SH3) domains of proto-Vav or to mutant Vav-SH2 proteins. The association of the phosphoproteins with Vav-SH2 requires induction of tyrosine phosphorylation of cellular proteins since proteins from lysates of herbimycin A-treated TCR-activated T cells fail to associate with Vav-SH2. Among the proteins from T cells that co-immunoprecipitate with the proto-Vav product and bind to its SH2 domain, specific antibodies identified the 70-kDa tyrosine phosphoprotein as ZAP-70, a protein tyrosine kinase (PTK) involved in TCR signal transduction. Binding of this PTK to Vav-SH2 is inhibited by a ZAP-70-specific synthetic tyrosine phosphopeptide. We suggest that ZAP-70 may function as a PTK for proto-Vav.	MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, PQ, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, PQ, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; CLEVELAND CLIN FDN, DEPT CANC BIOL, CLEVELAND, OH 44195 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT IMMUNOL & MICROBIOL, SAN FRANCISCO, CA 94143 USA	McGill University; McGill University; St Jude Children's Research Hospital; Cleveland Clinic Foundation; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	KATZAV, S (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL H3T 1E2, PQ, CANADA.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1992, BRIT J HAEMATOL, V81, P141, DOI 10.1111/j.1365-2141.1992.tb08198.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YI TL, 1991, BLOOD, V78, P2222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	131	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32579	32585						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798261				2022-12-25	WOS:A1994PX30400083
J	LOW, BC; ROSS, IK; GRIGOR, MR				LOW, BC; ROSS, IK; GRIGOR, MR			GLUCOSE DEPRIVATION AND ACUTE CYCLOHEXIMIDE TREATMENT STIMULATE SYSTEM-L AMINO-ACID TRANSPORT IN CULTURED VASCULAR SMOOTH MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC MURINE RETROVIRUSES; ELEVATED GLUCOSE; EXPRESSION CLONING; INSULIN-SECRETION; ENDOTHELIAL-CELLS; SURFACE RECEPTOR; GENE-EXPRESSION; RAT-KIDNEY; GROWTH; METABOLISM	The effect of glucose deprivation on the uptake of leucine has been examined in cultured vascular smooth muscle cells isolated from rat aortae. Equimolar substitution of sucrose or fructose for glucose in the culture medium enhanced the uptake of leucine in a time- and concentration-dependent manner. The effect was first detectable after 12 h and reached the maximum, 2-fold, after 48 h with an apparent half-maximal effect at 1 mM glucose and could be reversed after 48 h of glucose refeeding. The enhanced leucine uptake was completely inhibited by 2-amino-2-norbornane-carboxylic acid, a specific substrate for System L, but not by alpha-(methylamino)isobutyric acid or lysine. Kinetic analyses indicated that this stimulation was mediated via a homogenous system with a 1.7-fold increase in the V-max without any change in the K-m (0.15 mM). Prolonged treatments with cycloheximide (10 mu g/ml) or actinomycin D (10 mu g/ml) blocked this glucose deprivation effect and its reversal. However, cycloheximide also very rapidly stimulated leucine uptake, reaching the maximum, 2.5-fold over the basal at Ih. This effect occurred at concentrations that matched its inhibition on protein synthesis (half-maximal at 0.1 mu g/ml) and could be reproduced with puromycin as well as actinomycin D. The stimulatory effect of cycloheximide was also accompanied by an increase in the V-max but not in the K-m, being sensitive to 2-amino-2-norbornane-carboxylic acid inhibition only, and appeared to occur in an additive manner to that of glucose deprivation. Although the uptake of leucine was stimulated by glucose deprivation and brief exposure to cycloheximide, these treatments had no effect on the efflux of the substrate. These results are all consistent with the System L amino acids transport activity in cultured rat vascular smooth muscle cells being under the control of at least two non-hormonal regulatory mechanisms, one that is likely to involve a labile repressor molecule and the other involving de nova protein synthesis as a result of chronic glucose deprivation.	UNIV OTAGO,DEPT BIOCHEM,DUNEDIN,NEW ZEALAND	University of Otago			Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				ALIPUI C, 1993, CARDIOVASC RES, V27, P1229, DOI 10.1093/cvr/27.7.1229; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BERDANIER CD, 1994, FASEB J, V8, P4; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BROER S, 1994, BBA-BIOMEMBRANES, V1192, P95, DOI 10.1016/0005-2736(94)90147-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CONNELL JMC, 1986, TRENDS PHARMACOL SCI, V7, P412, DOI 10.1016/0165-6147(86)90404-9; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FELIPE A, 1992, BIOCHEM J, V284, P577, DOI 10.1042/bj2840577; GUMA A, 1992, BIOCHEM J, V281, P407, DOI 10.1042/bj2810407; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; Kakuda DK, 1993, TRANSGENE, V1, P91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOIBUCHI Y, 1992, CLIN RES, V40, P150; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LIU QR, 1993, J BIOL CHEM, V268, P22802; LOW BC, 1992, J BIOL CHEM, V267, P20740; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LOW SY, 1994, FASEB J, V8, P127, DOI 10.1096/fasebj.8.1.7905447; MAHADEVAN IC, 1991, NATURE, V249, P747; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MIYAMOTO K, 1993, BIOCHEM J, V295, P211, DOI 10.1042/bj2950211; MIZUTANI M, 1992, BIOCHEM BIOPH RES CO, V187, P664, DOI 10.1016/0006-291X(92)91246-M; MUNIZ R, 1993, PFLUG ARCH EUR J PHY, V423, P59, DOI 10.1007/BF00374961; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; NISHINO H, 1978, P NATL ACAD SCI USA, V75, P5048, DOI 10.1073/pnas.75.10.5048; OLIVETTI G, 1982, CIRC RES, V51, P19, DOI 10.1161/01.RES.51.1.19; ORTIZ PA, 1993, BIOCHEM J, V295, P67, DOI 10.1042/bj2950067; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; ULLREY D, 1975, ARCH BIOCHEM BIOPHYS, V167, P410, DOI 10.1016/0003-9861(75)90481-6; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEIR G C, 1986, Diabetes Metabolism Reviews, V2, P125; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1983, J BIOL CHEM, V258, P8028; WOODLOCK TJ, 1993, J BIOL CHEM, V268, P16020; YOREK MA, 1989, METABOLISM, V38, P16, DOI 10.1016/0026-0495(89)90174-1	54	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32098	32103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798204				2022-12-25	WOS:A1994PX30400016
J	WAKABAYASHI, Y; YAMADA, E; YOSHIDA, T; TAKAHASHI, H				WAKABAYASHI, Y; YAMADA, E; YOSHIDA, T; TAKAHASHI, H			ARGININE BECOMES AN ESSENTIAL AMINO-ACID AFTER MASSIVE RESECTION OF RAT SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMOLOGICAL EVIDENCE; CITRULLINE SYNTHESIS; RADIOCHEMICAL ASSAY; ENDOTHELIAL-CELLS; NITRIC-OXIDE; METABOLISM; GLUTAMATE; PYRROLINE-5-CARBOXYLATE; REQUIREMENTS; LIVER	We compared effects of feeding arginine- and/or proline- deficient diets (-Arg, -Pro, and -Arg,Pro) with those of a complete diet (Complete) in rats whose small intestine had been massively resected. After 4 weeks, the rats fed -Arg and -Arg,Pro lost weight (a mean of 28 and 32 g, respectively), whereas those fed Complete and -Pro gained 80 and 58 g,respectively, The average nitrogen balance was about 117, 100, -20 and -14 mg/day for Complete, -Pro, -Arg, and -Arg,Pro diets, respectively. The concentration of arginine in skeletal muscle was about 310, 330, 91, and 65 nmol/g for Complete, -Pro, -Arg, and -Arg,Pro, respectively; while plasma arginine concentration averaged 95, 107, 56, and 46 mu M, respectively. The weight loss, the negative nitrogen balance, and the markedly reduced arginine concentration in the muscle observed in rats fed -Arg and -Arg,Pro clearly indicate that arginine becomes a strictly essential amino acid in the rats with massive resection of the small intestine. However, sufficient proline can be synthesized from arginine in tissues such as the liver and kidney in the absence of the small intestine. Plasma glutamine, citrulline in the muscle and plasma, urinary excretion of erotic acid and nitrate (to assess nitric oxide formation from arginine) were also measured, and the changes in these metabolites are discussed.	KYOTO PREFECTURAL UNIV MED,DEPT ANESTHESIOL,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT CLIN LAB & MED,KYOTO 602,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT INTERNAL MED 1,KYOTO 602,JAPAN	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	WAKABAYASHI, Y (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT BIOCHEM,465 KAJIICHO HIROKOJI KAWARAMACHI KAMIKYOKU,KYOTO 602,JAPAN.							BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BONSNES RW, 1945, J BIOL CHEM, V158, P581; DEPOCAS F, 1951, REV CAN BIOL, V10, P289; DHANAKOTI SN, 1990, AM J PHYSIOL, V259, pE437, DOI 10.1152/ajpendo.1990.259.3.E437; DROTMAN RB, 1972, AM J PHYSIOL, V222, P973, DOI 10.1152/ajplegacy.1972.222.4.973; EAGLE H, 1965, J BIOL CHEM, V240, P3944; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; FEATHERSTON WR, 1973, AM J PHYSIOL, V224, P127, DOI 10.1152/ajplegacy.1973.224.1.127; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOSTER LB, 1971, CLIN CHEM, V17, P921; GIETZEN DW, 1993, J NUTR, V123, P610, DOI 10.1093/jn/123.4.610; GRAZER RE, 1984, ARCH INTERN MED, V144, P2278, DOI 10.1001/archinte.144.11.2278; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; HASSAN AS, 1981, METABOLISM, V30, P739, DOI 10.1016/0026-0495(81)90018-4; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HOOGENRAAD N, 1985, AM J PHYSIOL, V249, pG792, DOI 10.1152/ajpgi.1985.249.6.G792; IRWIN MI, 1971, J NUTR, V101, P539; JONES ME, 1961, ARCH BIOCHEM BIOPHYS, V95, P499, DOI 10.1016/0003-9861(61)90182-5; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; LEUNG PMB, 1968, J NUTR, V96, P303, DOI 10.1093/jn/96.3.303; MEZL VA, 1977, BIOCHEM J, V166, P105, DOI 10.1042/bj1660105; MILNER JA, 1979, J NUTR, V109, P663, DOI 10.1093/jn/109.4.663; MILNER JA, 1978, J NUTR, V108, P382, DOI 10.1093/jn/108.3.382; MILNER JA, 1975, METABOLISM, V24, P643, DOI 10.1016/0026-0495(75)90144-4; MILNER JA, 1974, J NUTR, V104, P1681, DOI 10.1093/jn/104.12.1681; MILNER JA, 1973, NATURE, V245, P212; MORGAN JF, 1958, J BIOL CHEM, V233, P664; Munro HN, 1970, MAMMALIAN PROTEIN ME, V4, P299; RAIJMAN L, 1974, BIOCHEM J, V138, P225, DOI 10.1042/bj1380225; RATNER S, 1980, ANAL BIOCHEM, V106, P134, DOI 10.1016/0003-2697(80)90129-3; RATNER S, 1983, ANAL BIOCHEM, V135, P479, DOI 10.1016/0003-2697(83)90716-9; Rose WC, 1938, PHYSIOL REV, V18, P109, DOI 10.1152/physrev.1938.18.1.109; SALLACH HJ, 1951, J AM CHEM SOC, V73, P4500, DOI 10.1021/ja01153a551; SCUDAMORE CH, 1983, GASTROENTEROLOGY, V84, P725; Scull CW, 1930, J BIOL CHEM, V89, P109; SMITH AD, 1967, BIOCHEM J, V104, P557, DOI 10.1042/bj1040557; STAJNER A, 1968, EXPERIENTIA, V24, P116, DOI 10.1007/BF02146929; Stetten MR, 1944, J BIOL CHEM, V153, P113; STETTEN MR, 1951, J BIOL CHEM, V189, P499; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P1, DOI 10.1016/0003-9861(91)90097-3; WAKABAYASHI Y, 1991, ARCH BIOCHEM BIOPHYS, V291, P9, DOI 10.1016/0003-9861(91)90098-4; WAKABAYASHI Y, 1983, J BIOL CHEM, V258, P3865; WENNMALM A, 1993, CIRC RES, V73, P1121, DOI 10.1161/01.RES.73.6.1121; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; WINDMUELLER HG, 1981, AM J PHYSIOL, V241, pE473, DOI 10.1152/ajpendo.1981.241.6.E473; WINDMUELLER HG, 1974, J BIOL CHEM, V249, P5070; WOMACK M, 1947, J BIOL CHEM, V171, P37; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; YAMADA E, 1993, LANCET, V341, P1542, DOI 10.1016/0140-6736(93)90687-C	49	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32667	32671						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798273				2022-12-25	WOS:A1994PX30400096
J	WESTWOOD, ME; MCLELLAN, AC; THORNALLEY, PJ				WESTWOOD, ME; MCLELLAN, AC; THORNALLEY, PJ			RECEPTOR-MEDIATED ENDOCYTIC UPTAKE OF METHYLGLYOXAL-MODIFIED SERUM-ALBUMIN - COMPETITION WITH ADVANCED GLYCATION END PRODUCT-MODIFIED SERUM-ALBUMIN AT THE ADVANCED GLYCATION END-PRODUCT RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-MODIFIED PROTEINS; NONENZYMATICALLY GLYCOSYLATED PROTEINS; ALDEHYDE-MODIFIED PROTEINS; LOW-DENSITY LIPOPROTEINS; SCAVENGER RECEPTOR; MAILLARD REACTION; CELL-SURFACE; REACTION INTERMEDIATE; MACROPHAGE RECEPTOR; GLYOXALASE SYSTEM	Methylglyoxal binds and irreversibly modifies arginine and lysine residues in bovine serum albumin (BSA) under physiological conditions, producing a protein with an increased net negative charge at physiological pH. At 4 degrees C, methylglyoxal-modified BSA (MG-BSA) was bound by cell surface receptors on murine P388D(1) macrophages. The apparent dissociation constant K-D value was 435 +/- 2 nM, and there were 8.89 +/- 0.02 x 10(5) receptors/cell (n = 6), compare with an apparent K-D value of 263 +/- 52 nM and 10.17 +/- 0.93 x 10(5) receptors/cell (n = 11) for advanced glycation end product-modified BSA (AGE-BSA). AGE-ESA competed with MG-BSA for binding to a common receptor; however, a component of AGE-BSA receptor binding could not be displaced by MG-BSA, and a component of MG-BSA receptor binding could not be displaced by AGE-BSA, suggesting that there are binding sites for both AGE-BSA and MG-BSA, competitive and noncompetitive, to MG-BSA and AGE-BSA on P388D cells at 4 degrees C. At 37 degrees C, receptor binding of AGE-BSA and MG-BSA was followed by endocytosis and lysosomal degradation of the modified protein. Methylglyoxal-modified proteins are ligands for the AGE receptor, and their formation and metabolism may be linked to the development of diabetic complications.	UNIV ESSEX,DEPT CHEM & BIOL CHEM,COLCHESTER CO4 3SQ,ESSEX,ENGLAND	University of Essex				Thornalley, Paul/0000-0001-7659-443X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED MU, 1986, J BIOL CHEM, V261, P4889; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COSARNO ME, 1983, J CHROMATOGR, V266, P105, DOI 10.1016/S0021-9673(01)90883-0; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1988, J BIOL CHEM, V263, P18821; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; IMANI F, 1993, J EXP MED, V178, P2165, DOI 10.1084/jem.178.6.2165; JOHANSSON BG, 1972, SCAND J CLIN LAB INV, V29, P7, DOI 10.3109/00365517209102747; KARONEN SL, 1975, ANAL BIOCHEM, V67, P1, DOI 10.1016/0003-2697(75)90266-3; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; KAWAKISHI S, 1991, CARBOHYD RES, V211, P167, DOI 10.1016/0008-6215(91)84156-9; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO TWC, 1994, J BIOL CHEM, V269, P32299; Lo TWC, 1993, AMINO ACIDS, V5, P172; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MCLELLAN AC, 1992, ANAL CHIM ACTA, V263, P137, DOI 10.1016/0003-2670(92)85435-9; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; NJOROGE FG, 1989, MAILLARD REACTION AG, P85; Phillips S. A., 1993, BIOCHEM SOC T, V21, P163, DOI DOI 10.1042/BST021163S; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHIN DB, 1988, AGR BIOL CHEM TOKYO, V52, P1451; SHINODA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1826, DOI 10.1271/bbb.57.1826; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SMITH PR, 1993, CLIN SCI, V84, P87, DOI 10.1042/cs0840087; SMITH RE, 1978, ANAL BIOCHEM, V90, P246, DOI 10.1016/0003-2697(78)90029-5; TAKATA K, 1988, J BIOL CHEM, V263, P14819; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V986, P18, DOI 10.1016/0005-2736(89)90267-8; TEZUKA M, 1993, BIOCHEM BIOPH RES CO, V193, P674, DOI 10.1006/bbrc.1993.1677; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1988, BIOCHEM J, V254, P751, DOI 10.1042/bj2540751; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515	54	94	98	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32293	32298						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798229				2022-12-25	WOS:A1994PX30400044
J	TAKEDA, S; NORTH, DL; DIAGANA, T; MIYAGOE, Y; LAKICH, MM; WHALEN, RG				TAKEDA, S; NORTH, DL; DIAGANA, T; MIYAGOE, Y; LAKICH, MM; WHALEN, RG			MYOGENIC REGULATORY FACTORS CAN ACTIVATE TATA-CONTAINING PROMOTER ELEMENTS VIA AN E-BOX INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; CREATINE-KINASE ENHANCER; MUSCLE-SPECIFIC ENHANCER; ALPHA-SUBUNIT GENE; DNA-BINDING; SKELETAL-MUSCLE; TRANSCRIPTION INITIATION; IMMUNOGLOBULIN ENHANCER; MYOD FAMILY; EXPRESSION	We have studied the effect of several myogenic regulatory factors on the activity of the promoter for a mouse gene encoding a skeletal myosin heavy chain (MyHC) expressed in adult (type IIB) muscle fibers. Co-transfection of myogenic factors is necessary for activity of the IIB promoter in mouse C2 myotubes in culture but not in quail myotubes in culture. Although this promoter contains one E-box within the first 199 base pairs upstream of the transcriptional start site, mutations in this motif demonstrate that it is not required for the transactivation effect of the myogenic factors. Analysis of other mutants suggests that the MEF2 and MHox DNA-binding factor binds to an evolutionarily conserved AT-rich motif. In addition, the RR promoter appears to require the conserved TATA motif (CTATAAAAG) in order to be activated by the AT-rich sequences. The IIB promoter constructs produce RNA transcripts which begin at the natural site of transcriptional initiation in quail myotubes and in mouse Ca myotubes after co-transfection with myogenic factors; a second, minor, start site is also used in the co-transfected C2 myotubes. Results obtained after transfection of the mouse IIB promoter constructs in quail myotube cultures suggest that the overexpression of myogenic factors in C2 cultures does not result in an environment in which the control of IIB MyHC promoter activity is aberrant. Therefore, either the myogenic factors themselves, or other proteins induced by them, seem to interact directly with the basal transcription machinery to allow muscle-specific gene expression.	INST PASTEUR,DEPT MOLEC BIOL,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								AURADE F, 1994, DIFFERENTIATION, V55, P185, DOI 10.1046/j.1432-0436.1994.5530185.x; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V8, P5022; GREENBLATT J, 1992, NATURE, V360, P16, DOI 10.1038/360016a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1983, J BIOL CHEM, V258, P3883; MONTARRAS D, 1991, NEW BIOL, V3, P592; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUSSELL SD, 1993, DEV BIOL, V157, P359, DOI 10.1006/dbio.1993.1141; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TAKEDA S, 1992, CR ACAD SCI III-VIE, V315, P467; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TIMMERS HTM, 1992, GENE DEV, V5, P1946; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	53	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15664	15670		10.1074/jbc.270.26.15664	http://dx.doi.org/10.1074/jbc.270.26.15664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797566	hybrid			2022-12-25	WOS:A1995RG53800037
J	SRINIVASAN, M; KALOUSEK, F; FARRELL, L; CURTHOYS, NP				SRINIVASAN, M; KALOUSEK, F; FARRELL, L; CURTHOYS, NP			ROLE OF THE N-TERMINAL-118 AMINO-ACIDS IN THE PROCESSING OF THE RAT RENAL MITOCHONDRIAL GLUTAMINASE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION; CLEAVAGE; PROTEINS; KIDNEY	Rat renal mitochondrial glutaminase (GA) is synthesized as a 74-kDa cytosolic precursor that is translocated into mitochondria and processed via a 72-kDa intermediate to yield a 3:1 ratio of mature 66- and 68-kDa subunits, respectively. The 66 kDa subunit is derived by removal of a 72-amino-acid presequence, The structural determinants necessary for translocation and proteolytic processing were further delineated by characterizing the processing of different chimeric constructs formed by fusing various segments of the N-terminal sequence of the GA precursor to chloramphenicol acetyl transferase (CAT). GA(1-118)CAT is translocated and processed in isolated rat liver mitochondria or cleaved by purified mitochondrial processing peptidase (MPP) to yield an intermediate peptide and two mature subunits that are analogous to the products of processing of the GA precursor. The two reactions also occur with kinetics which are similar to those observed for processing of the GA precursor, Thus, all of the information required for the translocation and synthesis of the mature subunits of GA reside in the N-terminal 118 amino acids of the GA precursor. In contrast, GA(1-72)CAT, a construct that contains the GA presequence fused to CAT, is apparently translocated and processed less efficiently. It yields only two peptides that are analogous to the intermediate and 68 kDa forms of GA. In addition, GA(1-31)CAT associates with mitochondria but is not proteolytically processed and GA(1-31,73-118)CAT is slowly translocated and processed to a single peptide that is analogous to the 66 kDa form of GA, The latter results suggest that the MPP cleavage reactions which yield the GA intermediate and the 66 kDa subunit depend primarily on information that is present C-terminal to the respective sites of cleavage.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06520	Colorado State University; Yale University					NIDDK NIH HHS [DK-37124, DK-09527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRETZ M, 1994, J BIOL CHEM, V269, P4959; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; CURTHOYS NP, 1988, PH HOMEOSTASIS MECHA, P323; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HASER WG, 1985, BIOCHEM J, V229, P399, DOI 10.1042/bj2290399; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERERA SY, 1990, J BIOL CHEM, V265, P17764; ROBBEN J, 1993, J BIOL CHEM, V268, P24555; ROISE D, 1993, AMPHIPATHIC HELIX, P257; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHAPIRO RA, 1991, J BIOL CHEM, V266, P18792; SRINIVASAN M, 1995, J BIOL CHEM, V270, P1185, DOI 10.1074/jbc.270.3.1185; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	23	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1191	1197		10.1074/jbc.270.3.1191	http://dx.doi.org/10.1074/jbc.270.3.1191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836379	hybrid			2022-12-25	WOS:A1995QB15600034
J	BOS, CR; SHANK, SL; SNIDER, MD				BOS, CR; SHANK, SL; SNIDER, MD			ROLE OF CLATHRIN-COATED VESICLES IN GLYCOPROTEIN TRANSPORT FROM THE CELL-SURFACE TO THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; INTEGRAL MEMBRANE-PROTEIN; CULTURED HUMAN-CELLS; FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; BREFELDIN-A; INTRACELLULAR MOVEMENT; CYTOPLASMIC DOMAIN	Plasma membrane glycoproteins recycle to the Golgi complex, but the route followed by these proteins is not known. To elucidate the pathway of transport, the involvement of clathrin-coated vesicles was tested. This was accomplished by comparing the traffic of wild type low density lipoprotein receptor (LDLR) and FEZ 683, a mutant receptor whose endocytosis from the cell surface in coated vesicles is reduced by 90-95%. Wild type LDLR traveled from the cell surface to the sialyltransferase compartment of the Golgi with a half-time of 2.5 h in K562 human leukemia cells expressing receptor from a transfected cDNA. In contrast, FH 683 LDLR recycled to the Golgi at 33% of the wild type rate, suggesting that wild type LDLR is largely transported to the Golgi by a pathway that involves clathrin-coated vesicles. Moreover, because clathrin coated vesicles that bud from the plasma membrane are transported to endosomes, surface-to-Golgi transport probably involves an endosomal intermediate. Finally, because there was substantial transport of mutant LDLR to the Golgi even though its endocytosis in coated vesicles was greatly reduced, there may be a second pathway of surface-to-Golgi traffic. Our results suggest that wild type LDLR may move from plasma membrane to Golgi by two routes. Two-thirds of the traffic proceeds via a coated vesicle-mediated pathway while the remainder may follow a clathrin-independent pathway.			BOS, CR (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038183] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BONIFACINO JS, 1989, J CELL SCI, V92, P701; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DRAPER RK, 1990, SCIENCE, V248, P1539, DOI 10.1126/science.2163108; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FISHMAN JB, 1987, CELL, V48, P157, DOI 10.1016/0092-8674(87)90366-7; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HUANG KM, 1993, J BIOL CHEM, V268, P9302; HULL SR, 1991, J BIOL CHEM, V266, P13580; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNTER A, 1989, EXP CELL RES, V182, P445, DOI 10.1016/0014-4827(89)90249-8; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; HURTLEY SM, 1993, J CELL SCI, V106, P649; JIN M, 1989, J BIOL CHEM, V264, P7675; JIN MJ, 1993, J BIOL CHEM, V268, P18390; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREISEL W, 1993, BIOL CHEM H-S, V374, P255, DOI 10.1515/bchm3.1993.374.1-6.255; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; ROBERTSON BJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P190, DOI 10.1016/0003-9861(92)90067-7; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SNIDER MD, 1991, INTRACELLULAR TRAFFI, P361; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOODS JW, 1985, J CELL BIOL, V102, P277	53	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					665	671		10.1074/jbc.270.2.665	http://dx.doi.org/10.1074/jbc.270.2.665			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822293	hybrid			2022-12-25	WOS:A1995QB81600027
J	CAO, XJ; ZHOU, YH; LEE, AS				CAO, XJ; ZHOU, YH; LEE, AS			REQUIREMENT OF TYROSINE AND SERINE/THREONINE KINASE IN THE TRANSCRIPTIONAL ACTIVATION OF THE MAMMALIAN GRP78/BIP PROMOTER BY THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; OKADAIC ACID; GENE-EXPRESSION; HAMSTER FIBROBLASTS; TUMOR PROMOTER; CELL-LINE; TRANSMEMBRANE PROTEIN; MALFOLDED PROTEINS; CALCIUM IONOPHORE; BREFELDIN-A	Depletion of endoplasmic reticulum (ER) Ca2+ store by thapsigargin (Tg) in mammalian cells induces a set of ER protein genes known as the glucose-regulated proteins. Recently, IRE1p, a transmembrane protein postulated to have a serine/threonine kinase activity, has been identified as required for the induction of ER resident proteins genes in Saccharomyces cerevisiae. To investigate whether IRE1p can stimulate mammalian grp transcription, a stable Chinese hamster ovary cell line containing amplified copies of IRE1p has been created. The IRE1p expressing transfectants exhibited a modest (2-fold) enhancement of both the basal and Tg induced level of grp78 and grp94, two coordinately regulated grp genes. Using okadaic acid as a specific inhibitor for the endogenous serine/threonine protein phosphatase activities, a mild (2-fold) stimulative effect was observed for Tg induction of grp78 transcription. The okadaic acid potentiating ef feet requires a 50-base pair region in the vicinity of the grp78 TATA element. In contrast, the transcriptional activation of grp78 by Tg is almost totally eliminated by genistein, a tyrosine kinase inhibitor. The grp core, the C3 and C1 elements which are major Tg response elements of the rat grp78 promoter, are also major targets of the inhibitive effects of genistein.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [R37 CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; BALDARI CT, 1994, EUR J IMMUNOL, V24, P1046, DOI 10.1002/eji.1830240506; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHAUHAN D, 1994, CANCER RES, V54, P2234; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUY GR, 1992, J BIOL CHEM, V267, P1846; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HYUN SW, 1994, J BIOL CHEM, V269, P364; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KIM YK, 1989, GENE, V77, P123, DOI 10.1016/0378-1119(89)90366-1; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LI X, 1989, MOL ENDOCRINOL, V3, P1944, DOI 10.1210/mend-3-12-1944; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LIU ES, 1992, J BIOL CHEM, V267, P7128; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; LIU Z, 1994, BIOTECHNIQUES, V16, P56; MORI K, 1993, CELL, V74, P743; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1992, NEW BIOL, V4, P16; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WERA S, 1993, MOL ENDOCRINOL, V7, P965, DOI 10.1210/me.7.8.965; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	45	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					494	502		10.1074/jbc.270.1.494	http://dx.doi.org/10.1074/jbc.270.1.494			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814417	hybrid			2022-12-25	WOS:A1995QA28700077
J	KORNER, C; NURNBERG, B; UHDE, M; BRAULKE, T				KORNER, C; NURNBERG, B; UHDE, M; BRAULKE, T			MANNOSE 6-PHOSPHATE INSULIN-LIKE GROWTH-FACTOR-II RECEPTOR FAILS TO INTERACT WITH G-PROTEINS - ANALYSIS OF MUTANT CYTOPLASMIC-RECEPTOR DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; BETA-ADRENERGIC-RECEPTOR; PERTUSSIS-TOXIN; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; LYSOSOMAL-ENZYMES; HUMAN-FIBROBLASTS; CALCIUM INFLUX; IGF RECEPTOR	The binding of insulin-like growth factor II (IGF II) to the mannose 6-phosphate (M6P)/IGF II receptor has previously been reported to induce the activation of trimeric G(12) proteins by functional coupling to a 14-amino acid region within the cytoplasmic receptor domain (Nishimoto, I., Murayama, Y,, Hatada, T,, Ui, M,, and Ogata, E, (1989) J, Biol, Chem, 264, 14029-14038), In the present study, we examined further the potential functional coupling of G-proteins with the human M6P/IGF II receptor and mutant receptors lacking the proposed G-protein activator sequence, IGF II treatment of mouse L-cells expressing either wild type or mutant M6P/IGF II receptors failed to attenuate the pertussis toxin-catalyzed modification of a 40-kDa protein or enhance GTPase activity, In broken L-cell membranes expressing wild type or mutant M6P/IGF II receptors, 30 nM IGF II also failed to affect the pertussis toxin substrate activity, By using phospholipid vesicles reconstituted with human wild type or mutant M6P/IGF II receptors and pertussis toxin-sensitive G-proteins, no stimulation of GTP gamma S binding to or GTPase activity of G(i2), G(o1), or G(i)/G(o) mixtures were observed in response to 1 mu M IGF II, Furthermore, in vesicles containing purified wild type M6P/IGF II receptors and monomeric G alpha(o1) or G alpha(i2), and beta gamma dimers no effects of IGF II on GTP gamma S binding could be detected, However, when vesicles reconstituted with M6P/IGF II receptors and G(i2) proteins were incubated with 100 mu M mastoparan GTP gamma S binding was stimulated and GTPase activity was increased significantly, These results indicate that the human M6P/IGF II receptor neither interacts with G proteins in mouse L-cell membranes nor is coupled to G(i2) proteins in phospholipid vesicles, This study suggests strongly that the M6P/IGF II receptor does not function in transmembrane signaling in response to IGF II.	UNIV GOTTINGEN, INST BIOCHEM 2, D-37073 GOTTINGEN, GERMANY; FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	University of Gottingen; Free University of Berlin			Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532; Nurnberg, Bernd/0000-0002-5995-6555				BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1990, EUR J BIOCHEM, V189, P609, DOI 10.1111/j.1432-1033.1990.tb15529.x; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BUERGISSER DM, 1991, J BIOL CHEM, V266, P1029; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHURCH JG, 1988, J BIOL CHEM, V263, P4242; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1991, METHOD ENZYMOL, V195, P177; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; DAMKE H, 1994, MOL CELL ENDOCRINOL, V99, pR25, DOI 10.1016/0303-7207(94)90026-4; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; GUSE AH, 1992, ENDOCRINOLOGY, V130, P145, DOI 10.1210/en.130.1.145; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARTMANN H, 1992, DIABETOLOGIA, V35, P216, DOI 10.1007/BF00400920; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KIESS W, 1987, J BIOL CHEM, V262, P12745; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MELLAS J, 1986, J BIOL CHEM, V261, P4437; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NURNBERG B, 1994, BIOCHEM J, V300, P387; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; ROSENTHAL W, 1986, EUR J BIOCHEM, V158, P255, DOI 10.1111/j.1432-1033.1986.tb09745.x; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SAYERS JR, 1989, PROTEIN FUNCTION PRA, P279; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; SHIMIZU M, 1986, AM J PHYSIOL, V251, pE611, DOI 10.1152/ajpendo.1986.251.5.E611; SPICHER K, 1992, FEBS LETT, V307, P215, DOI 10.1016/0014-5793(92)80770-H; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; TAKAHASHI K, 1993, P NATL ACAD SCI USA, V90, P11772, DOI 10.1073/pnas.90.24.11772; THAKKER JK, 1989, J BIOL CHEM, V264, P7169; TONG PY, 1988, J BIOL CHEM, V263, P2585; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WALKER F, 1993, J BIOL CHEM, V268, P19552; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379	66	89	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					287	295		10.1074/jbc.270.1.287	http://dx.doi.org/10.1074/jbc.270.1.287			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814388	hybrid			2022-12-25	WOS:A1995QA28700046
J	ZU, YL; AI, YX; HUANG, CK				ZU, YL; AI, YX; HUANG, CK			CHARACTERIZATION OF AN AUTOINHIBITORY DOMAIN IN HUMAN MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN-KINASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP-KINASE; SIGNAL-TRANSDUCTION; IDENTIFICATION; PHOSPHORYLATION; RAF; PURIFICATION; SEQUENCE; PATHWAY; INVITRO	Mitogen-activated protein (MAP) kinase-activated protein kinase 2, a Ser/Thr kinase, is phosphorylated and activated by MAP kinase. Sequence analysis of a clone isolated from the human HL-60 cell line revealed a 370-amino acid protein with a proline-rich N terminus, a highly conserved catalytic domain, and a C-terminal region containing a MAP kinase phosphorylation site. To better understand how the kinase is regulated, mutation analysis was used to map the functional domain(s). The wild type recombinant kinase had a low basal activity as detected by phosphorylation of a substrate peptide derived from the N terminus of glycogen synthase. Deletion of the proline rich N terminus showed little effect on the basal activity. Deletion of the C terminus resulted in a marked increase in catalytic activity either with or without the pretreatment of the kinase by MAP kinase. Further analysis indicated that amino acid residues 339-353 in the C-terminal region were acting as an autoinhibitory domain. A synthetic peptide (RVLKEDK-ERWEDVK-amide) derived from this autoinhibitory do main inhibited the kinase activity in a concentration-dependent manner. These results suggest a regulatory model for the kinase.	UNIV CONNECTICUT, CTR HLTH, DEPT PATHOL, FARMINGTON, CT 06030 USA	University of Connecticut					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020943] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20943] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ENGEL K, 1993, FEBS LETT, V336, P143, DOI 10.1016/0014-5793(93)81628-D; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HJELMQUIST G, 1974, BIOCHEM BIOPH RES CO, V61, P559, DOI 10.1016/0006-291X(74)90993-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MING Z, 1993, J BIOL CHEM, V268, P35; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566; ZU YL, 1992, J BIOL CHEM, V267, P20181	44	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					202	206		10.1074/jbc.270.1.202	http://dx.doi.org/10.1074/jbc.270.1.202			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814374	hybrid			2022-12-25	WOS:A1995QA28700034
J	BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF				BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF			CELL PROLIFERATION AND CELL-CYCLE PROGRESSION ARE NOT IMPAIRED IN FIBROBLASTS AND ES CELLS LACKING C-FOS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; CELL CYCLE; ES CELLS; FIBROBLASTS	EMBRYONIC STEM-CELLS; TRANSGENIC MICE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; NERVOUS-SYSTEM; ANTISENSE RNA; NULL MUTATION; AP-1 ACTIVITY; DNA-SYNTHESIS; JUN	The transcription factor AP-1 is thought to play an important role in the control of cell proliferation, but the function of individual Fos and Jun family members is a largely unresolved issue. To directly analyse the function of c-Fos in the control of cell proliferation we have used embryonic stem (ES) cells and fibroblasts lacking c-Fos due to a disruption of the c-fos gene by homologous recombination, Our results demonstrate that proliferation of normally cycling cells and reentry of quiescent cells into the cell cycle following serum stimulation are not c-Fos-dependent and occur with similar efficiency in c-fos-/- and control cells. We also show that there is no compensatory overexpression or activation of other known Pos or Jun family members. On the contrary, the c-fos-/- cells showed a reduced induction of fra-1 after serum stimulation which is in agreement with the previous identification of fra-1 as a c-Fos target gene. Comparison of the AP-1 binding and transactivation activities in c-fos-/- and +/+ fibroblasts by electrophoretic mobility antibody supershift and CAT assays suggests that c-Fos is not a major component of AP-1 complexes in these cells. It is therefore conceivable that the lack of any detectable effect on cell proliferation in c-fos-/- cells might be due to a functional redundancy among the different AP-1 family members.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Müller, Rolf/L-4997-2016; Martin, Schreiber/F-2175-2013	Müller, Rolf/0000-0003-3339-4248; Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BRASELMANN S, 1992, J CELL SCI S, V16, P97; BURKERT U, 1991, NEW BIOL, V3, P698; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GORMAN CM, 1982, P NATL ACAD SCI USA, V79, P433; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Grigoriadis Agamemnon E., 1993, P497; HILBERG F, 1992, ONCOGENE, V7, P2371; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OKUNO H, 1991, ONCOGENE, V6, P1491; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859	46	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824281				2022-12-25	WOS:A1995QA98000010
J	ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E				ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E			P53-DEPENDENT PATHWAY OF RADIO-INDUCED APOPTOSIS IS ALTERED IN FANCONI-ANEMIA	ONCOGENE			English	Article						P53; APOPTOSIS; FANCONI ANEMIA; RADIATIONS	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; CELL-CYCLE CONTROL; ATAXIA-TELANGIECTASIA; GROWTH-ARREST; GENE AMPLIFICATION; MICE DEFICIENT; LEUKEMIC-CELLS; G2 PHASE	Fanconi anemia belongs to a group of human genetic diseases characterized by chromosomal instability, sensitivity to genotoxic agents associated to impaired processing of DNA lesions, cell cycle anomalies and cancer predisposition. We recently added to this list of distinctive features reduced production of interleukin 6 and overproduction of tumor necrosis factor alpha. Since growth factor deprivation, TNF alpha treatment or DNA damage can trigger apoptosis, we monitored the apoptotic response of FA cell lines. We show here that, although the spontaneous rate of apoptosis is slightly more elevated in FA than in normal cell cultures, the apoptosis induced by gamma-irradiation is drastically reduced in FA. Since the induction of apoptosis by radiation is a p53-dependent mechanism, the induction of this protein in FA cells was also examined. We found that the p53 protein is not radio-induced in FA cells belonging to the two genetic complementation groups examined (C and D), in contrast to normal cells. Moreover, the same impairment in p53 induction is observed after exposure to mitomycin C, a chemical agent for which FA cells demonstrate a specific cellular and chromosomal hypersensitivity, as well as after u.v.-B irradiation, an agent known to cause oxidative stress. These observations are in line with recent reports showing that at least certain cell lines from other chromosome breakage syndromes, such as ataxia telangiectasia and Bloom syndrome, may be also defective for radiation-induced increase of p53 protein. As the p53 tumor suppressor gene encodes a transcriptional activator whose targets include genes that regulate genomic stability, cellular response to DNA damage and cell cycle progression, we suggest that altered expression of p53 may be relevant to the FA phenotype.	INST GENET MOLEC, INSERM, U301, F-75010 PARIS, FRANCE; INST CURIE, DEPT RADIOTHERAPIE, MED SECT, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROSSELLI, F (corresponding author), INST CURIE, CNRS, URA 1292, 26 RUE ULM, F-75231 PARIS 05, FRANCE.		Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; soussi, thierry/0000-0001-8184-3293				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; BAGNARA GP, 1993, STEM CELLS, V11, P137; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BEUTLER B, 1990, Critical Reviews in Oncogenesis, V2, P9; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GLUCKMAN E, 1990, RADIOTHER ONCOL S, V1, P88; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; JENSEN PO, 1994, CYTOMETRY, V15, P154, DOI 10.1002/cyto.990150209; JONVEAUX P, 1991, NOUV REV FR HEMATOL, V33, P343; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, ONCOGENE, V5, P973; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; PARSHAD R, 1983, P NATL ACAD SCI-BIOL, V80, P5612, DOI 10.1073/pnas.80.18.5612; PERDAHL EB, 1994, BLOOD, V83, P645; ROSSELLI F, 1994, BLOOD, V83, P1216; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; STRATHDEE CA, 1992, AM J PEDIAT HEMATOL, V14, P177; VANLAAR T, 1994, ONCOGENE, V9, P981; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGNER RD, 1991, ADV MUTAGENESIS RES, V3, P81; WEICHSELBAUM RR, 1980, CANCER RES, V40, P920; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEKSBERG R, 1979, J CELL PHYSIOL, V101, P311, DOI 10.1002/jcp.1041010211; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	65	65	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824283				2022-12-25	WOS:A1995QA98000002
J	SCHERF, T; HILLER, R; ANGLISTER, J				SCHERF, T; HILLER, R; ANGLISTER, J			NMR OBSERVATION OF INTERACTIONS IN THE COMBINING SITE REGION OF AN ANTIBODY USING A SPIN-LABELED PEPTIDE ANTIGEN AND NOESY DIFFERENCE SPECTROSCOPY	FASEB JOURNAL			English	Article						PROTEIN NMR; ANTIBODY STRUCTURE	3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; MAGNETIC-RESONANCE; PROTEINS; SEQUENCES; COMPLEXES; RESIDUES; LIGANDS; HAPTEN	A spin-labeled peptide antigen (TEMPO-VEVPGSQHIDSQ) was used to measure NOESY difference spectra that show interactions in the binding site region of the Fab fragment of the anti-cholera toxin peptide antibody TE33. In addition to identification of peptide-Fab interactions and interactions within the bound peptide, these difference spectra show well-resolved cross peaks due to interactions within the large Fab fragment (50 kDa). These difference spectra indicate that the conformational changes in the Fab upon peptide binding are confined to the combining site region of the antibody. The NOESY difference spectra of selectively deuterated Fab molecules were used in combination with HOHAHA measurements to assign the interactions to amino acid type and to identify the interactions within the Fab as either inter- or intraresidue interactions. The assignment of interactions within the Fab to corresponding aromatic residues in the Fab sequence was facilitated by an earlier NMR-derived model calculated on the basis of NOE restraints on Fab-peptide and intra-bound-peptide distances. The new restraints on distances within the Fab, combined with the previously obtained restraints, were used to generate a refined NMR-derived model for the TE33-peptide complex.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ANGLISTER J, 1984, BIOCHEMISTRY-US, V23, P5372, DOI 10.1021/bi00317a041; ANGLISTER J, 1984, BIOCHEMISTRY-US, V23, P1138, DOI 10.1021/bi00301a016; ANGLISTER J, 1989, BIOCHEMISTRY-US, V28, P3360, DOI 10.1021/bi00434a035; ANGLISTER J, 1990, BIOCHEMISTRY-US, V29, P921, DOI 10.1021/bi00456a011; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1989, METHOD ENZYMOL, V176, P151; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COHN M, 1971, ACCOUNTS CHEM RES, V4, P214, DOI 10.1021/ar50042a004; DEJONG EAM, 1988, J MAGN RESON, V80, P197, DOI 10.1016/0022-2364(88)90291-0; DWEK RA, 1975, EUR J BIOCHEM, V53, P25, DOI 10.1111/j.1432-1033.1975.tb04038.x; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; Kabat EA, 1991, SEQUENCES PROTEINS I, P647; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; MOONEN CTW, 1984, EUR J BIOCHEM, V141, P323, DOI 10.1111/j.1432-1033.1984.tb08195.x; NAKAYAMA T, 1993, BIOCHEMISTRY-US, V32, P13961, DOI 10.1021/bi00213a028; ODAKA A, 1992, BIOCHEMISTRY-US, V31, P10686, DOI 10.1021/bi00159a007; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; SCHERF T, 1993, BIOPHYS J, V64, P754, DOI 10.1016/S0006-3495(93)81436-X; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; WAGNER G, 1993, J BIOMOL NMR, V3, P375; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; ZILBER B, 1990, BIOCHEMISTRY-US, V29, P10032, DOI 10.1021/bi00495a004	25	10	10	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					120	126		10.1096/fasebj.9.1.7821751	http://dx.doi.org/10.1096/fasebj.9.1.7821751			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821751				2022-12-25	WOS:A1995QD20200019
J	KJELDSEN, T; WIBERG, FC; ANDERSEN, AS				KJELDSEN, T; WIBERG, FC; ANDERSEN, AS			CHIMERIC RECEPTORS INDICATE THAT PHENYLALANINE-39 IS A MAJOR CONTRIBUTOR TO INSULIN SPECIFICITY OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ALPHA-SUBUNIT; BINDING-SITE; LIGAND SPECIFICITY; GROWTH-FACTORS; AMINO-ACID; REGION; IDENTIFICATION; DETERMINANTS; DOMAIN	The exact nature of how the insulin molecule interacts with the insulin receptor is obscure although chimeric receptors have shown that the ligand specificity of the insulin receptor and the IGF-I receptor (i,e, the sequences that discriminate between insulin and insulinlike growth factor I) reside in different regions of a common binding site and that the N-terminal 68 amino acids of the insulin receptor are involved in conferring specificity for insulin on this receptor (Kjeldsen, T., Andersen, A, S,, Wiberg, F. C,, Rasmussen, J, S,, Schaffer, L,, Balschmidt, P,, Moller, K, B., and Moller, N, P, H. (1991) Proc, Natl. Acad. Sci, U,S. A, 88, 4404-4408), Using chimeric insulin/IGF-I receptors to elucidate how the insulin receptor interacts with the insulin molecule we identified phenylalanine 39 of the insulin receptor as a major contributor in determining the receptor specificity for insulin, increasing insulin affinity 15-fold when replacing the corresponding amino acid in the insulin-like growth factor I receptor. Furthermore, replacement of the insulin receptor amino acid phenylalanine 39 with the corresponding IGF-I receptor amino acid, serine 35, decreased insulin affinity 8-fold.	NOVO NORDISK AS,BIOSCI,DK-2880 BAGSVAERD,DENMARK	Novo Nordisk	KJELDSEN, T (corresponding author), NOVO NORDISK AS,DIABET RES,NOVO ALLE,DK-2880 BAGSVAERD,DENMARK.			Kjeldsen, Thomas/0000-0003-0094-9286				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HOLLENBERG MD, 1985, INSULIN ITS RECEPTOR, P57; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LEATHERBARROW RJ, 1992, GRAFIT VERSION 3 01; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	27	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32942	32946						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806523				2022-12-25	WOS:A1994QA63800036
J	OLESEN, OF				OLESEN, OF			EXPRESSION OF LOW-MOLECULAR-WEIGHT ISOFORMS OF MICROTUBULE-ASSOCIATED PROTEIN-2 - PHOSPHORYLATION AND INDUCTION OF MICROTUBULE ASSEMBLY IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MOUSE-BRAIN; TAU-PROTEIN; TUBULIN; KINASE; BINDING; DOMAINS; MAP2; POLYMERIZATION; HETEROGENEITY	In rat brain, the microtubule-associated protein 2 (MAPS) contains two low molecular weight isoforms, consisting of 467 and 498 amino acids and designated MAP2c and d, respectively. The present study describes the expression of these isoforms in Escherichia coli and their subsequent purification to homogeneity. On SDS-polyacrylamide gel electrophoresis, the recombinant proteins ran with apparent molecular masses of 69 and 74 kDa. A microtubule-assembling assay demonstrated that the recombinant protein was biologically active and that the tubulin polymerization rate for MAP2d was twice as fast as that for MAP2c. After dephosphorylation with alkaline phosphatase, preparations of low molecular weight MAPS from fetal rat brain aligned with recombinant MAP2c. Moreover, recombinant MAP2c could be phosphorylated with a brain extract kinase activity, resulting in a reduced electrophoretic mobility similar to that observed in fetal MAPS.	AARHUS UNIV,DIV BIOSTRUCT,DK-8000 AARHUS C,DENMARK	Aarhus University			Olesen, Ole/AGN-9447-2022	Olesen, Ole/0000-0002-3025-2466				AIZAWA H, 1988, J BIOL CHEM, V262, P3782; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CRANDALL JE, 1989, J NEUROCHEM, V53, P1910, DOI 10.1111/j.1471-4159.1989.tb09261.x; DOLL T, 1993, J CELL SCI, V106, P633; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KINDLER S, 1990, J BIOL CHEM, V265, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LICHTENBERG B, 1988, NATURE, V334, P359, DOI 10.1038/334359a0; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; Matus A, 1990, CURR OPIN CELL BIOL, V2, P10, DOI 10.1016/S0955-0674(05)80024-9; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; RAY LB, 1988, J BIOL CHEM, V263, P12721; RIEDERER B, 1988, P NATL ACAD SCI USA, V82, P6006; SILLIMAN CC, 1989, BIOCHEM BIOPH RES CO, V160, P993, DOI 10.1016/S0006-291X(89)80099-3; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TUCKER RP, 1988, J NEUROSCI, V8, P4503; VALLEE RB, 1981, J CELL BIOL, V90, P568, DOI 10.1083/jcb.90.3.568; WILLE H, 1992, J BIOL CHEM, V267, P10737	26	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32904	32908						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806517				2022-12-25	WOS:A1994QA63800030
J	REED, VS; WASTNEY, ME; YANG, DCH				REED, VS; WASTNEY, ME; YANG, DCH			MECHANISMS OF THE TRANSFER OF AMINOACYL-TRANSFER-RNA FROM AMINOACYL-TRANSFER-RNA SYNTHETASE TO THE ELONGATION-FACTOR 1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; FACTOR TU-GTP; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; AMPHIPHILIC HELIX; CRYSTAL-STRUCTURE; COMPLEX; YEAST; PYROPHOSPHATASE; DISCRIMINATION	Aspartylation of mammalian tRNA(Asp) by bacteria-expressed human aspartyl-tRNA synthetase (hDRS) was examined, The kinetics of the aspartylation of tRNA was consistent with the following reaction pathway, [GRAPHICS] where E, represents aspartyl-tRNA synthetase. A set of rate constants was obtained which fit single turnover time courses at varying concentrations of the enzyme, tRNA, and AMP using the SAAM program, The dissociation of Asp-tRNA (k(3)) was found to be rate limiting, The elongation factor 1 alpha (EF1 alpha) and GTP stimulated the hDRS aspartylation, The stimulation depended on the presence of both EF1 alpha and GTP, Kinetic analysis indicated that EF1 alpha formed a complex with the hDRS Asp-tRNA complex and stimulated the dissociation of Asp-tRNA In the presence of 0.5 at NH4Cl, which enhances the binding of Asp tRNA by EF1 alpha, hDRS-bound Asp-tRNA can be transferred directly to EF1 alpha. The implications of these results on the function of the multi-tRNA synthetase complex will be discussed.	GEORGETOWN UNIV, DEPT CHEM, WASHINGTON, DC 20057 USA; GEORGETOWN UNIV, DEPT PEDIAT, WASHINGTON, DC 20057 USA	Georgetown University; Georgetown University			Yang, David/A-7294-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-25848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERMAN M, 1962, BIOPHYS J, V2, P275, DOI 10.1016/S0006-3495(62)86855-6; Berman M, 1983, CONSAM USERS GUIDE; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; DIGNAM JD, 1979, BIOCHEMISTRY-US, V18, P3165, DOI 10.1021/bi00581a039; ELDRED EW, 1972, BIOCHEMISTRY-US, V11, P17, DOI 10.1021/bi00751a004; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FETT R, 1991, J BIOL CHEM, V266, P1448; FREIST W, 1984, BIOCHEMISTRY-US, V23, P5742, DOI 10.1021/bi00319a012; GEHRKE L, 1983, P NATL ACAD SCI-BIOL, V80, P3274, DOI 10.1073/pnas.80.11.3274; GHOSH HP, 1967, J MOL BIOL, V25, P275, DOI 10.1016/0022-2836(67)90142-8; HOD Y, 1976, J BIOL CHEM, V251, P4458; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; KHVOROVA AM, 1992, FEBS LETT, V311, P139, DOI 10.1016/0014-5793(92)81385-Y; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; LOUIE A, 1984, J BIOL CHEM, V259, P5010; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; REED VS, 1994, J BIOL CHEM, V269, P32937; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1	30	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32932	32936						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806521				2022-12-25	WOS:A1994QA63800034
J	YANG, L; YANG, YC				YANG, L; YANG, YC			REGULATION OF INTERLEUKIN (IL)-11 GENE-EXPRESSION IN IL-1 INDUCED PRIMATE BONE-MARROW STROMAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; MOLECULAR-CLONING; MAMMALIAN-CELLS; GRO-ALPHA; JUN-D; PROTEIN; TRANSCRIPTION; SEQUENCE	Interleukin (IL)-1 alpha treatment of a primate bone marrow stromal cell line, PU-34, transiently increased the steady state level of IL-11 mRNA, Nuclear run-on experiments showed that the transcription rate of the IL-11 gene was not affected appreciably by IL-1 alpha induction, but changes in the half-life of the IL-11 mRNA corresponded well with the changes in the steady state level of the IL-11 mRNA during the induction, Although transient transfection of PU-34 cells with IL-11 promoter constructs failed to respond to IL-1 alpha, a 10-base pair promoter region and JunD.AP-1 complex were found to be responsible for the basal level transcription of the IL-11 gene, The tyrosine kinase inhibitor genistein accelerated the degradation of the IL-11 mRNA without affecting the transcription rate of the IL-11 gene in IL-1 alpha stimulated cells, The insertion of DNA sequences corresponding spending to the 3'-untranslated region of the IL-11 gene into a rabbit beta-globin gene resulted in destabilization of the chimeric mRNA which failed to be induced by IL-1 alpha. Exogenous IL-11 expression generated from transient transfection with plasmid PCMV-IL-11, however, can be stabilized by IL-1 alpha. In contrast to the hypothesis that AUUUA motifs in the 3'-untranslated region are sufficient to regulate cytokine mRNA stability, our results suggest that IL-1 alpha induced stabilization of the IL-11 mRNA requires participation of RNA sequences from different regions of the IL-11 message.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER I, 1991, ONCOGENE, V6, P561; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1409, DOI 10.1073/pnas.75.3.1409; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELIAS JA, 1990, J IMMUNOL, V145, P161; ELIAS JA, 1994, J IMMUNOL, V152, P2421; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; MAIER R, 1993, J BIOL CHEM, V268, P21527; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MALTER JS, 1990, ENZYME, V44, P203, DOI 10.1159/000468758; MCKINLEY D, 1992, GENOMICS, V13, P814, DOI 10.1016/0888-7543(92)90158-O; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL SR, 1991, BLOOD, V77, P1723; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	44	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32732	32739						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806493				2022-12-25	WOS:A1994QA63800006
J	PASHMFOROUSH, M; YOSHIMASA, Y; STEINER, DF				PASHMFOROUSH, M; YOSHIMASA, Y; STEINER, DF			EXON-11 ENHANCES INSULIN FINDING AFFINITY AND TYROSINE KINASE-ACTIVITY OF THE HUMAN INSULIN PRORECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SPECIFICITY; RECEPTOR PRECURSOR; PROTEIN-KINASE; CLEAVAGE SITE; EXPRESSION; RESISTANCE; CELLS; PHOSPHORYLATION; GLYCOSYLATION; LYMPHOCYTES	Data presented here show that there are significant differences in the insulin binding affinity and the tyrosine kinase activity of the insulin proreceptor isoforms which contain or lack exon 11. The exon 11(+) proreceptor does not show significant variations from the mature processed insulin receptor and has only a 3- to 4-fold reduced affinity for insulin. In contrast, the exon 11(-) proreceptor showed a markedly reduced insulin binding (25- to 50-fold less) when assayed on intact cells. Upon solubilization of the cells, exon 11(-) proreceptor bound insulin with somewhat higher affinity. Mild trypsin sin treatment of the cells expressing either isoform of the insulin proreceptor restored insulin binding to near-normal levels. Analysis of tyrosine kinase activity revealed that the exon 11(+) proreceptor required somewhat higher concentrations of insulin than the mature processed receptor to achieve maximal autophosphorylation. The exon 11(-) proreceptor failed to fully phosphorylate even at 10(-6) M insulin. Thus, the presence or absence of this short sequence of 12 amino acids affects the folding and/or conformation of the proreceptor so as to confer altered binding of insulin. We suggest that in the absence of exon 11 the proreceptor assumes a strained conformation that disrupts the insulin binding site. Cleavage of the proreceptor at the alpha-beta-subunit junction then allows the alpha-subunit to achieve its normal binding conformation.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; Howard Hughes Medical Institute; University of Chicago					NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKAKI RF, 1989, BIOCHEM BIOPH RES CO, V160, P296, DOI 10.1016/0006-291X(89)91655-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P1277, DOI 10.1073/pnas.69.5.1277; CZECH MP, 1985, ANNU REV PHYSIOL, V47, P357, DOI 10.1146/annurev.ph.47.030185.002041; CZECH MP, 1977, ANNU REV BIOCHEM, V46, P359, DOI 10.1146/annurev.bi.46.070177.002043; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HEDO JA, 1983, J BIOL CHEM, V258, P20; KAHN CR, 1985, MOL BASIS INSULIN AC, P67; KAKEHI T, 1988, J CLIN INVEST, V81, P2020, DOI 10.1172/JCI113553; KASUGA M, 1982, J BIOL CHEM, V257, P392; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBAYASHI M, 1988, BIOCHEM BIOPH RES CO, V153, P657, DOI 10.1016/S0006-291X(88)81145-8; KUROSE T, 1994, J BIOL CHEM, V269, P29190; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOSTHAF L, 1991, P NATL ACAD SCI USA, V88, P4728, DOI 10.1073/pnas.88.11.4728; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PANG DT, 1984, J BIOL CHEM, V259, P8589; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PILCH PF, 1980, J BIOL CHEM, V255, P1722; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SASAOKA T, 1989, DIABETOLOGIA, V32, P371, DOI 10.1007/BF00277261; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VORM ERV, 1994, J BIOL CHEM, V269, P14297; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; YOSHIMASA Y, 1989, SCIENCE, V240, P783	42	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32639	32648						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798270				2022-12-25	WOS:A1994PX30400092
J	AOKI, Y; KIM, YT; STILLWELL, R; KIM, TJ; PILLAI, S				AOKI, Y; KIM, YT; STILLWELL, R; KIM, TJ; PILLAI, S			THE SH2 DOMAINS OF SRC FAMILY KINASES ASSOCIATE WITH SYK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES-B; ZETA-CHAIN; STIMULATION; EXPRESSION; GENE; PHOSPHORYLATION; ACTIVATION	Src family kinases (Lyn, Fyn, Lck, and Blk) and Syk, a tandem SH2 domain containing tyrosine kinase, have been demonstrated to be associated with the antigen receptor in B cells. Both of these categories of tyrosine kinases are presumed to be critical players in the process of antigen-mediated signal transduction. Cross linking of membrane immunoglobulin on the surface of B cells leads to the activation of Lyn, Fyn, and Blk, which presumably associate with the cytoplasmic tails of the membrane immunoglobulin-associated Ig alpha/beta heterodimer. Receptor ligation also leads to the tyrosine phosphorylation and catalytic activation of Syk, but the mechanism of association of this kinase with the antigen receptor remains to be established, A number of phosphoproteins that can associate with the SH2 domains of Blk, Lyn, and Fyn have been described in activated B cells. We demonstrate here that Syk is one of the proteins in the lysates of activated B cells which bind to the SH2 domains of Src family kinases. Syk binds directly to the SH2 domain of Blk and complexes in vivo with Lyn and Blk in activated B cells.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kim, Tae Jin/D-6544-2011	Kim, Tae Jin/0000-0001-9802-0568	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507, R29AI027835] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33507, AI-27835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1993, IMMUNOL REV, V132, P85, DOI 10.1111/j.1600-065X.1993.tb00838.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15658	15663		10.1074/jbc.270.26.15658	http://dx.doi.org/10.1074/jbc.270.26.15658			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797565	hybrid			2022-12-25	WOS:A1995RG53800036
J	GUO, WW; MORAN, JV; HOFFMAN, PW; HENKE, RM; BUTOW, RA; PERLMAN, PS				GUO, WW; MORAN, JV; HOFFMAN, PW; HENKE, RM; BUTOW, RA; PERLMAN, PS			THE MOBILE GROUP-I INTRON 3-ALPHA OF THE YEAST MITOCHONDRIAL COXI GENE ENCODES A 35-KDA PROCESSED PROTEIN THAT IS AN ENDONUCLEASE BUT NOT A MATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; SPLICE-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; DNA ENDONUCLEASE; POSTTRANSCRIPTIONAL PROCESSES; INTERVENING SEQUENCES; CYTOCHROME-OXIDASE; MEMBRANE SYSTEM; RIBOSOMAL-RNA; SCE-III	Three mitochondrial mutants were characterized that block the splicing of aI3 alpha, a mobile group I intron of the COXI gene of yeast mtDNA Mutant C1085 alters helical structures known to be important for splicing of group I introns. M44 and C1072 are point mutants in exon 3 that block correct splicing but allow some splicing at cryptic 5'-splice sites. M44 alters the P1 helix needed for 5'-splice site definition, while the mutation in C1072 is a new kind of mutation because it is located upstream of the exon sequence involved in the P1 helix. Ah three mutants accumulate novel proteins of 35 and 44 kDa (p35 and p44, respectively) detected both by labeling of mitochondrial translation products and by Western blotting, Partial protease digestions indicate that p44 and p35 are closely related, probably as precursor and processed protein. The level of the intron-encoded endonuclease activity, I-SceIII, is elevated similar to 10-fold in the mutants. Partial purification of I-SceIII from the mutants showed that most, if not all, of the activity is associated with p35. Finally, because aI3 alpha splices accurately in a petite mutant, we conclude that aI3 alpha splicing does not depend on a mtDNA-encoded maturase.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035510] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ANZIANO PQ, 1982, CELL, V30, P925, DOI 10.1016/0092-8674(82)90297-5; ANZIANO PQ, 1990, NUCLEIC ACIDS RES, V18, P3233, DOI 10.1093/nar/18.11.3233; ANZIANO PQ, 1984, THESIS OHIO STATE U; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BONITZ SG, 1982, J BIOL CHEM, V257, P6268; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; COOPER AA, 1993, BIOESSAYS, V15, P667, DOI 10.1002/bies.950151006; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DELASALLE H, 1982, CELL, V28, P721, DOI 10.1016/0092-8674(82)90051-4; Douglas M, 1979, Methods Enzymol, V56, P58; DUJARDIN G, 1982, NATURE, V298, P628, DOI 10.1038/298628a0; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; HALBREICH A, 1980, CELL, V19, P321, DOI 10.1016/0092-8674(80)90506-1; HALL DH, 1987, CELL, V48, P63, DOI 10.1016/0092-8674(87)90356-4; HANSON DK, 1982, J BIOL CHEM, V257, P3128; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; HENSGENS LAM, 1983, CELL, V32, P379, DOI 10.1016/0092-8674(83)90457-9; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HOFFMAN PW, 1989, THESIS OHIO STATE U; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3426; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1992, CR ACAD SCI III-VIE, V315, P37; MACREADIE IG, 1985, CELL, V41, P395, DOI 10.1016/S0092-8674(85)80012-X; MAHLER HR, 1976, GENETICS BIOGENESIS, P857; MECKLENBURG KL, 1987, THESIS OHIO STATE U; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1992, NUCLEIC ACIDS RES, V20, P4069, DOI 10.1093/nar/20.15.4069; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; PEREA J, 1993, NUCLEIC ACIDS RES, V21, P358, DOI 10.1093/nar/21.2.358; PEREA J, 1985, EMBO J, V4, P3281, DOI 10.1002/j.1460-2075.1985.tb04078.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PERLMAN PS, 1990, METHOD ENZYMOL, V181, P539; PERLMAN PS, 1983, METHOD ENZYMOL, V9, P374; PRICE JV, 1987, J MOL BIOL, V196, P49, DOI 10.1016/0022-2836(87)90510-9; RALPH D, 1986, THESIS OHIO STATE U; SARGUEIL B, 1991, MOL GEN GENET, V225, P340, DOI 10.1007/BF00269867; SCHAPIRA M, 1993, NUCLEIC ACIDS RES, V21, P3683, DOI 10.1093/nar/21.16.3683; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1992, GENE, V113, P1, DOI 10.1016/0378-1119(92)90663-A; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SZCZEPANEK T, 1994, GENE, V139, P1, DOI 10.1016/0378-1119(94)90516-9; TABAK H, 1987, CELL, V39, P623; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VANDERHORST G, 1985, CELL, V40, P759, DOI 10.1016/0092-8674(85)90335-6; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEISSBRUMMER B, 1982, CELL, V29, P527, DOI 10.1016/0092-8674(82)90169-6; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WINTER AJ, 1988, NUCLEIC ACIDS RES, V16, P3845, DOI 10.1093/nar/16.9.3845; WINTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3897, DOI 10.1093/nar/20.15.3897; WOODSON SA, 1992, NUCLEIC ACIDS RES, V20, P4027, DOI 10.1093/nar/20.15.4027; WOODSON SA, 1993, MOL CELL BIOL, V13, P1137, DOI 10.1128/MCB.13.2.1137; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	68	14	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15563	15570		10.1074/jbc.270.26.15563	http://dx.doi.org/10.1074/jbc.270.26.15563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797552	hybrid			2022-12-25	WOS:A1995RG53800022
J	SALZET, M; BULET, P; WATTEZ, C; VERGERBOCQUET, M; MALECHA, J				SALZET, M; BULET, P; WATTEZ, C; VERGERBOCQUET, M; MALECHA, J			STRUCTURAL CHARACTERIZATION OF A DIURETIC PEPTIDE FROM THE CENTRAL-NERVOUS-SYSTEM OF THE LEECH ERPOBDELLA-OCTOCULATA - ANGIOTENSIN-II AMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THEROMYZON-TESSULATUM OFM; MESSENGER-RNA SEQUENCES; RAT-BRAIN; OXYTOCIN; PHARMACOLOGY; FMRFAMIDE; BALANCE; RENIN	Purification of a material immunoreactive to an antiserum against angiotensin II and present in the central nervous system of the pharyngobdellid leech Erpobdella octoculata was performed by reversed-phase high pressure liquid chromatography combined with both enzyme-linked immunosorbent assay and dot immunobinding assays for angiotensin II. Establishment of the amino acid sequence by Edman degradation, electrospray, and fast atom bombardement mass spectrometry measurements and enzymatic treatment by carboxypeptidase A indicated that this ''central'' angiotensin II-like material, the first one fully characterized in the animal kingdom, is an angiotensin II amide. This finding constitutes also the first biochemical characterization of a peptide of the angiotensin family in an invertebrate. Synthetic angiotensin II amide exerts, when injected in leeches, a diuretic effect and is, 1 and 2 h postinjection, 100-fold more potent than vertebrate angiotensin II. An identification of the proteins immunoreactive to an antiserum against angiotensin II performed at the level of both central nervous system extracts and in vitro central nervous system-translated RNA products indicated that in the two cases, two proteins were detected. Their molecular masses, which were, respectively, similar to 14 and similar to 18 kDa for the central nervous system extracts and similar to 15 and similar to 19 kDa for in vitro central nervous system-translated RNA products, differ from that of angiotensinogen (similar to 60 kDa), the precursor of vertebrate angiotensin II.	INST BIOL MOLEC & CELLULAIRE,CNRS,UPR 9022,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	SALZET, M (corresponding author), UNIV SCI & TECH LILLE FLANDRES ARTOIS,PHYLOGENIE MOLEC ANNELIDES LAB,CNRS,ER 87,F-59655 VILLENEUVE DASCQ,FRANCE.		Salzet, Michel/A-7675-2011; BULET, Philippe/C-8557-2014	Salzet, Michel/0000-0003-4318-0817; BULET, Philippe/0000-0001-9016-265X				AGUILERA G, 1981, NATURE, V289, P507, DOI 10.1038/289507a0; Cochran WG, 1977, SAMPLING TECHNIQUES, Vthird, P1; DZAU VJ, 1987, AM J CARDIOL, V59, pA59, DOI 10.1016/0002-9149(87)90178-0; DZAU VJ, 1986, HYPERTENSION, V8, P544, DOI 10.1161/01.HYP.8.6.544; GOHLKE P, 1988, J KARDIOL S3, V77, P1; GRAY DA, 1989, J COMP PHYSIOL B, V158, P651, DOI 10.1007/BF00693003; HERMANN K, 1982, EXP BRAIN RES S, V4, P192; KHOSLA MC, 1985, PEPTIDES, V6, P289, DOI 10.1016/0196-9781(85)90388-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH KR, 1986, HYPERTENSION, V8, P540, DOI 10.1161/01.HYP.8.6.540; MALECHA J, 1983, GEN COMP ENDOCR, V49, P344, DOI 10.1016/0016-6480(83)90198-3; MALECHA J, 1989, CR ACAD SCI III-VIE, V309, P127; MULLER KJ, 1981, NEUROBIOLOGY LEECH, P1; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; PHILLIPS MI, 1985, CIRC RES, V56, P212, DOI 10.1161/01.RES.56.2.212; PHILLIPS MI, 1991, METHODS NEUROSCI, V6, P177; POHL M, 1988, J NEUROCHEM, V51, P1407, DOI 10.1111/j.1471-4159.1988.tb01105.x; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; SALZET M, 1993, EUR J BIOCHEM, V217, P897, DOI 10.1111/j.1432-1033.1993.tb18319.x; SALZET M, 1994, EUR J BIOCHEM, V221, P269, DOI 10.1111/j.1432-1033.1994.tb18738.x; SALZET M, 1993, BRAIN RES, V601, P173, DOI 10.1016/0006-8993(93)91708-Z; SALZET M, 1992, COMP BIOCHEM PHYS C, V102, P483, DOI 10.1016/0742-8413(92)90147-Y; SALZET M, 1992, COMP BIOCHEM PHYS A, V101, P83, DOI 10.1016/0300-9629(92)90632-Z; SALZET M, 1993, BRAIN RES, V631, P247, DOI 10.1016/0006-8993(93)91542-Z; Sambrook J, 1989, MOL CLONING LABORATO; Schooley David A., 1993, Molecular Comparative Physiology, V12, P22; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; VANDERLANDE VM, 1983, J ZOOL, V201, P377; WENNING A, 1993, J EXP BIOL, V182, P81; ZERBSTBOROFFKA I, 1973, J COMP PHYSIOL, V84, P185, DOI 10.1007/BF00697606	30	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1575	1582		10.1074/jbc.270.4.1575	http://dx.doi.org/10.1074/jbc.270.4.1575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829487	hybrid			2022-12-25	WOS:A1995QD20400017
J	PAVLOFF, N; POTEMPA, J; PIKE, RN; PROCHAZKA, V; KIEFER, MC; TRAVIS, J; BARR, PJ				PAVLOFF, N; POTEMPA, J; PIKE, RN; PROCHAZKA, V; KIEFER, MC; TRAVIS, J; BARR, PJ			MOLECULAR-CLONING AND STRUCTURAL CHARACTERIZATION OF THE ARG-GINGIPAIN PROTEINASE OF PORPHYROMONAS-GINGIVALIS - BIOSYNTHESIS AS A PROTEINASE-ADHESIN POLYPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLACK-PIGMENTED BACTEROIDES; PROTEASE GENE; COLLAGENASE ACTIVITY; ESCHERICHIA-COLI; PRTC GENE; PERIODONTITIS; DEGRADATION; EXPRESSION; VIRULENT	The identification of proteinases of Porphyromonas gingivalis that act as virulence factors in periodontal disease has important implications in the study of host-pathogen interactions as well as in the discovery of potential therapeutic and immunoprophylactic agents. We have cloned and characterized a gene that encodes the 50-kDa cysteine proteinase gingipain or Arg-gingipain-1 (RGP-1) described previously (Chen, Z., Potempa, J., Polanowski, A., Wikstrom, M., and Travis, J. (1992) J. Biol. Chem,.267, 18896-18901). Analysis of the amino acid sequence of RGP-1 deduced from the cloned DNA sequence showed that the biosynthesis of this proteinase involves processing of a polyprotein that contains multiple adhesin molecules located at its carboxyl terminus, This finding corroborates previous evidence (Pike R., McGraw, W., Potempa, J., and Travis, J. (1994) J. Biol. Chem. 269, 406-411) that RGP-1 is closely associated with adhesin molecules, and that high molecular weight forms of the proteinase are involved in the binding of erythrocytes.	JAGIELLONIAN UNIV,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,PL-31120 KRAKOW,POLAND; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Jagiellonian University; University System of Georgia; University of Georgia	PAVLOFF, N (corresponding author), LXR BIOTECHNOL INC,1401 MARINA WAY S,RICHMOND,CA 94804, USA.		Prochazka, Vaclav/M-2176-2019	Pike, Robert/0000-0002-2083-0269				ARNOTT MA, 1990, ARCH ORAL BIOL, V35, pS97, DOI 10.1016/0003-9969(90)90137-Y; BEDI GS, 1994, J BIOL CHEM, V269, P599; BOURGEAU G, 1992, INFECT IMMUN, V60, P3186, DOI 10.1128/IAI.60.8.3186-3192.1992; CARLSSON J, 1984, J MED MICROBIOL, V18, P39, DOI 10.1099/00222615-18-1-39; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; KATO T, 1992, J BACTERIOL, V174, P3889, DOI 10.1128/jb.174.12.3889-3895.1992; KILIAN M, 1981, INFECT IMMUN, V34, P757, DOI 10.1128/IAI.34.3.757-765.1981; KOLENBRANDER PE, 1993, J BACTERIOL, V175, P3247, DOI 10.1128/jb.175.11.3247-3252.1993; LALA A, 1994, BIOCHEM BIOPH RES CO, V199, P1489, DOI 10.1006/bbrc.1994.1399; Maniatis T., 1982, MOL CLONING; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; OTOGOTO JI, 1993, INFECT IMMUN, V61, P117, DOI 10.1128/IAI.61.1.117-123.1993; PARK Y, 1992, FEMS MICROBIOL LETT, V92, P273, DOI 10.1016/0378-1097(92)90721-Y; PIKE R, 1994, J BIOL CHEM, V269, P406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLOTS J, 1977, SCAND J DENT RES, V85, P114; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V3, P103, DOI 10.1111/j.1399-302X.1988.tb00093.x; TAKAHASHI N, 1991, FEMS MICROBIOL LETT, V84, P135; UITTO VJ, 1989, INFECT IMMUN, V57, P213, DOI 10.1128/IAI.57.1.213-218.1989; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x	27	164	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1007	1010		10.1074/jbc.270.3.1007	http://dx.doi.org/10.1074/jbc.270.3.1007			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836351	hybrid			2022-12-25	WOS:A1995QB15600006
J	PUCEAT, M; KORICHNEVA, I; CASSOLY, R; VASSORT, G				PUCEAT, M; KORICHNEVA, I; CASSOLY, R; VASSORT, G			IDENTIFICATION OF BAND-3-LIKE PROTEINS AND CL-/HCO3- EXCHANGE IN ISOLATED CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; ANION TRANSPORT-SYSTEM; RAT CARDIAC-CELLS; INDUCED ACIDIFICATION; CHLORIDE TRANSPORT; INTRACELLULAR PH; HEART-CELLS; MYOCYTES; CDNA; H+	The identification of the protein that exerts the function of Cl-/HCO3- exchange is still unresolved in cardiac tissue, We have addressed this issue by using a multiple technical approach, Western blotting analysis with an antibody raised against human erythroid whole band 3 protein, the so-called protein that mediates the Cl-/HCO3- exchange in erythrocytes, showed that adult cardiomyocytes expressed two proteins immunologically related to the erythroid band 3, These proteins migrated in SDS-polyacrylamide gel electrophoresis with apparent molecular masses of 80 and 120 kDa, They were specifically found in the membrane but not in the cytosolic or the myofibril fractions of adult cardiomyocytes. Confocal microscopy further indicated that the immunostained proteins were mainly located at the sarcolemma and along T-tubules, typical membrane structures of adult cardiomyocytes. Using an antibody raised against a cardiac: amino-terminal domain of rat AE3, we found that the 120-kDa protein is the translation product of the AE3 gene specifically expressed in heart and brain, Using an antiserum raised against a specific domain of mouse erythroid band 3 (AE1), which is not shared by AE3, we showed that the 80-kDa protein is likely to be a truncated translation product of the AE1 gene, Microinjection of the anti-human erythroid whole band 3 antibody into single isolated cardiac cells significantly inhibited the Cl-/HCO3-, exchange activity, Furthermore, the anti-AE1 antibody strongly decreased the efficiency of 4,4'-diisothiocyanatostiibene-2,2'-disulfonate to inhibit the ionic exchange, We thus suggest that the 80-kDa or both the 80 and the 120-kDa proteins immunologically related to the erythroid band 3 protein perform the anionic exchange in rat cardiomyocytes.	UNIV PARIS 07,INST JACQUES MONOD,CNRS,UNITE MIXTE RECH 9922,F-75251 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	PUCEAT, M (corresponding author), CHU ARNAUD & VILLENEUVE,INSERM,U390,PHYSIOPATHOL CARDIOVASC LAB,F-34295 MONTPELLIER,FRANCE.		PUCEAT, michel/R-6140-2017	PUCEAT, michel/0000-0001-9055-7563				ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CASSOLY R, 1983, J BIOL CHEM, V258, P3859; CHENG S, 1980, J BIOL CHEM, V255, P2637; DESILETS M, 1994, CIRC RES, V75, P862, DOI 10.1161/01.RES.75.5.862; DESILETS M, 1993, J PHYSIOL-LONDON, V459, pP223; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DRENCKHAHN D, 1984, EUR J CELL BIOL, V34, P114; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLIEGEL L, 1991, FEBS LETT, V279, P25, DOI 10.1016/0014-5793(91)80241-T; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FRELIN C, 1984, J BIOL CHEM, V259, P8880; FUNDER J, 1976, J PHYSIOL-LONDON, V262, P679, DOI 10.1113/jphysiol.1976.sp011615; GUNN RB, 1973, J GEN PHYSIOL, V61, P185, DOI 10.1085/jgp.61.2.185; KAY MMB, 1991, P NATL ACAD SCI USA, V88, P2778, DOI 10.1073/pnas.88.7.2778; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P6882, DOI 10.1073/pnas.80.22.6882; KIMURA A, 1992, J BIOCHEM-TOKYO, V112, P220, DOI 10.1093/oxfordjournals.jbchem.a123880; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINN SC, 1992, J BIOL CHEM, V267, P7927; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; PIWNICAWORMS D, 1983, AM J PHYSIOL, V244, pC422, DOI 10.1152/ajpcell.1983.244.5.C422; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; PUCEAT M, 1991, J PHYSIOL-LONDON, V444, P241, DOI 10.1113/jphysiol.1991.sp018875; PUCEAT M, 1993, J PHYSIOL-LONDON, V459, pP226; PUCEAT M, 1993, AM J PHYSIOL, V264, pH310, DOI 10.1152/ajpheart.1993.264.2.H310; RALEYSUSMAN KM, 1993, BRAIN RES, V614, P308, DOI 10.1016/0006-8993(93)91049-X; SALHANY JM, 1990, ERYTHROCYTE BAND, V3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSEUR C, 1988, PREP BIOCHEM, V18, P293, DOI 10.1080/00327488808062530; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; WHITE RL, 1990, J GEN PHYSIOL, V95, P1061, DOI 10.1085/jgp.95.6.1061	44	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1315	1322		10.1074/jbc.270.3.1315	http://dx.doi.org/10.1074/jbc.270.3.1315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836397	hybrid			2022-12-25	WOS:A1995QB15600052
J	WUEBBENS, MM; RAJAGOPALAN, KV				WUEBBENS, MM; RAJAGOPALAN, KV			INVESTIGATION OF THE EARLY STEPS OF MOLYBDOPTERIN BIOSYNTHESIS IN ESCHERICHIA-COLI THROUGH THE USE OF IN-VIVO LABELING STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; SULFITE OXIDASE; XANTHINE-OXIDASE; STRUCTURAL CHARACTERIZATION; C-13-LABELED PRECURSORS; CONVERTING FACTOR; XYLENE RING; RIBOFLAVIN; IDENTIFICATION; PURIFICATION	The early steps in the biosynthesis of the molybdopterin portion of the molybdenum cofactor have been investigated through the use of radiolabeled precursors. Labeled guanosine was added to growing cultures of the molybdopterin-deficient Escherichia coli mutant, moeB, which accumulates large amounts of precursor Z, the final intermediate in molybdopterin biosynthesis (Wuebbens, M. M., and Rajagopalan, K. V. (1993) J. Biol. Chem. 268, 13493-13498). Precursor Z is readily oxidized to the stable, fluorescent pterin, compound Z, which contains all 10 of the carbon atoms present in molybdopterin. For these experiments, compound Z was isolated from both the cells and culture media and analyzed for the presence of label. The development of a method for sequential cleavage of the compound Z side chain carbons facilitated determination of the distribution of label between the ring and the side chain of compound Z. Addition of uniformly labeled [C-14]guanosine to moeB cultures produced compound Z labeled in both the ring and the side chain. Growth on [8-C-14]guanosine resulted in transfer of label to the C-1' position of compound Z. The label present in compound Z purified from cultures grown on [8,5'-H-3]guanosine was lost by removal of the three terminal side chain carbons. These results indicate that although a guanosine compound serves as the initial precursor for molybdopterin biosynthesis, the early steps of this pathway in E. coli proceed via a pathway unlike that of any known pteridine biosynthetic pathway.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHER A, 1983, J BIOL CHEM, V258, P3431; BACHER A, 1985, J AM CHEM SOC, V107, P6380, DOI 10.1021/ja00308a037; Brown G. M., 1985, FOLATES PTERINS, P115; BURG AW, 1968, J BIOL CHEM, V243, P2349; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; FOOR F, 1975, J BIOL CHEM, V250, P3545; FORREST HS, 1954, J AM CHEM SOC, V76, P5658, DOI 10.1021/ja01651a017; GARDLIK S, 1991, J BIOL CHEM, V266, P16627; GARDLIK S, 1991, J BIOL CHEM, V266, P4889; GARDLIK S, 1990, J BIOL CHEM, V265, P13047; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; LEVAN Q, 1985, J BACTERIOL, V162, P1280, DOI 10.1128/JB.162.3.1280-1284.1985; LEVY CC, 1964, J BIOL CHEM, V239, P560; LOWRY OH, 1949, J BIOL CHEM, V180, P389; MCNUTT WS, 1961, J AM CHEM SOC, V83, P2303, DOI 10.1021/ja01471a020; MCNUTT WS, 1956, J BIOL CHEM, V219, P365; MCNUTT WS, 1954, J BIOL CHEM, V210, P511; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; REYNOLDS JJ, 1964, J BIOL CHEM, V239, P317; SHANMUGAM KT, 1992, MOL MICROBIOL, V6, P3452, DOI 10.1111/j.1365-2958.1992.tb02215.x; WATT WB, 1967, J BIOL CHEM, V242, P565; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; YIM JJ, 1976, J BIOL CHEM, V251, P5087	34	130	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1082	1087		10.1074/jbc.270.3.1082	http://dx.doi.org/10.1074/jbc.270.3.1082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836363	hybrid			2022-12-25	WOS:A1995QB15600018
J	ITOH, K; KASE, R; SHIMMOTO, M; SATAKE, A; SAKURABA, H; SUZUKI, Y				ITOH, K; KASE, R; SHIMMOTO, M; SATAKE, A; SAKURABA, H; SUZUKI, Y			PROTECTIVE PROTEIN AS AN ENDOGENOUS ENDOTHELIN DEGRADATION ENZYME IN HUMAN TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LYSOSOMAL BETA-GALACTOSIDASE; NEURAMINIDASE DEFICIENCY; CDNA CLONING; GALACTOSIALIDOSIS; EXPRESSION; PEPTIDE; PROTEASES; DEAMIDASE; SYSTEM; CELLS	An enzyme hydrolyzing the carboxyl terminus of endothelin-1 was detected in control human tissues but was deficient in tissues from a patient with galactosialidosis, a metabolic disease caused by the protective protein gene mutation. It was proportional to the amount of immunologically estimated mature protective protein. An antibody against the lysosomal protective protein/beta-galactosidase complex precipitated the enzyme activity almost completely. Transfection of the human cDNA for protective protein resulted in high expression of the enzyme activity in transformed fibroblasts from a galactosialidosis patient, These results indicated that the mature protective protein is a major soluble endogenous endothelin degradation enzyme in human tissues.			ITOH, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT CLIN GENET,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.							ABASSI ZA, 1992, HYPERTENSION, V20, P89, DOI 10.1161/01.HYP.20.1.89; AMANO N, 1983, ACTA NEUROPATHOL, V61, P283, DOI 10.1007/BF00691999; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; CHITAYAT D, 1988, AM J MED GENET, V31, P887, DOI 10.1002/ajmg.1320310423; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DENG AY, 1994, J BIOCHEM-TOKYO, V115, P120, DOI 10.1093/oxfordjournals.jbchem.a124285; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GALJART NJ, 1991, J BIOL CHEM, V266, P14574; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; ITOH K, 1993, J BIOL CHEM, V268, P1180; JACKMAN HL, 1992, J BIOL CHEM, V267, P2872; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KASE R, 1990, BIOCHEM BIOPH RES CO, V172, P1175, DOI 10.1016/0006-291X(90)91572-A; KIMURA S, 1988, BIOCHEM BIOPH RES CO, V156, P1182, DOI 10.1016/S0006-291X(88)80757-5; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; NAKAJIMA K, 1989, BIOCHEM BIOPH RES CO, V163, P424, DOI 10.1016/0006-291X(89)92153-0; NANBA E, 1987, BIOCHEM BIOPH RES CO, V144, P138, DOI 10.1016/S0006-291X(87)80486-2; NUNEZ DJR, 1990, J CLIN INVEST, V85, P1537, DOI 10.1172/JCI114601; RANDALL MD, 1991, PHARMACOL THERAPEUT, V50, P73, DOI 10.1016/0163-7258(91)90073-U; SAKURABA H, 1982, CLIN CHIM ACTA, V125, P275; SHIBOUTA Y, 1990, LIFE SCI, V46, P1611; SHIMMOTO M, 1993, J CLIN INVEST, V91, P2393, DOI 10.1172/JCI116472; SIMONSON MS, 1992, J LAB CLIN MED, V119, P622; SIMONSON MS, 1991, HYPERTENSION, V17, P856, DOI 10.1161/01.HYP.17.6.856; SORENSEN SB, 1989, CARLSBERG RES COMMUN, V54, P193, DOI 10.1007/BF02904473; Suzuki Y, 1988, BRAIN DYSFUNCT, V1, P285; Suzuki Y., 1985, DEV BRAIN ITS DISORD, P161; TAKAHASHI Y, 1991, CLIN CHIM ACTA, V203, P199, DOI 10.1016/0009-8981(91)90292-K; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIBAYASHI M, 1991, CIRCULATION, V84, P2280, DOI 10.1161/01.CIR.84.6.2280; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487	38	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					515	518		10.1074/jbc.270.2.515	http://dx.doi.org/10.1074/jbc.270.2.515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822272	hybrid			2022-12-25	WOS:A1995QB81600004
J	SCHWARZENBACH, H; NEWELL, JW; MATTHIAS, P				SCHWARZENBACH, H; NEWELL, JW; MATTHIAS, P			INVOLVEMENT OF THE ETS FAMILY FACTOR PU.1 IN THE ACTIVATION OF IMMUNOGLOBULIN PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; CELL-TYPE-SPECIFICITY; TRANSCRIPTION FACTOR-I; DNA-SEQUENCE ELEMENTS; HISTONE H2B GENE; CONSERVED SEQUENCE; PROTEIN-BINDING; REGULATES EXPRESSION; ENHANCER ACTIVITY; NUCLEAR FACTOR	The B cell-specific expression of immunoglobulin (Ig) genes is controlled by the concerted action of variable (V) region promoters and intronic or 3' enhancers, all of which are active in a lymphoid-specific manner, A crucial highly conserved element of the V region promoters is the octamer site -ATTTGCAT-, which can be bound by ubiquitous (Oct-1) as well as B cell-specific (Oct-2) factors. Another less conserved element found in many Ig promoters is pyrimidine-rich and has been shown to be functionally important, in particular for those Ig promoters that have only an imperfect octamer site. In this study we have analyzed the factors binding specifically to the pyrimidine-rich motif of the V kappa 19 promoter, a light chain gene promoter with an imperfect octamer site. Using nuclear extracts prepared from B cells, we detected two sets of specific complexes in electrophoretic mobility shift experiments. One complex appears to be ubiquitous but enriched in lymphoid cells and represents the binding of a potentially novel factor with an apparent molecular mass of similar to 50 kDa. The other complex was found only with extracts from pre-B or B cells as well as from a macrophage cell Line and appears to be caused by the binding of PU.1, a factor of the Ets family. We show that on this Ig promoter Oct factors (Oct-1 or Oct-2) and PU.1 can bind concomitantly but without synergism. By transfection experiments in non-B cells we demonstrate that PU.1 is indeed able to activate this promoter in concert with Oct-2. Furthermore, we show that PU.1 can bind with varying affinities to the pyrimidine rich elements of several other Ig promoters. These data suggest a more general role for PU.1 or other members of the Ets family in the activation of Ig promoters.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOHMANN D, 1987, NATURE, V325, P268, DOI 10.1038/325268a0; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; EATON S, 1987, P NATL ACAD SCI USA, V84, P7634, DOI 10.1073/pnas.84.21.7634; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KATAOKA T, 1982, J BIOL CHEM, V257, P277; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEE KH, 1987, J MOL BIOL, V195, P761, DOI 10.1016/0022-2836(87)90482-7; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MATHER EL, 1983, P NATL ACAD SCI-BIOL, V80, P4689, DOI 10.1073/pnas.80.15.4689; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOYNET D, 1985, J IMMUNOL, V135, P727; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAHMIAS C, 1988, J IMMUNOL, V140, P1304; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PICARD D, 1985, EMBO J, V4, P2831, DOI 10.1002/j.1460-2075.1985.tb04011.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; POGNONEC P, 1989, ONCOGENE, V4, P691; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIBLER U, 1978, CELL, V15, P1495, DOI 10.1016/0092-8674(78)90072-7; SCHREIBER E, 1989, TISSUE SPECIFIC GENE, P83; SETH A, 1993, ONCOGENE, V8, P1783; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	75	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					898	907		10.1074/jbc.270.2.898	http://dx.doi.org/10.1074/jbc.270.2.898			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822329	hybrid			2022-12-25	WOS:A1995QB81600063
J	TONG, ZB; NELSON, LM; DEAN, J				TONG, ZB; NELSON, LM; DEAN, J			INHIBITION OF ZONA-PELLUCIDA GENE-EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES INJECTED INTO MOUSE OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATERNAL MESSENGER-RNAS; SPERM RECEPTOR; DEVELOPMENTAL REGULATION; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; OOGENESIS; PROTEINS; BIOSYNTHESIS; TRANSLATION; ZP3	During murine oogenesis, the zona pellucida proteins (ZP1, ZP2, and ZP3) are synthesized and secreted to form an extracellular matrix that surrounds the oocyte and mediates specific biological functions essential to mammalian fertilization and early development. To investigate the relationship among the zona proteins during zona matrix assembly, we have undertaken to inhibit de novo biosynthesis of specific zona proteins with antisense oligonucleotides complementary to the 5'-ends of ZP2 (nucleotide position 19-42) and ZP3 (nucleotide 21-44) mRNAs, When injected into the cytoplasm of growing mouse oocytes, the antisense oligonucleotides targeted specific zona mRNAs for degradation, as confirmed by a RNase protection assay, Individual zona pellucida protein synthesis was followed by immunoprecipitation with ZP2- and ZP3-specific monoclonal antibodies, New zona protein synthesis from the targeted mRNA was abolished, but nontargeted zona protein continued to be synthesized, Interestingly, abolishment of either ZP2 or ZP3 protein synthesis prevented the incorporation of the other protein into the extracellular zona matrix, These results suggest that ZP2 and ZP3 proteins are independent of each other in their biosynthesis but are dependent upon each other for their incorporation into the zona pellucida matrix, This study provides an experimental system in which destruction of a targeted mRNA generates a transient loss-of-expression phenotype during mouse oocyte growth.	NICHHD, DEV ENDOCRINOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	TONG, ZB (corresponding author), NIDDK, CELLULAR & DEV BIOL LAB,BLDG 6,RM B1-26,6 CTR DR, MSC 2715, BETHESDA, MD 20892 USA.							AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; BACHVAROVA R, 1989, DEVELOPMENT, V106, P561; BEEBE SJ, 1992, DEV BIOL, V151, P48, DOI 10.1016/0012-1606(92)90212-Y; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1980, P NATL ACAD SCI-BIOL, V77, P1029, DOI 10.1073/pnas.77.2.1029; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CURCI A, 1991, DEV BIOL, V144, P362, DOI 10.1016/0012-1606(91)90428-6; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; EAST IJ, 1985, DEV BIOL, V109, P268, DOI 10.1016/0012-1606(85)90454-3; EAST IJ, 1984, J CELL BIOL, V98, P795, DOI 10.1083/jcb.98.3.795; GRAVES RA, 1985, P NATL ACAD SCI USA, V82, P5685, DOI 10.1073/pnas.82.17.5685; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; GREVE JM, 1982, CELL, V31, P749, DOI 10.1016/0092-8674(82)90329-4; GWATKIN RBL, 1967, J REPROD FERTIL, V13, P577; HAINES DS, 1992, BIOTECHNIQUES, V12, P736; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; MANGIA F, 1976, DEV BIOL, V54, P146, DOI 10.1016/0012-1606(76)90293-1; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; PHILLIPS DM, 1980, J ULTRA MOL STRUCT R, V72, P1, DOI 10.1016/S0022-5320(80)90129-X; PHILPOTT CC, 1987, DEV BIOL, V121, P568, DOI 10.1016/0012-1606(87)90192-8; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SALZMANN GS, 1983, EMBO J, V2, P1451, DOI 10.1002/j.1460-2075.1983.tb01607.x; SHIMIZU S, 1982, BIOCHEM BIOPH RES CO, V109, P449, DOI 10.1016/0006-291X(82)91742-9; SHIMIZU S, 1983, J BIOL CHEM, V258, P5858; SHUTTLEWORTH J, 1988, EMBO J, V7, P427, DOI 10.1002/j.1460-2075.1988.tb02830.x; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					849	853		10.1074/jbc.270.2.849	http://dx.doi.org/10.1074/jbc.270.2.849			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822321	hybrid			2022-12-25	WOS:A1995QB81600055
J	YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR				YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR			THE MICROPHTHALMIA GENE-PRODUCT INTERACTS WITH THE RETINOBLASTOMA PROTEIN IN-VITRO AND IS A TARGET FOR DEREGULATION OF MELANOCYTE-SPECIFIC TRANSCRIPTION	ONCOGENE			English	Article						MICROPHTHALMIA RETINOBLASTOMA; MELANOCYTE-SPECIFIC TRANSCRIPTION; E1A; TRANSCRIPTION REPRESSION; BASIC HELIX-LOOP-HELIX FACTOR	ADENOVIRUS E1A PROTEINS; TYROSINASE-RELATED PROTEIN; OCTAMER-BINDING-PROTEIN; HEAVY-CHAIN ENHANCER; DNA-SYNTHESIS; REGULATORY FUNCTIONS; INDIVIDUAL PRODUCTS; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; CELLULAR PROTEIN	Little is known of the molecular mechanisms underlying the differentiation of the melanocyte from the melanoblast or the progression from the melanocyte to a malignant melanoma. Since the adenovirus E1A products have proved a useful tool for understanding control of differentiation in other systems, we explored the possibility of using E1A as a probe for factors controlling melanocyte-specific gene expression and differentiation. The results obtained show that the adenovirus E1A 13S, but not the 12S, product can transform the highly pigmented and TPA-dependent melanocyte cell line melan-a, Transformation is characterised by a morphological change, loss of TPA-dependence, the ability to grow in soft agar and strikingly, loss of pigmentation which correlates with loss of expression of the melanocyte-specific TRP-1 and tyrosinase genes, Cotransfection assays demonstrated that repression of TRP-1 by E1A correlated with E1A binding to p105Rb and p300, with the target in the TRP-1 promoter being the M-box, an 11 bp basic-Helix-loop-Helix (bHLH) factor-binding motif conserved between melanocyte-specific promoters, Consistent with the M-box acting as a target for E1a-mediated transcription repression, we also show that the basic-helix-loop-helix-leucine zipper (bHLH-LZ) protein (Mi) encoded by the microphthalmia gene (mi), which is required for pigment cell differentiation, is a positive acting transcription factor which can interact with the retinoblastoma product in vitro and activate the TRP-1 promoter, Moreover, expression of the mi gene was reduced around 50-fold in the non-pigmented E1a-transformed melan-a cells compared to the nontransformed melan-a cell line, with ectopic expression of Mi able to prevent repression of the tyrosinase and TRP-1 promoters in the presence of E1A, Mi therefore appears to play a crucial role in melanocyte-specific gene expression. The parallels between repression of myogenesis and muscle cell bHLH factors, and Mi and melanocyte differentiation are discussed.	MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND				Vachtenheim, Jiri/I-6232-2017; Yavuzer, Ugur/C-1599-2016	Vachtenheim, Jiri/0000-0002-4923-9296; Goding, Colin/0000-0002-1614-3909				BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; BENTLEY NJ, 1994, IN PRESS MOL CELL BI; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ST, 1992, J VIROL, V66, P7452, DOI 10.1128/JVI.66.12.7452-7460.1992; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; DERY CV, 1987, ONCOGENE, V2, P15; DOOLEY TP, 1988, ONCOGENE, V3, P531; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEFF T, 1986, MOL CELL BIOL, V6, P201, DOI 10.1128/MCB.6.1.201; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PORTER SD, 1994, DEVELOPMENT, V120, P2103; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TANAKA S, 1990, DEVELOPMENT, V108, P223; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUKAMOTO K, 1992, PIGM CELL RES, P181; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	86	126	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					123	134						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824265				2022-12-25	WOS:A1995QA98000015
J	LEA, S; STUART, D				LEA, S; STUART, D			ANALYSIS OF ANTIGENIC SURFACES OF PROTEINS	FASEB JOURNAL			English	Article						EVOLUTION; IMMUNE SYSTEM; PROTEIN-PROTEIN INTERACTIONS	MOUTH-DISEASE VIRUS; 3-DIMENSIONAL STRUCTURE; ANTIBODY-BINDING; 2.8-A RESOLUTION; 3.0-A RESOLUTION; 2.0-A RESOLUTION; POLIOVIRUS; REFINEMENT; DETERMINANTS; CHEMISTRY	The processes underlying molecular evolution have proved difficult to understand due to the complexity and obscurity of the selective pressures at work. The strong selective pressure to optimize antigen recognition means that antibody paratopes are more favorable systems than most in which to investigate these processes, as are viral epitopes, which evolve under an inverse pressure, rapidly changing to avoid recognition. Because recognition is a property of the surfaces of these molecules we expect that their evolutionary development may be read in the changes in the 3-dimensional array of chemical groups displayed on their surface. We have analyzed the bulk properties of these surfaces and find that there are significant differences in exposed amino acid preferences among 1) a control group of immunologically secluded proteins, 2) binding surfaces of immunoglobulins, and 3) the outer surfaces of picornaviruses. Compared to the control group, the immunoglobulin complementarity determining regions possess a relative excess of serine residues whereas picornaviruses suppress serine but overuse threonine residues, suggesting that the differing selective pressure has led to perturbations in the population of amino acid types on the surface of these proteins. Although these changes may be rationalized in terms of the structure and chemistry of the different side chains, we suggest that there may be a further, genetic component behind the observations: point mutations in the respective codons for serine and threonine lead to markedly different forms of structural variability. The high rate of reselection observed for these residues is in line with this second mechanism.	UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND	University of Oxford; University of Oxford			Lea, Susan M/B-7678-2009	Lea, Susan M/0000-0001-9287-8053; Stuart, David/0000-0002-3426-4210				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DAVIES DR, 1989, COLD SH Q B, V54, P233; ENGH R, 1989, PROTEIN ENG, V2, P407, DOI 10.1093/protein/2.6.407; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOGLE JM, 1989, PHILOS T ROY SOC B, V323, P467, DOI 10.1098/rstb.1989.0024; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KITSON JDA, 1990, VIROLOGY, V179, P26, DOI 10.1016/0042-6822(90)90269-W; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MALE D, 1987, ADV IMMUNOLOGYY, P34; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MARTINEZ MA, 1992, J VIROL, V66, P3557; MORGUNOVA EY, 1994, FEBS LETT, V338, P267, DOI 10.1016/0014-5793(94)80281-5; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; OVERINGTON J, 1992, PROTEIN SCI, V1, P216; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; ROSSMANN MG, 1976, J MOL BIOL, V105, P75, DOI 10.1016/0022-2836(76)90195-9; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; TAUSSIG MJ, 1984, PROCESSES PATHOLOGY; TULIP WR, 1991, J MOL BIOL, V221, P487, DOI 10.1016/0022-2836(91)80069-7; 1991, PROGRAM MANUAL GCG P	38	16	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1995	9	1					87	93		10.1096/fasebj.9.1.7821764	http://dx.doi.org/10.1096/fasebj.9.1.7821764			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QD202	7821764				2022-12-25	WOS:A1995QD20200014
J	CREUTZ, CE; LIOU, A; SNYDER, SL; BROWNAWELL, A; WILLISON, K				CREUTZ, CE; LIOU, A; SNYDER, SL; BROWNAWELL, A; WILLISON, K			IDENTIFICATION OF THE MAJOR CHROMAFFIN GRANULE-BINDING PROTEIN, CHROMOBINDIN-A, AS THE CYTOSOLIC CHAPERONIN CCT (CHAPERONIN CONTAINING TCP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-COMPLEX POLYPEPTIDE-1; SECRETORY VESICLE; MEMBRANE; CA-2+; PARTICLE; SUBUNITS	Chromobindin A is a multisubunit complex ATPase that binds to chromaffin granule membranes in a calcium-dependent manner and requires ATP for release from the membrane (Martin, W. H., and Creutz, C. E. (1987) J. Biol. Chem. 262, 2803-2810). Here we report that the seven previously characterized subunits of chromobindin A cross react with antisera specific to subunits of CCT, the chaperonin containing TCP-1 (Kubota, H., Hynes, G., Came, A., Ashworth, A., and Willison, K. (1994) Curr. Biol. 4, 89-99). The chromobindin A subunits previously called chromobindins 12, 13, 14, 15, 16, 18, and 19 cross-react specifically with subunits beta, delta, theta, zeta, xi, and gamma, respectively, of CCT. Additional similarities in subunit molecular weights, isoelectric points, and the morphologies of the two protein complexes as determined by electron microscopy support identification of chromobindin A as an adrenal medullary form of CCT. The chromobindin A/CCT complex was found to bind at least 7-fold more efficiently to affinity columns of chromaffin granule membranes than of adrenal medullary cytosol proteins, suggesting a specific interaction occurs between the complex and membrane components. The results indicate that the previously described characteristics of chromobindin A are likely to be relevant to the functions of CCT and suggest that the adrenal medullary form of CCT may play a role in the activities of secretory vesicle membranes.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	CREUTZ, CE (corresponding author), UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.				NCI NIH HHS [CA40042] Funding Source: Medline; NIDDK NIH HHS [DK33151] Funding Source: Medline; NINDS NIH HHS [NS31618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CREUTZ CE, 1981, BIOCHEM BIOPH RES CO, V103, P1395, DOI 10.1016/0006-291X(81)90278-3; CREUTZ CE, 1985, J BIOL CHEM, V260, P7171; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CREUTZ CE, 1993, METHOD ENZYMOL, V221, P190, DOI 10.1016/0076-6879(93)21017-3; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEISOW MJ, 1982, J NEUROCHEM, V38, P1735, DOI 10.1111/j.1471-4159.1982.tb06656.x; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1994, IN PRESS GENE AMST; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MARTIN WH, 1987, J BIOL CHEM, V262, P2803; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; MARTIN WH, 1989, BIOCHEM BIOPH RES CO, V165, P37, DOI 10.1016/0006-291X(89)91030-9; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; ROOBOL A, 1993, J NEUROCHEM, V60, P2327, DOI 10.1111/j.1471-4159.1993.tb03524.x; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	24	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32035	32038						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798195				2022-12-25	WOS:A1994PX30400004
J	GAO, QS; SUN, M; TYUTYULKOVA, S; WEBSTER, D; REES, A; TRAMONTANO, A; MASSEY, RJ; PAUL, S				GAO, QS; SUN, M; TYUTYULKOVA, S; WEBSTER, D; REES, A; TRAMONTANO, A; MASSEY, RJ; PAUL, S			MOLECULAR-CLONING OF A PROTEOLYTIC ANTIBODY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CRYSTAL-STRUCTURE; AUTOANTIBODIES; COMPLEXES; SITES	The cDNA for an antibody light chain raised by immunization against vasoactive intestinal peptide (VIP) was cloned in a bacterial expression vector, and the recombinant light chain was purified to electrophoretic homogeneity, The light chain catalyzed the hydrolysis of VIP efficiently owing to its comparatively high affinity for the substrate, In control experiments, the catalytic activity was preserved at a constant level after further chromatography of the light chain on anion-exchange and gel-filtration fast protein liquid chromatography columns, and it was removed by immunoadsorption with immobilized anti-mouse light chain antibody. The amide bond linking methylcoumarinamide (MCA) and arginine in a tripeptide unrelated in sequence to VIP was cleaved by the light chain with lower affinity and kinetic efficiency (k(cat)/K-m). Hydrolysis of the peptidyl-MCA conjugate was inhibited competitively by the alternate substrate, VIP, The K-i and K-m values for MP were in the same range, indicating that peptide-MCA and VIP hydrolysis occurs at a common catalytic site in the light chain. Molecular modeling suggested the presence of a serine protease-like site in the light chain, This was supported by inhibition of the hydrolytic activity by serine protease inhibitors, but not by inhibitors of other classes of proteases, These observations suggest a poorly discriminatory catalytic site, with specificity for VIP arising chiefly by means of the antigen recognition function of the light chain combining site,	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT ANESTHESIOL, OMAHA, NE 68198 USA; UNIV BATH, DEPT BIOCHEM, BATH BA2 7AY, AVON, ENGLAND; IGEN INC, ROCKVILLE, MD 20852 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Bath					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44126] Funding Source: Medline; NIAID NIH HHS [AI31268] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KABAT EA, 1991, 913242 US DEP HLTH H; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAHANA W, 1994, SCAND J IMMUNOL, V39, P107, DOI 10.1111/j.1365-3083.1994.tb03347.x; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MODY R, 1994, INT J PEPT PROT RES, V44, P441; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; PAUL S, 1990, J IMMUNOL, V145, P1196; PEDERSEN JT, 1992, IMMUNOMETHODS, V1, P126; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STEIPE B, 1992, J MOL BIOL, V225, P739, DOI 10.1016/0022-2836(92)90398-4; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, IN PRESS ANN NY ACAD; SUN M, 1991, J BIOL CHEM, V266, P15571; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1556	30	73	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 23	1994	269	51					32389	32393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	PX304	7798238				2022-12-25	WOS:A1994PX30400057
J	CUOZZO, JW; TAO, K; WU, QL; YOUNG, W; SAHAGIAN, GG				CUOZZO, JW; TAO, K; WU, QL; YOUNG, W; SAHAGIAN, GG			LYSINE-BASED STRUCTURE IN THE PROREGION OF PROCATHEPSIN-L IS THE RECOGNITION SITE FOR MANNOSE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME PHOSPHORYLATION; CATHEPSIN-L; PROTEIN; OLIGOSACCHARIDES; CELLS; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; IDENTIFICATION; DETERMINANTS; FIBROBLASTS; 6-PHOSPHATE	The recognition of lysosomal enzymes by UDP-GlcNAc: lysosomal-enzyme GlcNAc-1-phosphotransferase (phosphotransferase) is mediated by a protein structure on lysosomal enzymes, It has been previously demonstrated that lysine residues are required for phosphorylation of procathepsin L and are a common feature of the site on many lysosomal proteins. In this work, the procathepsin L recognition structure was further defined by identification of the region of the protein containing the structure and the critical lysine residues involved, Removal of the cathepsin L propeptide by low pH-induced autocatalytic processing abolished phosphorylation, The addition of either the purified propeptide or a glutathione S-transferase-propeptide fusion protein to the processed protein restored phosphorylation, Mutagenesis of individual lysine residues demonstrated that two propeptide lysine residues (Lys-54 and Lys-99) were required for efficient phosphorylation of procathepsin L, By comparison of the phosphorylation rates of procathepsin L, lysine-modified procathepsin L, and the procathepsin L oligosaccharide, lysine residues were shown to account for most, if not all, of the protein-dependent interaction, On this basis, it is concluded that the proregion lysine residues are the major elements of the procathepsin L recognition site, In addition, lysine residues in cathepsin D were shown to be as important for phosphorylation as those in procathepsin L, supporting a general model of the recognition site as a specific three dimensional arrangement of lysine residues exposed on the surface of lysosomal proteins.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University				Cuozzo, John/0000-0002-6229-0395	NIDDK NIH HHS [DK36632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; DISTLER J, 1979, P NATL ACAD SCI USA, V76, P4235, DOI 10.1073/pnas.76.9.4235; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; JOHN M, 1994, J BIOL CHEM, V269, P16247; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAH T, 1984, BIOCHEM J, V218, P601, DOI 10.1042/bj2180601; LANG L, 1984, J BIOL CHEM, V259, P4663; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; SAHAGIAN GG, 1994, LIVER BIOL PATHOBIOL, P375; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIERKS MR, 1992, BIOCHEMISTRY-US, V31, P8972, DOI 10.1021/bi00152a038; SMITH DB, 1993, CURRENT PROTOCOLS MO; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; WITHERS SG, 1990, BIOCHEMISTRY-US, V29, P6405, DOI 10.1021/bi00479a010; YAGEL S, 1989, CANCER RES, V49, P3553	36	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15611	15619		10.1074/jbc.270.26.15611	http://dx.doi.org/10.1074/jbc.270.26.15611			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797559	hybrid			2022-12-25	WOS:A1995RG53800029
J	SHIBATA, N; IKUTA, K; IMAI, T; SATOH, Y; SATOH, R; SUZUKI, A; KOJIMA, C; KOBAYASHI, H; HISAMICHI, K; SUZUKI, S				SHIBATA, N; IKUTA, K; IMAI, T; SATOH, Y; SATOH, R; SUZUKI, A; KOJIMA, C; KOBAYASHI, H; HISAMICHI, K; SUZUKI, S			EXISTENCE OF BRANCHED SIDE-CHAINS IN THE CELL-WALL MANNAN OF PATHOGENIC YEAST, CANDIDA-ALBICANS - STRUCTURE-ANTIGENICITY RELATIONSHIP BETWEEN THE CELL-WALL MANNANS OF CANDIDA-ALBICANS AND CANDIDA-PARAPSILOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH B-792 STRAIN; PHOSPHO-D-MANNAN; SEROTYPE-A; ENZYME-IMMUNOASSAY; OLIGOMANNOSYL RESIDUES; MONOCLONAL-ANTIBODIES; NIH-B-792 STRAIN; SACCHAROMYCES-CEREVISIAE; INVASIVE CANDIDIASIS; SUPPRESSOR CELLS	Isolation of side chain oligosaccharides from mannans of Candida albicans NIH B-792 (serotype B) and Candida parapsilosis IFO 1396 strains has been conducted by acetolysis under mild conditions. Structural study of these oligosaccharides by H-1 and C-13 NMR and methylation analyses indicated the presence of novel branched side chains with the following structures in C. albicans mannan. GRAPHICS It was observed that the H-1 proton chemical shifts of the second and the third mannose units from the reducing terminus in each oligosaccharide are shifted upfield by substitution with an alpha-linked mannose unit at position 6 of the 3-O-substituted mannose unit. An agglutination inhibition assay between factor 4 serum and cells of Candida stellatoidea IFO 1397 lacking the beta-1,2-linked mannose unit, with oligosaccharides obtained from these mannans, indicated that only the branched oligosaccharides were active. This finding suggests that the branched oligosaccharides correspond to the epitope of antigenic factor 4, The presence of the branched structure in other mannans was detected by the characteristic H-1-H-2-correlated cross-peak of the alpha-1,2-linked mannose unit connected with the 3,6-di-O-substituted one by two-dimensional homonuclear Hartmann-Hahn spectroscopy.	TOHOKU COLL PHARMACEUT SCI, DEPT HYG CHEM 2, SENDAI, MIYAGI 981, JAPAN; TOHOKU COLL PHARMACEUT SCI, DEPT MED CHEM 1, SENDAI, MIYAGI 981, JAPAN	Tohoku Medical & Pharmaceutical University; Tohoku Medical & Pharmaceutical University								AMES BN, 1960, J BIOL CHEM, V235, P769; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; CARROW EW, 1985, INFECT IMMUN, V49, P172, DOI 10.1128/IAI.49.1.172-181.1985; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; CUFF CF, 1986, CELL IMMUNOL, V100, P47, DOI 10.1016/0008-8749(86)90005-5; DOMER JE, 1986, CELL IMMUNOL, V101, P403, DOI 10.1016/0008-8749(86)90153-X; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DURANDY A, 1987, J CLIN IMMUNOL, V7, P400, DOI 10.1007/BF00917018; FUNAYAMA M, 1984, MICROBIOL IMMUNOL, V28, P1359, DOI 10.1111/j.1348-0421.1984.tb00794.x; FUNAYAMA M, 1983, CARBOHYD RES, V117, P229, DOI 10.1016/0008-6215(83)88089-6; GARCIADELOMAS J, 1988, MYCOPATHOLOGIA, V102, P175, DOI 10.1007/BF00437401; GARNER RE, 1990, INFECT IMMUN, V58, P2613, DOI 10.1128/IAI.58.8.2613-2620.1990; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1988, J CHROMATOGR, V434, P15; HASENCLEVER H, 1961, J BACTERIOL, V82, P570, DOI 10.1128/JB.82.4.570-573.1961; HEARN VM, 1993, STRUCTURE ANTIGENS, P211; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; KAGAYA K, 1989, J IMMUNOL, V143, P3353; KANBE T, 1994, INFECT IMMUN, V62, P1662, DOI 10.1128/IAI.62.5.1662-1668.1994; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; KOBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V272, P364, DOI 10.1016/0003-9861(89)90230-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; KOGAN G, 1988, CARBOHYD RES, V172, P243, DOI 10.1016/S0008-6215(00)90858-9; KOGAN G, 1990, CARBOHYD POLYM, V14, P65, DOI 10.1016/0144-8617(90)90007-F; KORTING HC, 1988, J CLIN MICROBIOL, V26, P2626, DOI 10.1128/JCM.26.12.2626-2631.1988; LEHMANN PF, 1980, MYCOPATHOLOGIA, V70, P83, DOI 10.1007/BF00443072; LEMIEUX C, 1990, J CLIN MICROBIOL, V28, P249, DOI 10.1128/JCM.28.2.249-253.1990; LEW MA, 1982, J INFECT DIS, V145, P45, DOI 10.1093/infdis/145.1.45; LI RK, 1993, J BIOL CHEM, V268, P18293; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; MIYAKAWA Y, 1986, J CLIN MICROBIOL, V23, P881, DOI 10.1128/JCM.23.5.881-886.1986; NAKAMURA A, 1991, J CLIN MICROBIOL, V29, P2363, DOI 10.1128/JCM.29.11.2363-2367.1991; NELSON RD, 1991, CLIN MICROBIOL REV, V4, P1; NELSON RD, 1984, INFECT IMMUN, V43, P1041, DOI 10.1128/IAI.43.3.1041-1046.1984; NNALUE NA, 1991, INFECT IMMUN, V59, P229, DOI 10.1128/IAI.59.1.229-233.1991; Odds FC., 1988, CANDIDA CANDIDOSIS; OKAWA Y, 1994, FEBS LETT, V345, P167, DOI 10.1016/0014-5793(94)00434-X; OXLEY D, 1991, CARBOHYD RES, V212, P213, DOI 10.1016/0008-6215(91)84058-M; PODZORSKI RP, 1990, J IMMUNOL, V144, P707; REISS E, 1981, BIOMED MASS SPECTROM, V8, P252, DOI 10.1002/bms.1200080605; REISS E, 1986, J CLIN MICROBIOL, V24, P796, DOI 10.1128/JCM.24.5.796-802.1986; REISS E, 1982, CLIN CHEM, V28, P306; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1993, ARCH BIOCHEM BIOPHYS, V302, P113, DOI 10.1006/abbi.1993.1188; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1991, ARCH BIOCHEM BIOPHYS, V290, P535, DOI 10.1016/0003-9861(91)90578-7; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; SUZUKI M, 1982, MICROBIOL IMMUNOL, V26, P387, DOI 10.1111/j.1348-0421.1982.tb00189.x; SUZUKI S, 1991, FUNGAL CELL WALL IMM, P111; TOJO M, 1990, CARBOHYD RES, V199, P215, DOI 10.1016/0008-6215(90)84263-T; TSUCHIYA T, 1974, MYCOPATH MYCOL APPL, V53, P77, DOI 10.1007/BF02127199	59	122	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1113	1122		10.1074/jbc.270.3.1113	http://dx.doi.org/10.1074/jbc.270.3.1113			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836369	hybrid			2022-12-25	WOS:A1995QB15600024
J	MOUSTAKAS, A; TAKUMI, T; LIN, HY; LODISH, HF				MOUSTAKAS, A; TAKUMI, T; LIN, HY; LODISH, HF			GH3 PITUITARY-TUMOR CELLS CONTAIN HETEROMERIC TYPE-I AND TYPE-II RECEPTOR COMPLEXES FOR TRANSFORMING GROWTH-FACTOR-BETA AND ACTIVIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; RAT GRANULOSA-CELLS; TGF-BETA; XENOPUS EMBRYOS; EXPRESSION CLONING; THREONINE KINASE; INHIBIN; MESODERM; DIFFERENTIATION; PURIFICATION	Transforming growth factors beta (TGF-beta s) and activins induce and inhibins block secretion of follicle-stimulating hormone by rat GH3 pituitary tumor cells. Cheifetz et al. (Cheifetz, S., Ling, N., Guillemin, R., and Massague, J. (1988) J. Biol. Chem. 263, 17225-17228) reported that GH3 cells express a similar to 50-kDa surface protein, termed the type IV TGF-beta receptor, that directly binds all of these peptide hormones. Here we show that GH3 cells express the previously identified type I and type II receptors for TGF-beta and activin-A. Immunoprecipitation of affinity-labeled surface binding proteins with antisera specific to known receptors demonstrated independent heteromeric complexes of TGF-beta types I and II receptors and of activin types I and II receptors. As judged by ligand-binding and cross linking analysis, TGF-beta binding to the TGF-beta receptors is not inhibited by activin-A and activin-A binding to its receptors is not inhibited by TGF-beta. Screening of a cDNA library from GH3 cells for potential receptor serine-threonine kinases yielded the known types I and II TGF-beta and activin receptors. The presumed common intracellular signaling pathway for TGF-beta and activin in GH3 cells appears to be mediated by distinct cell-surface receptors.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [CA-63260] Funding Source: Medline; NHLBI NIH HHS [HL 41484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BRAND T, 1993, J BIOL CHEM, V268, P11500; BUSHAN A, 1994, MOL CELL BIOL, V14, P4280; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DODSON WC, 1987, ENDOCRINOLOGY, V120, P512, DOI 10.1210/endo-120-2-512; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KNECHT M, 1987, ENDOCRINOLOGY, V120, P1243, DOI 10.1210/endo-120-4-1243; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; NISHIMATSU S, 1992, FEBS LETT, V312, P169, DOI 10.1016/0014-5793(92)80928-A; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, V95, P421; RUSCETTI F W, 1991, Progress in Growth Factor Research, V3, P159, DOI 10.1016/S0955-2235(05)80006-7; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; TAKUMI T, 1994, IN PRESS BIOTECHNIQU; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; WEISER R, 1993, MOL CELL BIOL, V13, P7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YING SY, 1986, BIOCHEM BIOPH RES CO, V135, P950, DOI 10.1016/0006-291X(86)91020-X; YING SY, 1986, BIOCHEM BIOPH RES CO, V136, P969, DOI 10.1016/0006-291X(86)90427-4	51	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					765	769		10.1074/jbc.270.2.765	http://dx.doi.org/10.1074/jbc.270.2.765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822308	hybrid			2022-12-25	WOS:A1995QB81600042
J	MUMMANENI, P; WALKER, KA; BISHOP, PL; TURKER, MS				MUMMANENI, P; WALKER, KA; BISHOP, PL; TURKER, MS			EPIGENETIC GENE INACTIVATION INDUCED BY A CIS-ACTING METHYLATION CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; STEM-CELLS; APRT GENE; PATTERNS; EXPRESSION; LINE	In this report we test the hypothesis that a cis-acting methylation center can induce epigenetic gene inactivation. The cis-acting element used is an 838-base pair fragment that was shown previously to provide a de novo methylation signal (Mummaneni, P., Bishop, P. L., and Turker, M. S. (1993) J. Biol. Chem. 268, 552-558). Its normal location is approximately 1.3 kilobase pairs upstream of the mouse aprt (adenine phosphoribosyltransferase) gene. To determine if the methylation center could induce inactivation of the aprt gene, a plasmid construct was created in which the methylation center was moved next to the aprt promoter. Transfection experiments demonstrated inactivation of the aprt gene on the hybrid construct. The inactivation event was shown with a Southern blot analysis to correlate with hypermethylation and to be reversible by treatment with 2-deoxy-5'-azacytidine, a demethylating agent, Interestingly, gene inactivation induced by the methylation center required truncation of the aprt promoter. The results demonstrate that epigenetic gene inactivation can be induced by a DNA methylation center.	UNIV KENTUCKY,MARKEY CANC CTR,DEPT PATHOL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky				Walker, Kimberly A/0000-0002-6360-2792	NATIONAL CANCER INSTITUTE [R01CA056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG008199] Funding Source: NIH RePORTER; NCI NIH HHS [CA56383] Funding Source: Medline; NIA NIH HHS [AG08199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Bestor TH, 1993, J NIH RES, V5, P57; BOYCE J, 1992, EMBO J, V11, P327; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; COOPER GE, 1992, SOMAT CELL MOLEC GEN, V18, P215, DOI 10.1007/BF01233858; COOPER GE, 1993, SOMAT CELL MOLEC GEN, V19, P221, DOI 10.1007/BF01233070; DUSH MK, 1988, NUCLEIC ACIDS RES, V16, P8509, DOI 10.1093/nar/16.17.8509; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HASSE A, 1994, J BIOL CHEM, V269, P1821; Jones PA, 1984, DNA METHYLATION BIOC, P165; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LIU WM, 1993, NUCLEIC ACIDS RES, V21, P1351, DOI 10.1093/nar/21.6.1351; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; RAZIN A, 1991, MICROBIOL REV, P451; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAKAI T, 1991, AM J HUM GENET, V48, P880; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972; TURKER MS, 1984, SOMAT CELL MOLEC GEN, V10, P55, DOI 10.1007/BF01534473; TURKER MS, 1989, J BIOL CHEM, V264, P11632; TURKER MS, 1995, IN PRESS ADV EXP MED	27	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					788	792		10.1074/jbc.270.2.788	http://dx.doi.org/10.1074/jbc.270.2.788			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822312	hybrid			2022-12-25	WOS:A1995QB81600046
J	OSUNA, J; VIADIU, H; FINK, AL; SOBERON, X				OSUNA, J; VIADIU, H; FINK, AL; SOBERON, X			SUBSTITUTION OF ASP FOR ASN AT POSITION-132 IN THE ACTIVE-SITE OF TEM BETA-LACTAMASE - ACTIVITY TOWARD DIFFERENT SUBSTRATES AND EFFECTS OF NEIGHBORING RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-LICHENIFORMIS 749/C; STAPHYLOCOCCUS-AUREUS PC1; ACYL-ENZYME INTERMEDIATE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; RESOLUTION; HYDROLYSIS; LYSINE-234; CATALYSIS; MUTATION	Using a random, combinatorial scheme of mutagenesis directed against the conserved SDN region of TEM beta-lactamase, and selective screening in ampicillin-plates, we obtained the N132D mutant enzyme. The kinetic characterization of this mutant indicated relatively small effects compared to the wild-type, Both pK(1) and pK(2) for catalysis were decreased about 1 unit relative to the pK's for the wild type. This effect was predominantly due to changes in K-m. In contrast to the wild-type, the pH-rate profiles of the mutant showed that K-m for several side chain containing penicillin substrates increases when the pH is above 5.5. 6-Aminopenicillanic acid, which lacks a side chain, did not show this effect. With benzylpenicillin, ampicillin, and carbenicillin, k(cat) for the mutant showed a similar pH dependence as the wild type. With 6-aminopenicillanic acid, k(cat) for the mutant was greater than that for the wild type, The nature of the 104 side chain may affect the environment of Asp(132); double mutants N132D/E104X (where X can be Q or N) are unable to confer antibiotic resistance to bacterial cells. The computed contact interactions from modeling substrate complexes between benzylpenicillin or 6-aminopenicillanic acid with the N132D mutant confirmed the importance of the protonation state of residue Asp(132) for the complex stability with side chain containing substrates. The data indicate that the contact between the side chain of residue 132 and the substrate is relevant for the ground state recognition, but because of close contact with several important groups in its neighborhood, residue 132 is also indirectly involved in the catalytic step of the wild-type enzyme.	UNIV NACL AUTONOMA MEXICO, INST BIOTECNOL, CUERNAVACA 62271, MORELOS, MEXICO; UNIV CALIF SANTA CRUZ, DEPT CHEM & BIOCHEM, SANTA CRUZ, CA 95064 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California Santa Cruz			Soberon, Xavier/A-8826-2008; Viadiu, Hector/E-7785-2013	Osuna, Joel/0000-0002-8904-0724				ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; HARDY LW, 1984, BIOCHEMISTRY-US, V23, P1288, DOI 10.1021/bi00301a042; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; Herzberg O, 1991, CURR OPIN STRUC BIOL, V1, P946, DOI 10.1016/0959-440X(91)90090-G; JACOB F, 1990, PROTEIN ENG, V4, P79, DOI 10.1093/protein/4.1.79; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JUTEAU JM, 1992, PROTEIN ENG, V5, P693, DOI 10.1093/protein/5.7.693; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KNOX JR, 1993, PROTEIN ENG, V6, P11, DOI 10.1093/protein/6.1.11; LENFANT F, 1991, J BIOL CHEM, V266, P17187; MERINO E, 1992, BIOTECHNIQUES, V12, P508; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; WALEY SG, 1974, BIOCHEM J, V139, P789, DOI 10.1042/bj1390789	24	26	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	1995	270	2					775	780		10.1074/jbc.270.2.775	http://dx.doi.org/10.1074/jbc.270.2.775			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB816	7822310	hybrid			2022-12-25	WOS:A1995QB81600044
J	ALLEN, LA; ZHAO, XJ; CAUGHEY, W; POYTON, RO				ALLEN, LA; ZHAO, XJ; CAUGHEY, W; POYTON, RO			ISOFORMS OF YEAST CYTOCHROME-C-OXIDASE SUBUNIT-V AFFECT THE BINUCLEAR REACTION-CENTER AND AFTER THE KINETICS OF INTERACTION WITH THE ISOFORMS OF YEAST CYTOCHROME-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INFRARED-SPECTRA; CATALYTIC SITE; IONIC-STRENGTH; BAKERS-YEAST; BINDING; GENES; IDENTIFICATION; OXYGEN; HEME	Subunit V, one of the nuclear coded subunits of yeast cytochrome c oxidase, has two isoforms, Va and Vb. These alter the in vivo intramolecular rates of electron transfer within the holoenzyme (Waterland, R. A., Basu, A., Chance, B., and Poyton, R. O. (1991) J. Biol. Chen. 266, 4180-4186). The isozyme with Vb has a higher turnover rate and a higher intramolecular transfer rate than the isozyme with Va. To determine how these isoforms affect catalysis, we have examined their effects on the binuclear reaction center and on the interaction between cytochrome c oxidase and the two isoforms, iso-1 and iso-2, of yeast cytochrome c. Infrared spectroscopy of carbon monoxide liganded to heme a(3) has revealed a single conformer for the binuclear reaction center in the isozyme with Vb but two discrete conformers in the isozyme with Va. The kinetics of interaction for all four pairwise combinations of isozymes with each subunit V isoform and the two cytochrome c isoforms are biphasic, with high and low affinity electron transfer reactions. In general, the isoforms of cytochrome c and subunit V do not alter the K-m but do affect the TNmax. The TNmax for isozymes carrying Vb are higher at both high and low affinity sites for each cytochrome c isoform. Iso-1-cytochrome c supports a higher TNmax than Iso-2-cytochrome c. Surprisingly, the combinatorial effect of both sets of isoforms on TNmax is minimized with the pairs of isoforms (iso-1-cytochrome c and subunit Va or iso-2 and subunit Vb) that are co-expressed in cells. Together, these findings support the conclusion that the subunit V isoforms modulate catalysis and suggest that they do so by affecting the environment or structure of the binuclear reaction center. They also suggest that the coexpression of the two cytochrome c isoforms with two subunit V isoforms serves to minimize differences in electron transfer rates brought about by the subunit V isoforms.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA	University of Colorado System; University of Colorado Boulder; Colorado State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM030306, R01GM030306, R01GM039324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39324, GM30306] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEYNE TA, 1992, BIOCHEM J, V287, P951, DOI 10.1042/bj2870951; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BISSON R, 1977, FEBS LETT, V81, P147, DOI 10.1016/0014-5793(77)80948-4; BORDEN M, 1967, HDB BIOCH, V3, P268; BRUNORI M, 1987, EUR J BIOCHEM, V169, P1, DOI 10.1111/j.1432-1033.1987.tb13572.x; BRUNORI M, 1985, EMBO J, V4, P2365, DOI 10.1002/j.1460-2075.1985.tb03940.x; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1970, J CHEM SOC CHEM COMM, P950, DOI 10.1039/c29700000950; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DETHMERS JK, 1979, J BIOL CHEM, V254, P1973; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P13641; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GARBER EAE, 1988, OXIDASES RELATED RED, P749; GELLES J, 1986, BIOCHIM BIOPHYS ACTA, V853, P205, DOI 10.1016/0304-4173(87)90002-4; GEORGENASCIMENTO C, 1981, J BIOL CHEM, V256, P9363; HALL J, 1988, J BIOL CHEM, V263, P8142; HILL BC, 1991, J BIOL CHEM, V266, P2219; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; MASON TL, 1973, J BIOL CHEM, V248, P1346; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; MICHEL B, 1984, J BIOL CHEM, V259, P85; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MILLETT F, 1982, BIOCHEMISTRY-US, V21, P3857, DOI 10.1021/bi00259a021; NICHOLLS P, 1965, OXIDASES RELATED RED, P764; Osheroff N. O., 1978, FRONTIERS BIOL ENERG, V1, P439; PATTERSON TE, 1987, CYTOCHROME SYSTEMS M, P253; POTTER WT, 1990, BIOCHEMISTRY-US, V29, P6283, DOI 10.1021/bi00478a025; POWER SD, 1984, J BIOL CHEM, V259, P6564; POYTON RO, 1975, J BIOL CHEM, V250, P752; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; POYTON RO, 1992, BIOCHIM BIOPHYS ACTA, V1101, P252, DOI 10.1016/S0005-2728(05)80033-7; POYTON RO, 1995, IN PRESS METHODS ENZ; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SINJORGO KMC, 1986, BIOCHIM BIOPHYS ACTA, V850, P108, DOI 10.1016/0005-2728(86)90014-9; SMITH L, 1963, BIOCHEMISTRY-US, V2, P1432, DOI 10.1021/bi00906a040; SPECK SH, 1984, P NATL ACAD SCI-BIOL, V81, P347, DOI 10.1073/pnas.81.2.347; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAYLOR JR, 1982, INTRO ERROR ANAL, P153; TRUEBLOOD CE, 1988, GENETICS, V120, P671; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WILMS J, 1981, BIOCHIM BIOPHYS ACTA, V635, P13, DOI 10.1016/0005-2728(81)90003-7; WRIGHT RM, 1987, CYTOCHROME SYSTEMS M, P49; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOUNG LJ, 1984, BIOCHEM BIOPH RES CO, V123, P247, DOI 10.1016/0006-291X(84)90405-4	52	79	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					110	118		10.1074/jbc.270.1.110	http://dx.doi.org/10.1074/jbc.270.1.110			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814361	hybrid			2022-12-25	WOS:A1995QA28700022
J	BALASUBRAMANIAN, S; BEGER, RD; BENNETT, SE; MOSBAUGH, DW; BOLTON, PH				BALASUBRAMANIAN, S; BEGER, RD; BENNETT, SE; MOSBAUGH, DW; BOLTON, PH			SECONDARY STRUCTURE OF URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDIC ABASIC SITES; UV ENDONUCLEASE-V; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; NMR-SPECTROSCOPY; CYTOSINE RESIDUES; VACCINIA VIRUS; N-GLYCOSIDASE; DUPLEX DNA; BACTERIOPHAGE-PBS2	The Bacillus subtilis bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) is an acidic protein of 84 amino acids that inactivates uracil-DNA glycosylase from diverse organisms (Wang, Z., and Mosbaugh, D, W. (1989) J. Biol. Chem. 264, 1163-1171). The secondary structure of Ugi has been determined by solution state multidimensional nuclear magnetic resonance, The protein adopts a single well defined structure consisting of five anti parallel beta-strands and two alpha-helices. Six loop or turn regions were identified that contain approximately one half of the acidic amino acid residues and connect the beta-strands sequentially to one another, The secondary structure suggests which regions of Ugi may be involved in interactions with uracil-DNA glycosylase.	WESLEYAN UNIV,DEPT CHEM,MIDDLETOWN,CT 06450; OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Wesleyan University; Oregon State University; Oregon State University; Oregon State University				Balasubramanian, Suganthi/0000-0003-2243-5948	NIEHS NIH HHS [ES 00210] Funding Source: Medline; NIGMS NIH HHS [GM 32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; CARRADONNA SJ, 1981, J BIOL CHEM, V256, P9834; CLORE GM, 1993, J MOL BIOL, V231, P82, DOI 10.1006/jmbi.1993.1259; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DISTEFANO DL, 1987, BIOCHEMISTRY-US, V26, P7272, DOI 10.1021/bi00397a012; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FOCHER F, 1993, BIOCHEM J, V292, P883, DOI 10.1042/bj2920883; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOLJER I, 1992, BIOCHEMISTRY-US, V31, P11614, DOI 10.1021/bi00161a047; HITZEMAN RA, 1978, J BIOL CHEM, V253, P8518; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; KLUPP BG, 1994, J VIROL, V68, P3868, DOI 10.1128/JVI.68.6.3868-3878.1994; LEMASTER DM, 1994, PROG NUCL MAG RES SP, V26, P371, DOI 10.1016/0079-6565(94)80010-3; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; MOSBAUGH DW, 1993, PROG NUCLEIC ACID RE, V48, P315; OLSEN LC, 1991, NUCLEIC ACIDS RES, V19, P4473, DOI 10.1093/nar/19.16.4473; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PALMER AG, 1992, J MAGN RESON, V96, P416, DOI 10.1016/0022-2364(92)90097-Q; PRICE AR, 1975, J BIOL CHEM, V250, P8804; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; TARTAGLIA J, 1990, J GEN VIROL, V71, P1517, DOI 10.1099/0022-1317-71-7-1517; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WILDE JA, 1989, J AM CHEM SOC, V111, P1894, DOI 10.1021/ja00187a062; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988; WUTHRICH K, 1990, J BIOL CHEM, V265, P22059; Wuthrich K., 1986, NMR PROTEINS NUCL AC	45	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 6	1995	270	1					296	303		10.1074/jbc.270.1.296	http://dx.doi.org/10.1074/jbc.270.1.296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA287	7814390	hybrid			2022-12-25	WOS:A1995QA28700047
J	LARABADJEBARI, F; LEGROS, C; CREST, M; CEARD, B; ROMI, R; MANSUELLE, P; JACQUET, G; VANRIETSCHOTEN, J; GOLA, M; ROCHAT, H; BOUGIS, PE; MARTINEAUCLAIRE, MF				LARABADJEBARI, F; LEGROS, C; CREST, M; CEARD, B; ROMI, R; MANSUELLE, P; JACQUET, G; VANRIETSCHOTEN, J; GOLA, M; ROCHAT, H; BOUGIS, PE; MARTINEAUCLAIRE, MF			THE KALIOTOXIN FAMILY ENLARGED - PURIFICATION, CHARACTERIZATION, AND PRECURSOR NUCLEOTIDE-SEQUENCE OF KTX(2) FROM ANDROCTONUS-AUSTRALIS VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDES; DEPENDENT POTASSIUM CHANNELS; CENTRUROIDES-NOXIUS HOFFMANN; INSECT SELECTIVE NEUROTOXIN; K+-CHANNEL; BLOCKING PEPTIDE; SCORPION TOXINS; CHARYBDOTOXIN; EXPRESSION; CLONING	Kaliotoxin (KTX) has been originally described as an inhibitor of the intermediate conductance Ca2+-activated K+ channel (Crest, M., Jacquet, G., Cola, M., Zerrouk, H., Benslimane, A., Rochat, H., Mansuelle, P., and Martin-Eauclaire, M.-F. (1992) J. Biol. Chem. 267, 1640-1647). However, the radioiodinated I-125-KTX-(1-37) was also able to bind to the dendrotoxin sensitive voltage-dependent K+ channel (Romi, R., Crest, M., Cola, M., Sampieri, El, Jacquet, G., Zerrouk, H., Mansuelle, P., Sorokine, O., Van Dorsselaer, A., Rochat, H., Martin Eauclaire, M.-F., and Van Rietschoten, J. (1993) J. Biol. Chem. 268, 26302-26309). By following the ability to compete with I-125-KTX-(1-37) for binding to its receptor on rat brain synaptosomes, a new kaliotoxin-like peptide, KTX(2), was isolated from Androctonus australis scorpion venom. It is a 37-amino acid residue peptide, and its sequence shares 76% identity with KTX. The differences between the two peptides concern the NH2-terminal region and the residues 31 and 34 located in the region involved in the channel recognition. These differences may explain the 5-fold decrease of the molluscan Ca2+-activated K+ channel blocage by KTX(2) (k(d) = 135 nM) as well as of its binding affinity to rat brain synaptosomes (IC50 = 50 pM), compared with KTX. Specific antibodies raised against KTX-(1-37) were not able to recognize KTX(2). Using degenerate primers, a 370-base pair cDNA encoding the KTX(2) precursor was amplified by polymerase chain reaction from a cDNA library of A. australis venom glands. It encoded a presumed signal peptide of 22 residues followed by the sequence of the mature peptide.	FAC MED NORD,BIOCHIM INGN PROT LAB,CNRS,URA 1455,F-13916 MARSEILLE 20,FRANCE; CNRS,UPR 9024,NEUROBIOL LAB,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Legros, Christian/K-1346-2015; Fatima, Laraba-Djebari/N-8463-2016; BOUGIS, Pierre E/I-2111-2013	Fatima, Laraba-Djebari/0000-0003-4641-261X; LEGROS, Christian/0000-0002-3346-7059; mansuelle, pascal/0000-0002-4504-6809				BECERRIL B, 1993, GENE, V128, P165, DOI 10.1016/0378-1119(93)90559-L; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; CREST M, 1992, J BIOL CHEM, V267, P1640; DELORI P, 1981, TOXICON, V19, P393, DOI 10.1016/0041-0101(81)90044-1; DIMARCQ JL, 1990, EMBO J, V9, P2507, DOI 10.1002/j.1460-2075.1990.tb07430.x; ELAYEB M, 1983, TOXICON, V21, P709, DOI 10.1016/0041-0101(83)90276-3; FERNANDEZ I, 1994, IN PRESS BIOCHEMISTR; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; GOLA M, 1990, J PHYSIOL-LONDON, V420, P73, DOI 10.1113/jphysiol.1990.sp017902; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; HARVEY AL, 1994, IN PRESS TOXICON; HOFFMANN JA, 1992, M S-MED SCI, V8, P432, DOI 10.4267/10608/3159; KNAPP DR, 1990, METHOD ENZYMOL, V193, P314, DOI 10.1016/0076-6879(90)93423-I; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MARTINEAUCLAIRE MF, 1992, FEBS LETT, V302, P220, DOI 10.1016/0014-5793(92)80445-M; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PHILIPSON LH, 1992, TRENDS PHARMACOL SCI, V13, P8, DOI 10.1016/0165-6147(92)90005-Q; PONGS O, 1993, TRENDS PHARMACOL SCI, V14, P435, DOI 10.1016/0165-6147(93)90182-J; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; POSSANI LD, 1982, CARLSBERG RES COMMUN, V47, P285, DOI 10.1007/BF02907789; ROGOWSKI RS, 1994, P NATL ACAD SCI USA, V91, P1475, DOI 10.1073/pnas.91.4.1475; ROMI R, 1993, J BIOL CHEM, V268, P26302; RUPPERSBERG JP, 1993, CELL PHYSIOL BIOCHEM, V3, P250; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LA, 1990, J TOXICOL-TOXIN REV, V9, P243, DOI 10.3109/15569549009033116; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; TAUC M, 1993, PFLUG ARCH EUR J PHY, V425, P126, DOI 10.1007/BF00374512; VASQUEZ J, 1990, J BIOL CHEM, V265, P15564; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; WOODWARD SR, 1990, EMBO J, V9, P1015, DOI 10.1002/j.1460-2075.1990.tb08204.x; ZERROUK H, 1991, TOXICON, V29, P951, DOI 10.1016/0041-0101(91)90078-6; ZILBERBERG N, 1991, TOXICON, V29, P1155, DOI 10.1016/0041-0101(91)90213-B	46	69	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 30	1994	269	52					32835	32843						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QA638	7806508				2022-12-25	WOS:A1994QA63800021
